



# Health Economics, Outcomes & Epidemiology

Published Research and Presentations

---

COMPENDIUM

# Health Economics, Outcomes & Epidemiology

Published Research and Presentations

## A COMPENDIUM OF OUR RESEARCH

Health outcomes research is playing an increasingly important role in pharmaceutical development as new products enter competitive markets and face demands for economic evidence, safety, and efficacy. A clear and early understanding of value is critical to commercial success, and requires companies to have capabilities in health economics and associated disciplines of epidemiology, biostatistics, outcomes research, and pharmacoeconomics in place for ready use across their customers and therapeutic areas.

For nearly three decades, Analysis Group has been distinguished by a unique combination of expertise in health economics, outcomes research, epidemiology, biostatistics, and health policy. Our outcomes research has resulted in thought leadership and a robust record of publications and presentations across the leading medical, outcomes, and health economics journals and conferences, covering a range of clinical and methodological areas. This compendium includes published manuscripts as well as abstracts through October 2023.

For more information on our research activities and health care consulting practice, please visit our website, <https://www.analysisgroup.com/>.

---

## CONTENTS

Autoimmune/Inflammatory	4
Cardiovascular	23
Dermatology	50
Endocrine/Metabolic/Diabetes	71
Gastrointestinal	94
Hematology	111
Infectious Diseases	131
Neurology	146
Oncology	199
Renal	293
Respiratory	301
Substance Abuse	318
Other Diseases & Conditions	323
Other (Health Policy, Market Access, and other topics)	340

## Autoimmune/Inflammatory

### Journal Articles

#### **Cohabitation as a determinant of adaptive and innate immune cell profiles: Findings from the Health and Retirement Study.**

*Publication:* Brain Behav Immun Health 2023 08; 33: 100676. e-pub ahead of print 2023/09/04; doi: 10.1016/j.bbih.2023.100676.

*Authors:* Ramasubramanian R, Kim JW, Guan W, Meier HCS, Crimmins E, Faul J, Thyagarajan B.

#### **Health Care Costs With Sustained Oral Corticosteroid Use in Systemic Lupus Erythematosus.**

*Publication:* Clin Ther 2023 06. doi: 10.1016/j.clinthera.2023.04.013.

*Authors:* Huang SP, DerSarkissian M, Gu YM, Duh MS, Wang M-J, Benson J, Vu JD, Averell CM, Bell CF.

#### **Benefits of Autoantibody Enrichment in Early Rheumatoid Arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials.**

*Publication:* Rheumatol Ther 2023 05. e-pub ahead of print 2023/05/26; doi: 10.1007/s40744-023-00552-2.

*Authors:* Michaud K, Conaghan PG, Park SH, Lozenski K, Fillbrunn M, Khaychuk V, Swallow E, Vaile J, Lane H, Nguyen H, Pope J.

#### **Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study.**

*Publication:* ACR Open Rheumatol 2023 05. e-pub ahead of print 2023/05/25; doi: 10.1002/acr2.11550.

*Authors:* DerSarkissian M, Gu YM, Duh MS, Benson J, Huang SP, Averell C, Vu J, Wang MJ, Bell CF.

#### **Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims.**

*Publication:* Rheumatol Ther 2023 05. doi: 10.1007/s40744-023-00549-x.

*Authors:* Singer D, Thompson-Leduc P, Poston S, Gupta D, Cheng WY, Ma S, Devine F, Enrique A, Duh MS, Curtis JR.

#### **Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden.**

*Publication:* J Manag Care Spec Pharm 2023 04; 29(4): 365-377. e-pub ahead of print 2023/03/30; doi: 10.18553/jmcp.2023.29.4.365.

*Authors:* Huang SP, DerSarkissian M, Gu YM, Duh MS, Wang MJ, Benson J, Vu J, Averell C, Bell CF.

#### **Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in the United States.**

*Publication:* Neurol Ther 2023 03; 12(3): 849-861. doi: 10.1007/s40120-023-00463-y.

*Authors:* Kantor D, Pham T, Patterson-Lomba O, Swallow E, Dua A, Gupte-Singh K.

#### **Incidence of Herpes Zoster in Patients with Rheumatoid Arthritis in the United States: A Retrospective Cohort Study.**

*Publication:* J Rheumatol 2023 02. e-pub ahead of print 2023/02/02; doi: 10.3899/jrheum.220986.

*Authors:* Singer D, Thompson-Leduc P, Poston S, Gupta D, Cheng WY, Ma S, Devine F, Duh MS, Curtis JR.

#### **A 5-Year Retrospective, Observational Study Assessing Rheumatoid Arthritis Disease Outcome Measures to Characterize Systemic Lupus Erythematosus Burden in the USA.**

*Publication:* Rheumatol Ther 2022 12. e-pub ahead of print 2022/12/06; doi: 10.1007/s40744-022-00509-x.

*Authors:* Bell CF, Huang SP, Yu LH, DerSarkissian M, Germain G, Concoff AL, Averell CM, Rubin B, Gu YM, Duh MS, Wallace DJ.

**Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.**

*Publication:* Arthritis Res Ther 2022 06; 24(1): 155. e-pub ahead of print 2022/06/25; doi: 10.1186/s13075-022-02813-x.

*Authors:* Bergman M, Tundia N, Martin N, Suboticki JL, Patel J, Goldschmidt D, Song Y, Wright GC.

**Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease in the U.S. Real-World Settings.**

*Publication:* Rheumatol Ther 2021 12. e-pub ahead of print 2021/12/08; doi: 10.1007/s40744-021-00402-z.

*Authors:* Hur P, Yi E, Ionescu-Iltu R, Manceur AM, Lomax KG, Cammarota J, Xie J, Gautam R, Nakasato P, Sanghera N, Kim N, Grom AA.

**Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.**

*Publication:* Rheumatology 2021 12. doi: 10.1093/rheumatology/keab158.

*Authors:* Strand V, Tundia N, Bergman M, Ostor A, Durez P, Song I, Enejosa J, Schlacher C, Song Y, Fleischmann R.

**Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis.**

*Publication:* Rheumatol Ther 2021 11. e-pub ahead of print 2021/11/25; doi: 10.1007/s40744-021-00399-5.

*Authors:* Conaghan P, Cohen S, Burmester G, Mysler E, Nash P, Tanaka Y, Rigby W, Patel J, Shaw T, Betts KA, Patel P, Liu J, Sun R, Fleischmann R.

**Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review.**

*Publication:* Adv Ther 2021 11. e-pub ahead of print 2021/11/18; doi: 10.1007/s12325-021-01946-w.

*Authors:* Ostor AJ, Sawant R, Qi CZ, Wu A, Nagy O, Betts KA.

**Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis.**

*Publication:* Adv Ther 2021 10. e-pub ahead of print 2021/10/13; doi: 10.1007/s12325-021-01930-4.

*Authors:* Bergman M, Tundia N, Yang M, Orvis E, Clewell J, Bensimon A.

**Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States.**

*Publication:* Pediatr Rheumatol Online J 2021 09; 19(1): 143. e-pub ahead of print 2021/09/16; doi: 10.1186/s12969-021-00605-2.

*Authors:* Hur P, Lomax KG, Ionescu-Iltu R, Manceur AM, Xie J, Cammarota J, Gautam R, Sanghera N, Kim N, Grom AA.

**Higher Medication Adherence and Lower Opioid Use Among Individuals with Autoimmune Disease Enrolled in an Adalimumab Patient Support Program in the United States.**

*Publication:* Rheumatol Ther 2021 06: 889-901.

*Authors:* Fendrick A, Macaulay D, Goldschmidt D, Liu H, Brixner D, Ali T, Mittal M.

**Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY.**

*Publication:* Rheumatology 2020 12. doi: 10.1093/rheumatology/keaa770.

*Authors:* Strand V, Tundia N, Wells A, Buch MH, Radominski SC, Camp HS, Friedman A, Suboticki JL, Dunlap K, Goldschmidt D, Bergman M.

**A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis.**

*Publication:* Rheumatol Ther 2020 11. e-pub ahead of print 2020/11/28; doi: 10.1007/s40744-020-00257-w.

*Authors:* Edwards CJ, Sawant R, Garg V, Du EX, Friedman A, Betts KA.

**Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.**

*Publication:* Adv Ther 2020 04. e-pub ahead of print 2020/04/17; doi: 10.1007/s12325-020-01303-3.

*Authors:* Pope J, Sawant R, Tundia N, Du EX, Qi CZ, Song Y, Tang P, Betts KA.

**Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial.**

*Publication:* Blood Adv 2020 04; 4(7): 1432-1439. e-pub ahead of print 2020/04/10; doi:

10.1182/bloodadvances.2019001304.

*Authors:* Schuster SJ, Maziarz RT, Rusch ES, Li J, Signorovitch JE, Romanov VV, Locke FL, Maloney DG.

**Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.**

*Publication:* Arthritis Res Ther 2019 12; 21(1): 263. e-pub ahead of print 2019/12/04; doi: 10.1186/s13075-019-2059-8.

*Authors:* Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, Song Y, Pope J.

**Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.**

*Publication:* Arthritis Res Ther 2019 12; 21(1): 272. e-pub ahead of print 2019/12/10; doi: 10.1186/s13075-019-2037-1.

*Authors:* Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M.

**Predictors of High-cost Patients With Noninfectious Inflammatory Eye Diseases.**

*Publication:* Clin Ther 2019 10. e-pub ahead of print 2019/10/15; doi: 10.1016/j.clinthera.2019.09.011.

*Authors:* Nelson WW, Rice JB, White AG, Johnson M, Reiff J, Lima AF, Bartels-Peculis L, Ciepiewska G, Albini TA.

**Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis.**

*Publication:* Rheumatol Ther 2019 05; 6(2): 285-297. e-pub ahead of print 2019/05/06; doi: 10.1007/s40744-019-0158-2.

*Authors:* Song Y, Betts KA, Lu Y, Singh R, Clewell J, Griffith J.

**Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis.**

*Publication:* Adv Ther 2019 03. e-pub ahead of print 2019/04/01; doi: 10.1007/s12325-019-00929-2.

*Authors:* Zhou Z, Fan Y, Thomason D, Tang W, Liu X, Zhou ZY, Macaulay D, Fischer A.

**Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States.**

*Publication:* J Rheumatol 2019 02; jrheum.180445. e-pub ahead of print 2019/02/17; doi: 10.3899/jrheum.180445.

*Authors:* Zhou Z, Fan Y, Tang W, Liu X, Thomason D, Zhou ZY, Macaulay D, Fischer A.

**Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review.**

*Publication:* Rheumatol Ther 2019 01. e-pub ahead of print 2019/01/07; doi: 10.1007/s40744-018-0137-z.

*Authors:* Sunkureddi P, Latremouille-Viau D, Meiselbach MK, Xie J, Hur P, Joshi R.

**Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review.**

*Publication:* Drugs Real World Outcomes 2019 01. e-pub ahead of print 2019/01/09; doi: 10.1007/s40801-018-0146-9.

*Authors:* Joshi R, Latremouille-Viau D, Meiselbach MK, Xie J, Park Y, Sunkureddi P.

**Short-term costs associated with non-medical switching in autoimmune conditions.**

*Publication:* Clin Exp Rheumatol 2019 01; 37(1): 97-105. e-pub ahead of print 2018/07/13.

*Authors:* Gibofsky A, Skup M, Yang M, Mittal M, Macaulay D, Ganguli A.

**Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population.**

*Publication:* J Med Econ 2018 09; 21(9): 846-852. e-pub ahead of print 2018/05/10; doi:

10.1080/13696998.2018.1474750.

*Authors:* Rice JB, White AG, Johnson M, Wagh A, Qin Y, Bartels-Peculis L, Ciepielewska G, Nelson WW.

**Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population.**

*Publication:* Curr Med Res Opin 2018 08; 34(8): 1519-1527. e-pub ahead of print 2018/05/10; doi:

10.1080/03007995.2018.1474090.

*Authors:* Rice JB, White AG, Johnson M, Wagh A, Qin Y, Bartels-Peculis L, Ciepielewska G, Nelson WW.

**Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.**

*Publication:* J Manag Care Spec Pharm 2018 04; 24(4): 344-352. e-pub ahead of print 2018/03/27; doi:

10.18553/jmcp.2018.24.4.344.

*Authors:* Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M.

**Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis.**

*Publication:* BMC Rheumatology 2018 01; 2 (1) (no pagination)(3). doi: <http://dx.doi.org/10.1186/s41927-018-0011-1>.

*Authors:* Strand V, Elaine Husni M, Betts KA, Song Y, Singh R, Griffith J, Beppu M, Zhao J, Ganguli A.

**Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison.**

*Publication:* Rheumatol Ther 2017 12; 4(2): 349-362. e-pub ahead of print 2017/08/02; doi: 10.1007/s40744-017-0070-6.

*Authors:* Strand V, Betts KA, Mittal M, Song J, Skup M, Joshi A.

**Healthcare resource utilization and costs by age and joint location among osteoarthritis patients in a privately insured population.**

*Publication:* J Med Econ 2017 12; 20(12): 1299-1306. e-pub ahead of print 2017/09/08; doi:

10.1080/13696998.2017.1377717.

*Authors:* Wang SX, Ganguli AX, Bodhani A, Medema JK, Reichmann WM, Macaulay D.

**High-Cost Sarcoidosis Patients in the United States: Patient Characteristics and Patterns of Health Care Resource Utilization.**

*Publication:* J Manag Care Spec Pharm 2017 12; 23(12): 1261-1269. e-pub ahead of print 2017/11/28; doi:

10.18553/jmcp.2017.17203.

*Authors:* Rice JB, White A, Lopez A, Nelson WW.

**Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review.**

*Publication:* Clin Ther 2017 11; 39(11): 2216-2229. e-pub ahead of print 2017/10/23; doi:

10.1016/j.clinthera.2017.09.011.

*Authors:* Rice JB, White AG, Scarpati LM, Wan G, Nelson WW.

**Economic burden of sarcoidosis in a commercially-insured population in the United States.**

*Publication:* J Med Econ 2017 10; 20(10): 1048-1055. e-pub ahead of print 2017/07/06; doi: 10.1080/13696998.2017.1351371.

*Authors:* Rice JB, White A, Lopez A, Conway A, Wagh A, Nelson WW, Philbin M, Wan GJ.

**Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.**

*Publication:* Clin Exp Rheumatol 2017 09; 35(5): 791-798. e-pub ahead of print 2017/03/25.

*Authors:* Yang M, Galebach PJ, Signorovitch JE, Garg V.

**Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.**

*Publication:* Clin Ther 2017 08; 39(8): 1618-1627. e-pub ahead of print 2017/07/22; doi:

10.1016/j.clinthera.2017.06.009.

*Authors:* Li N, Betts KA, Messali AJ, Skup M, Garg V.

**Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis.**

*Publication:* Clin Ther 2017 08; 39(8): 1680-1694 e1682. e-pub ahead of print 2017/07/25; doi:

10.1016/j.clinthera.2017.06.013.

*Authors:* Wells AF, Curtis JR, Betts KA, Douglas K, Du EX, Ganguli A.

**Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective.**

*Publication:* Rheumatol Int 2017 06; 1-12. doi: 10.1007/s00296-017-3760-z.

*Authors:* Husni ME, Betts KA, Griffith J, Song Y, Ganguli A.

**Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons.**

*Publication:* Clin Ther 2017 04; 39(4): 849-862 e846. e-pub ahead of print 2017/04/02; doi:

10.1016/j.clinthera.2017.03.005.

*Authors:* Wolf D, Skup M, Yang H, Fang AP, Kageleiry A, Chao J, Mittal M, Lebowhl M.

**Economic Evaluation of Timely versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.**

*Publication:* Rheumatology Therapeutics 2016 09. doi: 10.1007/s40744-016-0042-2.

*Authors:* Strand V, Husni E, Griffith J, Zhou ZY, Signorovitch J, Ganguli A.

**Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia and Mexico.**

*Publication:* J Med Econ 2016 07; 1-49. e-pub ahead of print 2016/07/05; doi: 10.1080/13696998.2016.1209508.

*Authors:* Tundia N, Gustavo Kotze P, Rojas Serrano J, Mendes de Abreu M, Skup M, Macaulay D, Signorovitch J, Chaves L, Chao J, Bao Y.

**Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population.**

*Publication:* J Med Econ 2016 07; 19(7): 649-654. e-pub ahead of print 2016/02/07; doi:

10.3111/13696998.2016.1151433.

*Authors:* Bradford Rice J, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M.

**Network Meta-Analysis and Cost per Responder of Tumor Necrosis Factor-alpha and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis.**

*Publication:* Rheumatology Therapeutics 2016 07; 1-14. doi: 10.1007/s40744-016-0038-y.

*Authors:* Betts KA, Griffith J, Song Y, Mittal M, Joshi A, Wu EQ, Ganguli A.



**Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.**

*Publication:* Clin Ther 2016 05; 38(5): 1205-1216. e-pub ahead of print 2016/04/06; doi: 10.1016/j.clinthera.2016.03.013.

*Authors:* Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ.

**Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.**

*Publication:* Adv Ther 2016 05; 33(5): 807-823. e-pub ahead of print 2016/04/17; doi: 10.1007/s12325-016-0318-5.

*Authors:* Zhou ZY, Griffith J, Du EX, Chin D, Betts KA, Ganguli A.

**An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.**

*Publication:* Curr Med Res Opin 2016 04; 32(4): 721-729. e-pub ahead of print 2016/01/09; doi: 10.1185/03007995.2016.1140026.

*Authors:* Betts KA, Griffith J, Friedman A, Zhou ZY, Signorovitch JE, Ganguli A.

**ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.**

*Publication:* Rheumatology (Oxford) 2016 01; 55(1): 80-88. doi: 10.1093/rheumatology/kev267.

*Authors:* van der Heijde D, Joshi A, Pangan AL, Chen N, Betts K, Mittal M, Bao Y.

**Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study.**

*Publication:* Current Medical Research & Opinion 2015 08; 31(8): 1611-1620. doi: 10.1185/03007995.2015.1062750.

*Authors:* Shiozawa A, Cloutier M, Heroux J, Guerin A, Wu EQ, Jackson R.

**Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.**

*Publication:* Arthritis Care Res (Hoboken) 2015 05; 67(5): 708-717. doi: 10.1002/acr.22492.

*Authors:* Feldman SR, Zhao Y, Shi L, Tran MH, Lu J.

**Assessment of income growth in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy.**

*Publication:* J Med Econ 2015 01; 18(1): 37-44. doi: 10.3111/13696998.2014.925465.

*Authors:* Bergman M, De G, Ganguli A, Signorovitch J, Bao Y.

**Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs.**

*Publication:* Arthritis Res Ther 2014 08; 16(4): 420. doi: 10.1186/s13075-014-0420-5.

*Authors:* Zhang HF, Gauthier G, Hiscock R, Curtis JR.

**Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.**

*Publication:* Appl Health Econ Health Policy 2014 04; 12(2): 179-190. doi: 10.1007/s40258-014-0085-x.

*Authors:* Oglesby A, Korves C, Laliberte F, Dennis G, Rao S, Suthoff ED, Wei R, Duh MS.

**Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.**

*Publication:* QJM 2013 08; 106(8): 721-729. doi: 10.1093/qjmed/hct093.

*Authors:* Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk R, Liu J, Shi L.

**Serum urate and incidence of kidney disease among veterans with gout.**

*Publication:* J Rheumatol 2013 07; 40(7): 1166-1172. doi: 10.3899/jrheum.121061.

*Authors:* Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu E, Tawk RH, Liu J, Shi L.

**A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus.**

*Publication:* J Med Econ 2013 05; 16(6): 793-800. doi: 10.3111/13696998.2013.802241.

*Authors:* Kan H, Guerin A, Kaminsky MS, Yu AP, Wu EQ, Denio A, Priti J, Narayanan S, Molta C.

**Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.**

*Publication:* J Med Econ 2013 02; 16(4): 479-489. doi: 10.3111/13696998.2013.768530.

*Authors:* Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M.

**Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.**

*Publication:* Am J Ther 2012 11; 19(6): e157-166. doi: 10.1097/MJT.0b013e31820543c5.

*Authors:* Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M.

**Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).**

*Publication:* Inflamm Bowel Dis 2012 11; 18(11): 2043-2055. doi: 10.1002/ibd.22873.

*Authors:* Sussman DA, Kubiliun N, Mulani PM, Chao J, Gillis CA, Yang M, Lu M, M TA.

**Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain.**

*Publication:* Pain Medicine 2012 09; 13(9): 1110-1120. doi: 10.1111/j.1526-4637.2012.01454.x.

*Authors:* Kavanagh S, Kwong W, Hammond G, Nelson W, Upmalis D, Yang M.

**Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.**

*Publication:* Pain Pract 2012 09; 12(7): 533-540. doi: 10.1111/j.1533-2500.2011.00526.x.

*Authors:* Reed C, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Mullen RE, Swindle R.

**Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006.**

*Publication:* PharmacoEconomics 2012 04; 30(4): 323-336. doi: 10.2165/11589470-000000000-00000.

*Authors:* Birnbaum HG, Pike C, Banerjee R, Waldman T, Cifaldi M.

**Glucocorticoid-induced tumor necrosis factor receptor family-related protein exacerbates collagen-induced arthritis by enhancing the expansion of Th17 cells.**

*Publication:* Am J Pathol 2012 03; 180(3): 1059-1067. doi: 10.1016/j.ajpath.2011.11.018.

*Authors:* Wang S, Shi Y, Yang M, Ma J, Tian J, Chen J, Mao C, Jiao Z, Ko KH, Baidoo SE, Xu H, Hua Z, Lu L.

**Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.**

*Publication:* J Rheumatol 2011 10; 38(10): 2141-2149. doi: 10.3899/jrheum.101195.

*Authors:* McBride S, Sarsour K, White LA, Nelson DR, Chawla AJ, Johnston JA.

**Refractory gout brings economic pain.**

*Publication:* PharmacoEconomics & Outcomes News 2011 03; 623: 5.

*Authors:* Wu E.

**Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-alpha inhibitors.**

*Publication:* Arthritis Res Ther 2011 02; 13(1): R25. doi: 10.1186/ar3249.

*Authors:* Rendas-Baum R, Wallenstein GV, Koncz T, Kosinski M, Yang M, Bradley J, Zwillich SH.

**Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.**

*Publication:* Dermatology 2010 11; 220(1): 1-7. doi: 10.1159/000260371.

*Authors:* Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

**Societal cost of rheumatoid arthritis patients in the US.**

*Publication:* Current Medical Research & Opinion 2010 01; 26(1): 77-90. doi: 10.1185/03007990903422307.

*Authors:* Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M.

**Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis.**

*Publication:* Journal of Occupational Environmental Medicine 2009 10; 51(10): 1167-1176. doi: 10.1097/JOM.0b013e3181b8c397.

*Authors:* Birnbaum H, Pike C, Kaufman R, Cifaldi M.

**Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?**

*Publication:* J Rheumatol 2009 05; 36(5): 1032-1040. doi: 10.3899/jrheum.080487.

*Authors:* Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E.

**Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature.**

*Publication:* Expert Opin Pharmacother 2009 02; 10(2): 255-269. doi: 10.1517/14656560802682163.

*Authors:* Birnbaum H, Shi L, Pike C, Kaufman R, Sun P, Cifaldi M.

**Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States.**

*Publication:* J Occup Environ Med 2008 09; 50(9): 998-1005. e-pub ahead of print 2008/09/12; doi: 10.1097/JOM.0b013e3181715111.

*Authors:* White AG, Birnbaum HG, Janagap C, Buteau S, Schein J.

**Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.**

*Publication:* Current Medical Research & Opinion 2008 08; 24(8): 2229-2240. doi: 10.1185/03007990802229548.

*Authors:* Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.

**Disease-related and all-cause health care costs of elderly patients with gout.**

*Publication:* J Manag Care Pharm 2008 03; 14(2): 164-175.

*Authors:* Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, Krishnan E.

**Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.**

*Publication:* Current Medical Research & Opinion 2007 08; 23(8): 1749-1759. doi: 10.1185/030079907X210615.

*Authors:* Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.

**Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.**

*Publication:* Rheumatology (Oxford) 2006 10; 45(10): 1238-1246. doi: 10.1093/rheumatology/kel066.

*Authors:* Westhovens R, Cole JC, Li T, Martin M, Maclean R, Lin P, Blaisdell B, Wallenstein GV, Aranda R, Sherrer Y.

**Direct and indirect costs of rheumatoid arthritis to an employer.**

*Publication:* Journal of Occupational Environmental Medicine 2000 06; 42(6): 588-596.

*Authors:* Birnbaum HG, Barton M, Greenberg PE, Sisitsky T, Auerbach R, Wanke LA, Buatti MC.

## Abstracts

**Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous TNF Inhibitors.**

San Diego, CA September 7-10, 2023.

*Authors:* Walsh J, Lin I, Zhao R, Shiff NJ, Morrison L, Emond B, Yu L, Schwartzbein S, Lefebvre P, Pilon D, Chakravarty SD, Mease P.

**PREDICT-CU: Predicting time to clinical remission in chronic urticaria.**

Berlin, Germany December 7-8, 2022.

*Authors:* Pivneva I, Balp M-M, Geissbühler Y, Severin T, Smeets S, Signorovitch J, Cornwall T, Danyliv A, Walsh S, Soong W, Marsland AM.

**Economic burden associated with changes in Sjögren's disease activity among patients in a major Integrated Delivery Network in the United States.**

National Harbor, MD October 11-14, 2022.

*Authors:* Ndife B, Patel S, Pivneva I, Rossi C, Duna G, Lawrence M, Signorovitch J.

**Development of an administrative claims and electronic health record-based algorithm to classify systemic disease severity among patients with Sjögren's disease in an integrated delivery network in the United States.**

Washington, D.C. May 15-18 2022.

*Authors:* Ndife B, Pivneva I, Patel S, Rossi C, Duna G, Lawrence M, Signorovitch J.

**Economic Burden among Sjögren's Patients in an Integrated Delivery Network in the United States.**

*Abstract:* AMCP 2022, 2022 AMCP Annual Meeting March 29-April 1, 2022.

*Authors:* Ndife B, Pivneva I, Rossi C, Duna G, Lawrence M, Signorovitch J.

**Economic burden among Sjögren's patients in an Integrated Delivery Network in the United States**

Chicago, IL. March 29-April 1, 2022.

*Authors:* Ndife B, Patel S, Pivneva I, Rossi C, Duna G, Lawrence M, Signorovitch J.

**Assessment of EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Domains in Routine Clinical Practice in an Integrated Delivery Network in the United States.**

*Abstract:* American College of Rheumatology (ACR) Convergence 2021, Virtual November 3-11, 2021.

*Authors:* Ndife B, Pivneva I, Rossi C, Duna G, Lawrence M, Signorovitch J.

**Economic Benefit From Improvements in Health-Related Quality of Life With Upadacitinib and Comparisons to Tofacitinib and Methotrexate in Patients With Moderately to Severely Active Rheumatoid Arthritis.**

*Abstract:* European League Against Rheumatism (EULAR) Congress, Frankfurt, Germany June 3–6, 2020.

*Authors:* A. B, Yang M, Orvis E, Clewell J, Tundia N.

**Real-World Analysis of Treatment Switching among Patients Stable on Originator Infliximab (REMICADE®) Switching to an Infliximab Biosimilar or Remaining on Originator Infliximab.**

*Abstract:* AMCP 2020, Houston, TX April 21-24, 2020.

*Authors:* Emond B, Lafeuille M, Lefebvre P.

**Reasons for Initiation of Canakinumab of Patients with Systemic Juvenile Idiopathic Arthritis: A Retrospective Medical Chart Review from the United States.**

*Abstract:* 2019 ACR/ARP Annual Meeting, Atlanta, GA November 8–13, 2019.

*Authors:* Hur P, Ionescu-Iltu R, Manceur AM, Lomax KG, Cammarota J, Xie J, Sanghera N, Grom AA.

**A Retrospective Medical Chart Review of Patients with Periodic Fever Syndromes Initiating Canakinumab in the United States.**

*Abstract:* 2019 ACR/ARP Annual Meeting, Atlanta, GA November 8–13, 2019.

*Authors:* Hur P, Lomax KG, Ionescu-Iltu R, Manceur AM, J. X, Cammarota J, Sanghera N, Grom AA.

**Early Predictors of Sjogren's Syndrome: A Machine Learning Approach.**

*Abstract:* ISPOR 24th Annual International Meeting, New Orleans, LA May 18-22, 2019.

*Authors:* Royer JS, J; Pivneva, I; Huber, W; Capkun, G.

**Comparison of real-world treatment outcomes with infliximab vs. vedolizumab in biologic-naive patients with inflammatory bowel disease.**

*Abstract:* 14th Congress of ECCO - Inflammatory Bowel Diseases 2019, Copenhagen, Denmark Mar 6-9, 2019.

*Authors:* Latremouille-Viau D, Burne R, Shi S, Adsul S, Patel H.

**A systematic literature review to assess long-term outcomes associated with splenectomy in patients with chronic immune thrombocytopenia.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Nellesen D, Said Q, Shak N, Patton C, Lucas S, Graves JA, Nezami B, Cuker A.

**Incidence of inflammatory bowel disease (IBD) among patients (PTS) with other chronic inflammatory diseases (CID) treated with interleukin-17A (IL-17A) or phosphodiesterase 4 (PDE4) inhibitors.**

*Abstract:* ACR/ARHP Annual Meeting, Chicago, IL Oct 19-24, 2018.

*Authors:* Emond B, Ellis LA, Chakravarty SD, Ladouceur M, Lefebvre P.

**Inflammatory bowel disease is associated with a substantial economic burden in patients with psoriatic arthritis and in patients with ankylosing spondylitis.**

*Abstract:* ACR/ARHP Annual Meeting, Chicago, IL Oct 19-24, 2018.

*Authors:* Bergman MJ, Zueger P, Song J, Pivneva I, Betts KA, Joshi AD.

**Network meta-analysis of targeted immunomodulators in the treatment of psoriatic arthritis patients without prior biologic treatment.**

*Abstract:* ACR/ARHP Annual Meeting, Chicago, IL Oct 19-24, 2018.

*Authors:* Strand V, Husni ME, Griffith J, Song Y, Singh R, Zhao J, Betts KA.

**Upadacitinib monotherapy improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to methotrexate.**

*Abstract:* ACR/ARHP Annual Meeting, Chicago, IL Oct 19-24, 2018.

*Authors:* Strand V, Buch M, Tundia N, Camp HS, Suboticki J, Goldschmidt D, Wells AF.

**Estimating the economic value of a patient support program in rheumatoid arthritis in the United Kingdom.**

*Abstract:* Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, Netherlands Jun 13-16, 2018.

*Authors:* Ostor A, Garg V, Yang M, Chamberlain C, Skup M.

**Estimating the short-term costs associated with non-medical switching in rheumatic diseases.**

*Abstract:* Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, Netherlands Jun 13-16, 2018.

*Authors:* Gibofsky A, Garg V, Yang M, Qi CZ, Skup M.

**Patient reported outcomes of upadacitinib: Results from biologic inadequate responders (select beyond phase iii trial).**

*Abstract:* Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, Netherlands Jun 13-16, 2018.

*Authors:* Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, Song Y, Pope J.

**Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs: Results from selectnext.**

*Abstract:* Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, Netherlands Jun 13-16, 2018.

*Authors:* Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M.

**Burden of Illness of Systemic Sclerosis with Interstitial Lung Disease among Commercially Insured Patients.**

*Abstract:* American Thoracic Society International Conference, San Diego, CA May 19-23, 2018.

*Authors:* Zhou Z, Yu Y, Liu X, Tang W, Zhou Z, Thomason D, Macaulay D, Fischer A.

**Burden of Work Instability in Patients with Rheumatoid Arthritis in US and Its Association with Work Productivity and Transitions.**

*Abstract:* Academy of Managed Care & Specialty Pharmacy Annual Meeting, Boston, MA April 23-26, 2018.

*Authors:* Tundia N, Zhou J, Yang M, Macaulay D, JR C.

**Patterns of Immunosuppressive Therapy among Patients with Newly Diagnosed Systemic Sclerosis (SSc) and SSc-Associated Interstitial Lung Disease (SSc-ILD).**

*Abstract:* AMCP's 30th Annual Meeting, Boston, MA Apr 23-26, 2018.

*Authors:* Thomason D, Yu Y, Zhou Z, Tang W, Liu X, Zhou Z, Macaulay D, Fischer A.

**Burden of illness of systemic sclerosis among commercially insured patients.**

*Abstract:* 5th Systemic Sclerosis World Congress, Bordeaux, France Feb 15-17, 2018.

*Authors:* Yu Y, Tang W, Liu X, Zhou Z, MacAulay D, Fischer A.

**Economic burden of illness among commercially-insured patients with systemic sclerosis in the United States.**

*Abstract:* Systemic Sclerosis World Congress, 5th Annual, Bordeaux, France February 15-17, 2018.

*Authors:* Zhou Z, Yu Y, Tang W, Liu X, Thomason D, Zhou Z, Macaulay D, Fischer A.

**Association of corticosteroid exposure with ophthalmologic complications and systemic adverse events in non-infectious uveitis patients using administrative claims in the United States.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting, San Diego, CA Nov 3-8, 2017.

*Authors:* Acharya N, Betts KA, Patterson-Lomba O, Ganguli A, Schonfeld S, Griffith J.

**Quantifying clinical and economic outcomes associated with chronic corticosteroid exposure in a US population.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting, San Diego, CA Nov 3 - 8, 2017.

*Authors:* Rice JB, White A, Lopez A, Wagh A, Qin Y, Mitri G, Bartels-Peculis L, Ciepielewska G, Nelson W.

**Burden of high disease activity in systemic lupus erythematosus (SLE): Results of a targeted literature review.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Tan R, Adamski K, Tuttle E, Guenther O, Henke C.

**Network meta-analysis of targeted immunomodulators in the treatment of biologic-naïve psoriatic arthritis.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting, San Diego, CA Nov 3-8, 2017.

*Authors:* Strand V, Husni ME, Singh R, Betts K, Song Y, Griffith J, Ganguli A.

**HPR predicting the future development of spondyloarthritis among patients with idiopathic acute anterior uveitis using real-world data.**

*Abstract:* Annual European Congress of Rheumatology, Madrid, Spain June 14-17, 2017.

*Authors:* Haroon M, Betts KA, Mu F, Skup M, Anderson JK, Joshi AD.

**Association between disease activity level improvement and reduction in healthcare resource utilization in patients with rheumatoid arthritis receiving targeted therapy.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Lopez A, Priest J, Duh MS, McDonnell E, Bobbili PJ, Haider BA, Sundaresan D, Yood RA, Reed JI.

**The economic burden of dermatomyositis and polymyositis in the US.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting, Washington, DC Nov 11-16, 2016.

*Authors:* Rice JB, White A, Galebach P, Lopez A, Schepman P, Popelar B, Philbin M, Boing E.

**Economic burden of non-responders to biologic DMARD treatments in rheumatoid arthritis.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting, Washington, DC Nov 11-16, 2016.

*Authors:* Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M.

**Thresholds of benefit-risk trade-offs from the patient perspective for treatment decisions in moderate-to-severe rheumatoid arthritis.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting, Washington, DC Nov 11-16, 2016.

*Authors:* Husni ME, Griffith J, Betts K, Song Y, Ganguli A.

**Incremental benefit of radiographic inhibition on long-term outcomes in patients with rheumatoid arthritis.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting, Washington, DC Oct 11-16, 2016.

*Authors:* Keystone EC, Betts KA, Schlacher CA, Song Y, Ganguli A, Griffith J.

**Prediction of flaring in rheumatoid arthritis patients upon biologics dose tapering: a chart review study in Taiwan.**

*Abstract:* European League Against Rheumatism Congress, London, UK Jun 8-11, 2016.

*Authors:* Chang C, Chen K, Chen Y, Cheng T, Hsu P, Lai N, Lan J, Lee C, Lee S, Lin H, Tsay G, Yen J, Tsai C, Garg V, Bao Y, Yang M, Wun EQ.

**Real-world Impact of Taiwan Health Policy on Dose Tapering and Withdrawing Biologics in Rheumatoid Arthritis Patients: A Retrospective Chart Review Study.**

*Abstract:* European League Against Rheumatism Congress, London, UK Jun 8-11, 2016.

*Authors:* Chang C, Chen K, Chen Y, Cheng T, Hsu P, Lai N, Lan J, Lee C, Lee S, Lin H, Tsay G, Yen J, Tsai C, Bao Y, Skup M, Yang M, Wu EQ, wGarg V.

**Relative efficacy of adalimumab versus secukinumab in active ankylosing spondylitis: A matching-adjusted indirect comparison.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, London, UK Jun 8-11, 2016.

*Authors:* Betts KA, Mittal M, Song J, Skup M, Joshi A.

**Comparison of Annual Treatment Costs for Patients Treated with Infusion versus Injectable Biologics.**

*Abstract:* Academy of Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, CA Apr 19-22, 2016.

*Authors:* Skup M, Macaulay D, Wei J, Terasawa E, Chao J.

**Clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for non-medical reasons in psoriatic disease patients.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Lewwohl M, Skup M, Sundaram M, Yang H, Faust E, Kageleiry A, Chao J, Wolf D.

**Effects of Adalimumab on Health-related Quality of Life in Psoriasis Patients With and Without Comorbid Psoriatic Arthritis: Value of Reducing PASI Scores and Systemic Inflammation.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington DC March 4-8, 2016.

*Authors:* Okun M, Yang M, Koo V, Sundaram M, Signorovitch J.

**Evaluation of timely versus delayed use of tumor necrosis factor inhibitors in the treatment of psoriatic arthritis: Economic and clinical results from a modeling study.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Strand V, Husni ME, Griffith J, Zhou ZY, Signorovitch J, Ganguli A.

**Network Meta-Analysis and Cost per Responder of Tumor Necrosis Factor, Interleukin, and Phosphodiesterase Inhibitors in the Treatment of Psoriatic Arthritis.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington DC Mar 4-8, 2016.

*Authors:* Strand V HM, Betts K, Griffith J, Song Y, Beppu M, Ganguli A.

**Relative efficacy of adalimumab versus secukinumab in active psoriatic arthritis: A matching-adjusted indirect comparison.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Betts K, Mittal M, Joshi A, Song J, Bao Y.

**Comorbidity burden and medication use among patients with psoriatic arthritis in the US.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting San Francisco, CA Nov 6-11, 2015.

*Authors:* Merola J, Han S, Xie J, Song H, Herrera V, Wei J, Wu EQ, Palmer JB.

**Economic Burden and Treatment Patterns of Cycling between Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) among Patients with Rheumatoid Arthritis (RA).**

*Abstract:* ACR Annual Meeting, San Francisco, CA Nov 6-11, 2015.

*Authors:* Li N, Betts KA, Griffith J, Ristovska L, Douglas K, Ganguli A.

**Economic Impact of Expanded Use of Biologic Therapy for Crohn's Disease In Latin American Countries.**

*Abstract:* ISPOR 5th Latin America Conference, Santiago, Chile Sept 6-8, 2015.

*Authors:* Kotze PG, Tundia N, Gumen A, Macaulay D, Chaves L, Bao Y.

**Network Meta-Analysis of Tumor Necrosis Factor, Interleukins, and Phosphodiesterase-4 Inhibitor in the Treatment of Psoriatic Arthritis.**

*Abstract:* ACR/ARHP Annual Meeting, San Francisco, CA Nov 7-11, 2015.

*Authors:* Strand V, Husni ME, Reichmann W, Betts K, Griffith J, Song Y, Beppu M, Ganguli A.

**Relative efficacy of adalimumab versus secukinumab in active psoriatic arthritis: A matching-adjusted indirect comparison.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting, San Francisco, CA Nov 6-11, 2015.

*Authors:* Betts KA, Mittal M, Joshi A, Song J, Bao Y.

**Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured population in the US.**

*Abstract:* AMCP Nexus 2015, Orlando, FL Oct 26-29, 2015.

*Authors:* Bradford Rice J, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M.

**Impact of Taiwan health policy for dose tapering and withdrawing biologics in rheumatoid arthritis patients: A real-world chart review study.**

*Abstract:* 17th Congress of the Asia Pacific League of Associations for Rheumatology in Conjunction with IRA Annual Congress, Chennai, India Sep 6-9, 2015.

*Authors:* Chang CC, Chen KH, Chen YH, Cheng TT, Hsu PN, Lai NS, Lan JL, Lee CS, Lee SS, Lin HY, Tsay GJ, Yen JH, Bao YJ, Tundia N, Yang M, Macaulay D, Huang YC, Garg V.

**Projected economic impact of increased use of biologic treatments for rheumatoid arthritis in Argentina, Colombia, and Mexico over 10 years.**

*Abstract:* ISPOR 5th Latin America Conference, Santiago, Chile Sep 6-8, 2015.

*Authors:* Rojas Serrano J, de Abreu M, Tundia N, Skup M, Sorg R, Macaulay D, Bao Y, Chaves L, Chao J.

**Short-term clinical outcomes and healthcare resource utilization in patients with rheumatoid arthritis tapering anti-TNF agents in Taiwan.**

*Abstract:* 17th Asia Pacific League of Associations for Rheumatology Congress, Chennai, India Sep 6-9, 2015.

*Authors:* Chang C, Chen K, Chen Y, Cheng T, Hsu P, Lai N, Lan J, Lee C, Lee S, Lin H, Tsay G, Yen J, Bao Y, Tundia N, Yang M, Macaulay D, Huang Y, Garg Vishvas.

**Assessment of salary growth in patients with ankylosing spondylitis treated with and without anti-tumor necrosis factor therapy.**

*Abstract:* European League Against Rheumatism Congress, Rome, Italy Jun 10-13, 2015.

*Authors:* Deodhar A, Mittal M, Joshi A, Signorovitch JE, Yang M, Bao Y.



**Economic evaluation of timely versus delayed use of anti-tumor necrosis factor (TNF) biologics in the treatment of psoriatic arthritis (PSA) in the US.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Zhou Z, Signorovitch JE, Griffith JM, Zhong Y, Ganguli A.

**Comparison of Annual Treatment Costs for Patients Treated with Infusion versus Injectable Biologics. .**

*Abstract:* AMCP's 27th Annual Meeting, San Diego, CA Apr 7-10, 2015.

*Authors:* Macaulay D, Wei J, Terasawa E.

**Indirect Treatment Comparison of Adalimumab, Etanercept, Certolizumab, Golimumab, and Infliximab for the Treatment of Ankylosing Spondylitis.**

San Diego, CA Apr 7-10, 2015.

*Authors:* Betts KA, K. H.

**Network Meta-Analysis and Cost per Responder of Tumor Necrosis Factor and Phosphodiesterase Inhibitors in the Treatment of Psoriatic Arthritis.**

*Abstract:* AMCP's 27th Annual Meeting, San Diego, CA Apr 7-10, 2015.

*Authors:* Betts K, Reichmann W, Guo J.

**Comorbid psoriatic arthritis significantly impairs health-related quality of life in patients with moderate to severe psoriasis.**

*Abstract:* 73rd Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 20-24, 2015.

*Authors:* Kimball AB, Sundaram M, Signorovitch J, Yang M, Taska B.

**Rates and risk factors of PsA disease progression amongst newly diagnosed PsA patients.**

*Abstract:* 73rd Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 20-24, 2015.

*Authors:* Meroloa J, Guerin A, Sundaram M, Jarvis J, Cummings AK, Ghorayeb E.

**Clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for non-medical reasons.**

*Abstract:* 10th Congress of the European Crohn's and Colitis Organisation, Barcelona, Spain Feb 18-21, 2015.

*Authors:* Wolf D, Skup M, Yang H, Faust E, Kageleiry A, Chao J, Lebowohl M.

**Economic implications of flares among patients with early rheumatoid arthritis (ra).**

*Abstract:* 2014 ACR/ARHP Annual Meeting, Boston, MA Nov 14-19, 2014.

*Authors:* Signorovitch J, Betts K, Garg V, Bao Y.

**An indirect comparison and cost per responder analysis of adalimumab, methotrexate (MTX) and apremilast in the treatment of MTX-naïve psoriatic arthritis (PSA) patients.**

*Abstract:* 2014 ACR/ARHP Annual Meeting Boston, MA Nov 14-19, 2014.

*Authors:* Strand V, Griffith J, Betts K, Friedman A, Signorovitch J, Ganguli A.

**Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment.**

*Abstract:* International Congress of Drug Therapy in HIV Infection 2014 Glasgow, UK Nov 2-6, 2014.

*Authors:* Sweet D, Song J, Zhong Y, Signorovitch J.

**ASAS40 and ASDAS responses are associated with improved physical function, HRQOL, and work productivity in patients with non-radiographic axial spondyloarthritis.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Paris, France June 11-14, 2014.

*Authors:* Van Der Heijde D, Joshi A, Mittal M, Pangan A, Chen N, Betts K, Qi C, Bao Y.

**Claims database analysis of adherence to adalimumab therapy and health care costs for patients with rheumatoid arthritis.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Paris, France Jun 11-14, 2014.

*Authors:* Liu Y, Tundia N, Skup M, Ayyagari R, Du EX, Chao J, Mulani P, Bao Y.

**A prediction model that identifies patients most likely to benefit from first-line therapy with adalimumab plus methotrexate in early rheumatoid arthritis.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Paris, France Jun 11-14, 2014.

*Authors:* Van Vollenhoven RF, Betts K, Signorovitch J, Bao C, Shaw JW, Ganguli A.

**Real-world risk of fall-related injuries among rheumatoid arthritis (RA) patients treated with tumor necrosis factor inhibitors (anti-TNFs) or methotrexate (MTX).**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Paris, France Jun 11-14, 2014.

*Authors:* Bao Y, Ganguli A, De G, Kelkar S, Curtis JR.

**Real-world persistence with single versus multiple tablet regimens for HIV-1 treatment.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Sweet DE, Kim Y, Song J, Zhong Y, Signorovitch J.

**The economic burden of osteoarthritis in Americans: Analysis from a privately insured population.**

*Abstract:* 2014 Osteoarthritis Research Society International World Congress, Paris, France Apr 24-27, 2014.

*Authors:* Wang SX, Ganguli AX, Macaulay D, Reichmann W, Medema JK, Cifaldi MA.

**Real-world treatment patterns during and after an emergency room or acute care facility visit for gout.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Krishnan E, Cloutier M, Gu erin A, H eroux J.

**Incremental burden of psoriatic arthritis is substantial among patients with mild and moderate to severe psoriasis.**

*Abstract:* 72nd Annual Meeting of the American Academy of Dermatology, Denver, CO Mar 21-25, 2014.

*Authors:* Merola J, Guerin A, Jarvis JL, Wang K, Sundaram M.

**Cost-per-responder analysis of biological agents for the treatment of active ankylosing spondylitis in Germany.**

*Abstract:* ISPOR 16th Annual European Congress, Dublin, Ireland Nov 2-6, 2013.

*Authors:* Betts KA, Joshi AD, Yan SY, Zhou Z, Rao S, Wolff M, Cifaldi M.

**Indirect comparison of joint damage prevention with adalimumab v. Abatacept, each in combination with methotrexate, in early rheumatoid arthritis.**

*Abstract:* ISPOR 16th Annual European Congress, Dublin, Ireland Nov 2-6, 2013.

*Authors:* Wu EQ, Cifaldi M, Diener M, Kaltenboeck A, Ganguli A, Bergman M.

**Assessment of wage and salary growth in patients with rheumatoid arthritis (RA).**

*Abstract:* American College of Rheumatology Annual Scientific Meeting San Diego, CA Oct 25-30, 2013.

*Authors:* Bergman MJ, De G, Ganguli A, Signorovitch J, Bao Y.

**Cost-effectiveness of different treatment sequences including adalimumab in the treat-to-target framework for early rheumatoid arthritis in Germany.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting San Diego, CA Oct 25-30, 2013.

*Authors:* Wolff M, Zhou ZY, Signorovitch J, Shaw JW, Ganguli A.

**The economic burden of osteoarthritis in Americans: Analysis from a privately insured population.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting San Diego, CA Oct 25-30, 2013.

*Authors:* Wang SX, Ganguli AX, Macaulay D, Reichmann W, Medema J, Cifaldi MA.

**Spondyloarthritis epidemiology and burden phase 2 [speed 2] study: Disease progression in axial spondyloarthritis (SpA).**

*Abstract:* American College of Rheumatology Annual Scientific Meeting San Diego, CA Oct 25-30, 2013.

*Authors:* Ruderman E, Strand V, Joshi A, Bao Y, Betts K, Chopra P, McGuire MB, Rao SA.

**Clinical outcomes and healthcare utilization following early versus late diagnosis of systemic lupus.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism Berlin, Germany Jun 6-9, 2012.

*Authors:* Korves C, Laliberte F, Suthoff E, Wei R, Oglesby A, Dennis G, Duh MS.

**Effect of adalimumab on physical function, health-related quality of life, and work productivity in patients with peripheral spondyloarthritis: Results from the ability-2 clinical trial.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Madrid, Spain Jun 12-15, 2013.

*Authors:* Mease PJ, Rao S, Betts KA, Lu M, Fan L, Pangan AL, Van Der Heijde D, Cifaldi MA.

**The effect of adalimumab on risk of major adverse cardiovascular events in rheumatoid arthritis: A meta-analysis of randomized trials.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 2012.

*Authors:* Burmester G, Emery P, Signorovitch J, Williams D, Valdes J, Bao Y, Mulani PM.

**Progression from undifferentiated spondyloarthritis to ankylosing spondylitis: Is USPA a proxy for non-radiographic axial SPA?**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 2012.

*Authors:* Boonen A, Kirson NY, Rao SA, Birnbaum HG, Swallow E, Yushkina Y, Jarvis J, Mease PJ, Cifaldi MA.

**Switching from adalimumab to other disease-modifying antirheumatic drugs without apparent medical reasons in rheumatoid arthritis: Impact on health care service use.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 2012.

*Authors:* Signorovitch J, Bao Y, Samuelson T, Mulani PM.

**Treatment patterns in psoriatic arthritis (PSA) patients newly initiated on oral disease-modifying anti-rheumatic drugs (DMARDs).**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 2012.

*Authors:* Zhang F, Guerin A, Gauthier G, Curtis J.

**Use of anti-TNF therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 2012.

*Authors:* Nurmohamed MT, Bao Y, Signorovitch J, Mulani PM, Furst DE.

**Health care resource utilization (HRU) and costs associated with disease activity in systemic lupus erythematosus (SLE): A retrospective observational cohort analysis.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Kan H, Guerin A, Kaminsky M, Yu AP, Wu EQ, Denio AE, Jhingran PM, Narayanan S, Molta CT.

**Matching-adjusted indirect comparison of lipid profile at 48 weeks among treatment naive HIV-1 patients treated with atazanavir/ritonavir versus darunavir/ritonavir.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Xie J, Juday TR, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.

**Benefits of treat-to-target guideline compliance in patients with rheumatoid arthritis: A retrospective claims analysis.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14, 2012.

*Authors:* Bergman MJ, Shaw JW, Cifaldi MA, Guerin A, Chopra P, Signorovitch J.

**Comparison of rheumatoid arthritis-related health care resource use and comorbidities among patients with rheumatoid arthritis treated with adalimumab vs etanercept.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14, 2012.

*Authors:* Xie J, Ganguli A, Yang H, Parikh K, Wu EQ, Cifaldi M.

**Differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012, Washington, DC Nov 9-14, 2012.

*Authors:* Van Vollenhoven RF, Shaw JW, Cifaldi MA, Signorovitch J, Wu EQ, Samuelson T, Faust E, Emery P.

**Health care costs in psoriatic arthritis (PSA) patients newly initiated on a biologic disease-modifying anti-rheumatic drug (DMARDs) or methotrexate (MTX).**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Zhang F, Hiscock R, Curtis J.

**Healthcare costs in psoriatic arthritis patients newly initiated on a biologic disease-modifying anti-rheumatic drug or methotrexate.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14, 2012.

*Authors:* Zhang F, Hiscock R, Curtis J.

**Patient-reported outcomes associated with achieving and maintaining low disease activity in rheumatoid arthritis.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14 2012.

*Authors:* Bergman MJ, Shaw JW, Cifaldi M, De G, He T, Ayyagari R, Signorovitch J.

**Risk differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone.**

*Abstract:* 2012 ACR/ARHP Annual Meeting, Washington, DC Nov 9-14, 2012.

*Authors:* Van Vollenhoven R, Shaw JW, Cifaldi MA, Signorovitch JE, Wu EQ, Samuelson TM, Faust E, Emery P.

**Treatment patterns in psoriatic arthritis (PSA) patients newly initiated on non-biologic disease modifying anti-rheumatic drugs (DMARDs).**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Curtis J, Gauthier G, Hiscock R, Zhang F.

**Treatment patterns in psoriatic arthritis patients newly initiated on non-biologic disease-modifying anti-rheumatic drugs.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14, 2012.

*Authors:* Curtis J, Gauthier G, Hiscock R, Zhang F.

**Use of anti-tumor necrosis factor therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14, 2012.

*Authors:* Nurmohamed MT, Bao Y, Signorovitch J, Mulani PM, Furst DE.

**Adherence to subcutaneous vs. Oral disease-modifying antirheumatic drugs in rheumatoid arthritis.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 2012.

*Authors:* Bergman M, Bao Y, Ayyagari R, Mulani PM.

**Impact of early versus late systemic lupus erythematosus (SLE) diagnosis on clinical and economic outcomes.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Oglesby AK, Dennis GL, Korves C, Laliberte F, Suthoff ED, Wei R, Duh MS.

**Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

**Variation in the use of biologics in the management of rheumatoid arthritis across the United Kingdom.**

*Abstract:* British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meeting, Glasgow, UK May 1-3, 2012.

*Authors:* Choy E, McAuliffe S, Roberts K, Sargeant I.

**Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.**

*Abstract:* 70th Annual Meeting of the American Academy of Dermatology, San Diego, CA Mar 16-20, 2012.

*Authors:* Guerin A, Zhang F, Gauthier G, Day R, Khan Z.

**Adalimumab sustains deep remission for 3 years: Data from CHARM and ADHERE.**

*Abstract:* 7th Congress of ECCO European Crohn's and Colitis Organization, Barcelona, Spain Feb 16-18, 2012.

*Authors:* Sandborn WJ, Colombel J-F, Louis E, Panaccione R, Yang M, Chao J, Thakkar R, Robinson A, Pollack P, Mulani PM.

**Economic burden of psoriatic arthritis and diabetes in patients with psoriatic arthritis in the United States.**

*Abstract:* ACR/ARHP Annual Scientific Meeting, Chicago, IL Nov 4-9, 2011.

*Authors:* Guérin A, Gauthier G, Day R, Khan Z, Zhang F.

**Economic burden of psoriatic arthritis and obesity in patients with psoriatic arthritis in the United States.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL Nov 4-9, 2011.

*Authors:* Zhang F, Guerin A, Latremouille-Viau D, Day RR, Khan Z.

**Prevalence of autoimmune diseases and other comorbidities in patients with psoriatic arthritis in the United States.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL Nov 4-9, 2011.

*Authors:* Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

**Uncontrolled serum uric acid in veteran gout patients is associated with a higher risk of diabetes.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL Nov 4-9, 2011.

*Authors:* Pandya BJ, Marynchenko M, Sharma H, Yu A, Wu E, Shi L, Liu J.

**Uncontrolled serum uric acid is associated with an increased risk of developing renal disease in veterans with gout.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL Nov 4-9, 2011.

*Authors:* Krishnan E, Sharma H, Pandya BJ, Marynchenko M, Yu A, Wu E, Liu J.

**Economic model of workplace impacts of anti-TNF therapy for rheumatoid arthritis in Brazil.**

*Abstract:* ISPOR 3rd Latin America Conference Mexico City, Mexico Sep 8-10, 2011.

*Authors:* Teich V, Chaves L, Birnbaum H, Pike C, Waryas C, Cifaldi M.

**Indirect comparison of adalimumab versus etanercept for the treatment of psoriatic arthritis.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Kirson NR, S.; Birnbaum, H. G.; Kantor, E.; Wei, R.; Cifaldi, M.

**Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.**

*Abstract:* 30th Annual Scientific Meeting of the American Pain Society, Austin, TX May 19-21, 2011.

*Authors:* Swindle R, Birnbaum H, Ivanova J, Schiller M, Waldman T, Mullen R, Reed C.

**Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (Compairs).**

*Abstract:* Annual General Meeting of the British Society of Gastroenterology Conference, Birmingham, UK Mar 14-17, 2011.

*Authors:* Sussman DA, Kubiliun N, Chao J, Mulani PM, Gillis CA, Yang M, Lu M, Abreu MT.

**Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (compairs).**

*Abstract:* 75th Annual Scientific Meeting of the American College of Gastroenterology, San Antonio, TX Oct 15-20, 2010.

*Authors:* Sussman D, Kubiliun N, Chao J, Mulani P, Gillis C, Yang M, Lu M, Abreu M.

**Direct and indirect costs of spondyloarthritis patients pre-and post-diagnosis.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting Philadelphia, PA Oct 16-21, 2009.

*Authors:* Kirson N, Birnbaum H, Rao S, Swallow E, Waldman T, Dayoub E, Cifaldi M.

**Evaluation of cardiovascular diseases (CVDs) risk for patients with fibromyalgia syndrome in the United States.**

*Abstract:* 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Brighton, UK Aug 19-22, 2010.

*Authors:* Mease PJ, Duh MS, Vekeman F, Lefebvre P, Laliberte F, Boerstael-Streefland M, Jiang W, Zimetbaum PJ.

**Diagnostic and resource use profiles before and after diagnosis of spondyloarthritis.**

*Abstract:* European League Against Rheumatism Congress, Rome, Italy Jun 16-19, 2010.

*Authors:* Kirson N, Birnbaum H, Rao S, Swallow K, Waldman T, Dayoub E, Cifaldi M.

**Longer psoriasis duration is independently associated with greater persistent functional impairment in patients with psoriatic arthritis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Signorovitch J, Mulani P, Bao Y.

**Changes in health care utilization and costs for employed patients with rheumatoid arthritis from 1997-2006.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting Atlanta, GA Nov 6-11, 2010.

*Authors:* Birnbaum H, Pike C, Banerjee R, Waldman T, Cifaldi M.

**The costs of treatment failure gout: A claims-based analysis.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting Atlanta, GA Nov 6-11, 2010.

*Authors:* Wu EQ, Yu AP, Guerin A, Latremouille-Viau D, Tsaneva M, Forsythe A.

**Societal cost of rheumatoid arthritis (RA) in the United States: Methodology for incorporating intangible costs.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M.

**Impact of adalimumab treatment in the workplace in patients with rheumatoid arthritis.**

*Abstract:* British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meeting, Glasgow, UK Apr 28 - May 1, 2009.

*Authors:* Cifaldi MA, Birnbaum H, Pike C, Kaufman R, Schiller M, Shi L, Sun P, Ray S.

**Adalimumab reduces symptoms of depression in patients with moderate to severe psoriasis.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Menter A, Signorovitch J, Mulani P, Gupta S.

**Adalimumab reduces symptoms of psoriatic arthritis among psoriasis patients with comorbid psoriatic arthritis.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Mease P, Signorovitch J, Mulani P, Gupta S.

**The effect of adalimumab treatment for moderate to severe psoriasis on concurrent response for both psoriasis and psoriatic arthritis.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 3-10, 2009.

*Authors:* Mease P, Signorovitch J, Mulani P, Gupta S.

**Cost and Risk of Gout Flares among the Elderly: Does Serum Uric Acid Level Matter?**

*Abstract:* American Geriatrics Society Annual Scientific Meeting, Seattle, WA May 2-6, 2007.

*Authors:* Wu EQ, Patel P, Krishnan E, Yu AP, Cahill KE, Tang J, Mody R.

**Healthcare Cost of Gout in an Elderly Population: A Claims Database Analysis.**

*Abstract:* American Geriatrics Society Annual Scientific Meeting, Seattle, WA May 2-6, 2007.

*Authors:* Wu EQ, Patel P, Krishnan E, Yu AP, Cahill KE, Tang J, Mody R.

**Treatment Cost of Gout in an Elderly Population: A Claims Database Analysis.**

*Abstract:* American Geriatrics Society Annual Scientific Meeting, Seattle, WA May 2-6, 2007.

*Authors:* Wu EQ, Patel P, Krishnan E, Yu AP.

## Cardiovascular

### Journal Articles

**Real-World Incidence of Adverse Clinical Outcomes Among People With Coronary Artery Disease and/or Peripheral Artery Disease in Relation to Vascular Risk in the United States.**

*Publication:* Am J Cardiol 2023 10; 208: 44-52. e-pub ahead of print 2023/10/10; doi: 10.1016/j.amjcard.2023.08.110.

*Authors:* Desai U, Babcock A, Wang Y, Akbarnejad H, Lemus Wirtz E, Laliberte F, Lefebvre P, Kharat A.

**Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis.**

*Publication:* Adv Ther 2023 09. doi: 10.1007/s12325-023-02658-z.

*Authors:* Sargent T, Tsang Y, Panjabi S, Funtanilla V, Germack HD, Gauthier-Loiselle M, Manceur AM, Cloutier M, Lefebvre P.

**Ischemic stroke and systemic embolism among patients with non-valvular atrial fibrillation who abandon oral anticoagulant therapy.**

*Publication:* Curr Med Res Opin 2023 08: 1-13. e-pub ahead of print 2023/08/17; doi: 10.1080/03007995.2023.2247967.

*Authors:* Alberts MJ, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, Kharat A.

**Unintended Consequences of Increased Out-of-Pocket Costs During Medicare Coverage Gap on Anticoagulant Discontinuation and Stroke.**

*Publication:* Adv Ther 2023 08. e-pub ahead of print 2023/08/12; doi: 10.1007/s12325-023-02620-z.

*Authors:* Salam T, Desai U, Lefebvre P, Jian-Yu E, Greatsinger A, Zacharia N, Laliberté F, Bookhart B, Kharat A.

**Real-World Treatment Patterns and Switching Following Moderate/Severe Chronic Obstructive Pulmonary Disease Exacerbation in Patients with Commercial or Medicare Insurance in the United States.**

*Publication:* Int J Chron Obstruct Pulmon Dis 2023 07; 18: 1575-1586. e-pub ahead of print 2023/07/31; doi: 10.2147/copd.S398816.

*Authors:* Bogart M, Germain G, Laliberté F, Lejeune D, Duh MS.

**Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD).**

*Publication:* Pulm Circ 2023 04; 13(2): e12218. e-pub ahead of print 2023/04/14; doi: 10.1002/pul2.12218.

*Authors:* Tsang Y, Panjabi S, Funtanilla V, Germack HD, Gauthier-Loiselle M, Manceur AM, Liu S, Cloutier M, Lefebvre P.

**Heart Failure Across the Range of Mildly Reduced and Preserved Ejection Fraction in the United States.**

*Publication:* Circ Heart Fail 2023 04: e010430. e-pub ahead of print 2023/04/20; doi: 10.1161/circheartfailure.123.010430.

*Authors:* Greene SJ, Spertus JA, Tang W, Kang A, Zhong Y, Myers MC, Shen S, Jiang J, Liu X, Steffen DR, Viola MG, Felker GM.

**Association of Serum Calcium and Phosphate With Incident Cardiovascular Disease in Patients With Hypoparathyroidism.**

*Publication:* Am J Cardiol 2023 03; 194: 60-70. e-pub ahead of print 2023/03/30; doi: 10.1016/j.amjcard.2023.01.029.

*Authors:* Kaul S, Ayodele O, Chen K, Cook EE, Swallow E, Rejnmark L, Gosmanova EO.

**Ischemic Stroke and Systemic Embolism Among One-and-Done Direct Oral Anticoagulant Users with Non-valvular Atrial Fibrillation.**

*Publication:* Adv Ther 2023 03. e-pub ahead of print 2023/03/23; doi: 10.1007/s12325-023-02483-4.

*Authors:* Alberts M, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, Kharat A.

**Real-World Racial Variation in Treatment and Outcomes Among Patients with Peripheral Artery Disease.**

*Publication:* Adv Ther 2023 03. doi: 10.1007/s12325-023-02465-6.

*Authors:* Ferdinand KC, Sadik K, Browne R, Desai U, Lefebvre P, Lejeune D, Mahendran M, Laliberté F, Matay L, Armstrong DG.

**Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States.**

*Publication:* J Med Econ 2023 02; 26(1): 682-690. e-pub ahead of print 2023/05/12; doi: 10.1080/13696998.2023.2208966.

*Authors:* Naidu SS, Sutton MB, Gao W, Fine JT, Xie J, Desai NR, Owens AT.

**Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States.**

*Publication:* Am J Cardiol 2023 01; 192: 16-23. e-pub ahead of print 2023/01/30; doi: 10.1016/j.amjcard.2022.12.030.

*Authors:* Desai NR, Sutton MB, Xie J, Fine JT, Gao W, Owens AT, Naidu SS.



**Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: A retrospective United States claims database analysis.**

*Publication:* Clin Respir J 2022 11. e-pub ahead of print 2022/11/24; doi: 10.1111/crj.13554.

*Authors:* Thompson-Leduc P, Ghaswalla P, Cheng WY, Wang MJ, Bogart M, Patterson BJ, Duh MS, Park S, Yawn BP.

**Payer Formulary exclusions of apixaban: how patients respond and potential implications.**

*Publication:* Curr Med Res Opin 2022 09: 1-10. e-pub ahead of print 2022/09/28; doi: 10.1080/03007995.2022.2128189.

*Authors:* Deitelzweig S, Terasawa E, Kang A, Atreja N, Hines DM, Noman A, Luo X.

**Association Between Weight Gain and the Incidence of Cardiometabolic Conditions Among People Living with HIV-1 at High Risk of Weight Gain Initiated on Antiretroviral Therapy.**

*Publication:* Infect Dis Ther 2022 08. e-pub ahead of print 2022/08/03; doi: 10.1007/s40121-022-00673-1.

*Authors:* McComsey GA, Emond B, Shah A, Bookhart BK, Rossi C, Milbers K, Lafeuille MH, Donga P.

**Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study.**

*Publication:* Adv Ther 2022 08; 39(8): 3845-3856. e-pub ahead of print 2022/06/14; doi: 10.1007/s12325-022-02198-y.

*Authors:* Ayodele O, Mu F, Berman R, Swallow E, Rejnmark L, Gosmanova EO, Kaul S.

**The Risk of Chronic Kidney Disease Development in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study.**

*Publication:* Clin Endocrinol (Oxf) 2022 08. e-pub ahead of print 2022/08/17; doi: 10.1111/cen.14813.

*Authors:* Rejnmark L, Ayodele O, Lax A, Mu F, Swallow E, Gosmanova EO.

**The acute effects of azithromycin use on cardiovascular mortality as compared with amoxicillin-clavulanate in US Veterans.**

*Publication:* Pharmacoepidemiol Drug Saf 2022 05. e-pub ahead of print 2022/05/14; doi: 10.1002/pds.5451.

*Authors:* DerSarkissian M, Young-Xu Y, Duh MS, Bhak RH, Palmetto N, Mortensen E, Anzueto A, Nguyen C, Cheng M, Frajzyngier V, Park S, Lax A, Weatherby LB, Walker AM.

**Contemporary Outpatient Management of Patients with Worsening Heart Failure with Reduced Ejection Fraction: Rationale and Design of the CHART-HF Study.**

*Publication:* Am Heart J 2022 05. e-pub ahead of print 2022/06/01; doi: 10.1016/j.ahj.2022.05.016.

*Authors:* Greene SJ, Lautsch D, Gaggin HK, Djatche LM, Zhou M, Song Y, Signorovitch J, Stevenson AS, Blaustein RO, Butler J.

**Estimating the US pericarditis prevalence using National Health Encounter Surveillance Databases.**

*Publication:* Curr Med Res Opin 2022 04: 1-10. e-pub ahead of print 2022/04/27; doi: 10.1080/03007995.2022.2070381.

*Authors:* Luis SA, LeWinter MM, Magestro M, DerSarkissian M, Duh MS, Chang R, Kponee-Shovein K, Muthukumar A, Hu X, Lim-Watson MZ, Klein AL.

**Heart failure across the range of preserved ejection fraction in United States clinical practice.**

*Publication:* European Heart Journal 2022 04; 43(Supplement\_2). doi: 10.1093/eurheartj/ehac544.863.

*Authors:* Greene S, Spertus JA, Tang W, Kang A, Zhong Y, Myers M, Shen S, Jiang J, Liu X, Steffen DR, Viola M, Felker GM.

**Development and evaluation of a predictive algorithm for unsatisfactory response among patients with pulmonary arterial hypertension using health insurance claims data.**

*Publication:* Curr Med Res Opin 2022 03: 1-33. e-pub ahead of print 2022/03/05; doi: 10.1080/03007995.2022.2049162.

*Authors:* Gauthier-Loiselle M, Tsang Y, Lefebvre P, Agron P, Royer J, Bell Lynum KS, Bennett L, Panjabi S.

**Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study.**

*Publication:* *Cardiol Ther* 2022 03. e-pub ahead of print 2022/03/02; doi: 10.1007/s40119-022-00257-7.

*Authors:* Owens AT, Sutton MB, Gao W, Fine JT, Xie J, Naidu SS, Desai NR.

**Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial.**

*Publication:* *J Med Econ* 2021 12; 25(1): 51-58. e-pub ahead of print 2021/12/16; doi:

10.1080/13696998.2021.2011301.

*Authors:* Xie J, Wang Y, Xu Y, Fine JT, Lam J, Garrison LP.

**Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit.**

*Publication:* *Clin Ther* 2021 11. doi: <https://doi.org/10.1016/j.clinthera.2021.11.006>.

*Authors:* Desai N, Xie J, Wang Y, Sutton MB, Whang J, Fine JT, Garrison LP.

**Increased Health Care Resource Utilization and Costs Associated with Herpes Zoster Among Patients Aged  $\geq 50$  Years with Chronic Obstructive Pulmonary Disease in the United States.**

*Publication:* *Chronic Obstr Pulm Dis* 2021 10. e-pub ahead of print 2021/10/07; doi: 10.15326/jcopdf.2021.0222.

*Authors:* Ghaswalla P, Thompson-Leduc P, Cheng WY, Kunzweiler C, Wang MJ, Bogart M, Patterson BJ, Duh MS, Wojciehowski J, Park S, Yawn BP.

**Disease and Economic Burden Associated with Recurrent Pericarditis in a Privately Insured United States Population.**

*Publication:* *Adv Ther* 2021 08. e-pub ahead of print 2021/08/22; doi: 10.1007/s12325-021-01868-7.

*Authors:* Lin D, Laliberté F, Majeski C, Magestro M, Lejeune D, Duh MS, Lim-Watson M, Paolini JF.

**Risk of Cardiovascular Conditions in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study.**

*Publication:* *Adv Ther* 2021 08; 38(8): 4246-4257. e-pub ahead of print 2021/06/25; doi: 10.1007/s12325-021-01787-7.

*Authors:* Gosmanova EO, Chen K, Ketteler M, Rejnmark L, Mu F, Swallow E, Briggs A, Sherry N, Kaul S.

**Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.**

*Publication:* *BMC Pulm Med* 2021 08; 21(1): 253. e-pub ahead of print 2021/08/02; doi: 10.1186/s12890-021-01612-5.

*Authors:* Slade D, Ray R, Moretz C, Germain G, Laliberté F, Shen Q, Duh MS, Mahendran M, Hahn B.

**Development and Validation of a Healthcare Utilization-Based Algorithm to Identify Acute Exacerbations of Chronic Obstructive Pulmonary Disease.**

*Publication:* *Int J Chron Obstruct Pulmon Dis* 2021 06; 16: 1687-1698. e-pub ahead of print 2021/06/18; doi: 10.2147/copd.S302241.

*Authors:* Mapel DW, Roberts MH, Sama S, Bobbili PJ, Cheng WY, Duh MS, Nguyen C, Thompson-Leduc P, Van Dyke MK, Rothnie KJ, Sundaresan D, Certa JM, Whiting TS, Brown JL, Roblin DW.

**Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population.**

*Publication:* *Curr Med Res Opin* 2021 06; 37(6): 881-890. e-pub ahead of print 2021/03/19; doi:

10.1080/03007995.2021.1901223.

*Authors:* Berger JS, Laliberté F, Kharat A, Lejeune D, Moore KT, Jung Y, Lefebvre P, Ashton V.

**Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.**

*Publication:* *J Med Econ* 2021 05; 24(1): 1115-1123. e-pub ahead of print 2021/09/09; doi:

10.1080/13696998.2021.1978242.

*Authors:* Jain SS, Li SS, Xie J, Sutton MB, Fine JT, Edelberg JM, Gao W, Spertus JA, Cohen DJ.

**Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US).**

*Publication:* Adv Ther 2021 05; 38(7): 3771-3788. doi: 10.1007/s12325-021-01746-2.

*Authors:* Berger JS, Laliberté F, Kharat A, Lejeune D, Moore KT, Jung Y, Lefebvre P, Ashton V.

**Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population.**

*Publication:* J Med Econ 2021 04; 24(1): 550-562. e-pub ahead of print 2021/04/30; doi: 10.1080/13696998.2021.1915627.

*Authors:* Berger JS, Laliberté F, Kharat A, Lejeune D, Moore KT, Jung Y, Lefebvre P, Ashton V.

**Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization.**

*Publication:* Annals of Vascular Surgery 2021 04. doi: 10.1016/j.avsg.2021.02.025.

*Authors:* Desai U, Kharat A, Hess CN, Milentijevic D, Laliberté F, Zuckerman P, Benson J, Lefebvre P, Hiatt WR, Bonaca MP.

**Evaluating the use of pharmacological stress agents during single-photon emission computed tomography myocardial perfusion imaging tests after inadequate exercise stress test.**

*Publication:* Journal of Nuclear Cardiology 2021 03. doi: 10.1007/s12350-021-02546-5.

*Authors:* Yang H, Faust E, Gao E, Sethi S, Kitt TM, Kristy RM, Spalding JR, Xu Y.

**Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization.**

*Publication:* J Med Econ 2021 03; 24(1): 402-409.

*Authors:* Desai U, Kharat A, Hess CN, Milentijevic D, Laliberte F, Zuckerman P, Benson J, Lefebvre P, Hiatt WR, Bonaca MP.

**Outcomes and resource use of patients with large hemispheric infarction and cerebral edema: analysis of real-world data.**

*Publication:* Current Medical Research and Opinion 2021 03: 1-8. doi: 10.1080/03007995.2021.1900090.

*Authors:* Chen SY, Thompson-Leduc P, Sawyer RN, Fakhri I, Cheung HC, Machecha M, Kirson NY, Torbey M.

**Disease Management and Outcomes in Patients Hospitalized for Acute Heart Failure in Japan.**

*Publication:* Cardiology and Therapy 2021 02. doi: 10.1007/s40119-021-00212-y.

*Authors:* Chen L, Ionescu-Iltu R, Romdhani H, Guerin A, Kessler P, Borentain M, Friend K, DeSouza M, Sato N.

**Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19.**

*Publication:* JACC Heart Fail 2021 9(1): 65-73. e-pub ahead of print 2021/01/02; doi: 10.1016/j.jchf.2020.11.003.

*Authors:* Bhatt AS, Jering KS, Vaduganathan M, Claggett BL, Cunningham JW, Rosenthal N, Signorovitch J, Thune JJ, Vardeny O, Solomon SD.

**Burden of Recurrent Pericarditis on Health-Related Quality of Life.**

*Publication:* Am J Cardiol 2020 11. e-pub ahead of print 2020/11/22; doi: 10.1016/j.amjcard.2020.11.018.

*Authors:* LeWinter M, Kontzias A, Lin D, Cella D, DerSarkissian M, Zhou M, Duh MS, Lim-Watson M, Magestro M.

**Clinical characteristics and health-related quality of life of patients with recurrent pericarditis in the United States: findings from a patient survey.**

*Publication:* European Heart Journal 2020 11; 41 (SUPPL 2): 2156.

*Authors:* Lewinter M, Kontzias A, Lin D, Cella D, DerSarkissian M, Totev T, Duh MS, Lim-Watson M, Magestro M.

**In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States.**

*Publication:* JACC Heart Fail 2020 11; 8(11): 943-953. e-pub ahead of print 2020/08/18; doi: 10.1016/j.jchf.2020.05.013.

*Authors:* Greene SJ, Triana TS, Ionescu-Ittu R, Burne RM, Guérin A, Borentain M, Kessler PD, Tugcu A, DeSouza MM, Felker GM, Chen L.

**Real-World Economic Burden Among Patients With And Without Heart Failure Worsening After Cardiac Resynchronization Therapy.**

*Publication:* Adv Ther 2020 11. e-pub ahead of print 2020/11/04; doi: 10.1007/s12325-020-01536-2.

*Authors:* Chung ES, Rickard J, Lu X, DerSarkissian M, Zichlin ML, Cheung HC, Swartz N, Greatsinger A, Duh MS.

**In-hospital Therapy for Heart Failure with Reduced Ejection Fraction in the United States.**

*Publication:* JACC HF 2020 05.

*Authors:* Greene SJ, Triana TS, Ionescu-Ittu R, Burne RM, Guérin A, Borentain M, Kessler PD, Tugcu A, DeSouza MM, Felker GM, Chen L.

**Adherence to heart failure management medications following cardiac resynchronization therapy.**

*Publication:* Current Medical Research and Opinion 2020 02; 36(2): 199-207. doi: 10.1080/03007995.2019.1670474.

*Authors:* Shah BR, DerSarkissian M, Tsintzos SI, Xiao Y, May D, Lu X, Kinrich D, Davis E, Lefebvre P, Duh MS, Dasta JF.

**Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failure—DANISH-MRI.**

*Publication:* Am Heart J 2019 12. doi: <https://doi.org/10.1016/j.ahj.2019.10.020>.

*Authors:* Elming MB, Hammer-Hansen S, Voges I, Nyktari E, Raja AA, Svendsen JH, Pehrson S, Signorovitch J, Køber L, Prasad SK, Thune JJ.

**Factors that impact a patient's experience when undergoing single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) in the US: A survey of patients, imaging center staff, and physicians.**

*Publication:* J Nucl Cardiol 2019 08. e-pub ahead of print 2019/08/31; doi: 10.1007/s12350-019-01863-0.

*Authors:* Li J, Walker DR, Biesbrock G, Kristy RM, Yang H, Gao E, Koenigsberg S, Spalding JR, Kitt TM.

**Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial.**

*Publication:* JACC Heart Fail 2019 08; 7(8): 717-724. e-pub ahead of print 2019/07/16; doi: 10.1016/j.jchf.2019.03.019.

*Authors:* Kristensen SL, Levy WC, Shadman R, Nielsen JC, Haarbo J, Videbaek L, Bruun NE, Eiskjaer H, Wiggers H, Brandes A, Thogersen AM, Hassager C, Svendsen JH, Hofsten DE, Torp-Pedersen C, Pehrson S, Signorovitch J, Kober L, Thune JJ.

**Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation.**

*Publication:* Journal of Cardiac Failure 2019 06; 25(6): 436-447. doi: <http://dx.doi.org/10.1016/j.cardfail.2018.03.012>.

*Authors:* Berger JS, Peterson E, Lalibert EF, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir MR.

**Cardiac arrhythmia detection outcomes among patients monitored with the Zio patch system: a systematic literature review.**

*Publication:* Curr Med Res Opin 2019 05: 1-12. e-pub ahead of print 2019/05/03; doi:

10.1080/03007995.2019.1610370.

*Authors:* Yenikomshian M, Jarvis J, Patton C, Yee C, Mortimer R, Birnbaum H, Topash M.

**Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants.**

*Publication:* Journal of Medical Economics. 2019 05: 1-9. e-pub ahead of print 2019/04/04; doi:

<http://dx.doi.org/10.1080/13696998.2019.1603156>.

*Authors:* Rozjabeek HM, Coleman CI, Ashton V, Laliberte F, Oyefesobi P, Lejeune D, Germain G, Schein JR, Yuan Z, Lefebvre P, Peterson ED.

**The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure.**

*Publication:* Europace 2019 04. e-pub ahead of print 2019/07/20; doi: 10.1093/europace/euz114.

*Authors:* Rorth R, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, Signorovitch J, Bruun NE, Eiskjaer H, Hassager C, Svendsen JH, Hofsten DE, Torp-Pedersen C, Pehrson S, Kober L, Kristensen SL.

**Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients.**

*Publication:* Current Medical Research and Opinion 2019 04; 35(4): 653-660. doi:

<http://dx.doi.org/10.1080/03007995.2018.1530205>.

*Authors:* McHorney CA, Peterson ED, Ashton V, Laliberte F, Crivera C, Germain G, Sheikh N, Schein J, Lefebvre P.

**Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.**

*Publication:* J Med Econ 2019 03; 22(3): 280-287. e-pub ahead of print 2018/12/24; doi:

10.1080/13696998.2018.1562817.

*Authors:* Kamstra R, Durkin M, Cai J, Bookhart B, Lafeuille MH, Pilon D, Tiggelaar S, Manceur AM, Lefebvre P.

**Right Ventricular Dysfunction and the Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure.**

*Publication:* Circ Arrhythm Electrophysiol 2019 03; 12(3): e007022. e-pub ahead of print 2019/03/15; doi:

10.1161/CIRCEP.118.007022.

*Authors:* Elming MB, Hammer-Hansen S, Voges I, Nyktari E, Raja AA, Svendsen JH, Pehrson S, Signorovitch J, Kober LV, Prasad SK, Thune JJ.

**Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis).**

*Publication:* American Journal of Cardiology 2019 02; 123(3): 355-360. doi: 10.1016/j.amjcard.2018.10.033.

*Authors:* Korjian S, Daaboul Y, Laliberté F, Zhao Q, Mehran R, Bode C, Halperin J, Verheugt FWA, Lip GYH, Cohen M, Peterson ED, Fox KAA, Gibson CM, Pinto DS.

**Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population.**

*Publication:* Chest 2018 12; 154(6): 1371-1378. doi: <http://dx.doi.org/10.1016/j.chest.2018.08.1059>.

*Authors:* Wells PS, Prins MH, Beyer-Westendorf J, Lensing AWA, Haskell L, Levitan B, Laliberte F, Ashton V, Xiao Y, Lejeune D, Crivera C, Lefebvre P, Zhao Q, Yuan Z, Schein J, Prandoni P.

**Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.**

*Publication:* Menopause 2018 11; 25(11): 1297-1305. doi: <http://dx.doi.org/10.1097/GME.0000000000001232>.

*Authors:* Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

**Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).**

*Publication:* Circulation 2018 10; 138(14): 1387-1398. e-pub ahead of print 2018/10/10; doi:

10.1161/CIRCULATIONAHA.117.033200.

*Authors:* Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC, Lakdawala NK, Ware JS, Caeshu CA, Helms AS, Colan SD, Girolami F, Cecchi F, Seidman CE, Sajeev G, Signorovitch J, Green EM, Olivetto I.

**Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.**

*Publication:* Cardiovasc Diabetol 2018 08; 17(1): 118. e-pub ahead of print 2018/08/26; doi: 10.1186/s12933-018-0759-z.

*Authors:* Young JB, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Lafeuille MH, Duh MS, Bookhart B, Wysham CH.

**Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.**

*Publication:* J Med Econ 2018 06; 21(6): 587-594. doi: <http://dx.doi.org/10.1080/13696998.2018.1444615>.

*Authors:* Wells PS, Lensing AWA, Haskell L, Levitan B, Laliberte F, Durkin M, Ashton V, Xiao Y, Crivera C, Lejeune D, Schein J, Lefebvre P.

**A retrospective study evaluating the tolerability and effectiveness of adjunctive antihypertensive drugs in patients with inadequate response to initial treatment.**

*Publication:* J Clin Hypertens (Greenwich) 2018 06; 20(6): 1058-1066. e-pub ahead of print 2018/06/15; doi: 10.1111/jch.13312.

*Authors:* Ayyagari R, Xie J, Cheng D, Wu EQ, Huang XY, Chen S.

**Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.**

*Publication:* American Journal of Hematology 2018 05; 93(5): 664-671. e-pub ahead of print 2018/02/06; doi: <http://dx.doi.org/10.1002/ajh.25059>.

*Authors:* Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson WW, Laliberte F, Crivera C, Lefebvre P, Schein J, Khorana AA.

**Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function.**

*Publication:* Clinical Nephrology 2018 05; 89(5): 314-329. doi: <http://dx.doi.org/10.5414/CN109281>.

*Authors:* Weir MR, Haskell L, Berger JS, Ashton V, Laliberte F, Crivera C, Brown K, Lefebvre P, Schein J.

**Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users.**

*Publication:* PLoS One 2018 04; 13(4): e0194099. e-pub ahead of print 2018/04/06; doi: 10.1371/journal.pone.0194099.

*Authors:* McHorney CA, Crivera C, Laliberte F, Germain G, Wynant W, Lefebvre P.

**Community health workers improve disease control and medication adherence among patients with diabetes and/or hypertension in Chiapas, Mexico: an observational stepped-wedge study.**

*Publication:* BMJ Glob Health 2018 03; 3(1): e000566. e-pub ahead of print 2018/03/13; doi: 10.1136/bmjgh-2017-000566.

*Authors:* Newman PM, Franke MF, Arrieta J, Carrasco H, Elliott P, Flores H, Friedman A, Graham S, Martinez L, Palazuelos L, Savage K, Tymeson H, Palazuelos D.

**Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation.**

*Publication:* Current Medical Research and Opinion 2018 02; 34(2): 275-284. doi: <http://dx.doi.org/10.1080/03007995.2017.1409200>.

*Authors:* Kaatz S, Coleman CI, Bookhart B, Laliberte F, Nelson WW, Brown K, Martin S, Schein J, Lefebvre P.

**Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism.**

*Publication:* Research and Practice in Thrombosis and Haemostasis 2018 01; 2(1): 58-68. doi: <http://dx.doi.org/10.1002/rth2.12050>.

*Authors:* Berger JS, Seheult R, Laliberte F, Crivera C, Lejeune D, Xiao Y, Schein J, Lefebvre P, Kaatz S.

**Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure.**

*Publication:* Circulation 2017 11; 136(19): 1772-1780. e-pub ahead of print 2017/09/08; doi: 10.1161/CIRCULATIONAHA.117.028829.

*Authors:* Elming MB, Nielsen JC, Haarbo J, Videbaek L, Korup E, Signorovitch J, Olesen LL, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjaer H, Brandes A, Thogersen AM, Gustafsson F, Egstrup K, Videbaek R, Hassager C, Svendsen JH, Hofsten DE, Torp-Pedersen C, Pehrson S, Kober L, Thune JJ.

**Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.**

*Publication:* Curr Med Res Opin 2017 10; 33(10): 1891-1900. e-pub ahead of print 2017/06/08; doi: 10.1080/03007995.2017.1339674.

*Authors:* Weir MR, Berger JS, Ashton V, Laliberte F, Brown K, Lefebvre P, Schein J.

**Adherence to rivaroxaban compared with other oral anticoagulant agents among patients with nonvalvular atrial fibrillation.**

*Publication:* Journal of Managed Care and Specialty Pharmacy 2017 09; 23(9): 980-988. doi: <http://dx.doi.org/10.18553/jmcp.2017.23.9.980>.

*Authors:* McHorney CA, Ashton V, Laliberte F, Germain G, Wynant W, Crivera C, Schein JR, Lefebvre P, Peterson ED.

**Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests.**

*Publication:* J Med Econ 2017 08; 20(8): 777-785. e-pub ahead of print 2017/04/14; doi: 10.1080/13696998.2017.1314969.

*Authors:* Li J, Houle CR, Spalding JR, Yang H, Xiang CQ, Kitt TM, Kristy RM, Wu EQ.

**Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis.**

*Publication:* Research and Practice in Thrombosis and Haemostasis 2017 07; 1(1): 14-22. doi: <http://dx.doi.org/10.1002/rth2.12002>.

*Authors:* Khorana AA, McCrae KR, Milentijevic D, Fortier J, Nelson WW, Laliberte F, Crivera C, Lefebvre P, Yannicelli D, Schein J.

**Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.**

*Publication:* Clin Ther 2017 07; 39(7): 1396-1408. doi: <http://dx.doi.org/10.1016/j.clinthera.2017.05.357>.

*Authors:* Khorana AA, Berger JS, Wells PS, Seheult R, Ashton V, Laliberte F, Crivera C, Lejeune D, Schein J, Wildgoose P, Lefebvre P, Kaatz S.

**Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban.**

*Publication:* Curr Med Res Opin 2017 06; 33(6): 1033-1043. doi: 10.1080/03007995.2017.1297932.

*Authors:* Coleman C, Yuan Z, Schein J, Crivera C, Ashton V, Laliberte F, Lefebvre P, Peterson ED.

**A single-center experience with low-dose warfarin in patients undergoing total hip or knee replacement surgery.**

*Publication:* Current Orthopaedic Practice 2017 05; 23(3): 221-228.

*Authors:* Balcom WB, Mishol DN, Eapen S, Bookhart BK, Nutescu EA, Schein JR, Duh MS.

**Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk.**

*Publication:* Curr Med Res Opin 2017 04; 33(4): 631-638. doi: 10.1080/03007995.2016.1275936.

*Authors:* Nelson WW, Laliberte F, Patel AA, Germain G, Pilon D, McCormick N, Lefebvre P.

**Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate.**

*Publication:* J Am Acad Dermatol 2017 01; 76(1): 81-90. doi: 10.1016/j.jaad.2016.07.042.

*Authors:* Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P.

**Comparison of Adherence to Rivaroxaban versus Apixaban Among Patients with Atrial Fibrillation.**

*Publication:* Clin Ther 2016 11; 38(11): 2477-2488. doi: 10.1016/j.clinthera.2016.09.014.

*Authors:* McHorney CA, Peterson ED, Laliberte F, Germain G, Nelson WW, Crivera C, Schein J, Lefebvre P.

**The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older.**

*Publication:* PLoS One 2016 11; 11(11): e0166103. doi: 10.1371/journal.pone.0166103.

*Authors:* Agus DB, Gaudette E, Goldman DP, Messali A.

**Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.**

*Publication:* Clin Ther 2016 08; 38(8): 1803-1816.e1803. doi: <http://dx.doi.org/10.1016/j.clinthera.2016.07.002>.

*Authors:* Deitelzweig S, Laliberte F, Crivera C, Germain G, Bookhart BK, Olson WH, Schein J, Lefebvre P.

**Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.**

*Publication:* Menopause 2016 06; 23(6): 600-610. doi: <http://dx.doi.org/10.1097/GME.0000000000000590>.

*Authors:* Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

**Cost impact of switching from metoprolol to nebivolol for hypertension.**

*Publication:* American Journal of Pharmacy Benefits 2016 05; 8(3): e48-e54, 15-16.

*Authors:* Chen S, Swallow E, Jarvis J, Ohashi E, Kelley C, Xie J, Wu E.

**Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin.**

*Publication:* J Med Econ 2016 04; 19(1): 84-90. doi: <http://dx.doi.org/10.3111/13696998.2015.1096274>.

*Authors:* Merli GJ, Hollander JE, Lefebvre P, Laliberte F, Raut MK, Germain G, Bookhart B, Pollack CV.

**Impact of a Telehealth and Care Management Program on All-Cause Mortality and Healthcare Utilization in Patients with Heart Failure.**

*Publication:* Telemed J E Health 2016 01; 22(1): 2-11. doi: 10.1089/tmj.2015.0007.

*Authors:* Kao DP, Lindenfeld J, Macaulay D, Birnbaum HG, Jarvis JL, Desai US, Page RL, 2nd.

**Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy.**

*Publication:* J Med Econ 2015 12; 18(12): 1041-1049. doi: 10.3111/13696998.2015.1074583.

*Authors:* Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberte F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

**Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis.**

*Publication:* RMD Open 2015 11; 1(1): e000080. e-pub ahead of print 2015/11/05; doi: 10.1136/rmdopen-2015-000080.

*Authors:* Nurmohamed M, Bao Y, Signorovitch J, Trahey A, Mulani P, Furst DE.

**The Relationship between Local Economic Conditions and Acute Myocardial Infarction Hospital Utilization by Adults and Seniors in the United States, 1995-2011.**

*Publication:* Health Serv Res 2015 10; 50(5): 1688-1709. doi: 10.1111/1475-6773.12298.

*Authors:* Carls GS, Henke RM, Karaca Z, Marder WD, Wong HS.



**Glycemic and Cholesterol Control versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study.**

*Publication:* Diabetes Ther 2015 09; 6(3): 339-355. doi: 10.1007/s13300-015-0122-2.

*Authors:* Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Zhang M, Wang Y, Fonseca VA.

**Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users.**

*Publication:* J Med Econ 2015 08; 18(12): 1074-1084. doi: <http://dx.doi.org/10.3111/13696998.2015.1076429>.

*Authors:* Olson WH, Ma YW, Crivera C, Schein J, Lefebvre P, Laliberte F, Dea K, Germain G, Lynch SM.

**Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.**

*Publication:* J Acquir Immune Defic Syndr 2015 08; 69(4): 413-421. doi: 10.1097/QAI.0000000000000662.

*Authors:* Young J, Xiao Y, Moodie EE, Abrahamowicz M, Klein MB, Bernasconi E, Schmid P, Calmy A, Cavassini M, Cusini A, Weber R, Bucher HC, Swiss HIVCS.

**The economic impact of implementing a multiple inflammatory biomarker-based approach to identify, treat, and reduce cardiovascular risk.**

*Publication:* J Med Econ 2015 07; 18(7): 483-491. doi: 10.3111/13696998.2015.1029490.

*Authors:* Penn MS, Yenikomshian MA, Cummings AK, Klemes A, Damron JM, Purvis S, Beidelschies M, Birnbaum HG.

**Psoriasis and risk of diabetes-associated microvascular and macrovascular complications.**

*Publication:* J Am Acad Dermatol 2015 06; 72(6): 968-977 e962. doi: 10.1016/j.jaad.2015.02.1095.

*Authors:* Armstrong AW, Guerin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Iltu R, Mulani P.

**Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban.**

*Publication:* Hosp Pract (1995) 2015 04; 43(2): 85-93. doi: 10.1080/21548331.2015.1021659.

*Authors:* Merli GJ, Hollander JE, Lefebvre P, Laliberte F, Raut MK, Olson WH, Pollack CV, Jr.

**Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.**

*Publication:* Adv Ther 2015 03; 32(3): 216-227. doi: 10.1007/s12325-015-0189-1.

*Authors:* Laliberte F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P.

**Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.**

*Publication:* Clin Ther 2015 03; 37(3): 554-562. doi: 10.1016/j.clinthera.2015.02.001.

*Authors:* Laliberte F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P.

**Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy.**

*Publication:* Thromb Res 2015 02; 135(2): 303-310. doi: 10.1016/j.thromres.2014.11.024.

*Authors:* Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberte F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

**Economic benefits associated with beta blocker persistence in the treatment of hypertension: a retrospective database analysis.**

*Publication:* Current Medical Research & Opinion 2015 02: 1-30. doi: 10.1185/03007995.2015.1013624.

*Authors:* Chen S, Swallow E, Li N, Faust E, Kelley C, Xie J, Wu E.

**Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel.**

*Publication:* J Clin Pharm Ther 2014 12; 39(6): 663-672. doi: 10.1111/jcpt.12209.

*Authors:* Olson WH, Ma YW, Laliberte F, Lefebvre P, Crivera C, Schein JR, Fields LE, Dea K, Germain G, Lynch SM.

**Pulse pressure and stroke risk: development and validation of a new stroke risk model.**

*Publication:* Current Medical Research & Opinion 2014 12; 30(12): 2453-2460. doi: 10.1185/03007995.2014.971357.

*Authors:* Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

**Is addition of vasodilators to loop diuretics of value in the care of hospitalized acute heart failure patients? Real-world evidence from a retrospective analysis of a large United States hospital database.**

*Publication:* J Card Fail 2014 11; 20(11): 853-863. doi: 10.1016/j.cardfail.2014.08.006.

*Authors:* Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh MS.

**Gastrointestinal comorbidities associated with atrial fibrillation.**

*Publication:* Springerplus 2014 10; 3: 603. doi: 10.1186/2193-1801-3-603.

*Authors:* Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Schein JR, Lefebvre P.

**Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.**

*Publication:* Hosp Pract (1995) 2014 08; 42(3): 17-25. doi: 10.3810/hp.2014.08.1114.

*Authors:* Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

**Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?**

*Publication:* Current Medical Research & Opinion 2014 08; 30(8): 1521-1528. doi: 10.1185/03007995.2014.916159.

*Authors:* Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

**Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants.**

*Publication:* Current Medical Research & Opinion 2014 08; 30(8): 1513-1520. doi: 10.1185/03007995.2014.915801.

*Authors:* Laliberte F, Coleman CI, Bookhart B, Lefebvre P, Cloutier M, Damaraju CV, Schein JR, Kaatz S.

**Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.**

*Publication:* Current Medical Research & Opinion 2014 07; 30(7): 1317-1325. doi: 10.1185/03007995.2014.907140.

*Authors:* Laliberte F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P.

**Specialized adult congenital heart disease care: the impact of policy on mortality.**

*Publication:* Circulation 2014 05; 129(18): 1804-1812. doi: 10.1161/CIRCULATIONAHA.113.005817.

*Authors:* Mylotte D, Pilote L, Ionescu-Ittu R, Abrahamowicz M, Khairy P, Therrien J, Mackie AS, Marelli A.

**Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension.**

*Publication:* Current Medical Research & Opinion 2014 04; 30(4): 637-643. doi: 10.1185/03007995.2013.864267.

*Authors:* Chen S, Macaulay D, Swallow E, Diener M, Farooqui S, Xie J, Wu EQ.

**Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.**

*Publication:* Pharmacoepidemiol Drug Saf 2014 03; 23(3): 268-277.

*Authors:* Chawla AJ, Mytelka DS, McBride SD, Nellesen D, Elkins BR, Ball DE, Kalsekar A, Towse A, Garrison LP.

**Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China.**

*Publication:* PharmacoEconomics 2014 03; 32(3): 305-313. doi: 10.1007/s40273-014-0131-4.

*Authors:* Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

**Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.**

*Publication:* J Med Econ 2014 01; 17(1): 52-64. doi: 10.3111/13696998.2013.858634.

*Authors:* Lefebvre P, Coleman CI, Bookhart BK, Wang ST, Mody SH, Tran KN, Zhuo DY, Huynh L, Nutescu EA.

**Risk factors associated with myocardial infarction in venous thromboembolism patients.**

*Publication:* Current Medical Research & Opinion 2014 01; 30(1): 27-35. doi: 10.1185/03007995.2013.852525.

*Authors:* Laliberte F, Nutescu EA, Lefebvre P, Rondeau-Leclaire J, Bookhart BK, LaMori JC, Damaraju CV, Schein J, Kaatz S.

**All-cause and disease-related health care costs associated with recurrent venous thromboembolism.**

*Publication:* Thromb Haemost 2013 12; 110(6): 1288-1297. doi: 10.1160/TH13-05-0425.

*Authors:* Lefebvre P, Laliberte F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein J, Kaatz S.

**Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes.**

*Publication:* Diabetes Care 2013 10; 36(10): 3297-3304. doi: 10.2337/dc13-0149.

*Authors:* Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Fonseca VA.

**Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors.**

*Publication:* Circulation 2013 09; 128(13): 1412-1419. doi: 10.1161/CIRCULATIONAHA.113.001827.

*Authors:* Rushani D, Kaufman JS, Ionescu-Iltu R, Mackie AS, Pilote L, Therrien J, Marelli AJ.

**Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism.**

*Publication:* Patient 2013 07; 6(3): 213-224. doi: 10.1007/s40271-013-0020-5.

*Authors:* Laliberte F, Bookhart BK, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS.

**Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy.**

*Publication:* Int J Cardiol 2013 07; 167(2): 564-569. doi: 10.1016/j.ijcard.2012.01.047.

*Authors:* Guerin A, Lin J, Jhaveri M, Wu EQ, Yu AP, Cloutier M, Gauthier G, Alpert JS.

**Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study.**

*Publication:* Hypertension 2013 02; 61(2): 309-318. doi: 10.1161/HYPERTENSIONAHA.112.201566.

*Authors:* Gradman AH, Parise H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS.

**Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?**

*Publication:* Current Medical Research & Opinion 2013 30(4): 645-653.

*Authors:* Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

**Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients.**

*Publication:* Adv Ther 2012 08; 29(8): 675-690. doi: 10.1007/s12325-012-0040-x.

*Authors:* Laliberte F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS.

**All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.**

*Publication:* J Manag Care Pharm 2012 06; 18(5): 363-374.

*Authors:* Lefebvre P, Laliberte F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Schein J, Kaatz S.

**Resource utilization and costs following hospitalization of patients with chronic heart failure in the US.**

*Publication:* J Med Econ 2012 05; 15(5): 925-937. doi: 10.3111/13696998.2012.685136.

*Authors:* Korves C, Eldar-Lissai A, McHale J, Lafeuille MH, Hwa Ong S, Sheng Duh M.

**Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis.**

*Publication:* Current Medical Research & Opinion 2012 04; 28(4): 591-599. doi: 10.1185/03007995.2012.668495.

*Authors:* Signorovitch JE, Samuelson TM, Ramakrishnan K, Marynchenko M, Wu EQ, Blum SI, Ramasamy A, Chen S.

**In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty.**

*Publication:* J Med Econ 2012 02; 15(4): 644-653. doi: 10.3111/13696998.2012.669438.

*Authors:* Vekeman F, LaMori JC, Laliberte F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

**Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia.**

*Publication:* Qual Life Res 2011 12; 20(10): 1737-1744. doi: 10.1007/s11136-011-9912-9.

*Authors:* Signorovitch J, Brainsky A, Grotzinger KM.

**Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.**

*Publication:* Am J Ther 2011 11; 18(6): 436-448. doi: 10.1097/MJT.0b013e3181e4de68.

*Authors:* Simpson RJ, Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A.

**Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.**

*Publication:* Appl Health Econ Health Policy 2011 09; 9(5): 293-303. doi: 10.2165/11592430-000000000-00000.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

**Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States.**

*Publication:* Current Medical Research & Opinion 2011 09; 27(9): 1763-1768. doi: 10.1185/03007995.2011.604310.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

**Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.**

*Publication:* J Med Econ 2011 04; 14(3): 324-334. doi: 10.3111/13696998.2011.578698.

*Authors:* Vekeman F, LaMori JC, Laliberte F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

**Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy.**

*Publication:* J Med Econ 2011 03; 14(3): 267-278. doi: 10.3111/13696998.2011.570401.

*Authors:* Yang W, Kahler KH, Fellers T, Orloff J, Chang J, Bensimon AG, Wu EQ, Fan CP, Yu AP.

**Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data (February).**

*Publication:* Ann Pharmacother 2011 02; 179-188. doi: 10.1345/aph.1P391.

*Authors:* Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, Guerin A, Boerstoele-Streefland M, Jiang W, Lefebvre P.

**Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.**

*Publication:* Eur J Heart Fail 2011 02; 13(2): 148-153. doi: 10.1093/eurjhf/hfq194.

*Authors:* Thune JJ, Signorovitch JE, Kober L, McMurray JJ, Swedberg K, Rouleau J, Maggioni A, Velazquez E, Califf R, Pfeffer MA, Solomon SD.

**Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension.**

*Publication:* Am J Cardiovasc Drugs 2011 01; 11(1): 21-32. doi: 10.2165/11586570-000000000-00000.

*Authors:* Chang J, Yang W, Kahler KH, Fellers T, Orloff J, Bensimon AG, Yu AP, Fan CP, Wu EQ.

**Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement.**

*Publication:* Current Medical Research & Opinion 2010 09; 26(9): 2203-2212. doi: 10.1185/03007995.2010.500883.

*Authors:* Chang J, Yang W, Fellers T, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ.

**Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives.**

*Publication:* Current Medical Research & Opinion 2010 09; 26(9): 2065-2076. doi: 10.1185/03007995.2010.494462.

*Authors:* Yang W, Chang J, Kahler KH, Fellers T, Orloff J, Wu EQ, Bensimon AG.

**Clinical outcomes and medical care costs among Medicare beneficiaries receiving therapy for peripheral arterial disease.**

*Publication:* Ann Vasc Surg 2010 07; 24(5): 577-587. doi: 10.1016/j.avsg.2010.03.015.

*Authors:* Jaff MR, Cahill KE, Yu AP, Birnbaum HG, Engelhart LM.

**Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.**

*Publication:* Am J Med 2010 04; 123(4): 350-357. doi: 10.1016/j.amjmed.2009.08.022.

*Authors:* Kimball AB, Guerin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P.

**Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension.**

*Publication:* Current Medical Research & Opinion 2010 04; 26(4): 849-860. doi: 10.1185/03007991003613910.

*Authors:* Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH.

**Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.**

*Publication:* Mayo Clin Proc 2009 12; 84(12): 1065-1072. doi: 10.4065/mcp.2009.0298.

*Authors:* Simpson RJ, Jr., Signorovitch J, Birnbaum H, Ivanova J, Connolly C, Kidolezi Y, Kuznik A.

**Costs associated with cardiovascular events in patients with hypertension in US managed care settings.**

*Publication:* J Am Soc Hypertens 2009 11; 3(6): 403-415. doi: 10.1016/j.jash.2009.09.001.

*Authors:* Duh MS, Fulcher NM, White LA, Jayawant SS, Ramamurthy P, Moyneur E, Ong SH.

**Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction.**

*Publication:* Biostatistics 2009 04; 10(2): 275-281. doi: 10.1093/biostatistics/kxn034.

*Authors:* Tian L, Cai T, Pfeffer MA, Piankov N, Cremieux PY, Wei LJ.

**Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences.**

*Publication:* Circulation 2008 07; 118(5): 491-497. doi: 10.1161/CIRCULATIONAHA.107.752006.

*Authors:* Xie J, Wu EQ, Zheng ZJ, Sullivan PW, Zhan L, Labarthe DR.

**An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY).**

*Publication:* J Clin Hypertens (Greenwich) 2008 06; 10(6): 436-442.

*Authors:* Williams SA, Michelson EL, Cain VA, Yang M, Nesbitt SD, Egan BM, Julius S, Investigators TS.

**Effect of Persistence with Drug Therapy On the Risk of Myocardial Re-infarction.**

*Publication:* P&T 2008 05; 33(5): 288-295.

*Authors:* Shaya FT, Gu A, Yan X.

**Delay in filling the initial prescription for a statin: A potential early indicator of medication nonpersistence.**

*Publication:* Clin Ther 2008 04; 30(4): 761-774. e-pub ahead of print 2008/05/24; doi: 10.1016/j.clinthera.2008.04.015.

*Authors:* Yu AP, Yu YF, Nichol MB, Gwady-Sridhar F.

**Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.**

*Publication:* Hypertension 2008 01; 51(1): 48-54. doi: 10.1161/HYPERTENSIONAHA.107.093682.

*Authors:* Thune JJ, Signorovitch J, Kober L, Velazquez EJ, McMurray JJ, Califf RM, Maggioni AP, Rouleau JL, Howlett J, Zelenkofske S, Pfeffer MA, Solomon SD.

**Productivity costs associated with cardiometabolic risk factor clusters in the United States.**

*Publication:* Value in Health 2007 11; 10(6): 443-450. doi: 10.1111/j.1524-4733.2007.00199.x.

*Authors:* Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

**Prevalence, referral patterns, testing, and surgery in aortic valve disease: leaving women and elderly patients behind?**

*Publication:* J Heart Valve Dis 2007 07; 16(4): 362-369.

*Authors:* Bach DS, Radeva JI, Birnbaum HG, Fournier AA, Tuttle EG.

**The economic impact of a partnership-measurement model of disease management: Improving Cardiovascular Outcomes in Nova Scotia (ICONS).**

*Publication:* Healthc Q 2007 05; 10(2): 38-46.

*Authors:* Cremieux PY, Fortin P, Meilleur MC, Montague T, Royer J.

**Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S.**

*Publication:* Obesity (Silver Spring) 2007 02; 15(2): 511-521. doi: 10.1038/oby.2007.580.

*Authors:* Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

**The value of antihypertensive drugs: a perspective on medical innovation.**

*Publication:* Health Aff (Millwood) 2007 01; 26(1): 97-110. doi: 10.1377/hlthaff.26.1.97.

*Authors:* Cutler DM, Long G, Berndt ER, Royer J, Fournier AA, Sasser A, Cremieux P.

**Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States.**

*Publication:* Stroke 2006 10; 37(10): 2567-2572. doi: 10.1161/01.STR.0000240506.34616.10.

*Authors:* Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR.

**Economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT adapted to The Netherlands.**

*Publication:* J Med Econ 2006 9(131): 121.

*Authors:* Boersma C, Ivanova J, Koopmanschap MA, Voors AA, Postma MJ.

**Economic burden and co-morbidities of atrial fibrillation in a privately insured population.**

*Publication:* Current Medical Research & Opinion 2005 10; 21(10): 1693-1699. doi: 10.1185/030079905X65475.

*Authors:* Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W, Ruskin J.

**Assessing the economic impact of chronic conditions in postmenopausal women.**

*Publication:* Expert Opin Pharmacother 2005 09; 6(11): 1803-1814. doi: 10.1517/14656566.6.11.1803.

*Authors:* Sasser AC, Taylor M, Birnbaum HG, Schoenfeld MJ, Oster EF, Rousculp M.

**Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).**

*Publication:* Am Heart J 2005 08; 150(2): 323-329. doi: 10.1016/j.ahj.2004.08.037.

*Authors:* Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, Valiant-Investigators.

**Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.**

*Publication:* Womens Health Issues 2005 05; 15(3): 97-108. doi: 10.1016/j.whi.2004.11.006.

*Authors:* Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D.

**Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation.**

*Publication:* Clin Transplant 2005 02; 19(1): 122-129. doi: 10.1111/j.1399-0012.2004.00312.x.

*Authors:* Radeva JI, Reed SD, Kalo Z, Kauf TL, Cantu E, 3rd, Cretin N, Schulman KA.

**State-mandated continuing medical education and the use of proven therapies in patients with an acute myocardial infarction.**

*Publication:* J Am Coll Cardiol 2004 07; 44(1): 192-198. doi: 10.1016/j.jacc.2004.03.070.

*Authors:* Patel MR, Meine TJ, Radeva J, Curtis L, Rao SV, Schulman KA, Jollis JG.

**Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.**

*Publication:* Womens Health Issues 2003 11; 13(6): 204-213.

*Authors:* Birnbaum H, Leong S, Kabra A.

**Clinical and Economic Value of Cardiovascular Nuclear Medicine.**

*Publication:* Meniscus Health Care Communications 1996.

*Authors:* Mulhern C, Neels K.

## Abstracts

**Contemporary outpatient management of patients with and without worsening heart failure with reduced ejection fraction (HFrEF) within a single integrated system: results from electronic medical record data in the CHART-HF study.**

Chicago, IL November 5–7, 2022.

*Authors:* Gaggin HK, Greene SJ, Zhou M, Lautsch D, Song Y, Signorovitch J, Stevenson AS, Blaustein RO, Butler J.

**Medication changes and reasons for no medication change among outpatients with heart failure with reduced ejection fraction: results from CHART-HF.**

Chicago, IL November 5–7, 2022.

*Authors:* Greene SJ, Gaggin HK, Zhou M, Lautsch D, Song Y, Signorovitch J, Stevenson AS, Blaustein RO, Butler J.

**Real-world experience and unmet needs in the current management of recurrent pericarditis: a physician survey and medical chart review.**

Washington, DC April 2–4, 2022.

*Authors:* Raisinghani AB, Buckley LF, Song Y, Chatfield J, Wang Y, Malinowski A, Berman R, He C, Wu E, Martin DR.

**Clinical Characteristics and Health-Related Quality of Life of Patients with Recurrent Pericarditis in the United States: Findings from a Patient Survey.**

*Abstract:* European Society of Cardiology Congress 2020, Online Aug 29 - Sept 1, 2020.

*Authors:* LeWinter M, Kontzias A, Lin D, Cella D, DerSarkissian M, Totev T, Sheng Duh M, Lim-Watson M, Magestro M.

**Health-related quality of life of patients with recurrent pericarditis in the United States.**

May, 2020.

*Authors:* LeWinter MM, Kontzias A, Lin D, Cella D, DerSarkissian M, Zhou M, Duh MS, Lim-Watson M, Magestro M.

**Physician Preferences For Oral Anti-coagulation for Obese & Non-obese Patients With Non-valvular Atrial Fibrillation.**

*Abstract:* American Heart Association's Scientific Sessions 2019, Philadelphia November 16-18, 2019.

*Authors:* Dhamane A, Goldschmidt D, Swallow E, Russ C, Ferri M.

**Real-World Outcomes Among Patients Hospitalized For De Novo Versus Worsening Chronic Heart Failure With Reduced Ejection Fraction In The United States.**

*Abstract:* American Heart Association, Philadelphia, PA November 16-18, 2019.

*Authors:* Triana TS, R. I-I, R. B, Guerin A, Borentain M, Kessler P, Tugcu A, DeSouza M, Greene J, Felker GM, Chen L.

**Healthcare costs in patients with cancer increase with increasing risk of venous thromboembolism.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Streiff MB, McCrae KR, Kuderer NM, Milentijevic D, Germain G, Laliberte F, Le N, Lefebvre P, Lyman GH, Khorana AA.

**The rate of venous thromboembolism in cancer patients varies by khorana risk category.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Khorana AA, Kuderer NM, McCrae KR, Milentijevic D, Germain G, Laliberte F, Le N, Lefebvre P, Lyman GH, Streiff MB.

**Adherence to heart failure medications pre-and post-cardiac resynchronization therapy.**

*Abstract:* 39th Annual Scientific Sessions of the Heart Rhythm Society, Heart Rhythm 2018, Boston, MA May 9-12, 2018.

*Authors:* Shah B, DerSarkissian M, Xiao Y, Davis E, Kinrich D, Lefebvre P, Duh MS, May D, Tsintzos S, Dasta J.

**Healthcare costs associated with venous thromboembolism in cancer patients treated with anticoagulants.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* Streiff MB, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Khorana AA.

**VTE recurrence and safety of anticoagulants among patients with cancer treated for venous thromboembolism.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff MB.

**Anticoagulant treatment patterns for cancer-associated thrombosis in a commercial insurance population.**

*Abstract:* Resuscitation Science Symposium, Anaheim, CA Nov 11-15, 2017.

*Authors:* Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff M.

**Elevated b-type natriuretic peptide levels and cardiovascular outcomes in patients with heart failure across different ejection fraction levels.**

*Abstract:* Resuscitation Science Symposium, Anaheim, CA Nov 11-15, 2017.

*Authors:* Greenberg B, Berger JS, Peterson ED, Laliberte F, Zhao Q, Germain G, Lejeune D, Wu JW, Lefebvre P, Fonarow GC.

**Healthcare resource utilization associated with venous thromboembolism in cancer patients treated with anticoagulants in a commercial insurance population.**

*Abstract:* Resuscitation Science Symposium, Anaheim, CA Nov 11-15, 2017.



*Authors:* Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff M.

**Stroke and myocardial infarction risk among newly diagnosed heart failure patients with reduced, borderline, and preserved left ventricle ejection fraction.**

*Abstract:* 21st Annual Scientific Meeting of the Heart Failure Society of America, Grapevine, TX Sept 16-19, 2017.

*Authors:* Fonarow GC, Peterson ED, Greenberg B, Berger JS, Laliberte F, Zhao Q, Germain G, Lejeune D, Lefebvre P.

**Myocardial fibrosis and the effect of defibrillator implantation in patients with non-ischemic systolic heart failure - DANISH-MRI.**

*Abstract:* European Society of Cardiology, Barcelona, Spain Aug 26-30, 2017.

*Authors:* Elming MB, Hammer-Hansen S, Nyktari E, Voges I, Raja AA, Signorovitch J, Koeber L, Prasad S, Thune JJ.

**Impact of renal function on clinical outcomes among nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Weir MR, Haskell L, Berger JS, Ashton V, Laliberte F, Crivera C, Brown K, Lefebvre P, Schein JR.

**Adherence to rivaroxaban versus apixaban among patients with atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users.**

*Abstract:* American Heart Association's Quality of Care and Outcomes Research, Arlington, VA Apr 2-3, 2017.

*Authors:* McHorney CA, Crivera C, Laliberte F, Germain G, Wynant W, Lefebvre P.

**Impact of differences in once-vs twice-daily medications adherence on the risk of bleed and stroke in non-valvular atrial fibrillation: Analysis of randomized trials and claims data sources.**

*Abstract:* American Heart Association's Quality of Care and Outcomes Research, Arlington, VA Apr 2-3, 2017.

*Authors:* McHorney CA, Peterson ED, Durkin M, Ashton V, Laliberte F, Crivera C, Sheikh N, Germain G, Schein JR, Xiao Y, Lefebvre P.

**Importance of balanced follow-up time and other study design considerations when evaluating adherence using two novel oral anticoagulants.**

*Abstract:* American Heart Association's Quality of Care and Outcomes Research, Arlington, VA Apr 2-3, 2017.

*Authors:* Coleman C, Yuan Z, Schein J, Crivera C, Ashton V, Laliberte F, Lefebvre P, Peterson E.

**Incremental risk of ischemic stroke over time in newly diagnosed heart failure patients without atrial fibrillation.**

*Abstract:* 66th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, Washington, DC Mar 17-19, 2017.

*Authors:* Berger JS, Peterson E, Laliberte F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir M.

**Rivaroxaban users have significantly less treatment discontinuation compared with users of other oral anticoagulants in non-valvular atrial fibrillation.**

*Abstract:* 66th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, Washington, DC Mar 17-19, 2017.

*Authors:* McHorney C, Ashton V, Laliberte F, Germain G, Wynant W, Crivera C, Schein J, Lefebvre P, Peterson E.

**Adherence to QD vs. BID medications in nvaf patients is associated with reduced risk of ischemic stroke: A modeling study using rct and claims data.**

*Abstract:* American Heart Association's 2016 Scientific Sessions and Resuscitation Science Symposium, Nov 2016.

*Authors:* McHorney CA, Peterson E, Ashton V, Laliberte F, Crivera C, Sheikh N, Germain G, Schein J, Xiao Y, Lefebvre P.

**Cost of hyperkalemia among patients with heart failure.**

*Abstract:* American Heart Association's 2016 Scientific Sessions and Resuscitation Science Symposium., New Orleans, LA Nov 12-14, 2016.

*Authors:* Woolley JM, Betts K, Mu F, Xiang C, Tang W, Wu E.

**Patient characteristics and treatment patterns of venous thromboembolism (VTE) among hospitalized patients in China: An analysis of electronic medical record data.**

*Abstract:* ISPOR 19th Annual European Congress, Vienna, Austria Oct 29 - Nov 2, 2016.

*Authors:* Wu C, Chen H, Xie J, Han S, Horblyuk R, Wang PF, Liu L, Lu J, Song H, Du EX, Wu EQ.

**Risk of ischemic stroke in newly diagnosed heart failure patients.**

*Abstract:* American Heart Association's 2016 Scientific Sessions and Resuscitation Science Symposium, New Orleans, LA Nov 12-14, 2016.

*Authors:* Berger JS, Peterson E, Laliberte F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir M.

**The economic burden of hyperkalemia among patients with chronic kidney disease and/or heart failure.**

*Abstract:* AMCP Nexus 2016, Baltimore, MD Oct 3-6, 2016.

*Authors:* Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Pham H, Hollenack K, Singhanian A, Wu E.

**Cardiac resynchronization therapy and adherence to heart failure management regimens.**

*Abstract:* 20th Annual Scientific Meeting of the Heart Failure Society of America, Orlando, FL Sep 17-20, 2016.

*Authors:* Der Sarkissian M, Xiao Y, Shen Y, May D, Tsintzos SI, Lefebvre P, Duh MS.

**Clinical and economic outcomes of venous thromboembolism (VTE) among hospitalized patients in China: An analysis of electronic medical record data.**

*Abstract:* ISPOR 7th Asia-Pacific Conference, Singapore Sep 3-6, 2016.

*Authors:* Wu C, Chen H, Xie J, Han S, Horblyuk R, Wang P, Liu L, Lu J, Song H, Du E, Wu EQ.

**Time to treatment intensification and its association with subsequent microvascular outcomes among patients with type 2 diabetes.**

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany Sep 12-16, 2016.

*Authors:* Desai U, Kirson NY, Kim J, Khunti KK, King SB, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.

**Risk of venous thromboembolism recurrences in patients who continued versus discontinued rivaroxaban therapy after an initial six-month therapy.**

*Abstract:* European Society of Cardiology, Rome, Italy Aug 27-31, 2016.

*Authors:* Berger JS, Seheult R, Laliberte F, Crivera C, Lejeune D, Xiao Y, Schein J, Lefebvre P, Kaatz S.

**Healthcare costs among patients diagnosed with deep vein thrombosis in the outpatient setting and treated with Rivaroxaban versus low-molecular-weight Heparin and Warfarin.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Laliberte F, Germain G, Bookhart BK, Olson WH, Schein J, Lefebvre P.

**Development of a shared decision-making tool to assist patients and clinicians with assessing the individualized risks and benefits of oral anticoagulation therapy for atrial fibrillation.**

*Abstract:* ISPE's 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA August 22-26, 2015.

*Authors:* Kaiser K, Cheng W, Jensen S, Clayman M, Schwiep F, Thappa A, Chawla A, Goldberger J, Col N, Schein J.

**Effects of rivaroxaban vs warfarin on hospitalization days, healthcare resource utilization, and costs in nonvalvular atrial fibrillation patients using rivaroxaban.**

*Abstract:* American Heart Association Scientific Sessions, Chicago, IL Nov 15-19, 2014.

*Authors:* Laliberté F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein JR, Vanderpoel J, Germain G, Lefebvre P.

**Treatment and monitoring of venous thromboembolism (VTE) among hospitalized patients in China.**

*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8-12, 2014.

*Authors:* Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

**Economic benefits associated with medication persistence in the treatment of hypertension: a retrospective analysis in patients who received beta-blockers.**

*Abstract:* AMCP Nexus 2014, Boston, MA Oct 7-10, 2014.

*Authors:* Chen Y, Swallow E, Li N, Faust E, Kelly C, Xie J, Wu EQ.

**Pulse pressure and stroke risk: Development and validation of a new stroke risk model.**

*Abstract:* 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Taipei, Taiwan (Republic of China) Oct 24-27, 2014.

*Authors:* Vekeman F, Ayyagari R, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

**Treatment and monitoring of venous thromboembolism (VTE) among hospitalized patients in China.**

*Abstract:* ISPOR 6th Annual Asia-Pacific Conference, Beijing, China Sep 6-9, 2014.

*Authors:* Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

**Anticoagulant options and inpatient costs for patients with non-valvular atrial fibrillation.**

*Abstract:* Quality of Care and Outcomes Research (QCOR) Scientific Sessions 2014, Baltimore, MD June 02-04, 2014.

*Authors:* Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

**Economic impact of switching from metoprolol to nebivolol for the treatment of hypertension.**

*Abstract:* American Association of Nurse Practitioners 2014 National Conference, Nashville, TN June 17-22, 2014.

*Authors:* Chen S, Swallow E, Jarvis J, Ohashi E, Kelley C, Xie J, Wu EQ.

**Costs of venous thromboembolism (VTE) among hospitalized patients in China.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

**The economic impact of implementing a multiple inflammatory biomarker-based approach to identify, treat, and reduce cardiovascular risk.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Penn MS, Yenikomshian MA, Cummings AKG, Damron JM, Purvis S, Birnbaum HG.

**Effect of prasugrel vs clopidogrel on hospital readmission among acute coronary syndrome patients treated with prasugrel.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Olson WH, Ma Y, Lefebvre P, Laliberté F, Crivera C, Schein JR, Fields LE, Dea K, Germain G, Lynch SM.

**Hospital length of stay: Does rivaroxaban reduce inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Laliberté F, Pilon D, Raut M, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

**Real-World Comparative Effectiveness and Safety of Rivaroxaban and Warfarin in Nonvalvular Atrial Fibrillation Patients.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, P. L.

**Hospital length of stay: Does rivaroxaban reduce inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?**

*Abstract:* American Heart Association 2013 Scientific Sessions and Resuscitation Science Symposium, Dallas, TX Nov 16-20, 2013.

*Authors:* Laliberte F, Pilon D, Raut M, Nelson WW, Duh MS, Schein JR, Lefebvre P.

**Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.**

*Abstract:* American Heart Association 2013 Scientific Sessions and Resuscitation Science Symposium Dallas, TX Nov 16-20, 2013.

*Authors:* Laliberte F, Cloutier M, Nelson WW, Coleman CI, Sheng Duh M, Pilon D, Damaraju CV, Schein JR, Lefebvre P.

**Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.**

*Abstract:* 2013 Annual Meeting of the American College of Clinical Pharmacy, Albuquerque, NM Oct 13-16, 2013.

*Authors:* Lefebvre P, Coleman CI, Bookhart B, Wang ST, Mody SH, Tran K, Zhuo D, Huynh L, Nutescu EA.

**Venous thromboembolism and cardiovascular disease complications in women using transdermal versus oral menopausal estrogen therapy.**

*Abstract:* 24th Annual Meeting of the North American Menopause Society, Dallas, TX Oct 9-12, 2013.

*Authors:* Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

**Pulse pressure and stroke risk: Development and validation of a stroke risk equation.**

*Abstract:* ISPOR 4th Latin America Conference, Buenos Aires, Argentina Sep 12-14, 2013.

*Authors:* Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

**Risk of venous thromboembolism complications associated with recurrent venous thromboembolism.**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

**The effect of adalimumab on risk of major adverse cardiovascular events in rheumatoid arthritis: A meta-analysis of randomized trials.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 2012.

*Authors:* Burmester G, Emery P, Signorovitch J, Williams D, Valdes J, Bao Y, Mulani PM.

**All-cause and disease-related costs associated with recurrent venous thromboembolism.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Lefebvre P, Laliberte F, Nutescu E, Duh MS, LaMori JC, Bookhart B, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

**Association of patient characteristics with the initiation of dabigatran versus warfarin among anticoagulant naive patients with non-valvular atrial fibrillation.**

*Abstract:* American Heart Association's Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2013 Scientific Sessions, Baltimore, MD May 15-17, 2013.

*Authors:* Walker DR, Ivanova J, Betts KA, Rao S, Wu EQ.

**Risk of venous thromboembolism complications associated with recurrent venous thromboembolism.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

**Treating acute heart failure in the elderly: A comparison of three inpatient treatment alternatives in the united states.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Lacomte P, Ong SH, Duh MS.

**Integrated telehealth and care management program reduces all cause mortality in Medicare beneficiaries with heart failure.**

*Abstract:* American Heart Association 2012 Scientific Sessions and Resuscitation Science Symposium, Los Angeles, CA Nov 3-6, 2012.

*Authors:* Page RL, Kao DP, Macaulay D, Birnbaum HG, Jarvis J, Desai U, Lindenfeld J.

**Comparisons of costs and clinical outcomes in hypertensive patients treated with angiotensin receptor blockers plus chlorthalidone or hydrochlorothiazide.**

*Abstract:* AMCP's 2012 Educational Conference, Cincinnati, OH Oct 3-5, 2012.

*Authors:* Leahy MJ, Sun SX, Yu AP, Chen KS, Wu EQ, Mattson M, Tang J.

**Comparisons of costs and clinical outcomes in hypertensive patients treated with chlorthalidone or hydrochlorothiazide.**

*Abstract:* AMCP's 2012 Educational Conference, Cincinnati, OH Oct 3-5, 2012.

*Authors:* Sun SX, Leahy MJ, Dabbous O, Yu AP, Lu M, Chen KS, Wu EQ.

**Risk of venous thromboembolism complications associated with recurrent venous thromboembolism.**

*Abstract:* 2012 Annual Meeting of the American College of Clinical Pharmacy, Hollywood, FL Oct 21-24, 2012.

*Authors:* Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

**Tolerability and effectiveness of nebivolol compared to other add-on therapies for hypertension: A retrospective chart review.**

*Abstract:* Canadian Hypertension Congress, Toronto, Canada Oct 25-28, 2012.

*Authors:* Ayyagari R, Cheng D, Xie J, Huang XY, Wu EQ, Chen S.

**Are vasodilators of value in the care of patients hospitalized for acute heart failure?**

*Abstract:* 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012.

*Authors:* Duh MS, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Gradman AH.

**Chronic heart failure in the elderly: Clinical characteristics and resource utilization following initial hospitalization.**

*Abstract:* 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012.

*Authors:* Korves C, Eldar-Lissai A, Wei R, Sharma H, Chen K, Ong SH, Duh MS.

**Risk of gastrointestinal conditions among patients with atrial fibrillation.**

*Abstract:* 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012.

*Authors:* Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

**Acute heart failure patients with and without renal impairment: A study of heart failure-related resource utilization and costs in the United States.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Eldar-lissai A, Eapen S, Ong SH, Rodermund D, Duh MS.

**All-cause and disease-specific health care utilization and costs associated with venous thromboembolism in commercial, Medicare and Medicaid beneficiaries.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Lefebvre P, Laliberte F, Nutescu EA, Duh MS, Lamori JC, Bookhart B, Olson W, Dea K, Schein J, Kaatz S.

**Are vasodilators of value in the care of patients hospitalized for acute heart failure?**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh MS.

**Chronic heart failure in the elderly: Costs and resource utilization following initial hospitalization.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Eldar-lissai A, Korves C, Wei R, Sharma H, Chen K, Ong SH, Duh MS.

**Risk of gastrointestinal conditions among patients with atrial fibrillation.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Laliberte F, Dea K, Lamori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

**Associations of hypertension with risk of cardiovascular events among chinese stroke patients in the US.**

*Abstract:* American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition, New York, NY May 19-22, 2012.

*Authors:* Fung G, Kahler K, Xie J, Marynchenko M, Wu E, Kam I, Yang W.

**Compliance and persistence with nebivolol vs. Diuretics as first add-on hypertension treatment.**

*Abstract:* American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition New York, NY May 19-22, 2012.

*Authors:* Chen S, Macaulay D, Xie J, Swallow E, Diener M, Farooqui S, Wu E.

**Impact of once-daily vs. Twice-daily dosing frequency on adherence in chronic medications among patients with non-valvular atrial fibrillation.**

*Abstract:* Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2012 Scientific Sessions, Atlanta, GA May 9-11, 2012.

*Authors:* Laliberte F, Nelson WW, Schein JR, Rondeau-Leclerc J, Lefebvre P, Duh MS.

**Risk of cardiovascular events associated with hypertension among chinese and caucasian stroke patients in the US.**

*Abstract:* American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition, New York, NY May 19-22, 2012.

*Authors:* Fung G, Kahler K, Xie J, Liu N, Wu E, Kam I, Yang W.

**Are vasodilators of any value in the care of hospitalized acute heart failure patients?**

*Abstract:* 61th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, Chicago, IL Mar 24-27, 2012.

*Authors:* Gradman A, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh M.

**Gastrointestinal conditions among patients with atrial fibrillation.**

*Abstract:* 61th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, Chicago, IL Mar 24-27, 2012.

*Authors:* Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge M, Damaraju CV, Duh MS, Schein J, Lefebvre P.

**Comparison of bleeding rates between statin and statin-free patients on warfarin: A claims database approach.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Guerin A, Hylek EM, Frois C, Ponce De Leon Barido D, Marrone C, Bae JP, Zhao Z.

**Factors associated with failing to achieve low density lipoprotein cholesterol goal with existing statin therapy: A chart extraction-based approach.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Zhao Z, Ivanova J, Bae JP, Boykin SD, McCracken R, Molife C, Waldman T, Frois C.

**Low lipoprotein cholesterol goal attainment in dyslipidemic patients with existing statin therapy: A chart extraction-based approach.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Ivanova J, Frois C, Bae JP, Boykin SD, McCracken R, Molife C, Waldman T, Zhao Z.

**Risk of gastrointestinal conditions among patients with atrial fibrillation.**

*Abstract:* American Heart Association's Scientific Sessions, Orlando, FL Nov 12-16, 2011.

*Authors:* Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

**Does route of administration for estrogen hormone therapy and estradiol transdermal system dosage strength impact risk of venous thromboembolism.**

*Abstract:* 22nd Annual Meeting of the North American Menopause Society, Washington, DC Sept 21-24, 2011.

*Authors:* Kahler KH, Nyirady J, Beresford E, Laliberte F, Dea K, Sheng Duh M, Lefebvre P.

**Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.**

*Abstract:* 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Chicago, IL Aug 14-17, 2011.

*Authors:* Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

**Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the US.**

*Abstract:* 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) (ICPE), Chicago, IL Aug 14-17, 2011.

*Authors:* Korves C, Eldar-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS.

**Antithrombotic treatment patterns, hospitalizations, and associated costs in acute coronary syndrome (ACS) patients.**

*Abstract:* Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2011 Scientific Sessions, Washington, DC May 12-14, 2011.

*Authors:* Lefebvre P, Laliberte F, Dea K, Nelson W, Crivera C, Ellis L, Schein JR, Damaraju CV, Mody S, Duh MS.

**Clinical characteristics, blood pressure (BP) control, and antihypertensive treatment (TRX) patterns among elderly patients (PTS) with hypertension (HTN).**

*Abstract:* 26th Annual Scientific Meeting and Exposition of the American Society of Hypertension, Inc., New York, NY May 21-24, 2011.

*Authors:* Sarda SP, Wang ST, Ramamurthy P, Wei R, Parkt J, Andrews LM, Frech-Tamas F, Duh MS.

**Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system versus oral estrogen-only hormone therapy.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

**Impact of initial antihypertensive treatment with a single-pill combination on blood pressure (BP) goal attainment: A matched cohort study.**

*Abstract:* 26th Annual Scientific Meeting and Exposition of the American Society of Hypertension, Inc., New York, NY May 21-24, 2011.

*Authors:* Gradman AH, Parish H, Lafeuille MH, Falvey H, Lefebvre P, Duh MS.

**Impact of initial combination therapy vs monotherapy on major cardiovascular (CV) events: A matched cohort study.**

*Abstract:* 26th Annual Scientific Meeting and Exposition of the American Society of Hypertension, Inc., New York, NY May 21-24, 2011.

*Authors:* Gradman AH, Parish H, Lafeuille MH, Falvey H, Lefebvre P, Duh MS.

**Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the united states.**

*Abstract:* Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2011 Scientific Sessions, Washington, DC May 12-14, 2011.

*Authors:* Korves C, Eldar-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS.

**Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the United States.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Korves C, Eldar-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS.

**A single-center experience with low-dose warfarin in patients undergoing total hip or total knee replacement surgery.**

*Abstract:* Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2011 Scientific Sessions, Washington, DC May 12-14, 2011.

*Authors:* Balcom WB, Bookhart BK, Mishol DN, Eapen S, Nutescu EA, Schein JR, Duh MS.

**Treatment persistence among atrial fibrillation/flutter patients on combination warfarin and antiarrhythmic drug therapy in the real-world setting.**

*Abstract:* Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2011 Scientific Sessions, Washington, DC May 12-14, 2011.

*Authors:* Alpert JS, Guerin A, Lin J, Jhaveri M, Wu EQ.

**Evaluation of international normalized ratio monitoring and anticoagulation control in atrial fibrillation/flutter patients using warfarin and antiarrhythmic drug therapy.**

*Abstract:* 60th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, New Orleans, LA Apr 2-5, 2011.

*Authors:* Alpert JS, Guerin A, Lin J, Jhaveri M, Wu EQ.

**Long-term consequences and costs associated with venous thromboembolism.**

*Abstract:* AMCP's 23rd Annual Meeting, Minneapolis, MN Apr 27-29, 2011.

*Authors:* Mody S, Lefebvre P, Laliberte F, Nutescu E, Duh MS, LaMori J, Bookhart BK, Olson W, Dea K, Schein J, Kaatz S.

**Real-world clinical outcomes and costs in atrial fibrillation/flutter patients on combined warfarin and antiarrhythmic drug therapy.**

*Abstract:* AMCP's 23rd Annual Meeting, Minneapolis, MN Apr 27-29, 2011.

*Authors:* Guerin A, Lin J, Jhaveri M, Wu E, Alpert J.

**Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.**

*Abstract:* 21st Annual Meeting of the North American Menopause Society, Chicago, IL Oct 6-9 2010.

*Authors:* Laliberte F, Dea K, Dub MS, Kahler KH, Rolli M, Lefebvre P.

**Persistence with nebivolol compared to other beta-blockers in the treatment of hypertension: A retrospective claims analysis.**

*Abstract:* High Blood Pressure Research 2010 Scientific Sessions, HBPR 2010 Washington, DC Oct 13-16, 2010.

*Authors:* Signorovitch J, Samuelson T, Ramakrishnan K, Marynchenko M, Blum SI, Ramasamy A, Wu EQ.

**Pulmonary arterial hypertension (PAH) cost of illness in the U.S. Privately-insured population.**

*Abstract:* Chest 2010 Meeting, Vancouver, BC, Canada Oct 30 - Nov 4, 2010.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.



**The epidemiology, treatment and care patterns, and medical resource utilization following hospitalization for heart failure.**

*Abstract:* International Conference on Pharmacoepidemiology & Risk Management, Brighton, UK Aug 19-22, 2010.

*Authors:* Korves C, McHale J, Lafeuille MH, Ariely R, Duh MS.

**Aliskiren combined with angiotensin II-receptor blockers (ARB) resulted in better outcomes compared to ARB combined with angiotensin-converting enzyme inhibitors (ACEI): Results from a claims database analysis.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Chang JR, Yang W, Kahler KH, Fellers TS, Orloff J, Bensimon AG, Yu AP, Fan CPS, Wu EQ.

**Blood pressure goal achievement among hypertension patients treated with valsartan-based single pill combination vs. ARB-based free combination in South Central region.**

*Abstract:* ISPOR 15th Annual International Meeting Atlanta, GA May 15-19, 2010.

*Authors:* Chang JR, Yang W, Fellers TS, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ.

**Cardiovascular and economic outcomes following initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.**

*Abstract:* Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2010 Scientific Sessions, Washington, DC May 19-21, 2010.

*Authors:* Simpson Jr R, Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A.

**Compliance and health care utilization among patients with hypertension treated with single pill vs. free combination antihypertensive therapy: U.S. national and state level results from a claims database analysis.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Yang W, Chang JR, Kahler KH, Fellers TS, Orloff J, Wu EQ, Bensimon AG, Fan CPS, Yu AP.

**Economic impact of switching from valsartan to other angiotensin II receptor blockers (ARBS) in patients with hypertension.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani H, Kahler KH.

**Hospitalization due to heart failure is associated with significant medical resource utilization and costs.**

*Abstract:* Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2010 Scientific Sessions, Washington, DC May 19-21, 2010.

*Authors:* Korves C, McHale J, Lafeuille MH, Ariely R, Duh MS.

**Incidence rate of venous thromboembolism and hemorrhage in patients undergoing total hip or knee arthroplasty: A managed care perspective.**

*Abstract:* AMCP's 22nd Annual Meeting, San Diego, CA Apr 7-10, 2010.

*Authors:* Lefebvre P, Vekeman F, Nutescu E, Duh M, Bookhart B, Schein J, Dea K.

**Economic impact of switching from valsartan to other angiotensin II receptor blockers for nonmedical reasons in patients with hypertension.**

*Abstract:* AMCP's 2009 Educational Conference, San Antonio, TX Oct 7-9, 2009.

*Authors:* Wu EQ, Signorovitch J, Yu AP, Latremouille-Viau D, Dastani HB, Kahler K.

**Healthcare costs and resource utilization of patients receiving combination treatments of angiotensin receptor blocker with chlorthalidone or with hydrochlorothiazide.**

*Abstract:* European Society of Cardiology, Barcelona, Spain Aug 29 - Sep 2, 2009.

*Authors:* Sun S, Yu A, Chen K, Mattson M, Xu Y, Dabbous O.

**The association of aspirin use on risk of hospitalization in CHF patients taking ace inhibitors: A retrospective analysis of a national cohort of veterans.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Parikh NM, Shah DH, Deswal A, Ashton CM, Agarwal SJ, Chen H, Johnson M.

**Cost trend associated with cardiovascular (CV) events in patients (pts) with hypertension (HTN) in US managed care settings.**

*Abstract:* 24th Annual Scientific Meeting and Exposition of the American Society of Hypertension, San Francisco, CA May 6-9, 2009.

*Authors:* Jayawant SS, Fulcher N, Ramamurthy P, Moyneur E, Ong SH, Duh MS.

**The risk of coronary heart disease and stroke among psoriasis patients.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Kimball A, Guerin A, Mulani P, Gupta S.

**Impact of Single-Photon Emission Computed Tomography (SPECT) Use after Acute Myocardial Infarction (AMI) on Cardiac Procedures Rates and Hospital Length of Stay.**

*Abstract:* American Society of Nuclear Cardiology, San Diego, CA Sep 6-9, 2007.

*Authors:* Wu EQ, Persson B, Beaulieu N, White L, Spalding J, Mahmarian JJ.

**Comparison of Alternative Strategies for the Diagnosis of Acute Cardiac Ischemia in Emergency Departments: Standard of Care versus BMIPP.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR).

*Authors:* Wu EQ, Birnbaum H, Cremieux P, Carpenter S, Borys N, Babich J.

**Cost and Comorbidities Associated with Atrial Fibrillation.**

*Abstract:* NASPE - Heart Rhythm Society.

*Authors:* Wu EQ, Howard BG, Mareva MN.

**PCV22 Cost and comorbidities associated with atrial fibrillation in different age groups.**

*Abstract:* ISPOR, 2004.

*Authors:* Wu E, Birnbaum H, Milena M.

## Dermatology

### Journal Articles

**Burden of Herpes Zoster Among Patients with Psoriasis in the United States.**

*Publication:* Dermatol Ther (Heidelb) 2023 09. e-pub ahead of print 2023/09/23; doi: 10.1007/s13555-023-00988-y.

*Authors:* Singer D, Thompson-Leduc P, Ma S, Gupta D, Cheng WY, Sendhil SR, Sundar M, Hagopian E, Stempniewicz N, Duh MS, Poston S.

**Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study.**

*Publication:* Dermatol Ther (Heidelb) 2023 08. e-pub ahead of print 2023/08/08; doi: 10.1007/s13555-023-00965-5.

*Authors:* Kimball AB, Delevry D, Yang M, Chuang CC, Wang Z, Bégo-Le-Bagousse G, Martins B, Wu E, Shumel B, Wang J, Sierka D, Chao J, Strober B.

**Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections.**

*Publication:* J Manag Care Spec Pharm 2023 06: 1-13. e-pub ahead of print 2023/06/12; doi:

10.18553/jmcp.2023.22454.

*Authors:* Lodise TP, Gunter K, Mu F, Gao E, Yang D, Yim E, Sandor S, Berman G.

**Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis.**

*Publication:* J Dermatolog Treat 2023 02: 1-13. e-pub ahead of print 2023/02/02; doi: 10.1080/09546634.2023.2169574.

*Authors:* Signorovitch J, Diels J, Van Sanden S, Schubert A, Hassan F, Thilakarathne P, Ozturk B, Barthelmes N, Reich K.

**Predicting Clinical Remission of Chronic Urticaria Using Random Survival Forests: Machine Learning Applied to Real-World Data.**

*Publication:* Dermatol Ther (Heidelb) 2022 10. e-pub ahead of print 2022/10/28; doi: 10.1007/s13555-022-00827-6.

*Authors:* Pivneva I, Balp MM, Geissbühler Y, Severin T, Smeets S, Signorovitch J, Royer J, Liang Y, Cornwall T, Pan J, Danyliv A, McKenna SJ, Marsland AM, Soong W.

**Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database Analysis.**

*Publication:* Adv Ther 2022 07. e-pub ahead of print 2022/07/14; doi: 10.1007/s12325-022-02197-z.

*Authors:* Wu JJ, Lafeuille MH, Emond B, Fakhri I, Duh MS, Cappelleri JC, Yin N, Feeney C, Myers DE, DiBonaventura M.

**Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis: 1-Year Results From the RELIEVE-AD Study.**

*Publication:* JAMA Dermatol 2022 02; 158(2): 142-150. e-pub ahead of print 2021/12/16; doi: 10.1001/jamadermatol.2021.4778.

*Authors:* Strober B, Mallya UG, Yang M, Ganguli S, Gadkari A, Wang J, Sierka D, Delevry D, Kimball AB.

**The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis.**

*Publication:* J Am Acad Dermatol 2021 12. e-pub ahead of print 2021/12/27; doi: 10.1016/j.jaad.2021.12.032.

*Authors:* Ryan C, Puig L, Zema C, Thompson EH, Yang M, Wu E, Bensimon A, Huang X, Joshi AD, Elewski B.

**Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials.**

*Publication:* Dermatol Ther (Heidelb) 2021 12. e-pub ahead of print 2021/12/19; doi: 10.1007/s13555-021-00660-3.

*Authors:* Lebwohl MG, Soliman AM, Yang H, Wang J, Hagan K, Padilla B, Pinter A.

**Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis.**

*Publication:* Dermatol Ther (Heidelb) 2021 12. e-pub ahead of print 2021/12/05; doi: 10.1007/s13555-021-00647-0.

*Authors:* Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Stakias V, Puig L.

**Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis: 1-Year Results From the RELIEVE-AD Study.**

*Publication:* JAMA Dermatol 2021 12. e-pub ahead of print 2021/12/16; doi: 10.1001/jamadermatol.2021.4778.

*Authors:* Strober B, Mallya UG, Yang M, Ganguli S, Gadkari A, Wang J, Sierka D, Delevry D, Kimball AB.

**Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis: 1-Year Results From the RELIEVE-AD Study.**

*Publication:* JAMA Dermatol 2021 12; 158(2): 142-150. doi: 10.1001/jamadermatol.2021.4778.

*Authors:* Strober B, Mallya UG, Yang M, Ganguli S, Gadkari A, Wang J, Sierka D, Delevry D, Kimball AB.

**Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data.**

*Publication:* J Am Acad Dermatol 2021 09; 85(3): 572-581. e-pub ahead of print 2021/02/26; doi: 10.1016/j.jaad.2021.02.057.

*Authors:* Shear NH, Betts KA, Soliman AM, Joshi A, Wang Y, Zhao J, Gisondi P, Sinvhal R, Armstrong AW.

**Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model.**

*Publication:* Dermatol Ther (Heidelb) 2021 05. e-pub ahead of print 2021/05/22; doi: 10.1007/s13555-021-00550-8.

*Authors:* Papp KA, Soliman AM, Done N, Carley C, Lemus Wirtz E, Puig L.

**Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis.**

*Publication:* Journal of Dermatological Treatment 2021 04: 1-8. doi: 10.1080/09546634.2021.1919287.

*Authors:* Lebwohl M, Soliman AM, Yang H, Wang J, Freimark J, Puig L.

**Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.**

*Publication:* Dermatol Ther (Heidelb) 2021 03. doi: 10.1007/s13555-021-00511-1.

*Authors:* Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Puig L, Augustin M.

**Comparative Safety and Benefit-Risk Profile of Biologics and Oral Treatments for Moderate-to-Severe Plaque Psoriasis: a Network Meta-Analysis of Clinical Trial Data.**

*Publication:* J Am Acad Dermatol 2021 02. doi: 10.1016/j.jaad.2021.02.057.

*Authors:* Shear NH, Betts KA, Soliman AM, Joshi, Wang Y, Zhao J, Gisondi P, Sinvhal R, Armstrong AW.

**Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.**

*Publication:* JAMA Dermatol 2020 10. doi: 10.1001/jamadermatol.2020.3617.

*Authors:* Augustin M, Lambert J, Zema C, Thompson EH, Yang M, Wu EQ, Garcia-Horton V, Geng Z, Valdes JM, Joshi A, Gordon KB.

**Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.**

*Publication:* JAMA Dermatol 2020 02. e-pub ahead of print 2020/02/06; doi: 10.1001/jamadermatol.2019.4029.

*Authors:* Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M.

**Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis.**

*Publication:* BMC Dermatology 2019 10; 19(1): 15. doi: 10.1186/s12895-019-0095-3.

*Authors:* Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, Brown M, Reaney M, Mahajan P, Guillemin I, Boguniewicz M, Pariser D.

**Long-term omalizumab outcomes in chronic idiopathic urticaria: a real-world study.**

*Publication:* Allergy Asthma Proc 2019 09; 40(5): 321-328. e-pub ahead of print 2019/07/28; doi: 10.2500/aap.2019.40.4236.

*Authors:* Kavati A, Zhdanava M, Ortiz B, LeCocq J, Schiffman B, Pilon D, Ching Cheung H, Lefebvre P, Stone BD.

**Impact of hidradenitis suppurativa on work loss, indirect costs and income.**

*Publication:* Br J Dermatol 2019 08; 181(1): 147-154. e-pub ahead of print 2018/08/19; doi: 10.1111/bjd.17101.

*Authors:* Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J.

**Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.**

*Publication:* J Eur Acad Dermatol Venereol 2019 06; 33(6): 1107-1115. e-pub ahead of print 2018/11/26; doi: 10.1111/jdv.15369.

*Authors:* Bewley AP, Shear NH, Calzavara-Pinton PG, Hansen JB, Nyeland ME, Signorovitch J.

**Dupilumab versus Cyclosporine for Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.**

*Publication:* Acta Derm Venereol 2019 05.

*Authors:* Ariëns LF, Gadkari A, van Os-Medendorp H, Ayyagari R, Terasawa E, Kuznik A, Chen Z, Bégo-Le Bagousse G, Lu Y, Rizova E, Graham NM.

**The economic burden of psoriasis with high comorbidity among privately insured patients in the United States.**

*Publication:* J Med Econ 2019 02; 22(2): 196-203. e-pub ahead of print 2018/12/14; doi: 10.1080/13696998.2018.1557201.

*Authors:* Pilon D, Teeple A, Zhdanova M, Ladouceur M, Ching Cheung H, Muser E, Lefebvre P.

**Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa.**

*Publication:* J Eur Acad Dermatol Venereol 2018 12; 32(12): 2254-2256. e-pub ahead of print 2018/07/01; doi: 10.1111/jdv.15163.

*Authors:* Kimball AB, Ganguli A, Fleischer A.

**Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis.**

*Publication:* J Drugs Dermatol 2018 11; 17(11): 1211-1218. e-pub ahead of print 2018/12/01.

*Authors:* Wu JJ, Armstrong A, Singh R, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Arian D, Fleischer A, Guerin A, Ganguli A.

**Real-World Evidence of Disease Burden in Obese Patients Hospitalized With Acute Bacterial Skin and Skin-Structure Infections.**

*Publication:* Infectious Diseases in Clinical Practice 2018 11; 26(6): 333-338. doi: 10.1097/ipc.0000000000000688.

*Authors:* McGinnis E, Ayyagari R, Tan R-D, Tuttle E, Cammarata S, Tillotson G.

**The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis.**

*Publication:* Dermatol Ther (Heidelb) 2018 10. e-pub ahead of print 2018/10/12; doi: 10.1007/s13555-018-0264-z.

*Authors:* Kimball AB, Sundaram M, Gauthier G, Guerin A, Pivneva I, Singh R, Ganguli A.

**Adverse medical conditions in patients with psoriasis treated with biologic versus conventional systemic therapy: A United States claims-based analysis.**

*Publication:* J Am Acad Dermatol 2018 09; 79(3): AB32. doi: 10.1016/j.jaad.2018.05.170.

*Authors:* Wu J, Armstrong A, Singh R, Cloutier M, Gauthier-Loiselle M, Arian D, Fleischer A, Ganguli A.

**Multiple and more complex surgical procedures for hidradenitis suppurativa (HS) are associated with a substantial economic burden.**

*Publication:* J Am Acad Dermatol 2018 09; 79(3): AB196. doi: 10.1016/j.jaad.2018.05.791.

*Authors:* A.B. K, R. S, I. P, A.B. F, X. L, A. G, A. G.

**Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis.**

*Publication:* JAMA Dermatol 2018 08; 154(8): 903-912. e-pub ahead of print 2018/07/05; doi: 10.1001/jamadermatol.2018.1572.

*Authors:* Simpson EL, Guttman-Yassky E, Margolis DJ, Feldman SR, Qureshi A, Hata T, Mastey V, Wei W, Eckert L, Chao J, Arnold RJG, Yu T, Vekeman F, Suarez-Farinas M, Gadkari A.

**Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.**

*Publication:* Curr Med Res Opin 2018 07; 34(7): 1325-1333. e-pub ahead of print 2018/04/06; doi: 10.1080/03007995.2018.1457516.

*Authors:* Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

**The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus phototherapy: An observational cohort study.**

*Publication:* J Am Acad Dermatol 2018 07; 79(1): 60-68. doi: <http://dx.doi.org/10.1016/j.jaad.2018.02.050>.

*Authors:* Wu JJ, Sundaram M, Cloutier M, Gauthier-Loiselle M, Guerin A, Singh R, Ganguli A.

**Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: A real-world study in the United States.**

*Publication:* Allergy Asthma Proc 2018 05; 39(3): 201-211. e-pub ahead of print 2018/03/09; doi: 10.2500/aap.2018.39.4129.

*Authors:* Williams P, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Hernandez-Trujillo V.

**Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States.**

*Publication:* Allergy Asthma Proc 2018 05; 39(3): 191-200. e-pub ahead of print 2018/02/21; doi: 10.2500/aap.2018.39.4132.

*Authors:* Eghrari-Sabet J, Sher E, Kavati A, Pilon D, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Bernstein JA.

**Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States.**

*Publication:* Dermatol Ther (Heidelb) 2018 03; 8(1): 69-83. e-pub ahead of print 2018/02/13; doi: 10.1007/s13555-018-0225-6.

*Authors:* Williams PV, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Hernandez-Trujillo V.

**Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis.**

*Publication:* J Drugs Dermatol 2018 02; 17(2): 180-186. e-pub ahead of print 2018/02/21.

*Authors:* Kimball AB, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Ganguli A.

**Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.**

*Publication:* Journal of Dermatological Treatment 2018 02; 29(1): 24-31. e-pub ahead of print 2017/06/14; doi: <http://dx.doi.org/10.1080/09546634.2017.1341607>.

*Authors:* Imafuku S, Nakano A, Dakeshita H, Li J, Betts KA, Guerin A.

**Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis.**

*Publication:* J Drugs Dermatol 2018 02; 17(2): 187-194. e-pub ahead of print 2018/02/21.

*Authors:* Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Guerin A, Ganguli A.

**Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.**

*Publication:* Value Health 2018 01; 21(1): 1-8. e-pub ahead of print 2018/01/07; doi: 10.1016/j.jval.2017.05.025.

*Authors:* Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE.

**Network meta-analysis and cost per responder of targeted immunomodulators in the treatment of active psoriatic arthritis.**

*Publication:* BMC Rheumatology 2018 01; 2 (1) (no pagination)(3). doi: <http://dx.doi.org/10.1186/s41927-018-0011-1>.

*Authors:* Strand V, Elaine Husni M, Betts KA, Song Y, Singh R, Griffith J, Beppu M, Zhao J, Ganguli A.

**Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials.**

*Publication:* J Am Acad Dermatol 2017 12; 77(6): 1030-1037. e-pub ahead of print 2017/10/11; doi: 10.1016/j.jaad.2017.08.017.

*Authors:* Gordon KB, Betts KA, Sundaram M, Signorovitch JE, Li J, Xie M, Wu EQ, Okun MM.

**Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014.**

*Publication:* J Am Acad Dermatol 2017 07; 77(1): 55-62 e53. doi: 10.1016/j.jaad.2017.02.050.

*Authors:* Migden M, Xie J, Wei J, Tang W, Herrera V, Palmer JB.

**Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study.**

*Publication:* Journal of Dermatological Treatment 2017 06; 28(4): 290-298. doi: 10.1080/09546634.2016.1247946.

*Authors:* Wu JJ, Guerin A, Gauthier G, Sundaram M.

**Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate.**

*Publication:* J Am Acad Dermatol 2017 01; 76(1): 81-90. doi: 10.1016/j.jaad.2016.07.042.

*Authors:* Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P.

**Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naive patients with psoriasis.**

*Publication:* J Am Acad Dermatol 2016 10; 75(4): 740-746. e-pub ahead of print 2016/08/02; doi: 10.1016/j.jaad.2016.05.040.

*Authors:* Armstrong AW, Betts KA, Sundaram M, Thomason D, Signorovitch JE.

**Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population.**

*Publication:* J Med Econ 2016 07; 19(7): 649-654. e-pub ahead of print 2016/02/07; doi: 10.3111/13696998.2016.1151433.

*Authors:* Bradford Rice J, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M.

**What happens after a single surgical intervention for hidradenitis suppurativa? A retrospective claims-based analysis.**

*Publication:* J Med Econ 2016 07; 19(7): 710-717. doi: 10.3111/13696998.2016.1161636.

*Authors:* Jemec GB, Guerin A, Kaminsky M, Okun M, Sundaram M.

**Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review.**

*Publication:* J Community Support Oncol 2016 01; 14(1): 21-28. e-pub ahead of print 2016/02/13; doi: 10.12788/jcso.0193.

*Authors:* Brown J, Su Y, Nelleson D, Shankar P, Mayo C.

**Psoriasis and risk of diabetes-associated microvascular and macrovascular complications.**

*Publication:* J Am Acad Dermatol 2015 06; 72(6): 968-977 e962. doi: 10.1016/j.jaad.2015.02.1095.

*Authors:* Armstrong AW, Guerin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Iltu R, Mulani P.

**Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.**

*Publication:* Arthritis Care Res (Hoboken) 2015 05; 67(5): 708-717. doi: 10.1002/acr.22492.

*Authors:* Feldman SR, Zhao Y, Shi L, Tran MH, Lu J.

**Psoriasis Treatment Patterns: Phototherapy, Oral Nonbiologic, and Biologic Therapies.**

*Publication:* Am J Pharm Benefits 2015 05.

*Authors:* Kimball AB GG, Hiscock R, Zhang HF.

**Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response.**

*Publication:* Br J Dermatol 2015 02; 172(2): 504-512. doi: 10.1111/bjd.13437.

*Authors:* Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.

**Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.**

*Publication:* Br J Dermatol 2014 12; 171(6): 1434-1442. doi: 10.1111/bjd.13270.

*Authors:* Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M.

**Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.**

*Publication:* J Eur Acad Dermatol Venereol 2014 06; 28(6): 790-798. doi: 10.1111/jdv.12177.

*Authors:* Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y, Valdes JM, Mulani PM.

**Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.**

*Publication:* Br J Dermatol 2012 12; 167(6): 1374-1381. doi: 10.1111/bjd.12000.

*Authors:* Strober BE, Sobell JM, Duffin KC, Bao Y, Guerin A, Yang H, Goldblum O, Okun MM, Mulani PM.

**Risks of developing psychiatric disorders in pediatric patients with psoriasis.**

*Publication:* J Am Acad Dermatol 2012 10; 67(4): 651-657 e651-652. doi: 10.1016/j.jaad.2011.11.948.

*Authors:* Kimball AB, Wu EQ, Guerin A, Yu AP, Tsaneva M, Gupta SR, Bao Y, Mulani PM.

**The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.**

*Publication:* J Am Acad Dermatol 2012 02; 66(2): e67-76. doi: 10.1016/j.jaad.2010.10.020.

*Authors:* Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM.

**Economic burden of comorbidities in patients with psoriasis is substantial.**

*Publication:* J Eur Acad Dermatol Venereol 2011 02; 25(2): 157-163. doi: 10.1111/j.1468-3083.2010.03730.x.

*Authors:* Kimball AB, Guerin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

**Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.**

*Publication:* Am J Clin Dermatol 2011 02; 12(1): 51-62. doi: 10.2165/11530640-000000000-00000.

*Authors:* Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.

**Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.**

*Publication:* Clin Drug Investig 2011 01; 31(1): 51-60. doi: 10.2165/11539360-000000000-00000.

*Authors:* Papp KA, Signorovitch J, Ramakrishnan K, Yu AP, Gupta SR, Bao Y, Mulani PM.

**Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.**

*Publication:* J Am Acad Dermatol 2010 12; 63(6): 1011-1018. doi: 10.1016/j.jaad.2009.12.029.

*Authors:* Reich K, Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

**Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.**

*Publication:* Dermatology 2010 11; 220(1): 1-7. doi: 10.1159/000260371.

*Authors:* Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

**Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept.**



*Publication:* PharmacoEconomics 2010 09; 28(10): 935-945. doi: 10.2165/11538370-000000000-00000.

*Authors:* Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, Gupta SR, Mulani PM.

**The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.**

*Publication:* J Am Acad Dermatol 2010 05; 62(5): 812-818. doi: 10.1016/j.jaad.2009.07.022.

*Authors:* Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P.

**Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.**

*Publication:* Am J Med 2010 04; 123(4): 350-357. doi: 10.1016/j.amjmed.2009.08.022.

*Authors:* Kimball AB, Guerin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P.

**High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice.**

*Publication:* Dermatology 2010 02; 220(2): 128-137. doi: 10.1159/000275198.

*Authors:* Saurat JH, Guerin A, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, Bao Y, Mulani PM.

**Economic burden of psoriasis compared to the general population and stratified by disease severity.**

*Publication:* Current Medical Research & Opinion 2009 10; 25(10): 2429-2438. doi: 10.1185/03007990903185557.

*Authors:* Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, Mulani PM.

**Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population.**

*Publication:* Current Medical Research & Opinion 2008 12; 24(12): 3493-3501. doi: 10.1185/03007990802551057.

*Authors:* Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK.

**The impact of psoriasis on health care costs and patient work loss.**

*Publication:* J Am Acad Dermatol 2008 11; 59(5): 772-780. doi: 10.1016/j.jaad.2008.06.043.

*Authors:* Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G.

**The direct and indirect cost burden of atopic dermatitis: an employer-payer perspective.**

*Publication:* Manag Care Interface 2007 10; 20(10): 26-32.

*Authors:* Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G.

**A survey-based assessment of the prevalence and severity of chronic hand dermatitis in a managed care organization.**

*Publication:* Cutis 2006 06; 77(6): 385-392.

*Authors:* Fowler JF, Duh MS, Chang J, Person J, Thorn D, Raut M, Ghosh A, Den E, Emani S.

**Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs.**

*Publication:* J Am Acad Dermatol 2006 03; 54(3): 448-457. doi: 10.1016/j.jaad.2005.11.1053.

*Authors:* Fowler JF, Ghosh A, Sung J, Emani S, Chang J, Den E, Thorn D, Person J, Duh MS.

## Abstracts

**Resource utilization of different remission and relapse profiles in chronic urticaria.**

Copenhagen, Denmark November 12-15, 2023.

*Authors:* Balp M-M, Pivneva I, Danyliv A, Chen K, Cornwall T, Signorovitch J, Patil D, Kohli RK, Severin T, Soong W, Marsland A.

**Dupilumab Improves Patient-Reported Symptom Control Among Adults with Moderate-to-Severe Atopic Dermatitis in Clinical Practice: 4-Year Follow-up Results From the RELIEVE-AD Study.**

Berlin, Germany October 11-14, 2023.

*Authors:* Wang Z, Yang M, Chao J, Martins B, Bego-Le-Bagousse G, Shumel B, Sierka D, Strober B, Kimball AB.

**Predicting psoriasis incidence based on neighborhood characteristics using machine learning.**

Berlin, Germany October 11-14, 2023.

*Authors:* Muntyanu A, Milan R, Rahme E, Pivneva I, Netchiporouk E.

**Real-world impact of achieving higher skin clearance on patient reported outcomes in risankizumab-treated patients with moderate to severe psoriasis - Evidence from an interim analysis of Risankizumab for the treatment of moderate to severe Psoriasis - An International medical chart review (RAPID) study.**

Berlin, Germany October 11-14, 2023.

*Authors:* Pinter A, Soliman AM, Pivneva I, Ghanbariamin R, Yang M, Puig L, Lebwohl M.

**Real-world long-term skin clearance and patient-reported outcomes among patients with moderate to severe psoriasis treated with risankizumab – an interim analysis from an international medical chart review (RAPID) study.**

Berlin, Germany October 11-14, 2023.

*Authors:* Pinter A, Soliman AM, Pivneva I, Ghanbariamin R, Yang M, Puig L, Lebwohl M.

**Remission and relapse profiles in chronic urticaria using real-world data.**

Berlin, Germany 11-14 October 2023.

*Authors:* Balp M-M, Pivneva I, Danyliv A, Chen K, Cornwall T, Signorovitch J, Patil D, Kohli RK, Severin T, Soong W, Marsland A.

**Sustained Improvement in Atopic Dermatitis Disease Control and Treatment Satisfaction with Dupilumab in Clinical Practice: 4-Year Follow-up Results From the RELIEVE-AD Study.**

Berlin, Germany October 11-14, 2023.

*Authors:* Wang Z, Yang M, Chao J, Martins B, Bego-Le-Bagousse G, Shumel B, Sierka D, Strober B.

**Real-World Effectiveness of Dupilumab in Atopic Dermatitis - A Targeted Literature Review and Meta-Analysis.**

Gdańsk, Poland August 31-September 2, 2023.

*Authors:* de Bruin-Weller M, Silverberg J, Sierka D, Martins B, Yang M, Frean M, Guyot P, Noonan K, Wang JZ, Bégo-Le-Bagousse G.

**Real-World Effectiveness of Dupilumab in Atopic Dermatitis - A Targeted Literature Review and Meta-Analysis.**

Gdańsk, Poland August 31 - September 2, 2023.

*Authors:* de Bruin-Weller M, Silverberg J, Sierka D, Martins B, Yang M, Frean M, Guyot P, Noonan K, Wang JZ, Bégo-Le-Bagousse G.

**Treatment Patterns and Inadequate Symptom Control Among Commercially Insured Patients with Moderate-to-Severe Acne Vulgaris in the US: A Retrospective Cohort Study.**

New Orleans, Louisiana March 17-21, 2023.

*Authors:* Harper J, Dashputre AA, Serra E, Qu W, Borroto D, Gagnon-Sanschagrin P, Lin T, Bumpass B, Guérin A, Joseph G.

**Clinical features associated with a treatment-refractory phenotype in chronic spontaneous urticaria (CSU).**

San Antonio, TX February 24-27, 2023.

*Authors:* Soong W, Patil D, Pivneva I, Signorovitch J, Wells MA, Balp M-M, Kuruvilla M.

**Remission and comorbidities in chronic spontaneous and chronic inducible urticaria.**

Berlin, Germany December 7-8, 2022.

*Authors:* Pivneva I, Balp M-M, Danyliv A, Chen K, Cornwall T, Signorovitch J, Severin T, Soong W, Marsland AM.

**Predicting time to clinical remission in chronic urticaria: can it be done with a simplified model?**

Milan, Italy September 7-10, 2022.

*Authors:* Balp M-M, Pivneva I, Geissbühler Y, Severin T, Smeets S, Signorovitch J, Cornwall T, Danyliv A, Walsh S, Soong W, Marsland AM.

**Comorbidity burden and healthcare resource utilization (HRU) associated with non-response to H1-antihistamines (H1AH) alone or in combination with non-biologic treatments for chronic spontaneous urticaria.**

Prague, Czech Republic July 1-3, 2022.

*Authors:* Soong W, Patil D, Pivneva I, Bhak R, Signorovitch J, Balp M-M, Freedle K.

**Dupilumab Improves Patient-Reported Outcomes Among Adults With Moderate-to-Severe Atopic Dermatitis (AD) in Clinical Practice: 30-36 Month Results From the RELIEVE-AD Study.**

Boston, MA March 25–29, 2022.

*Authors:* Strober B, Chao J, Chuang C, Yang M, Shumel B, Wang J, Bego-Le-Bagousse G, Sierka D, Wang Z, Delevry D.

**Early and Sustained Improvement in Atopic Dermatitis (AD) Disease Control and Treatment Satisfaction with Dupilumab in Clinical Practice: Long-Term Data from the RELIEVE-AD Study.**

Boston, MA March 25–29, 2022.

*Authors:* Strober B, Chao J, Chuang C, Yang M, Shumel B, Wang J, Bego-Le-Bagousse G, Sierka D, Wang Z, Delevry D.

**Long-Term Dupilumab Effectiveness on Health-Related Quality of Life (HRQoL) and Work Productivity in Atopic Dermatitis (AD): Results from RELIEVE-AD.**

Boston, MA March 25–29, 2022.

*Authors:* Delevry D, Chao J, Chuang C, Yang M, Shumel B, Martins B, Bego-Le-Bagousse G, Sierka D, Wang Z, Strober B.

**Factors influencing natural remission in chronic urticaria – preliminary results from a machine learning real-world study.**

*Abstract:* EAACI Hybrid Congress 2021, Krakow, Poland July 10-12, 2021.

*Authors:* Balp MM, Pivneva I, Geissbühler Y, Severin T, Smeets S, Signorovitch J, Royer J, Liang Y, Cornwall T, Pan J, Danyliv A, Marsland A, Soong W.

**Predicting time to natural remission in chronic urticaria using random survival forest model.**

*Abstract:* EAACI Hybrid Congress 2021, Krakow, Poland July 10-12, 2021.

*Authors:* Pivneva I, Balp MM, Geissbühler Y, Severin T, Smeets S, Signorovitch J, Royer J, Liang A, Cornwall T, Pan J, Danyliv A, Marsland A, Soong W.

**Comparison of biologic initiation and healthcare costs among patients with psoriasis receiving halobetasol-propionate 0.01%/ tazarotene 0.045% (HP/TAZ) lotion vs calcipotriene 0.005%/ betamethasone dipropionate 0.064% (CAL/BD) foam.**

*Abstract:* American Academy of Dermatology Association, Virtual March 19-23, 2021.

*Authors:* Kircik L, Joseph G, Gagnon-Sanschagrin P, Bumpass B, Serra E, Lin Y, Jacobson A, Guérin A, Glick BP.

**Indirect Burden of Illness in Patients with Generalized Pustular Psoriasis in the United States.**

*Abstract:* Virtual ISPOR Europe, Dec 2020.

*Authors:* Hanna M, Singer D, Tang W, Zhou J, Macaulay D, Valdecantos WC, Wu JJ.

**Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database.**

*Abstract:* AMCP 2020, Houston, TX April 21-24, 2020.

*Authors:* Duh M, Fakhri I, Lefeuvre M.

**Opioid Use Among Privately Insured Patients with Moderate to Severe Psoriasis in the United States.**

*Abstract:* AMCP Nexus Conference, Maryland, USA October 29-November 1, 2019.

*Authors:* Zhdanova M, Teeple A, Pilon D, Shak N, Fitzgerald T, Lefeuvre P.

**Dupilumab improves outcomes in patients with atopic dermatitis (AD) in clinical practice – Results from the RELIEVE-AD study.**

*Abstract:* European Academy of Dermatology and Venereology (EADV) 28th Congress, Madrid, Spain October 9–13, 2019.

*Authors:* Strober B, Mallya UG, Yang M, Gadkari A, Boklage S, Fenton M, Chamberlain CX, Sierka D, Wu EQ, Kimball AB.

**Dupilumab improves treatment satisfaction and reduces treatment burden in adults with atopic dermatitis: Results from the RELIEVE-AD study.**

*Abstract:* European Academy of Dermatology and Venereology (EADV) 28th Congress, Madrid, Spain October 9-October 13, 2019.

*Authors:* Kimball AB, Mallya UG, Yang M, Gadkari A, Boklage S, Fenton M, Chamberlain CX, Sierka D, Wu EQ, Strober BE.

**Comparison of safety outcomes for treatments of moderate to severe plaque psoriasis through a network meta-analysis.**

*Abstract:* 24th World Congress of Dermatology, Italy June 11–15, 2019.

*Authors:* Shear N, Joshi A, Zhao J, Betts K, Sinval R, Gisondi P, Kalabina S, Williams D, Armstrong A.

**Opioid and Healthcare Resource Use among Privately Insured Moderate-to-Severe Psoriasis Patients in the Us.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Zhdanova M, Teeple A, Pilon D, Shak N, Fitzgerald T, Lefeuvre P.

**Number needed to treat and cost per responder for flexible adalimumab dosing in the treatment of psoriasis in patients with suboptimal response to 40 mg every other week dosing.**

*Abstract:* 6th Congress of the Skin Inflammation and Psoriasis International Network, Paris, France Apr 25-27, 2019.

*Authors:* Savage LJ, Garcia-Horton V, Li J, Yin L, Betts KA, Calimlim B.

**The Comparative Efficacy for Novel Treatments of Moderate to Severe Plaque Psoriasis: A Network Meta-Analysis.**

*Abstract:* American Academy of Dermatology (AAD) Annual Meeting 2019, Washington, DC Mar 1–5, 2019.

*Authors:* Armstrong A, Puig L, Joshi A, Skup M, Kalabina S, Williams D, Li J, Garcia-Horton V, Betts K, Augustin M.

**Long-Term Safety Profile of Adalimumab versus Ustekinumab in Psoriasis - A Real World Matching-Adjusted Indirect Comparison (MAIC).**

*Abstract:* American Academy of Dermatology (AAD) Annual Meeting 2019, Washington, DC Mar 1–5, 2019.

*Authors:* Wu J, Singh R, Yang M, Li J, Bereswill M, Garcia-Horton V, Valdecantos W, Arian D, Weiss S.

**Incremental benefits on patient-reported outcomes for achieving PASI90 or PASI100 over PASI75 in patients with moderate to severe psoriasis.**

*Abstract:* European Academy of Dermatology and Venereology, Paris, France Sep 12-16, 2018.

*Authors:* Ryan C, Puig L, Zema C, Thompson E, Yang M, Wu EQ, Huang X, Skup M, Elewski B.

**Incremental benefits on patient-reported outcomes for achieving PASI90 or PASI100 over PASI75 in patients with moderate to severe psoriasis.**

Paris, France September 12-16, 2018.

*Authors:* Ryan C, Puig L, Zema C, Thompson E, Yang M, Wu E, Huang X, Skup M, Elewski B.

**Indirect economic burden associated with multiple and more complex surgical procedures for hidradenitis suppurativa (HS).**

*Abstract:* 27th EADV Congress, Paris, France Sept 12-16, 2018.

*Authors:* Kimball A, Singh R, Pivneva I, Fleischer Jr. A, Liu O, Guerin A.

**Patient-Reported Outcomes from the IMMVent Trial: Comparison of Risankizumab with Adalimumab in Moderate to Severe Psoriasis Patients.**

*Abstract:* European Academy of Dermatology and Venereology, Paris, France Sep 12-16, 2018.

*Authors:* Crowley J, Skup M, Huang X, Yang M, Wu EQ, Thompson E, Zema C, Reich K.

**Risankizumab Significantly Improves Patient-Reported Outcomes in Moderate to Severe Psoriasis in Two Phase III UltIMMa Trials.**

*Abstract:* European Academy of Dermatology and Venereology, Paris, France Sept 12-16, 2018.

*Authors:* Augustin M, Lambert J, Zema C, Thompson E, Yang M, Wu EQ, Geng Z, Valdes J, Skup M, Gordon M.

**Comparison of the efficacy of dupilumab vs. ciclosporin using Eczema Area and Severity Index thresholds in adult patients with moderate-to-severe atopic dermatitis.**

*Abstract:* 10th George Rajka International Symposium on Atopic Dermatitis, Utrecht, Netherlands April 11-13, 2018.

*Authors:* Ariens LFM, Gadkari AS, Os-Medendorp H, Rajeev A, Terasawa E, Kuznik A, Chen Z, Le-Bagousse-Bego G, Lu Y, Rizova E, Graham NNMH, Pirozzi G, Shumel B, Eckert L, De Bruin-Weller MS.

**Economic outcomes associated with unsuitable immunosuppressant use in moderate-to-severe atopic dermatitis.**

*Abstract:* AMCP's 30th Annual Meeting, Boston, MA Apr 23-26, 2018.

*Authors:* Armstrong A, Chao J, Shah D, Garcia-Horton V, Macaulay D, Miao R, Mallya U.

**Adverse Medical Conditions across Treatment Options in Patients with Psoriasis: A Claims-Based Analysis.**

*Abstract:* Annual Meeting of the American Academy of Dermatology, San Diego, CA Feb 16-20, 2018.

*Authors:* Wu JJ, Armstrong A, Singh R, Ganguli A, Arian D, Fleishcher A, Cloutier M, Gauthier-Loiselle M.

**Risk of contraindication and drug-drug interaction (DDI) with use of systemic immunosuppressants (IMMs) in adult patients with atopic dermatitis (AD).**

*Abstract:* SID 2017, Portland, OR Apr 26-29, 2017.

*Authors:* Armstrong A, Wei W, Garcia-Horton V, Macaulay D, Schmerold L, Wu E, Shah D, Chao J.

**Drug cost per responder for the treatment of moderate-to-severe psoriasis and active psoriatic arthritis.**

*Abstract:* 75th Annual Meeting of the American Academy of Dermatology, Orlando, FL Mar 3-7, 2017.

*Authors:* Armstrong A, Merola J, Yang M, Li J, Zhao J, Sundaram M.

**Health-related quality of life and work productivity associated with HiSCR and NRS30 response among patients with moderate to severe hidradenitis suppurativa.**

*Abstract:* American Academy of Dermatology 75th Annual Meeting, Orlando, FL Mar 3-7, 2017.

*Authors:* Kimball A, Yang M, Song Y, Valdecantos W, Ganguli.

**High-Value Subpopulation for Skin Pain Improvement in Adalimumab-Treated Patients with Moderate to Severe Hidradenitis Suppurativa.**

*Abstract:* American Academy of Dermatology 75th Annual Meeting, Orlando, FL Mar 3-7, 2017.

*Authors:* Qureshi A, Yang M, Song Y, Zhang A, Sundaram M, Ganguli A.

**Patients' Willingness to Pay for a Subcutaneous Injection Device That Reduces Injection Site Pain in the Treatment of Psoriasis.**

*Abstract:* 25th European Academy of Dermatology and Venereology, Vienna, Austria Sep 28 - Oct 2, 2016.

*Authors:* Cividino A, Mittal M, Yang M, Signorovitch JE, M. S.

**Adalimumab Is Associated with Reduced Risk of Joint-related Signs and Symptoms Compared with Methotrexate in Patients with Moderate to Severe Psoriasis.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington DC March 4-8, 2016.

*Authors:* Merola J, Sundaram M, Yang M, Li J, Galebach P, Okun M.

**Cardiovascular (CV) event risk assessment in psoriasis (PS) patients treated with tumor necrosis factor-alpha inhibitors (TNFi) versus phototherapy.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Wu J, Cloutier M, Gauthier-Loiselle M, Guerin A, Sundaram M.

**Comparison of Outcomes between Psoriasis Patients who Switched from Etanercept to Adalimumab versus to Ustekinumab.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC March 4-8, 2016.

*Authors:* Jashin J, Wu J, Sundaram M, Guérin A, Gauthier G, Thompson-Leduc P.

**How is the severity of hidradenitis suppurativa measured in clinical practice?**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Sundaram M, Lin P, Thomason D, Signorovitch J.

**Long-term Effect of Achieving PASI90 Compared with PASI75 Response on Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis.**

Washington, DC March 4–8, 2016.

*Authors:* Ryan C, Sundaram M, Yang M, Goyal R, Signorovitch J.

**Numbers needed to treat and costs per responder for novel treatments of moderate to severe psoriasis.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Armstrong A, Betts K, Li J, Sundaram M, Wu E, Signorovitch J.

**Predicting PASI90 Response Among Adalimumab-Treated Patients with Moderate to Severe Psoriasis.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington DC March 4-8, 2016.

*Authors:* Ryan C, Sundaram M, Yang M, Goyal R, Zhou Z, Signorovitch J.

**Progression from a Milder to a More Severe Form of Hidradenitis Suppurativa is Associated with a Substantial Economic Burden.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC March 4-8, 2016.

*Authors:* Kimball A, Sundaram M, Gauthier G, Nitulescu R, Pivneva I, Guerin A.

**Progression from mild hidradenitis suppurativa (HS) to moderate-to-severe ( $m <sup>2</sup> /s$ ) HS is associated with a substantial economic burden.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Kimball A, Sundaram M, Gauthier G, Nitulescu R, Pivneva I, Guerin A.

**Psoriasis Plaque Resolution by Body Region and Plaque Signs with Adalimumab and Etanercept: an Indirect Comparison.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington DC March 4-8, 2016.

*Authors:* Papp K, Sundaram M, Yang M, Jarvis J, Signorovitch J.

**Relative efficacy and costs per responder for adalimumab versus secukinumab in the treatment of moderate to severe psoriasis.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Armstrong A, Betts K, Sundaram M, Li J, Wu E.

**Risk and economic burden of antibiotic failure in patients with moderate to severe hidradenitis suppurativa.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Kimball A, Sundaram M, Gauthier G, Pivneva I, Nitulescu R, Guerin A.

**Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured population in the US.**

*Abstract:* AMCP Nexus 2015, Orlando, FL Oct 26-29, 2015.

*Authors:* Bradford Rice J, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M.

**Cost per Responder Associated with Biologic Therapies for Psoriasis.**

*Abstract:* AMCP's 27th Annual Meeting, San Diego, CA Apr 7-10, 2015.

*Authors:* Liu Y, Reichmann W, Macaulay D.

**Comorbid psoriatic arthritis significantly impairs health-related quality of life in patients with moderate to severe psoriasis.**

*Abstract:* 73rd Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 20-24, 2015.

*Authors:* Kimball AB, Sundaram M, Signorovitch J, Yang M, Taska B.

**Comparative efficacy of methotrexate versus apremilast for methotrexatenaive psoriasis patients: An indirect comparison.**

*Abstract:* 73rd Annual Meeting of the American Academy of Dermatology San Francisco, CA Mar 20-24, 2015.

*Authors:* Armstrong AW, Betts K, Sundaram M, Thomason D, Signorovitch J.

**Health care resource utilization, health care costs, and dose escalation in biologic-naive psoriasis patients initiated on ustekinumab versus adalimumab.**

*Abstract:* 73rd Annual Meeting of the American Academy of Dermatology San Francisco, CA Mar 20-24, 2015.

*Authors:* Guerin A, Sundaram M, Gauthier G.

**Long-term Effect of Achieving PASI90 Compared with PASI75 Response on Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Ryan C, Sundaram M, Yang M, Goyal R, Signorovitch J.

**A practical model for early identification of response with methotrexate for moderate to severe psoriasis.**

*Abstract:* 73rd Annual Meeting of the American Academy of Dermatology San Francisco, CA Mar 20-24, 2015.

*Authors:* Gordon K, Sundaram M, Arunajadai S, Xie M, Signorovitch J, Betts K, Okun M.

**Rates and risk factors of PsA disease progression amongst newly diagnosed PsA patients.**

*Abstract:* 73rd Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 20-24, 2015.

*Authors:* Merolola J, Guerin A, Sundaram M, Jarvis J, Cummings AK, Ghorayeb E.

**Starting-dose trends over time in biologic-naive and biologic-experienced psoriasis patients initiated on ustekinumab or adalimumab.**

*Abstract:* 73rd Annual Meeting of the American Academy of Dermatology San Francisco, CA Mar 20-24, 2015.

*Authors:* Guerin A, Sundaram M, Gauthier G.

**Early identification of response with methotrexate for moderate-to-severe psoriasis.**

*Abstract:* 7th International Congress of Psoriasis: From Gene to Clinic, London, UK Dec 11-13, 2014.

*Authors:* Gordon K, Sundaram M, Arunajadai S, Xie M, Signorovitch J, Betts K, Okun M.

**Health care costs in psoriasis patients newly initiated on a biologic therapy or methotrexate.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Zhang F, Hiscock R.

**Severity, Healthcare Resource Use, and Costs of Patients Diagnosed with Hidradenitis Suppurativa in the United States: Evidence from a Large Administrative Claims Database. .**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Sundaram M, Guérin A, Styles A, M K.

**Higher health care costs and dose escalation rates in psoriasis patients treated with ustekinumab compared to adalimumab.**

*Abstract:* 72nd Annual Meeting of the American Academy of Dermatology Denver, CO Mar 21-25, 2014.

*Authors:* Guerin A, Wang K, Sundaram M.

**Incremental burden of psoriatic arthritis is substantial among patients with mild and moderate to severe psoriasis.**

*Abstract:* 72nd Annual Meeting of the American Academy of Dermatology, Denver, CO Mar 21-25, 2014.

*Authors:* Merola J, Guerin A, Jarvis JL, Wang K, Sundaram M.

**Nail psoriasis significantly impairs health-related quality of life among patients with chronic plaque psoriasis.**

*Abstract:* 72nd Annual Meeting of the American Academy of Dermatology Denver, CO Mar 21-25, 2014.

*Authors:* Okun M, Kageleiry A, Signorovitch J, Yang M, Sundaram M.

**Number needed to treat and cost per responder for biologic therapies for the treatment of moderate to severe psoriasis.**

*Abstract:* 72nd Annual Meeting of the American Academy of Dermatology, Denver, CO Mar 21-25, 2014.

*Authors:* Langley RG, Signorovitch J, Wang K, KA. B, Sundaram M, Mulani P, Yan S.

**Patient preferences and willingness to pay for enhancements to subcutaneous injection devices used to treat psoriasis.**

*Abstract:* 72nd Annual Meeting of the American Academy of Dermatology Denver, CO Mar 21-25, 2014.

*Authors:* Cividino A, Signorovitch JE, Skup M, Tundia N, Mulani P, Arulmani U, Bao Y.

**Economic and comorbidity burden of moderate-to-severe psoriasis.**

*Abstract:* Annual Maui Dermatology Conference, Maui, HI Jan 26-30, 2014.

*Authors:* Feldman S, Zhao Y, Tran MH, Shi L.

**Cost-effectiveness of biologic therapies for the treatment of moderate to severe psoriasis in the United Kingdom.**

*Abstract:* ISPOR 16th Annual European Congress, Dublin, Ireland Nov 2-6, 2013.

*Authors:* Betts KA, Sundaram M, Mughal F, Yan SY, Signorovitch J, Wang K, Wu EQ.

**Characteristics of psoriasis patients with self-assessed limited disease control despite physician-assessed clear or minimal skin disease.**

*Abstract:* 71st Annual Meeting of the American Academy of Dermatology, Miami Beach, FL Mar 1-5, 2013.

*Authors:* Kimball AB, Signorovitch JE, Sundaram M, Samuelson T.

**Detecting undiagnosed depression in patients with moderate to severe psoriasis: Development and validation of a risk score for use in dermatology.**

*Abstract:* American Academy of Dermatology 71st Annual Meeting, Miami Beach, FL Mar 1-5, 2013.

*Authors:* Cather JC, Sundaram M, Horn EJ, Yang M, Signorovitch JE.

**Economic burden of hidradenitis suppurativa after a single surgical intervention: Assessment of unmet needs using a retrospective claims-based analysis.**

*Abstract:* 71st Annual Meeting of the American Academy of Dermatology, Miami Beach, FL Mar 3-5, 2013.

*Authors:* Jemec G, Guerin A, Okun M, Kaminsky M, Sundaram M.

**Prevalence and incidence of hidradenitis suppurativa in the United States: Evidence from large administrative claims databases.**

*Abstract:* 71st Annual Meeting of the American Academy of Dermatology, Miami Beach, FL Mar 1-5, 2013.



*Authors:* Sundaram M, Styles A, Guerin A, Aberki C, Okun M, Hayes O, Mulani P.

**Validation of the hidradenitis suppurativa clinical response as a clinical endpoint for hidradenitis suppurativa treatment evaluation.**

*Abstract:* 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL Mar 1-5, 2013.

*Authors:* Okun M, Yang M, Sundaram M, Gu Y.

**Validation of the physician's global assessment of psoriasis of the hands and/or feet as a clinical endpoint.**

*Abstract:* American Academy of Dermatology 71st Annual Meeting, Miami Beach, FL Mar 1-5, 2013.

*Authors:* Goldblum O, Sundaram M, Yang M, Thomason D.

**Cost-effectiveness of biologic therapies for the treatment of moderate to severe psoriasis in Germany.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Betts K, Yan Y, Sundaram M, Hengst N, Wolff M, Bensimon AG.

**Characteristics of psoriasis patients with self-assessed limited disease control despite physician-assessed clear or minimal skin disease.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Kimball AB, Sundaram M, Samuelson TM, Signorovitch JE.

**Economic burden of hidradenitis suppurativa following a single surgical intervention: Assessment of unmet need using a retrospective claims-based analysis.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Jemec G, Guérin A, Sundaram M, Kaminsky MS, Okun MM.

**Indirect comparison suggests that adalimumab is associated with significantly more days of adverse event-free response versus etanercept.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Reich K, Signorovitch JE, Sundaram M, Mulani PM.

**Outcomes of switching to adalimumab vs. continuing methotrexate in patients with moderate to severe psoriasis stratified by initial response to methotrexate.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Reich K, Sundaram M, Signorovitch JE, Samuelson TM, Goldblum O, Fan L, Wu EQ, Mulani PM.

**Prevalence and incidence of hidradenitis suppurativa in the United States: Evidence from large administrative claims databases.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Sundaram M, Okun MM, Guérin A, Styles A, Hayes OA, Aberki C, Mulani PM.

**Psoriasis is significantly associated with lower rates of pregnancy and live births.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Cather JC, Horn EJ, Sundaram M, Latremouille-Viau D, Guérin A.

**Risk of developing micro- and macrovascular complications in diabetes patients with psoriasis.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Armstrong AW, Guérin A, Sundaram M, Faust E, Mulani PM.

**Treatment Patterns in Psoriasis Patients Newly Initiated on an Oral Conventional Systemic Therapy or on Phototherapy.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Zhang F, Guérin A, Hiscock R, Kimball A.

**Economic burden associated with workplace productivity losses (WPL) in patients with psoriasis in a population in the United States.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Zhang F, A G, Gauthier G, Day R, Khan Z.

**Economic burden of psoriasis (PSO) and obesity in patients with psoriasis in the United States.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

**Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

**Quality-of-life effects of psoriasis skin symptoms affecting different body regions.**

*Abstract:* 3rd World Psoriasis and Psoriatic Arthritis Conference 2012: "Psoriasis - A Global Health Challenge" Stockholm, Sweden Jun 27-Jul 1, 2012.

*Authors:* Kimball AB, Sundaram M, Signorovitch J, Yang M, Mulani PM.

**Sex differences in health-related quality of life in patients with moderate to severe psoriasis.**

*Abstract:* 3rd World Psoriasis and Psoriatic Arthritis Conference 2012: "Psoriasis - A Global Health Challenge" Stockholm, Sweden Jun 27-Jul 1, 2012.

*Authors:* Cather JC, Horn EJ, Sundaram M, Yang M, Farooqui S, Mulani PM.

**Economic burden of psoriasis and obesity in patients with psoriasis in the United States.**

*Abstract:* 70th Annual Meeting of the American Academy of Dermatology, San Diego, CA Mar 16-20, 2012.

*Authors:* Zhang F, Guerin A, Latremouille-Viau D, Day R, Khan Z.

**Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.**

*Abstract:* 70th Annual Meeting of the American Academy of Dermatology, San Diego, CA Mar 16-20, 2012.

*Authors:* Guerin A, Zhang F, Gauthier G, Day R, Khan Z.

**Psoriasis is significantly associated with lower rates of pregnancy and live births.**

*Abstract:* 70th Annual Meeting of the American Academy of Dermatology, San Diego, CA Mar 16-20, 2012.

*Authors:* Cather JC, Latremouille-Viau D, Horn EJ, Bao Y.

**Treatment patterns of psoriasis patients and trends over time.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Zhang F, Guérin A, Gauthier G, Day R, Khan Z.

**ABT-874 versus methotrexate in moderate to severe psoriasis: Effects on health-related quality-of-life outcomes.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Reich K, Tsaneva M, Sundaram M, Bao Y.

**Achieving long-term sustained response is associated with improvements in patient-reported outcomes in patients with psoriasis treated with ABT-874.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Yu A, Sundaram M, Bao Y.

**Adalimumab provides health-related quality of life benefits for patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Duffin K, Menter A, Yang H, Gupta S.

**Comparison of psoriasis sign and symptom reduction and complete clearance with adalimumab versus etanercept.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Signorovitch J, Mulani P, Bao Y.

**Effects of ABT-874 treatment on health-related quality of life and Work Productivity and Activity Impairment in patients with psoriasis.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Signorovitch J, Sundaram M, Bao Y.

**Fatigue outcomes following withdrawal from and retreatment with adalimumab among patients maintained on adalimumab for moderate to severe psoriasis.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Wu E, Goldblum O, Gupta S.

**Health care outcomes associated with continuous use of adalimumab versus continuous and intermittent use of etanercept in patients with psoriasis.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Latremouille-Viau D, Mulani P, Gupta S.

**Health-related quality of life in patients with moderate to severe psoriasis: Effects of treatment with ABT-874 versus etanercept or placebo.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Crowley J, Yang H, Sundaram M, Mulani P.

**Health-related quality of life outcomes in patients with moderate to severe psoriasis treated with ABT-874 versus etanercept or placebo.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Menter A, Signorovitch J, Sundaram M, Bao Y.

**Persistent impairment of work productivity and activity in patients with longer disease duration of psoriasis with hand/foot involvement.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA Feb 4-8, 2011.

*Authors:* Kimball A, Mulani P, Gupta S, Signorovitch J.

**Resource utilization and costs associated with adalimumab or etanercept for moderate to severe psoriasis in a real-world setting.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Guerin A, Gupta S, Bao Y.

**Resource utilization and costs associated with switching from etanercept to adalimumab versus dose escalating with etanercept in patients with psoriasis.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Guerin A, Mulani P, Gupta S.

**ABT-874 versus etanercept or placebo treatment for moderate to severe psoriasis: Health-related quality of life.**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden Oct 6-10, 2010.

*Authors:* Menter A, Signorovitch J, Parikh K, Yu A, Wu E, Yoo S, Gu Y, Valdes J, Sundaram M, Bao Y, Mulani P.

**Adalimumab improves sleep symptoms in patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy.**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden Oct 6-10, 2010.

*Authors:* Duffin K, Guérin A, Yang H, Wu E, Yu A, Gupta S, Goldblum O, Bao Y, Mulani P.

**Adalimumab provides health-related quality-of life benefits for patients with psoriasis with suboptimal response to etanercept methotrexate, or phototherapy.**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden Oct 6-10, 2010.

*Authors:* Menter A, Guérin A, Yang H, Wu EQ, Yu AP, Gupta SR, Goldblum O, Bao Y, Mulani PM.

**Benefit-risk analysis of adalimumab for patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy.**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden Oct 6-10, 2010.

*Authors:* Papp K, Guérin A, Parikh K, Signorovitch J, Yu AP, Wu EQ, Okun M, Gupta SR, Bao Y, Mulani PM.

**Effects of ABT-874 versus etanercept or placebo on health-related quality of life in patients with moderate to severe psoriasis.**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden Oct 6-10, 2010.

*Authors:* Crowley J, Signorovitch J, Tsaneva M, Ramakrishnan K, Yu AP, Yoo S, Valdes J, Sundaram M, Bao Y, Mulani P.

**Longer disease duration of psoriasis with hand/foot involvement is independently associated with persistent impairment of work productivity and activity.**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden Oct 6-10, 2010.

*Authors:* Kimball AB, Signorovitch J, Farooqui S, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

**Psoriasis treatment with ABT-874: Effects on health-related quality of life and work productivity and activity impairment.**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden Oct 6-10, 2010.

*Authors:* Papp K, Signorovitch J, Yang H, Yu AP, Wu EQ, Yoo S, Gu Y, Williams D, Valdes J, Sundaram M, Bao Y, Mulani P.

**Resource utilization and costs in patients with moderate to severe psoriasis treated with adalimumab or etanercept in a real-world setting.**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden Oct 6-10, 2010.

*Authors:* Wu EQ, Guérin A, Latremouille-Viau D, Yu AP, Cloutier M, Gupta SR, Bao Y, Mulani PM.

**Burden of illness in patients with hidradenitis suppurativa.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL May 5-9, 2010.

*Authors:* Guerin A, Mulani P, Gupta S.

**Adalimumab monotherapy versus adalimumab plus betamethasone/calcipotriol combination therapy: Effects on patient-reported outcomes in patients with psoriasis.**

*Abstract:* American Academy of Dermatology 68th Annual Meeting, Miami Beach, FL Mar 5-9, 2010.

*Authors:* Thaçi D, Xie J, Gupta S, Mulani P.

**Adalimumab versus ustekinumab treatment for psoriasis: Clinical efficacy, safety and cost per responder.**

*Abstract:* American Academy of Dermatology 68th Annual Meeting, Miami Beach, FL Mar 5-9, 2010.

*Authors:* Wu EQ, Signorovitch JE, Bao Y, Mulani PM.

**Comorbidity prevalence in psoriasis patients: A meta-analysis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Mrowietz U, Guerin A, Mulani P, Gupta S.

**Comorbidity risks increase over time in patients with psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Yu A, Mulani P, Bao Y.

**Comparative effectiveness of adalimumab versus ustekinumab treatment for psoriasis: Clinical efficacy, safety, and cost per responder.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Wu E, Signorovitch J, Mulani P, Bao Y.

**Comparison of benefit-risk profiles for adalimumab, methotrexate, and placebo in the treatment of moderate to severe psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Papp K, Signorovitch J, Mulani P, Bao Y.

**Comparison of response rates and drug costs during maintenance therapy with adalimumab versus ustekinumab in patients with moderate to severe psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Signorovitch J, Kantor E, Mulani P, Bao Y.

**Cost per responder for biologic treatment of psoriasis: Matching-adjusted comparisons of adalimumab with etanercept, infliximab, and ustekinumab.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Signorovitch J, Mulani P, Gupta S, Bao Y.

**Cost-effectiveness of continuous adalimumab vs. continuous or intermittent etanercept for the treatment of psoriasis.**

*Abstract:* American Academy of Dermatology 68th Annual Meeting, Miami Beach, FL Mar 5-9, 2010.

*Authors:* Signorovitch J, Gupta SR, Bao Y, Mulan PM.

**Direct and indirect economic burden of employees with moderate to severe psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Reich K, Wu E, Mulani P, Gupta S.

**Economic burden of comorbidities in patients with psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Wu E, Mulani P, Bao Y.

**Effects of adalimumab monotherapy versus adalimumab plus betamethasone/calcipotriol combination therapy on patient-reported outcomes in psoriasis patients.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Thaci D, Xie J, Mulani P, Gupta S.

**Effects of adalimumab monotherapy versus adalimumab plus betamethasone/calcipotriol on patient-reported outcomes in patients with palmo-plantar, nail, or scalp psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Thaci D, Xie J, Mulani P, Gupta S.

**Increased cancer risks among patients with psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Guerin A, Mulani P, Bao Y.

**Increased economic burden associated with moderate to severe psoriasis compared with mild psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Yu A, Mulani P, Bao Y.

**Increased risk of psychiatric disorders in a pediatric population with psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Yu A, Mulani P, Gupta S.

**Longer psoriasis duration is independently associated with greater persistent functional impairment in patients with psoriatic arthritis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Signorovitch J, Mulani P, Bao Y.

**Potential drugdrug interactions of oral systemic therapies for psoriasis have adverse outcomes in a real-world setting.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Saurat JH, Guerin A, Mulani P, Gupta S.

**Psoriasis is associated with increased mortality risk.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Guerin A, Mulani P, Bao Y.

**Associated Resource Utilization and Costs of Patients with Psoriasis Switching from Etanercept to Adalimumab versus Dose Escalating with Etanercept.**

*Abstract:* American Academy of Dermatology 69th Annual Meeting, New Orleans, LA Feb 4-8, 2010.

*Authors:* Wu EQ GA, Lyon-Caen S, Latremouille-Viau D, Yu AP, Gupta SR, Bao Y.

**Healthcare Outcomes Associated with the Continuous Use of Adalimumab versus the Continuous and Intermittent Use of Etanercept in Patients with Psoriasis.**

*Abstract:* American Academy of Dermatology 69th Annual Meeting, New Orleans, LA Feb 4-8, 2010.

*Authors:* Wu EQ, Latremouille-Viau D, Guérin A, Cloutier M, Yu AP, Gupta SR, Bao Y.

**Risk-benefit analysis of adalimumab versus methotrexate and placebo for the treatment of moderate to severe psoriasis: Comparison of adverse event-free response days in the CHAMPION trial.**

*Abstract:* 39th Annual Meeting of the European Society for Dermatological Research, Budapest, Hungary Sep 9-12, 2009.

*Authors:* Reich K, Signorovitch J, Ramakrishnan K, Gupta S, Mulani P.

**Adalimumab reduces symptoms of depression in patients with moderate to severe psoriasis.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Menter A, Signorovitch J, Mulani P, Gupta S.

**Adalimumab reduces symptoms of psoriatic arthritis among psoriasis patients with comorbid psoriatic arthritis.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Mease P, Signorovitch J, Mulani P, Gupta S.

**Adalimumab treatment for moderate psoriasis reduces the risk of transitioning to severe psoriasis.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Papp K, Signorovitch J, Mulani P, Gupta S.

**Adalimumab's benefits for patient-reported outcomes in psoriasis patients are consistent across subgroups with different disease histories.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Kimball AB, Wu EQ, Mulani P, Gupta S.

**The benefits of adalimumab on clinical and patient-reported outcomes among moderate to severe psoriasis patients with comorbidities.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Kimball A, Chen L, Mulani P, Gupta S.

**Comorbidities of psoriasis have an independent effect on impairing patient health-related quality of life and work productivity.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Strober B, Guerin A, Mulani P, Gupta S.

**Discontinuation of adalimumab treatment for psoriasis following sustained response: Effects on health-related quality of life.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Menter A, Wu EQ, Mulani P.

**The effect of adalimumab on improving work productivity among moderate to severe psoriasis patients.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Kimball AB, Yu AP, Mulani P, Gupta S.

**The effect of adalimumab treatment for moderate to severe psoriasis on concurrent response for both psoriasis and psoriatic arthritis.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 3-10, 2009.

*Authors:* Mease P, Signorovitch J, Mulani P, Gupta S.

**Health-related quality of life and work productivity among psoriasis patients by disease severity.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Kimball A, Chen L, Mulani P, Gupta S.

**Risk-benefit analysis of adalimumab versus methotrexate and placebo for the treatment of moderate to severe psoriasis: Comparison of adverse event-free remission days in the CHAMPION trial.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Reich K, Yu AP, Mulani P, Gupta S.

**Impact of Adalimumab (HUMIRA (R)) on Patient-Reported Outcomes.**

*Abstract:* American College of Gastroenterology, Philadelphia, PA Oct 12-17, 2007.

*Authors:* Loftus EV, Wu EQ, Yu AP.

## Endocrine/Metabolic/Diabetes

### Journal Articles

**Costs of pediatric liver transplantation among commercially insured and Medicaid-insured patients with cholestasis in the US.**

*Publication:* Liver Transpl 2023 07; 29(7): 735-744. e-pub ahead of print 2023/02/08; doi: 10.1097/lvt.000000000000082.

*Authors:* Miloh T, Goldstein A, Howard R, Mogul DB, Marden JR, Anderson A, Gaburo K, Kirson N, Rosenthal P.

**Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study.**

*Publication:* Adv Ther 2023 05. e-pub ahead of print 2023/05/04; doi: 10.1007/s12325-023-02518-w.

*Authors:* Agiro A, A NA, Cook EE, Mu F, Chen J, Desai P, Oluwatosin Y, Pollack CV, Jr.

**Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the recognize I study.**

*Publication:* Expert Rev Pharmacoecon Outcomes Res 2022 12: 1-10. e-pub ahead of print 2022/12/29; doi: 10.1080/14737167.2023.2161514.

*Authors:* Pollack CV, Jr., Agiro A, Mu F, Cook EE, Lemus Wirtz E, Young JA, Betts KA, Brahmbhatt YG.

**Health care resource utilization by patients with Alagille syndrome.**

*Publication:* J Pediatr 2022 09. doi: 10.1016/j.jpeds.2022.09.033.

*Authors:* Ebel NH, Goldstein A, Howard R, Mogul DB, Marden JR, Anderson A, Gaburo K, Kirson N, Rosenthal P.

**Maralixibat Treatment Response in Alagille Syndrome Is Associated with Improved Health-Related Quality of Life.**

*Publication:* J Pediatr 2022 09. e-pub ahead of print 2022/09/13; doi: 10.1016/j.jpeds.2022.09.001.

*Authors:* Kamath BM, Goldstein A, Howard R, Garner W, Vig P, Marden JR, Billmyer E, Anderson A, Kirson N, Jacquemin E, Gonzales E.

**Five-Year Estimated Glomerular Filtration Rate in Adults with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study.**

*Publication:* Adv Ther 2022 08. e-pub ahead of print 2022/08/27; doi: 10.1007/s12325-022-02292-1.

*Authors:* Ayodele O, Rejnmark L, Mu F, Lax A, Berman R, Swallow E, Gosmanova EO.

**Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States.**

*Publication:* J Manag Care Spec Pharm 2022 06; 28(7): 740-752. e-pub ahead of print 06; doi: 10.18553/jmcp.2022.28.7.740.

*Authors:* Kim N, Wang J, Burudpakdee C, Song Y, Ramasamy A, Xie Y, Sun R, Kumar N, Wu EQ, Sullivan SD.

**Economic Burden Associated With Nasal Polyposis Recurrence Among Commercially Insured Patients in the United States.**

*Publication:* Otolaryngol Head Neck Surg 2022 03: 1945998221089187. e-pub ahead of print 2022/03/30; doi: 10.1177/01945998221089187.

*Authors:* Zhdanava M, Ndife B, Pilon D, Rossi C, Vermette-Laforme M, Lefebvre P, Suh JD.

**Health-care resource use and costs associated with diabetic and idiopathic gastroparesis: A claims analysis of the first 3 years following the diagnosis of gastroparesis.**

*Publication:* Neurogastroenterol Motil 2022 03: e14366. e-pub ahead of print 2022/03/31; doi: 10.1111/nmo.14366.

*Authors:* Chen YJ, Tang W, Ionescu-Iltu R, Ayyagari R, Wu E, Huh SY, Parkman HP.

**The experience of a severe hypoglycaemic event from the perspective of people with diabetes and their caregivers: "What am I going to do?"**

*Publication:* Diabetic Medicine 2021 11; 39(4): e14745. doi: <https://doi.org/10.1111/dme.14745>.

*Authors:* Stuckey HL, Desai U, King SB, Popadic L, Levinson W, Kirson NY, Hankosky ER, Mitchell B.

**Determinants of Hyperkalemia Progression among Patients with Mild Hyperkalemia.**

*Publication:* Adv Ther 2021 09.



*Authors:* Israni R, Betts KA, Mu F, Davis J, Wang J, Anzalone D, Uwaifo GI, Szerlip H, Fonseca V, Wu E.

**Effects of metreleptin in patients with lipodystrophy with and without baseline concomitant medication use.**

*Publication:* Curr Med Res Opin 2021 09: 1. e-pub ahead of print 2021/09/08; doi: 10.1080/03007995.2021.1976125.

*Authors:* Adamski K, Cook K, Gupta D, Morris E, Tuttle E, Carr E, Cremasco F, Cochran E, Brown R.

**Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and Hyperkalemia.**

*Publication:* Adv Ther 2021 09. e-pub ahead of print 2021/09/03; doi: 10.1007/s12325-021-01886-5.

*Authors:* Cook EE, Davis J, Israni R, Mu F, Betts KA, Anzalone D, Yin L, Szerlip H, Uwaifo GI, Fonseca V, Wu EQ.

**Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study.**

*Publication:* Advances in Therapy. 2021 09.

*Authors:* Ketteler M, Chen K, Gosmanova EO, Signorovitch J, Mu F, Young JA, Sherry N, Rejnmark L.

**Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy.**

*Publication:* J Comp Eff Res 2021 08. e-pub ahead of print 2021/08/12; doi: 10.2217/ce-2021-0150.

*Authors:* Laliberté F, Ashton V, Kharat A, Lejeune D, Moore KT, Jung Y, Lefebvre P, Berger JS.

**Inpatient management and post-discharge outcomes of hyperkalemia.**

*Publication:* Hosp Pract (1995) 2021 05: 1-7. e-pub ahead of print 2021/05/27; doi: 10.1080/21548331.2021.1925554.

*Authors:* Davis J, Israni R, Mu F, Cook EE, Szerlip H, Uwaifo G, Fonseca V, Betts KA.

**Overcoming psychological insulin resistance: A practical guide for healthcare professionals.**

*Publication:* Primary Care Diabetes 2021 03. doi: 10.1016/j.pcd.2021.03.001.

*Authors:* Snoek FJ, Fisher L, Polonsky WH, Stuckey H, Hessler D, Tang T, Hermanns N, Mundet X, Silva M, Sturt J, Okazaki K, Hadjiyianni I, Desai U, Perez-Nieves M.

**Effects of Metreleptin on Patient Outcomes and Quality of Life in Generalized and Partial Lipodystrophy.**

*Publication:* Journal of the Endocrine Society 2021 02; 5(4). doi: 10.1210/jendso/bvab019.

*Authors:* Cook K, Adamski K, Gomes A, Tuttle E, Kalden H, Cochran E, Brown RJ.

**Real-World Management of Hyperkalemia in the Emergency Department: An Electronic Medical Record Analysis.**

*Publication:* Adv Ther 2021. e-pub ahead of print 2021/12/28; doi: 10.1007/s12325-021-02017-w.

*Authors:* Davis J, Israni R, Betts KA, Mu F, Cook EE, Anzalone D, Szerlip H, Yin L, Uwaifo GI, Wu EQ.

**Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study.**

*Publication:* Curr Med Res Opin 2020 10; 36(2): 219-227. e-pub ahead of print 2019/10/19; doi: 10.1080/03007995.2019.1682981.

*Authors:* Wysham CH, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Duh MS, Young JB.

**Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84).**

*Publication:* The Journal of Clinical Endocrinology & Metabolism 2020 10; 105(10): e3557-e3565. doi: 10.1210/clinem/dgaa490.

*Authors:* Chen KS, Gosmanova EO, Curhan GC, Ketteler M, Rubin M, Swallow E, Zhao J, Wang J, Sherry N, Krasner A, Bilezikian JP.

**Prevalence and economic burden of hyperkalemia in the United States Medicare population.**

*Publication:* Curr Med Res Opin 2020 08; 36(8): 1333-1341. e-pub ahead of print 2020/05/28; doi:

10.1080/03007995.2020.1775072.

*Authors:* Mu F, Betts KA, Woolley JM, Dua A, Wang Y, Zhong J, Wu EQ.

**Key Strategies for Overcoming Psychological Insulin Resistance in Adults with Type 2 Diabetes: The UK Subgroup in the EMOTION Study.**

*Publication:* Diabetes Therapy 2020 06. doi: 10.1007/s13300-020-00856-4.

*Authors:* Balogh EG, Perez-Nieves M, Cao D, Hadjiyianni II, Ashraf N, Desai U, Snoek FJ, Sturt JA.

**Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study.**

*Publication:* Diabetes Therapy 2020 04; 11(4): 995-1005. doi: 10.1007/s13300-020-00783-4.

*Authors:* Peng XV, Ayyagari R, Lubwama R, Shi L, Price-Haywood EG, Hollander P, Fonseca V.

**Successful Health Care Provider Strategies to Overcome Psychological Insulin Resistance in United States and Canada.**

*Publication:* J Am Board Fam Med 2020 03; 33(2): 198-210. e-pub ahead of print 2020/03/18; doi: 10.3122/jabfm.2020.02.190157.

*Authors:* Tang T, Hessler D, Polonsky WH, Fisher L, Reed B, Irani T, Desai U, Perez-Nieves M.

**Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trial.**

*Publication:* Curr Med Res Opin 2020 01; 36(4): 563-570. e-pub ahead of print 2020/01/10; doi: 10.1080/03007995.2019.1708285.

*Authors:* Manceur AM, Durkin M, Kharat A, Bookhart B, Lafeuille MH, Pilon D, Fakhri I, Lefebvre P.

**Key factors for overcoming psychological insulin resistance: an examination of patient perspectives through content analysis.**

*Publication:* BMJ Open Diabetes Research & Care 2019 12; 7(1): e000723. doi: 10.1136/bmjdr-2019-000723.

*Authors:* Stuckey H, Fisher L, Polonsky WH, Hessler D, Snoek FJ, Tang TS, Hermanns N, Mundet-Tuduri X, da Silva MER, Sturt J, Okazaki K, Cao D, Hadjiyianni I, Ivanova JI, Desai U, Perez-Nieves M.

**Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study.**

*Publication:* J Endocrinol Invest 2019 11; 43: 529-538. e-pub ahead of print 2019/11/20; doi: 10.1007/s40618-019-01138-y.

*Authors:* Colao A, Grasso LFS, Di Cera M, Thompson-Leduc P, Cheng WY, Cheung HC, Duh MS, Neary MP, Pedroncelli AM, Maamari R, Pivonello R.

**Basal insulin persistence in Brazilian participants with T2DM.**

*Publication:* Rev Assoc Med Bras (1992) 2019 11; 65(10): 1254-1264. e-pub ahead of print 2019/11/14; doi: 10.1590/1806-9282.65.10.1254.

*Authors:* Franco DR, Perez-Nieves M, Ivanova JI, Cao D, Vaz MSC.

**Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors.**

*Publication:* Pancreas 2019 10; 48(9): 1126-1135. e-pub ahead of print 2019/10/09; doi: 10.1097/mpa.0000000000001403.

*Authors:* Huynh L, Cai B, Cheng M, Lax A, Lejeune D, Duh MS, Kim MK.

**Direct, Absenteeism, and Disability Cost Burden of Obesity Among Privately Insured Employees: A Comparison of Healthcare Industry Versus Other Major Industries in the United States.**

*Publication:* J Occup Environ Med 2019 10; 62(2): 98-107. e-pub ahead of print 2019/11/13; doi: 10.1097/jom.0000000000001761.

*Authors:* Ramasamy A, Laliberte F, Aktavoukian SA, Lejeune D, DerSarkissian M, Cavanaugh C, Smolarz BG, Ganguly R, Duh MS.

**Direct and Indirect Cost of Obesity Among the Privately Insured in the United States: A Focus on the Impact by Type of Industry.**

*Publication:* J Occup Environ Med 2019 08; 61(11): 877-886. e-pub ahead of print 2019/08/20; doi: 10.1097/jom.0000000000001693.

*Authors:* Ramasamy A, Laliberte F, Aktavoukian SA, Lejeune D, DerSarkissian M, Cavanaugh C, Smolarz BG, Ganguly R, Duh MS.

**Comorbidities and Survival in Patients with Lipodystrophy: An International Chart Review Study.**

*Publication:* J Clin Endocrinol Metab 2019 07. e-pub ahead of print 2019/07/18; doi: 10.1210/jc.2018-02730.

*Authors:* Akinci B, Oral EA, Neidert A, Rus D, Cheng WY, Thompson-Leduc P, Cheung HC, Bradt P, Foss de Freitas MC, Montenegro RM, Fernandes VO, Cochran E, Brown RJ.

**Clinical burden and healthcare resource utilization among patients with chronic hypoparathyroidism, overall and by adequately versus not adequately controlled disease: a multi-country chart review.**

*Publication:* J Med Econ 2019 05; 1. e-pub ahead of print 2019/05/28; doi: 10.1080/13696998.2019.1624081.

*Authors:* Chen K, Krasner A, Li N, Xiang CQ, Totev T, Xie J.

**Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers.**

*Publication:* Orphanet J Rare Dis 2019 04; 14(1): 89. e-pub ahead of print 2019/05/01; doi: 10.1186/s13023-019-1060-2.

*Authors:* Harrington M, Whalley D, Twiss J, Rushton R, Martin S, Huynh L, Yang H.

**Real-world impact of glycosylated hemoglobin reduction on treatment intensification and glycosylated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i).**

*Publication:* Curr Med Res Opin 2019 04; 1-8. e-pub ahead of print 2019/04/10; doi: 10.1080/03007995.2019.1605160.

*Authors:* Brunton S, Rozjabek HM, Pilon D, Lafeuille MH, Kamstra R, Wynant W, Bookhart BK, Lefebvre P.

**Identifying solutions to psychological insulin resistance: An international study.**

*Publication:* Journal of Diabetes and its Complications. 2019 02. doi: <http://dx.doi.org/10.1016/j.jdiacomp.2019.01.001>.

*Authors:* Polonsky WH, Fisher L, Hessler D, Stuckey H, Snoek FJ, Tang T, Hermanns N, Mundet X, Silva M, Sturt J, Okazaki K, Hadjiyianni I, Cao D, Ivanova J, Desai U, Perez-Nieves M.

**An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records.**

*Publication:* J Diabetes Complications 2019 02; 33(2): 140-147. e-pub ahead of print 2018/12/18; doi: 10.1016/j.jdiacomp.2018.10.016.

*Authors:* Wysham CH, Lefebvre P, Pilon D, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Duh MS, Ingham M.

**A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United States.**

*Publication:* J Med Econ 2018 12; 21(12): 1183-1190. e-pub ahead of print 2018/09/07; doi: 10.1080/13696998.2018.1521415.

*Authors:* Cloutier M, Greene M, Touya M, Gagnon-Sanschagrín P, Guerin A.

**Are some neighborhoods bad for your waistline? A test of neighborhood exposure effects on BMI.**

*Publication:* J Health Econ 2018 11; 63: 52-63. e-pub ahead of print 2018/11/20; doi: 10.1016/j.jhealeco.2018.10.007.

*Authors:* Ou S.

**Associated factors that influenced persistence with basal analog insulin therapy among people with type 2 diabetes: An exploratory analysis from a UK real-world sample.**

*Publication:* Prim Care Diabetes 2018 11. e-pub ahead of print 2018/11/28; doi: 10.1016/j.pcd.2018.09.002.

*Authors:* Idris I, Gulati K, Perez-Nieves M, Hadjiyianni I, Cao D, Tahbaz A, Ivanova J, Hassan SW.

**Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.**

*Publication:* Menopause 2018 11; 25(11): 1297-1305. doi: <http://dx.doi.org/10.1097/GME.0000000000001232>.

*Authors:* Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

**Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes.**

*Publication:* Diabetes Care 2018 10; 41(10): 2096-2104. e-pub ahead of print 2018/08/23; doi: 10.2337/dc17-0662.

*Authors:* Desai U, Kirson NY, Kim J, Khunti K, King S, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.

**Predictors and clinical outcomes of treatment intensification in patients with type 2 diabetes uncontrolled on basal insulin in a real-world setting.**

*Publication:* Endocrine Practice 2018 09; 24(9): 805-814. doi: <http://dx.doi.org/10.4158/EP-2017-0261>.

*Authors:* Kallenbach L, Shui AM, Cheng WY, Fan T, Hu W, Zichlin ML, Duh MS, Ye F, Levin PA.

**Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.**

*Publication:* Cardiovasc Diabetol 2018 08; 17(1): 118. e-pub ahead of print 2018/08/26; doi: 10.1186/s12933-018-0759-z.

*Authors:* Young JB, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Lafeuille MH, Duh MS, Bookhart B, Wysham CH.

**Characteristics, Treatment Patterns, and Economic Outcomes of Patients Initiating Injectable Medications for Management of Type 2 Diabetes Mellitus in Japan: Results from a Retrospective Claims Database Analysis.**

*Publication:* Diabetes Ther 2018 06; 9(3): 1125-1141. e-pub ahead of print 2018/04/18; doi: 10.1007/s13300-018-0407-3.

*Authors:* Suzuki S, Desai U, Strizek A, Ivanova J, Garcia-Horton V, Cai Z, Schmerold L, Liu X, Perez-Nieves M.

**Clinical Trajectories, Healthcare Resource Use, and Costs of Diabetic Nephropathy Among Patients with Type 2 Diabetes: A Latent Class Analysis.**

*Publication:* Diabetes Ther 2018 06; 9(3): 1021-1036. e-pub ahead of print 2018/03/31; doi: 10.1007/s13300-018-0410-8.

*Authors:* Jiang R, Law E, Zhou Z, Yang H, Wu EQ, Seifeldin R.

**The prevalence of hyperkalemia in the United States.**

*Publication:* Curr Med Res Opin 2018 06; 34(6): 971-978. e-pub ahead of print 2018/01/26; doi: 10.1080/03007995.2018.1433141.

*Authors:* Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ.

**Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.**

*Publication:* Curr Med Res Opin 2018 06; 34(6): 1125-1133. e-pub ahead of print 2018/03/21; doi: 10.1080/03007995.2018.1454417.

*Authors:* Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P.

**Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida.**

*Publication:* Curr Med Res Opin 2018 06; 34(6): 1099-1115. e-pub ahead of print 2018/02/23; doi: 10.1080/03007995.2018.1444591.

*Authors:* Tanton D, Duh MS, Lafeuille MH, Lefebvre P, Pilon D, Zhdanova M, Emond B, Inman D, Bailey RA.

**Initiation of Basal Insulin Analog Treatment for Type 2 Diabetes and Reasons Behind Patients' Treatment Persistence Behavior: Real-World Data from Germany.**

*Publication:* Exp Clin Endocrinol Diabetes 2018 05; 126(5): 287-297. e-pub ahead of print 2017/09/13; doi: 10.1055/s-0043-116386.

*Authors:* Moennig E, Perez-Nieves M, Hadjiyianni I, Cao D, Ivanova J, Klask R.

**Insulin non-persistence among people with type 2 diabetes: how to get your patients to stay on insulin therapy.**

*Publication:* Postgrad Med 2018 05; 130(4): 394-401. e-pub ahead of print 2018/03/25; doi: 10.1080/00325481.2018.1457396.

*Authors:* Garnero TL, Davis NJ, Perez-Nieves M, Hadjiyianni I, Cao D, Ivanova JI, Peyrot M.

**Community health workers improve disease control and medication adherence among patients with diabetes and/or hypertension in Chiapas, Mexico: an observational stepped-wedge study.**

*Publication:* BMJ Glob Health 2018 03; 3(1): e000566. e-pub ahead of print 2018/03/13; doi: 10.1136/bmjgh-2017-000566.

*Authors:* Newman PM, Franke MF, Arrieta J, Carrasco H, Elliott P, Flores H, Friedman A, Graham S, Martinez L, Palazuelos L, Savage K, Tymeson H, Palazuelos D.

**The Cost of Hyperkalemia in the United States.**

*Publication:* Kidney Int Rep 2018 03; 3(2): 385-393. e-pub ahead of print 2018/05/05; doi: 10.1016/j.ekir.2017.11.003.

*Authors:* Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ.

**Hba1c control and cost-effectiveness in patients with type 2 diabetes mellitus initiated on canagliflozin or a glucagon-like peptide 1 receptor agonist in a real-world setting.**

*Publication:* Endocrine Practice 2018 03; 24(3): 273-287. doi: <http://dx.doi.org/10.4158/EP-2017-0066>.

*Authors:* Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P.

**Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin.**

*Publication:* Diabetes Obes Metab 2018 03; 20(3): 638-645. e-pub ahead of print 2017/10/21; doi: 10.1111/dom.13133.

*Authors:* Henry R, Rosenstock J, McCarthy JF, Carls G, Alessi T, Yee J, Baron M.

**Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes.**

*Publication:* Diabetes Care 2017 11; 40(11): 1469-1478. doi: 10.2337/dc16-2725.

*Authors:* Carls GS, Tuttle E, Tan R-D, Huynh J, Yee J, Edelman SV, Polonsky WH.

**Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey.**

*Publication:* Curr Med Res Opin 2017 10; 33(10): 1833-1842. e-pub ahead of print 2017/06/13; doi: 10.1080/03007995.2017.1341403.

*Authors:* Perez-Nieves M, Ivanova JI, Hadjiyianni I, Zhao C, Cao D, Schmerold L, Kalirai S, King S, DeLozier AM, Birnbaum HG, Peyrot M.

**Correlates of basal insulin persistence among insulin-naive people with type 2 diabetes: results from a multinational survey.**

*Publication:* Curr Med Res Opin 2017 10; 33(10): 1843-1851. e-pub ahead of print 2017/06/13; doi: 10.1080/03007995.2017.1341868.

*Authors:* Peyrot M, Perez-Nieves M, Ivanova J, Cao D, Schmerold L, Kalirai S, Hadjiyianni I.

**Apolipoprotein C-III and High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III in Relation to Diabetes Risk.**

*Publication:* American Journal of Epidemiology 2017 09; 186(6): 736-744. doi: <http://dx.doi.org/10.1093/aje/kwx143>.

*Authors:* Aroner SA, Yang M, Li J, Furtado JD, Sacks FM, Tjonneland A, Overvad K, Cai T, Jensen MK.

**Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence.**

*Publication:* Obesity Science and Practice 2017 09; 3(3): 342-351. doi: <http://dx.doi.org/10.1002/osp4.116>.

*Authors:* Carls GS, Tan R, Zhu JY, Tuttle E, Yee J, Edelman SV, Polonsky WH.

**Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014.**

*Publication:* Diabetes Ther 2017 06. e-pub ahead of print 2017/06/25; doi: 10.1007/s13300-017-0280-5.

*Authors:* Carls G, Huynh J, Tuttle E, Yee J, Edelman SV.

**Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study.**

*Publication:* Diabetes Ther 2017 06; 8(3): 555-571. e-pub ahead of print 2017/04/01; doi: 10.1007/s13300-017-0256-5.

*Authors:* Zhou Z, Chaudhari P, Yang H, Fang AP, Zhao J, Law EH, Wu EQ, Jiang R, Seifeldin R.

**Maintenance of weight loss or stability in subjects with obesity: a retrospective longitudinal analysis of a real-world population.**

*Publication:* Curr Med Res Opin 2017 06; 33(6): 1105-1110. e-pub ahead of print 2017/03/16; doi: 10.1080/03007995.2017.1307173.

*Authors:* DerSarkissian M, Bhak RH, Huang J, Buchs S, Vekeman F, Smolarz BG, Brett J, Ganguly R, Duh MS.

**Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.**

*Publication:* BMC Endocr Disord 2017 06; 17(1): 32. e-pub ahead of print 2017/06/10; doi: 10.1186/s12902-017-0180-8.

*Authors:* Wysham CH, Lefebvre P, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Chow W, Pfeifer M, Duh MS.

**Insulin initiation experiences in people with Type 2 diabetes: Data from the UK.**

*Publication:* Diabetic Medicine 2017 03; 34: 189. doi: <http://dx.doi.org/10.1111/dme.13302>.

*Authors:* Hassan SW, Hadjiyianni I, Ivanova J, Cao D, Gulati K, Tahbaz A, Perez-Nieves M.

**Basal Insulin Persistence, Associated Factors, and Outcomes after Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan.**

*Publication:* Diabetes Ther 2017 02; 8(1): 149-166. e-pub ahead of print 2016/12/04; doi: 10.1007/s13300-016-0215-6.

*Authors:* Hadjiyianni I, Desai U, Suzuki S, Ivanova JI, Cao D, Kirson NY, Chida D, Enloe C, Birnbaum HG, Perez-Nieves M.

**Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes.**

*Publication:* J Endocrinol Invest 2016 12; 39(12): 1391-1399. e-pub ahead of print 2016/06/12; doi: 10.1007/s40618-016-0495-8.

*Authors:* Bonora B, Maran A, Ciciliot S, Avogaro A, Fadini GP.

**Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.**

*Publication:* Diabetes Ther 2016 09; 7(3): 439-454. e-pub ahead of print 2016/08/10; doi: 10.1007/s13300-016-0189-4.

*Authors:* Thomas MC, Paldanius PM, Ayyagari R, Ong SH, Groop PH.

**Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.**

*Publication:* Curr Med Res Opin 2016 06; 32(6): 1151-1159. e-pub ahead of print 2016/04/27; doi: 10.1080/03007995.2016.1183604.

*Authors:* Lefebvre P, Pilon D, Robitaille MN, Lafeuille MH, Chow W, Pfeifer M, Duh MS.

**Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.**

*Publication:* Menopause 2016 06; 23(6): 600-610. doi: <http://dx.doi.org/10.1097/GME.0000000000000590>.

*Authors:* Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

**Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.**

*Publication:* Curr Med Res Opin 2016 04; 32(4): 669-680. e-pub ahead of print 2015/12/26; doi: 10.1185/03007995.2015.1135789.

*Authors:* Perez-Nieves M, Kabul S, Desai U, Ivanova JI, Kirson NY, Cummings AK, Birnbaum HG, Duan R, Cao D, Hadjiyianni I.

**Budget impact of pasireotide LAR for the treatment of acromegaly, a rare endocrine disorder.**

*Publication:* J Med Econ 2016 04; 19(4): 374-385. doi: 10.3111/13696998.2015.1127816.

*Authors:* Zhang JJ, Nellesen D, Ludlam WH, Neary MP.

**Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis.**

*Publication:* BMJ Open 2016 02; 6(2): e009421. e-pub ahead of print 2016/02/18; doi: 10.1136/bmjopen-2015-009421.

*Authors:* Freemantle N, Chou E, Frois C, Zhuo D, Lehmacher W, Vlajnic A, Wang H, Chung HW, Zhang Q, Wu E, Gerrits C.

**Retrospective Analysis of Dose Titration and Serum Testosterone Level Assessments in Patients Treated with Topical Testosterone.**

*Publication:* Am J Mens Health 2015 11; 9(6): 496-505. doi: 10.1177/1557988314551569.

*Authors:* Muram D, Kaltenboeck A, Boytsov N, Hayes-Larson E, Ivanova J, Birnbaum HG, Swindle R.

**Glycemic and Cholesterol Control versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study.**

*Publication:* Diabetes Ther 2015 09; 6(3): 339-355. doi: 10.1007/s13300-015-0122-2.

*Authors:* Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Zhang M, Wang Y, Fonseca VA.

**For a Step Change to Curb the Obesity Epidemic.**

*Publication:* PharmacoEconomics 2015 07; 33(7): 613-617. doi: 10.1007/s40273-015-0303-x.

*Authors:* Frois C, Cremieux PY.

**Gap Between Evidence and Patient Access: Policy Implications for Bariatric and Metabolic Surgery in the Treatment of Obesity and its Complications.**

*Publication:* PharmacoEconomics 2015 07; 33(7): 629-641. doi: 10.1007/s40273-015-0302-y.

*Authors:* Chawla AS, Hsiao CW, Romney MC, Cohen R, Rubino F, Schauer P, Cremieux P.

**Policy Makers' Views of Obesity-Related Challenges Around the World : An interview between Pierre Cremieux (of Analysis Group, Inc., and Guest Editor of this Special Issue) and policy makers from Brazil (Patricia Constante Jaime), Canada (Kimberly Elmslie), China (Bin Wang), France (Francois Cremieux), and the USA (Mark McClellan).**

*Publication:* PharmacoEconomics 2015 07; 33(7): 619-628. doi: 10.1007/s40273-015-0290-y.

*Authors:* Cremieux P.

**Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers.**

*Publication:* J Med Econ 2015 04; 18(8): 586-595. doi: 10.3111/13696998.2015.1031793.

*Authors:* Rice JB, Desai U, Ristovska L, Cummings AK, Birnbaum HG, Skornicki M, Margolis DJ, Parsons NB.

**Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.**

*Publication:* Value Health 2015 03; 18(2): 198-205. doi: 10.1016/j.jval.2014.12.016.

*Authors:* Ayyagari R, Wei W, Cheng D, Pan C, Signorovitch J, Wu EQ.

**Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control.**

*Publication:* J Med Econ 2015 02; 18(2): 113-125. doi: 10.3111/13696998.2014.980503.

*Authors:* Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

**Burden of diabetic foot ulcers for Medicare and private insurers.**

*Publication:* Diabetes Care 2014 11; 37(3): 651-658. doi: 10.2337/dc13-2176.

*Authors:* Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB.

**Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis.**

*Publication:* J Med Econ 2014 09; 17(9): 646-657. doi: 10.3111/13696998.2014.925905.

*Authors:* Bron M, Guerin A, Latremouille-Viau D, Ionescu-Iltu R, Viswanathan P, Lopez C, Wu EQ.

**Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease.**

*Publication:* Eur J Endocrinol 2014 07; 171(1): 89-98. doi: 10.1530/EJE-13-1013.

*Authors:* Webb SM, Ware JE, Forsythe A, Yang M, Badia X, Nelson LM, Signorovitch JE, McLeod L, Maldonado M, Zgliczynski W, de Block C, Portocarrero-Ortiz L, Gadelha M.

**Costs after initiating saxagliptin, sulfonylurea, or sitagliptin in patients with T2DM.**

*Publication:* American Journal of Pharmacy Benefits 2014 05; 6(3): e60-e69.

*Authors:* Kaltenboeck A, Ivanova J, Birnbaum H, Yushkina Y, Schwiep F, Bell K, Thomas N.

**Management of patients using combination therapy with pioglitazone and a dipeptidyl peptidase-4 inhibitor: an analysis of initial versus sequential combination therapy.**

*Publication:* Postgrad Med 2014 05; 126(3): 47-55. doi: 10.3810/pgm.2014.05.2755.

*Authors:* Bron M, Ayyagari R, Sharma H, Chen K, Bozas A, Wu E.

**Budget impact of pasireotide for the treatment of Cushing's disease, a rare endocrine disorder associated with considerable comorbidities.**

*Publication:* J Med Econ 2014 04; 17(4): 288-295. doi: 10.3111/13696998.2013.877470.

*Authors:* Truong HL, Nellesen D, Ludlam WH, Neary MP.

**Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.**

*Publication:* Pharmacoepidemiol Drug Saf 2014 03; 23(3): 268-277.

*Authors:* Chawla AJ, Mytelka DS, McBride SD, Nellesen D, Elkins BR, Ball DE, Kalsekar A, Towse A, Garrison LP.

**Opportunities for Improving Attainment of Quality Measures in Patients with Type 2 Diabetes Mellitus.**

*Publication:* American Journal of Managed Care 2014 01; 20(1).

*Authors:* Bailey R, Blonde L, Damaraju CV, Duh MS, Garber L, Gravel J, Grittner A, Lafeuille M, Lefebvre P, Martin S, Meiningner G, Rupnow M.

**Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes.**

*Publication:* Diabetes Care 2013 10; 36(10): 3297-3304. doi: 10.2337/dc13-0149.

*Authors:* Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Fonseca VA.



**Association of self-monitoring of blood glucose use on glycated hemoglobin and weight in newly diagnosed, insulin-naive adult patients with type 2 diabetes.**

*Publication:* J Diabetes Sci Technol 2013 09; 7(5): 1229-1242.

*Authors:* Virdi NS, Lefebvre P, Parise H, Duh MS, Pilon D, Laliberte F, Sundaresan D, Garber L, Dirani R.

**Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.**

*Publication:* QJM 2013 08; 106(8): 721-729. doi: 10.1093/qjmed/hct093.

*Authors:* Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk R, Liu J, Shi L.

**Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs.**

*Publication:* Diabetes Obes Metab 2013 04; 15(4): 335-341. doi: 10.1111/dom.12031.

*Authors:* Signorovitch JE, Macaulay D, Diener M, Yan Y, Wu EQ, Gruenberger JB, Frier BM.

**Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital.**

*Publication:* Hosp Pract (1995) 2012 10; 40(4): 40-48. doi: 10.3810/hp.2012.10.1002.

*Authors:* Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T.

**The direct and indirect costs among U.S. privately insured employees with hypogonadism.**

*Publication:* J Sex Med 2012 09; 9(9): 2438-2447. doi: 10.1111/j.1743-6109.2012.02810.x.

*Authors:* Kaltenboeck A, Foster S, Ivanova J, Diener M, Bergman R, Birnbaum H, Kinchen K, Swindle R.

**Outcomes associated with insulin therapy disruption after hospital discharge among patients with type 2 diabetes mellitus who had used insulin before and during hospitalization.**

*Publication:* Endocr Pract 2012 09; 18(5): 651-659. doi: 10.4158/EP11314.OR.

*Authors:* Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T.

**Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.**

*Publication:* Postgrad Med 2012 01; 124(1): 124-132. doi: 10.3810/pgm.2012.01.2525.

*Authors:* Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ.

**Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.**

*Publication:* Clin Drug Investig 2011 08; 31(9): 665-674. doi: 10.2165/11592490-000000000-00000.

*Authors:* Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB.

**Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus.**

*Publication:* Current Medical Research & Opinion 2011 01; 27(1): 189-195. doi: 10.1185/03007995.2010.536755.

*Authors:* Pandya BJ, Bron M, McCall T, Yu AP, Chen KS, Mattson ME, Wu EQ.

**Prevalence rates and costs of metabolic syndrome and associated risk factors using employees' integrated laboratory data and health care claims.**

*Publication:* Journal of Occupational Environmental Medicine 2011 01; 53(1): 27-33. doi:

10.1097/JOM.0b013e3181ff0594.

*Authors:* Birnbaum HG, Mattson ME, Kashima S, Williamson TE.

**Weighing the clinical benefits and economic impact of bariatric surgery in morbidly obese patients with diabetes.**

*Publication:* Canadian Journal of Diabetes 2011 35(2): 89-98.

*Authors:* Cremieux PY, Eapen S, Trask SW, Ghosh A.

**The impact of bariatric surgery on comorbidities and medication use among obese patients.**

*Publication:* *Obes Surg* 2010 07; 20(7): 861-870. doi: 10.1007/s11695-010-0163-6.

*Authors:* Cremieux PY, Ledoux S, Clerici C, Cremieux F, Buessing M.

**Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.**

*Publication:* *Diabetes Res Clin Pract* 2010 01; 87(1): 108-116. doi: 10.1016/j.diabres.2009.09.023.

*Authors:* Lee LJ, Yu AP, Johnson SJ, Birnbaum HG, Atanasov P, Buesching DP, Jackson JA, Davidson JA.

**Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.**

*Publication:* *J Manag Care Pharm* 2009 05; 15(4): 312-322.

*Authors:* Laliberte F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P.

**Impact of anemia on hospitalization rates and costs in a diabetic and a hypertensive cohort of chronic kidney disease patients.**

*Publication:* *Journal of Managed Care Medicine* 2009 (12 (3)): 41-50.

*Authors:* Laliberté F, Bookhart B, Corral M, Vekeman F, Duh M, Bailey R, Lefebvre P.

**Five Minutes with... The Economic Impact of Bariatric Surgery Study Investigators.**

*Publication:* *Bariatric Times* 2008 11.

*Authors:* Cremieux P, Buchwald H, Shikora S, Ghosh A, Yang E, Buessing M.

**A study on the economic impact of bariatric surgery.**

*Publication:* *Am J Manag Care* 2008 09; 14(9): 589-596.

*Authors:* Cremieux PY, Buchwald H, Shikora SA, Ghosh A, Yang HE, Buessing M.

**Direct and indirect costs among employees with diabetic retinopathy in the United States.**

*Publication:* *Current Medical Research & Opinion* 2008 05; 24(5): 1549-1559. doi: 10.1185/030079908X297303.

*Authors:* Lee LJ, Yu AP, Cahill KE, Oglesby AK, Tang J, Qiu Y, Birnbaum HG.

**Drug utilization and costs of erythropoietic-stimulating agents in chronic kidney disease patients not receiving dialysis.**

*Publication:* *Managed Care Interface* 2007 12; 20 (12): 14-19.

*Authors:* Duh M, Mody S, Laliberté F, McKenzie R, Bookhart B, Lefebvre P.

**Productivity costs associated with cardiometabolic risk factor clusters in the United States.**

*Publication:* *Value in Health* 2007 11; 10(6): 443-450. doi: 10.1111/j.1524-4733.2007.00199.x.

*Authors:* Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

**Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France.**

*Publication:* *Current Medical Research & Opinion* 2007 09; 23(9): 2035-2042. doi: 10.1185/030079907X210516.

*Authors:* Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S.

**Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.**

*Publication:* *Current Medical Research & Opinion* 2007 09; 23(9): 2157-2169. doi: 10.1185/0300799007X219544.

*Authors:* Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A.

**Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S.**

*Publication:* *Obesity (Silver Spring)* 2007 02; 15(2): 511-521. doi: 10.1038/oby.2007.580.

*Authors:* Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

**Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain.**

*Publication:* J Pain 2006 06; 7(6): 399-407. doi: 10.1016/j.jpain.2006.01.443.

*Authors:* Wu EQ, Birnbaum HG, Mareva MN, Le TK, Robinson RL, Rosen A, Gelwicks S.

**Prevalence of diabetic peripheral neuropathy and associated pain in French adults.**

*Publication:* Journal Of Neurology 2006 05; 253: 108-108.

*Authors:* Wu E, Borton J, Kahn E, Said G, Le T, Garcia-Cebrian A, Monz B.

**Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.**

*Publication:* Womens Health Issues 2003 11; 13(6): 204-213.

*Authors:* Birnbaum H, Leong S, Kabra A.

**Productivity and medical costs of diabetes in a large employer population.**

*Publication:* Diabetes Care 2002 01; 25(1): 23-29.

*Authors:* Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P.

**Identification of Diabetes Patients Using Claims Data: An Economic Analysis.**

*Publication:* Drug Benefit Trends 2001 13: 28-33.

*Authors:* Summers K, Leong S, Birnbaum H, Greenberg P, Kemner J, Ramsey S.

## Abstracts

**Characteristics of patients with complement 3 glomerulopathy (C3G) in a United States (US) multi-center assessment.**

Philadelphia, PA November 2-5, 2023.

*Authors:* Canetta P, Aldworth C, Murphy KP, Nguyen J, Pivneva I, Edwards ML, Anderson A, Signorovitch J, Ndife B.

**Real-World Trends in Hospitalizations for Hepatic Encephalopathy and Associated Costs Among Adults in the United States.**

Boston, MA May 7-10, 2023.

*Authors:* Wong R, Gagnon-Sanschagrin P, Heimanson Z, Maitland J, Qu W, Levesque-Leroux M, Gu  rin A, Dashputre AA, Bumpass B, Olujohungbe O, Borroto D, Joseph G.

**Real-world trends in the prevalence of cirrhosis and rates of hepatic encephalopathy among adults in the United States from 2006-2020.**

Chicago, IL May 6-9, 2023.

*Authors:* Wong R, Gagnon-Sanschagrin P, Heimanson Z, Maitland J, Qu W, Gu  rin A, Dashputre AA, Bumpass B, Olujohungbe O, Borroto D, Joseph G.

**Chronic kidney disease (CKD) progression in patients with complement 3 glomerulopathy (C3G) in a United States (US) multi-center assessment.**

Philadelphia, PA November 2-5, 2023.

*Authors:* Ndife B, Aldworth C, Murphy KP, Nguyen J, Pivneva I, Edwards ML, Anderson A, Signorovitch J, Canetta P.

**Prevalence of Metabolic Acidosis among Patients with CKD and Hyperkalemia.**

*Abstract:* National Kidney Foundation (NKF) Spring Clinical Meeting 2020 New Orleans, LA, USA March 25-29, 2020.

*Authors:* Erin Cook, Jill Davis, Rubeen Israni, Fan Mu, Keith A. Betts, Deborah Anzalone, Alex Pusch, Lei Yin, Harold Szerlip, Gabriel Uwaifo, Vivian Fonseca, Eric Q. Wu.

**Predictors of high healthcare utilisers among patients with chronic hypoparathyroidism – application of machine learning methodology.**

*Authors:* Chen K, Gao W, Wang Y, Swallow E.

**Pro4 Impact of Enzyme Replacement Therapy on the Risk of Developing Gaucher Disease-Related Complications.**

*Authors:* Vera-Llonch M, Qi CZ, Swallow E, Zichlin ML, Signorovitch J.

**Management, Post-Discharge Admission, and Recurrence among Hyperkalemic Patients in the Emergency Department Setting.**

*Abstract:* NKF 2019 Spring Clinical Meeting, Boston, MA May 8-12, 2019.

*Authors:* Davis J, Israni R, Betts KA, Mu F, Cook E, Anzalone D, Szerlip H, Doctor T, Yin L, Uwaifo G, Wu E.

**Outpatient Potassium Monitoring in Hyperkalemic Patients.**

*Abstract:* NKF 2019 Spring Clinical Meeting, Boston, MA May 8-12, 2019.

*Authors:* Davis J, Israni R, Betts KA, Mu F, Wang Y, Curhan GC, Anzalone D, Kinrich D, Pusch A, Uwaifo G, Fonseca V, Szerlip H.

**Management of Hyperkalemic Patients in the Inpatient Setting by Hyperkalemia Severity.**

*Abstract:* AMCP's 31st Annual Meeting, San Diego, CA Mar 25-28, 2019.

*Authors:* Davis J, Israni R, Betts K, Mu F, Cook E, Anzalone D, Szerlip H, Doctor T, Yin L, Uwaifo G, Fonseca V, Wu E.

**Reduced Renin-Angiotensin-Aldosterone System Inhibitors (RAASi) Use after Hyperkalemia (HK)-Related Hospitalization.**

*Abstract:* AMCP's 31st Annual Meeting, San Diego, CA Mar 25-28, 2019.

*Authors:* Davis J, Betts K, Mu F, Wang Y, Wang Y.

**Attitudes among adults with type 2 diabetes affecting insulin initiation and discontinuation.**

*Abstract:* 54th Annual Meeting of the European Association for the Study Diabetes, EASD 2018, Berlin, Germany Oct 1-5, 2018.

*Authors:* Perez-Nieves M, Polonsky W, Fisher L, Snoek F, Hadjiyianni I, Cao D, Ivanova J, Desai U, Hessler D.

**Patient-level predictors of delay in insulin initiation and periods of insulin discontinuation among adults with type 2 diabetes.**

*Abstract:* 54th Annual Meeting of the European Association for the Study Diabetes, EASD 2018, Berlin, Germany Oct 1-5, 2018.

*Authors:* Fisher L, Polonsky W, Hessler D, Ivanova J, Desai U, Cao D, Snoek FJ, Perez-Nieves M.

**Trends of insulin-like growth factor 1, growth hormone, and biochemical control of patients with acromegaly in Italy: A longitudinal retrospective chart review study.**

*Abstract:* 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Prague, Czech Republic Aug 22-26, 2018.

*Authors:* Colao A, Grasso L, Di Cera M, Cheng WY, Thompson-Leduc P, Cheung HC, Duh MS, Neary MP, Pedroncelli AM, Maamari R, Pivonello R.

**Association between biochemical control and comorbidities and symptoms among patients with acromegaly in Italy: Stratified analyses by age and gender.**

*Abstract:* ISPOR 23rd Annual International Meeting, May 18-23, 2018.

*Authors:* Colao A, Grasso L, Di Cera M, Cheng WY, Thompson-Leduc P, Cheung HC, Duh MS, Neary MP, Pedroncelli AM, Maamari R, Pivonello R.

**Healthcare costs associated with hyperprolactinemia in the United States.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Cloutier M, Greene M, Guerin A, Touya M, Gagnon-Sanschagrín P, Wu EQ.

**Reduced risk of hyperprolactinemia among patients treated with atypical antipsychotics that are associated with low or no prolactin elevation.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Cloutier M, Greene M, Guerin A, Touya M, Gagnon-Sanschagrin P, Wu EQ.

**Accepting insulin treatment for reluctant people with Type 2 diabetes: A global study to identify effective strategies (EMOTION): Results from the UK cohort.**

*Abstract:* 2018 Diabetes UK Professional Conference, London, UK Mar 14-16, 2018.

*Authors:* Sturt J, Fisher L, Ashraf N, Perez-Nieves M, Hadjiyianni I, Cao D, Balogh E, Ivanova J, Snoek F.

**Patient characteristics of premix insulin users in china: An analysis of electronic medical record data.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Han S, Wang K, Hou J, Wang J, Wu EQ.

**Real-world persistence and HbA1c goal attainment in type 2 diabetes mellitus patients initiated on canagliflozin or a glucagon-like peptide-1.**

*Abstract:* 47th Annual Conference Endocrine Society of India, Kerala, India Oct 13-15, 2017.

*Authors:* Rajani A, Pfeifer M, Lefebvre P, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Wysham CH.

**Glycaemic control, weight loss, and use of other antihyperglycaemics in patients with type 2 diabetes initiated on canagliflozin or sitagliptin: A real-world analysis.**

*Abstract:* 53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal Sep 11-15, 2017.

*Authors:* Ingham M, Lefebvre P, Pilon D, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Duh MS, Wysham C.

**Real-world persistence and HbA1c goal attainment in type 2 diabetes patients initiated on canagliflozin or a glucagon-like peptide-1.**

*Abstract:* 53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal Sep 11-15, 2017.

*Authors:* Pfeifer M, Lefebvre P, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Wysham C.

**Renal outcomes with DPP-4 inhibitors compared with sulfonylurea as add-on to metformin among patients with type 2 diabetes.**

*Abstract:* 53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal Sep 11-15, 2017.

*Authors:* Teh HH, Desai U, Kirson NY, Hellstern M, Leigh PS, Mukherjee J, Khunti K.

**Systematic literature review of clinical, humanistic, and economic burden in cushing's disease.**

*Abstract:* 99th Annual Meeting and Expo of the Endocrine Society, Orlando, FL June 7, 2017.

*Authors:* Watchko S, Nellesen D, Neary MP.

**Reasons for different patterns of basal insulin persistence after initiation among people with type 2 diabetes (T2D).**

*Abstract:* Deutsche Diabetes Gesellschaft (DDG) Diabetes Kongress, Hamburg, Germany May 24-27, 2017.

*Authors:* Peyrot M, Ivanova J, Zao C, Schmerold L, King S, Birnbaum HG, DeLozier AM, Adjiyianni IH, Kabul S, Cao D, Duan R, Perez-Nieves M.

**Reasons for treatment persistence patterns in people with Type 2 diabetes after initiation of basal insulin: Data from UK patients.**

*Abstract:* Diabetes UK Professional Conference, Manchester, UK Mar 3-10, 2018.

*Authors:* Hassan SW, Gulati K, Hadjiyianni I, Cao D, Tahbaz A, Ivanova J, Perez-Nieves M.

**The economic burden of hyperkalemia among patients with chronic kidney disease and/or heart failure.**

*Abstract:* AMCP Nexus 2016, Baltimore, MD Oct 3-6, 2016.

*Authors:* Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Pham H, Hollenack K, Singhanian A, Wu E.

**The Prevalence of Hyperkalemia in the United States.**

*Abstract:* AMCP Nexus 2016, Baltimore, MD Oct 3-6, 2016.

*Authors:* Betts K, Woolley JM, Mu F, McDonald E, Tang W, Singhania A, Pham H, Hollenack K, Wu EQ.

**A cloud-based electronic health records study of treatment intensification patterns in type 2 diabetes patients uncontrolled on >2 oral anti-diabetes drugs.**

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany Sep 12-16, 2016.

*Authors:* Kallenbach L, Pesuit J, Fan T, Hu W, Shui A, Cheng W, Duh M, Zichlin M, Levin P.

**Disease progression of diabetic nephropathy in adults with type 2 diabetes in the US.**

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany Sept 12-16, 2016.

*Authors:* Zhou Z, Yang H, Fang A, Zhao J, Wu E, Chaudhari P, Seifeldin R.

**The healthcare costs and utilisation associated with diabetic nephropathy in adult patients with type 2 diabetes in the US.**

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany Sept 12-16, 2016.

*Authors:* Yang H, Zhou Z, Zhao J, Fang A, Wu E, Chaudhari P, Seifeldin R.

**Real-world weight change among patients treated with GLP-1, SU, or DPP-4 therapy for type 2 diabetes and the influence of medication adherence.**

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany Sep 12-16, 2016.

*Authors:* Carls GS, Tan RD, Tuttle E, Yee J, Polonsky WH, Edelman SV.

**Time to treatment intensification and its association with subsequent microvascular outcomes among patients with type 2 diabetes.**

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany Sep 12-16, 2016.

*Authors:* Desai U, Kirson NY, Kim J, Khunti KK, King SB, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.

**Maintenance of weight loss or stable weight in subjects with obesity: A retrospective longitudinal analysis of electronic medical record data.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Der Sarkissian M, Bhak R, Huang J, Buchs S, Vekeman F, Ganguly R, Duh MS.

**Real-world evaluation of weight loss in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health record-based study.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Lefebvre P, Chow W, Pilon D, Emond B, Lafeuille M, Pfeifer M, Rupnow MF, Duh MS.

**Patterns of Weight Loss, Maintenance, and Gain in Patients with Obesity.**

*Abstract:* Endocrinology Society 2016, Boston, MA Apr 1-4, 2016.

*Authors:* Huang; J, Buchs; S, DerSarkissian; M, Bhak; R, Vekeman; F, Ganguly; R, Duh; MS.

**Real-world evaluation of weight loss in patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin (CANA) - an electronic health-record (EHR)-based study.**

*Abstract:* Obesity Week, Los Angeles, CA Nov 2-6, 2015.

*Authors:* P; L, W; C, D; P, B; E, MH; L, M; P, MFT; R, MS; D.

**Economic outcomes among Medicare patients receiving skin substitutes for treatment of diabetic foot ulcers.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Rice JB, Desai U, Ristovska L, Cummings AG, Birnbaum HG, Skornicki M, Margolis D, Parsons N.

**Glycated hemoglobin (Hba1c) control in patients with Type 2 Diabetes Mellitus (T2DM) treated with canagliflozin in a realworld setting.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 15-20, 2015.

*Authors:* Lefebvre P, Pilon D, Robitaille M, Lafeuille M, Chow W, Pfeifer M, Duh MS.

**Daily dose and costs associated with maintenance therapy of topical testosterone agents among hypogonadal men.**

*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8 - 12, 2014.

*Authors:* Kaltenboeck A, Boytsov N, Hayes-Larson E, San Roman A, Ivanova J, Birnbaum H, Foster S, Vazquez J, Muram D, Swindle R.

**Which newly-diagnosed diabetics should receive dietary counseling services? Estimating individualized treatment allocations that optimize cost-effectiveness in real-world data.**

*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8-12, 2014.

*Authors:* Signorovitch J, Betts KA, Meng X, Zhuo Y, Wu EQ, Shi L.

**The burden of "serial non-adherence" in type 2 diabetic patients.**

*Abstract:* 50th Annual Meeting of the European Association for the Study of Diabetes, Vienna, Austria Sept 15-19-2014.

*Authors:* Frois C, Dea K, Ling D, Dunn J, Baron M.

**Systematic Review of real-world evidence on treatment of Acromegaly.**

*Abstract:* 96th Annual Meeting and Expo of the Endocrine Society, Chicago, IL June 21-24, 2014.

*Authors:* Guérin A, Xu Y, Hiscock R, Begelman SM, Mu Y, Alaghband R, Wu EQ.

**Daily dose and costs associated with maintenance therapy of topical testosterone agents among hypogonadal men.**

*Abstract:* 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America, Miami, FL Nov 20-23, 2014.

*Authors:* Kaltenboeck A, Boytsov N, Hayes-Larson E, San Roman AM, Ivanova J, Birnbaum HG, Foster SA, Vazquez JA, Muram D, Swindle RW.

**Units and costs per day per claim of comparable insulins supplied to Medicaid patients.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Ivanova JI, Foster S, Desai U, Hayes-Larson E, King S, Birnbaum HG, Swindle R.

**Venous thromboembolism and cardiovascular disease complications in women using transdermal versus oral menopausal estrogen therapy.**

*Abstract:* 24th Annual Meeting of the North American Menopause Society, Dallas, TX Oct 9-12, 2013.

*Authors:* Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

**Cost predictors in type 2 diabetes mellitus: A retrospective claims database analysis.**

*Abstract:* 49th Annual Meeting of the European Association for the Study of Diabetes, Barcelona, Spain Sep 23-27, 2013.

*Authors:* Ionescu-Ittu R, Bron M, Latremouille-Viau D, Guerin A, Samp J, Wu E.

**Distribution of costs in patients with type 2 diabetes mellitus: A retrospective claims database analysis.**

*Abstract:* 49th Annual Meeting of the European Association for the Study of Diabetes, Barcelona, Spain Sep 23-27, 2013.

*Authors:* Bron M, Guerin A, Latremouille-Viau D, Ionescu-Ittu R, Lopez C, Viswanathan P, Wu E.

**Clinical characteristics, quality measure attainment, and diabetes-related healthcare costs in patients with type 2 diabetes mellitus (T2DM) receiving metformin (MET) and sulfonylurea (SU).**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Lafeuille MH, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

**Effects of insulin adherence and delivery device on real world outcomes among patients with Type 2 Diabetes Mellitus (T2DM).**

*Abstract:* 73rd Scientific Sessions of the American Diabetes Association, Chicago, IL Jun 21-25, 2013.

*Authors:* Ayyagari R, Wei W, Cheng D, Pan C, Wu EQ.

**Clinical characteristics, quality measure attainment, and diabetes-related health care costs in elderly versus overall people living with type-2 diabetes mellitus (T2DM) receiving metformin (MET) and sulfonylurea (SU).**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Lafeuille MH, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

**Economic Outcomes Associated with HbA1c and LDL-C Goal Achievement In Patients with Type 2 Diabetes Mellitus.**

*Abstract:* ISPOR 2013, May 18-22, 2013.

*Authors:* Shi L, Ye X, Lu M, Wu E, Sharma H, Thomason D, Fonseca V.

**Health care resource use and costs in patients with type 2 diabetes mellitus after treatment initiation with saxagliptin or sitagliptin.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Kaltenboeck A, Ivanova J, Thomas N, Bell K, Yushkina Y, Schwiep FA, Birnbaum H.

**Medical, drug, and work-loss costs of diabetic foot ulcers.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

**Trend in economic burden of diabetes in urban china from 2009 to 2011.**

*Abstract:* ISPOR, May 18-22, 2013.

*Authors:* Wu E, Xie J, Du E, Liu M, Liu G.

**Improved clinical outcomes associated with dual-goal (HBA1C and LDL-C) achievement in newly diagnosed type 2 diabetes mellitus.**

*Abstract:* American Heart Association's Epidemiology and Prevention/Physical Activity, Nutrition and Metabolism 2013 Scientific Sessions, New Orleans, LA Mar 3-22, 2013.

*Authors:* Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Kang AL, Fonseca VA.

**The importance of adjustment for placebo-arm effects in indirect comparisons of glycemic control in type 2 diabetes mellitus.**

*Abstract:* 1st American Diabetes Association Middle East Congress., Dubai, UAE Dec 4-6, 2012.

*Authors:* Ayyagari R, Ong SH, Signorovitch JE, Rikun A, Gruenberger JB.

**Clinical and resource utilization outcomes: Elderly type 2 diabetes patients initiating insulin pens versus vials.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Eby E, Frois C, Guerin A, Boggs JA, Nyhuis A, Swindle R.

**Hba1c reduction associated with initial versus sequential combination therapy with pioglitazone (PIO) and dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with type 2 diabetes mellitus (T2DM).**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Bron M, Chen K, Ayyagari R, Sharma H, Wu EQ.



**Physician beliefs about insulin pens versus vials, therapy choice factors, and patient characteristics among elderly type 2 diabetes patients.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Eby E, Frois C, Guerin A, Boggs JA, Nyhuis A, Swindle R.

**Comparison of clinical and economic outcomes associated with DPP4i versus SU in combination with MET or PIO for the treatment of type 2 diabetes mellitus.**

*Abstract:* 48th Annual Meeting of the European Association for the Study of Diabetes, Berlin, Germany Oct 2-5, 2012.

*Authors:* Chen K, Wu E, Cheng D, Bensimon A, Bron M.

**Comparison of Clinical and Economic Outcomes Associated with DPP4 Inhibitors (DPP4I) versus Sulfonylurea (SU) in Combination with Metformin (MET) or Pioglitazone (PIO) for the Treatment of Type 2 Diabetes Mellitus (T2DM).**

*Abstract:* ISPOR 2012, Sep 2-4, 2012.

*Authors:* Bron M, Chen K, Cheng D, Bensimon A, Wu E.

**Glycemic control and quality of life for patients with type 2 diabetes mellitus in China.**

*Abstract:* ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan (Republic of China) Sep 2-4, 2012.

*Authors:* Xie K, Wu J, Xie J, Zheng Y, Yang HY, Wu EQ.

**Predictors of reaching HbA1c goal in T2DM patients using dipeptidyl peptidase-4 inhibitors (DPP-4IS) combination therapy: A subgroup analysis.**

*Abstract:* ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan (Republic of China) Sep 2-4, 2012.

*Authors:* Chen K, Bron M, Cheng D, Sharma H, Wu EQ.

**Risk of developing micro- and macrovascular complications in diabetes patients with psoriasis.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Armstrong AW, Guérin A, Sundaram M, Faust E, Mulani PM.

**Assessment of Preferences and Willingness-to-Pay for a New Basal Insulin Across Insulin Naïve and Experienced Patients.**

*Abstract:* American Diabetes Association's 72nd Scientific Sessions, Philadelphia, PA June 8-10, 2012.

*Authors:* Yang M, Lin P, Wintfeld N, Frois C.

**A Discrete Choice Experiment to Evaluate Diabetes Patients Preferences and Willingness-to-Pay for a New Basal Insulin.**

*Abstract:* American Diabetes Association's 72nd Scientific Sessions, Philadelphia, PA June 8-10, 2012.

*Authors:* Yang M, Lin P, Wintfeld N, Frois C.

**Economic burden of type 2 diabetes mellitus in China.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Zheng Y, Wu EQ, Xie K, Zheng B, Yang HY, Xie J, Wu J.

**Effect of diabetes patient characteristics on the willingness-to-pay for a new basal insulin-a discrete choice experiment.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Yang M, Lin P, Wintfeld N, Frois C.

**Health utility for patients with type 2 diabetes mellitus in China.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Wu J, Xie J, Han R, Wang L, Yang HY, Wu EQ.

**Hypoglycaemia and accident risk in people with Type 2 diabetes treated with antidiabetes drugs without insulin.**

*Abstract:* Diabetes UK Professional Conference, Glasgow, UK Mar 7-9, 2012.

*Authors:* Chen S, Macaulay D, Xie J, Swallow E, Diener M, Farooqui S, Wu E.

**Hypoglycaemia and accident risk in people with Type 2 diabetes treated with antidiabetes drugs without insulin.**

*Abstract:* Diabetes UK Professional Conference 2012 Glasgow, UK Mar 7-9, 2012.

*Authors:* Signorovitch J, Macaulay D, Diener M, Wu EQ, Gruenberger JB, Frier BM.

**Cost and frequency of hypoglycemic events in adult and elderly diabetics from an insured managed care population in the U.S.**

*Abstract:* IDF World Diabetes Congress, Dubai, United Arab Emirates Dec 4-8, 2011.

*Authors:* Bron M, Yang HY, Yu AP, Marynchenko M, Fan L.

**Association between hypoglycemia and medication possession ratio among veterans with type 2 diabetes mellitus (T2DM).**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Zhao Y, Shi L, Fonseca V, Campbell C, Wu EQ.

**Economic burden of psoriasis and diabetes in patients with psoriasis in the United States.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Wu EQ, Guerin A, Latremouille-Viau D, Day R, Khan Z, Zhang F.

**Economic burden of psoriatic arthritis and diabetes in patients with psoriatic arthritis in the United States.**

*Abstract:* ACR/ARHP Annual Scientific Meeting, Chicago, IL Nov 4-9, 2011.

*Authors:* Guérin A, Gauthier G, Day R, Khan Z, Zhang F.

**Low lipoprotein cholesterol goal attainment in dyslipidemic patients with existing statin therapy: A chart extraction-based approach.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Ivanova J, Frois C, Bae JP, Boykin SD, McCracken R, Molife C, Waldman T, Zhao Z.

**Uncontrolled serum uric acid in veteran gout patients is associated with a higher risk of diabetes.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL Nov 4-9, 2011.

*Authors:* Pandya BJ, Marynchenko M, Sharma H, Yu A, Wu E, Shi L, Liu J.

**Comparison of hypoglycaemia risk and cost between oral antidiabetic monotherapies in elderly patients with type 2 diabetes mellitus in a U.S. population.**

*Abstract:* 47th Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal Sept 12-16, 2011.

*Authors:* Yang H, Marynchenko M, Bron M, Wu E, Yu AP.

**Does route of administration for estrogen hormone therapy and estradiol transdermal system dosage strength impact risk of venous thromboembolism.**

*Abstract:* 22nd Annual Meeting of the North American Menopause Society, Washington, DC Sept 21-24, 2011.

*Authors:* Kahler KH, Nyirady J, Beresford E, Laliberte F, Dea K, Sheng Duh M, Lefebvre P.

**Hypoglycaemia in adult vs. elderly type 2 diabetes mellitus patients: Risks, costs, and impact on treatment persistence in a U.S. population.**

*Abstract:* 47th Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal Sep 12-16, 2011.

*Authors:* Bron M, Marynchenko M, Yang H, Yang Y, Wu E, Yu AP.

**Outcomes associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes initiated on insulin during hospitalisation.**

*Abstract:* 47th Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal Sept 12-16, 2011.

*Authors:* Zhou S, Wu E, Peng Yu A, Lu M, Sharma H, Graf T.

**Outcomes following insulin therapy disruption after hospital discharge in patients with type 2 diabetes.**

*Abstract:* 47th Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal Sep 12-16, 2011.

*Authors:* Wu E, Zhou S, Peng Yu A, Lu M, Sharma H, Graf T.

**Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.**

*Abstract:* 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Chicago, IL Aug 14-17, 2011.

*Authors:* Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

**Comparison of hypoglycemia risk and cost between oral antidiabetic monotherapies in elderly patients with type 2 diabetes mellitus.**

*Abstract:* ADA 71st Scientific Session, San Diego, CA Jun 24-28, 2011.

*Authors:* Yang HY, Marynchenko M, Bron M, Wu EQ, Yu AP.

**Factors associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes initiated on insulin during a hospitalization.**

*Abstract:* 93rd Annual Meeting and Expo of the Endocrine Society, Boston, MA Jun 4-7, 2011.

*Authors:* Wu E, Zhou S, AP. Y, Lu M, Graf TR.

**Hypoglycemia in adult versus elderly type 2 diabetes mellitus patients: Risks, costs, and impact on treatment persistence.**

*Abstract:* ADA 71st Scientific Session, San Diego, CA Jun 24-28, 2011.

*Authors:* Bron M, Marynchenko M, Yang HY, Yang Y, Wu EQ, Yu AP.

**Hypoglycemia risk factors among veterans with type 2 diabetes treated with oral antidiabetic drugs.**

*Abstract:* ADA 71st Scientific Session, San Diego, CA Jun 24-28, 2011.

*Authors:* Shi L, Bron M, Zhao Y, Marynchenko M, Yu AP, Bensimon AG, Wu EQ.

**Outcomes associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes (T2D) initiated on insulin during hospitalization.**

*Abstract:* 93rd Annual Meeting and Expo of the Endocrine Society, Boston, MA Jun 4-7, 2011.

*Authors:* Wu E, Zhou S, Yu AP, Lu M, Graf TR.

**Outcomes associated with insulin therapy disruption after hospital discharge in patients with type 2 diabetes.**

*Abstract:* ADA 71st Scientific Session, San Diego, CA Jun 24-28, 2011.

*Authors:* Wu EQ, Zhou S, Yu AP, Lu M, Graf T.

**Use of insulin during and after hospitalization and factors associated with therapy disruption after hospital discharge in type 2 diabetes patients.**

*Abstract:* ADA 71st Scientific Session, San Diego, CA Jun 24-28, 2011.

*Authors:* Wu EQ, Zhou S, Yu AP, Lu M, Graf T.

**The direct and indirect costs associated with hypogonadism among privately-insured employees in the United States.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Kaltenboeck A, Foster S, Thomas N, Ivanova J, Diener M, Bergman R, Birnbaum H, Swindle R.

**Direct healthcare and indirect workloss costs associated with the addition of rosiglitazone (RSG) versus sitagliptin (STG) therapy to metformin (MET).**

*Abstract:* ISPOR 16th Annual International Meeting Baltimore, MD May 21-25, 2011.

*Authors:* Lefebvre P, Sarda SP, Laliberte F, Ramamurthy P, Wei R, Arondekar B, Menditto L, Martin AA, Duh MS.

**Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system versus oral estrogen-only hormone therapy.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

**Estimating the effect of medication adherence on health outcomes among patients with type 2 diabetes--an application of marginal structural models.**

*Abstract:* ISPOR, Dec 2010.

*Authors:* Yu AP, Yu YF, Nichol MB.

**PDB5 Total and diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs from a large US managed care cohort.**

*Abstract:* ISPOR, Sep 5-7, 2010.

*Authors:* Bron M, Yu A, Marynchenko M, Sun S, Yang H, Wu E.

**Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.**

*Abstract:* 21st Annual Meeting of the North American Menopause Society, Chicago, IL Oct 6-9 2010.

*Authors:* Laliberte F, Dea K, Dub MS, Kahler KH, Rolli M, Lefebvre P.

**Economic effect of the clinical impact of bariatric surgery on morbidly obese patients with diabetes.**

*Abstract:* American Society for Healthcare Engineering 47th Annual Conference, Tampa, FL Jul 11-14, 2010.

*Authors:* Ghosh A, Crémieux PY, Klein S, Eapen S, McGavock T.

**Relationship of hypoglycemia with medication, discontinuation and costs in type 2 diabetes mellitus patients.**

*Abstract:* American Diabetes Association, 70th Scientific Sessions, Orlando, FL Jun 25-29, 2010.

*Authors:* Bron M, Yu AP, Marynchenko M, Yang H, Sun SX, Dabbous O.

**Diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs.**

*Abstract:* AMCP's 22nd Annual Meeting, San Diego, CA Apr 7-10, 2010.

*Authors:* Bron M, Yu AP, Marynchenko M, Sun SX, Yang H, Wu EQ.

**Medical costs in a US managed care cohort with oral antidiabetics maintenance therapy in type 2 diabetes patients who achieved HbA1c < 7.0.**

*Abstract:* 45th EASD Annual Meeting of the European Association for the Study of Diabetes, Vienna, Austria Sep 30-Oct 2, 2009.

*Authors:* Pandya BJ, Bron M, Yu AP, Chen K, Wu E, Kaltenboeck A, Mattson M, Sun S.

**Anti-hypertensive drug use and risk of dementia in patients with diabetes mellitus (DM).**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Johnson ML, Parikh NM, Kunik M, Schulz P, Chen H, Aparasu R, Yadav R, Morgan R.

**Risk factors for dementia in elderly patients with diabetes mellitus.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Parikh NM, Morgan R, Kunik M, Schulz P, Chen H, Aparasu R, Yadav R, Johnson M.

**Achieving Glycemic Goal with Initial Combination Therapy versus Sequential Augmentation Therapy using Metformin and Pioglitazone.**

*Abstract:* 44th EASD Meeting, Rome, Italy Sep 7-11, 2008.

*Authors:* Pandya BJ, Yu A, Wu EQ, Chen K, Kaltenboeck A, Seale J, Mattson M, Bron M, Baran RW.

**Comparative Glycemic Goal Achievement among Type 2 Diabetes Mellitus Patients Treated with Oral Antidiabetic Monotherapies.**

*Abstract:* American Diabetes Association's 68th Scientific Sessions, San Francisco, CA Jun 6-10, 2008.

*Authors:* Wu EQ, Pandya BJ, Yu A, Chen K, Seale J, Kaltenboeck A, Mattson M, Bron M, Baran RW.

**Adult Economic Status and Obesity in the United States: 2000-2002.**

*Abstract:* ISPOR 2006, 2006.

*Authors:* Wu E, Xie J, Crémieux P, Sullivan P.

**Obesity and quality of life in the United States: 2000-2002.**

*Abstract:* ISPOR 2006, 2006.

*Authors:* Wu E, Xie J, Sullivan P.

**Glycemic Control, Hypoglycemic Therapy and Subsequent Weight Change among Type 2 Diabetes Patients.**

*Abstract:* American Diabetes Association (ADA), 2006.

*Authors:* Yu AP, Wu EQ, Birnbaum H, Emani S, Fay M, Oglesby A, Pohl G, Stockl K, Wintle M.

**Obesity's Impact on Diabetes Patients' Health-Related Quality Of Life In The U.S.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia-Pacific, 2006.

*Authors:* Cremieux P, Xie J, Greenberg P, Wu EQ, Castor A.

**Short Term Economic Impact of Weight Change among Patients with Type 2 Diabetes.**

*Abstract:* American Diabetes Association.

*Authors:* Wu EQ, Yu AP, Birnbaum H, Emani S, Fay M, Oglesby A, Pohl G, Stockl K, Wintle M, Yang E.

**Employment and Income Associated with Obesity and Overweight in the US.**

*Abstract:* North American Association for the Study of Obesity (NAASO).

*Authors:* Wu EQ, Xie J, Sullivan PW.

**Employment and Income Associated with Obesity and Overweight in the US.**

*Abstract:* AMCP 2005.

*Authors:* Colice G, Crivera C, Vearghese S, Faruqi R, Wu EQ, Birnbaum H, Daher M, Marynchenko MB.

**Quality of Life of Obese Adults in the US.**

*Abstract:* International Society for Quality of Life Research.

*Authors:* Wu EQ, Xie J, Hill JO, Wyatt H, Sullivan PW.

**Cost-Effectiveness of Duloxetine versus Routine Treatment for Painful Diabetic Neuropathy in a Randomized Trial from a Societal Perspective.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR).

*Authors:* Wu EQ, Birnbaum H, Mareva M, Le TK, Rosen A, Robinson R.

**A methodology to identify high-risk patients with diabetes in the California Medicaid population (MEDI-CAL).**

*Abstract:* ISPOR 2003, 2003.

*Authors:* Chaikledkaew U, Wu E, Johnson K.

**PDB6: Factors associated with high-risk diabetic patients in the California Medicaid populations (medi-cal).**

*Abstract:* ISPOR, 2003.

*Authors:* Chaikledkaew U, Wu E, Johnson K.

## Gastrointestinal

### Journal Articles

**Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett's Esophagus, and Barrett's Esophagus-Related Neoplasia in the United States.**

*Publication:* J Health Econ Outcomes Res 2023 09; 10(1): 51-58. doi: 10.36469/001c.68191.

*Authors:* Sharma P, Falk GW, Bhor M, Ozbay AB, Latremouille-Viau D, Guerin A, Shi S, Elvekrog MM, Limburg P.

**Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn's Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases.**

*Publication:* Pharmacoecoon Open 2023 08. e-pub ahead of print 2023/08/04; doi: 10.1007/s41669-023-00424-z.

*Authors:* Karki C, Latremouille-Viau D, Gilaberte I, Hantsbarger G, Romdhani H, Lightner AL.

**Long-term persistence and other treatment patterns among bio-naïve patients with Crohn's disease treated with ustekinumab or adalimumab.**

*Publication:* Curr Med Res Opin 2023 08: 1-16. e-pub ahead of print 2023/08/11; doi:

10.1080/03007995.2023.2246882.

*Authors:* Zhdanava M, Ding Z, Manceur AM, Zhao R, Holiday C, Kachroo S, Izanec J, Pilon D.

**Persistence and other treatment patterns among bio-experienced patients with Crohn's disease initiated on ustekinumab or adalimumab.**

*Publication:* J Manag Care Spec Pharm 2023 08; 29(8): 907-916. e-pub ahead of print 2023/07/31; doi:

10.18553/jmcp.2023.29.8.907.

*Authors:* Zhdanava M, Zhao R, Manceur AM, Ding Z, Kachroo S, Holiday C, Lefebvre P, Pilon D.

**Economic and Clinical Burden of Herpes Zoster Among Patients With Inflammatory Bowel Disease in the United States.**

*Publication:* Crohns Colitis 360 2023 07; 5(3): otad033. e-pub ahead of print 2023/07/27; doi: 10.1093/crocol/otad033.

*Authors:* Singer D, Thompson-Leduc P, Gupta D, Poston S, Cheng WY, Ma S, Pawlowski JE, Duh MS, Devine F, Banatwala A, Bernstein E, Farraye FA.

**Persistence Among Patients with Crohn Disease Previously Treated with an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic Agent.**

*Publication:* Clin Ther 2023 07. e-pub ahead of print 2023/07/14; doi: 10.1016/j.clinthera.2023.06.013.

*Authors:* Zhdanava M, Kachroo S, Manceur AM, Ding Z, Holiday C, Zhao R, Godwin B, Pilon D.

**Incidence and risk of herpes zoster in patients with ulcerative colitis and Crohn's disease in the USA.**

*Publication:* Gastroenterol Rep (Oxf) 2023 04; 11: goad016. e-pub ahead of print 2023/04/18; doi:

10.1093/gastro/goad016.

*Authors:* Singer D, Thompson-Leduc P, Gupta D, Cheng WY, Poston S, Ma S, Pawlowski JE, Duh MS, Morris ED, Devine F, Farraye FA.

**Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett's Esophagus, and Barrett's Esophagus-Related Neoplasia in the United States.**

*Publication:* J Health Econ Outcomes Res 2023 03; 10(1): 51-58. e-pub ahead of print 2023/03/09; doi:

10.36469/001c.68191.

*Authors:* Sharma P, Falk GW, Bhor M, Ozbay AB, Latremouille-Viau D, Guerin A, Shi S, Elvekrog MM, Limburg P.

**Real-world upper endoscopy utilization patterns among patients with gastroesophageal reflux disease, Barrett esophagus, and Barrett esophagus-related esophageal neoplasia in the United States.**

*Publication:* Medicine 2023 03; 102(12): e33072. doi: 10.1097/md.00000000000033072.

*Authors:* Sharma P, Falk GW, Bhor M, Ozbay AB, Latremouille-Viau D, Guérin A, Shi S, Elvekrog MM, Limburg P.

**Costs of pediatric liver transplantation among commercially- and medicaid-insured patients with cholestasis in the United States.**

*Publication:* Liver Transpl 2023 02. e-pub ahead of print 2023/02/08; doi: 10.1097/lvt.0000000000000082.

*Authors:* Miloh T, Goldstein A, Howard R, Mogul DB, Marden JR, Anderson A, Gaburo K, Kirson N, Rosenthal P.

**Treatment persistence among bio-naïve patients with Crohn's disease initiated on ustekinumab or adalimumab.**

*Publication:* Curr Med Res Opin 2023 02: 1-31. e-pub ahead of print 2023/02/09; doi: 10.1080/03007995.2023.2178148.

*Authors:* Zhdanova M, Ding Z, Manceur AM, Muser E, Lefebvre P, Holiday C, Lafeuille MH, Pilon D.

**Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn's Disease: A Retrospective Claims Database Analysis.**

*Publication:* Crohns Colitis 360 2022 08; 4(3): otac029. e-pub ahead of print 2022/09/06; doi: 10.1093/crocol/otac029.

*Authors:* Ungaro RC, Griffith J, Garcia-Horton V, Wang A, Cross RK.

**The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States.**

*Publication:* Adv Ther 2022 06. e-pub ahead of print 2022/06/11; doi: 10.1007/s12325-022-02202-5.

*Authors:* Woolley M, Cook EE, Mu F, Betts KA, Billmyer E, Yim E, Chen J, Wu EQ.

**Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn's Disease Initiated on Biologic or Conventional Agents.**

*Publication:* Crohns Colitis 360 2022 06; 4(3): otac021. e-pub ahead of print 2023/02/14; doi: 10.1093/crocol/otac021.

*Authors:* Pilon D, Ding Z, Muser E, Manceur AM, Vermette-Laforme M, Lafeuille MH, Lefebvre P.

**Opioid-Induced Constipation: Cost Impact of Approved Medications in the Emergency Department.**

*Publication:* Adv Ther 2022 03. doi: 10.1007/s12325-022-02090-9.

*Authors:* Peacock WF, Slatkin N, Gagnon-Sanschagrin P, Maitland J, Guérin A, Joseph G.

**Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe.**

*Publication:* Crohns Colitis 360 2022 01; 4(1). doi: 10.1093/crocol/otac001.

*Authors:* Huynh L, Hass S, Peyrin-Biroulet L, Duh MS, Sipsma H, Cheng M, Lax A, Nag A.

**Risk of Thromboembolic Events and Associated Healthcare Costs in Patients with Inflammatory Bowel Disease.**

*Publication:* Adv Ther 2021 12. e-pub ahead of print 2021/12/09; doi: 10.1007/s12325-021-01973-7.

*Authors:* Setyawan J, Mu F, Zichlin ML, Billmyer E, Downes N, Yang H, Azimi N, Strand V, Yarur A.

**Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support.**

*Publication:* Clin Nutr ESPEN 2021 06; 43: 420-427. e-pub ahead of print 2021/05/25; doi:

10.1016/j.clnesp.2021.03.011.

*Authors:* Chen K, Joly F, Mu F, Kelkar SS, Olivier C, Xie J, Seidner DL.

**Burden of illness for patients with cholangiocarcinoma in the United States: a retrospective claims analysis.**

*Publication:* J Gastrointest Oncol 2021 05; 12(2): 658-668. e-pub ahead of print 2021/05/21; doi: 10.21037/jgo-20-544.

*Authors:* Chamberlain CX, Faust E, Goldschmidt D, Webster N, Boscoe AN, Macaulay D, Peters ML.

**Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States.**

*Publication:* J Med Econ 2021 01; 24(1): 202-211. e-pub ahead of print 2021/01/20; doi:

10.1080/13696998.2021.1877148.

*Authors:* Volk ML, Burne R, Guérin A, Shi S, Joseph GJ, Heimanson Z, Ahmad M.

**Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs.**

*Publication:* J Med Econ 2020 10; 23(10): 1092-1101. e-pub ahead of print 2020/07/02; doi: 10.1080/13696998.2020.1789649.

*Authors:* Manceur AM, Ding Z, Muser E, Obando C, Voelker J, Pilon D, Kinkead F, Lafeuille MH, Lefebvre P.

**Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population.**

*Publication:* Curr Med Res Opin 2020 08; 36(8): 1285-1294. e-pub ahead of print 2020/05/20; doi: 10.1080/03007995.2020.1771293.

*Authors:* Pilon D, Ding Z, Muser E, Obando C, Voelker J, Manceur AM, Kinkead F, Lafeuille MH, Lefebvre P.

**Comparative evaluation of treatment persistence and dose intensification in patients with Crohn's disease treated with ustekinumab versus vedolizumab.**

*Publication:* 2020 07.

*Authors:* Chiorean M, Jiang J, Candela N, G. C, Romdhani H, Latremouille-Viau D, Shi S, Bungay R, Fan T.

**Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab.**

*Publication:* Crohns Colitis 360 2020 04; 2(2): otaa031. doi: 10.1093/crocol/otaa031.

*Authors:* Chiorean M, Afzali A, Cross RK, Macaulay D, Griffith J, Wang A, Garcia-Horton V.

**Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study.**

*Publication:* BMC Rheumatology 2020 04; 4(1): 16. doi: 10.1186/s41927-020-0115-2.

*Authors:* Hudesman DP, Chakravarty SD, Emond B, Ellis LA, Lefebvre P, Sadik K, Scher JU.

**Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system.**

*Publication:* PLoS One 2019 12; 14(12): e0225572. e-pub ahead of print 2019/12/05; doi: 10.1371/journal.pone.0225572.

*Authors:* Cross RK, Chiorean M, Vekeman F, Xiao Y, Wu E, Chao J, Wang AW.

**Comparison of Real-World Treatment Outcomes With Vedolizumab Versus Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease.**

*Publication:* Crohns Colitis 360 2019 07; 1(2). doi: 10.1093/crocol/otz022.

*Authors:* Patel H, Latremouille-Viau D, Burne R, Shi S, Adsul S.

**Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.**

*Publication:* J Med Econ 2019 07; 1. e-pub ahead of print 2019/07/12; doi: 10.1080/13696998.2019.1642900.

*Authors:* Ueno F, Doi M, Kawai Y, Ukawa N, Cammarota J, Betts KA.

**Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.**

*Publication:* Curr Med Res Opin 2019 05; 1-9. e-pub ahead of print 2019/05/21; doi: 10.1080/03007995.2019.1620713.

*Authors:* Emond B, Ellis LA, Chakravarty SD, Ladouceur M, Lefebvre P.

**Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure.**

*Publication:* Journal of Parenteral and Enteral Nutrition. 2019 04. doi: <http://dx.doi.org/10.1002/jpen.1588>.

*Authors:* Chen K, Mu F, Xie J, Kelkar SS, Olivier C, Signorovitch J, Jeppesen PB.

**Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome.**

*Publication:* Therap Adv Gastroenterol 2019 01; 12(no pagination). doi: <http://dx.doi.org/10.1177/1756284818818326>.



*Authors:* Lacy B, Ayyagari R, Guerin A, Lopez A, Shi S, Luo M.

**Incidence of catheter-related complications among Japanese patients with central venous catheters as well as patients with short bowel syndrome.**

*Publication:* Clin Exp Gastroenterol 2018 12; 11: 439-445. e-pub ahead of print 2018/12/21; doi: 10.2147/CEG.S172430.

*Authors:* Wing VK, Song Y, Xiang C, Liu X, Macaulay D, Ponsillo M, Blumentals WA.

**Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome.**

*Publication:* Ther Clin Risk Manag 2018 08; 14: 1267-1277. e-pub ahead of print 2018/08/14; doi: 10.2147/TCRM.S166081.

*Authors:* Chen KS, Xie J, Tang W, Zhao J, Jeppesen PB, Signorovitch JE.

**Public health impact of Rotarix vaccination among commercially insured children in the United States.**

*Publication:* Vaccine 2017 09; 35(37): 5065-5072. e-pub ahead of print 2017/08/06; doi: 10.1016/j.vaccine.2017.06.034.

*Authors:* Krishnarajah G, Kageleiry A, Korves C, Lefebvre P, Duh MS.

**Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea.**

*Publication:* Cancer Res Treat 2017 07; 49(3): 578-587. e-pub ahead of print 2016/09/14; doi: 10.4143/crt.2016.001.

*Authors:* Carter GC, Kaltenboeck A, Ivanova J, Liepa AM, San Roman A, Koh M, Rajan N, Cheng R, Birnbaum HG, Kim JS, Bang YJ.

**Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis.**

*Publication:* Curr Med Res Opin 2017 03; 33(3): 529-536. e-pub ahead of print Published online: 12 Jan 2017; doi: 10.1080/03007995.2016.1267616.

*Authors:* Rubin DT, Patel H, Shi S, Mody R.

**Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims Analysis.**

*Publication:* Dig Dis Sci 2016 10; 61(10): 2823-2830. e-pub ahead of print 2016/07/16; doi: 10.1007/s10620-016-4219-x.

*Authors:* Guandalini S, Tundia N, Thakkar R, Macaulay D, Essenmacher K, Fuldeore M.

**Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.**

*Publication:* Curr Med Res Opin 2016 07; 32(7): 1233-1241. doi: 10.1185/03007995.2016.1168290.

*Authors:* Sandborn WJ, Sakuraba A, Wang A, Macaulay D, Reichmann W, Wang S, Chao J, Skup M.

**Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia and Mexico.**

*Publication:* J Med Econ 2016 07: 1-49. e-pub ahead of print 2016/07/05; doi: 10.1080/13696998.2016.1209508.

*Authors:* Tundia N, Gustavo Kotze P, Rojas Serrano J, Mendes de Abreu M, Skup M, Macaulay D, Signorovitch J, Chaves L, Chao J, Bao Y.

**Rotavirus vaccination in a Medicaid infant population from four US states: compliance, vaccination completion rate, and predictors of compliance.**

*Publication:* Hum Vaccin Immunother 2016 05; 12(5): 1235-1243. e-pub ahead of print 2016/02/24; doi: 10.1080/21645515.2015.1136041.

*Authors:* Calnan M, Krishnarajah G, Duh MS, Haider BA, Yermakov S, Davis M, Yan S.

**Cost-analysis model of colonoscopy preparation using split-dose reduced-volume oral sulfate solution (OSS) and polyethylene glycol with electrolytes solution (PEG-ELS).**

*Publication:* J Med Econ 2016 04; 19(4): 356-363. e-pub ahead of print 2015/11/27; doi: 10.3111/13696998.2015.1125907.

*Authors:* Huynh L, Yermakov S, Davis M, Campbell R, Cleveland M, Farraye FA, Yenikomshian M.

**Variation in Care for Patients with Irritable Bowel Syndrome in the United States.**

*Publication:* PLoS One 2016 04; 11(4): e0154258. e-pub ahead of print 2016/04/27; doi: 10.1371/journal.pone.0154258.

*Authors:* Lacy BE, Patel H, Guerin A, Dea K, Scopel JL, Alaghband R, Wu EQ, Mody R.

**Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication.**

*Publication:* PLoS One 2016 01; 11(1): e0145504. doi: 10.1371/journal.pone.0145504.

*Authors:* Guerin A, Mody R, Carter V, Ayas C, Patel H, Lasch K, Wu E.

**Public Health Impact of Complete and Incomplete Rotavirus Vaccination among Commercially and Medicaid Insured Children in the United States.**

*Publication:* PLoS One 2016 01; 11(1): e0145977. e-pub ahead of print 2016/01/12; doi: 10.1371/journal.pone.0145977.

*Authors:* Krishnarajah G, Duh MS, Korves C, Demissie K.

**Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.**

*Publication:* J Med Econ 2015 06; 18(6): 447-456. doi: 10.3111/13696998.2015.1021353.

*Authors:* Cohen R, Skup M, Ozbay AB, Rizzo J, Yang M, Diener M, Chao J.

**Prevalence and risk of developing comorbid conditions in patients with chronic constipation.**

*Publication:* Current Medical Research & Opinion 2014 12; 30(12): 2505-2513. doi: 10.1185/03007995.2014.964854.

*Authors:* Mody R, Guerin A, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ.

**Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States.**

*Publication:* Hum Vaccin Immunother 2014 11; 10(8): 2255-2266. doi: 10.4161/hv.29511.

*Authors:* Krishnarajah G, Demissie K, Lefebvre P, Gaur S, Sheng Duh M.

**Gastrointestinal comorbidities associated with atrial fibrillation.**

*Publication:* Springerplus 2014 10; 3: 603. doi: 10.1186/2193-1801-3-603.

*Authors:* Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Schein JR, Lefebvre P.

**The impact of moderate-to-severe Crohn's Disease on employees' salary growth.**

*Publication:* Inflamm Bowel Dis 2014 10; 20(10): 1734-1738. doi: 10.1097/MIB.000000000000133.

*Authors:* Loftus EV, Jr., Skup M, Ozbay AB, Wu E, Guerin A, Chao J, Mulani P.

**The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population.**

*Publication:* J Med Econ 2014 08; 17(8): 577-586. doi: 10.3111/13696998.2014.919926.

*Authors:* Guerin A, Carson RT, Lewis B, Yin D, Kaminsky M, Wu E.

**Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation.**

*Publication:* Aliment Pharmacol Ther 2014 07; 40(1): 83-92. doi: 10.1111/apt.12789.

*Authors:* Guerin A, Mody R, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ.

**A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.**

*Publication:* J Manag Care Pharm 2013 11; 19(9): 755-764.

*Authors:* Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT.

**A health-related quality-of-life study comparing Vitala continence control device versus traditional pouch system only in patients with end colostomy.**

*Publication:* Eur J Gastroenterol Hepatol 2013 06; 25(6): 739-747. doi: 10.1097/MEG.0b013e32835d5f3c.

*Authors:* Hoch J, Yang M, Yan S, van den Broek N, Xie J, Warusavitarne J.

**Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade.**

*Publication:* Postgrad Med 2013 03; 125(2): 40-50. doi: 10.3810/pgm.2013.03.2640.

*Authors:* Nellesen D, Chawla A, Oh DL, Weissman T, Lavins BJ, Murray CW.

**Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).**

*Publication:* Inflamm Bowel Dis 2012 11; 18(11): 2043-2055. doi: 10.1002/ibd.22873.

*Authors:* Sussman DA, Kubiliun N, Mulani PM, Chao J, Gillis CA, Yang M, Lu M, M TA.

**Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.**

*Publication:* Adv Ther 2012 07; 29(7): 620-634. doi: 10.1007/s12325-012-0035-7.

*Authors:* Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.

**Increased risks of developing anxiety and depression in young patients with Crohn's disease.**

*Publication:* Am J Gastroenterol 2011 09; 106(9): 1670-1677. doi: 10.1038/ajg.2011.142.

*Authors:* Loftus EV, Jr., Guerin A, Yu AP, Wu EQ, Yang M, Chao J, Mulani PM.

**Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease.**

*Publication:* Inflamm Bowel Dis 2011 01; 17(1): 127-140. doi: 10.1002/ibd.21341.

*Authors:* Loftus EV, Jr., Johnson SJ, Wang ST, Wu E, Mulani PM, Chao J.

**The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.**

*Publication:* Aliment Pharmacol Ther 2010 11; 32(10): 1228-1239. doi: 10.1111/j.1365-2036.2010.04466.x.

*Authors:* Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD.

**Systematic review: the costs of ulcerative colitis in Western countries.**

*Publication:* Aliment Pharmacol Ther 2010 04; 31(7): 693-707. doi: 10.1111/j.1365-2036.2010.04234.x.

*Authors:* Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J.

**Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.**

*Publication:* Eur J Gastroenterol Hepatol 2009 11; 21(11): 1302-1309. doi: 10.1097/MEG.0b013e32832a8d71.

*Authors:* Loftus EV, Jr., Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM.

**Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.**

*Publication:* Current Medical Research & Opinion 2009 11; 25(11): 2703-2709. doi: 10.1185/03007990903307755.

*Authors:* Kothari S, Nelson SP, Wu EQ, Beaulieu N, McHale JM, Dabbous OH.

**Impact of compliance with proton pump inhibitors on NSAID treatment.**

*Publication:* Am J Manag Care 2009 10; 15(10): 681-688.

*Authors:* Duh MS, Gosselin A, Luo R, Lohoues H, Lewis BE, Crawley JA.

**Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy.**

*Publication:* J Med Econ 2009 10; 12(4): 348-355. doi: 10.3111/13696990903378680.

*Authors:* Nelson SP, Kothari S, Wu EQ, Beaulieu N, McHale JM, Dabbous OH.

**Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.**

*Publication:* Pharmacoeconomics 2009 08; 27(7): 609-621. doi: 10.2165/11312710-000000000-00000.

*Authors:* Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, Chao J, Mulani PM.

**Treatment patterns and symptom control in patients with GERD: US community-based survey.**

*Publication:* Current Medical Research & Opinion 2009 08; 25(8): 1869-1878. doi: 10.1185/03007990903035745.

*Authors:* Chey WD, Mody RR, Wu EQ, Chen L, Kothari S, Persson B, Beaulieu N, Lu M.

**Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.**

*Publication:* Am J Gastroenterol 2009 05; 104(5): 1170-1179. doi: 10.1038/ajg.2009.59.

*Authors:* Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.

**Corrigendum: Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients with Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial.**

*Publication:* American Journal of Gastroenterology 2009 104(7).

*Authors:* Loftus EV, Feagan BG, Colombel J-F, Rubin DT, Wu EQ, Yu AP, Pollack PF, Jingdong C, Mulani P.

**Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.**

*Publication:* Am J Gastroenterol 2008 12; 103(12): 3132-3141. doi: 10.1111/j.1572-0241.2008.02175.x.

*Authors:* Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.

**Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.**

*Publication:* Gastroenterology 2008 11; 135(5): 1493-1499. doi: 10.1053/j.gastro.2008.07.069.

*Authors:* Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Jr., Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P.

**Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective.**

*Publication:* Value in Health 2008 10; 11(5): 820-829. doi: 10.1111/j.1524-4733.2008.00335.x.

*Authors:* Wu EQ, Mulani PM, Yu AP, Tang J, Pollack PF.

**The costs of Crohn's disease in the United States and other Western countries: a systematic review.**

*Publication:* Current Medical Research & Opinion 2008 02; 24(2): 319-328. doi: 10.1185/030079908X260790.

*Authors:* Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J.

**Effect of sustained remission and clinical response on the risk of hospitalization in patients with Crohn's disease.**

*Publication:* Manag Care Interface 2008 21: 20-23.

*Authors:* Wu E, Yu A, Tang J, Atanasov P, Chao J, Mulani P.

**Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation.**

*Publication:* Pharmacoepidemiol Drug Saf 2006 01; 15(1): 47-56. doi: 10.1002/pds.1118.

*Authors:* Sands BE, Duh MS, Cali C, Ajene A, Bohn RL, Miller D, Cole JA, Cook SF, Walker AM.

**The economic consequences of irritable bowel syndrome: a US employer perspective.**

*Publication:* Arch Intern Med 2003 04; 163(8): 929-935. doi: 10.1001/archinte.163.8.929.

*Authors:* Leong SA, Barghout V, Birnbaum HG, Thibeault CE, Ben-Hamadi R, Frech F, Ofman JJ.

## Abstracts

**Association Between Gut Microbiota and Health-Related Quality of Life in Patients with Recurrent Clostridioides difficile Infection: Results from the PUNCH CD3 Clinical Trial.**

Boston, MA October 11 - 15, 2023.

*Authors:* Feuerstadt P, Blount K, Guo A, Yang M, García-Horton V, Fillbrunn M, Glenn GS, Dubberke ER, Gao Y, Garey KW.

**A Matching-Adjusted Indirect Comparison of Filgotinib Versus Tofacitinib for Moderately to Severely Active Ulcerative Colitis.**

*Abstract:* ISPOR 2022, Washington, D. C. May 15-18, 2022.

*Authors:* Lu X, Gray E, X. Y, Zhou ZY, Jairath V, Lindsay JO.

**A step towards personalized Crohn's disease treatment: comparative evaluation of real-world treatment persistence in a subpopulation of bio-naïve patients with Crohn's disease treated with anti-TNF, vedolizumab, or ustekinumab**

*Abstract:* ECCO 2022, Vienna, Austria February 16-19, 2022.

*Authors:* Bressler B, Agboton C, Romdhani H, Latremouille-Viau D, Wang S, Kamble P.

**Real-world treatment patterns and recurrence rates of rectovaginal fistulas in patients with Crohn's disease: A retrospective cohort database analysis.**

*Abstract:* 16th Congress of ECCO 2021, Virtual July 2-3., 2021

July 8-10, 2021.

*Authors:* Karki C, Latremouille-Viau D, Gilaberte I, Hantsbarger G, Romdhani H, Lightner A.

**Real-world effectiveness of first-line biologic vedolizumab in crohn's disease: analysis of higher treatment effect subpopulation from the evolve study.**

*Abstract:* Digestive Disease Week® (DDW) 2021, Virtual May 21 – 23, 2021.

*Authors:* Bressler B, Yarur A, Wang S, Adsul S, Kamble P, Luo M, Cook E, Sajeev G, Dieye I, Mantzaris GJ.

**Disease Burden and Quality of Life Impacts in Patients With Celiac Disease on a Gluten-Free Diet: An Analysis of the ICureCeliac Registry.**

*Abstract:* American College of Gastroenterology (ACG) Virtual Meeting, Oct 23-28, 2020.

*Authors:* Chen K, Geller M, Leffler D, Meckley L, Mu F, Kponee-Shovein K, Swallow E.

**Comparative Evaluation of Treatment Outcomes in Patients With Crohn's Disease Treated With Ustekinumab Versus Vedolizumab.**

*Abstract:* American College of Gastroenterology (ACG) 2020 Virtual Annual Scientific Meeting.

*Authors:* Chiorean M, Jiang J, Candela N, Chen G, Romdhani H, Latremouille-Viau D, Shi S, Bungay R, Fan T.

**Identification of Factors Associated With Response to Teduglutide Within 24 Weeks Among Pediatric Patients With Short Bowel Syndrome–Associated Intestinal Failure.**

*Abstract:* 11th International Pediatric Intestinal Failure and Rehabilitation Symposium (PIFRS) Virtual Town Hall, Virtual.

*Authors:* Venick R, Chen K, Carter B, Hill S, Kocoshis S, Mercer D, Mu F, Swallow E, Zhao J, Wales P, Grimm A.

**The Cost Impact of Increased Molecular Testing Rates for the Treatment of Patients with Gastrointestinal Stromal Tumors.**

*Abstract:* AMCP 2020, Houston, TX April 21-24.

*Authors:* Nellesen D.

**Patients With Crohn's Disease Treated With Ustekinumab Versus Vedolizumab in Real-World Settings.**

*Abstract:* ECCO (European Crohn's & Colitis Organisation), Vienna, Austria February 12–15, 2020.

*Authors:* Chiorean M, Jiang J, Candela N, Chen G, Romdhani H, Latremouille-Viau D, Shi S, Bungay R, Fan T.

**Anti-TNF treatment effectively reduced rate of hospitalization in patients with inflammatory bowel disease with or without extraintestinal manifestations: real world data in Germany.**

*Abstract:* United European Gastroenterology Week Barcelona, Spain October 19-23, 2019.

*Authors:* Bettenworth D, Lee WJ, Clark RS, Rath S, Yang M, Cook EE, Vavricka S.

**Anti-TNF treatment effectively reduced rate of hospitalization in patients with inflammatory bowel disease with or without extra-intestinal manifestations: real world data in Germany.**

Barcelona, Spain October 19-23, 2019.

*Authors:* Bettenworth D, Lee WJ, Clark RS, Rath S, Yang M, Cook EE, Vavricka S.

**A Specialty Pharmacy Cohort Study Evaluating the Effectiveness of Teduglutide in Subgroups of Patients With Short Bowel Syndrome Receiving Parenteral Support Defined by Bowel Anatomy.**

*Abstract:* United European Gastroenterology Week 2019, Barcelona, Spain October 19–23, 2019.

*Authors:* Chen KS, Yang H, Zhao J, Briggs A.

**Use of Different Statistical Approaches to Compare Real-World Outcomes Associated with Vedolizumab Versus Infliximab in Biologic-Naive Patients with Inflammatory Bowel Disease.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Latremouille-Viau D, Burne R, Shi S, Patel H.

**Impact of anti-TNF treatment on extra-intestinal manifestations in patients with inflammatory bowel disease: real world data in Germany.**

Copenhagen, Denmark March 6–9, 2019.

*Authors:* D. B, Lee WJ, Clark RS, Rath S, Yang M, Bensimon A, Vavricka S.

**Impact of anti-TNF treatment on extra-intestinal manifestations in patients with inflammatory bowel disease: Real-world data in Germany.**

*Abstract:* 14th Annual Congress of ECCO - Inflammatory Bowel Disease 2019, Copenhagen, Denmark Mar 6-9, 2019.

*Authors:* Bettenworth D, Lee WJ, Clark RS, Rath S, Yang M, Bensimon A, Vavricka S.

**Real World Effectiveness of Teduglutide in Patients with Short Bowel Syndrome Receiving Parenteral Support: A Retrospective Study from a US Specialty Infusion Pharmacy.**

*Abstract:* Aspen 2019, Phoenix, AZ March 23 - March 26, 2019.

*Authors:* Chen KS, Yang H, Zhao J, Briggs A.

**Incidence of inflammatory bowel disease (IBD) among patients (PTS) with other chronic inflammatory diseases (CID) treated with interleukin-17A (IL-17A) or phosphodiesterase 4 (PDE4) inhibitors.**

*Abstract:* ACR/ARHP Annual Meeting, Chicago, IL Oct 19-24, 2018.

*Authors:* Emond B, Ellis LA, Chakravarty SD, Ladouceur M, Lefebvre P.

**Inflammatory bowel disease is associated with a substantial economic burden in patients with psoriatic arthritis and in patients with ankylosing spondylitis.**

*Abstract:* ACR/ARHP Annual Meeting, Chicago, IL Oct 19-24, 2018.

*Authors:* Bergman MJ, Zueger P, Song J, Pivneva I, Betts KA, Joshi AD.

**Real-world use of faecal calprotectin testing in patients with inflammatory bowel disease.**

*Abstract:* 13th Congress of European Crohn's and Colitis Organisation, Vienna, Austria Feb 14-17, 2018.

*Authors:* Rubin DT, Yang M, Wu EQ, Skup M, Lee WJ.

**Realworld adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).**

*Abstract:* ASCO Annual Meeting, Chicago, IL June 2-6, 2017.

*Authors:* Patel AK, Duh MS, Barghout VE, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS.

**Association of clinical complications and surgery treatment on recurrence of acute diverticulitis.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Kawatkar AA, Chu L, Nichol MB.

**Association of socio-demographics and clinical complications with future medical expenditures in diverticulitis.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Kawatkar AA, Chu L, Nichol MB.

**Evaluation of age, multimorbidity and clinical complications as risk factors for urgent surgical treatment for diverticulitis.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Kawatkar AA, Chu L, Nichol MB.

**Incremental expenditures associated with recurrence of diverticulitis.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Kawatkar AA, Chu L, Nichol MB.

**Trajectories of expenditures associated with acute gastrointestinal diseases.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Kawatkar AA, Chu L, Nichol MB.

**Identifying higher-value subpopulations for treatment in heterogenous rare diseases: An example study of early responders to teduglutide for short bowel syndrome.**

*Abstract:* ISPOR 19th Annual European Congress, Vienna, Austria Oct 29 - Nov 2, 2016.

*Authors:* Chen K, Xie J, Tang C, Zhao J, Olivier C, Jeppesen PB, Signorovitch J.

**Predictors of response to teduglutide among patients with parenteral nutrition-dependent short bowel syndrome.**

*Abstract:* 81st Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 21-26, 2016.

*Authors:* Seidner DL, Joly F, Gabe SM, Mu F, Xie J, Kelkar SS, Chen K, Olivier C.

**Predictors of response to teduglutide among patients with parenteral nutrition-dependent short bowel syndrome.**

*Abstract:* 24th United European Gastroenterology Week, Vienna, Austria Oct 15-19, 2016.

*Authors:* Joly F, Gabe SM, Seidner DL, Mu F, Xie J, Kelkar SS, Chen K, Olivier C.

**Assessment of the real-world safety profile of vedolizumab using the united states food and drug administration adverse event reporting system (FAERS).**

*Abstract:* Digestive Disease Week, San Diego, CA May 21-24, 2016.

*Authors:* Cross R, Vekeman F, Xiao Y, Wu EQ, Chao J, Wang A.

**Diagnostic testing in IBS patients: Which factors are most strongly associated with more frequent diagnostic tests and procedures?**

*Abstract:* Digestive Disease Week, San Diego, CA May 21-24, 2016.

*Authors:* Luo M, Guerin A, Ayyagari R, Shi S, Lopez A, Lacy B.

**Economic Impact of Expanded Use of Biologic Therapy for Crohn's Disease In Latin American Countries.**

*Abstract:* ISPOR 5th Latin America Conference, Santiago, Chile Sept 6-8, 2015.

*Authors:* Kotze PG, Tundia N, Gumen A, Macaulay D, Chaves L, Bao Y.

**Comparison of real-world outcomes of adalimumab and infliximab for patients with moderate or severe ulcerative colitis in the United States.**

*Abstract:* ACG 2015 Annual Scientific Meeting & Post Graduate Course, Honolulu, HI Oct 10-21, 2015.

*Authors:* Sakuraba A, Sandborn W, Skup M, Macaulay D, Reichmann W, Chao J.

**Effect of adalimumab dose escalation on hospitalization risk in patients with moderately to severely active ulcerative colitis.**

*Abstract:* American College of Gastroenterology 80th Annual Meeting, Honolulu, HI Oct 16-21, 2015.

*Authors:* Feagan B, Skup M, Ozbay AB, Thakkar RB, Lazar A, Yang M, Macaulay D, Chao J, Sandborn W.

**A cost comparison of split-dose reduced-volume oral sulfate solution (OSS) and polyethylene glycol with electrolytes solution (PEG-ELS).**

*Abstract:* ISPE's 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA Aug 22-26, 2015.

*Authors:* Huynh L, Yermakov S, Davis M, Campbell R, Cleveland M, Farraye FA, Yenikomshian M.

**Direct costs in patients with celiac disease-a retrospective claims analysis.**

*Abstract:* 16th International Celiac Disease Symposium, Prague, Czech Republic Jun 21-24, 2015.

*Authors:* Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M.

**Prevalence of comorbidities in patients with celiac disease.**

*Abstract:* 16th International Celiac Disease Symposium, Prague, Czech Republic Jun 21-24, 2015.

*Authors:* Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M.

**A cost comparison of split-dose reduced-volume oral sulfate solution (OSS) and polyethylene glycol with electrolytes solution (PEG-ELS).**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Cleveland M, Yermakov S, Davis M, Campbell R, Huynh L, Farraye F, Yenikomshian M.

**Cost of hospitalisations among moderate-to-severe Ulcerative Colitis patients treated with adalimumab and conventional non-biologic therapies.**

*Abstract:* 10th Congress of the European Crohn's and Colitis Organisation, Barcelona, Spain Feb 18-21, 2015.

*Authors:* Wang S, Yang H, Faust E, Bao Y.

**Age-related health care disparities in patients with irritable bowel syndrome: Findings from a sample of commercially insured patients.**

*Abstract:* 79th Annual Scientific Meeting of the American College of Gastroenterology, Philadelphia, PA Oct 17-22, 2014.

*Authors:* Lacy B, Patel H, Guerin A, Dea K, Alaghband R, Wu EQ, Scopol J, Mody R.

**Comparison of cost per responder and remitter in patients with inflammatory bowel disease in the united states: An indirect comparison of adalimumab and vedolizumab.**

*Abstract:* 79th Annual Scientific Meeting of the American College of Gastroenterology Philadelphia, PA Oct 17-22, 2014.

*Authors:* Liu Y, Ozbay AB, Skup M, Reichmann W, Diener M, Chao J.

**Cost-effectiveness of adalimumab in moderately to severely active ulcerative colitis (sub-acute) in the UK. .**

*Abstract:* 22nd United European Gastroenterology Week, Vienna, Austria Oct 18-22, 2014.

*Authors:* Yang H, Curry A, Wang S, Yang M, Skup M, Chao J, Baofill Y.



**Indirect comparison of adalimumab and vedolizumab in inflammatory bowel disease in the United Kingdom: cost per responder/remitter analysis.**

*Abstract:* 22nd Annual United European Gastroenterology Week, Vienna, Austria Oct 18-22, 2014.

*Authors:* Liu Y, Reichmann W, Wang S, Macaulay D, Skup M, Chao J, Bao Y.

**Regional variation of care for irritable bowel syndrome in the United States.**

*Abstract:* 79th Annual Scientific Meeting of the American College of Gastroenterology Philadelphia, PA Oct 17-22, 2014.

*Authors:* Lacy B, Patel H, Guerin A, Dea K, Alaghband R, Wu EQ, Scopel J, Mody R.

**Cost-effectiveness of adalimumab for the treatment of moderately to severely active ulcerative colitis in Canada.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Ghosh S, Desjardins O, Skup M, Wang S, Yang M, Yang H, Qi C, Bao Y, Chao J.

**Association between adherence to adalimumab therapy and health care costs for patients with crohn's disease: Claims database analysis.**

*Abstract:* 78th Annual Scientific Meeting of the American College of Gastroenterology, San Diego, CA Oct 11-16, 2013.

*Authors:* Schifrien B, Yen E, Liu Y, Skup M, Tundia N, Ayyagari R, Yang H, Bao Y, Mulani P, Chao J.

**Impact of the FDA safety communication on prescription trends of clopidogrel in combination with proton pump inhibitors.**

*Abstract:* 78th Annual Scientific Meeting of the American College of Gastroenterology, San Diego, CA Oct 11-16, 2013.

*Authors:* Guerin A, Mody R, Carter V, Wu E.

**Indirect comparison of adalimumab and infliximab in ulcerative colitis: Cost per remitter analysis.**

*Abstract:* 78th Annual Scientific Meeting of the American College of Gastroenterology, San Diego, CA Oct 11-16, 2013.

*Authors:* Liu Y, Reichmann B, Yan S, Macaulay D, Skup M, Mulani P, Chao J.

**Quality of life and life enjoyment: An analysis of end colostomy patients.**

*Abstract:* 12th European Council of Enterostomal Therapy, Paris, France June 23-26, 2013.

*Authors:* Yan S, Yang M, Hoch J, van den Broek N, Xie J, Warusavitarne J.

**Budgetary impact of linaclotide in the treatment of US adult patients with irritable bowel syndrome with constipation (IBS-C) or chronic constipation (CC).**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Taylor DCA, Carson RT, Xie J, Dean J, Du EX, Sarocco P, Blum SI.

**Impact of Chronic Constipation Severity on the Risk of Developing Colorectal Cancer and Benign Neoplasm.**

*Abstract:* Digestive Disease Week 2013, Orlando, FL May 18-21, 2013.

*Authors:* Guérin A, Mody R, Fok B, Wu EQ, Lasch K, Talley NJ.

**Medical costs associated with treatment failure with over-the-counter or prescription constipation treatments in patients with IBS-C in a Medicaid population.**

*Abstract:* AMCP's 25th Annual Meeting, San Diego, CA Apr 3-5, 2013.

*Authors:* Guérin A, Carson RT, Yin D, Kaminsky MS, Taylor DCA, Sarocco P, Wu EQ.

**High risk of leaving the workforce in US employees with ulcerative colitis.**

*Abstract:* 8th Congress of the European Crohn's and Colitis Organisation, Vienna, Austria Feb 14 - 16, 2013.

*Authors:* Cohen R, Rizzo J, Yang M, Skup M, Macaulay D, Behrer C, Fok B, Mulani PM, Chao J.

**Direct and indirect utilization and costs associated with ulcerative colitis.**

*Abstract:* 2012 Advances in Inflammatory Bowel Diseases Crohn's and Colitis Foundation's National Clinical and Research, Hollywood, FL Dec 13-15, 2012.

*Authors:* Cohen R, Rizzo J, Diener M, Yang M, Skup M, Mulani P, Chao J.

**Cost-effectiveness of adalimumab for treatment of CROHN's disease in Germany.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Yang M, Skup M, Zhou ZY, Hengst N, Wolff M, Mulani PM, Chao J.

**Comparative colorectal cancer risk in patients with ulcerative colitis treated with adalimumab versus conventional therapy.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.

*Authors:* Colombel JF, Thakkar R, Robinson A, Yang M, Skup M, Swallow E, Betts K, Chao J, Mulani P.

**Cost-effectiveness model of adalimumab for the treatment of moderate to severe ulcerative colitis in the United Kingdom.**

*Abstract:* 20th United European Gastroenterology Week, Amsterdam, Netherlands Oct 20-24, 2012.

*Authors:* Ali T, Yang M, Skup M, Yang M, Wu EQ, Chao J, Mulani PM.

**Cost-effectiveness of adalimumab in moderately to severely active ulcerative colitis in the US.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.

*Authors:* Ali T, Skup M, Yang M, Wu E, Mulani P, Chao J.

**Direct and indirect utilization and costs associated with ulcerative colitis.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.

*Authors:* Cohen R, Rizzo J, Diener M, Yang M, Skup M, Mulani P, Chao J.

**Prevalence and risk of developing gastrointestinal conditions in patients with chronic constipation.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.

*Authors:* Guerin A, Mody R, Fok B, Zhou Z, Wu E, Zhou W, Lasch K, Talley N.

**Prevalence and risk of developing non-gastrointestinal physical and mental comorbidities in patients with chronic constipation.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.

*Authors:* Guerin A, Mody R, Fok B, Zhou Z, Wu E, Zhou W, Lasch K, Talley NJ.

**Risk of developing colorectal cancer and benign neoplasm in patients with chronic constipation.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.

*Authors:* Mody R, Guerin A, Fok B, Zhou Z, Wu E, Brewer K, Zhou W, Lasch K, Talley N.

**Risk of malignancy, infection, serious infection, and acute health care use in patients with Crohn's disease treated with adalimumab vs. Immunosuppressants.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.

*Authors:* Colombel JF, Thakkar R, Castillo M, Robinson A, Skup M, Yang M, Swallow E, Sorg R, Chao J, Mulani P.

**Treatment benefit-risk preferences of patients with early Crohn's disease.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology Las Vegas, NV Oct 19-24, 2012.

*Authors:* Loftus E, Yang M, Skup M, Ivanova J, Sorg R, Chao J, Mulani P.

**Risk of gastrointestinal conditions among patients with atrial fibrillation.**

*Abstract:* 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012.

*Authors:* Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

**The economic burden of unmet treatment needs in Medicaid patients with chronic constipation.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Carson RT, Guerin A, Lewis B, Yin D, Kaminsky M, Ramakrishnan K, Wu EQ.

**Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease.**

*Abstract:* Digestive Disorders Federation Meeting 2012, Liverpool, UK Jun 17-20, 2012.

*Authors:* Colombel JF, Rutgeerts PJ, Sandborn WJ, Reinisch W, Loftus Jr EV, Tang J, Pollack PF, Yang M, Patel SP, Huang B, Chao J, Mulani PM.

**Risk of gastrointestinal conditions among patients with atrial fibrillation.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Laliberte F, Dea K, Lamori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

**Treatment patterns and indicators of unmet needs in Medicaid patients with irritable bowel syndrome with constipation and chronic constipation.**

*Abstract:* Digestive Disease Week, San Diego, CA May 19-22, 2012.

*Authors:* Carson R, Guérin A, Lewis B, Yin D, Kaminsky MS, Ramakrishnan K, Wu EQ.

**The economic burden of treatment failure in Medicaid patients with irritable bowel syndrome with constipation.**

*Abstract:* AMCP's 24th Annual Meeting, San Francisco, CA Apr 18-20, 2012.

*Authors:* Guérin A, Carson RT, Lewis B, Yin D, Kaminsky MS, Ramakrishnan K, Wu EQ.

**Gastrointestinal conditions among patients with atrial fibrillation.**

*Abstract:* 61th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, Chicago, IL Mar 24-27, 2012.

*Authors:* Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge M, Damaraju CV, Duh MS, Schein J, Lefebvre P.

**Adalimumab sustains deep remission for 3 years: Data from CHARM and ADHERE.**

*Abstract:* 7th Congress of ECCO European Crohn's and Colitis Organization, Barcelona, Spain Feb 16-18, 2012.

*Authors:* Sandborn WJ, Colombel J-F, Louis E, Panaccione R, Yang M, Chao J, Thakkar R, Robinson A, Pollack P, Mulani PM.

**Assessing preference for deep remission in patients with Crohn's disease.**

*Abstract:* 7th Congress of the European Crohn's and Colitis Organisation, Barcelona, Spain Feb 16-18, 2012.

*Authors:* Sandborn W, Colombel JF, Louis E, Panaccione R, Yang M, Wu E, Mulani P, Chao J.

**Development of three practical indices for mucosal healing among patients with moderate to severe Crohn's disease.**

*Abstract:* 7th Congress of ECCO European Crohn's and Colitis Organization, Barcelona, Spain Feb 16-18, 2012.

*Authors:* Sandborn WJ, Panaccione R, Colombel J-F, Louis E, Yang M, Thakkar R, Chao J, Mulani PM.

**Markov model projection of remission status for early vs. delayed step-up adalimumab use in moderate to severe Crohn's disease.**

*Abstract:* 2010 Advances in Inflammatory Bowel Diseases Crohn's and Colitis Foundation's National Clinical and Research Conference Hollywood, FL Dec 9-12, 2010.

*Authors:* Loftus EV, Chao J, Yang M, Pollack PF, Li Z, Thakkar RB, Mulani PM.

**C-reactive protein levels in moderate to severe crohn's disease patients decreased rapidly and significantly during adalimumab therapy.**

*Abstract:* 76th Annual Scientific Meeting of the American College of Gastroenterology Washington, DC Oct 28 - Nov 2, 2011.

*Authors:* Ghosh S, Wu E, Bensimon A, Mulani P, Yang M, Chao J.

**A retrospective comparison of health care outcomes in Crohn's disease patients with and without prolonged steroid monotherapy.**

*Abstract:* 19th United European Gastroenterology Week, Stockholm, Sweden Oct 22-26, 2011.

*Authors:* Siegel CA, Yang HY, Yu AP, Yang M, Mulani PM, Chao J.

**The economic and quality of life burden of illness in chronic constipation (CC) and irritable bowel syndrome (IBS): A systematic review.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Yee K, Nellesen D, Chawla A, Carson R, Lewis B.

**Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (Compairs).**

*Abstract:* Annual General Meeting of the British Society of Gastroenterology Conference, Birmingham, UK Mar 14-17, 2011.

*Authors:* Sussman DA, Kubiliun N, Chao J, Mulani PM, Gillis CA, Yang M, Lu M, Abreu MT.

**Markov model projection of remission status for early versus delayed step-up adalimumab use in moderate to severe crohn's disease.**

*Abstract:* Annual General Meeting of the British Society of Gastroenterology, Birmingham, UK Mar 14-17, 2011.

*Authors:* Loftus EV, Chao J, Yang M, Pollack PF, Li Z, Thakkar RB, Mulani PM.

**Racial differences in use of biologics for crohn's disease in a Medicaid population.**

*Abstract:* Annual General Meeting of the British Society of Gastroenterology Conference, Birmingham, UK Mar 14-17, 2011.

*Authors:* Flasar M, Mulani P, Yang M, Chao J, Lu M, Cross R.

**Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease.**

*Abstract:* 6th Congress of the European Crohn's and Colitis Organisation, Dublin, Ireland Feb 24-26, 2011.

*Authors:* Colombel J, Rutgeerts P, Sandborn WJ, Reinisch W, Loftus Jr EV, Tang J, Pollack PF, Yang M, Huang B, Chao J, Mulani PM.

**Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (compairs).**

*Abstract:* 75th Annual Scientific Meeting of the American College of Gastroenterology, San Antonio, TX Oct 15-20, 2010.

*Authors:* Sussman D, Kubiliun N, Chao J, Mulani P, Gillis C, Yang M, Lu M, Abreu M.

**Markov model projection of remission status for early vs. delayed step-Up Adalimumab use in moderate to severe crohn's disease.**

*Abstract:* 75th Annual Scientific Meeting of the American College of Gastroenterology, San Antonio, TX Oct 15-20, 2010.

*Authors:* Loftus EV, Chao J, Yang M, Pollack PF, Li Z, Thakkar RB, Mulani PM.

**Racial differences in use of biologics for crohn's disease in a Medicaid population.**

*Abstract:* 75th Annual Scientific Meeting of the American College of Gastroenterology San Antonio, TX Oct 15-20, 2010.

*Authors:* Flasar M, Mulani P, Yang M, Chao J, Lu M, Cross R.

**Impact of Nighttime Symptoms (NTS) on Treatment Patterns and Healthcare Costs Among Gastroesophageal Reflux Disease (GERD) Patients.**

*Abstract:* Digestive Disease Week 2010, New Orleans, LA Jun 1-6, 2010.

*Authors:* Mody R, Beaulieu N, Wu EQ, Dabbous F, McHale J, Chey WD.

**Quality-of-Life Benefits for Adalimumab-Treated Patients with Moderate to Severe Crohn's Disease are Predicted by Early Mucosal Healing Status.**

*Abstract:* Digestive Disease Week 2010, New Orleans, Louisiana May 1-5, 2010.

*Authors:* Rutgeerts PJ, Thakkar R, Wu EQ, Kaltenboeck A, Yang M, Mulani P, Chao J.

**Cost-effectiveness analysis of adalimumab vs. certolizumab maintenance therapies for moderate to severe Crohn's disease.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Jonasson S, Kaltenboeck A, Horn C, Mulani P, Majethia S, Chao J.

**Increased Risk of Clinical Relapse Is Associated with Longer Disease Duration in Crohn's Disease.**

*Abstract:* Digestive Disease Week 2009, Chicago, IL May 30 - Jun 4, 2009.

*Authors:* Rubin DT, Bensimon AG, Yu AP, Wu E, Chao J, Mulani P.

**Number-needed-to-treat (NNT) analysis: Remission rates for adalimumab vs. Infliximab in Crohn's disease.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Jonasson S, Kaltenboeck A, Horn C, Wu E, Majethia S, Mulani P, Chao J.

**S1030 Increased Risk of Psychiatric Disorders in Young Patients with Crohn's Disease.**

*Abstract:* Digestive Disease Week Annual Conference, Chicago, IL May 30 - Jun 4, 2009.

*Authors:* Loftus EV, Guérin A, Yu AP, Wu E, Chao J, Mulani P.

**Rate of dosage escalation in patients with crohn's disease treated with infliximab.**

*Abstract:* Canadian Digestive Diseases Week 2009, Banff, AB Canada Feb 27-Mar 2, 2009.

*Authors:* Plevy S, Wu E, Yu A, Chao J, Mulani P.

**Young patients with Crohn's disease are at increased risk for psychiatric disorders.**

*Abstract:* European Crohn's & Colitis Organisation 4th Congress, Hamburg, Germany Feb 5-7, 2009.

*Authors:* Loftus E, Guérin A, Yu A, Wu E, Chao J, Mulani P.

**The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease.**

*Abstract:* ISPOR 2009.

*Authors:* Gosselin A, Luo R, Lohoues H, Toy E, Lewis B, Crawley J, Duh MS.

**Adalimumab Treatment Significantly Reduces Hospitalization Risk for TNF-Antagonist-Naïve Patients with Crohn's Disease.**

*Abstract:* American College of Gastroenterology 2008 Annual Meeting, Orlando, FL Oct 3-8, 2008.

*Authors:* Loftus E, Feagan B, Colombel JF, Wu EQ, Yu A, Chao J, Mulani P.

**Health-Related Quality Of Life in TNF-Antagonist-Naïve Patients with Crohn's Disease during Short- and Long-Term Adalimumab Treatment.**

*Abstract:* American College of Gastroenterology 2008 Annual Meeting, Orlando, FL Oct 3-8, 2008.

*Authors:* Rubin D, Rutgeerts P, Colombel JF, Wu EQ, Yu A, Chao J, Mulani P.

**Infliximab Dosage-Increase Rate in Patients with Crohn's Disease.**

*Abstract:* American College of Gastroenterology 2008 Annual Meeting, Orlando, FL Oct 3-8, 2008.

*Authors:* Plevy S, Wu EQ, Yu A, Chao J, Mulani P.

**Adherence to Infliximab Maintenance Therapy and Its Impact on Hospitalization of Patients with Crohn's Disease.**

*Abstract:* ISPOR 13th Annual International Meeting, Toronto, ON, Canada May 3-7, 2008.

*Authors:* Kane S, Wu EQ, Chen L, Yu A, Tsaneva M, Chao J, Mulani P.

**Are Proton Pump Inhibitors (PPIs) Sufficient in Controlling Symptoms of Gastro-Esophageal Reflux Disease (GERD)? A Community-Based US Survey Study.**

*Abstract:* Digestive Week 2008, San Diego, CA May 17-22, 2008.

*Authors:* Chey WD, Mody R, Kothari S, Wu E, Chen L, Persson B, Beaulieu N, Lu M.

**Improvement in short inflammatory bowel disease questionnaire scores in adalimumab-treated Crohn's disease patients who failed infliximab (CHOICE trial).**

*Abstract:* Digestive Disease Week 2008, San Diego, CA May 17-22, 2008.

*Authors:* Lichtiger S, Present DH, Wu E, Beaulieu N, Kent JD, Lomax KG, Chao J, Mulani P.

**Nighttime Symptoms and Sleep Impairment Among Patients with Gastro-Esophageal Reflux Disease (GERD) Receiving Prescription (Rx) Proton Pump Inhibitors (PPIs).**

*Abstract:* Digestive Week 2008, San Francisco, CA May 17-22, 2008.

*Authors:* Chey WD, Mody R, Chen L, Kothari S, Persson B, Wu E, Lu M.

**A Risk-Benefit Analysis of Adalimumab vs. Standard of Care in Patients with Crohn's Disease.**

*Abstract:* Digestive Disease Week 2008, San Diego, CA May 17-22, 2008.

*Authors:* Loftus EV, Colombel J-F, Johnson SJ, Wu E, Chao J, Mulani P.

**T1062 Improvement in Work Productivity with Adalimumab in Crohn's Disease Patients Who Failed Prior Infliximab: An Analysis of the CHOICE Trial.**

*Abstract:* Digestive Disease Week, San Diego, CA May 17-22, 2008.

*Authors:* Lichtiger S, Present DH, Persson B, Wu E, Kent JD, Lomax KG, Chao J, Mulani P.

**PG117 Adherence to infliximab maintenance therapy and its impact on hospitalization of patients with crohn's disease.**

*Abstract:* ISPOR, 2008.

*Authors:* Kane S, Wu E, Chen L, Yu A, Tsaneva M, Chao J, Mulani P.

**Differences in Health Care Visits Coded for Potential Proxy Conditions/Symptoms of Gastroesophageal Reflux Disease (GERD) before and after a GERD Diagnosis: A Pediatric Database Study.**

*Abstract:* American College of Gastroenterology, Philadelphia, PA Oct 12-17, 2007.

*Authors:* Nelson SP, Kothari S, Wu EQ, Persson B, Beaulieu N, Arana M, Orenstein SR, El-Serag H.

**Healthcare Utilization and Cost in Pediatric Gastroesophageal Reflux Disease (GERD) Patients on Continuous vs. Intermittent Proton Pump Inhibitor (PPI) Treatment Regimens.**

*Abstract:* American College of Gastroenterology, Philadelphia, PA Oct 12-17, 2007.

*Authors:* Nelson SP, Kothari S, Wu EQ, Persson B, Beaulieu N, Arana M, Lu M.

**Impact of adalimumab (HUMIRA (R)) on Patient-Reported Outcomes among Patients with Fistulizing Crohn's Disease in the CHARM Trial.**

*Abstract:* American College of Gastroenterology, Philadelphia, PA Oct 12-17, 2007.

*Authors:* Colombel JF, Wu EQ, Yu AP.

**Lower Disease Activity And Clinical Remission Are Associated with Reduced Hospitalization Risk In Crohn's Disease.**

*Abstract:* ISPOR 12th Annual International Meeting, Arlington, VA May 19-23, 2007.

*Authors:* Wu EQ, Yu AP, Tang J, Atanasov PD, Chao J, Mulani PM.

**Lower disease activity and clinical remission are associated with reduced hospitalization risk in crohn's disease.**

*Abstract:* ISPOR 2007, 2007.

*Authors:* Wu E, Yu A, Atanasov P, Tang J, Pollack P, Lomax K, Mulani P.

**Loss of Treatment Response among Crohn's Disease Patients Receiving Infliximab Maintenance Therapy.**

*Abstract:* AMCP's 18th Annual Meeting, Seattle, WA Apr 5-8, 2006.

*Authors:* Wu EQ, Yu A, Tang J, Yermakov S, Naeem A, Beaulieu N, Mulani P.

**Alternative Management Strategies for Dyspepsia.**

*Abstract:* ISPOR, 2001.

*Authors:* Wu E, Hay J.

## Hematology

### Journal Articles

**Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study.**

*Publication:* Ther Adv Hematol 2023 07; 14: 20406207231179856. e-pub ahead of print 2023/07/19; doi:

10.1177/20406207231179856.

*Authors:* Oladapo A, Kolodny S, Vredenburg M, Swallow E, Goldschmidt D, Sarathy K, Lopez P, Maitland H, Yee J.

**Burden of Illness and Treatment Patterns Among Patients With von Willebrand Disease in US Clinical Practice.**

*Publication:* Clinical and Applied Thrombosis/Hemostasis 2023 06; 29: 10760296231177023. doi:

10.1177/10760296231177023.

*Authors:* Swallow E, Marden JR, Billmyer E, Yim E, Sun SX.

**Venous thromboembolism recurrence among one-and-done direct oral anticoagulant users: a retrospective longitudinal study.**

*Publication:* Int J Clin Pharm 2023 05. e-pub ahead of print 2023/05/19; doi: 10.1007/s11096-023-01589-7.

*Authors:* Alberts M, Zhdanova M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, Kharat A.

**Hypereosinophilic syndrome in Europe: retrospective study of treatment patterns, clinical manifestations, and healthcare resource utilization.**

*Publication:* Ann Allergy Asthma Immunol 2023 02. e-pub ahead of print 2023/03/03; doi: 10.1016/j.anai.2023.02.022.

*Authors:* Hwee J, Huynh L, Du S, Kwon N, Jakes RW, Alfonso-Cristancho R, Baylis L, Requena G, Khanal A, Rothenberg ME, Duh MS.

**Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood.**

*Publication:* Transplant Cell Ther 2023 01; 29(1): 52.e51-52.e59. e-pub ahead of print 2022/10/01; doi:

10.1016/j.jtct.2022.09.018.

*Authors:* Lin C, Sajeev G, Stiff PJ, Brunstein CG, Cutler C, Sanz G, Lindemans CA, Rezvani AR, Hanna R, Koh LP, Maziarz RT, Hwang WYK, Song Y, Liu Q, Manghani R, Sivaraman S, Signorovitch J, Horwitz ME, Sung AD.

**Health-Related Quality of Life Following Allogeneic Hematopoietic Stem Cell Transplantation With Omidubicel Versus Standard Umbilical Cord Blood.**

*Publication:* Clinical Lymphoma Myeloma and Leukemia 2022 10; 22: S432-S433. doi: [https://doi.org/10.1016/S2152-2650\(22\)01643-3](https://doi.org/10.1016/S2152-2650(22)01643-3).

*Authors:* Lin C, Sajeev G, Stiff P, Brunstein C, Cutler C, Sanz G, Lindemans C, Rezvani A, Hanna R, Koh LP, Maziarz R, Hwang W, Song Y, Liu Q, Manghani R, Sivaraman S, Signorovitch J, Galamidi-Cohen E, Horwitz M, Sung A.

**MDS-254 A Matching-Adjusted Indirect Comparison of the Efficacy of Pegcetacoplan using PRINCE Trial Data versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria.**

*Publication:* Clin Lymphoma Myeloma Leuk 2022 10; 22 Suppl 2: S306-s307. e-pub ahead of print 2022/09/28; doi: [10.1016/s2152-2650\(22\)01400-8](https://doi.org/10.1016/s2152-2650(22)01400-8).

*Authors:* Desai D, Wong R, Fishman J, Wilson K, Yeh M, Hakimi Z, Yee C, Huynh L, Duh MS.

**Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications.**

*Publication:* Hemasphere 2022 10; 6(10): e778. e-pub ahead of print 2022/10/08; doi: [10.1097/hs9.0000000000000778](https://doi.org/10.1097/hs9.0000000000000778).

*Authors:* Gerds AT, Bose P, Hobbs GS, Kuykendall AT, Neilson LM, Song J, Klencke B, Harrison CN.

**Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.**

*Publication:* J Med Econ 2022 03; 1-39. e-pub ahead of print 2022/03/05; doi: [10.1080/13696998.2022.2046388](https://doi.org/10.1080/13696998.2022.2046388).

*Authors:* Cheng WY, Avery RK, Thompson-Leduc P, Cheung HC, Bo T, Duh MS, Hirji I.

**Literature Review of Fatigue Scales and Association with Clinically Meaningful Improvements in Outcomes Among Patients With and Without Paroxysmal Nocturnal Hemoglobinuria.**

*Publication:* Adv Ther 2022 03. e-pub ahead of print 2022/03/23; doi: [10.1007/s12325-022-02111-7](https://doi.org/10.1007/s12325-022-02111-7).

*Authors:* Krishnan S, Sarda S, Kunzweiler C, Wu M, Sundaresan S, Huynh L, Duh MS, Escalante CP.

**Burden of central nervous system complications in sickle cell disease: A systematic review and meta-analysis.**

*Publication:* Pediatr Blood Cancer 2022 01; e29493. e-pub ahead of print 2022/01/18; doi: [10.1002/pbc.29493](https://doi.org/10.1002/pbc.29493).

*Authors:* Lee S, Lucas S, Proudman D, Nellesen D, Paulose J, Sheehan VA.

**The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases.**

*Publication:* Adv Ther 2021 12. e-pub ahead of print 2021/12/15; doi: [10.1007/s12325-021-02004-1](https://doi.org/10.1007/s12325-021-02004-1).

*Authors:* Setyawan J, Billmyer E, Mu F, Yarur A, Zichlin ML, Yang H, Downes N, Azimi N, Strand V.

**Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States.**

*Publication:* J Manag Care Spec Pharm 2021 12; 1-12. e-pub ahead of print 2021/12/28; doi: [10.18553/jmcp.2021.21368](https://doi.org/10.18553/jmcp.2021.21368).

*Authors:* Thornburg CD, Adamski K, Cook K, Vembusubramanian M, Sendhil SR, Hinds D, Chen E, Sammon J, Solari P, Garrison LP, Croteau SE.

**Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations.**

*Publication:* Value in Health 2021 10. doi: [10.1016/j.jval.2021.05.008](https://doi.org/10.1016/j.jval.2021.05.008).

*Authors:* Garrison LP, Pezalla E, Towse A, Yang H, Faust E, Wu EQ, Li N, Sawyer EK, Recht M.

**Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.**

*Publication:* Curr Med Res Opin 2021 08; 1-11. e-pub ahead of print 2021/08/28; doi: [10.1080/03007995.2021.1971182](https://doi.org/10.1080/03007995.2021.1971182).

*Authors:* Bhak RH, Mody-Patel N, Baver SB, Kunzweiler C, Yee CW, Sundaresan S, Swartz N, Duh MS, Krishnan S, Sarda SP.



**Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia.**

*Publication:* J Manag Care Spec Pharm 2021 07; 1-10. e-pub ahead of print 2021/07/20; doi: 10.18553/jmcp.2021.21080.

*Authors:* Patwardhan P, Proudman D, Allen J, Lucas S, Nellesen D.

**Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population.**

*Publication:* Adv Ther 2021 07; 38(8): 4461-4479. e-pub ahead of print 2021/07/19; doi: 10.1007/s12325-021-01825-4.

*Authors:* Cheng WY, Sarda SP, Mody-Patel N, Krishnan S, Yenikomshian M, Mahendran M, Lejeune D, Yu LH, Duh MS.

**Risk of thromboembolic events and associated risk factors, including treatments, in patients with immune-mediated diseases.**

*Publication:* Clin Ther 2021 07. e-pub ahead of print 2021/07/10; doi: 10.1016/j.clinthera.2021.06.008.

*Authors:* Setyawan J, Mu F, Yarur A, Zichlin ML, Yang H, Fernan C, Billmyer E, Downes N, Azimi N, Strand V.

**Health care resource utilization and cost burden of hemophilia B in the United States.**

*Publication:* Blood Adv 2021 04; 5(7): 1954-1962. doi: 10.1182/bloodadvances.2020003424.

*Authors:* Buckner TW, Bocharova I, Hagan K, Bensimon AG, Yang H, Wu EQ, Sawyer EK, Li N.

**Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.**

*Publication:* J Med Econ 2021 02; 24(1): 234-243. doi: 10.1080/13696998.2021.1876714.

*Authors:* Stein EM, Bonifacio G, Latrémouille-Viau D, Shi S, Guérin A, Wu EQ, Sadek I, Cao X.

**Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes.**

*Publication:* Hematology 2021 02; 26(1): 261-270. doi: 10.1080/16078454.2021.1889161.

*Authors:* Cheng WY, Satija A, Cheung HC, Hill K, Wert T, Laliberté F, Lefebvre P.

**An Overview of patients with hemophilia A in China: epidemiology, disease severity, and treatment strategies**

*Publication:* Haemophilia 2020 11.

*Authors:* Song X, Zhong J, Xue F, Chen L, Li H, Yuan D, Xie J, Shi J, Zhang L, Wu E, Yang R.

**Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population.**

*Publication:* Blood 2020 11; 136(Supplement 1): 13-13. doi: 10.1182/blood-2020-141636.

*Authors:* Cheng WY, Sarda SP, Mody-Patel N, Krishnan S, Yenikomshian M, Scoble PJ, Kunzweiler C, Vu JD, Cheung HC, Duh MS.

**Real-World Treatment Patterns and Healthcare Resource Utilization (HRU) of Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population.**

*Publication:* Blood 2020 11; 136(Supplement 1): 15-16. doi: 10.1182/blood-2020-141648.

*Authors:* Cheng WY, Sarda SP, Mody-Patel N, Krishnan S, Yenikomshian M, Scoble PJ, Mahendran M, Lejeune D, Yu L, Duh MS.

**Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid and Medicare Insurance - The perspective of private and public payers.**

*Publication:* J Med Econ 2020 11; 23(11): 1345-1355. e-pub ahead of print 2020/08/21; doi:

10.1080/13696998.2020.1813144.

*Authors:* Shah NR, Bhor M, Latremouille-Viau D, Kumar Sharma V, Puckrein GA, Gagnon-Sanschagrin P, Khare A, Kumar Singh M, Serra E, Davidson M, Xu L, Guerin A.

**Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era.**

*Publication:* Kidney Med 2020 08. doi: <https://doi.org/10.1016/j.xkme.2020.06.008>.

*Authors:* Cizman B, Smith HT, Camejo RR, Casillas L, Dhillon H, Mu F, Wu E, Xie J, Zuckerman P, Coyne D.

**Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study.**

*Publication:* Ann Hematol 2020 04; 99(4): 743-752. e-pub ahead of print 2020/02/18; doi: 10.1007/s00277-019-03809-5.

*Authors:* Peffault de Latour R, Huynh L, Ivanova JI, Totev T, Bilginsoy M, Antin J, Roy A, Duh MS.

**Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial.**

*Publication:* Blood Adv 2020 04; 4(7): 1440-1447. e-pub ahead of print 2020/04/10; doi: 10.1182/bloodadvances.2019001305.

*Authors:* Maziarz RT, Schuster SJ, Romanov VV, Rusch ES, Li J, Signorovitch JE, Maloney DG, Locke FL.

**Real-world analysis of hemophilia patients in China: A single center's experience.**

*Publication:* Haemophilia 2020 04.

*Authors:* Song X, Liu W, Xue F, Zhong J, Yifan Y, Liu Y, Xie J, Wu E, Zhang L, Shi J, Yang R.

**Grading of neurological toxicity in patients treated with tisaenlecleucel in the JULIET trial.**

*Publication:* Am Heart Journal 2020 03.

*Authors:* Maziarz RT, Schuster SJ, Romanov VV, Rusch ES, Li J, Singnorovitch JE, Maloney DG, Lock FL.

**Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A.**

*Publication:* J Med Econ 2020 01; 1. e-pub ahead of print 2020/01/24; doi: 10.1080/13696998.2020.1721508.

*Authors:* Cook K, Forbes SP, Adamski K, Ma JJ, Chawla A, Garrison LP, Jr.

**Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A.**

*Publication:* J Blood Med 2019 08; 10: 147-159. e-pub ahead of print 2019/08/17; doi: 10.2147/JBM.S206806.

*Authors:* Batt K, Gao W, Ayyagari R, Deschaseaux C, Vashi PB, Yao Z, Wang Y, Kessabi S, Klamroth R.

**Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective.**

*Publication:* Leuk Lymphoma 2019 06; 60(6): 1476-1484. e-pub ahead of print 2019/01/23; doi: 10.1080/10428194.2018.1538510.

*Authors:* Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL.

**Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review.**

*Publication:* PharmacoEconomics - Open 2019 04; 3(4): 463-478. doi: 10.1007/s41669-019-0132-5.

*Authors:* Pergola PE, Pecoits-Filho R, Winkelmayer WC, Spinowitz B, Rochette S, Thompson-Leduc P, Lefebvre P, Shafai G, Bozas A, Sanon M, Krassa HB.

**Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients.**

*Publication:* Current Medical Research and Opinion 2019 04; 35(4): 653-660. doi: <http://dx.doi.org/10.1080/03007995.2018.1530205>.

*Authors:* McHorney CA, Peterson ED, Ashton V, Laliberte F, Crivera C, Germain G, Sheikh N, Schein J, Lefebvre P.

**Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis.**

*Publication:* American Journal of Hematology. 2019 02. doi: <http://dx.doi.org/10.1002/ajh.25408>.

*Authors:* Taher AT, Origa R, Perrotta S, Kouraklis A, Belhoul K, Huang V, Han J, Bruederle A, Bobbili P, Duh MS, Porter JB.

**Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.**

*Publication:* Current Medical Research and Opinion 2018 11; 34(11): 1959-1966. e-pub ahead of print 2018/04/28; doi: <http://dx.doi.org/10.1080/03007995.2018.1470500>.

*Authors:* Cheng WY, Said Q, Hao Y, Xiao Y, Vekeman F, Bobbili P, Duh MS, Nandal S, Blinder M.

**Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.**

*Publication:* Am J Hematol 2018 11; 200-208. e-pub ahead of print 2018/11/13; doi: 10.1002/ajh.25348.

*Authors:* Khelif A, Saleh MN, Salama A, Portella M, Duh MS, Ivanova J, Grotzinger K, Roy AN, Bussel JB.

**Risk factors for self-reported cholera within HIV-affected households in rural Haiti.**

*Publication:* Open Forum Infect Dis 2018 07; 5(6). doi: <http://dx.doi.org/10.1093/ofid/ofy127>.

*Authors:* Richterman A, Cheung HC, Meiselbach MK, Jerome G, Ternier R, Ivers LC.

**Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma.**

*Publication:* Leuk Lymphoma 2018 05; 59(5): 1133-1142. e-pub ahead of print 2017/09/22; doi: 10.1080/10428194.2017.1375100.

*Authors:* Maziarz RT, Hao Y, Guerin A, Gauthier G, Gauthier-Loiselle M, Thomas SK, Eldjerou L.

**Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.**

*Publication:* American Journal of Hematology 2018 05; 93(5): 664-671. e-pub ahead of print 2018/02/06; doi: <http://dx.doi.org/10.1002/ajh.25059>.

*Authors:* Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson WW, Laliberte F, Crivera C, Lefebvre P, Schein J, Khorana AA.

**Efficacy and Safety of Procalcitonin Guidance in Patients With Suspected or Confirmed Sepsis: A Systematic Review and Meta-Analysis.**

*Publication:* Crit Care Med 2018 05; 46(5): 691-698. e-pub ahead of print 2017/12/23; doi: 10.1097/CCM.0000000000002928.

*Authors:* Iankova I, Thompson-Leduc P, Kirson NY, Rice B, Hey J, Krause A, Schonfeld SA, DeBrase CR, Bozzette S, Schuetz P.

**Value of transfusion independence in severe aplastic anemia from patients' perspectives – a discrete choice experiment.**

*Publication:* Journal of Patient-Reported Outcomes 2018 03; 2(1): 13. doi: 10.1186/s41687-018-0032-y.

*Authors:* Pickard AS, Huynh L, Ivanova JI, Totev T, Graham S, Mühlbacher AC, Roy A, Duh MS.

**Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014.**

*Publication:* Diabetes Ther 2017 06. e-pub ahead of print 2017/06/25; doi: 10.1007/s13300-017-0280-5.

*Authors:* Carls G, Huynh J, Tuttle E, Yee J, Edelman SV.

**Disease-stratified adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.**

*Publication:* Value in Health 2017 05; 20 (5): A232.

*Authors:* Cheng WY, Duh MS, Xiao Y, Coe A, Hao Y, Vekeman F, Bobbili PJ, Blinder M.

**Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.**

*Publication:* Haemophilia 2017 05; 23(3): 408-416. doi: <http://dx.doi.org/10.1111/hae.13160>.

*Authors:* Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Yermakov S, Karner P.

**A Risk Score for Fluconazole Failure among Patients with Candidemia.**

*Publication:* Antimicrob Agents Chemother 2017 05; 61(5). e-pub ahead of print 2017/03/08; doi: 10.1128/AAC.02091-16.

*Authors:* Ostrosky-Zeichner L, Harrington R, Azie N, Yang H, Li N, Zhao J, Koo V, Wu EQ.

**Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.**

*Publication:* J Med Econ 2017 04; 20(4): 337-344. doi: <http://dx.doi.org/10.1080/13696998.2016.1265973>.

*Authors:* Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Yermakov S, Karner P.

**Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.**

*Publication:* J Med Econ 2016 12; 19(4): 364-373. e-pub ahead of print 2015/12/02; doi: 10.3111/13696998.2015.1127252.

*Authors:* LaMori J, Tandon N, Laliberte F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

**Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A.**

*Publication:* J Blood Med 2016 07; 7: 129-137. e-pub ahead of print 2016/07/23; doi: 10.2147/JBM.S104074.

*Authors:* Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J.

**Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.**

*Publication:* J Med Econ 2016 03; 19(3): 292-303. e-pub ahead of print 2015/12/01; doi: 10.3111/13696998.2015.1117979.

*Authors:* Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Qiu Y, Duh MS, Paley C, Adams-Graves P.

**Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.**

*Publication:* J Comp Eff Res 2016 03; 5(2): 129-139. e-pub ahead of print 2015/09/22; doi: 10.2217/ce.15.49.

*Authors:* Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Mu F, Kim S, Noviello S, Signorovitch J.

**Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.**

*Publication:* Clin Ther 2016 02; 38(2): 404-412. doi: 10.1016/j.clinthera.2015.12.017.

*Authors:* Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Ackerman P, Signorovitch J.

**Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure.**

*Publication:* Curr Med Res Opin 2015 12; 31(12): 2167-2173. e-pub ahead of print 2015/09/24; doi: 10.1185/03007995.2015.1096242.

*Authors:* McHorney CA, Crivera C, Laliberte F, Nelson WW, Germain G, Bookhart B, Martin S, Schein J, Lefebvre P, Deitelzweig S.

**Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease.**

*Publication:* J Emerg Med 2015 10; 49(4): 513-522 e511. doi: 10.1016/j.jemermed.2014.12.080.

*Authors:* Blinder MA, Duh MS, Sasane M, Trahey A, Paley C, Vekeman F.

**Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.**

*Publication:* Leuk Lymphoma 2015 10; 56(10): 2803-2811. doi: 10.3109/10428194.2015.1016933.

*Authors:* Vekeman F, Cheng WY, Sasane M, Huynh L, Duh MS, Paley C, Mesa RA.

**Direct and Indirect Cost Burden of Chronic Hepatitis C.**

*Publication:* The American Journal of Pharmacy Benefits 2015 07; 7(4): e90-e100.

*Authors:* Tandon N, Reddy K, Balart L, Fastenau J, Lefebvre P, Parisé H, Laliberté F, Pilon D, Duh M, Cho M, Prabhakar A.

**Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications.**

*Publication:* Curr Med Res Opin 2015 07; 31(10): 1889-1895. e-pub ahead of print 2015/07/28; doi: 10.1185/03007995.2015.1077213.

*Authors:* Crivera C, Nelson WW, Bookhart B, Martin S, Germain G, Laliberte F, Schein J, Lefebvre P.

**Costs and Resource Utilization Associated with Anemia and Rash in Chronic Hepatitis C Patients Treated with Direct-Acting Antiviral Agents in the United States.**

*Publication:* Clin Ther 2015 06. doi: 10.1016/j.clinthera.2015.05.503.

*Authors:* Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ.

**Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir.**

*Publication:* J Manag Care Spec Pharm 2015 04; 21(4): 308-318.

*Authors:* Le TK, Kalsekar A, Macaulay D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ.

**Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy.**

*Publication:* Current Medical Research & Opinion 2015 03; 31(3): 513-523. doi: 10.1185/03007995.2014.998815.

*Authors:* Jordan L, Adams-Graves P, Kanter-Washko J, Oneal PA, Sasane M, Vekeman F, Bieri C, Magestro M, Marcellari A, Duh MS.

**Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.**

*Publication:* J Med Econ 2014 12; 17(12): 862-871. doi: 10.3111/13696998.2014.964720.

*Authors:* Tandon N, Balart LA, Laliberte F, Pilon D, Lefebvre P, Germain G, Prabhakar A.

**A cost-analysis model for anticoagulant treatment in the hospital setting.**

*Publication:* J Med Econ 2014 07; 17(7): 492-498. doi: 10.3111/13696998.2014.914032.

*Authors:* Mody SH, Huynh L, Zhuo DY, Tran KN, Lefebvre P, Bookhart B.

**Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.**

*Publication:* Pediatr Blood Cancer 2013 05; 60(5): 828-835. doi: 10.1002/pbc.24459.

*Authors:* Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS.

**Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.**

*Publication:* J Clin Pharm Ther 2012 04; 37(2): 173-181. doi: 10.1111/j.1365-2710.2011.01276.x.

*Authors:* Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

**Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia.**

*Publication:* Current Medical Research & Opinion 2012 01; 28(1): 79-87. doi: 10.1185/03007995.2011.644849.

*Authors:* Fogarty PF, Tarantino MD, Brainsky A, Signorovitch J, Grotzinger KM.

**Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.**

*Publication:* J Med Econ 2012 01; 15(2): 352-360. doi: 10.3111/13696998.2011.649326.

*Authors:* Lafeuille MH, Bailey RA, Vekeman F, Scott McKenzie R, Lefebvre P.

**The economics of the hematopoietic growth factors.**

*Publication:* Cancer Treat Res 2011 11; 157: 403-418. doi: 10.1007/978-1-4419-7073-2\_22.

*Authors:* Eldar-Lissai A, Lyman GH.

**Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.**

*Publication:* Consult Pharm 2010 08; 25(8): 493-500. doi: 10.4140/TCP.n.2010.493.

*Authors:* Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbetta M, Piech CT, Lefebvre P.

**Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.**

*Publication:* Transfusion 2010 01; 50(1): 190-199. doi: 10.1111/j.1537-2995.2009.02361.x.

*Authors:* Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.

**Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.**

*Publication:* Cancer 2009 10; 115(20): 4839-4848. doi: 10.1002/cncr.24535.

*Authors:* Heaney ML, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Duh MS.

**Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.**

*Publication:* Transfusion 2009 05; 49(5): 895-902. doi: 10.1111/j.1537-2995.2008.02072.x.

*Authors:* Vekeman F, Bookhart BK, White J, McKenzie RS, Duh MS, Piech CT, Lefebvre P.

**Drug utilization and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.**

*Publication:* J Med Econ 2009 03; 12(1): 1-8. doi: 10.3111/13696990802648167.

*Authors:* Vekeman F, McKenzie RS, Bookhart BK, Laliberte F, Duh MS, Tak Piech C, Lefebvre P.

**An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.**

*Publication:* Cancer 2009 02; 115(4): 706-715. doi: 10.1002/cncr.24090.

*Authors:* Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V.

**Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.**

*Publication:* Ann Hematol 2008 07; 87(7): 527-536. doi: 10.1007/s00277-008-0450-7.

*Authors:* Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S.

**Anaemia and the risk of injurious falls in a community-dwelling elderly population.**

*Publication:* Drugs Aging 2008 04; 25(4): 325-334.

*Authors:* Duh MS, Mody SH, Lefebvre P, Woodman RC, Buteau S, Piech CT.

**Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.**

*Publication:* Ann Pharmacother 2008 01; 42(1): 16-23. doi: 10.1345/aph.1K061.

*Authors:* Sikand H, Decker A, Greco T, Watson SH, Kang YJ, Mody SH, Piech CT, Duh MS, Naeem A.

**Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents.**

*Publication:* PharmacoEconomics 2008 01; 26(2): 99-120.

*Authors:* Duh MS, Weiner JR, White LA, Lefebvre P, Greenberg PE.

**Medical and work loss burden of pre-dialysis chronic kidney disease and related anemia: An employer's perspective.**

*Publication:* Journal of Health & Productivity 2007 10: 309.

*Authors:* Moyneur E BB, Mody SH, Founier A, Mallet D, Duh MS.

**Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.**

*Publication:* Am J Health Syst Pharm 2007 09; 64(18): 1943-1949. doi: 10.2146/ajhp060585.

*Authors:* Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS.

**Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study.**

*Publication:* Crit Care 2007 06; 11(3): R63. doi: 10.1186/cc5934.

*Authors:* Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF.

**Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.**

*Publication:* Drugs Aging 2006 12; 23(12): 969-976.

*Authors:* Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT.

**Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease.**

*Publication:* J Am Soc Nephrol 2006 12; 17(12): 3497-3502. doi: 10.1681/ASN.2006030289.

*Authors:* Lefebvre P, Duh MS, Buteau S, Bookhart B, Mody SH.

**Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of four observational studies.**

*Publication:* Clin Ther 2006 10; 28(10): 1701-1708. doi: 10.1016/j.clinthera.2006.10.009.

*Authors:* Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS.

**Impact and treatment of anemia in the elderly: clinical, epidemiological and economic perspectives.**

*Publication:* Expert Rev Pharmacoecon Outcomes Res 2006 10; 6(5): 577-590. doi: 10.1586/14737167.6.5.577.

*Authors:* Duh MS, Latypova A, Greenberg P.

**Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.**

*Publication:* Current Medical Research & Opinion 2006 10; 22(10): 1929-1937. doi: 10.1185/030079906X132541.

*Authors:* Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY.

**Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application.**

*Publication:* J Oncol Pharm Pract 2006 09; 12(3): 165-178. doi: 10.1191/1078155206069925.

*Authors:* Cremieux P, Vekeman F, Lefebvre P.

**Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.**

*Publication:* Clin Ther 2006 09; 28(9): 1443-1450. doi: 10.1016/j.clinthera.2006.09.020.

*Authors:* Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C.

**Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations.**

*Publication:* Current Medical Research & Opinion 2006 09; 22(9): 1623-1631. doi: 10.1185/030079906X120968.

*Authors:* Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS.

**Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy.**

*Publication:* J Support Oncol 2006 05; 4(5): 243-250.

*Authors:* Chu E, Einhorn LH, Lefebvre P.

**Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.**

*Publication:* PharmacoEconomics 2006 05; 24(5): 479-494.

*Authors:* Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA.

**Dose-conversion ratio for epoetin alfa and darbepoetin alfa in chemotherapy patients with anemia and cancer.**

*Publication:* P AND T 2006 31(10): 594.

*Authors:* Gosselin A, McKenzie R, Lefebvre P, Mody S, Piech C, Duh M.

**Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.**

*Publication:* J Natl Compr Canc Netw 2005 11; 3(6): 807-816.

*Authors:* Campos SM, Duh MS, Lefebvre P, Rosberg J.

**The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.**

*Publication:* Current Medical Research & Opinion 2005 10; 21(10): 1677-1682. doi: 10.1185/030079905X65501.

*Authors:* Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.

**Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia.**

*Publication:* Current Medical Research & Opinion 2005 10; 21(10): 1527-1533. doi: 10.1185/030079905X65394.

*Authors:* Reed SD, Radeva JI, Daniel DB, Fastenau JM, Williams D, Schulman KA.

**Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia.**

*Publication:* Expert Rev Pharmacoecon Outcomes Res 2005 08; 5(4): 383-394. doi: 10.1586/14737167.5.4.383.

*Authors:* Duh MS, L Mark T.

**Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve.**

*Publication:* Oncologist 2005 06; 10(6): 438-448. doi: 10.1634/theoncologist.10-6-438.

*Authors:* Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ.

**Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia : a meta-analysis.**

*Publication:* Clin Drug Investig 2005 25(1): 33-48.

*Authors:* Rosberg JH, Ben-Hamadi R, Cremieux PY, Fastenau JM, Piech CT.

**Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia.**

*Publication:* J Manag Care Pharm 2004 11; 10(6): 531-537.

*Authors:* Cremieux PY, Fastenau JM, Kosicki G, Piech CT, Fendrick AM.

**Red blood cell transfusion and ventilator-associated pneumonia: A potential link?**

*Publication:* Crit Care Med 2004 03; 32(3): 666-674. e-pub ahead of print 2004/04/20.

*Authors:* Shorr AF, Duh MS, Kelly KM, Kollef MH.

**The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States.**

*Publication:* Crit Care Med 2004 01; 32(1): 39-52. doi: 10.1097/01.CCM.0000104112.34142.79.



*Authors:* Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ.

**Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.**

*Publication:* Cancer 2002 08; 95(4): 888-895. doi: 10.1002/cncr.10763.

*Authors:* Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA.

**Anemia-related costs for cancer patients.**

*Publication:* Journal of Managed Care Medicine 2002 6(1): 20-28.

*Authors:* Barnett A, Cremieux P, Fendrick A, George M, Slavin M.

**Cost Effectiveness of rHuEPO in Oncology.**

*Publication:* Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology: Scientific and Clinical Aspects of Anemia in Cancer 2002.

*Authors:* Cremieux P, Dial E, Gustafson M, Saraokhan B, Slavin M.

**Costs Associated with Anemia and Cancer.**

*Publication:* ONE: Oncology Economics 2000 1(11): 1-7.

*Authors:* Cremieux PY GM, Holland M, Slavin MB.

**Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia.**

*Publication:* PharmacoEconomics 1999 11; 16(5 Pt 1): 459-472.

*Authors:* Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB.

## Abstracts

**Impact of rifaximin use post-discharge of an overt hepatic encephalopathy (OHE) hospitalization on the annual rates of OHE-related inpatient stays.**

Vienna, Austria June 21 - 24, 2023.

*Authors:* Jesudian A, Gagnon-Sanschagrín P, Heimanson Z, Bungay R, Chen J, Guérin A, Dashputre A, Bumpass B, Borroto D, Joseph G.

**Healthcare Utilization of Patients with Hypereosinophilic Syndrome in Europe.**

May 7 - 10, 2023.

*Authors:* Hwee J, Kwon N, Alfonso-Cristancho R, Baylis L, Requena G, Du S, Khanal A, Huynh L, Duh MS, Jakes R.

**1806 Patient Characteristics, Treatment Patterns, and Outcomes Following Covalent Btki Discontinuation in a Contemporary Cohort of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients.**

New Orleans, LA December 10 - 13, 2022.

*Authors:* Lin KH, Huynh I, Yang X, Lema N, Matay L, Balasubramanian S, Liborski D, McDonough MM, Foreman J, Farooqui M, De Nigris E, Gandra SR, Sarpong E, Duh MS, Brown JR, Davids MS.

**A Retrospective Database Analysis Study to evaluate Disease Burden and Treatment Patterns among Patients with Hemophilia A in China.**

London, UK July 9-13, 2022.

*Authors:* Song X, Liu W, Xue F, Yang Y, Sun S, Zhong J, Liu Y, Shi J, Zhang L, Wu E, Yang R.

**Health-related quality of life (HRQL) following transplantation with omidubicel versus umbilical cord blood (UCB) in patients with hematologic malignancies: Results from a phase III randomized, multicenter study.**

Salt Lake City, UT April 23-26, 2022.

*Authors:* Horwitz ME, Sajeev G, Stiff P, Brunstein CG, Cutler C, Sanz G, Lindemans CA, Rezvani AR, Hanna R, Koh LP, Mariarz RT, Hwang WYK, Song Y, Liu Q, Manghani R, Sivaraman S, Signorovitch J, Galamidi-Cohen E.

**Projected impact of omidubicel on racial and ethnic disparities in allogeneic hematopoietic cell transplant access and outcomes for patients with hematologic malignancies in the US.**

Salt Lake City, UT April 23–26, 2022.

*Authors:* Gergis U, Khera N, Edwards ML, Song Y, Sun R, Simantov R, Sivaraman S, Manghani R, Signorovitch J.

**Total costs of care and complication rates among patients with hematologic malignancies who receive allogeneic hematopoietic cell transplants in the US.**

Salt Lake City, UT April 23–26, 2022.

*Authors:* Maziarz RT, Edwards ML, Gergis U, Song Y, Liu Q, Noman A, Anderson A, Simantov R, Manghani R, Sivaraman S, Signorovitch J.

**Indirect comparison of annualised bleeding rate and annual consumption between extended half-life RFVIII products shows differences in consumption with similar outcome.**

*Abstract:* Conference abstract

Congress of the European Association for Haemophilia and Allied Disorders, Virtual Feb 3-5, 2021.

*Authors:* Batt K, Mancuso ME, Mantovani LG, Ayyagari R, Majewska R, Vashi P, Klamroth R.

**The incremental rate of thromboembolic events in patients with inflammatory bowel disease compared to patients without immune-mediated diseases.**

*Abstract:* ACG 2020 Annual Scientific Meeting & Postgraduate Course, Online October 23 – 28, 2020.

*Authors:* Yarur A, Setyawan J, Mu F, Zichlin ML, Fernan C, Billmyer E, Downes N, Yang H, Azimi N.

**Risk Factors for Thromboembolic Events among Patients with Immune-mediated Diseases.**

*Abstract:* ACG 2020 Annual Scientific Meeting & Postgraduate Course, Online October 23 – 28, 2020.

*Authors:* Yarur A, Mu F, Setyawan J, Zichlin ML, Yang H, Fernan C, Billmyer E, Downes N, Azimi N, Strand V.

**Real-world clinical outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents in the US: A SEER-Medicare analysis.**

*Abstract:* European Hematology Association, Frankfurt, Germany June 11-14, 2020.

*Authors:* Eytan M. Stein, Dominick Latremouille-Viau, Sherry Shi, Annie Guérin, Eric Q. Wu, Gaetano Bonifacio, Xiting Cao.

**Healthcare Resource Utilization and Costs in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis.**

*Abstract:* ISPOR 2020 conference, Virtual conference May 18-20, 2020

*Authors:* Stein E, Latremouille-Viau D, Shi S, Guerin A, Wu E, Bonifacio G, Cao X.

**A Cost Minimization Analysis of Eltrombopag and Romiplostim for the Treatment of Adult Patient with Chronic Immune Thrombocytopenia.**

*Abstract:* AMCP 2020, Houston, TX April 21-24, 2020.

*Authors:* Nellesen D.

**Severe Hemophilia A Patients Receiving Prophylactic Factor VIII in US Claims Data: Identification, Resource Use, and Costs.**

*Abstract:* AMCP 2020, Houston, TX April 21-24, 2020.

*Authors:* Chawla A, Cook K.

**Vaso-Occlusive Crises and Costs of Sickle Cell Disease in Medicaid and Medicare Beneficiaries - The Perspective of Public Payers.**

*Abstract:* AMCP 2020, Houston, TX April 21-24, 2020.

*Authors:* Latremouille-Viau D, Bhor M, Kumar Sharma V, Puckrein GA, Gagnon-Sanschagrin P, Khare A, Singh MK, Serra E, Davidson M, Xu L, Gu erin A, Shah NR.

**Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: A SEER-Medicare analysis.**

*Abstract:* 61st American Society of Hematology (ASH) Annual Meeting and Exposition, Orlando, FL December 7-10, 2019.

*Authors:* Stein E, Latremouille-Viau D, Joseph G, Shi S, Guerin A, Wu E, Bonifacio G, Cao XY.

**Rapid Initiation of Antiretroviral Treatment (Art) Following Diagnosis of Human Immunodeficiency Virus (HIV) among Medicaid Beneficiaries: A Real-World Evaluation.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Benson C, Emond B, Romdhani H, Lefebvre P, Tandon N, Chow W, Dunn K.

**Model of short and long-term outcomes of emicizumab prophylaxis treatment for persons with hemophilia A.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Mahajerin A, Zhou ZY, Raimundo K, Patel A, Han S, Ji Y, Zhong J, Betts K.

**Health care resource burden among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: A retrospective chart review study.**

*Abstract:* 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Prague, Czech Republic Aug 22-26, 2018.

*Authors:* Huynh L, Ivanova JI, Totev T, Bilginsoy M, Antin J, Roy A, Duh MS, De Latour RP.

**Mediation by patient-reported outcomes of the association between filmcoated or dispersible formulations of deferasirox and serum ferritin reduction: A post hoc analysis of the eclipse trial.**

*Abstract:* 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Prague, Czech Republic Aug 22-26, 2018.

*Authors:* Taher AT, Origa R, Perrotta S, Kouraklis A, Huang V, Han J, Bruederle A, Bobbili PJ, Cheng WY, Duh MS, Porter JB.

**Health resource burden among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: A retrospective chart review study.**

*Abstract:* ISPOR 23rd Annual International Meeting . United States.

*Authors:* Huynh L, Ivanova JI, Totev T, Bilginsoy M, Antin JH, Roy A, Bobbili PJ, Duh MS, Peffault De Latour R.

**Matching-adjusted indirect comparisons (MAICs) of efficacy and consumption of bay 94-9027 versus three recombinant factor VIII (RFVIII) for prophylaxis of severe hemophilia A.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Ayyagari R, Deschaseaux C, Vashi PB, Kessabi S, Gao W.

**Health care resource utilization and costs associated with treatment of acute bleeding events among patients with hemophilia A in the United States.**

*Abstract:* AMCP's 30th Annual Meeting, Boston, MA Apr 23-26, 2018.

*Authors:* Song J, Chamberlain C, Rokito A, Cammarota J, Ma E, Xu Y, Betts K.

**Bay 81-8973 prophylaxis frequency and long-term bleed outcomes in the leopold i extension study.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington DC Dec 9-12, 2017.

*Authors:* Saxena K, Sajeev G, Ayyagari R, Dua A, Church N, Sanabria M, Afonja OO.

**A retrospective chart review to assess burden of illness among patients with severe aplastic anemia with insufficient response to immunosuppressive therapy.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* De Latour RP, Huynh L, Ivanova JI, Bilginsoy M, Totev T, Antin JH, Roy A, Duh MS.

**Mediation by patient-reported outcomes on the association between film-coated versus dispersible formulations of deferasirox and serum ferritin reduction: A post hoc analysis of the eclipse trial.**

*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain Jun 22-25, 2017.

*Authors:* Taher AT, Origa R, Perrotta S, Kouraklis A, Belhoul K, Huang V, Han J, Bruederle A, Bobbili P, Duh MS, Porter JB.

**Real-world adherence to iron chelation therapy: Comparing a film-coated tablet versus dispersible tablet of deferasirox.**

*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain June 22-25, 2017.

*Authors:* Cheng W, Xiao Y, Bobbili P, Coe A, Hao Y, Paley C, Said Q, Huang V, Duh MS, Blinder M.

**Value of transfusion independence in severe aplastic anemia from patients' perspectives-a discrete choice experiment.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Pickard AS, Huynh L, Ivanova JI, Totev T, Graham S, Muhlbacher AC, Roy A, Duh MS.

**Pharmacokinetic parameters, prophylaxis frequency and bleed outcomes of severe hemophilia a patients treated with BAY 81-8973.**

*Abstract:* 10th Scientific Symposium of the Hemostasis and Thrombosis Research Society.

*Authors:* Sajeev G, Ayyagari R, Shah A, Wang Y, Church N, Guerin A, Afonja O.

**Characteristics of treatment-experienced HIV-1-infected patients switching from multi-tablet to single-tablet regimens in the veterans affairs health care system.**

Oct 28, 2016.

*Authors:* Dersarkissian M, Schulman K, Zelt S, D'Amico R, Bhak R, Hellstern M, Altomare A, Ercolano E, Duh MS, Young-Xu Y.

**Epidemiologic and clinical characteristics of thalassemia (THAL) intermedia (TI) in the US.**

*Abstract:* 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland Aug 25-28, 2016.

*Authors:* Vichinsky E, Kwiatkowski JL, Giardina PJ, Paley C, Vekeman F, Cheng WY, Damron J, McCormick N, Sasane M, Qiu Y, Duh MS, Thompson A.

**Economic burden of hematologic adverse events (AEs) associated with metastatic colorectal cancer (mCRC) treatment in the United States (US).**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C.

**Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.**

*Abstract:* European Association for the Study of the Liver, 50th International Liver Congress, Vienna, Austria Apr 22-26, 2015.

*Authors:* Fontana RJ, Brown RS, Jr., Moreno-Zamora A, Prieto M, Joshi S, Londono MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, Lionetti R, Bahirwani R, Weiland O, Mubarak A, ElSharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, Ionescu-Ittu R, Emond B, Reddy KR.

**Bleed occurrence after bay 81-8973 injection and characteristics of patients who respond to prophylaxis: Analyses from leopold I and II.**

*Abstract:* 9th Annual Congress of the European Association for Haemophilia and Allied Disorders, Malmo, Sweden Feb 3-5, 2016.

*Authors:* Church N, Ayyagari R, Pocoski J, Sajeev G, Sneha K, Du EX, Shi S, Mass Enriquez M, Xie J.

**History of sucrose-formulated recombinant factor VIII (rFVIII-FS) Use and reduction in bleeds following bay 81-8973 prophylaxis in leopold I.**

*Abstract:* 9th Annual Congress of the European Association for Haemophilia and Allied Disorders, Malmo, Sweden Feb 2-5, 2016.

*Authors:* Pocoski J, Ayyagari R, Church N, Sajeev G, Shi S, Mass Enriquez M, Xie J.

**Matching-adjusted indirect comparisons (MAICS) of efficacy of bay 81-8973 vs. 2 Recombinant Factor VIII (rFVIII) for prophylaxis of severe hemophilia A.**

*Abstract:* 9th Annual Congress of the European Association for Haemophilia and Allied Disorders, Malmo, Sweden Feb 3-5, 2016.

*Authors:* Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Xie J.

**The healthcare resource utilization, costs, and predictors of progression among relapsed and refractory CLL patients.**

*Abstract:* 57th Annual Meeting of the American Society of Hematology, Orlando, FL Dec 5-8, 2015.

*Authors:* Guerin A, Ray S, Gauthier G, Hsu L.-I, Zhdanova M, Wu E.

**Patterns of prior treatment and bleeds among patients with severe hemophilia a: Impact on frequency of dosing with bay 81-8973 in the leopold I trial.**

*Abstract:* 57th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 3-6, 2016.

*Authors:* Church N, Ayyagari R, Pocoski J, Sajeev G, Kelkar SS, Du EX, Mass-Enriquez M, Xie J.

**Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin in patients with chronic hepatitis C coinfecting with HIV: A matching-adjusted indirect comparison.**

*Abstract:* 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015, San Francisco, CA Nov 13-17, 2015.

*Authors:* Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Noviello S, Signorovitch J.

**Comparisons of factor consumption for routine prophylaxis and bleeding during episodic therapy with recombinant factor VIII FC fusion protein and conventional recombinant factor VIII.**

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Iorio A, Krishnan S, Myren K, Lethagen S, McCormick N, Karner P.

**Factor consumption for prophylaxis and treatment of bleeding: Recombinant factor IX FC fusion protein compared with conventional recombinant factor IX.**

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Iorio A, Krishnan S, Myren K, Lethagen S, McCormick N, Karner P.

**Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor IX FC fusion protein and other recombinant factor IX products.**

*Abstract:* 25th Congress of the International Society on Thrombosis and Haemostasis, Toronto, ON, Canada Jun 20-25, 2015.

*Authors:* Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Karner P.

**Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor VIII FC fusion protein and other recombinant factor VIII products.**

*Abstract:* 25th Congress of the International Society on Thrombosis and Haemostasis, Toronto, ON, Canada Jun 20-25, 2015.

*Authors:* Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Karner P.

**Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with thalassemia.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Vekeman F, Sasane M, Cheng WY, Agnihotram RV, Fortier J, Duh MS, Paley C, Adams-Graves P.

**Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Tandon N, Laliberté F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

**Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for hepatitis c genotype 3: A matching-adjusted indirect comparison.**

*Abstract:* 50th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress, Vienna, Austria Apr 22-26, 2015.

*Authors:* Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Noviello S, Signorovitch J.

**A descriptive analysis of a real-world population with chronic hepatitis C (CHC) treated with simeprevir (SMV)- and/or sofosbuvir (SOF)-based regimens: findings from a U.S. payer database.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA Apr 22-26, 2015.

*Authors:* Forlenza J, Fortier J, Laliberté F, Lefebvre P, Tandon N.

**Comparative efficacy and tolerability of combination treatment with daclatasvir and asunaprevir versus peginterferon alpha ribavirin based regimens for patients infected with genotype 1B hepatitis C virus.**

*Abstract:* 24th Annual Conference of the Asian Pacific Association for the Study of the Liver, Istanbul, Turkey Mar 12-15, 2015.

*Authors:* Signorovitch J, Betts K, Song Y, Sorg R, Li J, Behl A, Kalsekar A.

**Economic consequences of cytomegalovirus disease among stem cell transplant recipients.**

*Abstract:* 2015 BMT Tandem Meetings, San Diego, CA Feb 11-15, 2015.

*Authors:* Macalalad AR, Yang H, Zhou A, Wu EQ, Chaudhari P, Snyderman DR.

**Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease.**

*Abstract:* 56th Annual Meeting of the American Society of Hematology, San Francisco, CA Dec 6-9, 2014.

*Authors:* Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Duh MS, Paley C, Adams-Graves P.

**Associations between joint damage and quality of life among patients with severe hemophilia a in the 3-year spinart trial.**

*Abstract:* 56th Annual Meeting of the American Society of Hematology, San Francisco, CA Dec 6-9, 2014.

*Authors:* Pocoski J, Lin PL, Hong W, Kelkar SS, Jiao T, Du EX, Humphries TJ, Xie J.

**Subcutaneous (SQ) bortezomib (BTZ) in patients (PTS) with relapsed mantle cell lymphoma (MCL): Retrospective, observational study of treatment patterns and outcomes in US community oncology practices.**

*Abstract:* 56th Annual Meeting of the American Society of Hematology, San Francisco, CA Dec 6-9, 2014.

*Authors:* Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, Ng Y, Van De Velde H, Dow E, Niculescu L, Bonthapally V, Goy A.

**Demographics, Comorbidities, Clinical Characteristics, and Post-treatment Outcomes for Treated Patients with Chronic Hepatitis C (CHC): A Descriptive Analysis of Real-world U.S. Commercially-insured and Medicare Populations.**

*Abstract:* AASLD/EASL Special Conference on Hepatitis C, New York, NY Sep 12-13, 2014.

*Authors:* Forlenza JB, Fortier J, Laliberté F, Lefebvre P, Tandon N.

**Associations between clinical outcomes, health care resources utilization, and quality of life among patients with severe hemophilia A.**

*Abstract:* World Federation of Hemophilia, World Congress Melbourne, VIC Australia May 11-15, 2014.

*Authors:* Lin PL, Pocoski J, Du EX, Kelkar SS, Silberman C, Xie J.

**Contraindications for HCV therapy in United States patients with untreated chronic hepatitis C (CHC).**

*Abstract:* ISPOR 2014, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ.

**High cost patients and cost patterns from pediatric to adult care in a Medicaid population with sickle cell disease.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Blinder MA, Sasane M, Fortier J, Paley CS, Duh MS, Vekeman F.

**High utilizers of health care resources: Results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Jordan L, Adams-Graves P, Kanter-Washko J, Oneal P, Sasane M, Magestro M, Marcellari A, Vekeman F, Bieri C, Adams A, Duh MS.

**Impact of chronic hepatitis C (CHC) treatment on post therapy healthcare cost.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

**An indirect comparison of the efficacy of prophylactic use of rF VIII Fc and other rFVIII products and model of the effect of compliance.**

*Abstract:* World Federation of Hemophilia, World Congress Melbourne, VIC Australia May 11-15, 2014.

*Authors:* Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

**An indirect comparison of the efficacy of prophylactic use of rFIXFc and other rFIX products and simulation of the effect of compliance on effectiveness.**

*Abstract:* World Federation of Hemophilia, Melbourne, VIC Australia May 11-15, 2014.

*Authors:* Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

**Indirect comparison of the efficacy of recombinant factor IX Fc fusion protein and other factor IX products for prophylaxis: Simulating the effect of compliance on real-world effectiveness.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

**Indirect comparison of the efficacy of recombinant factor VIII Fc fusion protein and other factor VIII products for prophylaxis modeling the effect of compliance.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

**Medical complications and resource utilization in blood transfusion-dependent patients with myelofibrosis by iron chelation therapy use.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Vekeman F, Huynh L, Sasane M, Cheng W, Duh MS, Paley C, Mesa R.

**Comparable outcomes with bortezomib-cyclophosphamide-dexamethasone (VCD) and bortezomib-lenalidomide-dexamethasone (VRD) for initial treatment of newly diagnosed multiple myeloma (MM).**

*Abstract:* 55th Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 7-10, 2013.

*Authors:* Kumar SK, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Yap M, Saravanan S, Pan I, Rembert D, Dhanda R, Niculescu L, Ba-Mancini A, Ma E, Quick M, Rajkumar SV.

**Impact chronic hepatitis C (CHC) treatment on post therapy healthcare cost.**

*Abstract:* HEP DART frontiers in drug development for viral hepatitis 2013, Big Island, Hawaii Dec 8-12, 2013.

*Authors:* Tandon N, Balart L, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

**Medical complications in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.**

*Abstract:* 55th Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 7-10, 2013.

*Authors:* Vekeman F, Cheng WY, Sasane M, Huynh L, Kaminsky M, Duh MS, Paley C, Mesa RA.

**Transition from pediatric to adult care of high cost patients in a Medicaid population with sickle cell disease.**

*Abstract:* 55th Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 7-10, 2013.

*Authors:* Blinder MA, Sasane M, Fortier J, Paley CS, Duh MS, Vekeman F.

**Age-related emergency department reliance (EDR) and healthcare resource utilization in patients with sickle cell disease (SCD).**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS.

**Final results from the multicenter compact study of complications in patients with sickle cell disease (SCD) and utilization of iron chelation therapy: A retrospective medical records review.**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Jordan LB, Adams-Graves P, Kanter-Washko J, Oneal P, Vekeman F, Bieri C, Sasane M, Marcellari A, Magestro M, Gorn Z, Duh MS.

**Final results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy: A retrospective medical records review.**

*Abstract:* 18th Congress of the European Hematology Association, Stockholm, Sweden Jun 13-16, 2013.

*Authors:* L J, Adams-Graves P, Kanter-Washko J, Oneal P, Sasane M, Vekeman F, Bieri C, Marcellari A, Magestro M, Gorn Z, Duh M.

**Age-related emergency department reliance (EDR) and health care resource utilization in patients with sickle cell disease (SCD).**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Blinder M, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS.

**Direct and indirect cost burden of chronic hepatitis c infection in privately-insured patients, stratified by liver disease severity.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Tandon N, Reddy KR, Lefebvre P, Parise H, Laliberte F, Pilon D, Duh MS, Prabhakar A, Cho M, Balart LA, Fastenau J.

**Direct and indirect cost burden of chronic hepatitis C stratified by liver disease severity in privately insured patients.**

*Abstract:* Digestive Disease Week, Orlando, FL May 18-21, 2013.

*Authors:* Tandon N, Reddy KR, Lefebvre P, Parisé H, Laliberté F, Pilon D, Duh MS, Prabhakar A, Cho M, Balart LA, Fastenau J.

**Key cost drivers in the cost of care for sickle cell disease patients: Results of a systematic literature search and a survey of payers and key opinion leaders.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Jordan L, Duh MS, Vekeman F, Matter S, Bieri C, Sasane M.

**Dynamics of improvement in health-related quality of life (HRQoL) with long-term eltrombopag treatment in adults with chronic immune thrombocytopenia (ITP) in EXTEND.**

*Abstract:* 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.



*Authors:* Grotzinger KM, Bussel JB, Saleh MN, Bieri C, Orlova Y, Brainsky A.

**Development and validation of a classification algorithm for prophylactic versus on-demand factor VIII therapy in patients with hemophilia A.**

*Abstract:* 30th International Congress of the World Federation of Hemophilia, Paris France July 8-12, 2012.

*Authors:* Pocoski J, Vekeman F, Cheng W, Trahey A, Sarda S, Valluri S, Preblich R, Duh M.

**Improvement in health-related quality of life (HRQoL) with long-term eltrombopag treatment in adults with chronic immune thrombocytopenia (ITP): Results of extend from june 2006 to february 2011.**

*Abstract:* 17th Congress of the European Hematology Association, Amsterdam, Netherlands Jun 14-17, 2012.

*Authors:* Grotzinger K, Bieri C, Olney H, Saleh M, Sheng Duh M, Brainsky A.

**Interim results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy: A retrospective medical records review.**

*Abstract:* 17th Congress of the European Hematology Association, Amsterdam, Netherlands Jun 24-17, 2012.

*Authors:* Jordan L, Adams-Graves P, Kanter-Washko J, Lau H, Vekeman F, Bieri C, Sasane M, Marcellari A, Magestro M, Steele V, Bluett-Mills G, Gorn Z, Duh M.

**Age-related blood transfusion patterns in patients with Sickle Cell Disease (SCD) and the association with sickle cell complications.**

*Abstract:* 53rd Annual Meeting of the American Society of Hematology, San Diego, CA Dec 10-13, 2011.

*Authors:* Blinder MA, Vekeman F, Trahey A, Sasane M, Paley CS, Duh MS.

**Age-related iron chelation utilization and healthcare costs in patients with Sickle Cell Disease (SCD).**

*Abstract:* 53rd Annual Meeting of the American Society of Hematology, San Diego, CA Dec 10-13, 2011.

*Authors:* Blinder MA, Vekeman F, Trahey A, Sasane M, Paley CS, Duh MS.

**Preoperative hemoglobin levels, characteristics, and resource utilization in total hip replacement patients with an anemia diagnosis versus without an anemia diagnosis: An electronic medical record analysis.**

*Abstract:* 53rd Annual Meeting of the American Society of Hematology, San Diego, CA Dec 10-13, 2011.

*Authors:* Forlenza JB, Ellis L, Parise H, Lafeuille MH, Lefebvre P.

**Dosing pattern and cost comparison of epoetin alfa and darbepoetin alfa in chronic kidney disease and chemotherapy-induced anemia inpatients.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Lafeuille MH, Bailey RA, Senbetta M, McKenzie RS, Lefebvre P.

**Transfusional iron overload (TIO) monitoring and treatment: Findings from an electronic medical records review study at the moffitt cancer center and research institute.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Duh MS, Wetzstein G, Guo A, Sasane M, Sarda SP, Korves C, Wang ST, Wei R, Clinton B, Ray L.

**Risk of venous thromboembolism complications.**

*Abstract:* 2011 Annual Scientific Symposium of the Hemostasis and Thrombosis Research Society, Chicago, IL Apr 28-30, 2011.

*Authors:* Lefebvre P, Laliberte F, Nutescu E, Duh MS, Lamori J, Bookhart BK, Olson W, Dea K, Schein J, Kaatz S.

**Monitoring and treatment of transfusional iron overload: Findings from an electronic medical records review study at the Moffitt cancer center and research institute.**

*Abstract:* 52nd Annual Meeting of the American Society of Hematology, Orlando, FL Dec 4-7, 2010.

*Authors:* Ray LA, Wetzstein GA, Wang ST, Guo A, Korves C, Clinton B, Wei R, Duh MS.

**Monitoring and treatment among patients with trans-fusional iron overload: Preliminary findings from an electronic medical records review study at H. Lee moffitt cancer center and research institute.**

*Abstract:* 2010 Annual Meeting of the American College of Clinical Pharmacy, Austin, TX Oct 17-20, 2010.

*Authors:* Ray LA, Wetzstein GA, Korves C, Wang ST, Clinton B, Wei R, Corral M, Duh MS.

**Persistence and compliance of deferoxamine (DFO) versus deferasirox (DFX) in Medicaid patients with sickle-cell disease (SCD).**

*Abstract:* 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Brighton, UK Aug 19-22, 2010.

*Authors:* Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

**Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease (SCD).**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

**The cost-effectiveness of bortezomib for the initial treatment of multiple myeloma in the United States.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Wang ST, Huang H, Shi H, Duh MS, Chen K, Chang E, Korves C, Dhawan R, Cakana A, Van De Velde H, Esseltine DL, Garrison L.

**Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

**Comparison of infection-related hospitalization risk among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* Duh MS, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Heaney ML.

**Pattern of utilization of pegfilgrastim (PEGFIL) in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* Skarin AT, Vekeman F, Laliberte F, Afonja O, Lafeuille MH, Barghout V, Duh MS.

**Association of health-related quality of life (HRQoL), bleeding, and platelet levels in chronic idiopathic thrombocytopenic purpura (itp): Results from RAISE and EXTEND.**

*Abstract:* 14th Congress of the European Hematology Association, Berlin, Germany June 4-7, 2009.

*Authors:* Bussel J, Grotzinger KM, Duh M, Signorovitch J, Stone NL, Brainsky A.

**Improvement in fatigue and health-related quality of life (HRQoL) with long-term Eltrombopag therapy in chronic idiopathic thrombocytopenic purpura: results of phase 3, double-blind study(raise).**

*Abstract:* 14th Congress of the European Hematology Association, Berlin, Germany Jun 4-7, 2009.

*Authors:* Provan D, Bussel JB, Cheng G, Grotzinger KM, Duh M, Signorovitch J, Stone NL, Aivado M.

**Improvement in fatigue and health-related quality of life with long-term Eltrombopag treatment in adults with chronic idiopathic thrombocytopenic purpura: The EXTEND study.**

*Abstract:* 14th Congress of the European Hematology Association, Berlin, Germany Jun 4-7, 2009.

*Authors:* Bussel J, Saleh M, Salama A, Grotzinger KM, Duh M, Signorovitch J, Stone NL, Aivado M.

**Budget impact analysis of sargramostim use in patients with chemotherapy-induced neutropenia.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Toy EL, Porter CL, Books P, Vekeman F, Barghout V, Duh M, Skarin AT.

**Comparison of infection-related hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Duh MS, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Heaney ML.

**Pattern of utilization of pegfilgrastim in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Vekeman F, Laliberte F, Afonja O, Lafeuille MH, Barghout V, Duh MS, Skarin AT.

**Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: Data from multi-center clinical practices.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.

**Health-Related Quality Of Life of Anemia Patients in the U.S.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia-Pacific.

*Authors:* Cremieux P, Xie J, Wu EQ, Castor A.

**Dose conversion of erythropoietic agents in chemotherapy-induced anemia: A meta-analysis.**

*Abstract:* ISPOR 2003, 2003.

*Authors:* Rosberg J, Oster E, Wu E, Fastenau J, Piech C.

## Infectious Diseases

### Journal Articles

**Treatment and comorbidity burden among people living with HIV: a review of systematic literature reviews.**

*Publication:* J Drug Assess 2023 12; 12(1): 1-11. e-pub ahead of print 2022/12/31; doi:

10.1080/21556660.2022.2149963.

*Authors:* Taiwo BO, Romdhani H, Lafeuille MH, Bhojwani R, Milbers K, Donga P.

**Clinical burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States.**

*Publication:* BMC Infect Dis 2023 08; 23(1): 550. e-pub ahead of print 2023/08/23; doi: 10.1186/s12879-023-08479-3.

*Authors:* Hernandez-Pastor L, Geurtsen J, Baugh B, El Khoury AC, Kalu N, Gauthier-Loiselle M, Bungay R, Cloutier M, Sarnecki M, Saade E.

**Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens.**

*Publication:* Infect Dis Ther 2023 08. e-pub ahead of print 2023/08/08; doi: 10.1007/s40121-023-00848-4.

*Authors:* Priest J, Germain G, Laliberté F, Duh MS, Mahendran M, Fakhri I, Oglesby A.

**Economic burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States.**

*Publication:* J Manag Care Spec Pharm 2023 08; 29(8): 873-883. e-pub ahead of print 2023/07/31; doi:

10.18553/jmcp.2023.29.8.873.

*Authors:* Hernandez-Pastor L, Geurtsen J, Baugh B, El Khoury AC, Kalu N, Krishnarajah G, Gauthier-Loiselle M, Bungay R, Cloutier M, Saade E.

**Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Clinical Trial.**

*Publication:* Open Forum Infect Dis 2023 08; 10(8). doi: 10.1093/ofid/ofad383.

*Authors:* Garey KW, Dubberke ER, Guo A, Harvey A, Yang M, García-Horton V, Fillbrunn M, Wang H, Tillotson GS, Bancke LL, Feuerstadt P.

**Enhancement and external validation of algorithms using diagnosis codes to identify invasive Escherichia Coli disease.**

*Publication:* Curr Med Res Opin 2023 08: 1-27. e-pub ahead of print 2023/08/23; doi: 10.1080/03007995.2023.2247968.

*Authors:* Hernandez-Pastor L, Geurtsen J, El Khoury AC, Fortin SP, Gauthier-Loiselle M, Yu LH, Cloutier M.

**Escherichia coli resistance, treatment patterns and clinical outcomes among females with uUTI in Germany: a retrospective physician-based chart review study.**

*Publication:* Sci Rep 2023 07; 13(1): 12077. e-pub ahead of print 2023/07/27; doi: 10.1038/s41598-023-38919-8.

*Authors:* Naber KG, Wagenlehner F, Kresken M, Cheng WY, Catillon M, Duh MS, Yu L, Khanal A, Mulgirigama A, Joshi AV, Ju S, Mitrani-Gold FS.

**Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1.**

*Publication:* Clinicoecon Outcomes Res 2023 07; 15: 579-591. e-pub ahead of print 2023/07/31; doi: 10.2147/ceor.S413800.

*Authors:* Donga P, Emond B, Rossi C, Bookhart BK, Lee J, Caron-Lapointe G, Wei F, Lafeuille MH.

**Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.**

*Publication:* J Int AIDS Soc 2023 06; 26(6): e26123. e-pub ahead of print 2023/06/12; doi: 10.1002/jia2.26123.

*Authors:* Rebeiro PF, Emond B, Rossi C, Bookhart BK, Shah A, Caron-Lapointe G, Lafeuille MH, Donga P.

**Same-day testing with initiation of antiretroviral therapy or tuberculosis treatment versus standard care for persons presenting with tuberculosis symptoms at HIV diagnosis: A randomized open-label trial from Haiti.**

*Publication:* PLoS Med 2023 06; 20(6): e1004246. e-pub ahead of print 2023/06/09; doi: 10.1371/journal.pmed.1004246.

*Authors:* Dorvil N, Rivera VR, Riviere C, Berman R, Severe P, Bang H, Lavoile K, Devieux JG, Faustin M, Saintyl G, Mendicuti MD, Pierre S, Apollon A, Dumond E, Forestal GPL, Rouzier V, Marcelin A, McNairy ML, Walsh KF, Dupnik K, Reif LK, Byrne AL, Bousleiman S, Orvis E, Joseph P, Cremieux PY, Pape JW, Koenig SP.

**Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis.**

*Publication:* Adv Ther 2023 05. doi: 10.1007/s12325-023-02498-x.

*Authors:* Reveles KR, Yang M, Garcia-Horton V, Edwards ML, Guo A, Lodise T, Bochan M, Tillotson G, Dubberke ER.

**Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan.**

*Publication:* Therap Adv Gastroenterol 2023 05; 16: 17562848231168714. doi: 10.1177/17562848231168714.

*Authors:* Howden CW, Cook EE, Swallow E, Yang K, Guo H, Pelletier C, Jacob R, Sugano K.

**Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US.**

*Publication:* Adv Ther 2023 04. doi: 10.1007/s12325-023-02506-0.

*Authors:* Lodise T, Guo A, Yang M, Cook EE, Song W, Yang D, Wang Q, Zhao A, Bochan M.

**Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.**

*Publication:* Adv Ther 2023 04. doi: 10.1007/s12325-023-02505-1.

*Authors:* Lodise T, Guo A, Yang M, Cook EE, Song W, Yang D, Wang Q, Zhao A, Bochan M.

**Economic burden of acute otitis media, pneumonia, and invasive pneumococcal disease in children in the United States after the introduction of 13-valent pneumococcal conjugate vaccines during 2014-2018.**

*Publication:* BMC Health Serv Res 2023 04; 23(1): 398. e-pub ahead of print 2023/04/26; doi: 10.1186/s12913-023-09244-7.

*Authors:* Hu T, Song Y, Done N, Mohanty S, Liu Q, Sarpong EM, Lemus-Wirtz E, Signorovitch J, Weiss T.

**Assessing barriers to access and equity for COVID-19 vaccination in the US.**

*Publication:* BMC Public Health 2022 12; 22(1): 2263. e-pub ahead of print 2022/12/04; doi: 10.1186/s12889-022-14636-1.

*Authors:* Kuehn M, LaMori J, DeMartino JK, Mesa-Frias M, Doran J, Korrapati L, Bhojwani R, Lefebvre P, Kirson N.

**Characteristics, Treatment Patterns, and Clinical Outcomes of Chronic Hepatitis B Across 3 Continents: Retrospective Database Study.**

*Publication:* Adv Ther 2022 11. doi: 10.1007/s12325-022-02284-1.

*Authors:* Gillespie IA, Chan KA, Liu Y, Hsieh S, Schindler C, Cheng W, Chang R, Kap E, Morais E, Duh MS, Park S, Ketz M, Jenner S, Boxall N, Kendrick S, Theodore D.

**Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors.**

*Publication:* J Comp Eff Res 2022 11. e-pub ahead of print 2022/11/30; doi: 10.2217/ce-2022-0147.

*Authors:* Donga P, Emond B, Shah A, Bookhart BK, Anderson D, Vermette-Laforme M, Rossi C, Lafeuille MH.

**Development of the PREDS score to predict in-hospital mortality of patients with Ebola virus disease under advanced supportive care: Results from the EVISTA cohort in the Democratic Republic of the Congo.**

*Publication:* EClinicalMedicine 2022 10; 54: 101699. e-pub ahead of print 2022/10/21; doi: 10.1016/j.eclinm.2022.101699.

*Authors:* Jaspard M, Mulangu S, Juchet S, Serra B, Dicko I, Lang HJ, Baka BM, Komanda GM, Katsavara JM, Kabuni P, Mambu FM, Isnard M, Vanhecke C, Letord A, Dieye I, Patterson-Lomba O, Mbaya OT, Isekusu F, Mangala D, Biampata JL, Kitenge R, Kinda M, Anglaret X, Muyembe JJ, Kojan R, Ezzedine K, Malvy D.

**Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.**

*Publication:* BMC Public Health 2022 09; 22(1): 1677. e-pub ahead of print 2022/09/06; doi: 10.1186/s12889-022-14051-6.

*Authors:* Hu T, Song Y, Done N, Liu Q, Sarpong EM, Lemus-Wirtz E, Signorovitch J, Mohanty S, Weiss T.

**Assessment of the Impact of a Meningitis/Encephalitis Panel on Hospital Length of Stay: A Systematic Review and Meta-Analysis.**

*Publication:* Antibiotics (Basel) 2022 07; 11(8). e-pub ahead of print 2022/08/27; doi: 10.3390/antibiotics11081028.

*Authors:* Hueth KD, Thompson-Leduc P, Totev TI, Milbers K, Timbrook TT, Kirson N, Hasbun R.

**Direct health care costs associated with COVID-19 in the United States.**

*Publication:* J Manag Care Spec Pharm 2022 06; 1-12. e-pub ahead of print 2022/06/21; doi: 10.18553/jmcp.2022.22050.

*Authors:* DeMartino JK, Swallow E, Goldschmidt D, Yang K, Viola M, Radtke T, Kirson N.

**Increasing COVID-19 vaccination in the United States: projected impact on cases, hospitalizations, and deaths by age and racial group.**

*Publication:* Public Health 2022 06; 210: 99-106. e-pub ahead of print 2022/08/04; doi: 10.1016/j.puhe.2022.06.019.

*Authors:* Kirson N, Swallow E, Lu J, Froughi C, Bookhart B, DeMartino JK, Maynard J, Shivdasani Y, Eid D, Lefebvre P.

**Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.**

*Publication:* BMC Infect Dis 2022 03; 22(1): 294. e-pub ahead of print 2022/03/30; doi: 10.1186/s12879-022-07275-9.

*Authors:* Hu T, Done N, Petigara T, Mohanty S, Song Y, Liu Q, Lemus-Wirtz E, Signorovitch J, Sarpong E, Weiss T.

**Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom.**

*Publication:* Vaccine 2022 02. e-pub ahead of print 2022/03/03; doi: 10.1016/j.vaccine.2022.02.067.

*Authors:* Daniels V, Saxena K, Patterson-Lomba O, Gomez-Lievano A, Saah A, Luxembourg A, Velicer C, Chen YT, Elbasha E.

**Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States.**

*Publication:* J Health Econ Outcomes Res 2022 02; 9(1): 39-49. e-pub ahead of print 2022/03/03; doi: 10.36469/jheor.2022.31825.

*Authors:* Emond B, Rossi C, Rogers R, Lefebvre P, Lafeuille MH, Donga P.

**The societal economic value of COVID-19 vaccines in the United States.**

*Publication:* J Med Econ 2022 01; 25(1): 119-128. e-pub ahead of print 2022/01/07; doi: 10.1080/13696998.2022.2026118.

*Authors:* Kirson N, Swallow E, Lu J, Mesa-Frias M, Bookhart B, Maynard J, Shivdasani Y, Lefebvre P.

**Time to Culture Conversion of Bedaquiline and High-Dose Isoniazid for Drug-Resistant Tuberculosis.**

*Publication:* Open Forum Infect Dis 2022 9(9): ofac440. e-pub ahead of print 2022/09/30; doi: 10.1093/ofid/ofac440.

*Authors:* Walsh KF, Vilbrun SC, Souroutzidis A, Ellis J, Delva S, Joissaint G, Dupnik KM, Joseph P, Pape JW, Koenig SP.

**Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bicitgravir/emtricitabine/tenofovir alafenamide in the United States.**

*Publication:* Curr Med Res Opin 2021 12: 1-26. e-pub ahead of print 2021/11/24; doi:

10.1080/03007995.2021.2007006.

*Authors:* Emond B, Rossi C, Côté-Sergent A, Bookhart B, Anderson D, Lefebvre P, Lafeuille MH, Donga P.

**Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti.**

*Publication:* Open Forum Infect Dis 2021 12; 8(12). doi: 10.1093/ofid/ofab559.

*Authors:* Pierre S, Bocharova I, Nguyen C, Homeus F, Julmiste G, Macius Y, Rouzier V, Severe P, Marcelle Deschamps M, Moise CG, Bellot C, Wu J, Rivera VR, Sun R, Pape JW, Liautaud B, Koenig SP.

**Retrospective analysis of adherence to HIV treatment and healthcare utilization in a commercially insured population.**

*Publication:* J Med Econ 2021 10: 1. e-pub ahead of print 2021/10/20; doi: 10.1080/13696998.2021.1995868.

*Authors:* Priest J, Bhak RH, Dersarkissian M, Oglesby A, Kunzweiler C, Fuqua E, Park S, Duh MS, Garris C.

**Impact of the COVID-19 pandemic on adolescent vaccinations: projected time to reverse deficits in routine adolescent vaccination in the United States.**

*Publication:* Current Medical Research and Opinion 2021 09: 1-11. doi: 10.1080/03007995.2021.1981842.

*Authors:* Saxena K, Marden JR, Carias C, Bhatti A, Patterson-Lomba O, Gomez-Lievano A, Yao L, Chen Y.

**Long-term mortality after tuberculosis treatment among persons living with HIV in Haiti.**

*Publication:* J Int AIDS Soc 2021 07; 24(7): e25721. doi: <https://doi.org/10.1002/jia2.25721>.

*Authors:* Joseph Y, Yao Z, Dua A, Severe P, Collins SE, Bang H, Antoine Jean-Juste M, Ocheretina O, Apollon A, McNairy ML, Dupnik K, Cremieux E, Byrne A, Pape JW, Koenig SP.

**Success of community approach to HPV vaccination in school-based and non-school-based settings in Haiti.**

*Publication:* PLoS One 2021 06; 16(6): e0252310. e-pub ahead of print 2021/06/25; doi: 10.1371/journal.pone.0252310.

*Authors:* Riviere C, Bell T, Cadot Y, Perodin C, Charles B, Bertil C, Cheung J, Bane S, Cheung HC, Pape JW, Deschamps MM.

**Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study.**

*Publication:* J Health Econ Outcomes Res 2021 06; 8(1): 88-98. e-pub ahead of print 2021/06/29; doi: 10.36469/001c.24535.

*Authors:* Emond B, Rossi C, Côté-Sergent A, Dunn K, Lefebvre P, Lafeuille MH, Donga P.

**The Economic Value of Improved Productivity from Treatment of Chronic Hepatitis C Virus Infection: A Retrospective Analysis of Earnings, Work Loss, and Health Insurance Data.**

*Publication:* Adv Ther 2020 09. e-pub ahead of print 2020/09/16; doi: 10.1007/s12325-020-01492-x.

*Authors:* Sulkowski M, Ionescu-Ittu R, Macaulay D, Sanchez-Gonzalez Y.

**The Economic Value of Improved Productivity from Treatment of Chronic Hepatitis C Virus Infection: A Retrospective Analysis of Earnings, Work Loss, and Health Insurance Data.**

*Publication:* Adv Ther 2020 09. doi: 10.1007/s12325-020-01492-x.

*Authors:* Sulkowski M, Ionescu-Ittu R, Macaulay D, Sanchez-Gonzalez Y.

**An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus.**

*Publication:* Curr Med Res Opin 2020 08; 36(8): 1313-1323. e-pub ahead of print 2020/05/28; doi: 10.1080/03007995.2020.1775074.

*Authors:* Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille MH, Emond B, Hardy H.

**Determinants of Meningococcal ACWY vaccination in adolescents in the US: completion and compliance with the CDC recommendations.**

*Publication:* Hum Vaccin Immunother 2020 08; 16(1): 176-188. e-pub ahead of print 2019/08/17; doi: 10.1080/21645515.2019.1632679.

*Authors:* Cheng WY, Chang R, Novy P, O'Connor C, Duh MS, Hoge CS.

**An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with Human Immunodeficiency Virus.**

*Publication:* Current Medical Research and Opinion 2020 03: 1-1. doi: 10.1080/03007995.2020.1775074.

*Authors:* Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille M-H, Emond B, Hardy H.

**Retrospective analysis of comorbidities and treatment burden among patients with HIV infection in a US Medicaid population.**

*Publication:* Curr Med Res Opin 2020 01; 36(5): 781-788. e-pub ahead of print 2020/01/17; doi: 10.1080/03007995.2020.1716706.

*Authors:* DerSarkissian M, Bhak RH, Oglesby A, Priest J, Gao E, Macheca M, Sharperson C, Duh MS.

**Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide.**

*Publication:* Patient Prefer Adherence 2020 14: 2315-2326. e-pub ahead of print 2020/12/03; doi: 10.2147/ppa.S272211.

*Authors:* Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille MH, Hardy H, Emond B.

**Diagnostic yield of active case finding for tuberculosis at human immunodeficiency virus testing in Haiti.**

*Publication:* Int J Tuberc Lung Dis 2019 11; 23(11): 1217-1222. e-pub ahead of print 2019/11/14; doi: 10.5588/ijtld.18.0835.

*Authors:* Rivera VR, Lu L, Ocheretina O, Jean Juste MA, Julma P, Archange D, Moise CG, Homeus F, Phanor PD, Petión S, Cremieux PY, Fitzgerald DW, Pape JW, Koenig SP.

**Long-Term Benefits of Rapid Antiretroviral Therapy Initiation in Reducing Medical and Overall Health Care Costs Among Medicaid-Covered Patients with Human Immunodeficiency Virus.**

*Publication:* J Manag Care Spec Pharm 2019 11; 0(0): 1-12. doi: 10.18553/jmcp.2019.19174.

*Authors:* Benson C, Emond B, Romdhani H, Lefebvre P, Côté-Sergent A, Shohoudi A, Tandon N, Chow W, Dunn K.

**Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage.**

*Publication:* J Manag Care Spec Pharm 2019 11; 0(0): 1-13. doi: 10.18553/jmcp.2019.19175.

*Authors:* Benson C, Emond B, Lefebvre P, Lafeuille M-H, Côté-Sergent A, Tandon N, Chow W, Dunn K.

**Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in Haiti.**

*Publication:* Clin Infect Dis 2019 08; 69(4): 717-719. e-pub ahead of print 2019/01/31; doi: 10.1093/cid/ciz039.

*Authors:* Walsh KF, Vilbrun SC, Souroutzidis A, Delva S, Joissaint G, Mathurin L, Ocheretina O, Cremieux P, Pape JW, Koenig SP.

**Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections.**

*Publication:* Adv Ther 2019 06. e-pub ahead of print 2019/06/27; doi: 10.1007/s12325-019-01012-6.

*Authors:* Welzel TM, Yang M, Sajeev G, Chen YJ, Pinsky B, Bao Y, Wu EQ, Dieterich D.

**Clinical and Economic Burden of Patients with Chronic Hepatitis C with Versus Without Antiviral Treatment in Japan: An Observational Cohort Study Using Hospital Claims Data.**

*Publication:* Infect Dis Ther 2019 06; 8(2): 285-299. e-pub ahead of print 2019/02/17; doi: 10.1007/s40121-019-0234-5.

*Authors:* Yamazaki K, Macaulay D, Song Y, Sanchez Gonzalez Y.

**The role of provider characteristics on the hepatitis A and B vaccination status of adults in the United States during 2007-2015.**

*Publication:* Preventive Medicine Reports 2019 06; 14 (no pagination)(100833). doi:

<http://dx.doi.org/10.1016/j.pmedr.2019.100833>.

*Authors:* Ghaswalla PK, Patterson BJ, Cheng WY, Duchesneau E, Machecha M, Duh MS, Trofa AF.

**Beyond multidrug resistance: Leveraging rare variants with machine and statistical learning models in Mycobacterium tuberculosis resistance prediction.**

*Publication:* EBioMedicine 2019 05. e-pub ahead of print 2019/05/03; doi: 10.1016/j.ebiom.2019.04.016.

*Authors:* Chen ML, Doddi A, Royer J, Freschi L, Schito M, Ezewudo M, Kohane IS, Beam A, Farhat M.

**Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.**

*Publication:* The American journal of tropical medicine and hygiene 2019 02; 100(2): 392-398. doi:

<http://dx.doi.org/10.4269/ajtmh.18-0493>.

*Authors:* Walsh KF, Souroutzidis A, Vilbrun SC, Peebles M, Joissaint G, Delva S, Widmann P, Royal G, Pry J, Bang H, Pape JW, Koenig SP.

**A Successful Model of Expedited Antiretroviral Therapy for Clinically Stable Patients Living With HIV in Haiti.**

*Publication:* Journal of acquired immune deficiency syndromes 2018 09; 79(1): 70-76. doi:

<http://dx.doi.org/10.1097/QAI.0000000000001725>.



*Authors:* Guiteau Moise C, Rivera VR, Hennessey KA, Bellot C, Nicholas C, Fang AP, Verdier RI, Severe P, Sainvil A, Charles B, Dorval D, St Amour J, Pape JW, Koenig SP.

**Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis.**

*Publication:* Curr Med Res Opin 2018 07; 34(7): 1261-1269. e-pub ahead of print 2017/12/13; doi: 10.1080/03007995.2017.1416347.

*Authors:* Yan S, DerSarkissian M, Bhak RH, Lefebvre P, Duh MS, Krishnarajah G.

**Risk factors for self-reported cholera within HIV-affected households in rural Haiti.**

*Publication:* Open Forum Infect Dis 2018 07; 5(6). doi: <http://dx.doi.org/10.1093/ofid/ofy127>.

*Authors:* Richterman A, Cheung HC, Meiselbach MK, Jerome G, Ternier R, Ivers LC.

**Efficacy and Safety of Procalcitonin Guidance in Patients With Suspected or Confirmed Sepsis: A Systematic Review and Meta-Analysis.**

*Publication:* Crit Care Med 2018 05; 46(5): 691-698. e-pub ahead of print 2017/12/23; doi: 10.1097/CCM.0000000000002928.

*Authors:* Iankova I, Thompson-Leduc P, Kirson NY, Rice B, Hey J, Krause A, Schonfeld SA, DeBrase CR, Bozzette S, Schuetz P.

**A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population.**

*Publication:* Infect Dis Ther 2018 05. e-pub ahead of print 2018/05/16; doi: 10.1007/s40121-018-0201-6.

*Authors:* Chawla A, Wang C, Patton C, Murray M, Puneekar Y, de Ruiter A, Steinhart C.

**The Impact of a Community-Based Intervention Including a Monthly Food Ration on Food Insecurity Among HIV-Positive Adults During the First Year of Antiretroviral Therapy.**

*Publication:* AIDS Behav 2018 01; 22(1): 154-163. e-pub ahead of print 2017/08/30; doi: 10.1007/s10461-017-1897-0.

*Authors:* Rothman J, Kayigamba F, Hills V, Gupta N, Machara F, Niyigena P, Franke MF.

**Diagnostic yield of active case finding for tuberculosis and HIV at the household level in slums in Haiti.**

*Publication:* Int J Tuberc Lung Dis 2017 11; 21(11): 1140-1146. e-pub ahead of print 2017/10/19; doi: 10.5588/ijtld.17.0049.

*Authors:* Rivera VR, Jean-Juste MA, Gluck SC, Reeder HT, Sainristil J, Julma P, Peck M, Joseph P, Ocheretina O, Perodin C, Secours R, Duran-Mendicuti M, Hashiguchi L, Cremieux PY, Koenig SP, Pape JW.

**Retention in Care among Patients with Early HIV Disease in Haiti.**

*Publication:* J Int Assoc Provid AIDS Care 2017 11; 16(6): 523-526. e-pub ahead of print 2017/12/01; doi: 10.1177/2325957417742670.

*Authors:* Hennessey KA, Leger TD, Rivera VR, Marcelin A, McNairy ML, Guiteau C, Devieux JG, Marcelin Y, Charles B, Cremieux PY, Koenig SP, Pape JW.

**Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial.**

*Publication:* PLoS Med 2017 07; 14 (7) (no pagination)(e1002357). doi: <http://dx.doi.org/10.1371/journal.pmed.1002357>.

*Authors:* Koenig SP, Dorvil N, Devieux JG, Hedt-Gauthier BL, Riviere C, Faustin M, Lavoile K, Perodin C, Apollon A, Duverger L, McNairy ML, Hennessey KA, Souroutzidis A, Cremieux PY, Severe P, Pape JW.

**Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy.**

*Publication:* Hepatology Communications 2017 05; 1(5): 439-452. doi: <http://dx.doi.org/10.1002/hep4.1049>.

*Authors:* Reau N, Vekeman F, Wu E, Bao Y, Gonzalez YS.

**Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis.**

*Publication:* Adv Ther 2017 01; 34(1): 207-220. e-pub ahead of print 2016/12/04; doi: 10.1007/s12325-016-0443-1.

*Authors:* Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J.

**Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.**

*Publication:* J Med Econ 2016 12; 19(4): 364-373. e-pub ahead of print 2015/12/02; doi: 10.3111/13696998.2015.1127252.

*Authors:* LaMori J, Tandon N, Laliberte F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

**Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study.**

*Publication:* BMC Infect Dis 2016 12; 16(1): 730. e-pub ahead of print 2016/12/03; doi: 10.1186/s12879-016-2023-z.

*Authors:* Kontoyiannis DP, Yang H, Song J, Kelkar SS, Yang X, Azie N, Harrington R, Fan A, Lee E, Spalding JR.

**Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients.**

*Publication:* Antimicrob Agents Chemother 2016 06; 60(6): 3398-3406. e-pub ahead of print 2016/03/24; doi: 10.1128/AAC.00054-16.

*Authors:* Andes D, Azie N, Yang H, Harrington R, Kelley C, Tan RD, Wu EQ, Franks B, Kristy R, Lee E, Khandelwal N, Spalding J.

**Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.**

*Publication:* J Comp Eff Res 2016 05; 5(3): 273-279. e-pub ahead of print 2016/01/23; doi: 10.2217/ce.15.69.

*Authors:* Swallow E, Kelley C, Signorovitch J, Wygant G, McPhee F.

**Rotavirus vaccination in a Medicaid infant population from four US states: compliance, vaccination completion rate, and predictors of compliance.**

*Publication:* Hum Vaccin Immunother 2016 05; 12(5): 1235-1243. e-pub ahead of print 2016/02/24; doi: 10.1080/21645515.2015.1136041.

*Authors:* Calnan M, Krishnarajah G, Duh MS, Haider BA, Yermakov S, Davis M, Yan S.

**Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.**

*Publication:* J Comp Eff Res 2016 03; 5(2): 129-139. e-pub ahead of print 2015/09/22; doi: 10.2217/ce.15.49.

*Authors:* Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Mu F, Kim S, Noviello S, Signorovitch J.

**Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.**

*Publication:* Clin Ther 2016 02; 38(2): 404-412. doi: 10.1016/j.clinthera.2015.12.017.

*Authors:* Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Ackerman P, Signorovitch J.

**Public Health Impact of Complete and Incomplete Rotavirus Vaccination among Commercially and Medicaid Insured Children in the United States.**

*Publication:* PLoS One 2016 01; 11(1): e0145977. e-pub ahead of print 2016/01/12; doi: 10.1371/journal.pone.0145977.

*Authors:* Krishnarajah G, Duh MS, Korves C, Demissie K.

**Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.**

*Publication:* J Comp Eff Res 2015 11; 4(6): 593-605. doi: 10.2217/ce.15.33.

*Authors:* Signorovitch JE, Betts KA, Song Y, Sorg RA, Li J, Behl AS, Kalsekar A.

**A second look at the association between gender and mortality on antiretroviral therapy.**

*Publication:* PLoS One 2015 11; 10 (11) (no pagination)(e0142101). doi:

<http://dx.doi.org/10.1371/journal.pone.0142101>.

*Authors:* Koenig SP, Bornstein A, Severe K, Fox E, Devieux JG, Severe P, Joseph P, Marcelin A, Bright DA, Pham N, Cremieux P, Pape JW.

**Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.**

*Publication:* J Acquir Immune Defic Syndr 2015 08; 69(4): 413-421. doi: 10.1097/QAI.0000000000000662.

*Authors:* Young J, Xiao Y, Moodie EE, Abrahamowicz M, Klein MB, Bernasconi E, Schmid P, Calmy A, Cavassini M, Cusini A, Weber R, Bucher HC, Swiss HIVCS.

**Direct and Indirect Cost Burden of Chronic Hepatitis C.**

*Publication:* The American Journal of Pharmacy Benefits 2015 07; 7(4): e90-e100.

*Authors:* Tandon N, Reddy K, Balart L, Fastenau J, Lefebvre P, Parisé H, Laliberté F, Pilon D, Duh M, Cho M, Prabhakar A.

**Simulations Show Diagnostic Testing For Malaria In Young African Children Can Be Cost-Saving Or Cost-Effective.**

*Publication:* Health Aff (Millwood) 2015 07; 34(7): 1196-1203. doi: 10.1377/hlthaff.2015.0095.

*Authors:* Phillips V, Njau J, Li S, Kachur P.

**Costs and Resource Utilization Associated with Anemia and Rash in Chronic Hepatitis C Patients Treated with Direct-Acting Antiviral Agents in the United States.**

*Publication:* Clin Ther 2015 06. doi: 10.1016/j.clinthera.2015.05.503.

*Authors:* Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ.

**Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir.**

*Publication:* J Manag Care Spec Pharm 2015 04; 21(4): 308-318.

*Authors:* Le TK, Kalsekar A, Macaulay D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ.

**The epidemiology of herpes zoster and its complications in Medicare cancer patients.**

*Publication:* BMC Infect Dis 2015 02; 15: 106. doi: 10.1186/s12879-015-0810-6.

*Authors:* Yenikomshian MA, Guignard AP, Haguinet F, LaCasce AS, Skarin AT, Trahey A, Karner P, Duh MS.

**CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from CIPRA HT-001.**

*Publication:* Int J Tuberc Lung Dis 2015 01; 19(1): 50-57. doi: 10.5588/ijtld.14.0217.

*Authors:* Collins SE, Jean Juste MA, Koenig SP, Secours R, Ocheretina O, Bernard D, Riviere C, Calnan M, Dunning A, Hurtado Rua SM, Johnson WD, Jr., Pape JW, Fitzgerald DW, Severe P.

**Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.**

*Publication:* J Med Econ 2014 12; 17(12): 862-871. doi: 10.3111/13696998.2014.964720.

*Authors:* Tandon N, Balart LA, Laliberte F, Pilon D, Lefebvre P, Germain G, Prabhakar A.

**Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States.**

*Publication:* Hum Vaccin Immunother 2014 11; 10(8): 2255-2266. doi: 10.4161/hv.29511.

*Authors:* Krishnarajah G, Demissie K, Lefebvre P, Gaur S, Sheng Duh M.

**Superior outcomes and lower outpatient costs with scale-up of antiretroviral therapy at the GHESKIO clinic in Port-au-Prince, Haiti.**

*Publication:* J Acquir Immune Defic Syndr 2014 08; 66(4): e72-79. e-pub ahead of print 2014/07/02; doi: 10.1097/qai.0000000000000200.

*Authors:* Riviere C, Faust E, Miller T, Beck EJ, Baruwa E, Severe P, Severe K, Riché CT, Cassagnol R, Atwood S, Esperance M, Webster L, Cremieux P, Pape JW, Koenig SP.

**Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.**

*Publication:* Appl Health Econ Health Policy 2014 02; 12(1): 85-93. doi: 10.1007/s40258-013-0072-7.

*Authors:* Yang H, Chaudhari P, Zhou ZY, Wu EQ, Patel C, Horn DL.

**Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors.**

*Publication:* Circulation 2013 09; 128(13): 1412-1419. doi: 10.1161/CIRCULATIONAHA.113.001827.

*Authors:* Rushani D, Kaufman JS, Ionescu-Iltu R, Mackie AS, Pilote L, Therrien J, Marelli AJ.

**Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications.**

*Publication:* Pain Medicine 2010 03; 11(3): 369-378. doi: 10.1111/j.1526-4637.2010.00811.x.

*Authors:* Michna E, Duh MS, Korves C, Dahl JL.

**Lower respiratory tract infections: impact on the workplace.**

*Publication:* PharmacoEconomics 2003 06; 21(10): 749-759.

*Authors:* Birnbaum H, Morley M, Leong S, Greenberg P, Colice G.

**Economic burden of respiratory infections in an employed population.**

*Publication:* Chest 2002 08; 122(2): 603-611.

*Authors:* Birnbaum HG, Morley M, Greenberg PE, Colice GL.

## Abstracts

**Early Experience with a Simple Administration of a Novel Fecal Microbiome Replacement for Prevention of Recurrent Clostridioides difficile.**

Boston, MA October 11 - 15, 2023.

*Authors:* Hengel RL, Krishan S, Rosenburg JA, Ritter TE, Baker KA, Van Anglen LJ, Guo A, Moosapanah M, Yang M, Garey KW.

**Cost-Effectiveness Analysis of RBX2660 for Preventing/Reducing Recurrent Clostridioides difficile Infections in the US.**

San Antonio, TX March 21-24, 2023.

*Authors:* Lodise T, Guo A, Yang M, Cook E, Song W, Yang D, Wang Q, Zhao A, Bochan M.

**Improvement in Health-Related Quality of Life and Estimated Economic Benefits in Patients with Recurrent Clostridioides Difficile Infection with No Further Recurrences: Pooled Results from the RBX2660 Phase 2 Randomized, Placebo-Controlled Trial.**

San Antonio, TX.

*Authors:* Feuerstadt P, Dubberke E, Guo A, Harvey A, Yang M, García-Horton V, Fillbrunn M, Salcedo J, Bancke LL, Garey KW.

**Payer Budget Impact Analysis of RBX2660 for Preventing/Reducing Recurrent Clostridioides difficile Infections in the US.**

San Antonio, TX March 21-24, 2023.

*Authors:* Lodise T, Guo A, Yang M, Cook E, Song W, Yang D, Wang Q, Zhao A, Bochan M.

**Conducting research in a setting of severe political instability: The GHESKIO model.**

Seattle, Washington February 19-22, 2023.

*Authors:* Pierre S, Duchatellier CF, Rivera VR, Dorvil N, Pierre MF, Bajo Joseph J, Apollon A, Collins SE, Israelski D, St Preux S, Sundaresan S, Wang H, Severe P, Pape JW, Koenig SP.

**Burden of Invasive Extraintestinal Pathogenic E. coli Disease Among Older Adult Patients Treated in Hospitals in the US.**

*Abstract:* ISPOR 2022, Washington D.C. May 15-18, 2022.

*Authors:* Pastor LH, Geurtsen J, Baugh B, El Houry AC, Kalu N, Gauthier-Loiselle M, Bungay R, Cloutier M.

**Pre-exposure prophylaxis (PrEP) prescriptions among individuals at high risk for HIV in the United States, 2012-2018.**

Virtual September 29–October 2, 2021.

*Authors:* Zhou M, Song Y, Gao E, Whiteside Y, Billmyer E, Signorovitch J.

**Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapies.**

Orlando, FL May 18–21, 2022.

*Authors:* Puenpatom A, Williams MG, Song Y, Yi D, Wang J, Gu M, He C, Berman R, Igbo-Osagie E.

**Real-World Healthcare Costs of Patients Receiving Dolutegravir/Lamivudine and Other Single Tablet Regimens for the Treatment of HIV-1 in the US.**

*Abstract:* Virtual IPSOR 2021, Virtual May 17-20, 2021.

*Authors:* Priest j, Germain G, Laliberté F, Duh MS, Mahendran M, Fakhri I, Oglesby A.

**Rapid Initiation of Antiretroviral Treatment (Art) Following Diagnosis of Human Immunodeficiency Virus (HIV) among Medicaid Beneficiaries: A Real-World Evaluation.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Benson C, Emond B, Romdhani H, Lefebvre P, Tandon N, Chow W, Dunn K.

**Outcomes with Continuation of Tenofovir-Lamivudine versus Switching to Zidovudine- Lamivudine in Second-Line Antiretroviral Therapy in Haiti.**

Bogota, Colombia April 4-6 2019.

*Authors:* Pierre S, Bocharova I, Nguyen C, Cremieux P, Koenig SP, Liautaud B, Pape J.

**Outcomes with continuation of tenofovir-lamivudine versus switching to zidovudine-lamivudine in second-line antiretroviral therapy in Haiti.**

*Abstract:* HIV and Hepatitis in the Americas, Bogotá, Colombia Apr 4-6, 2019.

*Authors:* Pierre S, Bocharova I, Nguyen C, Cremieux P, Koenig S, Pape J.

**Substantial declines in HIV, syphilis, genital ulcers and urethral discharge over two decades, with recent increases in sexually transmitted infection (STI) prevalence in an STI clinic in urban Haiti.**

*Abstract:* HIV and Hepatitis in the Americas, Bogota, Columbia April 4-6, 2019.

*Authors:* Liautaud B, Koenig S, Greenberg M, Serra E, Hilaire G, Marcelin A, Bernadin J, Macheca M, Pape J.

**Trends in CD4 cell count at diagnosis of HIV and initiation of ART in Haiti (2004 to 2016).**

*Abstract:* HIV and Hepatitis in the Americas, Bogota, Columbia April 4-6, 2019.

*Authors:* Dua A, Bousleiman S, Marcelin A, Rivera V, Koenig S, Cremieux P, Deschamps M, Pape J.

**Early treatment with direct-acting antivirals (DAAs) saves medical costs in non-cirrhotic patients with chronic hepatitis C (CHC) virus infection in the United States (US).**

*Abstract:* 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA Nov 9-13, 2018.

*Authors:* Cacoub P, Gonzalez YS, Ionescu-Ittu R, Bondin M, Macaulay D.

**Adherence to antiretrovirals in medicaid-insured patients living with hiv: Predictors and economic consequences.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Dunn K, Lafeuille M, Jiao X, Romdhani H, Emond B, Woodruff K, Pesa J, Tandon N, Lefebvre P.

**Comorbidity and treatment burden among HIV-infected patients in a US medicaid population.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Der Sarkissian M, Bhak R, Oglesby AK, Priest J, Gao E, Macheca M, Sharperson C, Laliberte F, Duh MS.

**Assessing patient preferences for and relative importance of features of new direct acting antiviral (DAA) treatments for chronic hepatitis C virus (HCV) infections.**

*Abstract:* 68th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC Oct 20-24, 2017.

*Authors:* Welzel TM, Yang M, Sajeev G, Pinsky B, Mehta D, Bao Y, Wu E, Chen YJ.

**Real-world burden of care for patients with chronic hepatitis C before, during and after treatment with novel direct-acting antiviral agents (DAAs).**

*Abstract:* AMCP Nexus 2017, Dallas, TX Oct 16-19, 2017.

*Authors:* Yang M, Mu F, Macaulay D, Kort JJ, Chen YJ.

**A claims-based analysis of hepatitis a, b, and a/b vaccination series completion and compliance among US adults.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Patterson BJ, Cheng WY, Trofa AF, Duchesneau ED, Macheca M, Masseria C, Duh MS.

**The cumulative prevalence and incidence of extra-hepatic manifestations in patients with hepatitis C virus infection: Real-world evidence from the United States.**

*Abstract:* International Liver Congress 2017 - 52nd Annual Meeting of the European Association for the Study of the Liver, Amsterdam, Netherlands Apr 19-23, 2017.

*Authors:* Reau N, Vekeman F, Wu E, Bao C, Gonzalez YS.

**Daclatasvir +asunaprevir versus sofosbuvir/ledipasvir for the treatment of chronic hepatitis c genotype 1 in Japanese patients: A matching-adjusted indirect comparison.**

*Abstract:* 18th European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Milan, Italy Nov 7-11, 2015.

*Authors:* Swallow E, Kelley C, Ristovska L, Signorovitch JE, McPhee F, Wygant G.

**Characteristics of patients hospitalized for acute bacterial skin and skin structure infections (ABSSSI) from 2009 to 2013.**

*Abstract:* ID Week 2016, New Orleans, LA Oct 26-30, 2016.

*Authors:* McGinnis E, Cammarata S, Tan RD, Barrett M, Tuttle E.

**Characteristics of treatment-experienced HIV-1-infected patients switching from multi-tablet to single-tablet regimens in the veterans affairs health care system.**

Oct 28, 2016.

*Authors:* Dersarkissian M, Schulman K, Zelt S, D'Amico R, Bhak R, Hellstern M, Altomare A, Ercolano E, Duh MS, Young-Xu Y.

**Comparative hepatotoxicity of echinocandins in hospitalized patients (pts): A retrospective cohort study.**

*Abstract:* 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland Aug 25-28, 2016.

*Authors:* Vekeman F, Weiss LS, Aram J, Ionescu-Iltu R, Moosavi S, Xiao Y, Cheng WY, Bhak R, Tawadrous M, Duh MS.

**Same-day HIV testing and antiretroviral therapy initiation results in higher rates of treatment initiation and retention in care.**

*Abstract:* 21st International AIDS Conference, Durban, South Africa Jul 18-22, 2016.

*Authors:* Koenig S, Dorvil N, Severe P, Riviere C, Faustin M, Perodin C, Paul C, Apollon A, Saintil G, Duverger L, Dumont E, Hedt-Gauthier B, Hennessey K, Rivera V, Devieux J, Pape JW.

**Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.**

*Abstract:* European Association for the Study of the Liver, 50th International Liver Congress, Vienna, Austria Apr 22-26, 2015.

*Authors:* Fontana RJ, Brown RS, Jr., Moreno-Zamora A, Prieto M, Joshi S, Londono MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, Lionetti R, Bahirwani R, Weiland O, Mubarak A, ElSharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, Ionescu-Iltu R, Emond B, Reddy KR.

**High rate of linkage to care and antiretroviral therapy initiation in Haiti and improvements over time.**

*Abstract:* Congress of the HIV and Hepatitis in the Americas 2016.

*Authors:* Dorvil N, Hennessey K, Guiteau C, Rivera V, Devieux J, McNairy M, Severe P, Marcelin A, Julma P, Attwood S, Koenig S, Pape JW.

**Indirect comparison of daclatasvir+asunaprevir vs sofosbuvir/ledipasvir for HCV in Japanese patients.**

*Abstract:* 25th APASL Conference, Tokyo, Japan Feb 20-24, 2016.

*Authors:* Swallow E, Kelley C, Signorovitch J, McPhee F, Wygant G.

**Predictors of CD4 count recovery in the CIPRA HT-001 trial of early ART.**

*Abstract:* 23rd Conference on Retroviruses and Opportunistic Infections, Boston, MA Feb 22 - 25, 2016.

*Authors:* Collins SE, Calnan M, Juste MAJ, Severe P, Secours R, Bernard D, Batavia A, Fitzgerald DW, Koenig SP, Pape JW.

**Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin in patients with chronic hepatitis C coinfecting with HIV: A matching-adjusted indirect comparison.**

*Abstract:* 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015, San Francisco, CA Nov 13-17, 2015.

*Authors:* Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Noviello S, Signorovitch J.

**Association of Obesity with 30-day readmission rates among patients Hospitalized with Acute Bacterial Skin and Skin-Structure Infections (ABSSI).**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Ayyagari R, Revol C, Tang W, Faust E, Tuttle EG.

**Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Tandon N, Laliberté F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

**Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for hepatitis C genotype 3: A matching-adjusted indirect comparison.**

*Abstract:* 50th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress, Vienna, Austria Apr 22-26, 2015.

*Authors:* Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Noviello S, Signorovitch J.

**Daclatasvir (DCV) combined with sofosbuvir (SOF) or simeprevir (SMV) in liver transplant (LT) recipients with severe recurrent HCV genotype 1 infection.**

*Abstract:* 50th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress, Vienna, Austria Apr 22-26, 2015.

*Authors:* Fontana RJ, Brown Jr R, Herzer J, Stauber K, Moreno-Zamora RE, Londono A, Prieto MC, Castells M, Chacko L, Ferenci K, Jafri P, Knop SM, Bahirwani V, Durand R, Lionetti C, Loiacono R, Berg L, Joshi C, Montalbano S, Mubarak M, Pellicelli A, Elsharkawy A, Stenmark A, Torti S, Vekeman C, Ionescu-Ittu F, Edmond R, Reddy B.

**A descriptive analysis of a real-world population with chronic hepatitis C (CHC) treated with simeprevir (SMV)- and/or sofosbuvir (SOF)-based regimens: findings from a U.S. payer database.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA Apr 22-26, 2015.

*Authors:* Forlenza J, Fortier J, Laliberté F, Lefebvre P, Tandon N.

**Comparative efficacy and tolerability of combination treatment with daclatasvir and asunaprevir versus peginterferon alpha ribavirin based regimens for patients infected with genotype 1B hepatitis C virus.**

*Abstract:* 24th Annual Conference of the Asian Pacific Association for the Study of the Liver, Istanbul, Turkey Mar 12-15, 2015.

*Authors:* Signorovitch J, Betts K, Song Y, Sorg R, Li J, Behl A, Kalsekar A.

**Economic consequences of cytomegalovirus disease among stem cell transplant recipients.**

*Abstract:* 2015 BMT Tandem Meetings, San Diego, CA Feb 11-15, 2015.

*Authors:* Macalalad AR, Yang H, Zhou A, Wu EQ, Chaudhari P, Snyderman DR.

**Demographics and clinical characteristics associated with high healthcare resource utilization (hru) and costs among chronic hepatitis c (chc) patients.**

*Abstract:* American Association for the Study of Liver Diseases Annual Meeting, Boston, MA Nov 7-11, 2014.

*Authors:* LaMori J, Tandon N, Laliberte F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

**The pharmacoconomics review of 7-valent pneumococcal conjugate vaccination in Asian-pacific region.**

*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8-12, 2014.

*Authors:* Zhu L.

**Cost burden of cytomegalovirus (CMV) disease among solid organ transplant recipients.**

*Abstract:* 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC Sep 5-9, 2014.

*Authors:* Yang H, Zhuo D, Zhou Z, Wu EQ, Chaudhari P, Snyderman DR.

**Demographics, Comorbidities, Clinical Characteristics, and Post-treatment Outcomes for Treated Patients with Chronic Hepatitis C (CHC): A Descriptive Analysis of Real-world U.S. Commercially-insured and Medicare Populations.**

*Abstract:* AASLD/EASL Special Conference on Hepatitis C, New York, NY Sep 12-13, 2014.

*Authors:* Forlenza JB, Fortier J, Laliberté F, Lefebvre P, Tandon N.

**Contraindications for HCV therapy in U.S. patients with untreated chronic hepatitis C.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ.

**Contraindications for HCV therapy in United States patients with untreated chronic hepatitis C (CHC).**

*Abstract:* ISPOR 2014, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ.

**Cost-effectiveness of single versus multiple tablet regimens for treatment of HIV-1 infection.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Sweet DE, Zhuo DY, Macalalad AR, Signorovitch J.

**Impact of chronic hepatitis C (CHC) treatment on post therapy healthcare cost.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.



**Real-world persistence with single versus multiple tablet regimens for HIV-1 treatment.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Sweet DE, Kim Y, Song J, Zhong Y, Signorovitch J.

**Treatment patterns, health care resource utilization and costs in united states patients diagnosed with chronic hepatitis C infection.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Arunajadai SG, Wei J, Wu EQ.

**Impact chronic hepatitis C (CHC) treatment on post therapy healthcare cost.**

*Abstract:* HEP DART frontiers in drug development for viral hepatitis 2013, Big Island, Hawaii Dec 8-12, 2013.

*Authors:* Tandon N, Balart L, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

**The epidemiology of herpes zoster (HZ) and its complications in Medicare cancer patients.**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Yenikomshian MA, La Casce AS, AT. S, Trahey A, Guignard A, Haguinet FF, Karner PE, Duh MS.

**Budget impact analysis of liposomal amphotericin b and amphotericin b lipid complex for treating invasive fungal infections in hospitalized patients.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Chaudhari P, Yang H, Zhou ZY, Patel C, Wu EQ.

**Direct and indirect cost burden of chronic hepatitis c infection in privately-insured patients, stratified by liver disease severity.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Tandon N, Reddy KR, Lefebvre P, Parise H, Laliberte F, Pilon D, Duh MS, Prabhakar A, Cho M, Balart LA, Fastenau J.

**Direct and indirect cost burden of chronic hepatitis C stratified by liver disease severity in privately insured patients.**

*Abstract:* Digestive Disease Week, Orlando, FL May 18-21, 2013.

*Authors:* Tandon N, Reddy KR, Lefebvre P, Parisé H, Laliberté F, Pilon D, Duh MS, Prabhakar A, Cho M, Balart LA, Fastenau J.

**Matching-adjusted indirect comparison of lipid profile at 48 weeks among treatment naive HIV-1 patients treated with atazanavir/ritonavir versus darunavir/ritonavir.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Xie J, Juday TR, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.

**Direct and indirect cost burden is higher in HCV infection compared with a matched nonHCV infected cohort in a privately-insured population.**

*Abstract:* 48th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress, Amsterdam, Netherlands Apr 24-28, 2013.

*Authors:* Tandon N, Reddy KR, Lefebvre P, Parise H, Laliberte F, Pilon D, Duh MS, Prabhakar A, Cho M, Balart LA, Fastenau J.

**Comparative efficacy at 48 weeks of atazanavir/ritonavir versus darunavir/ritonavir in treatment naive HIV-1 patients: A matching adjusted indirect comparison of randomized trials.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Xie J, Juday T, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.

**Current trends in utilization and dosage patterns of micafungin and caspofungin in the United States.**

*Abstract:* American Society for Microbiology Conference on Candida and Candidiasis, San Francisco, CA Mar 29 - Apr 2, 2012.

*Authors:* Wu EQ, Chaudhari P, Sharma H, Macalalad AR, Horn D.

**Prevalence of pseudomonas aeruginosa infection and antibiotic resistance by age group in the CFF patient registry in 2003 and 2008.**

*Abstract:* 25th Annual North American Cystic Fibrosis Conference, Anaheim, CA Nov 3-5, 2011.

*Authors:* Latremouille-Viau D, Zhang J, DeBonnett L, Signorovitch J, Von Wartbu M, Wu EQ, Shi L.

**Rates and Predictors of Chlamydia re-Screening among Privately insured Patients with Chlamydia in 2007-2009.**

*Abstract:* ISPOR 2011, Madrid, Spain Nov 5-8, 2011.

*Authors:* Shi L, Liu J, Kissinger P, Khan M, Wu E.

**Rates and predictors of gonorrhea re-screening among privately insured patients with gonorrhea in 2007-2009.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Shi L, Liu J, Kissinger P, Khan M, Wu EQ.

## Neurology

### Journal Articles

**Patient journey before and after a formal post-traumatic stress disorder diagnosis in adults in the United States - a retrospective claims study.**

*Publication:* Curr Med Res Opin 2023 10: 1-14. e-pub ahead of print 2023/10/11; doi: 10.1080/03007995.2023.2269839.

*Authors:* Davis LL, Urganus A, Gagnon-Sanschagrín P, Maitland J, Qu W, Cloutier M, Guérin A, Aggarwal J.

**Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs.**

*Publication:* J Med Econ 2023 09: 1-14. e-pub ahead of print 2023/09/04; doi: 10.1080/13696998.2023.2255074.

*Authors:* Jesudian AB, Gagnon-Sanschagrín P, Heimanson Z, Bungay R, Chen J, Guérin A, Bumpass B, Borroto D, Joseph G, Dashputre AA.

**Patient and Caregiver Outcomes After Onasemnogene Apeparvovec Treatment: Findings from the Cure SMA 2021 Membership Survey.**

*Publication:* Adv Ther 2023 09. e-pub ahead of print 2023/10/01; doi: 10.1007/s12325-023-02685-w.

*Authors:* Toro W, Yang M, Georgieva M, Anderson A, LaMarca N, Patel A, Akbarnejad H, Dabbous O.

**Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.**

*Publication:* Adv Ther 2023 08. e-pub ahead of print 2023/08/17; doi: 10.1007/s12325-023-02621-y.

*Authors:* Toro W, Yang M, Georgieva M, Song W, Patel A, Jiang AX, Zhao A, LaMarca N, Dabbous O.

**Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA.**

*Publication:* J Comp Eff Res 2023 08: e230086. e-pub ahead of print 2023/08/23; doi: 10.57264/ceor-2023-0086.

*Authors:* Iff J, Zhong Y, Tuttle E, Gupta D, Paul X, Erik H.

**Treatment Patterns and Healthcare Resource Use in Medicare Beneficiaries with Parkinson's Disease.**

*Publication:* Clinicoecon Outcomes Res 2023 08; 15: 631-643. e-pub ahead of print 2023/08/08; doi: 10.2147/ceor.S422023.

*Authors:* Song Y, E JY, Guo T, Sasane R, Arcona S, Keshava N, Wu E.

**Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance.**

*Publication:* Curr Med Res Opin 2023 07: 1-12. e-pub ahead of print 2023/07/26; doi: 10.1080/03007995.2023.2239045.

*Authors:* Teeple A, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Joshi K.

**Continuity of care among patients newly initiated on second-generation oral or long-acting injectable antipsychotics during a schizophrenia-related inpatient stay.**

*Publication:* Curr Med Res Opin 2023 07: 1-16. e-pub ahead of print 2023/07/18; doi: 10.1080/03007995.2023.2237833.

*Authors:* Patel C, Pilon D, Morrison L, Holiday C, Lafeuille MH, Lefebvre P, Benson C.

**Treatment Patterns and Healthcare Resource Use in Medicare Beneficiaries with Parkinson's Disease.**

*Publication:* ClinicoEconomics and Outcomes Research 2023 07. doi: <https://doi.org/10.2147/CEOR.S422023>.

*Authors:* Song Y, E JY, Guo T, Sasane R, Arcona S, Keshava N, Wu E.

**Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.**

*Publication:* J Med Econ 2023 05: 1-14. e-pub ahead of print 2023/05/02; doi: 10.1080/13696998.2023.2208993.

*Authors:* Zhdanava M, Teeple A, Pilon D, Shah A, Caron-Lapointe G, Joshi K.

**Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group.**

*Publication:* Patient Relat Outcome Meas 2023 05; 14: 153-169. e-pub ahead of print 2023/05/25; doi: 10.2147/prom.S399658.

*Authors:* Rizio AA, White MK, D'Souza A, Hsu K, Schmitt P, Quock TP, Signorovitch J, Lousada I, Sanchorawala V.

**Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.**

*Publication:* Expert Opinion on Pharmacotherapy 2023 05: 1-10. doi: 10.1080/14656566.2023.2215925.

*Authors:* Merkel M, Danese D, Chen C, Wang J, Wu A, Yang H, Lin H.

**Epidemiology and patient journey of Rett syndrome in the United States: a real-world evidence study.**

*Publication:* BMC Neurol 2023 04; 23(1): 141. e-pub ahead of print 2023/04/05; doi: 10.1186/s12883-023-03181-y.

*Authors:* May D, Kponee-Shovein K, Mahendran M, Downes N, Sheng K, Lefebvre P, Cheng WY.

**Impact of Tardive Dyskinesia on Physical, Psychological, Social, and Professional Domains of Patient Lives: A Survey of Patients in the United States.**

*Publication:* J Clin Psychiatry 2023 04; 84(3). e-pub ahead of print 2023/04/07; doi: 10.4088/JCP.22m14694.

*Authors:* Jain R, Ayyagari R, Goldschmidt D, Zhou M, Finkbeiner S, Leo S.

**Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in the United States.**

*Publication:* Neurol Ther 2023 03. e-pub ahead of print 2023/04/01; doi: 10.1007/s40120-023-00463-y.

*Authors:* Kantor D, Pham T, Patterson-Lomba O, Swallow E, Dua A, Gupte-Singh K.

**Treatment Patterns Among Patients with Attention-Deficit/Hyperactivity Disorder and Comorbid Anxiety and/or Depression in the United States: A Retrospective Claims Analysis.**

*Publication:* Adv Ther 2023 03. e-pub ahead of print 2023/03/14; doi: 10.1007/s12325-023-02458-5.

*Authors:* Schein J, Childress A, Gagnon-Sanschagrin P, Maitland J, Bedard J, Cloutier M, Guérin A.

**Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on Esketamine intranasal spray and covered by US commercial health plans.**

*Publication:* J Med Econ 2023 03: 1-24. e-pub ahead of print 2023/03/17; doi: 10.1080/13696998.2023.2188845.

*Authors:* Joshi K, Pilon D, Shah A, Holiday C, Karkare S, Zhdanava M.

**Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison.**

*Publication:* Mult Scler Relat Disord 2023 02; 71: 104551. e-pub ahead of print 2023/02/16; doi: 10.1016/j.msard.2023.104551.

*Authors:* Swallow E, Pham T, Patterson-Lomba O, Yin L, Gomez-Lievano A, Liu J, Tencer T, Gupte-Singh K.

**Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies.**

*Publication:* Schizophrenia (Heidelb) 2023 02; 9(1): 9. e-pub ahead of print 2023/02/12; doi: 10.1038/s41537-023-00334-3.

*Authors:* Correll CU, Benson C, Emond B, Patel C, Lafeuille MH, Lin D, Morrison L, Ghelerter I, Lefebvre P, Mavros P.

**Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.**

*Publication:* J Comp Eff Res 2023 02: e220190. e-pub ahead of print 2023/02/08; doi: 10.57264/ceer-2022-0190.

*Authors:* McDonald CM, Marden JR, Shieh PB, Wong BL, Lane H, Zhang A, Nguyen H, Frean M, Trifillis P, Koladicz K, Signorovitch J.

**DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials.**

*Publication:* Neurology 2023 02. e-pub ahead of print 2023/02/02; doi: 10.1212/wnl.0000000000201626.

*Authors:* Muntoni F, Signorovitch J, Sajeev G, Lane H, Jenkins M, Dieye I, Ward SJ, McDonald C, Goemans N, Niks EH, Wong B, Servais L, Straub V, Guglieri M, de Groot IJM, Chesshyre M, Tian C, Manzur AY, Mercuri E, Aartsma-Rus A.

**Longitudinal Assessment of Creatine Kinase, Creatine/Creatinine(ratio), and Myostatin as Monitoring Biomarkers in Becker Muscular Dystrophy.**

*Publication:* Neurology 2023 02; 100(9): e975-e984. e-pub ahead of print 2023/02/28; doi: 10.1212/wnl.0000000000201609.

*Authors:* van de Velde NM, Koeks Z, Signorelli M, Verwey N, Overzier M, Bakker JA, Sajeev G, Signorovitch J, Ricotti V, Verschuuren J, Brown K, Spitali P, Niks EH.

**Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson's disease: Post-hoc analyses from a large 54-week trial.**

*Publication:* Clin Park Relat Disord 2023 01; 8: 100181. doi: <https://doi.org/10.1016/j.prdoa.2022.100181>.

*Authors:* Pahwa R, Aldred J, Merola A, Gupta N, Terasawa E, Garcia-Horton V, Steffen DR, Kandukuri PL, Bao Y, Ladhani O, Yan CH, Chaudhari V, Isaacson SH.

**The Economic Burden of Adults with Major Depressive Disorder in the United States (2019).**

*Publication:* Adv Ther 2023. e-pub ahead of print 2023/07/31; doi: 10.1007/s12325-023-02622-x.

*Authors:* Greenberg P, Chitnis A, Louie D, Suthoff E, Chen SY, Maitland J, Gagnon-Sanschagrin P, Fournier AA, Kessler RC.

**Functional and Clinical Outcomes Associated with Steroid Treatment among Non-ambulatory Patients with Duchenne Muscular Dystrophy1.**

*Publication:* J Neuromuscul Dis 2022 12. e-pub ahead of print 2022/12/25; doi: 10.3233/jnd-221575.

*Authors:* McDonald CM, Mayer OH, Hor KN, Miller D, Goemans N, Henricson EK, Marden JR, Freimark J, Lane H, Zhang A, Frean M, Trifillis P, Koladicz K, Signorovitch J.

**Disease Progression and Longitudinal Clinical Outcomes of Lewy Body Dementia in the NACC Database.**

*Publication:* Neurol Ther 2022 11. e-pub ahead of print 2022/11/16; doi: 10.1007/s40120-022-00417-w.

*Authors:* Chandler J, Georgieva M, Desai U, Kirson N, Lane H, Cheung HC, Westermeyer B, Biglan K.

**Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate.**

*Publication:* J Manag Care Spec Pharm 2022 11: 1-11. e-pub ahead of print 2022/11/11; doi: 10.18553/jmcp.2022.22215.

*Authors:* Morrison L, Lin D, Benson C, Ghelerter I, Vermette-Laforme M, Lefebvre P, Pilon D.

**Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine.**

*Publication:* Curr Med Res Opin 2022 10: 1-14. e-pub ahead of print 2022/10/04; doi: 10.1080/03007995.2022.2131299.

*Authors:* Mahon R, Vo P, Pannagl K, Tiwari S, Heemstra H, Ferraris M, Zhao J, Betts KA, Proot P.

**Characteristics of Real-World Commercially Insured Patients With Treatment-Resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.**

*Publication:* Clin Ther 2022 10. e-pub ahead of print 2022/10/08; doi: 10.1016/j.clinthera.2022.09.005.

*Authors:* Karkare S, Zhdanova M, Pilon D, Nash AI, Morrison L, Shah A, Lefebvre P, Joshi K.

**The Economic Burden of Schizophrenia in the United States.**

*Publication:* J Clin Psychiatry 2022 10; 83(6). e-pub ahead of print 2022/10/17; doi: 10.4088/JCP.22m14458.

*Authors:* Kadakia A, Catillon M, Fan Q, Williams GR, Marden JR, Anderson A, Kirson N, Dembek C.

**Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Chart Review Study.**

*Publication:* Adv Ther 2022 10. e-pub ahead of print 2022/10/12; doi: 10.1007/s12325-022-02329-5.

*Authors:* Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Guerin A, Childress A.

**Identifying individuals with undiagnosed post-traumatic stress disorder in a large United States civilian population - a machine learning approach.**

*Publication:* BMC Psychiatry 2022 09; 22(1): 630. e-pub ahead of print 2022/09/29; doi: 10.1186/s12888-022-04267-6.

*Authors:* Gagnon-Sanschagrin P, Schein J, Urganus A, Serra E, Liang Y, Musingarimi P, Cloutier M, Guérin A, Davis LL.

**Symptoms associated with ADHD/treatment-related adverse side effects and their impact on quality of life and work productivity in adults with ADHD.**

*Publication:* Curr Med Res Opin 2022 09: 1-11. e-pub ahead of print 2022/09/10; doi: 10.1080/03007995.2022.2122228.

*Authors:* Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Guerin A, Childress A.

**The real-world health resource use and costs of misdiagnosing bipolar I disorder.**

*Publication:* J Affect Disord 2022 08; 316: 26-33. e-pub ahead of print 2022/08/12; doi: 10.1016/j.jad.2022.07.069.

*Authors:* McIntyre RS, Laliberté F, Germain G, MacKnight SD, Gillard P, Harrington A.

**Treatment patterns among children and adolescents with attention-deficit/hyperactivity disorder in the United States - a retrospective claims analysis.**

*Publication:* BMC Psychiatry 2022 08; 22(1): 555. e-pub ahead of print 2022/08/19; doi: 10.1186/s12888-022-04188-4.

*Authors:* Schein J, Childress A, Adams J, Gagnon-Sanschagrin P, Maitland J, Qu W, Cloutier M, Guérin A.

**Long-Term Treatment Effects of Inotersen on Health-Related Quality of Life in Patients with hATTR Amyloidosis with Polyneuropathy: Analysis of the Open-Label Extension of the NEURO-TTR Trial.**

*Publication:* Muscle Nerve 2022 07. e-pub ahead of print 2022/07/09; doi: 10.1002/mus.27675.

*Authors:* Karam C, Brown D, Yang M, Done N, Zhu JJ, Greatsinger A, Bozas A, Vera-Llonch M, Signorovitch J.

**Burden Among Caregivers of Pediatric Patients with Neurofibromatosis Type 1 (NF1) and Plexiform Neurofibroma (PN) in the United States: A Cross-Sectional Study.**

*Publication:* Neurol Ther 2022 06. e-pub ahead of print 2022/06/10; doi: 10.1007/s40120-022-00365-5.

*Authors:* Yang X, Yoo HK, Amin S, Cheng WY, Sundaresan S, Zhang L, Duh MS.

**Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy.**

*Publication:* Muscle Nerve 2022 06. e-pub ahead of print 2022/06/19; doi: 10.1002/mus.27662.

*Authors:* Iff J, Gerrits C, Zhong Y, Tuttle E, Birk E, Zheng Y, Paul X, Henricson EK, McDonald CM.

**Disease Progression Stages and Burden in Patients with Duchenne Muscular Dystrophy Using Administrative Claims Supplemented by Electronic Medical Records.**

*Publication:* Adv Ther 2022 06; 39(6): 2906-2919. e-pub ahead of print 2022/04/24; doi: 10.1007/s12325-022-02117-1.

*Authors:* Iff J, Zhong Y, Gupta D, Paul X, Tuttle E, Henricson E, Schrader R.

**Reasons for treatment changes in adults with attention-deficit/hyperactivity disorder: a chart review study.**

*Publication:* BMC Psychiatry 2022 06; 22(1): 377. e-pub ahead of print 2022/06/07; doi: 10.1186/s12888-022-04016-9.

*Authors:* Schein J, Childress A, Cloutier M, Desai U, Chin A, Simes M, Guerin A, Adams J.

**Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA.**

*Publication:* Childs Nerv Syst 2022 05. e-pub ahead of print 2022/05/18; doi: 10.1007/s00381-022-05513-8.

*Authors:* Yang X, Yoo HK, Amin S, Cheng WY, Sundaresan S, Zhang L, Duh MS.

**Excess healthcare resource utilization and healthcare costs among privately and publicly insured patients with major depressive disorder and acute suicidal ideation or behavior in the United States.**

*Publication:* J Affect Disord 2022 05. e-pub ahead of print 2022/05/22; doi: 10.1016/j.jad.2022.05.086.

*Authors:* Zhdanava M, Voelker J, Pilon D, Joshi K, Morrison L, Sheehan JJ, Vermette-Laforme M, Lefebvre P, Citrome L.

**National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States.**

*Publication:* J Med Econ 2022 05; 1-40. e-pub ahead of print 2022/06/01; doi: 10.1080/13696998.2022.2084234.

*Authors:* Patel C, Pilon D, Gupta D, Morrison L, Lafeuille MH, Lefebvre P, Benson C.

**Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.**

*Publication:* J Headache Pain 2022 05; 23(1): 56. e-pub ahead of print 2022/05/17; doi: 10.1186/s10194-022-01415-x.

*Authors:* Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R.

**Economic Burden of Commercially Insured Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United States.**

*Publication:* J Clin Psychiatry 2022 04; 83(3). e-pub ahead of print 2022/04/08; doi: 10.4088/JCP.21m14090.

*Authors:* Pilon D, Neslusan C, Zhdanava M, Sheehan JJ, Joshi K, Morrison L, Rossi C, Lefebvre P, Greenberg PE.

**The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal Perspective.**

*Publication:* J Clin Psychiatry 2022 04; 83(3). e-pub ahead of print 2022/04/30; doi: 10.4088/JCP.21m14116.

*Authors:* Davis LL, Schein J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Urganus A, Guerin A, Lefebvre P, Houle CR.

**Epidemiology and economic burden of Lewy body dementia in the United States.**

*Publication:* Curr Med Res Opin 2022 04; 1-12. e-pub ahead of print 2022/04/21; doi:

10.1080/03007995.2022.2059978.

*Authors:* Desai U, Chandler J, Kirson N, Georgieva M, Cheung HC, Westermeyer B, Lane H, Biglan K.

**Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study.**

*Publication:* J Headache Pain 2022 04; 23(1): 47. e-pub ahead of print 2022/04/13; doi: 10.1186/s10194-022-01411-1.

*Authors:* Driessen MT, Cohen JM, Patterson-Lomba O, Thompson SF, Seminerio M, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R.

**Systematic Literature Review of Clinical and Economic Evidence for Spinal Muscular Atrophy.**

*Publication:* Adv Ther 2022 03. doi: 10.1007/s12325-022-02089-2.

*Authors:* Yang M, Awano H, Tanaka S, Toro W, Zhang S, Dabbous O, Igarashi A.

**Defining Utility Values for Chorea Health States in Patients with Huntington's Disease.**

*Publication:* Adv Ther 2022 02. e-pub ahead of print 2022/02/24; doi: 10.1007/s12325-022-02046-z.

*Authors:* Claassen DO, Ayyagari R, Goldschmidt D, Zhou M, Leo S, Ribalov R.

**Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson's Disease: Clinical Trial Post Hoc Analyses.**

*Publication:* Neurol Ther 2022 02. doi: 10.1007/s40120-022-00332-0.

*Authors:* Pahwa R, Aldred J, Gupta N, Terasawa E, Garcia-Horton V, Steffen DR, Kandukuri PL, Chaudhari VS, Jalundhwala YJ, Bao Y, Kukreja P, Isaacson SH.

**Defining utility values for patients with tardive dyskinesia.**

*Publication:* Curr Med Res Opin 2022 01: 1-7. e-pub ahead of print 2022/01/21; doi: 10.1080/03007995.2021.2022918.

*Authors:* Ayyagari R, Goldschmidt D, Zhou M, Ribalov R, Caroff SN, Leo S.

**Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspective.**

*Publication:* J Med Econ 2022 01: 1-48. e-pub ahead of print 2022/01/25; doi: 10.1080/13696998.2022.2032097.

*Authors:* Schein J, Adler LA, Childress A, Cloutier M, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Guerin A, Lefebvre P.

**Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes.**

*Publication:* J Comp Eff Res 2022 01. e-pub ahead of print 2022/01/25; doi: 10.2217/ce-2021-0178.

*Authors:* Thach A, Zichlin ML, Kirson N, Yang K, Gaburo K, Pappert E, Mehta D, Williams GR.

**Real-World Adherence to Tetrabenazine or Deutetrabenazine Among Patients With Huntington's Disease: A Retrospective Database Analysis.**

*Publication:* Neurol Ther 2021 12. e-pub ahead of print 2021/12/15; doi: 10.1007/s40120-021-00309-5.

*Authors:* Claassen DO, Ayyagari R, Garcia-Horton V, Zhang S, Alexander J, Leo S.

**Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective.**

*Publication:* J Manag Care Spec Pharm 2021 11: 1-12. e-pub ahead of print 2021/11/23; doi:

10.18553/jmcp.2021.21290.

*Authors:* Schein J, Adler LA, Childress A, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Cloutier M, Guérin A, Lefebvre P.

**Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy.**

*Publication:* J Med Econ 2021 11: 1-31. e-pub ahead of print 2021/11/13; doi: 10.1080/13696998.2021.2003673.

*Authors:* Pilon D, Karkare S, Zhdanova M, Sheehan JJ, Côté-Sergent A, Shah A, Lopena OJ, Lefebvre P, Joshi K, Citrome L.

**Mental Health and Health-Related Quality of Life Among Nephrology Nurses: A Survey-Based Cross-Sectional Study.**

*Publication:* Nephrol Nurs J 2021 10; 48(5): 447-461. e-pub ahead of print 2021/11/11.

*Authors:* Montoya V, Donnini K, Gauthier-Loiselle M, Sanon M, Cloutier M, Maitland J, Guérin A, Dutka P, Pryor L, Thomas-Hawkins C, Voegel A, Hoffmann M, Savin S, Kurzman A, Kear T.

**Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.**

*Publication:* Adv Ther 2021 10: 1-20. e-pub ahead of print 2021/10/30; doi: 10.1007/s12325-021-01938-w.

*Authors:* Gauthier-Loiselle M, Cloutier M, Toro W, Patel A, Shi S, Davidson M, Bischof M, LaMarca N, Dabbous O.

**The Impact of Antipsychotic Dose Reduction on Clinical Outcomes and Health Care Resource Use Among Medicare Patients with Schizophrenia.**

*Publication:* Clin Drug Investig 2021 09. e-pub ahead of print 2021/09/05; doi: 10.1007/s40261-021-01060-3.

*Authors:* Zichlin ML, Mu F, Leo S, Ayyagari R.

**Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression.**

*Publication:* Adv Ther 2021 09; 38(9): 4900-4916. e-pub ahead of print 2021/08/10; doi: 10.1007/s12325-021-01862-z.

*Authors:* Zhdanava M, Karkare S, Pilon D, Joshi K, Rossi C, Morrison L, Sheehan J, Lefebvre P, Lopena O, Citrome L.

**A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment.**

*Publication:* J Neuromuscul Dis 2021 08. e-pub ahead of print 2021/08/24; doi: 10.3233/jnd-210665.

*Authors:* Mitelman O, Abdel-Hamid HZ, Byrne BJ, Connolly AM, Heydemann P, Proud C, Shieh PB, Wagner KR, Dugar A, Santra S, Signorovitch J, Goemans N, McDonald CM, Mercuril E, Mendelld JR.

**Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries.**

*Publication:* Curr Med Res Opin 2021 08: 1-9. e-pub ahead of print 2021/07/21; doi: 10.1080/03007995.2021.1954894.

*Authors:* Pilon D, Patel C, Lafeuille MH, Zhdanava M, Lin D, Cote-Sergent A, Rossi C, Joshi K, Lefebvre P.

**Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims study.**

*Publication:* Curr Med Res Opin 2021 08: 1. e-pub ahead of print 2021/08/25; doi: 10.1080/03007995.2021.1968814.

*Authors:* Schein J, Childress A, Adams J, Cloutier M, Gagnon-Sanschagrín P, Maitland J, Bungay R, Guérin A, Lefebvre P.

**Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics.**

*Publication:* J Manag Care Spec Pharm 2021 07; 27(7): 904-914. e-pub ahead of print 2021/06/30; doi:

10.18553/jmcp.2021.27.7.904.

*Authors:* Pilon D, Patel C, Lafeuille MH, Zhdanava M, Lin D, Côté-Sergent A, Rossi C, Lefebvre P, Joshi K.

**Impact of agitation in long-term care residents with dementia in the United States.**

*Publication:* Int J Geriatr Psychiatry 2021 07. e-pub ahead of print 2021/07/22; doi: 10.1002/gps.5604.

*Authors:* Fillit H, Aigbogun MS, Gagnon-Sanschagrín P, Cloutier M, Davidson M, Serra E, Guérin A, Baker RA, Houle CR, Grossberg G.

**Prevalence of post-traumatic stress disorder in the United States: a systematic literature review.**

*Publication:* Current Medical Research and Opinion 2021 07: 1-11. doi: 10.1080/03007995.2021.1978417.

*Authors:* Schein J, Houle C, Urganus A, Cloutier M, Patterson-Lomba O, Wang Y, King S, Levinson W, Guérin A, Lefebvre P, Davis LL.



**Real-world migraine-related healthcare resource utilization and costs associated with improved vs. worsened/stable migraine: a panel-based chart review in France, Germany, Italy, and Spain.**

*Publication:* J Med Econ 2021 07; 24(1): 1900-1907. e-pub ahead of print 2021/07/28; doi: 10.1080/13696998.2021.1953301.

*Authors:* Vo P, Swallow E, Wu E, Zichlin ML, Katcher N, Maier-Peuschel M, Naclerio M, Ritrovato D, Tiwari S, Joshi P, Ferraris M.

**Steroid switching in dystrophinopathy treatment: a US chart review of patient characteristics and clinical outcomes.**

*Publication:* J Comp Eff Res 2021 07. e-pub ahead of print 2021/07/20; doi: 10.2217/ceer-2021-0110.

*Authors:* Marden JR, Santos C, Pfister B, Able R, Lane H, Somma M, Zhao J, Signorovitch J, Parsons J, Apkon S.

**The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018).**

*Publication:* PharmacoEconomics 2021 06; 39(6): 653-665. e-pub ahead of print 2021/05/06; doi: 10.1007/s40273-021-01019-4.

*Authors:* Greenberg PE, Fournier AA, Sisitsky T, Simes M, Berman R, Koenigsberg SH, Kessler RC.

**Introduction to the Special Issue of PharmacoEconomics on Major Depressive Disorders.**

*Publication:* PharmacoEconomics 2021 06; 39(6): 617. e-pub ahead of print 2021/05/14; doi: 10.1007/s40273-021-01041-6.

*Authors:* Greenberg PE, Sisitsky T.

**Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA.**

*Publication:* PharmacoEconomics 2021 05. e-pub ahead of print 2021/05/28; doi: 10.1007/s40273-021-01042-5.

*Authors:* Zhdanava M, Voelker J, Pilon D, Cornwall T, Morrison L, Vermette-Laforme M, Lefebvre P, Nash AI, Joshi K, Neslusan C.

**Disruption of Pharmacotherapy During the Transition from Adolescence to Early Adulthood in Patients with Attention-Deficit/Hyperactivity Disorder: A Claims Database Analysis Across the USA.**

*Publication:* CNS Drugs 2021 05; 35(5): 575-589. e-pub ahead of print 2021/04/16; doi: 10.1007/s40263-021-00808-x.

*Authors:* Farahbakhshian S, Ayyagari R, Barczak DS, Gill SK, Tang W, Kulalert T, Jenkins M, Spalding W.

**The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers.**

*Publication:* PharmacoEconomics 2021 05; 39(6): 619-625. doi: 10.1007/s40273-021-01040-7.

*Authors:* Proudman D, Greenberg P, Nellesen D.

**Health-related quality of life (HRQoL) among pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) in the United States (U.S.).**

*Publication:* Journal of Clinical Oncology 2021 05; 39(15\_suppl): 10042-10042. doi:

10.1200/JCO.2021.39.15\_suppl.10042.

*Authors:* Yang X, Yoo HK, Amin S, Cheng WY, Sipsma H, Sundaresan S, Zhang L, Duh MS.

**Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.**

*Publication:* CNS Drugs 2021 05; 35(5): 469-481. e-pub ahead of print 2021/04/29; doi: 10.1007/s40263-021-00815-y.

*Authors:* Lin D, Thompson-Leduc P, Ghelerter I, Nguyen H, Lafeuille MH, Benson C, Mavros P, Lefebvre P.

**Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis.**

*Publication:* Multiple Sclerosis Journal - Experimental, Translational and Clinical 2021 04; 7(2): 2055217321999070. doi: 10.1177/2055217321999070.

*Authors:* Healy BC, Glanz BI, Swallow E, Signorovitch J, Hagan K, Silva D, Pelletier C, Chitnis T, Weiner H.

**Real-world impact of antiepileptic drug combinations with versus without perampanel on healthcare resource utilization in patients with epilepsy in the United States.**

*Publication:* Epilepsy Behav 2021 04; 118: 107927. e-pub ahead of print 2021/04/04; doi: 10.1016/j.yebeh.2021.107927.

*Authors:* Laliberte F, Duh MS, Barghout V, Germain G, Frech F, Plauschinat C, Lejeune D, Malhotra M, Faught E.

**Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers.**

*Publication:* Neurol Ther 2021 04. doi: 10.1007/s40120-021-00245-4.

*Authors:* Faust E, Pivneva I, Yang K, Betts KA, Ahmed Z, Joshi S, Hogan R, Blumenfeld A, Schim J, Feoktistov A, Carnes K, Bensink M, Wu EQ, Chou DE, Chandler D.

**The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States.**

*Publication:* J Clin Psychiatry 2021 03; 82(2). e-pub ahead of print 2021/05/15; doi: 10.4088/JCP.20m13699.

*Authors:* Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, Sheehan JJ.

**Cost-Effectiveness of Apomorphine Sublingual Film as an "On-Demand" Treatment for "OFF" Episodes in Patients with Parkinson's Disease.**

*Publication:* J Health Econ Outcomes Res 2021 02; 8(2): 82-92. e-pub ahead of print 2022/02/19; doi: 10.36469/jheor.2021.29488.

*Authors:* Thach A, Kirson N, Zichlin ML, Dieye I, Pappert E, Williams GR.

**Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression.**

*Publication:* J Comp Eff Res 2021 02; 0(0): null. doi: 10.2217/cer-2020-0276.

*Authors:* Desai U, Kirson NY, Guglielmo A, Le HH, Spittle T, Tseng-Tham j, Shawi M, Sheehan JJ.

**Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder.**

*Publication:* Curr Med Res Opin 2021 01; 37(1): 123-133. e-pub ahead of print 2020/10/31; doi: 10.1080/03007995.2020.1844645.

*Authors:* Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C.

**Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis.**

*Publication:* Neurol Ther 2020 11. e-pub ahead of print 2020/11/11; doi: 10.1007/s40120-020-00219-y.

*Authors:* Rice JB, Panaccio MP, White A, Simes M, Billmyer E, Downes N, Niewoehner J, Wan GJ.

**Economic burden associated with tuberous sclerosis complex in patients with epilepsy.**

*Publication:* Epilepsy Behav 2020 11; 112: 107494. e-pub ahead of print 2020/11/14; doi: 10.1016/j.yebeh.2020.107494.

*Authors:* Betts KA, Stockl KM, Yin L, Hollenack K, Wang MJ, Yang X.

**Healthcare resource utilization and costs associated with postpartum depression among commercially insured households.**

*Publication:* Curr Med Res Opin 2020 10; 36(10): 1707-1716. e-pub ahead of print 2020/07/23; doi: 10.1080/03007995.2020.1799772.

*Authors:* Epperson CN, Huang MY, Cook K, Gupta D, Chawla A, Greenberg PE, Eldar-Lissai A.

**Disease severity at the time of initial cognitive assessment is related to prior health-care resource use burden.**

*Publication:* Alzheimers Dement (Amst) 2020 08; 12(1): e12093. e-pub ahead of print 2020/08/15; doi: 10.1002/dad2.12093.

*Authors:* Desai U, Kirson NY, Lu Y, Bruemmer V, Andrews JS.

**Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review.**

*Publication:* Journal of Alzheimer's Disease 2020 08; Preprint: 1-14. doi: 10.3233/JAD-200127.

*Authors:* Aigbogun MS, Cloutier M, Gauthier-Loiselle M, Guerin A, Ladouceur M, Baker RA, Grundman M, Duffy RA, Hartry A, Gwin K, Fillit H.

**Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesia.**

*Publication:* BMC Psychiatry 2020 07; 20(1): 365. doi: 10.1186/s12888-020-02748-0.

*Authors:* Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B.

**Suitability of external controls for drug evaluation in Duchenne muscular dystrophy.**

*Publication:* Neurology 2020 07. e-pub ahead of print 2020/07/03; doi: 10.1212/wnl.0000000000010170.

*Authors:* Goemans N, Signorovitch J, Sajeev G, Yao Z, Gordish-Dressman H, McDonald CM, Vandeborne K, Miller D, Ward SJ, Mercuri E.

**Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.**

*Publication:* J Manag Care Spec Pharm 2020 06; 0(0): 1-12. doi: 10.18553/jmcp.2020.20017.

*Authors:* Zhdanova M, Kuvadua H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C.

**Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration.**

*Publication:* PLoS One 2020 06; 15(6): e0232870. doi: 10.1371/journal.pone.0232870.

*Authors:* Goemans N, Wong B, Van den Hauwe M, Signorovitch J, Sajeev G, Cox D, Landry J, Jenkins M, Dieye I, Yao Z, Hossain I, Ward SJ, the Collaborative Trajectory Analysis P.

**115 An Experimental Study to Assess the Professional and Social Consequences of Mild-to-Moderate Tardive Dyskinesia.**

*Publication:* CNS Spectrums 2020 04; 25(2): 275-275. e-pub ahead of print 2020/04/24; doi: 10.1017/S1092852920000334.

*Authors:* Ayyagari R, Goldschmidt D, Mu F, Caroff SN, Carroll B.

**An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia.**

*Publication:* CNS Spectrums 2020 04; 25(2): 275-276. e-pub ahead of print 2020/04/26; doi: 10.1017/s1092852920000346.

*Authors:* Ayyagari R, Goldschmidt D, Mu F, Caroff SN, Carroll B.

**Suicidal ideation and attempts in the United States of America among stimulant-treated, non-stimulant-treated, and untreated patients with a diagnosis of attention-deficit/hyperactivity disorder.**

*Publication:* J Affect Disord 2020 04; 266: 109-119. doi: <https://doi.org/10.1016/j.jad.2020.01.075>.

*Authors:* Siffel C, DerSarkissian M, Kponee-Shovein K, Spalding W, Gu YM, Cheng M, Duh MS.

**Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders.**

*Publication:* J Med Econ 2020 02; 23(2): 204-212. e-pub ahead of print 2019/10/31; doi:

10.1080/13696998.2019.1685818.

*Authors:* Ayyagari R, Thomason D, Mu F, Philbin M, Carroll B.

**Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia.**

*Publication:* J Manag Care Spec Pharm 2020 02; 26(2): 176-185. e-pub ahead of print 2020/02/06; doi:

10.18553/jmcp.2020.26.2.176.

*Authors:* El Khoury AC, Pilon D, Morrison L, Shak N, Llana A, Kim E, Lefebvre P.

**Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study.**

*Publication:* Curr Med Res Opin 2020 02; 36(2): 261-270. e-pub ahead of print 2019/11/07; doi: 10.1080/03007995.2019.1690440.

*Authors:* Vieira MC, Conway D, Cox GM, Peeples M, Bensimon AG, Macheca M, Herrera V.

**Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.**

*Publication:* J Comp Eff Res 2020 01; 0(0): null. doi: 10.2217/cer-2019-0169.

*Authors:* Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, Sheffield JK, Stonehouse T, Signorovitch J.

**Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center.**

*Publication:* J Comp Eff Res 2020 01. e-pub ahead of print 2020/01/11; doi: 10.2217/cer-2019-0170.

*Authors:* Marden JR, Freimark J, Yao Z, Signorovitch J, Tian C, Wong BL.

**Use of home health and other healthcare delivery pathways among privately-insured patients with and without treatment-resistant depression.**

*Publication:* Current Medical Research and Opinion 2020 01: 1-1. doi: 10.1080/03007995.2020.1722081.

*Authors:* Pilon D, Szukis H, Singer D, Morrison L, Sheehan JJ, Lefebvre P.

**The long-term direct and indirect economic burden among Parkinson's disease caregivers in the United States.**

*Publication:* Mov Disord 2019 12; 34(2): 236-245. e-pub ahead of print 2018/12/28; doi: 10.1002/mds.27579.

*Authors:* Martinez-Martin P, Macaulay D, Jalundhwala YJ, Mu F, Ohashi E, Marshall T, Sail K.

**Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans.**

*Publication:* Current Medical Research and Opinion. 2019 12. doi: <http://dx.doi.org/10.1080/03007995.2018.1560220>.

*Authors:* Emond B, El Khoury AC, Patel C, Pilon D, Morrison L, Zhdanova M, Lefebvre P, Tandon N, Joshi K.

**Temporal and Geographic Variation in the Incidence of Alzheimer's Disease Diagnosis in the US between 2007 and 2014.**

*Publication:* J Am Geriatr Soc 2019 12. e-pub ahead of print 2019/12/05; doi: 10.1111/jgs.16262.

*Authors:* Kirson NY, Meadows ES, Desai U, Smith BP, Cheung HC, Zuckerman P, Matthews BR.

**Trends in health service use and potentially avoidable hospitalizations before Alzheimer's disease diagnosis: A matched, retrospective study of US Medicare beneficiaries.**

*Publication:* Alzheimers Dement (Amst) 2019 12; 11: 125-135. e-pub ahead of print 2019/02/23; doi: 10.1016/j.dadm.2018.12.005.

*Authors:* Desai U, Kirson NY, Ye W, Mehta NR, Wen J, Andrews JS.

**Institutionalization risk and costs associated with agitation in Alzheimer's disease.**

*Publication:* Alzheimer's & Dementia: Translational Research & Clinical Interventions 2019 11; 5: 851-861. doi: <https://doi.org/10.1016/j.trci.2019.10.004>.

*Authors:* Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Hartry A, Baker RA, Duffy R, Gwin K, Sanon Aigbogun M.

**Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate.**

*Publication:* Drugs Real World Outcomes 2019 11. e-pub ahead of print 2019/12/02; doi: 10.1007/s40801-019-00172-9.

*Authors:* Patel C, Emond B, Lafeuille MH, Cote-Sergent A, Lefebvre P, Tandon N, El Khoury AC.

**Are Medicaid Coverage Gaps Associated with Higher Health Care Resource Utilization and Costs in Patients with Schizophrenia?**

*Publication:* Popul Health Manag 2019 10. e-pub ahead of print 2019/10/09; doi: 10.1089/pop.2019.0147.

*Authors:* Pilon D, El Khoury AC, Manceur AM, Zhdanava M, Benson C, Lefebvre P, Doshi JA.

**Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.**

*Publication:* PLoS One 2019 10; 14(10): e0223255. e-pub ahead of print 2019/10/11; doi:

10.1371/journal.pone.0223255.

*Authors:* Pilon D, Joshi K, Sheehan JJ, Zichlin ML, Zuckerman P, Lefebvre P, Greenberg PE.

**Deflazacort versus prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials.**

*Publication:* Muscle Nerve 2019 10. e-pub ahead of print 2019/10/11; doi: 10.1002/mus.26736.

*Authors:* McDonald CM, Sajeev G, Yao Z, McDonnell E, Elfring G, Souza M, Peltz SW, Darras BT, Shieh PB, Cox DA, Landry J, Signorovitch J.

**Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex.**

*Publication:* Epilepsia Open 2019 10; 4(4): 581-592. e-pub ahead of print 2019/12/11; doi: 10.1002/epi4.12365.

*Authors:* Vergeer M, de Ranitz-Greven WL, Neary MP, Ionescu-Iltu R, Emond B, Sheng Duh M, Jansen F, Zonnenberg BA.

**Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.**

*Publication:* PLoS One 2019 09; 14(9): e0221097. e-pub ahead of print 2019/09/04; doi:

10.1371/journal.pone.0221097.

*Authors:* Muntoni F, Domingos J, Manzur AY, Mayhew A, Guglieri M, Sajeev G, Signorovitch J, Ward SJ.

**Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials.**

*Publication:* Alzheimers Dement (N Y) 2019 08; 5: 354-363. e-pub ahead of print 2019/08/17; doi:

10.1016/j.trci.2019.06.005.

*Authors:* Andrews JS, Desai U, Kirson NY, Zichlin ML, Ball DE, Matthews BR.

**Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?**

*Publication:* J Affect Disord 2019 08; 255: 50-59. doi: <http://dx.doi.org/10.1016/j.jad.2019.04.100>.

*Authors:* Pilon D, Sheehan JJ, Szukis H, Morrison L, Zhdanava M, Lefebvre P, Joshi K.

**Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis.**

*Publication:* BMC Neurol 2019 07; 19(1): 174. e-pub ahead of print 2019/07/22; doi: 10.1186/s12883-019-1385-4.

*Authors:* Patterson-Lomba O, Ayyagari R, Carroll B.

**Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate.**

*Publication:* PharmacoEconomics - Open 2019 06; 3(2): 177-188. doi: <http://dx.doi.org/10.1007/s41669-018-0089-9>.

*Authors:* Emond B, Joshi K, Khoury ACE, Lafeuille MH, Pilon D, Tandon N, Romdhani H, Lefebvre P.

**Initiation of antidepressant medication and risk of incident stroke: using the Adult Changes in Thought cohort to address time-varying confounding.**

*Publication:* Annals of Epidemiology 2019 06. doi: <http://dx.doi.org/10.1016/j.annepidem.2019.04.010>.

*Authors:* Glymour MM, Gibbons LE, Gilsanz P, Gross AL, Mez J, Brewster PW, Marden J, Zahodne LB, Nho K, Hamilton J, Li G, Larson EB, Crane PK.

**Mild traumatic brain injury in the United States: demographics, brain imaging procedures, health-care utilization and costs.**

*Publication:* Brain Inj 2019 06; 33(9): 1151-1157. e-pub ahead of print 2019/06/27; doi: 10.1080/02699052.2019.1629022.

*Authors:* Pavlov V, Thompson-Leduc P, Zimmer L, Wen J, Shea J, Beyhaghi H, Toback S, Kirson N, Miller M.

**US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study.**

*Publication:* PharmacoEconomics Open 2019 06. e-pub ahead of print 2019/06/30; doi: 10.1007/s41669-019-0154-z.

*Authors:* Pilon D, Szukis H, Joshi K, Singer D, Sheehan JJ, Wu JW, Lefebvre P, Greenberg P.

**The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders.**

*Publication:* Current Medical Research and Opinion 2019 05; 35(7): 1205-1214. e-pub ahead of print 2019/01/15; doi: <http://dx.doi.org/10.1080/03007995.2019.1569871>.

*Authors:* McEvoy J, Park T, Schilling T, Terasawa E, Ayyagari R, Carroll B.

**Economic burden of relapse/recurrence in patients with major depressive disorder.**

*Publication:* J Drug Assess 2019 04; 8(1): 97-103. e-pub ahead of print 2019/06/14; doi: 10.1080/21556660.2019.1612410.

*Authors:* Gauthier G, Mucha L, Shi S, Guerin A.

**Medicaid spending burden among beneficiaries with treatment-resistant depression.**

*Publication:* J Comp Eff Res 2019 04; 8(6): 381-392. e-pub ahead of print 2019/02/09; doi: 10.2217/ce-2018-0140.

*Authors:* Pilon D, Sheehan JJ, Szukis H, Singer D, Jacques P, Lejeune D, Lefebvre P, Greenberg PE.

**Development of a classifier to identify patients with probable Lennox-Gastaut syndrome in health insurance claims databases via random forest methodology.**

*Publication:* Curr Med Res Opin 2019 03: 1-6. e-pub ahead of print 2019/03/15; doi: 10.1080/03007995.2019.1595552.

*Authors:* Vekeman F, Pina-Garza JE, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Sheng Duh M, Shen V, Saurer TB, Montouris GD, Isojarvi J.

**The humanistic burden of postpartum depression: a systematic literature review.**

*Publication:* Curr Med Res Opin 2019 03; 35(3): 383-393. e-pub ahead of print 2018/11/24; doi: 10.1080/03007995.2018.1552039.

*Authors:* Moore Simas TA, Huang MY, Patton C, Reinhart M, Chawla AJ, Clemson C, Eldar-Lissai A.

**Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3years: a retrospective US claims database analysis.**

*Publication:* J Neurol Sci 2019 03; 398: 163-170. e-pub ahead of print 2019/02/08; doi: 10.1016/j.jns.2019.01.036.

*Authors:* Fox E, Vieira MC, Johnson K, Peeples M, Bensimon AG, Signorovitch J, Herrera V.

**The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia.**

*Publication:* Current Medical Research and Opinion. 2018 12. doi: <http://dx.doi.org/10.1080/03007995.2018.1558195>.

*Authors:* El Khoury AC, Pilon D, Morrison L, Shak N, Vermette-Laforme M, Amos TB, Kim E, Lefebvre P.

**Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease.**

*Publication:* J Alzheimers Dis 2018 11; 61(1): 295-307. e-pub ahead of print 2017/11/21; doi: 10.3233/JAD-170078.

*Authors:* Kirson NY, Scott Andrews J, Desai U, King SB, Schonfeld S, Birnbaum HG, Ball DE, Kahle-Wroblewski K.

**Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis.**

*Publication:* Curr Med Res Opin 2018 09; 1-9. e-pub ahead of print 2018/08/15; doi: 10.1080/03007995.2018.1512477.  
*Authors:* Pilon D, Amos TB, Kamstra R, Manceur AM, El Khoury AC, Lefebvre P.

**Epilepsy treatment patterns among patients with tuberous sclerosis complex.**

*Publication:* J Neurol Sci 2018 08; 391: 104-108. e-pub ahead of print 2018/08/15; doi: 10.1016/j.jns.2018.06.011.  
*Authors:* Song J, Swallow E, Said Q, Peeples M, Meiselbach M, Signorovitch J, Kohrman M, Korf B, Krueger D, Wong M, Sparagana S.

**Health Care Resource Utilization and Costs Associated with Transitioning to 3-Month Paliperidone Palmitate Among US Veterans.**

*Publication:* Clin Ther 2018 08; 40(9): 1496-1508. e-pub ahead of print 2018/08/27; doi: 10.1016/j.clinthera.2018.07.011.  
*Authors:* DerSarkissian M, Lefebvre P, Joshi K, Brown B, Lafeuille MH, Bhak RH, Hellstern M, Bobbili P, Shiner B, El Khoury AC, Young-Xu Y.

**Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics.**

*Publication:* Curr Med Res Opin 2018 08; 34(8): 1377-1388. e-pub ahead of print 2018/02/18; doi: 10.1080/03007995.2018.1442822.  
*Authors:* Kamstra R, Pilon D, Lefebvre P, Emond B, Joshi K.

**Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States.**

*Publication:* J Atten Disord 2018 07; 1087054718784668. e-pub ahead of print 2018/07/12; doi: 10.1177/1087054718784668.  
*Authors:* Zhou Z, Betts KA, Bocharova I, Kinrich D, Spalding WM.

**Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials.**

*Publication:* Epilepsy Res 2018 07; 143: 120-129. e-pub ahead of print 2018/05/23; doi: 10.1016/j.eplepsyres.2017.10.004.  
*Authors:* Slater J, Chung S, Huynh L, Duh MS, Gorin B, McMicken C, Ziemann A, Isojarvi J.

**Treatment patterns among adults with ADHD receiving long-acting therapy.**

*Publication:* Am J Manag Care 2018 07; 24(8 Spec No.): SP329-SP337. e-pub ahead of print 2018/07/19.  
*Authors:* Zhou Z, Zhou ZY, Kellar SS, Sikirica V, Xie J, Grebla R.

**Examining a Statewide Educational Consulting Program for Pediatric Brain Injury.**

*Publication:* Clin Pediatr (Phila) 2018 06; 57(6): 645-655. e-pub ahead of print 2017/09/22; doi: 10.1177/0009922817732146.  
*Authors:* Myers RK, Eagan-Brown BL, Conway AT, Nagele DA, Vaccaro MJ, Kendi S, Zonfrillo MR.

**Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis.**

*Publication:* J Neurol Sci 2018 05; 388: 168-174. e-pub ahead of print 2018/04/09; doi: 10.1016/j.jns.2018.03.018.  
*Authors:* Kantor D, Johnson K, Vieira MC, Signorovitch J, Li N, Gao W, Koo V, Duchesneau E, Herrera S.

**Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States.**

*Publication:* Curr Med Res Opin 2018 04; 34(4): 585-592. e-pub ahead of print 2017/12/01; doi: 10.1080/03007995.2017.1411792.  
*Authors:* Zhou Z, Zhou ZY, Kelkar SS, Sikirica V, Xie J, Grebla R.

**One-Year Effect of the Medicare Annual Wellness Visit on Detection of Cognitive Impairment: A Cohort Study.**

*Publication:* J Am Geriatr Soc 2018 04. e-pub ahead of print 2018/04/03; doi: 10.1111/jgs.15330.

*Authors:* Fowler NR, Campbell NL, Pohl GM, Munsie LM, Kirson NY, Desai U, Trieschman EJ, Meiselbach MK, Andrews JS, Boustani MA.

**Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database.**

*Publication:* J Clin Psychiatry 2018 03; 79(2). e-pub ahead of print 2018/02/24; doi: 10.4088/JCP.17m11725.

*Authors:* Amos TB, Tandon N, Lefebvre P, Pilon D, Kamstra RL, Pivneva I, Greenberg PE.

**Reliability of coded data to identify earliest indications of cognitive decline, cognitive evaluation and Alzheimer's disease diagnosis: a pilot study in England.**

*Publication:* BMJ Open 2018 03; 8(3): e019684. e-pub ahead of print 2018/03/24; doi: 10.1136/bmjopen-2017-019684.

*Authors:* Dell'Agnello G, Desai U, Kirson NY, Wen J, Meiselbach MK, Reed CC, Belger M, Lenox-Smith A, Martinez C, Rasmussen J.

**Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.**

*Publication:* J Med Econ 2018 02; 21(2): 135-143. e-pub ahead of print 2017/09/13; doi: 10.1080/13696998.2017.1379413.

*Authors:* Pilon D, Alcusky M, Xiao Y, Thompson-Leduc P, Lafeuille MH, Lefebvre P, Benson C.

**A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.**

*Publication:* Eur J Health Econ 2018 01; 19(1): 21-35. e-pub ahead of print 2017/01/18; doi: 10.1007/s10198-016-0864-4.

*Authors:* Zimovetz EA, Joseph A, Ayyagari R, Mauskopf JA.

**The economic burden of bipolar I disorder in the United States in 2015.**

*Publication:* J Affect Disord 2018 01; 226: 45-51. e-pub ahead of print 2017/09/30; doi: 10.1016/j.jad.2017.09.011.

*Authors:* Cloutier M, Greene M, Guerin A, Touya M, Wu E.

**Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting.**

*Publication:* Curr Med Res Opin 2017 10; 33(10): 1763-1772. e-pub ahead of print 2017/07/26; doi: 10.1080/03007995.2017.1359516.

*Authors:* Joshi K, Lafeuille MH, Brown B, Wynant W, Emond B, Lefebvre P, Tandon N.

**Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?**

*Publication:* CNS Drugs 2017 10; 31(10): 899-910. e-pub ahead of print 2017/09/01; doi: 10.1007/s40263-017-0462-8.

*Authors:* Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S.

**Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.**

*Publication:* J Med Econ 2017 10; 20(10): 1056-1065. e-pub ahead of print 2017/07/14; doi: 10.1080/13696998.2017.1355310.

*Authors:* Yang H, Duchesneau E, Foster R, Guerin A, Ma E, Thomas NP.

**Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States.**

*Publication:* Epilepsia 2017 10; 58(10): 1742-1748. e-pub ahead of print 2017/07/26; doi: 10.1111/epi.13857.

*Authors:* Fought E, Laliberte F, Wang Z, Barghout V, Haider B, Lejeune D, Germain G, Choi J, Wagh A, Duh MS.



**Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.**

*Publication:* Curr Med Res Opin 2017 10; 33(10): 1891-1900. e-pub ahead of print 2017/06/08; doi: 10.1080/03007995.2017.1339674.

*Authors:* Weir MR, Berger JS, Ashton V, Laliberte F, Brown K, Lefebvre P, Schein J.

**Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.**

*Publication:* Clin Ther 2017 10; 39(10): 1972-1985 e1972. e-pub ahead of print 2017/09/19; doi: 10.1016/j.clinthera.2017.08.008.

*Authors:* Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K.

**Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.**

*Publication:* J Stroke Cerebrovasc Dis 2017 09; 26(9): 1996-2003. e-pub ahead of print 2017/07/12; doi: 10.1016/j.jstrokecerebrovasdis.2017.06.010.

*Authors:* Betts KA, Hurley D, Song J, Sajeev G, Guo J, Du EX, Paschoalin M, Wu EQ.

**Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome.**

*Publication:* Epilepsy Behav 2017 08; 73: 46-50. e-pub ahead of print 2017/06/14; doi: 10.1016/j.yebeh.2017.05.021.

*Authors:* Pina-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, Duh MS, Shen V, Saurer TB, Isojarvi J.

**Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.**

*Publication:* Eur Child Adolesc Psychiatry 2017 08; 26(8): 875-897. e-pub ahead of print 2017/03/05; doi: 10.1007/s00787-017-0962-6.

*Authors:* Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, Sikirica V.

**Health Services Utilization Among Fee-for-Service Medicare and Medicaid Patients Under Age 65 with Behavioral Health Illness at an Urban Safety Net Hospital.**

*Publication:* J Manag Care Spec Pharm 2017 07; 23(7): 781-788. e-pub ahead of print 2017/06/27; doi: 10.18553/jmcp.2017.23.7.781.

*Authors:* Cancino RS, Jack BW, Jarvis J, Cummings AK, Cooper E, Cremieux PY, Burgess JF, Jr.

**Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse.**

*Publication:* Clin Ther 2017 07; 39(7): 1380-1395 e1384. e-pub ahead of print 2017/06/24; doi: 10.1016/j.clinthera.2017.05.356.

*Authors:* Lefebvre P, Muser E, Joshi K, DerSarkissian M, Bhak RH, Duh MS, Shiner B, Young-Xu Y.

**Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis.**

*Publication:* J Manag Care Spec Pharm 2017 07; 23(7): 771-780. e-pub ahead of print 2017/06/27; doi: 10.18553/jmcp.2017.23.7.771.

*Authors:* Guo A, Niyazov A, Macaulay D, Terasawa E, Schmerold L, Wu EQ, Krieger S.

**Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis.**

*Publication:* BMC Psychiatry 2017 06; 17(1): 222. e-pub ahead of print 2017/06/21; doi: 10.1186/s12888-017-1385-0.

*Authors:* Gauthier G, Guerin A, Zhdanova M, Jacobson W, Nomikos G, Merikle E, Francois C, Perez V.

**Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk.**

*Publication:* Curr Med Res Opin 2017 04; 33(4): 631-638. doi: 10.1080/03007995.2016.1275936.

*Authors:* Nelson WW, Laliberte F, Patel AA, Germain G, Pilon D, McCormick N, Lefebvre P.

**Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program.**

*Publication:* Curr Med Res Opin 2017 04; 33(4): 713-721. doi: 10.1080/03007995.2016.1277989.

*Authors:* Pilon D, Amos TB, Germain G, Lafeuille MH, Lefebvre P, Benson CJ.

**Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.**

*Publication:* J Clin Mov Disord 2017 03; 4: 3. e-pub ahead of print 2017/03/08; doi: 10.1186/s40734-017-0051-5.

*Authors:* Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D.

**Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic.**

*Publication:* Patient Preference and Adherence 2017 03; 11: 619-629. doi: <http://dx.doi.org/10.2147/PPA.S127623>.

*Authors:* Pilon D, Joshi K, Tandon N, Lafeuille MH, Kamstra RL, Emond B, Lefebvre P.

**Functional limitations and health care resource utilization for individuals with cognitive impairment without dementia: Findings from a United States population-based survey.**

*Publication:* Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring 2017 02; 6: 65-74. doi: <http://dx.doi.org/10.1016/j.dadm.2016.11.005>.

*Authors:* Desai U, Kirson NY, Enloe CJ, Ristovska L, King S, Birnbaum HG.

**Real-world costs of ischemic stroke by discharge status.**

*Publication:* Curr Med Res Opin 2017 02; 33(2): 371-378. e-pub ahead of print 2016/11/09; doi: 10.1080/03007995.2016.1257979.

*Authors:* Mu F, Hurley D, Betts KA, Messali AJ, Paschoalin M, Kelley C, Wu EQ.

**Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia.**

*Publication:* Am Health Drug Benefits 2016 10; 9(7): 399-410. e-pub ahead of print 2016/12/21.

*Authors:* Lafeuille MH, Frois C, Cloutier M, Duh MS, Lefebvre P, Pesa J, Clancy Z, Fastenau J, Durkin M.

**Impact of Paliperidone Palmitate versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia.**

*Publication:* J Clin Psychiatry 2016 10; 77(10): e1332-e1341. e-pub ahead of print 2016/08/31; doi: 10.4088/JCP.16m10745.

*Authors:* Young-Xu Y, Duh MS, Muser E, DerSarkissian M, Faust E, Kageleiry A, Bhak RH, Fu DJ, Lefebvre P, Shiner B.

**Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.**

*Publication:* PLoS One 2016 10; 11(10): e0164684. e-pub ahead of print 2016/10/14; doi: 10.1371/journal.pone.0164684.

*Authors:* Goemans N, Vanden Hauwe M, Signorovitch J, Swallow E, Song J, Collaborative Trajectory Analysis P.

**Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.**

*Publication:* Neuromuscul Disord 2016 09; 26(9): 576-583. e-pub ahead of print 2016/07/18; doi: 10.1016/j.nmd.2016.05.016.

*Authors:* Mercuri E, Signorovitch JE, Swallow E, Song J, Ward SJ, Group DMDI, Trajectory Analysis P.

**Assessing the economic burden of Alzheimer's disease patients first diagnosed by specialists.**

*Publication:* BMC Geriatr 2016 07; 16: 138. e-pub ahead of print 2016/07/13; doi: 10.1186/s12877-016-0303-5.

*Authors:* Kirson NY, Desai U, Ristovska L, Cummings AK, Birnbaum HG, Ye W, Andrews JS, Ball D, Kahle-Wroblewski K.

**The Economic Burden of Schizophrenia in the United States in 2013.**

*Publication:* J Clin Psychiatry 2016 06; 77(6): 764-771. e-pub ahead of print 2016/05/03; doi: 10.4088/JCP.15m10278.

*Authors:* Cloutier M, Aigbogun MS, Guerin A, Nitulescu R, Ramanakumar AV, Kamat SA, DeLucia M, Duffy R, Legacy SN, Henderson C, Francois C, Wu E.

**Excess Costs Associated with Possible Misdiagnosis of Alzheimer's Disease Among Patients with Vascular Dementia in a UK CPRD Population.**

*Publication:* J Alzheimers Dis 2016 05; 53(1): 171-183. doi: 10.3233/JAD-150685.

*Authors:* Happich M, Kirson NY, Desai U, King S, Birnbaum HG, Reed C, Belger M, Lenox-Smith A, Price D.

**Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database.**

*Publication:* Pharmacoepidemiol Drug Saf 2016 04; 25(4): 413-421. e-pub ahead of print 2016/02/19; doi: 10.1002/pds.3975.

*Authors:* Quinlan SC, Cheng WY, Ishihara L, Irizarry MC, Holick CN, Duh MS.

**Burden of illness among patients with fragile X syndrome (FXS): a Medicaid perspective.**

*Publication:* Current Medical Research & Opinion 2016 03; 32(3): 405-416. e-pub ahead of print 2015/11/14; doi: 10.1185/03007995.2015.1119678.

*Authors:* Nazareth T, Li N, Marynchenko M, Zhou Z, Chopra P, Signorovitch J, Wu E, Ahmed S, Marvel J, Sasane R.

**Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine.**

*Publication:* Patient Prefer Adherence 2016 03; 10: 391-405. doi: 10.2147/PPA.S98498.

*Authors:* Joseph A, Cloutier M, Guerin A, Nitulescu R, Sikirica V.

**Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.**

*Publication:* Curr Med Res Opin 2016 02; 32(4): 759-769. e-pub ahead of print 2016/01/12; doi: 10.1185/03007995.2016.1140634.

*Authors:* Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P.

**Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review.**

*Publication:* Neurol Sci 2016 02; 37(2): 165-179. e-pub ahead of print 2015/11/06; doi: 10.1007/s10072-015-2400-1.

*Authors:* Vollmer T, Huynh L, Kelley C, Galebach P, Signorovitch J, DiBernardo A, Sasane R.

**Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.**

*Publication:* J Neurol 2015 11; 262(11): 2425-2432. doi: 10.1007/s00415-015-7853-x.

*Authors:* Tauhid S, Chu R, Sasane R, Glanz BI, Neema M, Miller JR, Kim G, Signorovitch JE, Healy BC, Chitnis T, Weiner HL, Bakshi R.

**Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients.**

*Publication:* J Comp Eff Res 2015 11; 4(6): 579-592. doi: 10.2217/CER.15.34.

*Authors:* Xiao Y, Muser E, Lafeuille MH, Pesa J, Fastenau J, Duh MS, Lefebvre P.

**The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis.**

*Publication:* J Neurol Sci 2015 10; 357(1-2): 8-18. doi: 10.1016/j.jns.2015.07.014.

*Authors:* Vollmer T, Signorovitch J, Huynh L, Galebach P, Kelley C, DiBernardo A, Sasane R.

**Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.**

*Publication:* PharmacoEconomics 2015 10; 33(10): 1049-1067. doi: 10.1007/s40273-015-0285-8.

*Authors:* Kruse G, Wong BJ, Duh MS, Lefebvre P, Lafeuille MH, Fastenau JM.

**Patient and Caregiver Burden Associated with Fragile X Syndrome in the United States.**

*Publication:* Am J Intellect Dev Disabil 2015 09; 120(5): 444-459. doi: 10.1352/1944-7558-120.5.444.

*Authors:* Vekeman F, Gauthier-Loiselle M, Faust E, Lefebvre P, Lahoz R, Duh MS, Sacco P.

**Medical costs of Alzheimer's disease misdiagnosis among US Medicare beneficiaries.**

*Publication:* Alzheimers Dement 2015 07. doi: 10.1016/j.jalz.2015.06.1889.

*Authors:* Hunter CA, Kirson NY, Desai U, Cummings AK, Faries DE, Birnbaum HG.

**Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder.**

*Publication:* J Med Econ 2015 06; 18(11): 919-929. doi: 10.3111/13696998.2015.1061534.

*Authors:* Zhou ZY, Sun S, Chopra P, Zhong Y, Totev T, Signorovitch J.

**Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis.**

*Publication:* J Med Econ 2015 06; 18(9): 711-720. doi: 10.3111/13696998.2015.1044276.

*Authors:* Yermakov S, Davis M, Calnan M, Fay M, Cox-Buckley B, Sarda S, Duh MS, Iyer R.

**Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics.**

*Publication:* Am J Health Syst Pharm 2015 03; 72(5): 378-389. doi: 10.2146/ajhp140219.

*Authors:* Lafeuille MH, Grittner AM, Fortier J, Muser E, Fastenau J, Duh MS, Lefebvre P.

**The economic burden of adults with major depressive disorder in the United States (2005 and 2010).**

*Publication:* J Clin Psychiatry 2015 02; 76(2): 155-162. doi: 10.4088/JCP.14m09298.

*Authors:* Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC.

**The Growing Economic Burden of Depression in the U.S. .**

*Publication:* Scientific American MIND Guest Blog 2015 02.

*Authors:* Greenberg P.

**Pulse pressure and stroke risk: development and validation of a new stroke risk model.**

*Publication:* Current Medical Research & Opinion 2014 12; 30(12): 2453-2460. doi: 10.1185/03007995.2014.971357.

*Authors:* Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

**Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in quebec.**

*Publication:* Can J Psychiatry 2014 11; 59(11): 597-608.

*Authors:* Lachaine J, De G, Sikirica V, Van Stralen J, Hodgkins P, Yang H, Heroux J, Ben Amor L.

**Combination and switching of stimulants in children and adolescents with attention deficit/hyperactivity disorder in Quebec.**

*Publication:* J Can Acad Child Adolesc Psychiatry 2014 09; 23(3): 157-166.

*Authors:* Ben Amor L, Sikirica V, Cloutier M, Lachaine J, Guerin A, Carter V, Hodgkins P, van Stralen J.

**Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorder.**

*Publication:* Am J Manag Care 2014 09; 20(9): 711-721.

*Authors:* Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson TM, Xie J, Erder MH, Dammerman RS, Robertson B, Wu EQ.

**Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review.**

*Publication:* Neuropsychiatric Disease Treatments 2014 08; 10: 1543-1569. doi: 10.2147/NDT.S65721.

*Authors:* Gajria K, Lu M, Sikirica V, Greven P, Zhong Y, Qin P, Xie J.

**Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia.**

*Publication:* Current Medical Research & Opinion 2014 08; 30(8): 1643-1655. doi: 10.1185/03007995.2014.915211.

*Authors:* Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.

**Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009.**

*Publication:* J Child Adolesc Psychopharmacol 2014 06; 24(5): 260-268. doi: 10.1089/cap.2013.0107.

*Authors:* Betts KA, Sikirica V, Hodgkins P, Zhou Z, Xie J, DeLeon A, Erder MH, Wu EQ.

**Burden of schizophrenia on selected comorbidity costs.**

*Publication:* Expert Rev Pharmacoecon Outcomes Res 2014 04; 14(2): 259-267. doi: 10.1586/14737167.2014.894463.

*Authors:* Lafeuille MH, Dean J, Fastenau J, Panish J, Olson W, Markowitz M, Duh MS, Lefebvre P.

**HD-PRO-TRIAD Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease.**

*Publication:* Tremor Other Hyperkinet Mov (N Y) 2014 04; 4: 223. doi: 10.7916/D8PN93NZ.

*Authors:* Carlozzi NE, Victorson D, Sung V, Beaumont JL, Cheng W, Gorin B, Duh MS, Samuelson D, Tulsy D, Gutierrez S, Nowinski CJ, Mueller A, Shen V, Frank S.

**Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives.**

*Publication:* Tremor Other Hyperkinet Mov (N Y) 2014 04; 4: 224. doi: 10.7916/D8JW8BWS.

*Authors:* Victorson D, Carlozzi NE, Frank S, Beaumont JL, Cheng W, Gorin B, Duh MS, Samuelson D, Tulsy D, Gutierrez S, Nowinski CJ, Mueller A, Shen V, Sung V.

**Implications of early treatment among Medicaid patients with Alzheimer's disease.**

*Publication:* Alzheimers Dement 2014 03; 10(2): 214-224. doi: 10.1016/j.jalz.2013.01.015.

*Authors:* Geldmacher DS, Kirson NY, Birnbaum HG, Eapen S, Kantor E, Cummings AK, Joish VN.

**The effectiveness of hydrotherapy in the treatment of social and behavioral aspects of children with autism spectrum disorders: a systematic review.**

*Publication:* J Multidiscip Healthc 2014 02; 7: 93-104. doi: 10.2147/JMDH.S55345.

*Authors:* Mortimer R, Privopoulos M, Kumar S.

**Cost utility of hub-and-spoke telestroke networks from societal perspective.**

*Publication:* Am J Manag Care 2013 12; 19(12): 976-985.

*Authors:* Demaerschalk BM, Switzer JA, Xie J, Fan L, Villa KF, Wu EQ.

**Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.**

*Publication:* CNS Drugs 2013 11; 27(11): 943-953. doi: 10.1007/s40263-013-0102-x.

*Authors:* Sikirica V, Findling RL, Signorovitch J, Erder MH, Dammerman R, Hodgkins P, Lu M, Xie J, Wu EQ.

**Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.**

*Publication:* J Med Econ 2013 11; 16(11): 1290-1299. doi: 10.3111/13696998.2013.841705.

*Authors:* Lafeuille MH, Gravel J, Lefebvre P, Fastenau J, Muser E, Doshi D, Duh MS.

**Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.**

*Publication:* J Med Econ 2013 11; 16(11): 1275-1289. doi: 10.3111/13696998.2013.839947.

*Authors:* Setyawan J, Guerin A, Hodgkins P, Gauthier G, Cloutier M, Wu E, Erder MH.

**Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.**

*Publication:* J Med Econ 2013 10; 16(10): 1203-1215. doi: 10.3111/13696998.2013.832258.

*Authors:* Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder MH.

**Costs of Parkinson's disease in a privately insured population.**

*Publication:* PharmacoEconomics 2013 09; 31(9): 799-806. doi: 10.1007/s40273-013-0075-0.

*Authors:* Johnson SJ, Kaltenboeck A, Diener M, Birnbaum HG, Grubb E, Castelli-Haley J, Siderowf AD.

**Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis.**

*Publication:* BMC Psychiatry 2013 09; 13: 221. doi: 10.1186/1471-244X-13-221.

*Authors:* Lafeuille MH, Laliberte-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS.

**Pre-diagnosis excess acute care costs in Alzheimer's patients among a US Medicaid population.**

*Publication:* Appl Health Econ Health Policy 2013 08; 11(4): 407-413. doi: 10.1007/s40258-013-0038-9.

*Authors:* Geldmacher DS, Kirson NY, Birnbaum HG, Eapen S, Kantor E, Cummings AK, Joish VN.

**Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis.**

*Publication:* J Med Econ 2013 07; 16(7): 962-975. doi: 10.3111/13696998.2013.800524.

*Authors:* Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu EQ, Erder MH.

**Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers.**

*Publication:* J Neurol Sci 2013 07; 330(1-2): 71-77. doi: 10.1016/j.jns.2013.04.007.

*Authors:* Parise H, Laliberte F, Lefebvre P, Duh MS, Kim E, Agashivala N, Abouzaid S, Weinstock-Guttman B.

**Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.**

*Publication:* J Clin Psychiatry 2013 06; 74(6): 568-575. doi: 10.4088/JCP.12r08167.

*Authors:* Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Greenberg PE, Wong BJ.

**An economic model of Parkinson's disease: implications for slowing progression in the United States.**

*Publication:* Movement Disorders 2013 03; 28(3): 319-326. doi: 10.1002/mds.25328.

*Authors:* Johnson SJ, Diener MD, Kaltenboeck A, Birnbaum HG, Siderowf AD.

**Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals' perspectives.**

*Publication:* Circ Cardiovasc Qual Outcomes 2013 01; 6(1): 18-26. doi: 10.1161/CIRCOUTCOMES.112.967125.

*Authors:* Switzer JA, Demaerschalk BM, Xie J, Fan L, Villa KF, Wu EQ.

**Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.**

*Publication:* J Manag Care Pharm 2012 11; 18(9): 676-689.

*Authors:* Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder H, Dammerman R, Robertson B, Wu EQ.

**Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.**

*Publication:* Appl Health Econ Health Policy 2012 11; 10(6): 381-395. doi: 10.2165/11641870-000000000-00000.

*Authors:* Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V.

**Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization.**

*Publication:* Neurology 2012 10; 79(18): 1908-1916. doi: 10.1212/WNL.0b013e318271f77e.

*Authors:* Manjunath R, Paradis PE, Parise H, Lafeuille MH, Bowers B, Duh MS, Lefebvre P, Faught E.

**Direct and indirect costs of patients treated with extended-release oxycodone HCl or controlled-release oxycodone HCl.**

*Publication:* J Med Econ 2012 10; 15(1): 87-95. e-pub ahead of print 2011/10/29; doi: 10.3111/13696998.2011.629261.

*Authors:* Kirson NY, White AG, Birnbaum HG, Schiller M, Waldman T, Peterson K, Ben-Joseph RH, Berner T, Summers KH.

**Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy.**

*Publication:* Eur J Paediatr Neurol 2012 09; 16(5): 449-458. doi: 10.1016/j.ejpn.2012.01.001.

*Authors:* Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

**Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.**

*Publication:* Pain Pract 2012 09; 12(7): 533-540. doi: 10.1111/j.1533-2500.2011.00526.x.

*Authors:* Reed C, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Mullen RE, Swindle R.

**Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.**

*Publication:* Pharmacoeconomics 2012 08; 30(8): e1-15. doi: 10.2165/11632920-000000000-00000.

*Authors:* Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ.

**Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.**

*Publication:* CNS Drugs 2012 07; 26(7): 581-600. doi: 10.2165/11633900-000000000-00000.

*Authors:* Wu EQ, Hodgkins P, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH.

**Direct costs and survival of Medicare beneficiaries with early and advanced Parkinson's disease.**

*Publication:* Parkinsonism Relat Disord 2012 05; 18(4): 321-326. doi: 10.1016/j.parkreldis.2011.11.015.

*Authors:* Kaltenboeck A, Johnson SJ, Davis MR, Birnbaum HG, Carroll CA, Tarrants ML, Siderowf AD.

**Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.**

*Publication:* J Med Econ 2012 03; 15(3): 601-609. doi: 10.3111/13696998.2012.667027.

*Authors:* Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM.

**Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a Medicaid population.**

*Publication:* Manag Care 2012 01; 21(1): 49-58.

*Authors:* Wu EQ, Ben-Hamadi R, Lu M, Beaulieu N, Yu AP, Erder MH.

**Economic Outcomes of Switching Treatment in Major Depressive Disorder Patients.**

*Publication:* American Journal of Pharmacy Benefits 2011 12; 3(6): e111-e120. e-pub ahead of print Dec 6, 2011.

*Authors:* Marynchenko M YA, Lauzon V, Ramakrishnan K, Wu EQ, Ben-Hamadi R, Blum S, Erder HM, Bose A. .

**Early retirement and income loss in patients with early and advanced Parkinson's disease.**

*Publication:* Appl Health Econ Health Policy 2011 11; 9(6): 367-376. doi: 10.2165/11596900-000000000-00000.

*Authors:* Johnson S, Davis M, Kaltenboeck A, Birnbaum H, Grubb E, Tarrants M, Siderowf A.

**Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy.**

*Publication:* Epilepsy Behav 2011 10; 22(2): 370-375. doi: 10.1016/j.yebeh.2011.07.020.

*Authors:* Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

**Cost of post-traumatic stress disorder vs major depressive disorder among patients covered by Medicaid or private insurance.**

*Publication:* Am J Manag Care 2011 08; 17(8): e314-323.

*Authors:* Ivanova JI, Birnbaum HG, Chen L, Duhig AM, Dayoub EJ, Kantor ES, Schiller MB, Phillips GA.

**Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs.**

*Publication:* J Med Econ 2011 06; 14(4): 508-515. doi: 10.3111/13696998.2011.593602.

*Authors:* Yu AP, Ben-Hamadi R, Wu EQ, Kaltenboeck A, Bergman R, Xie J, Blum S, Erder MH.

**Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors.**

*Publication:* Current Medical Research & Opinion 2011 06; 27(6): 1089-1096. doi: 10.1185/03007995.2011.567255.

*Authors:* Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Yu AP, Wu EQ, Dworak H, Erder MH.

**Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.**

*Publication:* Ann Pharmacother 2011 04; 45(4): 441-451. doi: 10.1345/aph.1P482.

*Authors:* Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH.

**Switch to generic SSRIs may boost costs in MDD.**

*Publication:* PharmacoEconomics & Outcomes News 2011 04; 625: 2.

*Authors:* Wu E.

**Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram.**

*Publication:* Am Health Drug Benefits 2011 03; 4(2): 78-87.

*Authors:* Wu EQ, Greenberg PE, Ben-Hamadi R, Yu AP, Yang EH, Erder MH.

**Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine.**

*Publication:* Cephalalgia 2011 02; 31(3): 357-367. doi: 10.1177/0333102410379890.

*Authors:* Yang M, Rendas-Baum R, Varon SF, Kosinski M.

**Physicians' decisions to prescribe antidepressant therapy in older patients with depression in a US managed care plan.**

*Publication:* Drugs Aging 2011 01; 28(1): 51-62. doi: 10.2165/11539900-000000000-00000.

*Authors:* Ivanova JI, Bienfait-Beuzon C, Birnbaum HG, Connolly C, Emani S, Sheehy M.

**Economic outcomes of switching to another generic SSRI, escitalopram, or an SNRI among MDD patients treated with generic SSRI therapy.**

*Publication:* American Journal of Pharmacy Benefits 2011.

*Authors:* Marynchenko M, Yu AP, Lauzon V, Ramakrishnan K, Wu EQ, Ben-Hamadi R, Blum S, Erder MH, Bose A.

**Perceptions and prescribing considerations among US psychiatrists regarding drug-drug interactions associated with oral atypical antipsychotics.**

*Publication:* Current Medical Research & Opinion 2010 12; 26(12): 2735-2744. doi: 10.1185/03007995.2010.530159.

*Authors:* Frois C, Guerin A, Saraogi A, Panish J, Dirani R.



**A novel approach to estimate the minimally important difference for the Fatigue Impact Scale in multiple sclerosis patients.**

*Publication:* Qual Life Res 2010 11; 19(9): 1349-1358. doi: 10.1007/s11136-010-9704-7.

*Authors:* Rendas-Baum R, Yang M, Cattelin F, Wallenstein GV, Fisk JD.

**Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.**

*Publication:* Drugs Aging 2010 11; 27(11): 903-913. doi: 10.2165/11584290-000000000-00000.

*Authors:* Scharre DW, Vekeman F, Lefebvre P, Mody-Patel N, Kahler KH, Duh MS.

**Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder.**

*Publication:* Current Medical Research & Opinion 2010 10; 26(10): 2475-2484. doi: 10.1185/03007995.2010.517716.

*Authors:* Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, Khan SA, Stensland MD.

**Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study.**

*Publication:* J Med Econ 2010 10; 13(4): 599-609. doi: 10.3111/13696998.2010.521736.

*Authors:* Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Blum S, Haim Erder M.

**Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.**

*Publication:* J Med Econ 2010 08; 13(3): 482-491. doi: 10.3111/13696998.2010.506176.

*Authors:* Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Puenpatom RA, Ben-Joseph RH, Summers KH.

**Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%.**

*Publication:* J Med Econ 2010 08; 13(3): 472-481. doi: 10.3111/13696998.2010.499819.

*Authors:* Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Amy Puenpatom R, Ben-Joseph RH, Summers KH.

**Economic burden associated with the use of generic antiepileptic drugs in the United States.**

*Publication:* Epilepsy Behav 2010 08; 18(4): 437-444. e-pub ahead of print 2010/06/29; doi: 10.1016/j.yebeh.2010.05.015.

*Authors:* Helmers SL, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latremouille-Viau D, Lefebvre P, Labiner DM.

**Economic burden of epilepsy among the privately insured in the US.**

*Publication:* PharmacoEconomics 2010 07; 28(8): 675-685. doi: 10.2165/11535570-000000000-00000.

*Authors:* Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Caleo S.

**Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance.**

*Publication:* Depress Anxiety 2010 07; 27(1): 78-89. e-pub ahead of print 2009/07/02; doi: 10.1002/da.20580.

*Authors:* Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE.

**Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States.**

*Publication:* Epilepsia 2010 05; 51(5): 838-844. doi: 10.1111/j.1528-1167.2009.02422.x.

*Authors:* Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Caleo S.

**The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.**

*Publication:* J Am Acad Dermatol 2010 05; 62(5): 812-818. doi: 10.1016/j.jaad.2009.07.022.

*Authors:* Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P.

**Generic antiepileptic drugs and associated medical resource utilization in the United States.**

*Publication:* Neurology 2010 05; 74(20): 1566-1574. doi: 10.1212/WNL.0b013e3181df091b.

*Authors:* Labiner DM, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latremouille-Viau D, Lefebvre P, Helmers SL.

**Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons.**

*Publication:* J Med Econ 2010 05; 13(2): 314-323. doi: 10.3111/13696998.2010.488985.

*Authors:* Wu EQ, Ben-Hamadi R, Yu AP, Tang J, Haim Erder M, Bose A.

**Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey Initiative.**

*Publication:* Depress Anxiety 2010 04; 27(4): 351-364. doi: 10.1002/da.20634.

*Authors:* Kessler RC, Birnbaum HG, Shahly V, Bromet E, Hwang I, McLaughlin KA, Sampson N, Andrade LH, de Girolamo G, Demyttenaere K, Haro JM, Karam AN, Kostyuchenko S, Kovess V, Lara C, Levinson D, Matschinger H, Nakane Y, Browne MO, Ormel J, Posada-Villa J, Sagar R, Stein DJ.

**Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.**

*Publication:* Am J Med 2010 04; 123(4): 350-357. doi: 10.1016/j.amjmed.2009.08.022.

*Authors:* Kimball AB, Guerin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P.

**Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States.**

*Publication:* Journal of Occupational Environmental Medicine 2010 02; 52(2): 115-124. doi: 10.1097/JOM.0b013e3181cb5b10.

*Authors:* Birnbaum HG, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Kantor E, Cremieux PY, Greenberg PE.

**Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version.**

*Publication:* Cephalalgia 2009 11; 29(11): 1180-1187.

*Authors:* Cole JC, Lin P, Rupnow MF.

**The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.**

*Publication:* Expert Opin Pharmacother 2009 10; 10(14): 2317-2328. doi: 10.1517/14656560903140525.

*Authors:* Duh MS, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE.

**The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.**

*Publication:* PharmacoEconomics 2009 08; 27(8): 681-691. doi: 10.2165/11314700-000000000-00000.

*Authors:* Ivanova JI, Birnbaum HG, Samuels S, Davis M, Phillips AL, Meletiche D.

**Determinants of direct cost differences among US employees with major depressive disorders using antidepressants.**

*Publication:* PharmacoEconomics 2009 07; 27(6): 507-517. doi: 10.2165/00019053-200927060-00006.

*Authors:* Birnbaum HG, Ben-Hamadi R, Greenberg PE, Hsieh M, Tang J, Reygrobellet C.

**Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries.**

*Publication:* Current Medical Research & Opinion 2009 07; 25(7): 1793-1805. doi: 10.1185/03007990903044374.

*Authors:* Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS.

**The risks and costs of multiple-generic substitution of topiramate.**

*Publication:* Neurology 2009 06; 72(24): 2122-2129. doi: 10.1212/WNL.0b013e3181aa5300.

*Authors:* Duh MS, Paradis PE, Latremouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MF, LeLorier J.

**Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs.**

*Publication:* J Med Econ 2009 06; 12(2): 124-135. doi: 10.3111/13696990903093537.

*Authors:* Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH.

**Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs.**

*Publication:* Current Medical Research & Opinion 2009 04; 25(4): 869-877. doi: 10.1185/03007990902743869.

*Authors:* Birnbaum HG, Ivanova JI, Samuels S, Davis M, Cremieux PY, Phillips AL, Meletiche D.

**Antidepressant treatment patterns and costs among US employees.**

*Publication:* J Med Econ 2009 03; 12(1): 36-45. doi: 10.3111/13696990902757389.

*Authors:* Birnbaum H, Greenberg PE, Tang J, Hsieh M, Wu EQ, Amand C, Ben-Hamadi R.

**Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population.**

*Publication:* Current Medical Research & Opinion 2009 03; 25(3): 755-764. doi: 10.1185/03007990802683579.

*Authors:* Yu AP, Ben-Hamadi R, Birnbaum HG, Atanasov P, Stensland MD, Philips G.

**Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.**

*Publication:* Epilepsia 2009 03; 50(3): 501-509. doi: 10.1111/j.1528-1167.2008.01794.x.

*Authors:* Faught RE, Weiner JR, Guerin A, Cunningham MC, Duh MS.

**Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study.**

*Publication:* Neurology 2008 11; 71(20): 1572-1578. doi: 10.1212/01.wnl.0000319693.10338.b9.

*Authors:* Faught E, Duh MS, Weiner JR, Guerin A, Cunningham MC.

**Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.**

*Publication:* Current Medical Research & Opinion 2008 10; 24(10): 2805-2813. doi: 10.1185/03007990802336780.

*Authors:* Wu E, Greenberg P, Yang E, Yu A, Ben-Hamadi R, Erder MH.

**Antipsychotic medication utilization trends among Texas veterans: 1997-2002.**

*Publication:* Ann Pharmacother 2008 09; 42(9): 1229-1238. doi: 10.1345/aph.1L155.

*Authors:* Yang M, Barner JC, Lawson KA, Rascati KL, Wilson JP, Crismon ML, Worchel J, Mascarenas CA.

**Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population.**

*Publication:* Current Medical Research & Opinion 2008 09; 24(9): 2587-2595. doi: 10.1185/03007990802303525.

*Authors:* Wu E, Greenberg PE, Yang E, Yu A, Erder MH.

**Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.**

*Publication:* Neurology 2008 05; 70(22 Pt 2): 2179-2186. e-pub ahead of print 2008/05/30; doi: 10.1212/01.wnl.0000313154.55518.25.

*Authors:* LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O.

**Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting.**

*Publication:* Current Medical Research & Opinion 2008 04; 24(4): 1069-1081. doi: 10.1185/030079908X280572.

*Authors:* LeLorier J, Duh MS, Paradis PE, Latremouille-Viau D, Lefebvre P, Manjunath R, Sheehy O.

**Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France.**

*Publication:* Current Medical Research & Opinion 2007 09; 23(9): 2035-2042. doi: 10.1185/030079907X210516.

*Authors:* Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S.

**Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.**

*Publication:* J Manag Care Pharm 2007 09; 13(7): 561-569.

*Authors:* Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.

**The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.**

*Publication:* Dis Manag 2007 08; 10(4): 216-225. doi: 10.1089/dis.2007.104649.

*Authors:* Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY.

**Factors related to antipsychotic oversupply among Central Texas Veterans.**

*Publication:* Clin Ther 2007 06; 29(6): 1214-1225. doi: 10.1016/j.clinthera.2007.06.013.

*Authors:* Yang M, Barner JC, Worchel J.

**Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication.**

*Publication:* Arch Gen Psychiatry 2007 05; 64(5): 543-552. doi: 10.1001/archpsyc.64.5.543.

*Authors:* Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC.

**Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.**

*Publication:* Epilepsia 2007 03; 48(3): 464-469. doi: 10.1111/j.1528-1167.2007.01007.x.

*Authors:* Andermann F, Duh MS, Gosselin A, Paradis PE.

**Considering the costs of bipolar depression.**

*Publication:* Behav Healthc 2007 01; 27(1): 45-47.

*Authors:* Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg PE, Hirschfeld RM, Wang PS.

**Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach.**

*Publication:* Psychol Med 2006 11; 36(11): 1535-1540. doi: 10.1017/S0033291706008191.

*Authors:* Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R.

**Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States.**

*Publication:* Stroke 2006 10; 37(10): 2567-2572. doi: 10.1161/01.STR.0000240506.34616.10.

*Authors:* Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR.

**Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers.**

*Publication:* Am J Psychiatry 2006 09; 163(9): 1561-1568. doi: 10.1176/appi.ajp.163.9.1561.

*Authors:* Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM, Jin R, Merikangas KR, Simon GE, Wang PS.

**Unemployment drives high cost of schizophrenia in the US.**

*Publication:* PharmacoEconomics & Outcomes News 2005 12; 493: 17.

*Authors:* Wu E.

**The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R).**

*Publication:* Biol Psychiatry 2005 10; 58(8): 668-676. doi: 10.1016/j.biopsych.2005.04.034.

*Authors:* Kessler RC, Birnbaum H, Demler O, Falloon IR, Gagnon E, Guyer M, Howes MJ, Kendler KS, Shi L, Walters E, Wu EQ.

**Economic burden of illness for employees with painful conditions.**

*Publication:* J Occup Environ Med 2005 09; 47(9): 884-892. e-pub ahead of print 2005/09/13.

*Authors:* White AG, Birnbaum HG, Mareva MN, Henckler AE, Grossman P, Mallett DA.

**The economic burden of schizophrenia in the United States in 2002.**

*Publication:* J Clin Psychiatry 2005 09; 66(9): 1122-1129.

*Authors:* Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J.

**Costs of schizophrenia have shifted.**

*Publication:* PharmacoEconomics & Outcomes News 2005 06; 480: 18.

*Authors:* Wu E.

**The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers.**

*Publication:* Journal of Occupational Environmental Medicine 2005 06; 47(6): 565-572.

*Authors:* Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum H, Greenberg P, Johnston JA, Spencer T, Ustun TB.

**The economic burden of depression in the US: societal and patient perspectives.**

*Publication:* Expert Opin Pharmacother 2005 03; 6(3): 369-376. doi: 10.1517/14656566.6.3.369.

*Authors:* Greenberg PE, Birnbaum HG.

**Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000.**

*Publication:* Current Medical Research & Opinion 2005 02; 21(2): 195-206. doi: 10.1185/030079904X20303.

*Authors:* Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR.

**Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients.**

*Publication:* J Adolesc Health 2004 10; 35(4): 346 e341-349.

*Authors:* Swensen A, Birnbaum HG, Ben Hamadi R, Greenberg P, Cremieux PY, Secnik K.

**Economic implications of treatment-resistant depression among employees.**

*Publication:* PharmacoEconomics 2004 04; 22(6): 363-373.

*Authors:* Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A.

**What's so different about anxiety disorders (such as phobias).**

*Publication:* WPA series evidence and experience in psychiatry 2004 7.

*Authors:* Greenberg P, Birnbaum H, Sisitsky T.

**Attention-deficit/hyperactivity disorder: increased costs for patients and their families.**

*Publication:* J Am Acad Child Adolesc Psychiatry 2003 12; 42(12): 1415-1423. doi: 10.1097/00004583-200312000-00008.

*Authors:* Swensen AR, Birnbaum HG, Secnik K, Marynchenko M, Greenberg P, Claxton A.

**The economic burden of depression in the United States: how did it change between 1990 and 2000?**

*Publication:* J Clin Psychiatry 2003 12; 64(12): 1465-1475.

*Authors:* Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK.

**Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis.**

*Publication:* J Clin Psychiatry 2003 10; 64(10): 1201-1209.

*Authors:* Birnbaum HG, Shi L, Dial E, Oster EF, Greenberg PE, Mallett DA.

**Economic impact of olanzapine plus fluoxetine combination therapy among patients treated for depression: a pilot study.**

*Publication:* Psychopharmacol Bull 2003 08; 37(3): 90-98.

*Authors:* Corey-Lisle PK, Birnbaum H, Greenberg P, Marynchenko M, Dube S.

**The economics of women and depression: an employer's perspective.**

*Publication:* J Affect Disord 2003 03; 74(1): 15-22.

*Authors:* Birnbaum HG, Leong SA, Greenberg PE.

**Identification of a claims data "signature" and economic consequences for treatment-resistant depression.**

*Publication:* J Clin Psychiatry 2002 08; 63(8): 717-726.

*Authors:* Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ.

**An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts.**

*Publication:* J Ment Health Policy Econ 2002 03; 5(1): 3-19.

*Authors:* Berndt ER, Bhattacharjya A, Mishol DN, Arcelus A, Lasky T.

**The economic burden of anxiety and stress disorders.**

*Publication:* Neuropsychopharmacology: The fifth generation of progress 2002 67: 982-992.

*Authors:* Kessler RC, Greenberg PE.

**Cost of depression: current assessment and future directions.**

*Publication:* Expert Rev Pharmacoecon Outcomes Res 2001 10; 1(1): 69-76. doi: 10.1586/14737167.1.1.69.

*Authors:* Greenberg PE, Birnbaum SA.

**Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD.**

*Publication:* Neurology 2001 09; 57(6): 957-964.

*Authors:* Neumann PJ, Araki SS, Arcelus A, Longo A, Papadopoulos G, Kosik KS, Kuntz KM, Bhattacharjya A.

**Assessing the economic impact of psychiatric disorders: where to begin?**

*Publication:* Expert Opin Pharmacother 2001 04; 2(4): 641-652. doi: 10.1517/14656566.2.4.641.

*Authors:* Greenberg PE, Leong SA, Birnbaum HG.

**Depression and work productivity: the comparative costs of treatment versus nontreatment.**

*Publication:* Journal of Occupational Environmental Medicine 2001 01; 43(1): 2-9.

*Authors:* Simon GE, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, Wang PS, Kessler RC.

**The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.**

*Publication:* Int Clin Psychopharmacol 2000 09; 15(5): 279-289.

*Authors:* Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, Rowland C, Williamson T.

**The Economics of Anxiety Disorders.**

*Publication:* Psychiatric Times' Mental Health Economics: Practical Information on Changes in the U.S. Health Care System 2000.

*Authors:* Greenberg P, Sisitsky T.

**Management of major depression in the workplace.**

*Publication:* Disease Management and Health Outcomes 2000 7(3): 163-171.

*Authors:* Birnbaum HG, Cremieux PY, Greenberg PE, Kessler RC.

**The workplace burden of depression: underlying causes, recent empirical findings, and future directions.**

*Publication:* TEN 2000 2(6): 37-40.

*Authors:* Greenberg P, Birnbaum H.

**Depression in the workplace: effects on short-term disability.**

*Publication:* Health Aff (Millwood) 1999 09; 18(5): 163-171.

*Authors:* Kessler RC, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, Simon GE, Wang P.

**The economic burden of anxiety disorders in the 1990s.**

*Publication:* J Clin Psychiatry 1999 07; 60(7): 427-435.

*Authors:* Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, Ballenger JC, Fyer AJ.

**Workplace burden of depression: a case study in social functioning using employer claims data.**

*Publication:* Drug Benefits Trends 1999 11: 6BH-12BH.

*Authors:* Birnbaum H, Greenberg P, Barton M, Kessler R, Rowland C, Williamson T.

**Workplace performance effects from chronic depression and its treatment.**

*Publication:* J Health Econ 1998 10; 17(5): 511-535.

*Authors:* Berndt ER, Finkelstein SN, Greenberg PE, Howland RH, Keith A, Rush AJ, Russell J, Keller MB.

**Improvement in subjective work performance after treatment of chronic depression: some preliminary results. Chronic Depression Study Group.**

*Publication:* Psychopharmacol Bull 1996 01; 32(1): 33-40.

*Authors:* Finkelstein SN, Berndt ER, Greenberg PE, Parsley RA, Russell JM, Keller MB.

**Depression in the workplace: an economic perspective.**

*Publication:* Selective Serotonin Re-Uptake Inhibitors: Advances in Basic Research and Clinical Practice. 2nd ed. New York, NY: John Wiley & Sons 1996: 327-363.

*Authors:* Greenberg PE, Kessler RC, Nells TL, Finkelstein SN, Berndt ER.

**The effectiveness of surgery on the treatment of acute spinal cord injury and its relation to pharmacological treatment.**

*Publication:* Neurosurgery 1994 08; 35(2): 240-248; discussion 248-249.

*Authors:* Duh MS, Shepard MJ, Wilberger JE, Bracken MB.

**The Economics of Clinical Depression.**

*Publication:* MIT Management Magazine 1994 Spring.

*Authors:* Greenberg P.

**Depression: a neglected major illness.**

*Publication:* J Clin Psychiatry 1993 11; 54(11): 419-424.

*Authors:* Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER.

**The economic burden of depression in 1990.**

*Publication:* J Clin Psychiatry 1993 11; 54(11): 405-418.

*Authors:* Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER.

## Abstracts

**Healthcare resource utilization and costs associated with psychiatric comorbidities in pediatric patients with attention-deficit/hyperactivity disorder.**

Orlando, FL October 16–19, 2023.

*Authors:* Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Chan D, Chen K, A. G, Childress A.

**Impact of social determinants of health on esketamine initiation among patients with treatment-resistant depression in the United States.**

Orlando, FL.

*Authors:* Harding L, Zhdanova M, Shah A, Voegel A, Chen C, Pilon D, Joshi K.

**Subcutaneous immunoglobulin treatment preferences among patients with chronic inflammatory demyelinating polyradiculoneuropathy: A discrete choice experiment.**

Montreal, Canada October 15 - 19, 2023.

*Authors:* Yang M, Zhou M, Ay H, Zichlin ML, Fix C, Wood J, Yang D, Butler L, Anderson-Smits C.

**A Real-World Assessment of Healthcare Costs Related to Agitation Associated with Alzheimer's Dementia.**

Boston, MA May 7 - 10, 2023.

*Authors:* Grossberg G, Urganus A, Schein J, Bungay R, Cloutier M, Gauthier-Loiselle M, Chan D, Guérin A, Aggarwal J.

**Real-world patient profile, treatment patterns and clinical outcomes for patients with migraine initiating gepants for acute treatment: a multicenter retrospective US chart review**

Austin, TX June 15-18, 2023.

*Authors:* Pivneva I, Vuvu F, Ye D, Watson T, Rhyne C, Joshi S, Betts KA, Bensink ME, Khodavirdi AC.

**Characterization of Patients with Duchenne Muscular Dystrophy across Previously Developed Health States.**

Boston, MA May 7-10, 2023.

*Authors:* Signorovitch J, Johnson M, Gomez-Lievano A.

**“Impact of living with an adult with major depressive disorder among households in the United States.**

San Antonio, Texas March 21-24, 2023.

*Authors:* Chitnis A, O’Callaghan L, Fournier A-A, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Greenberg P.

**Treatment patterns and outcomes in patients with spinal muscular atrophy (SMA): real-world findings of a retrospective US claims database analysis.**

San Antonio, TX March 21-24, 2023.

*Authors:* Toro W, Yang M, Georgieva M, Song W, Patel A, Jiang A, Zhao A, LaMarca N, Dabbous O.

**Healthcare Resource Use Among Patients Treated with Lurasidone or Cariprazine for Depressive Episodes Associated with Bipolar I Disorder.**

Washington D.C. May 15-18, 2022.

*Authors:* Niu X, Goldschmidt D, Edwards ML, Laubmeier K, Nelson M, Chin A, Zhou J, M T.

**Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): A Chart Review Study.**

*Abstract:* ISPOR 2022, Washington D.C. May 15-18, 2022.

*Authors:* Schein j, Cloutier m, Gauthier-Loiselle M, Bungay R, Guerin A, Childress A.

**Real-world Effectiveness of Fremanezumab Treatment for Reducing Monthly Migraine and Headache Days in US Patients Having Different Numbers of Prior Migraine Preventive Treatment Failures.**

Virtual 30 November-3 December 2021.

*Authors:* Thompson SF, Cohen JM, Sun R, Driessen MT, Seminerio M, Carr K, Mu F.

**Real-world Effectiveness of Quarterly and Monthly Fremanezumab for Reducing Migraine Days and Headache Days in Adult Patients With Migraine in the US.**

Virtual 20-21 November 2021.

*Authors:* Driessen M, Cohen JM, Ayyagari R, Seminerio M, Carr K, Thompson S, Jung A, Yim E.

**Reductions in Migraine and Headache Days After Initiating Fremanezumab for Patients With Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway in a US Real-world Setting.**

Virtual 30 November-3 December 2021.

*Authors:* Driessen MT, Patterson-Lomba O, Mu F, Thompson SF, Seminerio M, Carr K, Sun R, Totev T, Yim E, Ayyagari R, Cohen JM.

**Reductions in Migraine and Headache Days With Quarterly and Monthly Fremanezumab in Adult Patients With Migraine in a US Real-world Setting.**

Virtual 30 November-3 December 2021.

*Authors:* Thompson S, Cohen JM, Ayyagari R, Driessen M, Seminerio M, Carr K, Yim E.



**DMD/BMD - OUTCOME MEASURES: EP.125 Minimal detectable changes in functional measures in Duchenne muscular dystrophy (DMD): A study of multiple centers, networks and trial arms.**

*Abstract:* WMS 2021 Virtual Congress, Virtual Oct. 2021.

*Authors:* Muntoni F, Signorovitch J, Sajeev G, Done N, Yao Z, Goemans N, McDonald C, Mercuri E, Niks E, Wong B, Servais L, Straub V, de Groot I, Tian C, Manzur A, Vandenborne K, Dieye I, Lane H, Ward S.

**DMD/BMD - OUTCOME MEASURES: EP.122 Prognostic factors for pulmonary milestones in Duchenne muscular dystrophy (DMD).**

*Abstract:* WMS 2021 Virtual Congress, Virtual Sept, 2021.

*Authors:* Goemans N, Signorovitch J, Sajeev G, Wong B, Tian C, McDonald C, Mercuri E, Niks E, Freimark J, Jenkins M, Xu C, Ward S.

**SMA - Outcome Measures and Registries: EP.258 Health care resource utilization in pediatric patients with spinal muscular atrophy: Interim analysis of a US retrospective chart review study.**

*Abstract:* WMS 2021 Virtual Congress, Virtual Sept. 16-21, 2021.

*Authors:* Dabbous O, Yang M, Georgieva M, Toro W, LaMarca N, Patel A, Minkoff N, Carley C, Zhu J, Anderson A, Wu E.

**SMA - Treatment: EP.285 Nusinersen dosing patterns in US patients with spinal muscular atrophy (SMA) type 1: Findings from a retrospective claims database analysis.**

*Abstract:* WMS 2021 Virtual Congress, Virtual Sept 20, 2021.

*Authors:* Gauthier-Loiselle M, Cloutier M, Toro W, Patel A, Shi S, Davidson M, Bischof M, LaMarca N, Dabbous O.

**Migraine-related healthcare resource use and costs associated with migraine chronification: a panel-based chart review.**

*Abstract:* 7th EAN Congress, Virtual June 19-22, 2021.

*Authors:* Vo P, Swallow E, Wu E, Ellis M, Katcher N, Maier-Peuschel M, Naclerio M, Ritrovato D, Joshi P, Ferraris M.

**Real-world Reductions in Migraine and Headache Days After Initiating Fremanezumab for US Patients With Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway.**

Virtual June 3-6, 2021.

*Authors:* Driessen MT, Patterson-Lomba O, Mu F, Thompson S, Seminerio M, Carr K, Sun R, Totev T, Yim E, Ayyagari R, Cohen JM.

**Assessment of Patient Out-of-Pocket Costs for Antipsychotic Treatments Among Medicaid Beneficiaries with Schizophrenia.**

*Abstract:* Virtual ISPOR 2021, Virtual May 17-20, 2021.

*Authors:* Lin D, Pilon D, Benson C, Morrison L, Shah A, Lafeuille MH, Lefebvre P.

**Characteristics of Real-world Commercially Insured Patients with Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies.**

*Abstract:* Virtual ISPOR 2021, Virtual May 17-20, 2021.

*Authors:* Karkare S, Zhdanova M, Nash A, Pilon D, Morrison L, Shah A, Lefebvre P, Joshi K.

**Economic Burden of Attention-Deficit/Hyperactivity Disorder (ADHD) among Adults in the United States: A Societal Perspective.**

*Abstract:* Virtual ISPOR 2021, Virtual May 17-20, 2021.

*Authors:* Adler LA, M. C, P. G-S, Davidson M, Kinkead F, Guérin A, Lefebvre P, Schein J.

**Economic Burden of Attention-Deficit/Hyperactivity Disorder (ADHD) Among Children and Adolescents in the United States (US): A Societal Perspective.**

*Abstract:* Virtual ISPOR 2021, Virtual May 17-20, 2021.

*Authors:* Adler LA, M. C, P. G-S, Davidson M, Kinkead F, Guérin A, Lefebvre P, Schein J.

**Economic Burden of Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the United States.**

*Abstract:* Virtual ISPOR 2021, Virtual May 17-20, 2021.

*Authors:* Zhdanova M, Voelker J, Pilon D, Sheehan J, Morrison L, Joshi K, Vermette-Laforme M, Lefebvre P, Citrome L.

**Fremanezumab Treatment Reduced Monthly Migraine Days and Anxiety or Depression Symptoms for Migraine Patients With Comorbid Major Depressive Disorder or Generalized Anxiety Disorder in This US Real-world Study.**

Virtual May 1-3, 2021.

*Authors:* Cohen JM, Thompson S, Patterson-Lomba O, Driessen M, Seminerio M, Carr K, Totev T.

**Projecting the Economic Outcomes of Switching Patients with Schizophrenia from Oral Atypical Antipsychotics to Once-Monthly Paliperidone Palmitate and Once-Every-Three-Months Paliperidone Palmitate.**

*Abstract:* Virtual ISPOR 2021, Virtual May 17-20, 2021.

*Authors:* Lin D, Morrison L, Pilon D, Benson C, Ghelerter I, Vermette-Laforme M, Lefebvre P.

**The Economic Burden of Post-traumatic Stress Disorder in Adults in the United States from a 2018 Societal Perspective.**

*Abstract:* AMCP 2021, Virtual April 13-14, 2021.

*Authors:* Davis LL, Schein J, Cloutier M, Gagnon-Sanschagrín P, Maitland J, Urganus A, Guérin A, Lefebvre P, Houle C.

**Fremanezumab Treatment Results in Real-world Reductions in Monthly Migraine and Headache Days in Patients Having Different Numbers of Prior Migraine Preventive Treatment Failures in this US Study.**

Virtual April 12-16, 2021.

*Authors:* Cohen JM, Thompson SF, Sun R, Driessen M, Seminerio M, Carr K, Mu F.

**Real-World Adherence to Tetrabenazine or Deutetrabenazine Among Patients With Huntington's Disease.**

*Abstract:* Virtual AMCP 2021, Virtual April 12-16, 2021.

*Authors:* Claassen DO, Ayyagari R, Garcia-Horton V, Yang K, Noman A, Alexander J, Leo S.

**Real-world Data on Quarterly and Monthly Fremanezumab for Reducing Migraine Days and Headache Days in US Adult Patients With Migraine: Results From a Physician Chart Review Study.**

Virtual April 17th, 2021 - April 22nd, 2021.

*Authors:* Cohen JM, Thompson S, Ayyagari R, Driessen MT, Seminerio M, Carr K, Yim E.

**Real-world Data on Reductions in Migraine and Headache Days With Fremanezumab Treatment for US Patients With Chronic and Episodic Migraine: Results From a Physician Chart Review Study.**

Virtual June 3-6, 2021.

*Authors:* Cohen JM, Thompson S, Patterson-Lomba O, Driessen MT, Seminerio M, Carr K, Mu F.

**Treatment Patterns among Adults with Attention-Deficit/Hyperactivity Disorder in the United States – A Retrospective Claims Analysis.**

*Abstract:* AMCP 2021 Virtual April 13-14, 2021

*Authors:* Schein J, Childress A, Adams J, Cloutier M, Gagnon-Sanschagrín P, Maitland J, Bungay R, Guérin A, Lefebvre P.

**US Real-world Effectiveness of Quarterly and Monthly Fremanezumab for Reducing Migraine Days and Headache Days in Adult Patients With Migraine.**

Virtual April 17th, 2021 - April 22nd, 2021.

*Authors:* Cohen JM, Thompson S, Ayyagari R, Driessen MT, Seminerio M, Carr K, Yim E.

**US Real-World Reductions in Migraine and Headache Days for Patients With Chronic and Episodic Migraine Initiating Fremanezumab.**

April 17th, 2021 - April 22nd, 2021.

*Authors:* Cohen JM, Thompson s, Patterson-Lomba O, Driessen MT, Seminerio M, Carr K, Mu F.

**Caregiver perspectives on the burden and impact of agitation in caring for loved ones with dementia/Alzheimer's disease: A collaboration with UsAgainstAlzheimer's A-LIST®.**

*Abstract:* Clinical Trials on Alzheimer's Disease 2020, November 4-7, 2020.

*Authors:* Aigbogun MS, Cloutier M, Serra E, Frangiosa T, Biggar V, Baker R, Michael M, Gandhi H, Gauthier-Loiselle M.

**Reductions in migraine frequency and duration in patients with chronic migraine treated with erenumab: Interim results from a real-world multicenter chart-review study of US headache centers.**

*Abstract:* Migraine Trust Virtual Symposium 2020, Virtual October 3-9, 2020.

*Authors:* Faust E, Pivneva I, Yang K, Betts KA, Ahmed Z, Hogan R, Blumenfeld AM, Schim J, Feoktistov A, Carnes K, Bensink ME, Wu EQ, Chou DE, Chandler D.

**The Impact of Antipsychotic Dose Reduction Within a Medicare Population.**

*Abstract:* MDS 2020, Virtual September 12-16, 2020.

*Authors:* Ayyagari R, Mu F, Lax A, Carroll B.

**Healthcare Resource Use and Costs among Medicaid Beneficiaries with Prior Schizophrenia Relapse before and after Initiation of Once-Monthly Paliperidone Palmitate.**

*Abstract:* AMCP 2020, Houston, TX April 21-24, 2020.

*Authors:* Zhdanava M, Lafeuille M, Isabelle G, Morrison L, Lefebvre P.

**Medicaid Spending Associated with Relapse Episodes in Beneficiaries with Schizophrenia.**

*Abstract:* AMCP 2020, Houston, TX April 21-24, 2020.

*Authors:* Cote-Sergent A, Lafeuille M, Pilon D, Lefebvre P.

**Real-World Treatment Patterns With Second-Generation Oral Antipsychotics Among People With Schizophrenia Insured by Medicaid.**

*Abstract:* AMCP 2020, Houston, TX April 21-24, 2020.

*Authors:* Garcia Horton V, Signorovitch J, Macaulay D.

**A composite prognostic score for time to loss of walking ability in Duchenne muscular dystrophy (DMD).**

*Authors:* Goemans N, Signorovitch J, Sajeev G, Fillbrunn M, Wong H, Ward SJ, McDonald C, Mercuri E.

**Economic Burden of Privately Insured Patients Diagnosed With Major Depressive Disorder and Suicide Ideation or Suicide Attempt in the United States.**

*Abstract:* AMCP Nexus Conference, Maryland, USA October 29 - November 1, 2019

*Authors:* Zhdanava M, Neslusan C, Pilon D, Sheehan JJ, Morrison L, Shak N, Lefebvre P, Greenberg PE.

**Indirect comparison of the efficacy of fremanezumab versus erenumab in episodic migraine patients who had failed 2-4 prior migraine preventative treatments.**

*Abstract:* ISPOR Europe 2019 Copenhagen, Denmark 2-6 November 2019.

*Authors:* Mu F.

**Suitability of natural history data for external controls in Duchenne muscular dystrophy.**

*Authors:* Goemans N, Wong B, Muntoni F, McDonald C, Mercuri E, Manzur A, Signorovitch J, Sajeev G, Wong H, Hossain I, Jenkins M, Ward SJ.

**An Experimental Study to Assess the Professional and Social Consequences of Mild-to-Moderate Tardive**

*Abstract:* AMCP Nexus Conference Maryland, USA October 29 - November 1, 2019.

*Authors:* Goldschmidt D, Zhou M, Bousleiman S, Caroff SN, Carroll B.

**Treatment Patterns, Healthcare Resource Use, and Outcomes of Patients with Chronic and Episodic Migraines Treated with Erenumab: A Multicenter Chart-Review Study.**

*Abstract:* 61st Annual Scientific Meeting American Headache Society, Philadelphia, PA, USA July 11-14, 2019.

*Authors:* Faust E, Pivneva I, Betts KA, Ahmed Z, Joshi S, Hogan R, Blumenfeld A, Feoktistov A, Bensink M, Wu EQ, Chandler D.

**Cost Efficiency of Esketamine Nasal Spray Versus Standard of Care for Treatment Resistant Depression.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Desai U, Kirson NY, Guglielmo A, Le H, Spittle T, Tseng-Tham J, Shawi M, Sheehan JJ.

**Impact of Antipsychotic Treatment Switching in Patients With Schizophrenia, Bipolar Disorder, And Major Depressive Disorder.**

*Abstract:* American Academy of Neurology 71st Annual Meeting, Philadelphia, PA May 4-10, 2019.

*Authors:* Carroll B, Ayyagari R, Thomason D, Mu F, Philbin M.

**Is Increased Severity Status Associated with Incremental Economic Burden in Privately Insured US Patients with Treatment Resistant Depression?**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Zhdanova M, Pilon D, Szukis H, Sheehan J, Morrison L, Lefebvre P, Joshi K.

**A Phase 1b/2 study of RG6206(BMS-986089)in boys with Duchenne muscular dystrophy: 72-week update.**

*Abstract:* 61th Annual Meeting of the Japanese Society of Child Neurology. Japan, Nagoya, Japan May 31 - Jun 2, 2019.

*Authors:* Dregheci R, Wagner KR, Wong BL, Byrne BJ, Tian C, Jacobsen LK, Tirucherai GS, Rabbia M, Kletzl H, Yen K, Sajeev G, Signorovitch J, Ward SJ, Krishnan M.

**Level of Care Dependency and Functional Status Among Patients with Alzheimer's Disease and Agitation/Aggression Symptoms.**

*Abstract:* American Association for Geriatric Psychiatry (AAGP) 2019 Annual Meeting, Atlanta, GA Mar 1-4, 2019.

*Authors:* Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Sanon M.

**Real-world Utilization of Non-Pharmacological Therapy Prior to Initiation of Antipsychotic Treatment in the Management of Agitation in Patients with Dementia: Findings from a Large Retrospective Chart Review.**

*Abstract:* American Association for Geriatric Psychiatry (AAGP) 2019 Annual Meeting, Atlanta, GA Mar 1-4, 2019.

*Authors:* Sanon M, Gauthier-Loiselle M, Ladouceur M, Guerin A, Hartry A, Baker RA, Grundman M, Duffy R, Gwin K, Mergel V, Fillit H, Cloutier M.

**Severity of Agitation in Alzheimer's Disease: Proportion of Individuals Transitioning to Long-Term Residential Care using US National Alzheimer's Coordinating Center Data.**

*Abstract:* American Association for Geriatric Psychiatry (AAGP) 2019 Annual Meeting, Atlanta, GA Mar 1-4, 2019.

*Authors:* Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Sanon M.

**Ambulatory Function in Duchenne Muscular Dystrophy (Dmd): The Characteristic Trajectory and Variation across Individuals.**

*Abstract:* ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Signorovitch J, Muntoni F, Sajeev G, Yao Z, Ward SJ, Abrams KR.

**The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders.**

*Abstract:* 2017 Neuroscience Education Institute Psychopharmacology Congress, NEI 2017, Colorado Springs, CO Nov 8-12, 2017.

*Authors:* McEvoy J, Park T, Schilling T, Terasawa E, Ayyagari R, Carroll B.

**Hospital utilization rates following antipsychotic dose reductions among patients with schizophrenia.**

*Abstract:* 2017 Neuroscience Education Institute Psychopharmacology Congress, NEI 2017, Colorado Springs, CO Nov 8-12, 2017.

*Authors:* Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B.

**Mild traumatic brain injury in United States. Timing and modalities of brain imaging.**

*Abstract:* 3rd Joint Symposium of the International and National Neurotrauma Societies and AANS/CNS Section on Neurotrauma and Critical Care, Toronto, Canada Aug 11-16, 2018.

*Authors:* Pavlov V, Thompson-Leduc P, Toback S, Wen J, Shea J, Berdugo M, Zimmer L, Kirson N, Miller M.

**Development of a prognostic model for 1-year change in timed 4 stair-climb in duchenne patients.**

*Abstract:* 15th International Congress on Neuromuscular Diseases, ICNMD 2018, Vienna, Austria Jul 6-10, 2018.

*Authors:* Goemans N, Vanden Hauwe M, Signorovitch J, Sajeev G, Yao Z, Jenkins M, McDonald E, Dieye I, Ward SJ.

**The humanistic burden of postpartum depression: A systematic literature review.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Reinhart M, Patton C, Chawla A, Clemson C, Huang M.

**Outcomes among medicaid recipients with schizophrenia treated with once-every-three month paliperidone palmitate.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Joshi K, Lafeuille M, Pilon D, Emond B, Romdhani H, Lefebvre P, El Khoury AC.

**Treatment patterns and medicaid spending in comorbid schizophrenia populations: Once-monthly paliperidone palmitate vs oral atypical antipsychotics.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Kamstra R, Pilon D, Lefebvre P, Emond B, Joshi K.

**A systematic literature review and meta-analysis of prevalence estimates in migraine.**

*Abstract:* 11th European Headache Federation Congress Jointly with 31st Congress of the Italian Society for the Study of Headaches, Rome, Italy Dec 1-3, 2017.

*Authors:* Bilitou A, Vo P, Lopez-Leon S, Kelkar S, Cheung C, Gao E, Betts KA, Zhou Z.

**Adherence and Persistence on Long-acting Monotherapy and Combination Therapy in Adults with Attention-Deficit Hyperactivity Disorder (ADHD) in the US.**

*Abstract:* AMCP Nexus 2017, Dallas, TX Oct 16-19, 2017.

*Authors:* Zhou Z, ZY Zhou, Kelkar SS, Xie J, Grebla R.

**Deflazacort or prednisone treatment for duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Signorovitch JE, Sajeev G, McDonnell E, Yao Z.

**Impact of ocrelizumab vs. interferon beta-1a in delaying the deterioration of patients' daily functions and associated costs in relapsing-remitting multiple sclerosis.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Yang H, Duchesneau ED, Guerin A, Ma E, Thomas NP.

**The Burden of Tardive Dyskinesia Secondary to Antipsychotic Medication Use among Patient with Mental Disorders.**

*Abstract:* The 30th Annual Psych Congress, New Orleans, LA Sept 16-19, 2017.

*Authors:* McEnvoy J, Park T, Schilling T, Terasawa E, Ayyagari R, Carroll B.

**Stroke and myocardial infarction risk among newly diagnosed heart failure patients with reduced, borderline, and preserved left ventricle ejection fraction.**

*Abstract:* 21st Annual Scientific Meeting of the Heart Failure Society of America, Grapevine, TX Sept 16-19, 2017.  
*Authors:* Fonarow GC, Peterson ED, Greenberg B, Berger JS, Laliberte F, Zhao Q, Germain G, Lejeune D, Lefebvre P.

**Health care resource utilization before and after perampanel initiation for the treatment of epilepsy in the United States.**

*Abstract:* 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Montreal, QC, Canada Aug 26-30, 2017.  
*Authors:* Faught E, Laliberte F, Wang Z, Barghout V, Choi J, Haider B, Lejeune D, Germain G, Duh MS.

**Is the annual wellness visit adequate to impact cognitive care?**

*Abstract:* Alzheimer's Association International Conference, London, UK July 14-20, 2017.  
*Authors:* Fowler NR, Campbell NL, Pohl GM, Munsie LM, Kirson NY, Desai U, Trieschman EJ, Meiselbach MK, Andrews JS, Tanaka Y, Boustani MA.

**Trends in health service use and potentially avoidable hospitalizations prior to Alzheimer's disease diagnosis: A matched, retrospective study of U.S. medicare beneficiaries.**

*Abstract:* Alzheimer's Association International Conference, London, UK July 16-20, 2017.  
*Authors:* Desai U, Kirson NY, Mehta N, Wen J, Sheng Y, Ye W, Andrews JS.

**A systematic literature review and meta-analysis of epidemiologic studies in chronic and episodic migraine.**

*Abstract:* 3rd Congress of the European Academy of Neurology, Amsterdam, Netherlands June 24-27, 2017.  
*Authors:* Bilitou A, Vo P, Lopez S, Kelkar S, Cheung C, Gao E, Betts K, Zhou Z.

**Healthcare costs among patients with lennox-gastaut syndrome treated with clobazam.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.  
*Authors:* Pina-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Shen Y, Duh MS, Chatamra K, Kymes SM.

**Healthcare resource utilization and costs among adult schizophrenia patients using once-monthly versus twice-monthly long-acting antipsychotics.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.  
*Authors:* Benson C, Alcusky M, Pilon D, Durkin M, Xiao Y, Thompson-Leduc P, Lafeuille M, Lefebvre P.

**Assessing Preferences for Attributes of Disease-Modifying Therapies among Patients with Relapsing-Form of Multiple Sclerosis: A Discrete Choice Study.**

*Abstract:* American Academy of Neurology 69th Annual Meeting, Boston, MA Apr 22-28, 2017.  
*Authors:* Ye X, Kantor D, Barbato LM, Wakeford C, Yang M, Macaulay D, Marshall T.

**Healthcare resource utilization among patients with lennox-gastaut syndrome treated with clobazam.**

*Abstract:* 69th American Academy of Neurology Annual Meeting, Boston, MA April 22-28, 2017.  
*Authors:* Pina-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Shen Y, Sheng Duh M, Isojarvi J, Kymes S, Saurer TB.

**Economic burden of illness for patients with traumatic brain injury resulting in chronic motor impairment.**

*Abstract:* 12th World Congress on Brain Injury of the International Brain Injury Association, New Orleans, LA Mar 29-Apr 1, 2017.  
*Authors:* Swallow E, Liu WJ, Wen J, Fang A, Kirson N, Birnbaum H, Bates D.

**Incremental risk of ischemic stroke over time in newly diagnosed heart failure patients without atrial fibrillation.**

*Abstract:* 66th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, Washington, DC Mar 17-19, 2017.  
*Authors:* Berger JS, Peterson E, Laliberte F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir M.

**Adherence to QD vs. BID medications in nvaf patients is associated with reduced risk of ischemic stroke: A modeling study using rct and claims data.**

*Abstract:* American Heart Association's 2016 Scientific Sessions and Resuscitation Science Symposium, Nov 2016.

*Authors:* McHorney CA, Peterson E, Ashton V, Laliberte F, Crivera C, Sheikh N, Germain G, Schein J, Xiao Y, Lefebvre P.

**Risk of ischemic stroke in newly diagnosed heart failure patients.**

*Abstract:* American Heart Association's 2016 Scientific Sessions and Resuscitation Science Symposium, New Orleans, LA Nov 12-14, 2016.

*Authors:* Berger JS, Peterson E, Laliberte F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir M.

**Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the first-HD and tetra-HD trials.**

*Abstract:* 141st Annual Meeting of the American Neurological Association, Baltimore, MD Oct 16-18, 2016.

*Authors:* Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D.

**Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare resource use and costs in veterans with schizophrenia with limited antipsychotic exposure in the prior 12 months.**

*Abstract:* 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland Aug 25-28, 2016.

*Authors:* Lefebvre P, Muser E, Joshi K, DerSarkissian M, Bhak R, Kageleiry A, Duh MS, Shiner B, Young-Xu Y.

**Prognostic model for 1-year change in 6-minute walk distance (6MWD) in patients with duchenne muscular dystrophy (DMD).**

*Abstract:* 14th International Congress on Neuromuscular Diseases, Toronto, CA July 5-9, 2016.

*Authors:* Goemans NM, Signorovitch J, Swallow E, Song J, Ward SJ.

**Non-motor symptoms in advanced Parkinson's disease patients treated with levodopa/carbidopa intestinal gel, deep brain stimulation, or continuous subcutaneous apomorphine: A systematic literature review and pooled analysis.**

*Abstract:* 20th International Congress of Parkinson's Disease and Movement Disorders, Berlin, Germany Jun 19-23, 2016.

*Authors:* Chaudhuri KR, Terasawa E, Jalundhwala Y, Macaulay D, Ayyagari R, Zhou ZY, Marshall T, Chatamra K, Yucel A, Sail K.

**Can indirect comparison methods mitigate evolving trial populations in adjunctive antiepileptic drug trials? A propensity score matched indirect comparison of brivaracetam and levetiracetam.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S.

**A life-course assessment of medication use and medical costs of lennox-gastaut syndrome (LGS).**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Montouris G, Pina-Garza JE, Vekeman F, Cheng WY, Tuttle EG, Giguere-Duval P, Duh MS, Isojarvi J.

**Real-world costs of ischemic stroke by discharge status.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Mu F, Hurley D, Betts K, Messali A, Paschoalin M, Wu EQ.

**Association of Rescue Medication Use with Clinical Outcomes and Health Care Costs in Patients with Seizure Clusters.**

*Abstract:* AMCP's 28th Annual Meeting, San Francisco, CA Apr 19-22, 2016.

*Authors:* Vazquez B, Hesdorffer D, Wu E, Macaulay D, Sorg R, Squillacote D, Sidovar M, Guo A.

**Persistent use of dalfampridine extended release on healthcare resource utilization and cost in multiple sclerosis: A claims database analysis.**

*Abstract:* 68th American Academy of Neurology Annual Meeting, Vancouver, BC, Canada Apr 15-21, 2016.

*Authors:* Krieger S, Niyazov A, Macaulay D, Terasawa E, Wu E, Aupperle P, Guo A.

**Real-world durability of long-term relapse rates among patients with multiple sclerosis receiving fingolimod therapy: A retrospective US claims database analysis.**

*Abstract:* 68th American Academy of Neurology Annual Meeting, Vancouver, BC, Canada Apr 15-21, 2016.

*Authors:* Fox E, Johnson K, Lin F, Signorovitch J, Li N, Peeples M, Ristovska L, Souroutzidis A, Hong W, Herrera V.

**Development of a classifier to identify patients with Lennox–Gastaut syndrome in health insurance claims databases via the random forest methodology.**

*Abstract:* 69th Annual Meeting of the American Epilepsy Society, Philadelphia, PA Dec 4-8, 2015.

*Authors:* Vekeman F, Piña-Garza JE, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Duh MS, Shen V, Isojarvi J, Montouris GD.

**A life-course assessment of treatment patterns and healthcare costs of Lennox-Gastaut syndrome.**

*Abstract:* 69th Annual Meeting of the American Epilepsy Society, Philadelphia, PA; Dec 4-8, 2015.

*Authors:* Montouris GD, Piña-Garza JE, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, Duh MS, Shen V, Isojarvi J.

**Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.**

*Abstract:* ISPOR, Sep 2015.

*Authors:* Setyawan J, Yang H, Cheng D, Cai X, Signorovitch J, Xie J, Erder MH.

**Predicting factors for reaching stabilized maintenance with once-monthly paliperidone almitate in Medicaid patients with schizophrenia.**

*Abstract:* US Psychiatric & Mental Health Congress, San Diego, CA Sep 10-13, 2015.

*Authors:* Muser E, Pilon D, Emond B, Xiao Y, Amos T, Lefebvre P, Benson C.

**Treatment patterns in schizophrenia patients reaching stabilized maintenance therapy with once-monthly paliperidone palmitate.**

*Abstract:* US Psychiatric & Mental Health Congress, San Diego, CA Sep 10-13, 2015.

*Authors:* Amos T, Pilon D, Muser E, Emond B, Xiao Y, Lefebvre P, Benson C.

**Functional limitations and healthcare resource utilization for individuals with cognitive impairment without dementia: Findings from a U.S. population-based survey.**

*Abstract:* 2015 Alzheimer's Association International Conference, Washington, DC Jul 18-23, 2015.

*Authors:* Andrews JS, Kirson NY, Desai U, Enloe CJ, L R, King S, Birnbaum HG, Fleisher AS, Ye W, Wroblewski KK.

**Development of a risk score to guide individualized treatment selection in attention-deficit/hyperactivity disorder.**

*Abstract:* 16th International Congress of European Society for Child and Adolescent Psychiatry, Madrid, Spain Jun 20-24, 2015.

*Authors:* Grebla R, Setyawan J, Yang H, Cheng D, Cai X, Signorovitch J, Xie J, Erder M.

**Systematic literature review and mixed treatment comparison of guanfacine extended release (GXR) versus other pharmacotherapies in children and adolescents with attention deficit/hyperactivity disorder (ADHD).**

*Abstract:* 16th International Congress of European Society for Child and Adolescent Psychiatry, Madrid, Spain Jun 20-24, 2015.

*Authors:* Joseph A, Xie J, Bischof M, Zhanabekova Z, Cai S, Zhuo Y, Huss M, Sikirica V.

**Bone pain, skeletal related events and opioid use in patients with prostate cancer and bone metastases.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Valderrama A, Eapen S, Hennessey KA, Jones C, Wen L, Germino J, Duh MS.



**The burden of treatment switch in patients with major depression: A US retrospective administrative claims analysis.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Perez V, Gauthier G, Guerin A, Francois C, Merikle E.

**Description of prophylactic drug utilization patterns in migraine patients.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Shei A, Woolley JM, Desai PR, Enloe CJ, Kirson NY, Birnbaum HG, Corey-Lisle PK, Sapra S.

**Healthcare resource utilization associated with rescue medication use in adult patients with seizure clusters: A retrospective chart review.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Vazquez B, Sidovar M, Squillacote D, Wu E, Macaulay D, Sorg R, Guo A.

**Healthcare Utilization and costs among Adults with Major depressive Disorder treated with Vilazodone vs. Other selective Serotonin Reuptake Inhibitors.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Zhou Z, Sun SX, Chopra P, Zhong Y, Totev T, Signorovitch JE.

**Predictors of receiving at least 5 claims for once monthly paliperidone palmitate among Medicaid patients with schizophrenia.**

*Abstract:* American Psychiatric Association Convention 168th Annual Meeting, Toronto, ON, Canada May 16-20, 2015.

*Authors:* Lafeuille MH, Xiao Y, Muser E, Pesa J, Fastenau J, Duh MS, Lefebvre P.

**Real-world treatment outcomes in adults with attention deficit/hyperactivity disorder treated with lisdexamfetamine versus atomoxetine following methylphenidate treatment.**

*Abstract:* World Congress of ADHD, Glasglow, Scotland May 28-31, 2015.

*Authors:* A. Joseph, M. Cloutier, A. Gu erin, R. Nitulescu, V. Sikirica.

**Relative efficacy and tolerability of vortioxetine versus approved antidepressants for major depressive disorder: A meta-regression of clinical trials.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Diamand F, Danchenko N, Brignone M, Rive B, Perez V, Ereshefsky L, Francois C, Merikle E.

**Treatment patterns among chronic users of immediate-release oxycodone initiating treatment with extended-release opioids.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Pergolizzi JV, Kirson NY, Bell J, Jones C, Mantovanelli F, Cummings AG, Birnbaum HG, Ben-Jospeh R.

**Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.**

*Abstract:* AMCP's 27th Annual Meeting, San Diego, CA Apr 7-10, 2015.

*Authors:* Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P.

**Development of a claims-based classifier to identify Lennox-Gastaut Syndrome.**

*Abstract:* 67th Annual Meeting of the American Academy of Neurology, Washington, DC Apr 18-25, 2015.

*Authors:* Pina-Garza EJ, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Duh MS, Shen V, Isojarvi J, Montouris GD.

**A systematic review and network meta-analysis of eslicarbazepine acetate and other recently-approved anti-epileptic drugs for adjunctive treatment of partial-onset seizures in adults.**

*Abstract:* 68th Annual Meeting of the American Epilepsy Society, Seattle, WA Dec 5-9, 2014.

*Authors:* Betts K, Bollu V, De G, Blum D, Velez F.

**Clinical characteristics and treatment pattern in cluster seizures: A preliminary chart review analysis.**

*Abstract:* 68th Annual Meeting of the American Epilepsy Society, Seattle, WA Dec 5-9, 2014.

*Authors:* Vazquez B, Wu E, Macaulay D, Sidovar M, Roberts H, Squillacote D, Rabinowicz AL, Guo A.

**The economic burden of central nervous system events among patients with partial onset seizures treated with antiepileptic drugs.**

*Abstract:* 2013 Annual Meeting of the American Epilepsy Society, Washington, DC Dec 6-10, 2013.

*Authors:* Velez F, Bollu V, M. C, Guerin A, Carter V, Heroux J, Nitulescu R, Wu EQ.

**Impact of treatment-associated adverse events on healthcare resource utilization and costs among patients with partial onset seizures: A longitudinal analysis.**

*Abstract:* 2013 Annual Meeting of the American Epilepsy Society, Washington, DC Dec 6-10, 2013.

*Authors:* Bollu V, Velez F, Cloutier M, Guerin A, Carter V, Heroux J, Dea K, Wu EQ.

**Systematic literature review and mixed treatment comparison of GXR versus other treatments in children and adolescents with attention deficit hyperactivity disorder (ADHD).**

*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8-12, 2014.

*Authors:* Joseph A, Ayyagari R, Bischof M, Cai S, Xie M, Zhanabekova Z, Sikirica V.

**Comparison of re-hospitalization and emergency room visit patterns among patients with schizophrenia receiving paliperidone palmitate or oral atypical antipsychotics in an inpatient setting.**

*Abstract:* 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Taipei, Taiwan (Republic of China) Oct 24-27, 2014.

*Authors:* Lafeuille MH, Grittner A, Muser E, Fastenau J, Duh MS, Lefebvre P.

**Healthcare resource utilization preceding first diagnosis for fragile x syndrome (fxs).**

*Abstract:* ANA 2014 Annual Meeting, Baltimore, MD Oct 12-14, 2014.

*Authors:* Nazareth T, Marynchenko M, Chopra P, Li N, Zhou Z, Signorovitch J, Wu E, Marvel J, Ahmed S, Sasane R.

**Medical specialists involved in caring for patients with fragile x syndrome (FXS): a Medicaid perspective.**

*Abstract:* ANA 2014 Annual Meeting, Baltimore, MD Oct 12-14, 2014.

*Authors:* Nazareth T, Marynchenko M, Li N, Chopra P, Zhou Z, Signorovitch J, Wu EQ, Ahmed S MJ, Sasane R. .

**Pulse pressure and stroke risk: Development and validation of a new stroke risk model.**

*Abstract:* 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Taipei, Taiwan (Republic of China) Oct 24-27, 2014.

*Authors:* Vekeman F, Ayyagari R, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

**Assessing the impact of time-dependent treatment with once-monthly paliperidone palmitate or oral atypical antipsychotics on healthcare resource utilization and Medicaid spending among patients with schizophrenia using marginal structural models.**

*Abstract:* US Psych 27th Annual Meeting, Orlando, FL Sep 20-23, 2014.

*Authors:* Muser E, Lafeuille M, Xiao Y, Lefebvre P, Pesa J, Fastenau J, Duh MS.

**Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.**

*Abstract:* 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting Boston, MA Sept 9-13, 2014.

*Authors:* Tauhid S, Chu R, Sasane R, Glanz BI, Neema M, Miller JR, Kim G, Sigornivich JE, Healy BC, Chitnis T, Weiner HL, Bakshi R.

**Comparison of healthcare resource utilization and Medicaid spending among patients with schizophrenia treated with once monthly paliperidone palmitate or oral atypical antipsychotics using the inverse probability of treatment weighting approach.**

*Abstract:* US Psych 27th Annual Meeting, Orlando, FL Sep 20-23, 2014.

*Authors:* Muser E, Lafeuille M, Xiao Y, Lefebvre P, Pesa J, Fastenau J, Duh MS.

**Impact of improved adherence to disease-modifying therapies on healthcare resource utilization and medical costs for patients with multiple sclerosis.**

*Abstract:* 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting, Boston, MA Sep 10-13, 2014.

*Authors:* Yermakov S, Davis M, Calnan M, Fay M, Buckley B, Sarda S, Duh MS, Iyer R.

**The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis.**

*Abstract:* 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting, Boston, MA Sep 10-13, 2014.

*Authors:* Vollmer T, Signorovitch JE, Huynh L, Galebach P, Kelley C, Marvel J, Di Bernardo A, Sasane R.

**Real-world titration of disease modifying therapies in the treatment of multiple sclerosis: Findings from a survey of neurologists.**

*Abstract:* 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting, Boston, MA Sep 10-13, 2014.

*Authors:* Nazareth T, Marvel J, Sikirica S, Xie J, Reichmann W, Zhao C, Sasane R.

**Assessing the economic burden of Alzheimer's disease patients treated by specialists within three months of preliminary diagnosis of cognitive decline.**

*Abstract:* Alzheimer's Association International Conference, Copenhagen, Denmark July 12-17, 2014.

*Authors:* Hunter CA, Kirson NY, Desai U, Ristovska L, Cummings AK, Birnbaum HG, Kahle-Wroblewski K, Ye W, Andrews JS.

**Excess costs associated with possible misdiagnosis of Alzheimer's disease among patients with vascular dementia in a UK CPRD population.**

*Abstract:* Alzheimer's Association International Conference, Copenhagen, Denmark Jul 12-17, 2014.

*Authors:* Happich M, Kirson NY, Desai U, King S, Birnbaum HG, Price D, Belger M, Hunter CA, Lenox-Smith AJ, Reed CC.

**Comparison of re-hospitalization, emergency room visits, and hospital costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics in an inpatient setting.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Lafeuille MH, Grittner AM, Fortier J, Muser E, Fastenau J, Duh MS, Lefebvre P.

**Effect of improving adherence to disease-modifying agents on health care resource utilization and medical costs in patients with multiple sclerosis.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Yermakov S, Davis M, Calnan M, Fay M, Duh M, Iyer R.

**Factors associated with performance on the Medicaid HEDIS measure: Continuity of antipsychotic (AP) medications for treatment of schizophrenia.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Lafeuille MH, Frois C, Cloutier M, Duh MS, Lefebvre P, Pesa JA, Clancy Z, Fastenau J, Durkin M.

**Healthcare resource utilization prior to first diagnosis in patients with newly diagnosed fragile x syndrome (FXS): A multi-state Medicaid perspective.**

*Abstract:* APA 167th Annual Meeting, New York, NY May 3-7, 2014.

*Authors:* Signorovitch J, Wu E, Li N, Chopra P.

**Medication use, medical services and comorbidities associated with fragile x syndrome (FXS): A multi-state Medicaid perspective.**

*Abstract:* APA 167th Annual Meeting, New York, NY May 3-7, 2014.

*Authors:* Signorovitch J, Wu E, Li N, Chopra P.

**Systematic review of long-acting injectables (LAI) versus oral atypical antipsychotics (OA) on hospitalization in schizophrenia.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Lafeuille MH, Cloutier M, Fortier J, Duh MS, Fastenau J, Dirani R, Lefebvre P.

**Treatment patterns of patients receiving paliperidone palmitate in an inpatient setting.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Lafeuille MH, Fortier J, Grittner AM, Muser E, Fastenau J, Duh MS, Lefebvre P.

**Glioblastoma treatment patterns and outcomes and resource use in the united states.**

*Abstract:* 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in Conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology, San Francisco, CA Nov 21-24, 2013.

*Authors:* Girvan A, Carter G, Li L, Kaltenboeck A, Chawla A, Ivanova J, Koh M, Stevens J, Lahn M.

**Health care resource use and direct costs associated with fragile x syndrome (FXS) in the United States.**

*Abstract:* ISPOR 16th Annual European Congress, Dublin, Ireland Nov 2-6, 2013.

*Authors:* Vekeman F, Gauthier-Loiselle M, Faust E, Lefebvre P, Lahoz R, Duh MS, Sacco P.

**Health care resource utilization and costs associated with atypical antipsychotics use in children and adolescents with attention deficit/hyperactivity disorder in Quebec, Canada.**

*Abstract:* ISPOR 16th Annual European Congress, Dublin Ireland Nov 2-6, 2013.

*Authors:* Lachaine J, Sikirica V, De G, Van Stralen J, BenAmor L, Hodgkins P, Yang H, Heroux J.

**Pulse pressure and stroke risk: Development and validation of a stroke risk equation.**

*Abstract:* ISPOR 4th Latin America Conference, Buenos Aires, Argentina Sep 12-14, 2013.

*Authors:* Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

**Development and validation of a claims-based algorithm to identify urinary retention in patients receiving antiepileptic drugs.**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Duh MS, Ishihara L, Cheng W, Quinlan SC, Zhao Y, Irizarry M.

**Incidence of stimulant augmentation among children and adolescents with attention/deficit hyperactivity disorder (ADHD) during 2010.**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Betts KA, Sikirica V, Hodgkins P, Du E, Zhou Z, Erder HM, Wu EQ.

**Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Lafeuille MH, Gravel J, Lefebvre P, Fasteneau J, Muser E, Doshi D, Duh MS.

**Period prevalence of therapy combination and switching among children and adolescents with attention deficit/hyperactivity disorder (ADHD) treated with stimulants in the Canadian province of Quebec.**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Lachaine J, Sikirica V, Cloutier M, BenAmor L, Hodgkins P, Van Stralen J, Carter V, Guerin A.

**Excess costs associated with misdiagnosis of Alzheimer's disease among u.s. Medicare beneficiaries with vascular dementia or parkinson's disease.**

*Abstract:* Alzheimer's Association International Conference, Boston, MA Jul 13-18, 2013.

*Authors:* Kirson N, Hunter C, Desai U, Cummings A, San Roman A, Faries D, Hardwick C, Birnbaum H.

**Therapy combination: a prevalent pattern among children and adolescents with attention-deficit/hyperactivity disorder treated with stimulants in the Canadian province of Quebec. .**

*Abstract:* World Congress on ADHD, Milan, Italy June 6-9, 2013.

*Authors:* BenAmor L, Sikirica V, De G, Lachaine J, Cloutier M, van Stralen J, Héroux J, Yang H, Hodgkins P.

**Assessing the impact of a Medicaid prior authorization (PA) policy for duloxetine on antipsychotic use among patients with depression.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Birnbaum HG, Ivanova JI, Waldman T, Swallow E, Cummings AK, Clark T, Peng X, Swindle R.

**Burden of schizophrenia on selected comorbidities costs.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Lafeuille MH, Dean J, Fastenau J, Panish JM, Olson WH, Markowitz M, Duh MS, Lefebvre P.

**A meta-analysis of efficacy and safety of prescription opioids, including formulations with tamper-resistant technologies, in non-cancer pain management.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Michna E, Cheng W, Korves C, Schaaf D, Andrews R, Zhou Z, Mardekian J, Joshi AV, Birnbaum H, Duh MS.

**Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Lafeuille MH, Gravel J, Lefebvre P, Fasteneau J, Muser E, Doshi D, Duh MS.

**Guanfacine immediate release vs. Guanfacine extended release: Comparative medication adherence, resource utilization, and healthcare costs among children and adolescents with attention-deficit/hyperactivity disorder (ADHD).**

*Abstract:* 16th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Colorado Springs, CO Apr 21-24, 2013.

*Authors:* Sikirica V, Xie J, He TL, Erder MH, Hodgkins P, Yang H.

**Detecting undiagnosed depression in patients with moderate to severe psoriasis: Development and validation of a risk score for use in dermatology.**

*Abstract:* American Academy of Dermatology 71st Annual Meeting, Miami Beach, FL Mar 1-5, 2013.

*Authors:* Cather JC, Sundaram M, Horn EJ, Yang M, Signorovitch JE.

**An economic model of improved acute stroke care in the management of acute ischemic stroke from a state Medicaid perspective.**

*Abstract:* 2013 International Stroke Conference and Nursing Symposium of the American Heart Association/American Stroke Association, Honolulu, HI Feb 6-8, 2013.

*Authors:* Zhou ZY, Fan L, Chen E, Xie J, Wu EQ.

**Differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012, Washington, DC Nov 9-14, 2012.

*Authors:* Van Vollenhoven RF, Shaw JW, Cifaldi MA, Signorovitch J, Wu EQ, Samuelson T, Faust E, Emery P.

**Economic value of screening for early parkinson's disease in a european setting.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Johnson S, Birnbaum HG, Kaltenboeck A, Diener M, Siderowf A.

**Economic value of slowing Parkinson's disease in Germany: Modeling progression through Hoehn and Yahr stages.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Johnson S, Birnbaum HG, Kaltenboeck A, Diener M, Siderowf A.

**A comparison of rates and reasons for urgent care utilization among children with ADHD treated with atypical antipsychotics vs. nonantipsychotics.**

*Abstract:* Institute of Psychiatric Services Meeting, New York, NY Oct 4-7, 2012.

*Authors:* Betts KA, Pliszka SR, Sikirica V, Dammerman R, Hodgkins PS, Samuelson TM, Xie J, Robertson B, Wu EQ, Erder MH.

**Impact of the frequency of multiple sclerosis relapses on the direct and indirect cost burden of family caregivers.**

*Abstract:* 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Lyon, France Oct 10-13, 2012.

*Authors:* Parise H, Laliberte F, Lefebvre P, Duh MS, Kim E, Agashivala N, Abouzaid S, Weinstock-Guttman B.

**Period prevalence of stimulant augmentation among pediatric attention deficit/hyperactivity disorder (ADHD) patients during 2009: A retrospective analysis of a managed care population.**

*Abstract:* 59th AACAP Annual Meeting, San Francisco, CA Oct 23-28, 2012.

*Authors:* Sikirica V, DiBello J, Betts KA, Hodgkins PS, Zhou ZY, Xie J, DeLeon A, Erder MH, EQ W.

**Economic value of screening for early parkinson's disease in a european setting.**

*Abstract:* 16th Congress of the European Federation of Neurological Societies, Stockholm, Sweden Sep 8-11, 2012.

*Authors:* Johnson S, Siderowf AD.

**Economic value of slowing parkinson's disease in germany: Modelling progression through hoehn and yahr stages.**

*Abstract:* 16th Congress of the European Federation of Neurological Societies, Stockholm, Sweden Sep 8-11, 2012.

*Authors:* Johnson SJ, Birnbaum HG, Siderowf AD.

**The impact of long-acting injectable vs oral antipsychotics on hospitalization rates in patients with schizophrenia: A systematic review and meta-analysis.**

*Abstract:* 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012.

*Authors:* Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.

**Impact of long-acting injectable vs. oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients.**

*Abstract:* 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012.

*Authors:* Lafeuille MH, Laliberte-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS.

**Comparison of discontinuation risk in patients initiated on lisdexamfetamine dimesylate (LDX) vs. other medications for the treatment of attention deficit/hyperactivity disorder (ADHD): A retrospective claims analysis.**

*Abstract:* 20th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions, Paris France Jul 21-25, 2012.

*Authors:* Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder MH.

**Prevalence, comorbidity burden and treatment of alzheimer's disease among the elderly in the united states.**

*Abstract:* Alzheimer's Association International Conference, Vancouver, BC, Canada Jul 14-19, 2012.

*Authors:* Ivanova J, Birnbaum H, Desai U, Kirson N, Cummings A, San Roman A, Rao S, Andrews R, Doan Q, Zachry W.

**An application of group-based modeling approach for trajectory recognition: The developmental courses of hyperactivity and inattentive symptoms.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Cheng W, Goodwin R, Wu P, Vitaro F, Tremblay R.

**Economic value of screening for early parkinson's disease.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Johnson S, Siderowf A.

**Economic value of slowing parkinson's disease to payers and patients: Modeling progression through hoehn and Yahr stages.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Johnson S, Diener M, Kaltenboeck A, Birnbaum H, Grubb E, Siderowf A.

**The impact of long-acting injectable versus oral antipsychotics on hospitalization rates in patients with schizophrenia: A systematic review and meta-analysis.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.

**Impact of long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Lafeuille MH, Laliberte-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS.

**Incremental clinical and economic burden of uncontrolled partial-onset seizures in a privately-insured population.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Paradise PE, Parise H, Duh MS, Bowers BW, Faught E.

**Model of rasagiline versus standard of care for parkinson's disease: Comparison of progression effects.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Johnson S, Wang ST, Birnbaum H, Grubb E.

**Treatment patterns, resource utilization and costs associated with guanfacine immediate release versus guanfacine extended release among children and adolescents with attention deficit/hyperactivity disorder (ADHD).**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* DiBello J, Sikirica V, Samuelson T, Xie J, He T, Erder MH.

**Associations of hypertension with risk of cardiovascular events among chinese stroke patients in the US.**

*Abstract:* American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition, New York, NY May 19-22, 2012.

*Authors:* Fung G, Kahler K, Xie J, Marynchenko M, Wu E, Kam I, Yang W.

**Characteristics and use patterns of chronic hydrocodone users.**

*Abstract:* 31st Annual Scientific Meeting of the American Pain Society, Honolulu, HI May 16-19, 2012.

*Authors:* Rice J, Samuelson T, Birnbaum H, Katz N.

**A comparison of rates and reasons for urgent care utilization among children with ADHD treated with atypical antipsychotics vs. nonantipsychotics.**

*Abstract:* 165th APA Annual Meeting, Philadelphia, PA May 5-9, 2012.

*Authors:* Betts KA, Pliszka SR, Sikirica V, Dammerman R, Hodgkins PS, Samuelson TM, Xie J, Robertson B, Wu EQ, Erder MH.

**Risk of cardiovascular events associated with hypertension among chinese and caucasian stroke patients in the US.**

*Abstract:* American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition, New York, NY May 19-22, 2012.

*Authors:* Fung G, Kahler K, Xie J, Liu N, Wu E, Kam I, Yang W.

**Urgent care utilization for adolescents treated with atypical antipsychotics or nonantipsychotics: A comparison of rates and reasons.**

*Abstract:* 165th APA Annual Meeting, Philadelphia, PA May 5-9, 2012.

*Authors:* Pliszka SR, Sikirica V, Betts K, Hodgkins PS, Samuelson TM, Xie J, Dammerman R, Robertson B, Wu EQ, Erder MH.

**Cost implications of early treatment among patients with alzheimer's disease - A Medicaid perspective.**

*Abstract:* 64th American Academy of Neurology Annual Meeting, New Orleans, LA Apr 21-28, 2015.

*Authors:* Geldmacher D, Kirson N, Birnbaum H, Eapen S, Cummings K, A, Joish V.

**Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke.**

*Abstract:* 64th American Academy of Neurology Annual Meeting, New Orleans, LA Apr 21-28, 2012.

*Authors:* Switzer J, Demaerschalk B, Xie J, Fan L, Villa K, Wu E.

**Cost-utility analysis of hub-and-spoke telestroke networks for the management of acute ischemic stroke from a societal perspective.**

*Abstract:* 64th American Academy of Neurology Annual Meeting, New Orleans, LA Apr 21-28, 2012.

*Authors:* Demaerschalk B, Switzer J, Xie J, Fan L, Villa K, Wu E.

**Atypical antipsychotics versus non-antipsychotics: Comparative treatment patterns, resource utilization, and costs in stimulant-treated adolescents with adhd who require subsequent pharmacotherapy.**

*Abstract:* AMCP's 24th Annual Meeting, San Francisco, CA Apr 18-20, 2012.

*Authors:* Sikirica V, Pliszka SR, Betts K, Hodgkins P, Samuelson T, Xie J, Dammerman R.

**Comparison of Deviation Rates from the Labeled Daily Average Consumption in Patients Initiated on Stimulant Medication for the Treatment of Attention-Deficit/Hyperactivity Disorder.**

*Abstract:* ISPOR 2012, 2012.

*Authors:* Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder M.

**Characteristics, clinical and economic outcomes in Medicaid pediatric vagus nerve stimulation (VNS) therapy patients for the treatment of refractory epilepsy.**

*Abstract:* 65th Annual Meeting of the American Epilepsy Society, Baltimore, MD Dec 2-6, 2011.

*Authors:* Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

**Comparison of treatment adherence in patients initiated on lisdexamfetamine dimesylate vs. other medications for the treatment of attention deficit/ hyperactivity disorder: A retrospective study.**

*Abstract:* The American Professional Society of ADHD and Related Disorders, Current Concepts and Future Developments Conference, Philadelphia, PA Nov 19, 2011.

*Authors:* Setyawan J, Hodgkins PS, Wu EQ, Guérin A, Gauthier G, Cloutier M, Erder MH.

**Cost-Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Psychostimulant Compared to Psychostimulant Monotherapy for the Treatment of Attention Deficit/Hyperactivity Disorder in Children and Adolescents.**

*Abstract:* ISPOR 2011, Nov 5-8, 2011.

*Authors:* Sikirica V, Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu E.



**Effect of treatment timing on risk of institutionalization among patients with Alzheimer's disease.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Geldmacher DS, Kirson NY, Birnbaum HG, Kantor E, Eapen S, Joish VN.

**Comparative efficacy of guanfacine extended release and atomoxetine for the treatment of oppositional symptoms in children with attention-deficit/ hyperactivity disorder (ADHD) and comorbid oppositional defiant disorder (ODD).**

*Abstract:* CADDRA 2011 Annual ADHD Conference, Toronto, ON, Canada Oct 14-16, 2011.

*Authors:* Signorovitch JE, Sikirica V, Lu M, Xie J, Wu EQ, Erder MH.

**Comparison of treatment adherence in patients initiated on lisdexamfetamine dimesylate (LDX) vs. other medications for the treatment of ADHD: A retrospective study.**

*Abstract:* AACAP/CACAP Joint Annual Meeting, Toronto, ON, Canada Oct 18-23, 2011.

*Authors:* Setyawan J, Hodgkins PS, Wu EQ, Guérin A, Gauthier G, Cloutier M, Erder MH.

**Treatment patterns, resource utilization, and costs associated with atypical antipsychotics vs. non-antipsychotics added to or switched from stimulants among children with attention-deficit/ hyperactivity disorder (ADHD).**

*Abstract:* AMCP's 2011 Educational Conference, Atlanta, GA Oct 19-21, 2011.

*Authors:* Sikirica V, Betts KA, Erder MH, Xie J, Samuelson TM, Hodgkins PS, Wu EQ.

**Characteristics, clinical and economic outcomes in Medicaid patients 17 years and younger receiving vagus nerve stimulation (VNS) therapy for the treatment of refractory epilepsy.**

*Abstract:* 29th International Epilepsy Congress, Rome, Italy Aug 28-Sept 1, 2011.

*Authors:* Helmers SL, Duh MS, Guirin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

**Impact of vagus nerve stimulation (VNS) therapy on clinical outcomes and costs in Medicaid patients with drug-resistant epilepsy.**

*Abstract:* 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Chicago, IL Aug 14-17, 2011.

*Authors:* Duh MS, Faught E, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Helmers SL.

**Assessment of parkinson's disease progression rates by stage of disease.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Johnson SJ, Kaltenboeck A, Diener M, Tarrants M, Birnbaum H.

**Comparison of real-world health care costs after the initiation of second-line duloxetine or generic selective serotonin reuptake inhibitors in patients with major depressive disorder.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Swindle R, Ivanova JI, Birnbaum HG, Cummings AK, Kantor E, Schiller M, Clark T, Reed C.

**The cost-effectiveness of guanfacine extended release (GXR) versus atomoxetine (ATX) for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children and adolescents.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Erder M, Chen K, Wu EQ, Hodgkins P, Sikirica V.

**Direct and indirect costs of privately-insured patients treated with oxycodone extended-release or oxycodone controlled-release tablets.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Kirson NY, White AG, Birnbaum HG, Schiller M, Waldman T, Ben-Joseph RH, Berner T, KH S.

**Impact of vagus nerve stimulation (VNS) therapy on clinical outcomes and costs in Medicaid patients with drug-resistant epilepsy.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Duh MS, Faught E, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Helmers SL.

**Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.**

*Abstract:* 30th Annual Scientific Meeting of the American Pain Society, Austin, TX May 19-21, 2011.

*Authors:* Swindle R, Birnbaum H, Ivanova J, Schiller M, Waldman T, Mullen R, Reed C.

**Uncontrolled epilepsy in a Medicaid population.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Mishagina N, Parise H, Rovba L, Lefebvre P, Faught E.

**Burden of uncontrolled epilepsy in a privately insured population.**

*Abstract:* 63rd Annual Meeting of the American Academy of Neurology, Honolulu, HI Apr 9-16, 2011.

*Authors:* Manjunath R, Faught E, Paradis PE, Parisé H, Lafeuille MH, Lefebvre P, Duh MS.

**Relationship between adherence to diseasemodifying drugs and severe relapses, direct and indirect costs among employees with multiple sclerosis.**

*Abstract:* 63rd Annual Meeting of the American Academy of Neurology, Honolulu, HI Apr 9-16, 2011.

*Authors:* Philips AL, Ivanova JI, Bergman RE, Birnbaum HG, Stewart M, Meletiche DM.

**Characteristics and clinical and economic outcomes in Medicaid patients receiving vagus nerve stimulation (VNS) therapy for the treatment of refractory epilepsy.**

*Abstract:* 64th Annual Meeting of the American Epilepsy Society and 3rd Biennial North American Regional Epilepsy Congress, San Antonio, TX Dec 3-7, 2010.

*Authors:* Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Faught E.

**Compliance and persistence to single-tablet levodopa/ carbidopa/entacapone compound versus levodopa/carbidopa in idiopathic parkinson's disease.**

*Abstract:* 2010 Annual Meeting of the American College of Clinical Pharmacy, Austin, TX Oct 17-20, 2010.

*Authors:* Stacy MA, Laliberte F, Kulkarni AS, Somogyi M, Vekeman F, Duh MS, Lefebvre P.

**Cost of illness of post-traumatic stress disorder compared with major depressive disorder.**

*Abstract:* ISPOR 15th Annual International Meeting Atlanta, GA May 15-19, 2010.

*Authors:* Ivanova J, Birnbaum H, Chen L, Dayoub E, Kantor E, Phillips G.

**Descriptive profile of Medicaid patients with post herpetic neuralgia treated and untreated with lidocaine patch 5%.**

*Abstract:* 29th Annual Scientific Meeting of the American Pain Society, Baltimore, MD May 6-8, 2010.

*Authors:* Kirson N, Puenpatom R, Ivanova J, Birnbaum H, Wei R, Kantor E, Schiller M, Summers K.

**Economic value of lidocaine patch 5% vs. gabapentin or pregabalin in Medicaid patients with post herpetic neuralgia.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Ivanova JI, Puenpatom RA, Kirson NY, Birnbaum HG, Wei R, Kantor E, Summers K.

**Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Ivanova JI, Phillips AL, Bergman RE, Birnbaum HG, Stewart M, Meletiche DM.

**Economic value of lidocaine patch 5% versus gabapentin or pregabalin in Medicaid patients with post-herpetic neuralgia.**

*Abstract:* AMCP's 22nd Annual Meeting, San Diego, CA Apr 7-10, 2010.

*Authors:* Ivanova J, Puenpatom A, Kirson NY, Birnbaum HG, Wei R, Kantor E, Summers K.

**Impact of medication adherence to diseasemodifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis.**

*Abstract:* 62nd American Academy of Neurology Annual Meeting, Toronto, ON, Canada Apr 10-17, 2010.

*Authors:* Phillips A, Ivanova J, Bergman R, Birnbaum H, Stewart M, Meletiche D.

**Increased risk of psychiatric disorders in a pediatric population with psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Yu A, Mulani P, Gupta S.

**Impact of levodopa/carbidopa/entacapone compound versus levodopa/carbidopa on hospitalization rates in patients with idiopathic parkinson's disease.**

*Abstract:* 2010 Annual Meeting of the American College of Clinical Pharmacy, Austin, TX Jan 17-20, 2010.

*Authors:* Stacy MA, Laliberte F, Kulkarni AS, Somogyi M, Vekeman F, Duh MS, Lefebvre P.

**Economic consequence of switching to citalopram after its generic entry among major depressive disorder patients treated with escitalopram.**

*Abstract:* AMCP's 2009 Educational Conference San Antonio, TX Oct 7-9, 2009.

*Authors:* Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Erder H.

**Economic impact of generic entry of topiramate in Germany: Conversion of the canadian experience into the settings of Germany.**

*Abstract:* ISPOR 12th Annual European Congress, Paris, France Oct 24-27, 2009.

*Authors:* Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS.

**The Economic Outcomes of Early Education with Second Generation Antidepressants among Adolescents with Depression.**

*Abstract:* AMCP's 2009 Educational Conference, San Antonio, TX Oct 7-9, 2009.

*Authors:* Yu AP, Kaltenboeck A, Bergman R, Xie J, Ben-Hamadi R, Wu EQ, Erder H.

**The potential economic impact of generic substitution of topiramate on health care costs in the G4 European countries.**

*Abstract:* ISPOR 12th Annual European Congress, Paris, France Oct 24-27, 2009.

*Authors:* Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS.

**Impact of generic substitution of topiramate for patients with epilepsy.**

*Abstract:* 13th Congress of the EFNS, Florence, Italy Sep 12 - 15, 2009.

*Authors:* Paradis PE, Latremouille-Viau D, Lefebvre P, Lafeuille MH, Mishagina N, Moore Y, Gaudig M, Duh MS.

**Evaluation of cardiovascular diseases (CVDs) risk in French patients receiving milnacipran (MLN) relative to patients receiving other antidepressants therapies.**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* Mease PJ, Duh MS, Vekeman F, Guerin A, Boerstoele-Streefland M, Jiang W, Lefebvre P, Zimetbaum PJ.

**Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.**

*Abstract:* 2009 International Society for Pharmacoeconomics and Outcomes Research, Aug 2009.

*Authors:* Yu AP, Atanasov P, Ben-Hamadi R, Birnbaum H, Stensland MD, Philips G.

**Compliance, persistence, and outcomes in patients with Alzheimer's disease treated with oral cholinesterase inhibitors.**

*Abstract:* Alzheimer's Association International Conference, Vienna, Austria July 11-16, 2009.

*Authors:* Mody-Patel N, Vekeman F, Laliberte F, Kahler KH, Duh MS, Lefebvre P.

**Clinical consequences of generic substitution of topiramate.**

*Abstract:* 28th International Epilepsy Congress, Budapest, Hungary Jun 28-Jul 2, 2009.

*Authors:* Paradis P, Dominick L, Patrick L, Marie-Helene L, Natalia M, Moore Y, Gaudig M, Duh M.

**Economic impact of generic entry of topiramate in Germany.**

*Abstract:* 6th Joint Meeting of the German, Austrian, and Swiss Sections of the International League Against Epilepsy, 2009.

*Authors:* Paradis P, Mishagina N, Moore Y, Lefebvre P, Gaudig M, Duh MS.

**Impact of generic substitution of topiramate for patients with epilepsy.**

*Abstract:* 6th Joint Meeting of the German, Austrian, and Swiss Sections of the International League Against Epilepsy.

*Authors:* Paradis P, Latremouille-Viau D, Lefebvre P, Lafeuille M, Mishagina N, Moore Y, Gaudig M, Duh MS.

**The impact of generic substitution of topiramate on healthcare costs: Conversion of the Canadian experience into the settings of Germany.**

*Abstract:* 6th Joint Meeting of the German, Austrian, and Swiss Sections of the International League Against Epilepsy, 2009.

*Authors:* Paradis P, Latremouille-Viau D, Lafeuille M, Lefebvre P, Gaudig M, Duh MS.

**Antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine versus donepezil: Evidence from health claims data.**

*Abstract:* ISPOR 14th Annual International Meeting Orlando, FL May 16-20, 2009.

*Authors:* Lefebvre P, Vekeman F, Kahler K, Mody-Patel N, Duh MS, Scharre DW.

**Comparison of hospitalizations and health care costs of elderly major depressive disorder (MDD) patients treated with escitalopram, generic SSRIs, or SNRIs.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20., 2009.

*Authors:* Wu EQ, Cahill KE, Bieri C, Ben-Hamadi R, Yu AP, Erder MH.

**Compliance and persistence of oral cholinesterase inhibitors in patients with Alzheimer's disease.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Vekeman F, Laliberte F, Kahler K, Mody-Patel N, Lefebvre P, Duh MS.

**Direct costs in older patients with depression treated and untreated with antidepressant therapy.**

*Abstract:* ISPOR 14th Annual International Meeting Orlando, FL May 16-20, 2009.

*Authors:* Ivanova J, Birnbaum HG, Samuels S, Emani S, Sheehy M, Cattelin F.

**Direct costs of patients with treatment resistant and non-treatment resistant major depressive disorder.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Ivanova J, Birnbaum HG, Kidolezi Y, Subramanian G, Stensland MD, Khan SA.

**Economic assessment of second-line treatment: Switching from a generic SSRI to escitalopram, an SNRI, or another generic SSRI by patients with major depressive disorder (MDD).**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Marynchenko M, Yu AP, Lauzon V, Ramakrishnan K, Wu EQ, Ben-Hamadi R, Erder MH, Bose A.

**Economic impact of generic entry of topiramate in the G4 European countries.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Paradis PE, Mishagina N, Moore Y, Lefebvre P, Gaudig M, Duh M.

**The economic impact of generic switching for patients with major depressive disorder (MDD) treated with escitalopram or a patented SSRI.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Lauzon V, Kaltenboeck A, Yu AP, Ramakrishnan K, Marynchenko M, Wu EQ, Ben-Hamadi R, Erder MH, Bose A.

**Economic implication of dose escalation in depressed patients treated with escitalopram or venlafaxine XR.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Yu AP, Bensimon AG, Wu EQ, Ben-Hamadi R, Bourezak A, Erder MH.

**The impact of generic substitution of topiramate on health care costs: Conversion of the Canadian experience into the settings of G4 European countries.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Paradis PE, Latremouille-Viau D, Lafeuille MH, Lefebvre P, Gaudig M, Duh M.

**Physicians' attitude to prescribing antidepressant therapy in older patients with depression.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Ivanova JI, Birnbaum HG, Connolly C, Emani S, Sheehy M, Bienfait-Beuzon C.

**The risk of coronary heart disease and stroke among psoriasis patients.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Kimball A, Guerin A, Mulani P, Gupta S.

**Assessing the relationship between compliance with antidepressant therapy and costs among employees in the United States.**

*Abstract:* 17th European Psychiatric Association Congress, Lisbon, Portugal Jan 24-28, 2009.

*Authors:* Birnbaum H, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Cremieux P, Greenberg P.

**Healthcare resource utilization and costs of mild, moderate, and severe depression in the workforce in the united states.**

*Abstract:* 17th European Psychiatric Association Congress, Lisbon, Portugal Jan 24-28, 2009.

*Authors:* Birnbaum H, Kessler R, Joish V, Kelley D, Ben-Hamadi R, M. H, Greenberg P.

**Health care utilization and costs of depressed patients treated with escitalopram versus SNRIs.**

*Abstract:* 21st ECNP Congress Barcelona, Spain Aug 30 - Sep 3, 2008.

*Authors:* Erder MH, Wu E, Ben-Hamadi R, Beaulieu N, Lu M.

**Treatment compliance and health care costs of Medicaid depressed adult patients treated with escitalopram versus citalopram.**

*Abstract:* 21st ECNP Congress, Barcelona, Spain Aug 30 - Sep 03, 2008.

*Authors:* Erder MH, Wu E, Lu M, Ben-Hamadi R, Beaulieu N.

**Health Care Resource Utilization and Costs Comparison For MDD Patients on 10mg Escitalopram Who Increased to 20mg Dose vs. Those Who Were Switched to SNRI.**

*Abstract:* ISPOR 13th Annual International Meeting, Toronto, ON, Canada May 3-7, 2008.

*Authors:* Wu EQ, Yu A, Buessing M, Ben-Hamadi R, Tang J, Seale J, Erder M, Bose A.

**Antidepressant Treatment Patterns and Related Costs among U.S. Employees.**

*Abstract:* Institute on Psychiatric Services (APA-I), New Orleans, LA Oct 11-14, 2007.

*Authors:* Birnbaum H, Greenberg P, Tang J, Hsieh M, Wu EQ, Reygrobellet C, Ben-Hamadi R.

**Comparing Treatment Compliance, Hospitalizations, and Costs of Elderly MDD Patients on Escitalopram and Citalopram.**

*Abstract:* Institute on Psychiatric Services (APA-I), New Orleans, LA Oct 11-14, 2007.

*Authors:* Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M.

**Comparing Treatment Compliance, Hospitalization, and Costs of Elderly MDD Patients on Escitalopram and Citalopram.**

*Abstract:* International Health Economics Association, Copenhagen, Denmark Jul 8-11, 2007.

*Authors:* Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M.

**Comparing Treatment Compliance and Hospitalization of Elderly MDD Patients on Escitalopram and Other SSRI/SNRIS.**

*Abstract:* New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL Jun 13-16, 2007.

*Authors:* Wu EQ, Elaine Y, Greenberg P, Erder M.H., Yu A.

**Health care costs and resource use in patients with major depressive disorder: a comparison between escitalopram and other antidepressants (SSRI/SNRI).**

*Abstract:* ISPOR 12th Annual International Meeting, Arlington, VA May 19-23, 2007.

*Authors:* Wu EQ, Yang E, Greenberg P, Erder MH, Yu A, Buessing M.

**MH2 Comparison of health care costs and hospitalization days of elderly major depressive disorder patients treated with escitalopram and other antidepressants.**

*Abstract:* 2007 International Society for Pharmacoeconomics and Outcomes Research, May 19-23, 2007.

*Authors:* Wu E, Yang E, Greenberg P, Erder M, Yu A, Buesing M.

**Treatment Compliance of Adult Depressed Patients on Escitalopram and Citalopram.**

*Abstract:* European College of Neuropsychopharmacology (ECNP) Regional Meeting, Sofia, Bulgaria Apr 27-29, 2007.

*Authors:* Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M.

**Health Economics Impact in the Treatment of Depression.**

*Abstract:* 2007 National Association of Managed Care Physicians (NAMCP), 2007.

*Authors:* Navarro R, Wu EQ.

**Medical costs and hospitalization of adults diagnosed with attention-deficit/hyperactivity disorder who received alternative therapies.**

*Abstract:* ISPOR 2006, 2006.

*Authors:* Wu E, Birnbaum H, Zhang H, Radeva J, Yang E, Castor A.

**Annual costs associated with patterns of antidepressant treatment response among employees.**

*Abstract:* ISPOR 2006, 2006.

*Authors:* Wu E, Birnbaum H, Ben-Hamadi R, Yu A, Tang J, Greenberg P, Gilloteau I, Smadja E.

**Employer Burden for Adults Diagnosed with Attention-Deficit/Hyperactivity Disorder who Received Alternative Therapies.**

*Abstract:* 2006 American Psychiatric Association.

*Authors:* Wu EQ, Birnbaum H, Zhang HF, Radeva J, Yang E, Castor A.

**Health-Related Quality Of Life of Stroke Survivors in the U.S.**

*Abstract:* 2006 International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia- Pacific.

*Authors:* Xie J, Wu EQ, Zheng ZJ, Croft JB, Mensah GA, Labarthe D.

**Patterns of Antidepressant Treatment Response in an Employed Population.**

*Abstract:* 2006 American Psychiatric Association.

*Authors:* Wu EQ, Birnbaum H, Ben-Hamadi R, Tang J, Greenberg P, Gilloteau I, Smadja E.

**The economic burden of schizophrenia in the United States in 2002.**

*Abstract:* ISPOR 2005, 2005.

*Authors:* Wu E, Birnbaum H, Shi L, Ball D, Kessler R, Moulis M, Aggarwal J.

**Estimating annual US prevalence of schizophrenia in 2002.**

*Abstract:* ISPOR 2005, 2005.

*Authors:* Wu E, Birnbaum H, Aggarwal J, Moulis M.

**Direct Health Care Costs of Schizophrenia in the United States: 2002.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR).

*Authors:* Wu EQ, Birnbaum H, Kessler R, Beaulieu N, Daher M, Aggarwal J, Svanum H, Shi L.

**Economic Burden of Lost Productivity due to Schizophrenia in the United States: 2002.**

*Abstract:* American Psychiatric Association.

*Authors:* Wu EQ, Birnbaum H, Kessler R, Shi L, Ball D.

**Using Claims Data to Estimate the Annual Prevalence of Schizophrenia in the United States, 2002.**

*Abstract:* 2005 International Society for Pharmacoeconomics & Outcomes Research (ISPOR) European, 2005.

*Authors:* Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J.

**Comorbidities and Cost Associated with Bipolar Disorder.**

*Abstract:* 2004 American Public Health Association.

*Authors:* Parece A, Wu EQ, Birnbaum H, Greenberg P, Huang Z, Victor T, Kessler RC.

**Cost and Comorbidities Associated with Bipolar Disorder.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR).

*Authors:* Parece A, Wu EQ, Birnbaum HG, Greenberg P, Huang Z, Victor T, Kessler RC.

**Drug Treatment Patterns of Bipolar Disorder and Associated Costs.**

*Abstract:* 2004 National Institute of Mental Health's (NIMH) New Clinical Drug Evaluation Unit (NCDEU) Meeting.

*Authors:* Wu EQ, Birnbaum H, Greenberg P, Huang Z, Kessler R, Parece A, T. V.

**The comparison of different methods for determining the impact of migraine prophylaxis on costs.**

*Abstract:* ISPOR 2003, 2003.

*Authors:* Barlev A, Globe D, Wu E, Yu W, Johnson K.

**Survival and Nursing Home Free Survival (NHFS) of Alzheimer's Disease (AD) Patients.**

*Abstract:* 2001 International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2001.

*Authors:* Wu EQ, Hay J.

**The Impact of an Over-the-Counter Migraine Medication on Quality of Life.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research.

*Authors:* Burk C, Nichol MB, Wu EQ, Gilderman A, Salas J.

**Assessment of access barriers to rifaximin among patients with overt hepatic encephalopathy using adjudicated claims data.**

Orlando, FL Oct. 16 - Oct. 19, 2023.

*Authors:* Jesudian A, Dashputre AA, Gagnon-Sanschagrín P, Jessica Maitland J, Yokoji K, Guérin A, Heimanson Z, Brock Bumpass B, Olujohungbe O, Danellys Borroto D, Joseph G.

## Oncology

### Journal Articles

**Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint Inhibitor.**

*Publication:* Clin Genitourin Cancer 2023 10; 21(5): e343-e351. e-pub ahead of print 2023/04/23; doi: 10.1016/j.clgc.2023.03.017.

*Authors:* Zakharia Y, Huynh L, Du S, Chang R, Pi S, Sundaresan S, Duh MS, Zanotti G, Thomaidou D.

**Comparative Efficacy of Venetoclax-based Combination Therapies and Other Therapies in Treatment Naïve Patients with Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.**

*Publication:* Value Health 2023 09. e-pub ahead of print 2023/09/24; doi: 10.1016/j.jval.2023.09.001.

*Authors:* Li X, Suh HS, Lachaine J, Schuh AC, Pratz K, Betts KA, Song J, Dua A, Bui CN.

**Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.**

*Publication:* J Manag Care Spec Pharm 2023 09: 1-14. e-pub ahead of print 2023/09/30; doi: 10.18553/jmcp.2023.23031.

*Authors:* Sanchez L, Chari A, Cheng M, Cherepanov D, DerSarkissian M, Huang F, Stull DM, Dabora J, Young M, Noga SJ, Pi S, Zhang M, Banatwala A, Duh MS, Ailawadhi S.

**Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: Analysis of Number Needed To Treat and Number Needed To Harm.**

*Publication:* Clin Ther 2023 09. e-pub ahead of print 2023/09/26; doi: 10.1016/j.clinthera.2023.08.014.

*Authors:* Sugarman R, Betts KA, Nie X, Hartman J, Nguyen H.

**Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma.**

*Publication:* Curr Med Res Opin 2023 09; 39(9): 1227-1235. e-pub ahead of print 2023/08/02; doi: 10.1080/03007995.2023.2243815.

*Authors:* Lu X, Emond B, Qureshi ZP, Wu LH, Forbes SP, Hilts A, Liu S, Lafeuille MH, Lefebvre P, Huang Q, Rogers KA.

**Treatment Patterns and Adverse Event-Related Hospitalization Among Patients with Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non-small Cell Lung Cancer After Treatment with EGFR Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy Regimens.**

*Publication:* Drugs Real World Outcomes 2023 09. doi: 10.1007/s40801-023-00383-1.

*Authors:* Marrett E, Kwong WJ, Xie J, Manceur AM, Sendhil SR, Wu E, Ionescu-Ittu R, Subramanian J.

**Association between event-free survival and overall survival in early-stage triple-negative breast cancer.**

*Publication:* Future Oncol 2023 08. e-pub ahead of print 2023/08/21; doi: 10.2217/fon-2023-0315.

*Authors:* Huang M, Fasching PA, Haiderali A, Xue W, Pan W, Karantza V, Yang F, Truscott J, Xin Y, O'Shaughnessy J.

**A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation.**

*Publication:* Cancers (Basel) 2023 08; 15(16). e-pub ahead of print 2023/08/26; doi: 10.3390/cancers15164161.

*Authors:* Nicolini FE, Huguet F, Huynh L, Xu C, Bouvier C, Yocolly A, Etienne G.

**Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia.**

*Publication:* Patient Prefer Adherence 2023 08; 17: 2073-2084. e-pub ahead of print 2023/08/29; doi: 10.2147/ppa.S417180.

*Authors:* Lu X, Emond B, Morrison L, Kinkead F, Lefebvre P, Lafeuille MH, Khan W, Wu LH, Qureshi ZP, Jacobs R.

**Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA.**

*Publication:* Drugs Real World Outcomes 2023 08. e-pub ahead of print 2023/08/04; doi: 10.1007/s40801-023-00378-y.

*Authors:* Barzi A, Lin F, Song J, Lam C, Nie X, Noman A, Kwong WJ.



**Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: a retrospective study using the SEER-Medicare database.**

*Publication:* Leukemia Research 2023 07: 107353. doi: <https://doi.org/10.1016/j.leukres.2023.107353>.

*Authors:* Brunner AM, Huggar D, Copher R, Zhou Z-Y, Zichlin ML, Anderson A, Downes N, McBride A.

**Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer.**

*Publication:* J Manag Care Spec Pharm 2023 07; 29(7): 749-757. e-pub ahead of print 2023/07/05; doi: [10.18553/jmcp.2023.29.7.749](https://doi.org/10.18553/jmcp.2023.29.7.749).

*Authors:* West H, Hu X, Zhang S, Song Y, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A.

**Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy.**

*Publication:* Adv Ther 2023 07. doi: [10.1007/s12325-023-02601-2](https://doi.org/10.1007/s12325-023-02601-2).

*Authors:* Goldschmidt J, Hart L, Scott J, Boykin K, Bailey R, Heritage T, Lopez-Gonzalez L, Zhou ZY, Edwards ML, Monnette A, Ogbonnaya A, Deyoung K, Venkatesetty D, Shi P, Aton L, Huang H, Conkling PR, Gordan L.

**Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.**

*Publication:* Future Oncol 2023 07. e-pub ahead of print 2023/07/21; doi: [10.2217/fon-2023-0436](https://doi.org/10.2217/fon-2023-0436).

*Authors:* Jacobs R, Lu X, Emond B, Morrison L, Kinkead F, Lefebvre P, Lafeuille MH, Khan W, Wu LH, Qureshi ZP, Levy MY.

**Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States.**

*Publication:* Adv Ther 2023 05. e-pub ahead of print 2023/05/16; doi: [10.1007/s12325-023-02525-x](https://doi.org/10.1007/s12325-023-02525-x).

*Authors:* Zhang S, Bensimon AG, Xu R, Jiang R, Greatsinger A, Zhang A, Fukunaga-Kalabis M, Krepler C.

**Real-World Comparative Effectiveness of Acalabrutinib and Ibrutinib in Patients with Chronic Lymphocytic Leukemia.**

*Publication:* Blood Adv 2023 05. e-pub ahead of print 2023/05/10; doi: [10.1182/bloodadvances.2023009739](https://doi.org/10.1182/bloodadvances.2023009739).

*Authors:* Roeker LE, DerSarkissian M, Ryan K, Chen Y, Duh MS, Wahlstrom SK, Hakre S, Yu L, Guo H, Mato A.

**Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data.**

*Publication:* Clin Genitourin Cancer 2023 05. e-pub ahead of print 2023/05/30; doi: [10.1016/j.clgc.2023.04.014](https://doi.org/10.1016/j.clgc.2023.04.014).

*Authors:* Swami U, Aggarwal H, Zhou M, Jiang S, Kim J, Li W, Laliberté F, Emond B, Agarwal N.

**Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide.**

*Publication:* Urol Oncol 2023 04. e-pub ahead of print 2023/04/16; doi: [10.1016/j.urolonc.2023.03.003](https://doi.org/10.1016/j.urolonc.2023.03.003).

*Authors:* Lowentritt B, Pilon D, Khilfeh I, Rossi C, Muser E, Kinkead F, Waters D, Ellis L, Lefebvre P, Brown G.

**Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study.**

*Publication:* Urol Oncol 2023 04. e-pub ahead of print 2023/04/21; doi: [10.1016/j.urolonc.2023.03.013](https://doi.org/10.1016/j.urolonc.2023.03.013).

*Authors:* Lowentritt B, Pilon D, Waters D, Rossi C, Muser E, Kurteva S, Shah A, Khilfeh I, Du S, Ellis L, Lefebvre P, Brown G.

**Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States.**

*Publication:* Clin Genitourin Cancer 2023 04. e-pub ahead of print 2023/05/04; doi: [10.1016/j.clgc.2023.03.016](https://doi.org/10.1016/j.clgc.2023.03.016).

*Authors:* Lai Y, Bensimon AG, Gao E, Bhattacharya R, Xu R, Chevure J, Imai K, Haas NB.

**Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting.**

*Publication:* Clin Cancer Res 2023 04; 29(7): 1360-1367. e-pub ahead of print 2023/01/19; doi: 10.1158/1078-0432.Ccr-22-2920.

*Authors:* Wainberg ZA, Xie J, Valderrama A, Yin L, Zhang S, Shih CS, Bhagia P, Gu Q, Shitara K, Janjigian YY, Tabernero J.

**Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis.**

*Publication:* Pharmacocon Open 2023 04. e-pub ahead of print 2023/04/19; doi: 10.1007/s41669-023-00407-0.

*Authors:* Vanderpoel J, Emond B, Ghelerter I, Milbers K, Lafeuille MH, Lefebvre P, Ellis LA.

**Time and personnel costs associated with adverse event (AE) management among patients with chronic lymphocytic leukemia (CLL).**

*Publication:* Expert Rev Pharmacoecon Outcomes Res 2023 04. e-pub ahead of print 2023/04/07; doi: 10.1080/14737167.2023.2200167.

*Authors:* Patel H, Wahlstrom SK, DerSarkissian M, Kunzweiler C, Castriota F, Chang R, Gu Y, Guo H, Duh MS, Ryan KJ.

**Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.**

*Publication:* Clin Lymphoma Myeloma Leuk 2023 03. e-pub ahead of print 2023/04/20; doi: 10.1016/j.clml.2023.03.010.

*Authors:* Shadman M, Manzoor BS, Sail K, Tuncer HH, Allan JN, Ujjani C, Emechebe N, Kamalakar R, Coombs CC, Leslie L, Barr PM, Brown JR, Eyre TA, Rampotas A, Schuh A, Lamanna N, Skarbnik A, Roeker LE, Bannerji R, Eichhorst B, Fleury I, Davids MS, Alhasani H, Jiang D, Hill BT, Schuster SJ, Brander DM, Pivneva I, Burne R, Guerin A, Mato AR.

**Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices.**

*Publication:* Curr Oncol 2023 02; 30(2): 2348-2365. e-pub ahead of print 2023/02/25; doi: 10.3390/curroncol30020180.

*Authors:* Sheffield BS, Eaton K, Emond B, Lafeuille MH, Hiltz A, Lefebvre P, Morrison L, Stevens AL, Ewara EM, Cheema P.

**Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results-Medicare data.**

*Publication:* Int J Urol 2023 02. e-pub ahead of print 2023/02/16; doi: 10.1111/iju.15104.

*Authors:* Haas NB, Song Y, Willemann Rogerio J, Zhang S, Carley C, Zhu J, Bhattacharya R, Signorovitch J, Sundaram M.

**Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).**

*Publication:* Journal of Clinical Oncology 2023 02. doi: 10.1200/JCO.2023.41.6\_suppl.673.

*Authors:* Lemelin A, Ernst MS, Wells C, Navani V, McGregor BA, Wong SS, Pal SM, Basappa NS, Kapoor A, Lee J-L, Donskov F, Li H, Yuasa T, Chang R, Huynh L, Nguyen C, Holub A, Clear L, Duh MS, Yick Chin Heng D.

**Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.**

*Publication:* Cancer Med 2023 02. e-pub ahead of print 2023/02/03; doi: 10.1002/cam4.5584.

*Authors:* Richter J, Lin PL, Garcia-Horton V, Guyot P, Singh E, Zhou ZY, Sievert M, Taiji R.

**A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.**

*Publication:* Eur Urol Oncol 2023 02. e-pub ahead of print 2023/02/27; doi: 10.1016/j.euo.2023.01.012.

*Authors:* McGregor B, Geynisman DM, Burotto M, Suárez C, Bourlon MT, Barata PC, Gulati S, Huo S, Ejzykowicz F, Blum SI, Del Tejo V, Hamilton M, May JR, Du EX, Wu A, Kral P, Ivanescu C, Chin A, Betts KA, Lee CH, Choueiri TK, Cella D, Porta C.

**Retrospective Study to Examine Prognostic Value of C-Reactive Protein in Patients With Surgically Resectable Non-Small-Cell Lung Cancer.**

*Publication:* Clin Lung Cancer 2023 02. e-pub ahead of print 2023/02/27; doi: 10.1016/j.clcc.2023.01.014.

*Authors:* Azzoli C, Huynh L, Yi D, Duh MS, Cai B.

**Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.**

*Publication:* Future Oncol 2023 02. e-pub ahead of print 2023/02/17; doi: 10.2217/fon-2022-1123.

*Authors:* Shore N, Garcia-Horton V, Terasawa E, Ayyagari R, Grossman JP, Waldeck AR.

**Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States.**

*Publication:* Adv Ther 2023 01. e-pub ahead of print 2023/01/18; doi: 10.1007/s12325-022-02365-1.

*Authors:* Huang M, P AF, Haiderali A, Xue W, Yang C, Pan W, Zhou ZY, Hu P, Chaudhuri M, Le Bailly De Tillegem C, Cappoen N, O'Shaughnessy J.

**Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.**

*Publication:* Hematology 2023 01; 28(1): 2156731. e-pub ahead of print 2023/01/07; doi: 10.1080/16078454.2022.2156731.

*Authors:* DerSarkissian M, Cranmer H, Dabora J, Bocharova I, Cherepanov D, Cheng M, Bhak RH, Duh MS.

**Assessing the Impact of Open-Label Designs in Patient-Reported Outcomes: Investigation in Oncology Clinical Trials.**

*Publication:* JNCI Cancer Spectr 2023. e-pub ahead of print 2023/01/21; doi: 10.1093/jncics/pkad002.

*Authors:* Lord-Bessen J, Signorovitch J, Yang M, Georgieva M, Roydhouse J.

**Epidemiology and Economic Burden of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States.**

*Publication:* Clin Genitourin Cancer 2022 12. e-pub ahead of print 2023/01/23; doi: 10.1016/j.clgc.2022.12.008.

*Authors:* Jonasch E, Song Y, Freimark J, Berman R, Nguyen H, Signorovitch J, Sundaram M.

**Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data.**

*Publication:* Clin Lung Cancer 2022 12. e-pub ahead of print 2023/01/15; doi: 10.1016/j.clcc.2022.12.005.

*Authors:* West H, Hu X, Zhang S, Song Y, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A.

**Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study.**

*Publication:* Leuk Lymphoma 2022 11: 1-9. e-pub ahead of print 2022/11/22; doi: 10.1080/10428194.2022.2140284.

*Authors:* Wang PF, Yee CW, Gorsh B, Zichlin ML, Paka P, Bhak RH, Boytsov N, Khanal A, Noman A, DerSarkissian M, Ferrante S, Duh MS.

**Early prostate-specific antigen response among Black and non-Black patients with advanced prostate cancer treated with apalutamide.**

*Publication:* Future Oncol 2022 10. e-pub ahead of print 2022/10/06; doi: 10.2217/fon-2022-0791.

*Authors:* Bivins VM, Durkin M, Khilfeh I, Rossi C, Kinkead F, Waters D, Lefebvre P, Pilon D, Ellis L.

**Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.**

*Publication:* Cancer Immunol Immunother 2022 10. e-pub ahead of print 2022/10/06; doi: 10.1007/s00262-022-03302-5.

*Authors:* Weber JS, Poretta T, Stwalley BD, Sakkal LA, Du EX, Wang T, Chen Y, Wang Y, Betts KA, Shoushtari AN.

**Real-world healthcare resource utilization and costs among patients with multiple myeloma in the United States.**

*Publication:* Journal of Clinical Oncology 2022 10; 40(16\_suppl): e18811-e18811. doi: 10.1200/JCO.2022.40.16\_suppl.e18811.

*Authors:* Gupta N, Tai MH, Kaila S, Thompson-Leduc P, Ghelerter I, Kurteva S, Lefebvre P, Lafeuille MH.

**Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis.**

*Publication:* Curr Oncol 2022 10; 29(10): 7524-7536. e-pub ahead of print 2022/10/28; doi: 10.3390/curroncol29100592.

*Authors:* Guinan K, Mathurin K, Au Y, Schuh AC, Bui CN, Chai X, Lachaine J.

**Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.**

*Publication:* J Manag Care Spec Pharm 2022 09; 28(9): 1033-1045. e-pub ahead of print 2022/07/12; doi: 10.18553/jmcp.2022.22075.

*Authors:* Rogers KA, Lu X, Emond B, Côté-Sergent A, Kinkead F, Lafeuille MH, Lefebvre P, Huang Q.

**Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.**

*Publication:* J Manag Care Spec Pharm 2022 09; 1-12. e-pub ahead of print 2022/09/02; doi: 10.18553/jmcp.2022.22133.

*Authors:* Sundaram M, Song Y, Rogerio JW, Zhang S, Bhattacharya R, Adejoro O, Carley C, Zhu JJ, Signorovitch J, Haas NB.

**PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials.**

*Publication:* BMC Cancer 2022 09; 22(1): 1002. e-pub ahead of print 2022/09/22; doi: 10.1186/s12885-022-10078-5.

*Authors:* Fillbrunn M, Signorovitch J, André F, Wang I, Lorenzo I, Ridolfi A, Park J, Dua A, Rugo HS.

**Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective.**

*Publication:* J Health Econ Outcomes Res 2022 08; 9(2): 30-36. e-pub ahead of print 2022/08/19; doi: 10.36469/001c.36976.

*Authors:* Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A.

**Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States.**

*Publication:* J Health Econ Outcomes Res 2022 08; 9(2): 19-29. e-pub ahead of print 2022/08/19; doi: 10.36469/001c.36975.

*Authors:* Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P.

**The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison.**

*Publication:* Adv Ther 2022 08. e-pub ahead of print 2022/08/27; doi: 10.1007/s12325-022-02245-8.

*Authors:* Shore N, Jiang S, Garcia-Horton V, Terasawa E, Steffen D, Chin A, Ayyagari R, Partridge J, Waldeck AR.

**Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States.**

*Publication:* Current Medical Research and Opinion 2022 08: 1-11. doi: 10.1080/03007995.2022.2112872.

*Authors:* Liu J, Emond B, Maiese EM, Lafeuille MH, Lefebvre P, Ghelerter I, Wu C, Hurteau JA, Thaker PH.

**Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer.**

*Publication:* Immunotherapy 2022 07. e-pub ahead of print 2022/07/08; doi: 10.2217/imt-2022-0082.

*Authors:* Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou ZY, Hu P, Chaudhuri M, Bailly De Tillegem CL, Cappoen N, O'Shaughnessy J.

**Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis.**

*Publication:* Leukemia 2022 07. e-pub ahead of print 2022/07/06; doi: 10.1038/s41375-022-01615-z.

*Authors:* Reiter A, Gotlib J, Álvarez-Twose I, Radia DH, Lübke J, Bobbili PJ, Wang A, Norregaard C, Dimitrijevic S, Sullivan E, Louie-Gao M, Schwaab J, Galinsky IA, Perkins C, Sperr WR, Sriskandarajah P, Chin A, Sendhil SR, Duh MS, Valent P, DeAngelo DJ.

**Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke.**

*Publication:* Clin Lymphoma Myeloma Leuk 2022 07. e-pub ahead of print 2022/08/17; doi: 10.1016/j.clml.2022.07.004.

*Authors:* Narezkina A, Akhter N, Lu X, Emond B, Panjabi S, Forbes SP, Hilts A, Liu S, Lafeuille MH, Lefebvre P, Huang Q, Choi M.

**Adherence to Adjuvant Therapy in Patients with Resected Melanoma: an Application of the Theory of Planned Behavior.**

*Publication:* Adv Ther 2022 06.

*Authors:* Beisel C, Poretta T, Sheppard VB, Hurtado-de Mendoza A, Sipsma H, Fuqua E, Stwalley B, Salvatore A, Yang M.

**Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.**

*Publication:* PharmacoEconomics 2022 06. e-pub ahead of print 2022/06/14; doi: 10.1007/s40273-022-01145-7.

*Authors:* Pratz KW, Chai X, Xie J, Yin L, Nie X, Montez M, Iantuono E, Downs L, Ma E.

**Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.**

*Publication:* J Manag Care Spec Pharm 2022 06: 1-9. e-pub ahead of print 2022/06/17; doi: 10.18553/jmcp.2022.22021.

*Authors:* Choi M, Song J, Bui CN, Ma E, Chai X, Yin L, Betts KA, Kapustyan T, Montez M, LeBlanc TW.

**The Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia in the United States: A Cost of Care and Budget Impact Model of Venetoclax Plus Obinutuzumab Sequences.**

*Publication:* J Clin Pathways 2022 06.

*Authors:* Davids MS, Manzoor BS, Hazra NC, Fang H, Ravelo A, Han F, Guerin A, Sail K, Shapouri S, Shadman M.

**Impact of clinical pathways on treatment patterns and outcomes for patients with non-small-cell lung cancer: real-world evidence from a community oncology practice.**

*Publication:* J Comp Eff Res 2022 06; 11(8): 609-619. e-pub ahead of print 2022/05/14; doi: 10.2217/cer-2021-0290.

*Authors:* Dickson NR, Beauchamp KD, Perry TS, Roush A, Goldschmidt D, Edwards ML, Blakely LJ.

**Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.**

*Publication:* Clinical Drug Investigation 2022 06. doi: 10.1007/s40261-022-01170-6.

*Authors:* Geynisman DM, Burotto M, Porta C, Suarez C, Bourlon MT, Huo S, Del Tejo V, Du EX, Yang X, Betts KA, Choueiri TK, McGregor B.

**Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.**

*Publication:* J Med Econ 2022 05; 1-25. e-pub ahead of print 2022/05/21; doi: 10.1080/13696998.2022.2080463.

*Authors:* Proudman D, DeVito NC, Belinson S, Allo MA, Morris ED, Signorovitch J, Patel AK.

**Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.**

*Publication:* Oncologist 2022 04. e-pub ahead of print 2022/04/25; doi: 10.1093/oncolo/oyac067.

*Authors:* Jakubowiak AJ, Kumar S, Medhekar R, Pei H, Lefebvre P, Kaila S, He J, Lafeuille MH, Cortoos A, Londhe A, Mavros P, Lin TS, Usmani SZ.

**Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma.**

*Publication:* Clin Lymphoma Myeloma Leuk 2022 04. e-pub ahead of print 2022/05/07; doi: 10.1016/j.clml.2022.04.006.

*Authors:* Hamadani M, Chen L, Song Y, Xu MK, Liao L, Caimi PF, Carlo-Stella C.

**Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers.**

*Publication:* Cancers (Basel) 2022 03; 14(7). e-pub ahead of print 2022/04/13; doi: 10.3390/cancers14071793.

*Authors:* Garcia-Foncillas J, Bokemeyer C, Italiano A, Keating K, Paracha N, Fellous M, Marian M, Fillbrunn M, Gao W, Ayyagari R, Lassen U.

**Real-World Prostate-Specific Antigen Response and Treatment Adherence of Apalutamide in Patients with Non-Metastatic Castration-Resistant Prostate Cancer.**

*Publication:* Urology 2022 03. e-pub ahead of print 2022/03/24; doi: 10.1016/j.urology.2022.02.024.

*Authors:* Lowentritt B, Brown G, Pilon D, Ellis L, Germain G, Rossi C, Lefebvre P, Kernen K, Sieber P, Shore N.

**Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer.**

*Publication:* J Med Econ 2022 03; 25(1): 457-468. doi: 10.1080/13696998.2022.2053403.

*Authors:* Vanderpoel J, Stevens AL, Emond B, Lafeuille M, Hiltz A, Lefebvre P, Morrison L.

**Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia.**

*Publication:* JTO Clin Res Rep 2022 02; 3(3): 100290. e-pub ahead of print 2022/03/18; doi: 10.1016/j.jtocrr.2022.100290.

*Authors:* Loong HH, Wong CKH, Chan CPK, Chang A, Zhou ZY, Tang W, Gibbs M.

**Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma.**

*Publication:* PLoS One 2022 01; 17(1): e0261336. e-pub ahead of print 2022/01/25; doi: 10.1371/journal.pone.0261336.

*Authors:* Harvey MJ, Zhong Y, Morris E, Beverage JN, Epstein RS, Chawla AJ.

**Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.**

*Publication:* Leuk Lymphoma 2022 01; 1-10. e-pub ahead of print 2022/01/04; doi: 10.1080/10428194.2021.2010069.

*Authors:* Schuster SJ, Zhang J, Yang H, Agarwal A, Tang W, Martinez-Prieto M, Bollu V, Kuzan D, Maziarz RT, Kersten MJ.

**Indirect Comparison of Tisagenlecleucel and Historical Treatments for Relapsed/Refractory Diffuse Large B-cell Lymphoma.**

*Publication:* Blood Adv 2022 01. e-pub ahead of print 2022/01/15; doi: 10.1182/bloodadvances.2021006280.

*Authors:* Maziarz RT, Zhang J, Yang H, Chai X, Yuan C, Schwarz E, Jakovac M, Martinez-Prieto M, Agarwal A, Degtyarev E, Tam CS, Salles GA.

**Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma.**

*Publication:* Future Oncol 2022 01. e-pub ahead of print 2022/01/21; doi: 10.2217/fon-2021-1054.

*Authors:* Signorovitch J, Moshyk A, Zhao J, Le TK, Burns L, Gooden K, Hamilton M.

**Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.**

*Publication:* Leuk Lymphoma 2022 01: 1-11. doi: 10.1080/10428194.2022.2060503.

*Authors:* Maziarz RT, Yang H, Liu Q, Wang T, Zhao J, Lim S, Lee S, Dalal A, Bollu V.

**Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy - a retrospective cohort study using CMS 100% Medicare claims database.**

*Publication:* Leuk Lymphoma 2022: 1-10. e-pub ahead of print 2022/11/22; doi: 10.1080/10428194.2022.2147395.

*Authors:* Yang H, Bollu V, Lim S, Tesfaye M, Dalal AA, Lax A, Sethi S, Zhao J.

**A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.**

*Publication:* Adv Ther 2022. e-pub ahead of print 2022/02/15; doi: 10.1007/s12325-022-02054-z.

*Authors:* Proudman D, Nellesen D, Gupta D, Adib D, Yang J, Mamlouk K.

**The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States.**

*Publication:* Adv Ther 2021 12. e-pub ahead of print 2021/12/18; doi: 10.1007/s12325-021-01913-5.

*Authors:* Sieluk J, Song Y, Freimark J, Huang M, Haiderali A, Berman R, Wang T, Signorovitch J, Hirshfield KM.

**Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.**

*Publication:* Future Oncol 2021 12. e-pub ahead of print 2021/12/24; doi: 10.2217/fon-2021-1109.

*Authors:* Geynisman DM, Du EX, Yang X, Sendhil SR, Tejo VD, Betts KA, Huo S.

**Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.**

*Publication:* Oncologist 2021 12; 26(12): e2161-e2169. e-pub ahead of print 2021/08/19; doi: 10.1002/onco.13942.

*Authors:* Patel AK, Abhyankar R, Brais LK, Duh MS, Barghout VE, Huynh L, Yenikomshian MA, Ng K, Fuchs CS.

**Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer.**

*Publication:* JCO Precis Oncol 2021 11; 5: 1611-1624. e-pub ahead of print 2022/01/08; doi: 10.1200/po.20.00540.

*Authors:* Harvey MJ, Cunningham R, Sawchyn B, Montesion M, Reddy P, McBride A, Chawla AJ.

**Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models.**

*Publication:* PharmacoEconomics 2021 11. e-pub ahead of print 2021/11/30; doi: 10.1007/s40273-021-01113-7.

*Authors:* Huang M, Ramsey S, Xue W, Xie J, Pellissier J, Briggs A.

**Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial.**

*Publication:* Leuk Lymphoma 2021 11: 1-3. doi: 10.1080/10428194.2021.2001467.

*Authors:* Zeidan AM, Qi CZ, Yang H, Garnham A, Shah MV, Pandya BJ.

**Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes.**

*Publication:* Eur J Haematol 2021 11; 107(5): 553-565. e-pub ahead of print 2021/07/22; doi: 10.1111/ejh.13692.

*Authors:* Griffin JD, Song Y, Yang H, Freimark J, Shah MV.

**Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study.**

*Publication:* BMC Cancer 2021 11; 21(1): 1207. e-pub ahead of print 2021/11/14; doi: 10.1186/s12885-021-08881-7.

*Authors:* Atrash S, Thompson-Leduc P, Tai MH, Kaila S, Gray K, Ghelerter I, Lafeuille MH, Lefebvre P, Rossi A.

**Cost-effectiveness of gilteritinib for relapsed/refractory FLT3mut+ acute myeloid leukemia.**

*Publication:* J Manag Care Spec Pharm 2021 10; 27(10): 1469-1481. doi: 10.18553/jmcp.2021.27.10.1469.

*Authors:* Pandya BJ, Qi CZ, Garnham A, Yang H, Shah MV, Zeidan AM.

**Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia.**

*Publication:* Blood Adv 2021 10. doi: 10.1182/bloodadvances.2020004045.

*Authors:* Verneris MR, Ma Q, Zhang J, Keating AK, Tiwari R, Li J, Yang H, Agarwal A, Pacaud L.

**CML-311: Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia by Line of Therapy in the United States (US) from a Commercial Perspective.**

*Publication:* Clinical Lymphoma Myeloma and Leukemia 2021 09; 21: S333. doi: [https://doi.org/10.1016/S2152-2650\(21\)01780-8](https://doi.org/10.1016/S2152-2650(21)01780-8).

*Authors:* Atallah E, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Patwardhan P.

**Prostate-specific antigen response among Black and non-Black patients with advanced prostate cancer treated with apalutamide in a urology setting.**

*Publication:* Journal of Clinical Oncology 2021 09; 39(28\_suppl): 124-124. doi: 10.1200/JCO.2020.39.28\_suppl.124.

*Authors:* Durkin M, D. P, Rossi C, Khilfeh I, Kinkead F, Wu C, Ellis L, Lefebvre P.

**Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study.**

*Publication:* Clin Genitourin Cancer 2021 08. e-pub ahead of print 2021/08/11; doi: 10.1016/j.clgc.2021.07.009.

*Authors:* Shore ND, Ionescu-Iltu R, Laliberté F, Yang L, Lejeune D, Yu L, Duh MS, Mahendran M, Kim J, Ghate SR.

**Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era.**

*Publication:* Curr Med Res Opin 2021 08: 1-10. e-pub ahead of print 2021/08/05; doi: 10.1080/03007995.2021.1957806.

*Authors:* Xie J, Wu A, Liao L, Nastoupil LJ, Du EX, Noman A, Chen L.

**Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study.**

*Publication:* Clin Genitourin Cancer 2021 08; 19(4): 354-361. e-pub ahead of print 2021/04/18; doi: 10.1016/j.clgc.2021.03.006.

*Authors:* Wells JC, Dudani S, Gan CL, Stukalin I, Azad AA, Liow E, Donskov F, Yuasa T, Pal SK, De Velasco G, Hansen AR, Beuselinck B, Kollmannsberger CK, Powles T, McGregor BA, Duh MS, Huynh L, Heng DYC.



**Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.**

*Publication:* Clin Ther 2021 08. e-pub ahead of print 2021/08/13; doi: 10.1016/j.clinthera.2021.06.011.

*Authors:* Qi CZ, Bollu V, Yang H, Dalal A, Zhang S, Zhang J.

**Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.**

*Publication:* Future Oncol 2021 08; 17(22): 2907-2921. e-pub ahead of print 2021/04/29.

*Authors:* Shore N, Ionescu-Ittu R, Yang L, Laliberte F, Mahendran M, Lejeune D, Yu L, Burgents J, Duh MS, Ghatge SR.

**Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors.**

*Publication:* Adv Ther 2021 08; 38(8): 4520-4540. e-pub ahead of print 2021/07/21; doi: 10.1007/s12325-021-01823-6.

*Authors:* Shore ND, Laliberté F, Ionescu-Ittu R, Yang L, Mahendran M, Lejeune D, Yu LH, Burgents J, Duh MS, Ghatge SR.

**Treatment patterns among patients with mantle cell lymphoma and comparison of healthcare resource utilization and costs among relapsed/refractory patients treated with ibrutinib or chemoimmunotherapy: A real-world retrospective study.**

*Publication:* Clin Ther 2021 08. e-pub ahead of print 2021/08/02; doi: 10.1016/j.clinthera.2021.06.012.

*Authors:* Ghosh N, Emond B, Lafeuille MH, Côté-Sergent A, Lefebvre P, Huang Q.

**Trifluridine/tipiracil (FTD/TPI) and regorafenib in patients with metastatic colorectal cancer (mCRC): a retrospective study at a tertiary oncology center.**

*Publication:* Oncologist 2021 08. e-pub ahead of print 2021/08/19; doi: 10.1002/onco.13942.

*Authors:* Patel AK, Abhyankar R, Brais LK, Duh MS, Barghout VE, Huynh L, Yenikomshian MA, Ng K, Fuchs CS.

**Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan.**

*Publication:* Front Oncol 2021 07; 11: 678070. e-pub ahead of print 2021/08/03; doi: 10.3389/fonc.2021.678070.

*Authors:* Yu KH, Hendifar AE, Alese OB, Draper A, Abdelrahim M, Burns E, Khan G, Cockrum P, Bhak RH, Nguyen C, DerSarkissian M, Duh MS, Bahary N.

**Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.**

*Publication:* J Urol 2021 07: 101097ju0000000000002121. e-pub ahead of print 2021/07/24; doi:

10.1097/ju.0000000000002121.

*Authors:* Ryan CJ, Ke X, Lafeuille MH, Romdhani H, Kinkead F, Lefebvre P, Petrilla A, Pulungan Z, Kim S, D'Andrea DM, Francis P, Freedland SJ.

**Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.**

*Publication:* J Med Econ 2021 06. doi: 10.1158/1538-7445.Sabcs20-ps10-29.

*Authors:* Balu S, Burne R, Guerin A, Bungay R, Paul ML, Sin R.

**Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan.**

*Publication:* Transplant Cell Ther 2021 06; 27(6): 506.e501-506.e510. e-pub ahead of print 2021/04/07; doi:

10.1016/j.jtct.2021.03.005.

*Authors:* Wakase S, Teshima T, Zhang J, Ma Q, Fujita T, Yang H, Chai X, Qi CZ, Liu Q, Wu EQ, Igarashi A.

**Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.**

*Publication:* Leuk Lymphoma 2021 06; 62(6): 1411-1421. e-pub ahead of print 2021/01/13; doi: 10.1080/10428194.2020.1869959.

*Authors:* Stein EM, Bonifacio G, Latremouille-Viau D, Shi S, Guerin A, Wu EQ, Sadek I, Cao X.

**Treatment patterns following first-line pertuzumab + trastuzumab in patients with HER2+ metastatic breast cancer in the United States.**

*Publication:* Journal of Clinical Oncology 2021 06; 39(15\_suppl): e18746-e18746. doi: 10.1200/JCO.2021.39.15\_suppl.e18746.

*Authors:* Mehta S, Pavilack M, Xie J, Ionescu-Iltu R, Nie X, Lei Y, Kwong J.

**Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with Venetoclax.**

*Publication:* Curr Med Res Opin 2021 05; 1. e-pub ahead of print 2021/05/19; doi: 10.1080/03007995.2021.1929894.

*Authors:* Rogers KA, Emond B, Manceur AM, Kinkead F, Lafeuille MH, Lefebvre P, Huang Q.

**Treatment response among patients with multiple myeloma initiating daratumumab across different lines of therapy: A real-world chart review study.**

*Publication:* Journal of Clinical Oncology 2021 05; 39(15\_suppl): e18737-e18737. doi: 10.1200/JCO.2021.39.15\_suppl.e18737.

*Authors:* Atrash S, Thompson-Leduc P, Tai M, Kaila S, Gray K, Ghelerter I, Lafeuille M, Lefebvre P, Rossi AC.

**Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data.**

*Publication:* Curr Med Res Opin 2021 04; 37(4): 609-622. e-pub ahead of print 2021/01/22; doi: 10.1080/03007995.2021.1879753.

*Authors:* Freedland SJ, Ke X, Lafeuille MH, Romdhani H, Kinkead F, Lefebvre P, Petrilla A, Pulungan Z, Kim S, D'Andrea DM, Francis P, Ryan CJ.

**Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.**

*Publication:* Journal of Urology 2021 04; 0(0): 10.1097/JU.0000000000001767. doi: doi:10.1097/JU.0000000000001767.

*Authors:* Halabi S, Jiang S, Terasawa E, Garcia-Horton V, Ayyagari R, Waldeck AR, Shore N.

**Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan.**

*Publication:* Transplant Cell Ther 2021 03; 27(3): 241.e241-241.e211. e-pub ahead of print 2021/03/31; doi: 10.1016/j.jtct.2020.12.023.

*Authors:* Wakase S, Teshima T, Zhang J, Ma Q, Watanabe Y, Yang H, Qi CZ, Chai X, Xie Y, Wu EQ, Igarashi A.

**Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates.**

*Publication:* Leuk Lymphoma 2021 03; 1-14. e-pub ahead of print 2021/03/03.

*Authors:* Atallah EL, Sadek I, Maegawa R, Cao X, Latremouille-Viau D, Pivneva I, Rossi C, Guerin A, Kota V.

**Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer.**

*Publication:* Current Medical Research and Opinion 2021 02; 1-14. doi: 10.1080/03007995.2021.1888704.

*Authors:* Freedland SJ, Li S, Pilon D, Bhak RH, Narkhede S, Lefebvre P, Young-Xu Y.

**Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.**

*Publication:* Oncologist 2021 02; 26(5): e817-e826. e-pub ahead of print 2021/02/23; doi: 10.1002/onco.13721.

*Authors:* Yang X, Laliberte F, Germain G, Raut M, Duh MS, Sen SS, Lejeune D, Desai K, Armand P.

**Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study.**

*Publication:* Drugs Real World Outcomes 2021 02. doi: 10.1007/s40801-020-00226-3.

*Authors:* Gordan L, Chang MH, Lafeuille MH, Romdhani H, Paramasivam F, Maiese EM, McKay C.

**A budget impact analysis of gilteritinib for the treatment of relapsed or refractory FLT3 (mut+) acute myeloid leukemia in a US health plan.**

*Publication:* J Med Econ 2021 01; 24(1): 19-28. e-pub ahead of print 2020/12/08; doi: 10.1080/13696998.2020.1851698.

*Authors:* Pandya BJ, Yang H, Schmeichel C, Qi CZ, Shah MV.

**Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States.**

*Publication:* J Med Econ 2021 01; 24(1): 131-139. e-pub ahead of print 2021/01/06; doi: 10.1080/13696998.2020.1867470.

*Authors:* Cai B, Zhou ZY, Xue W, Hazra NC, Singh M, Mishra D, Brixner D, Oderda G, Biskupiak J.

**The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis.**

*Publication:* Adv Ther 2021 01. doi: 10.1007/s12325-020-01616-3.

*Authors:* Yang M, Georgieva MV, Bocharova I, Vembusubramanian M, Qian K, Guo A, Kamat AM.

**Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma.**

*Publication:* J Comp Eff Res 2021 01; 0(0): null. doi: 10.2217/ce-2020-0236.

*Authors:* Parikh ND, Marshall A, Betts KA, Song J, Zhao J, Yuan M, Wu A, Huff KD, Kim R.

**Treatment patterns, healthcare resource utilization, and costs of patients diagnosed with primary mediastinal B-cell lymphoma in the United States.**

*Publication:* J Med Econ 2021 01; 24(1): 469-478. e-pub ahead of print 2021/04/01; doi: 10.1080/13696998.2021.1908001.

*Authors:* Yang X, Laliberte F, Germain G, Raut M, Duh MS, Sen SS, Lejeune D, Desai K, Armand P.

**Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis.**

*Publication:* Cancer Research 2020 12; 80(24): 5427-5434. doi: 10.1158/0008-5472.Can-20-1792.

*Authors:* Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortés J, Ramsey SD, Briggs A, Hu P, Karantza V, Aktan G, Qi CZ, Gu C, Xie J, Yuan M, Cook J, Untch M, Schmid P, Fasching PA.

**Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma.**

*Publication:* Clin Genitourin Cancer 2020 12; 18(4): e350-e359. e-pub ahead of print 2020/01/14; doi: 10.1016/j.clgc.2019.12.007.

*Authors:* Wells JC, Graham J, Beuselink B, Bjarnason GA, Donskov F, Hansen AR, McKay RR, Vaishampayan U, De Velasco G, Duh MS, Huynh L, Nguyen C, Zanotti G, Ramaswamy K, Choueiri TK, Heng DYC.

**Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer.**

*Publication:* Urol Oncol 2020 12; 38(12): 930.e913-930.e921. e-pub ahead of print 2020/08/03; doi: 10.1016/j.urolonc.2020.07.002.

*Authors:* Freedland SJ, Pilon D, Bhak RH, Lefebvre P, Li S, Young-Xu Y.

**Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA.**

*Publication:* Target Oncol 2020 12. e-pub ahead of print 2020/12/08; doi: 10.1007/s11523-020-00778-y.

*Authors:* Laliberté F, Raut M, Yang X, Germain G, Nahar A, Desai KD, MacKnight SD, Sen SS, Duh MS.

**Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.**

*Publication:* Cancer 2020 12; n/a(n/a). e-pub ahead of print 2020/12/10; doi: <https://doi.org/10.1002/cncr.33365>

*Authors:* Gounder MM, Merriam P, Ratan R, Patel SR, Chugh R, Villalobos VM, Thornton M, Van Tine BA, Abdelhamid AH, Whalen J, Yang J, Rajarethinam A, Duh MS, Bobbili PJ, Huynh L, Totev TI, Lax AK, Agarwal S, Demetri GD.

**Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels.**

*Publication:* Cancer Med 2020 11; 9(21): 8062-8073. e-pub ahead of print 2020/09/22; doi: 10.1002/cam4.3437.

*Authors:* Khorana AA, Kuderer NM, McCrae K, Milentijevic D, Germain G, Laliberté F, MacKnight SD, Lefebvre P, Lyman GH, Streiff MB.

**Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong.**

*Publication:* Cost Eff Resour Alloc 2020 11; 18(1): 50. e-pub ahead of print 2020/12/10; doi: 10.1186/s12962-020-00244-6.

*Authors:* Loong HH, Wong CKH, Leung LKS, Chan CPK, Chang A, Zhou ZY, Xie J, Gibbs M.

**A budget impact analysis of gilteritinib for the treatment of relapsed or refractory FLT3 mut+ acute myeloid leukemia in a U.S. health plan.**

*Publication:* J Med Econ 2020 10; 1-1. doi: 10.1080/13696998.2020.1851698.

*Authors:* Pandya BJ, Yang H, Schmeichel C, Qi CZ, Shah MV.

**Cost-effectiveness analysis of olaparib as a maintenance monotherapy for patients with newly diagnosed advanced ovarian cancer and a <em>BRCA</em> 1/2 mutation: A United States payer perspective.**

*Publication:* Gynecologic Oncology 2020 10; 159: 140-141. doi: 10.1016/j.ygyno.2020.05.186.

*Authors:* Muston DRG, Monberg MJ, McLaurin K, Sackeyfio A, Hettle R, Signorovitch J, Swallow E, Gao W, Zhang S, Kalemaj I, Moore KN.

**Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.**

*Publication:* Current Medical Research and Opinion 2020 10; 1-10. doi: 10.1080/03007995.2020.1835851.

*Authors:* Huang Q, Emond B, Lafeuille M, Gupta D, Lefebvre P, Sundaram M, Mato A.

**Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib.**

*Publication:* Oncologist 2020 10; 25(1): e75-e84. e-pub ahead of print 2019/10/09; doi: 10.1634/theoncologist.2019-0240.

*Authors:* Patel AK, Barghout V, Yenikomshian MA, Germain G, Jacques P, Laliberte F, Duh MS.

**Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome.**

*Publication:* Cancer Management and Research 2020 10; 12: 9713-9719.

*Authors:* Metz DC, Liu E, Joish VN, Huynh L, Totev T, Duh MS, Seth K, Giacalone S, Lapuerta P, Morse MA.

**US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.**

*Publication:* J Comp Eff Res 2020 10; 9(14): 1003-1015. e-pub ahead of print 2020/10/09; doi: 10.2217/ce-2020-0057.

*Authors:* Betts K, Thuresson PO, Felizzi F, Du E, Dieye I, Li J, Schulz M, Masaquel AS.

**Association of Pathological Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-analysis.**

*Publication:* Cancer Res 2020 09. e-pub ahead of print 2020/09/16; doi: 10.1158/0008-5472.Can-20-1792.

*Authors:* Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortés J, Ramsey SD, Briggs A, Hu P, Karantza V, Aktan G, Qi CZ, Gu C, Xie J, Yuan M, Cook J, Untch M, Schmid P, Fasching PA.

**Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels.**

*Publication:* Cancer Medicine 2020 09; n/a(n/a). doi: 10.1002/cam4.3437.

*Authors:* Khorana AA, Kuderer NM, McCrae K, Milentijevic D, Germain G, Laliberté F, MacKnight SD, Lefebvre P, Lyman GH, Streiff MB.

**Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.**

*Publication:* Gynecol Oncol 2020 09; 159(2): 491-497. e-pub ahead of print 2020/09/22; doi: 10.1016/j.ygyno.2020.08.013.

*Authors:* Muston D, Hettle R, Monberg M, McLaurin KK, Gao W, Swallow E, Zhang S, Kalemaj I, Signorovitch J, Moore K.

**Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.**

*Publication:* Curr Med Res Opin 2020 09; 36(9): 1507-1517. e-pub ahead of print 2020/07/23; doi: 10.1080/03007995.2020.1799771.

*Authors:* Bensimon AG, Zhong Y, Swami U, Briggs A, Young J, Feng Y, Song Y, Signorovitch J, Adejoro O, Chakravarty A, Chen M, Perini RF, Geynisman DM.

**A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.**

*Publication:* PharmacoEconomics 2020 08; 38(11): 1201-1218. e-pub ahead of print 2020/08/15; doi: 10.1007/s40273-020-00949-9.

*Authors:* Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, Swallow E, Zhang S, Kalemaj I, Signorovitch J, McQueen RB.

**Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer.**

*Publication:* 2020 08; 18(8): 1096. doi: 10.6004/jnccn.2020.7550.

*Authors:* Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey S, Briggs A, Karantza V, Aktan G, Qi CZ, Gu C, Xie J, Yuan M, Cook J, Untch M, Schmid P, Fasching PA.

**Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center.**

*Publication:* Prostate Cancer and Prostatic Diseases 2020 08. e-pub ahead of print 2020/08/21; doi: 10.1038/s41391-020-00271-7.

*Authors:* McKay RR, Silver R, Bhak RH, Korves C, Cheng M, Appukkuttan S, Simmons SJ, Duh MS, Taplin ME.

**Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study.**

*Publication:* Cancer Management and Research 2020 07; 2020:12: 6607-6614.

*Authors:* Morse MA, Liu E, Joish VN, Huynh L, Cheng M, Sheng Duh M, Seth K, Lapuerta P, Metz DC.

**Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma.**

*Publication:* European Urology Open Science 2020 07; 19: e1105-e1106. doi: [https://doi.org/10.1016/S2666-1683\(20\)33322-X](https://doi.org/10.1016/S2666-1683(20)33322-X).

*Authors:* Wells JC, Dudani S, Gan CL, Stukalin I, Azad A, Liow E, Donskov F, Yuasa T, Pal S, De Velasco G, Wood L, Hansen A, Beuselinck B, Kollmannsberger C, Powles T, McGregor B, Duh MS, Huynh L, Heng DYC.

**Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study.**

*Publication:* Hered Cancer Clin Pract 2020 06; 18: 13. e-pub ahead of print 2020/06/11; doi: 10.1186/s13053-020-00144-z.

*Authors:* Bobbili P, Olufade T, DerSarkissian M, Shenolikar R, Yu H, Duh MS, Tung N.

**Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective.**

*Publication:* J Manag Care Spec Pharm 2020 06; 0(0): 1-12. doi: 10.18553/jmcp.2020.20052.

*Authors:* Yang H, Hao Y, Qi CZ, Chai X, Wu EQ.

**An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.**

*Publication:* Clinical Drug Investigation 2020 05. doi: 10.1007/s40261-020-00922-6.

*Authors:* Bensimon AG, Zhou Z-Y, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Scherrer E, Wang J, Aguiar-Ibáñez R.

**Management of pyrexia in metastatic melanoma patients: A real-world clinical experience survey study.**

*Publication:* Journal of Clinical Oncology 2020 05; 38(15\_suppl): e22102-e22102. doi: 10.1200/JCO.2020.38.15\_suppl.e22102.

*Authors:* Satija A, Pickard AS, Ionescu-Iltu R, Laliberté F, Ling Y, Nakasato AR, Kang B, Duh MS, Patel J.

**PIK3CA mutation status and progression-free survival in advanced hormone receptor positive (HR+)/ human endocrine receptor negative (HER2-) metastatic breast cancer (mBC): A meta-analysis of published clinical trials.**

*Publication:* Journal of Clinical Oncology 2020 05; 38(15\_suppl): 1069-1069. doi: 10.1200/JCO.2020.38.15\_suppl.1069.

*Authors:* Signorovitch J, Andre F, Wang R, Lorenzo I, Ridolfi A, Park J, Fillbrunn M, Dua A, Rugo HS.

**Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.**

*Publication:* Oncologist 2020 05; 25(5): 422-430. e-pub ahead of print 2020/01/24; doi: 10.1634/theoncologist.2019-0605.

*Authors:* Savard MF, Wells JC, Graham J, Dudani S, Steinharter JA, McGregor BA, Donskov F, Bjarnason GA, Vaishampayan UN, Hansen AR, Iafolla MAJ, Zanotti G, Huynh L, Chang R, Duh MS, Heng DYC.

**A Review of Two Regulatory Approved Anti-CD19 CAR T-cell Therapies in Diffuse Large B-Cell Lymphoma: Why are Indirect Treatment Comparisons Not Feasible?**

*Publication:* Adv Ther 2020 05.

*Authors:* Zhang J, Li J, Ma Q, Yang H, Signorovitch j, Wu E.

**EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.**

*Publication:* BMC Cancer 2020 04; 20(1): 356. e-pub ahead of print 2020/04/30; doi: 10.1186/s12885-020-06826-0.

*Authors:* Chiang AC, Fernandes AW, Pavilack M, Wu JW, Laliberte F, Duh MS, Chehab N, Subramanian J.

**Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.**

*Publication:* Eur Urol Oncol 2020 03; 3(3): 318-340. e-pub ahead of print 2020/03/24; doi: 10.1016/j.euo.2020.02.006.

*Authors:* Kamat AM, Lerner SP, O'Donnell M, Georgieva MV, Yang M, Inman BA, Kassouf W, Boorjian SA, Tyson MD, Kulkarni GS, Chang SS, Konety BR, Svatek RS, Balar A, Witjes JA.

**Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer.**

*Publication:* PLoS One 2020 03; 15(3): e0230444. e-pub ahead of print 2020/03/19; doi: 10.1371/journal.pone.0230444.

*Authors:* Bobbili P, Ryan K, DerSarkissian M, Dua A, Yee C, Duh MS, Gomez JE.

**Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective.**

*Publication:* J Med Econ 2020 02: 1-1. doi: 10.1080/13696998.2020.1769109.

*Authors:* Yang H, Hao Y, Chai X, Qi CZ, Wu EQ.

**Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.**

*Publication:* Clin Genitourin Cancer 2020 02; 18(1): e37-e45. doi: 10.1016/j.clgc.2019.10.010.

*Authors:* Cao X, Tang D, Ratto B, Poole A, Ravichandran S, Jin L, Gao W, Swallow E, Vogelzang NJ.

**Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.**

*Publication:* Adv Ther 2020 01; 37(1): 501-511. doi: 10.1007/s12325-019-01156-5.

*Authors:* Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Ladouceur M, Behl AS, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.

**Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.**

*Publication:* The Oncologist 2020 01; 25(5): 422-430. doi: 10.1634/theoncologist.2019-0605.

*Authors:* Savard M-F, Wells JC, Graham J, Dudani S, Steinharter JA, McGregor BA, Donskov F, Bjarnason GA, Vaishampayan UN, Hansen AR, Iaforla MAJ, Zanotti G, Huynh L, Chang R, Duh MS, Heng DYC.

**Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study.**

*Publication:* Leuk Lymphoma 2020 01; 61(1): 98-107. e-pub ahead of print 2019/08/15; doi: 10.1080/10428194.2019.1644332.

*Authors:* Cortes J, Huynh L, Mendelson E, Brandt P, Dalal D, DerSarkissian M, Cortina D, Narkhede S, Sheng Duh M.

**Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.**

*Publication:* Adv Ther 2019 12. e-pub ahead of print 2019/12/10; doi: 10.1007/s12325-019-01157-4.

*Authors:* Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Lefebvre P, McQuarrie K, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.

**The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.**

*Publication:* Lung Cancer 2019 12; 138: 131-138. doi: 10.1016/j.lungcan.2019.07.021.

*Authors:* Subramanian J, Fernandes AW, Laliberté F, Pavilack M, DerSarkissian M, Duh MS.

**Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.**

*Publication:* Clin Ther 2019 11. e-pub ahead of print 2019/11/09; doi: 10.1016/j.clinthera.2019.09.012.

*Authors:* Telford C, Kabadi SM, Abhyankar S, Song J, Signorovitch J, Zhao J, Yao Z.

**Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immunology Checkpoint Inhibitors.**

*Publication:* Eur Urol Oncol 2019 11. e-pub ahead of print 2019/12/02; doi: 10.1016/j.euo.2019.11.001.

*Authors:* Graham J, Shah AY, Wells JC, McKay RR, Vaishampayan U, Hansen A, Donskov F, Bjarnason GA, Beuselinck B, De Velasco G, Iaforla M, Duh MS, Huynh L, Chang R, Zanotti G, Ramaswamy K, Choueiri TK, Tannir NM, Heng DYC.

**Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.**

*Publication:* Drug Saf 2019 10. e-pub ahead of print 2019/10/07; doi: 10.1007/s40264-019-00867-6.

*Authors:* Schultz NM, Penson DF, Wilson S, Song Y, Yang H, Ramaswamy K, Lowentritt B.

**Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA.**

*Publication:* Future Oncol 2019 10; 15(33): 3809-3818. e-pub ahead of print 2019/10/10; doi: 10.2217/fon-2019-0434.

*Authors:* Grivas P, DerSarkissian M, Shenolikar R, Laliberte F, Doleh Y, Duh MS.

**Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis.**

*Publication:* Blood Adv 2019 10; 3(20): 2986-2994. doi: 10.1182/bloodadvances.2019000308.

*Authors:* Ailawadhi S, Parikh K, Abouzaid S, Zhou Z, Tang W, Clancy Z, Cheung C, Zhou ZY, Xie J.

**Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America.**

*Publication:* Adv Ther 2019 10. e-pub ahead of print 2019/10/21; doi: 10.1007/s12325-019-01109-y.

*Authors:* Queiroz Muniz D, Ratto B, Yang H, Zhao J, Jenkins M, Signorovitch J, Dezzani L, Salman P, Lema Medina M, Lopera D, Lerzo G, Del Castillo C, Chacon M, Martin A, Campos-Gomez S.

**Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer.**

*Publication:* Future Oncol 2019 10; 15(29): 3381-3393. e-pub ahead of print 2019/09/24; doi: 10.2217/fon-2019-0282.

*Authors:* Bobbili P, Ryan K, Duh MS, Dua A, Fernandes AW, Pavilack M, Gomez JE.

**Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.**

*Publication:* Oncologist 2019 10. e-pub ahead of print 2019/10/04; doi: 10.1634/theoncologist.2019-0244.

*Authors:* Klempler SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, Sokol ES, Frampton G, Schrock AB, Anhorn R, Reddy P.

**Adjuvant Therapy versus Watch-and-Wait Post Surgery for Stage III Melanoma: A Multi-Country Retrospective Chart Review.**

*Publication:* Melanoma Management 2019 09.

*Authors:* Mohr P, Kiecker F, Soriano VT, Dereure O, Mujika K, Saiag P, Utikal J, Koneru R, Robert C, Cuadros F, Chacón M, Villarroel R, Najjar YG, Kottschade L, Muñoz Couselo E, Koruth R, Guérin A, Burne R, Ionescu-Iltu R, Perrinjaquet M, Zager JS.

**Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer.**

*Publication:* J Med Econ 2019 09; 1-7. doi: 10.1080/13696998.2019.1703190.

*Authors:* Khorana AA, McCrae KR, Milentijevic D, Laliberté F, Lejeune D, Crivera C, Lefebvre P.

**Real-world treatment patterns among patients with advanced gastric cancer in Russia: a chart review study.**

*Publication:* J Drug Assess 2019 09; 8(1): 150-158. e-pub ahead of print 2019/10/28; doi:

10.1080/21556660.2019.1669610.

*Authors:* Tjulandin SA, Tryakin AA, Besova NS, Sholokhova E, Ivanova JI, Cheng WY, Schmerold LM, Thompson-Leduc P, Novick D.

**Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy.**

*Publication:* Clin Lymphoma Myeloma Leuk 2019 08. e-pub ahead of print 2019/11/05; doi:

10.1016/j.clml.2019.08.004.



*Authors:* Emond B, Sundaram M, Romdhani H, Lefebvre P, Wang S, Mato A.

**Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data.**

*Publication:* Adv Ther 2019 08.

*Authors:* Freeman M, Betts KA, Jiang S, Du EX, Gupte-Singh K, Lu Y, Rao S, Shoushtari AN.

**Patient and Oncologist Preferences for the Treatment of Adults with Advanced Soft Tissue Sarcoma: A Discrete Choice Experiment.**

*Publication:* Patient 2019 08; 12(4): 393-404. e-pub ahead of print 2019/01/20; doi: 10.1007/s40271-019-00355-0.

*Authors:* Ivanova J, Hess LM, Garcia-Horton V, Graham S, Liu X, Zhu Y, Nicol S.

**Second-line rituximab-bendamustine versus rituximab-gemcitabine-oxaliplatin in diffuse large B-cell lymphoma in the real world.**

*Publication:* J Comp Eff Res 2019 08. e-pub ahead of print 2019/08/28; doi: 10.2217/cer-2019-0062.

*Authors:* Ionescu-Iltu R, Shang A, Velde NV, Guerin A, Lin Y, Shi L, Shi S, Qayum N.

**Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer.**

*Publication:* Breast Journal. 2019 07. doi: <http://dx.doi.org/10.1111/tbj.13345>.

*Authors:* Patterson-Lomba O, Dalal AA, Ayyagari R, Liu O, Dervishi E, Platt E, Chandiwana D, O'Shaughnessy JA.

**Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model.**

*Publication:* JCO Precision Oncology 2019 06; (3): 1-9. doi: 10.1200/po.18.00356.

*Authors:* Pennell NA, Mutebi A, Zhou Z-Y, Ricculli ML, Tang W, Wang H, Guerin A, Arnhart T, Dalal A, Sasane M, Wu KY, Culver KW, Otterson GA.

**Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer.**

*Publication:* Curr Oncol 2019 06; 26(3): e300-e308. e-pub ahead of print 2019/07/10; doi: 10.3747/co.26.4485.

*Authors:* Levy BP, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Parisi M.

**Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.**

*Publication:* J Manag Care Spec Pharm 2019 06: 1-10. doi: <http://dx.doi.org/10.18553/jmcp.2019.19109>.

*Authors:* Schultz NM, Penson DF, Wilson SD, Song Y, Yang H, Ramaswamy K, Lowentritt B.

**Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.**

*Publication:* Melanoma Res 2019 06; 29(3): 301-310. e-pub ahead of print 2018/09/25; doi: 10.1097/CMR.0000000000000504.

*Authors:* Ghate S, Ionescu-Iltu R, Burne R, Ndife B, Laliberte F, Nakasato A, Duh MS.

**Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective.**

*Publication:* Leuk Lymphoma 2019 06; 60(6): 1476-1484. e-pub ahead of print 2019/01/23; doi: 10.1080/10428194.2018.1538510.

*Authors:* Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL.

**Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants.**

*Publication:* J Med Econ 2019 05: 1. doi: <http://dx.doi.org/10.1080/13696998.2019.1620752>.

*Authors:* Streiff M, Milentijevic D, McCrae KR, Laliberte F, Lejeune D, Lefebvre P, Schein J, Khorana AA.

**A budget impact analysis of the introduction of copanlisib for treatment of relapsed follicular lymphoma in the United States.**

*Publication:* Journal of Managed Care and Specialty Pharmacy 2019 04; 25(4): 437-446b.

*Authors:* Appukkuttan S, Yaldo A, Gharibo M, Babajanyan S, Duchesneau E, Zichlin ML, Bhak RH, Duh MS.

**Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.**

*Publication:* J Med Econ 2019 04; 1. e-pub ahead of print 2019/04/24; doi: 10.1080/13696998.2019.1609485.

*Authors:* Bensimon AG, Zhou ZY, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Liu FX, Wang J, Aguiar-Ibanez R.

**Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study.**

*Publication:* Eur J Haematol 2019 04; 102(4): 341-350. e-pub ahead of print 2018/12/24; doi: 10.1111/ejh.13205.

*Authors:* Griffin JD, Yang H, Song Y, Kinrich D, Shah MV, Bui CN.

**Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome.**

*Publication:* BMC Cancer 2019 03; 19(1): 274. e-pub ahead of print 2019/03/30; doi: 10.1186/s12885-019-5459-x.

*Authors:* Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak RH, Narkhede S, Totev T, Duh MS, Neary MP, Cella D.

**Association between pathological complete responses and long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant chemotherapy.**

*Publication:* JNCCN Journal of the National Comprehensive Cancer Network. 2019 03; 17(3.5). e-pub ahead of print 2019/03/08.

*Authors:* Qi CZ, Huang M, Haiderali A, Xie J, Zhou Z-Y, Wu EQ, Fasching P.

**Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.**

*Publication:* J Med Econ 2019 02; 22(2): 140-150. e-pub ahead of print 2018/11/16; doi: 10.1080/13696998.2018.1549056.

*Authors:* Signorovitch J, Zhou Z, Ryan J, Anhorn R, Chawla A.

**Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration.**

*Publication:* Eur Urol Oncol 2019 02; 2(1): 12-20. e-pub ahead of print 2019/04/02; doi: 10.1016/j.euo.2018.07.003.

*Authors:* Vander Velde N, Guerin A, Ionescu-Iltu R, Shi S, Wu EQ, Lin SW, Hsu LI, Saum KU, de Ducla S, Wang J, Li S, Thastrom A, Liu S, Shi L, Leppert JT.

**Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.**

*Publication:* PharmacoEconomics. 2019 02; 37(2): 239-253. e-pub ahead of print 2018/11/02; doi:

<http://dx.doi.org/10.1007/s40273-018-0732-4>.

*Authors:* Stein E, Xie J, Duchesneau E, Bhattacharyya S, Vudumula U, Ndife B, Bonifacio G, Guerin A, Li N, Joseph G.

**Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma.**

*Publication:* Clin Ther 2019 02; 41(3): 477-493 e477. e-pub ahead of print 2019/02/19; doi: 10.1016/j.clinthera.2019.01.009.

*Authors:* Ailawadhi S, DerSarkissian M, Duh MS, Lafeuille MH, Posner G, Ralston S, Zagadailov E, Ba-Mancini A, Rifkin R.

**Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective.**

*Publication:* J Manag Care Spec Pharm 2019 02; 25(2): 246-259. doi: <http://dx.doi.org/10.18553/jmcp.2019.25.2.246>.

*Authors:* Frois C, Howe A, Jarvis J, Grice K, Wong K, Zacker C, Sasane R.

**Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia.**

*Publication:* Adv Ther 2019 02. e-pub ahead of print 2019/02/14; doi: 10.1007/s12325-019-0873-7.

*Authors:* Song J, Ma Q, Gao W, Cong Z, Xie J, Zimmerman Z, Belton L, Franklin J, Palmer S.

**Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study.**

*Publication:* Future Oncol 2019 02; 15(4): 359-370. e-pub ahead of print 2018/10/16; doi: 10.2217/fon-2018-0671.

*Authors:* Tarhini A, Ghate S, Ionescu-Iltu R, Shi S, Nakasato A, Ndife B, Laliberte F, Burne R, Duh MS.

**Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls.**

*Publication:* Current Medical Research and Opinion 2019 01; 35(1): 105-111. doi:

<http://dx.doi.org/10.1080/03007995.2018.1541443>.

*Authors:* Li J, Knoll S, Bocharova I, Tang W, Signorovitch J.

**Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.**

*Publication:* Oncologist 2019 01; 24(8): 1056-1065. e-pub ahead of print 2019/01/05; doi:

10.1634/theoncologist.2018-0519.

*Authors:* Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK.

**Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.**

*Publication:* Oncologist 2019 01; 24(8): 1066-1075. e-pub ahead of print 2019/01/06; doi:

10.1634/theoncologist.2018-0520.

*Authors:* Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH.

**Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy.**

*Publication:* Curr Med Res Opin 2018 12; 34(12): 2169-2176. e-pub ahead of print 2018/07/17; doi:

10.1080/03007995.2018.1501351.

*Authors:* Ghate SR, Ionescu-Iltu R, Burne R, Ndife B, Laliberte F, Nakasato A, Duh MS.

**Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.**

*Publication:* Melanoma Res 2018 12; 28(6): 618-628. e-pub ahead of print 2018/09/15; doi:

10.1097/CMR.0000000000000507.

*Authors:* Tarhini A, Ghate SR, Ionescu-Iltu R, Manceur AM, Ndife B, Jacques P, Laliberte F, Nakasato A, Burne R, Duh MS.

**Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study.**

*Publication:* Medicine (Baltimore) 2018 11; 97(47): e13390. e-pub ahead of print 2018/11/22; doi:

10.1097/MD.00000000000013390.

*Authors:* Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak RH, Duh MS, Neary MP, Cella D.

**Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus.**

*Publication:* PLoS One 2018 11; 13(11): e0204646. e-pub ahead of print 2018/11/16; doi:

10.1371/journal.pone.0204646.

*Authors:* Zonnenberg BA, Neary MP, Duh MS, Ionescu-Ittu R, Fortier J, Vekeman F.

**Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.**

*Publication:* Urol Oncol 2018 11; 36(11): 500 e501-500 e509. e-pub ahead of print 2018/09/12; doi: 10.1016/j.urolonc.2018.08.002.

*Authors:* Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Sztatowski TP.

**The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation.**

*Publication:* Am J Hematol 2018 11. e-pub ahead of print 2018/11/27; doi: 10.1002/ajh.25361.

*Authors:* Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff MB.

**Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.**

*Publication:* Adv Ther 2018 10; 35(10): 1564-1577. e-pub ahead of print 2018/09/14; doi: 10.1007/s12325-018-0784-z.

*Authors:* Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL.

**Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.**

*Publication:* BMC Urol 2018 10; 18(1): 84. e-pub ahead of print 2018/10/05; doi: 10.1186/s12894-018-0397-5.

*Authors:* Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

**Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.**

*Publication:* Cancer 2018 10; 124(20): 4032-4043. e-pub ahead of print 2018/09/12; doi: 10.1002/cncr.31680.

*Authors:* Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG.

**Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.**

*Publication:* Adv Ther 2018 10; 35(10): 1639-1655. e-pub ahead of print 2018/09/08; doi: 10.1007/s12325-018-0774-1.

*Authors:* Schultz NM, Flanders SC, Wilson S, Brown BA, Song Y, Yang H, Lechpammer S, Kassabian V.

**Antiepileptic Drug Titration and Related Health Care Resource Use and Costs.**

*Publication:* J Manag Care Spec Pharm 2018 09; 24(9): 929-938. e-pub ahead of print 2018/02/28; doi: 10.18553/jmcp.2018.17337.

*Authors:* Fishman J, Kalilani L, Song Y, Swallow E, Wild I.

**Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States.**

*Publication:* Health Qual Life Outcomes 2018 09; 16(1): 193. e-pub ahead of print 2018/09/23; doi: 10.1186/s12955-018-1013-9.

*Authors:* Stein EM, Yang M, Guerin A, Gao W, Galebach P, Xiang CQ, Bhattacharyya S, Bonifacio G, Joseph GJ.

**Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.**

*Publication:* BMC Urol 2018 09; 18(1): 77. e-pub ahead of print 2018/09/08; doi: 10.1186/s12894-018-0387-7.

*Authors:* Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

**Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.**

*Publication:* Current Medical Research and Opinion 2018 09; 34(9): 1645-1652. e-pub ahead of print 2018/05/22; doi: <http://dx.doi.org/10.1080/03007995.2018.1479246>.

*Authors:* Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA.

**Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib.**

*Publication:* Clinical Colorectal Cancer 2018 09; 17(3): e531-e539. e-pub ahead of print 2018/05/29; doi: <http://dx.doi.org/10.1016/j.clcc.2018.04.002>.

*Authors:* Patel AK, Duh MS, Barghout V, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS.

**Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast Cancer.**

*Publication:* Adv Ther 2018 09; 35(9): 1356-1367. e-pub ahead of print 2018/08/15; doi: 10.1007/s12325-018-0764-3.

*Authors:* Dalal AA, Gauthier G, Gagnon-Sanschagrין P, Burne R, Guerin A, Niravath P, Small T.

**Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States.**

*Publication:* Adv Ther 2018 08; 35(10): 1671-1685. e-pub ahead of print 2018/08/30; doi: 10.1007/s12325-018-0772-3.

*Authors:* Seiter K, Latremouille-Viau D, Guerin A, Ndife B, Habucky K, Tang DH, Pivneva I, Gagnon-Sanschagrין P, Joseph GJ.

**Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data.**

*Publication:* BMJ Open 2018 08; 8(8): e021642. e-pub ahead of print 2018/08/20; doi: 10.1136/bmjopen-2018-021642.

*Authors:* Li J, Sasane M, Zhang J, Zhao J, Ricculli ML, Yao Z, Redhu S, Signorovitch J.

**Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2-Metastatic Breast Cancer.**

*Publication:* Adv Ther 2018 08; 35(8): 1251-1264. e-pub ahead of print 2018/06/28; doi: 10.1007/s12325-018-0740-y.

*Authors:* Guerin A, Goldschmidt D, Small T, Gagnon-Sanschagrין P, Romdhani H, Gauthier G, Kelkar S, Wu EQ, Niravath P, Dalal AA.

**Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis.**

*Publication:* Adv Ther 2018 07; 35(7): 1035-1048. e-pub ahead of print 2018/06/28; doi: 10.1007/s12325-018-0734-9.

*Authors:* Li J, Sasane M, Zhao J, Horton VG, Zhang P, Ricculli ML, Zhou ZY, Signorovitch J.

**Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies.**

*Publication:* Cancer Biol Ther 2018 07; 19(7): 636-643. e-pub ahead of print 2018/03/28; doi: 10.1080/15384047.2018.1449616.

*Authors:* Mato AR, Samp JC, Gauthier G, Terasawa E, Brander DM.

**Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.**

*Publication:* J Med Econ 2018 07; 21(7): 649-655. e-pub ahead of print 2018/03/09; doi: 10.1080/13696998.2018.1450261.

*Authors:* Dalal AA, Guerin A, Mutebi A, Culver KW.

**Overall survival and health care costs of Medicare patients with previously treated chronic lymphocytic leukemia.**

*Publication:* Journal of Cancer Therapy 2018 07.  
*Authors:* Reyes C, Gauthier G, Shi S, Guerin A.

**Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.**

*Publication:* J Med Econ 2018 06; 21(6): 577-586. e-pub ahead of print 2018/02/21; doi: 10.1080/13696998.2018.1443111.

*Authors:* Zhou ZY, Mutebi A, Han S, Bensimon AG, Louise Ricculli M, Xie J, Dalal A, Culver K.

**Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer.**

*Publication:* Adv Ther 2018 06; 35(6): 768-778. e-pub ahead of print 2018/06/06; doi: 10.1007/s12325-018-0701-5.

*Authors:* Dalal AA, Gagnon-Sanschagrin P, Burne R, Guerin A, Gauthier G, Small T, Niravath P.

**Economic burden of treatment failure in chronic lymphocytic leukemia patients.**

*Publication:* Curr Med Res Opin 2018 06; 34(6): 1135-1142. e-pub ahead of print 2018/04/14; doi: 10.1080/03007995.2018.1464904.

*Authors:* Wang S, Lafeuille MH, Lefebvre P, Romdhani H, Emond B, Senbetta M.

**Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.**

*Publication:* J Manag Care Spec Pharm 2018 06; 24(6): 525-533. e-pub ahead of print 2018/05/26; doi: 10.18553/jmcp.2018.24.6.525.

*Authors:* Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.

**Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers.**

*Publication:* J Med Econ 2018 06; 21(6): 543-552. e-pub ahead of print 2018/01/04; doi: <http://dx.doi.org/10.1080/13696998.2017.1423488>.

*Authors:* Chawla A, Peeples M, Li N, Anhorn R, Ryan J, Signorovitch J.

**Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations.**

*Publication:* J Med Econ 2018 06; 21(6): 556-563. e-pub ahead of print 2018/01/07; doi: 10.1080/13696998.2018.1425209.

*Authors:* Stein EM, Bonifacio G, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagrin P, Briggs O, Joseph GJ.

**Overall survival in patients with glioblastoma before and after bevacizumab approval.**

*Publication:* Curr Med Res Opin 2018 05; 34(5): 813-820. e-pub ahead of print 2017/10/14; doi: 10.1080/03007995.2017.1392294.

*Authors:* Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ilttu R, Shi S, Macalalad A, Uhm JH.

**Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.**

*Publication:* Lung Cancer 2018 05; 119: 112-119. e-pub ahead of print 2018/04/17; doi: 10.1016/j.lungcan.2018.02.011.

*Authors:* Borghaei H, Yim YM, Guerin A, Pivneva I, Shi S, Gandhi M, Ionescu-Ilttu R.

**Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis.**

*Publication:* J Drug Assess 2018 05; 7(1): 21-27. e-pub ahead of print 2018/05/01; doi: 10.1080/21556660.2018.1445092.

*Authors:* Dalal AA, Guerin A, Mutebi A, Culver KW.

**The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.**

*Publication:* J Manag Care Spec Pharm 2018 04; 24(4): 335-343. e-pub ahead of print 2018/03/27; doi: 10.18553/jmcp.2018.24.4.335.

*Authors:* Swallow E, Messali A, Ghate S, McDonald E, Duchesneau E, Perez JR.

**Assessment of costs associated with adverse events in patients with cancer.**

*Publication:* PLoS One 2018 04; 13(4): e0196007. e-pub ahead of print 2018/04/14; doi: 10.1371/journal.pone.0196007.

*Authors:* Wong W, Yim YM, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrין P, Guerin A.

**Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study.**

*Publication:* Adv Ther 2018 04; 35(4): 482-493. e-pub ahead of print 2018/03/28; doi: 10.1007/s12325-018-0676-2.

*Authors:* Goldschmidt D, Dalal AA, Romdhani H, Kelkar S, Guerin A, Gauthier G, Wu EQ, Niravath P, Small T.

**Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women.**

*Publication:* Adv Ther 2018 04; 35(4): 503-514. e-pub ahead of print 2018/03/21; doi: 10.1007/s12325-018-0689-x.

*Authors:* Gauthier G, Gagnon-Sanschagrין P, Guerin A, Burne R, Small T, Niravath P, Dalal AA.

**Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.**

*Publication:* Clin Lymphoma Myeloma Leuk 2018 04; 18(4): 257-265. e-pub ahead of print 2018/03/10; doi: 10.1016/j.clml.2018.02.010.

*Authors:* Jabbour E, DerSarkissian M, Duh MS, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, O'Brien S, Ravandi F, Kantarjian HM.

**Epidemiologic and clinical characteristics of nontransfusion-dependent thalassemia in the United States.**

*Publication:* Pediatr Blood Cancer 2018 04; 65(7): e27067. e-pub ahead of print 2018/04/11; doi: 10.1002/pbc.27067.

*Authors:* Vichinsky E, Cohen A, Thompson AA, Giardina PJ, Lal A, Paley C, Cheng WY, McCormick N, Sasane M, Qiu Y, Kwiatkowski JL.

**Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer: A Network Meta-analysis.**

*Publication:* Clin Ther 2018 04; 40(4): 628-639 e623. e-pub ahead of print 2018/04/04; doi: 10.1016/j.clinthera.2018.03.004.

*Authors:* Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA.

**Factors associated with the number and size of renal angiomyolipomas in sporadic angiomyolipoma (sAML): a study of adult patients with sAML managed in a Dutch tertiary referral center.**

*Publication:* International Urology and Nephrology 2018 03; 50(3): 459-467. doi: <http://dx.doi.org/10.1007/s11255-017-1766-9>.

*Authors:* Ruud Bosch JLH, Vekeman F, Duh MS, Neary M, Magestro M, Fortier J, Karner P, Ionescu-Ittu R, Zonnenberg BA.

**Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis.**

*Publication:* J Drugs Dermatol 2018 02; 17(2): 180-186. e-pub ahead of print 2018/02/21.

*Authors:* Kimball AB, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrין P, Guerin A, Ganguli A.

**Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting.**

*Publication:* Clin Genitourin Cancer 2018 02; 16(1): 50-57. doi: <http://dx.doi.org/10.1016/j.clgc.2017.06.004>.

*Authors:* Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS.

**Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer.**

*Publication:* American Journal of Managed Care 2018 02.

*Authors:* Nellesen D, Dea K, Guerin A, Culver K, Mutebi A, Dalal A.

**First-line treatment disruption among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.**

*Publication:* Curr Med Res Opin 2017 12; 33(12): 2137-2143. e-pub ahead of print 2017/10/11; doi: 10.1080/03007995.2017.1390447.

*Authors:* Tang DH, Li N, Du EX, Peebles M, Chu L, Xie J, Barghout V.

**Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.**

*Publication:* Adv Ther 2017 12; 34(12): 2566-2584. e-pub ahead of print 2017/11/17; doi: 10.1007/s12325-017-0644-2.

*Authors:* Zhou Z, Tang DH, Xie J, Ayyagari R, Wu E, Niravath PA.

**Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer.**

*Publication:* Clin Lung Cancer 2017 11; 18(6): 640-650 e642. e-pub ahead of print 2017/05/20; doi: 10.1016/j.clcc.2017.04.010.

*Authors:* Ganti AK, Hirsch FR, Wynes MW, Ravelo A, Ramalingam SS, Ionescu-Ittu R, Pivneva I, Borghaei H.

**Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.**

*Publication:* Adv Ther 2017 11; 34(11): 2452-2465. e-pub ahead of print 2017/10/28; doi: 10.1007/s12325-017-0628-2.

*Authors:* Vogelzang NJ, Pal SK, Ghate SR, Swallow E, Li N, Peebles M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.

**Comparing the cost of treatment with octreotide long-acting release versus lanreotide in patients with metastatic gastrointestinal neuroendocrine tumors.**

*Publication:* American Health and Drug Benefits 2017 11; 10(8): 408-415.

*Authors:* Ayyagari R, Neary M, Li S, Rokito A, Yang H, Xie J, Benson AB.

**Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA.**

*Publication:* Med Oncol 2017 11; 34(12): 193. e-pub ahead of print 2017/11/06; doi: 10.1007/s12032-017-1049-4.

*Authors:* Ivanova JI, Saverno KR, Sung J, Duh MS, Zhao C, Cai S, Vekeman F, Peevyhouse A, Dhawan R, Fuchs CS.

**Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea.**

*Publication:* Asia Pac J Clin Oncol 2017 10; 13(5): e239-e245. e-pub ahead of print 2017/04/19; doi: 10.1111/ajco.12645.

*Authors:* Lim SH, Yoh KA, Lee JS, Ahn MJ, Kim YJ, Kim SH, Zhang J, Patel D, Swallow E, Kageleiry A, Galebach P, Lee D, Stein K, Degun R, Park K.

**Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.**

*Publication:* J Med Econ 2017 09; 20(9): 945-951. e-pub ahead of print 2017/06/01; doi: 10.1080/13696998.2017.1337019.

*Authors:* Huynh L, Totev T, Vekeman F, Neary MP, Duh MS, Benson AB.

**Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases.**



*Publication:* Prostate Cancer Prostatic Dis 2017 09; 20(3): 276-282. e-pub ahead of print 2017/02/22; doi: 10.1038/pcan.2017.4.

*Authors:* McKay R, Haider B, Duh MS, Valderrama A, Nakabayashi M, Fiorillo M, Ristovska L, Wen L, Kantoff P.

**Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.**

*Publication:* Cancer 2017 08; 123(15): 2875-2880. e-pub ahead of print 2017/04/08; doi: 10.1002/cncr.30558.

*Authors:* Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE.

**Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.**

*Publication:* Med Oncol 2017 08; 34(9): 160. e-pub ahead of print 2017/08/11; doi: 10.1007/s12032-017-1014-2.

*Authors:* Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS.

**Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2-metastatic breast cancer.**

*Publication:* Expert Opin Pharmacother 2017 08; 18(12): 1167-1178. e-pub ahead of print 2017/07/13; doi: 10.1080/14656566.2017.1351947.

*Authors:* Li N, Du EX, Chu L, Peeples M, Xie J, Barghout V, Tang DH.

**Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.**

*Publication:* Clin Genitourin Cancer 2017 08; 15(4): e573-e582. e-pub ahead of print 2017/02/01; doi: 10.1016/j.clgc.2016.12.005.

*Authors:* Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ.

**Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices.**

*Publication:* Leuk Lymphoma 2017 08; 58(8): 1968-1972. e-pub ahead of print 2017/01/18; doi: 10.1080/10428194.2016.1272688.

*Authors:* Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, van de Velde H, Niculescu L, Bonthapally V, Goy A.

**Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014.**

*Publication:* J Am Acad Dermatol 2017 07; 77(1): 55-62 e53. doi: 10.1016/j.jaad.2017.02.050.

*Authors:* Migden M, Xie J, Wei J, Tang W, Herrera V, Palmer JB.

**Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients.**

*Publication:* Adv Ther 2017 07; 34(7): 1673-1685. e-pub ahead of print 2017/06/05; doi: 10.1007/s12325-017-0551-6.

*Authors:* Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guerin A.

**Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea.**

*Publication:* Cancer Res Treat 2017 07; 49(3): 578-587. e-pub ahead of print 2016/09/14; doi: 10.4143/crt.2016.001.

*Authors:* Carter GC, Kaltenboeck A, Ivanova J, Liepa AM, San Roman A, Koh M, Rajan N, Cheng R, Birnbaum HG, Kim JS, Bang YJ.

**Real-world Characteristics and Outcomes of Patients with Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy versus Androgen Receptor-targeted Therapy after Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting.**

*Publication:* Clin Genitourin Cancer 2017 06: 50-57. e-pub ahead of print 2017/07/22; doi: 10.1016/j.clgc.2017.06.004.

*Authors:* Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS.

**Treatment patterns in patients with advanced gastric cancer in Taiwan.**

*Publication:* Asia-Pacific Journal of Clinical Oncology 2017 06; 13(3): 185-194. doi: <http://dx.doi.org/10.1111/ajco.12497>.

*Authors:* Cuyun Carter G, Kaltenboeck A, Ivanova J, Liepa AM, San Roman A, Koh M, Rajan N, Cheng R, Birnbaum H, Chen JS.

**Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy.**

*Publication:* American Health and Drug Benefits 2017 05; 10(3): 143-152.

*Authors:* Pilon D, Behl AS, Ellis LA, Robitaille MN, Lefebvre P, Dawson NA.

**Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.**

*Publication:* Med Oncol 2017 05; 34(5): 88. e-pub ahead of print 2017/04/11; doi: 10.1007/s12032-017-0927-0.

*Authors:* Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E.

**Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.**

*Publication:* Adv Ther 2017 05; 34(5): 1145-1156. e-pub ahead of print 2017/04/14; doi: 10.1007/s12325-017-0527-6.

*Authors:* Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guerin A.

**Assessment of Evidence-Based Standards in the Treatment of Advanced Prostate Cancer in a Community Practice.**

*Publication:* Urology Practice. 2017 04; 4(3): 218-224. doi: <http://dx.doi.org/10.1016/j.urpr.2016.06.004>.

*Authors:* Pilon D, Ellis LA, Behl AS, Gozalo L, Emond B, Lefebvre P, Calabrese R, Prime H, Gaylis F.

**Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.**

*Publication:* J Med Econ 2017 04; 20(4): 395-404. e-pub ahead of print 2016/12/17; doi: 10.1080/13696998.2016.1273228.

*Authors:* Rose DB, Nellesen D, Neary MP, Cai B.

**Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.**

*Publication:* J Med Econ 2017 04; 20(4): 328-336. doi: 10.1080/13696998.2016.1261032.

*Authors:* Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, Bhattacharyya S, Joseph G.

**Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.**

*Publication:* Int J Urol 2017 04; 24(4): 272-278. e-pub ahead of print 2017/03/03; doi: 10.1111/iju.13314.

*Authors:* Pal SK, Signorovitch JE, Li N, Zichlin ML, Liu Z, Ghate SR, Perez JR, Vogelzang NJ.

**Utility values associated with advanced or metastatic non-small cell lung cancer: data needs for economic modeling.**

*Publication:* Expert Rev Pharmacoecon Outcomes Res 2017 04; 17(2): 153-164. e-pub ahead of print 2017/03/25; doi: 10.1080/14737167.2017.1311210.

*Authors:* Brown J, Cook K, Adamski K, Lau J, Bargo D, Breen S, Chawla A.

**Duration of treatment in prostate cancer patients treated with abiraterone acetate or enzalutamide.**

*Publication:* Journal of Managed Care and Specialty Pharmacy 2017 02; 23(2): 225-235. doi: <http://dx.doi.org/10.18553/jmcp.2016.16233>.

*Authors:* Pilon D, Behl AS, Ellis LA, Emond B, Lefebvre P, Dawson NA.

**Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency.**

*Publication:* Journal of Managed Care and Specialty Pharmacy 2017 02; 23(2): 214-224. doi: <http://dx.doi.org/10.18553/jmcp.2017.23.2.214>.

*Authors:* Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ.

**Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.**

*Publication:* J Med Econ 2017 02; 20(2): 121-128. doi: 10.1080/13696998.2016.1229670.

*Authors:* Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S.

**The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.**

*Publication:* J Med Econ 2017 01; 20(1): 54-62. e-pub ahead of print 2016/09/08; doi: 10.1080/13696998.2016.1225577.

*Authors:* Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C.

**Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.**

*Publication:* J Med Econ 2017 01; 20(1): 63-71. e-pub ahead of print 2016/09/08; doi: 10.1080/13696998.2016.1225578.

*Authors:* Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L.

**Association between time to progression and subsequent survival in crizotinib-treated patients with advanced ALK-positive non-small-cell lung cancer.**

*Publication:* Curr Med Res Opin 2016 11; 32(11): 1911-1918. e-pub ahead of print 2016/08/05; doi: 10.1080/03007995.2016.1220934.

*Authors:* Liu G, Zhang J, Zhou ZY, Li J, Cai X, Signorovitch J.

**An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed with Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records from US Community Oncology Practices.**

*Publication:* Clin Lymphoma Myeloma Leuk 2016 11; 16(11): 625-636 e623. e-pub ahead of print 2016/10/01; doi: 10.1016/j.clml.2016.08.006.

*Authors:* Ma E, Bonthapally V, Chawla A, Lefebvre P, Swords R, Lafeuille MH, Fortier J, Emond B, Duh MS, Dezube BJ.

**Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant.**

*Publication:* International Journal of Hematologic Oncology 2016 09; 5(2): 63-75. doi: <http://dx.doi.org/10.2217/ijh-2016-0001>.

*Authors:* Maziarz RT, Guerin A, Gauthier G, Heroux J, Zhdanova M, Wu EQ, Thomas SK, Chen L.

**Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.**

*Publication:* Lung Cancer 2016 08; 98: 9-14. e-pub ahead of print 2016/07/10; doi: 10.1016/j.lungcan.2016.05.004.

*Authors:* Cadranel J, Park K, Arrieta O, Pless M, Bendaly E, Patel D, Sasane M, Nosal A, Swallow E, Galebach P, Kageleiry A, Stein K, Degun R, Zhang J.

**Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.**

*Publication:* J Med Econ 2016 08; 19(8): 777-784. doi: 10.3111/13696998.2016.1173042.

*Authors:* Pilon D, Queener M, Lefebvre P, Ellis LA.

**Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2-Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.**

*Publication:* Adv Ther 2016 06; 33(6): 983-997. doi: 10.1007/s12325-016-0328-3.

*Authors:* Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Guerin A.

**Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.**

*Publication:* Expert Opin Pharmacother 2016 06; 17(9): 1189-1196. e-pub ahead of print 2016/04/08; doi:

10.1080/14656566.2016.1176148.

*Authors:* Guerin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry A, Koo V, Li N, Wu EQ.

**Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada.**

*Publication:* J Med Econ 2016 05; 1-17. doi: 10.1080/13696998.2016.1187151.

*Authors:* Hurry M, Zhou ZY, Zhang J, Zhang C, Liangyi F, Rebeira M, Xie J.

**Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.**

*Publication:* Breast Cancer Res Treat 2016 05; 157(1): 145-156. e-pub ahead of print 2016/04/25; doi: 10.1007/s10549-016-3790-3.

*Authors:* Gallagher CM, More K, Kamath T, Masaquel A, Guerin A, Ionescu-Iltu R, Gauthier-Loiselle M, Nitulescu R, Sicignano N, Butts E, Wu EQ, Barnett B.

**The economic burden of brain metastasis among lung cancer patients in the United States.**

*Publication:* J Med Econ 2016 05; 19(5): 526-536. doi: 10.3111/13696998.2016.1138962.

*Authors:* Guerin A, Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, Wu EQ, Macalalad AR.

**Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.**

*Publication:* J Med Econ 2016 05; 19(5): 462-468. doi: 10.3111/13696998.2015.1131705.

*Authors:* Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ.

**Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.**

*Publication:* Curr Med Res Opin 2016 05; 32(5): 817-827. e-pub ahead of print 2016/01/09; doi:

10.1185/03007995.2016.1140030.

*Authors:* Smith BD, Liu J, Latremouille-Viau D, Guerin A, Fernandez D, Chen L.

**Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.**

*Publication:* Curr Med Res Opin 2016 04; 32(4): 741-747. doi: 10.1185/03007995.2016.1140028.

*Authors:* Vogelzang NJ, Pal SK, Signorovitch JE, Reichmann WM, Li N, Yang C, Liu Z, Perez JR, Jonasch E.

**Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2-metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.**

*Publication:* J Med Econ 2016 04; 19(4): 414-423. doi: 10.3111/13696998.2015.1131704.

*Authors:* Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, Guerin A.

**Effectiveness of Everolimus versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients with Multiple Metastatic Sites.**

*Publication:* Clin Ther 2016 04; 38(4): 905-917. e-pub ahead of print 2016/03/08; doi: 10.1016/j.clinthera.2016.02.009.

*Authors:* Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ.

**Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.**

*Publication:* Clin Genitourin Cancer 2016 04; 14(2): 160-167 e163. doi: 10.1016/j.clgc.2015.11.011.

*Authors:* Pal SK, Signorovitch JE, Reichmann WM, Li N, Koo V, Liu Z, Perez JR, Vogelzang NJ.

**Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.**

*Publication:* Leukemia 2016 04; 30(4): 995-998. e-pub ahead of print 2015/08/15; doi: 10.1038/leu.2015.225.

*Authors:* Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV.

**Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice.**

*Publication:* Springerplus 2016 03; 5: 395. e-pub ahead of print 2016/04/06; doi: 10.1186/s40064-016-2008-9.

*Authors:* Gallagher CM, More K, Masaquel A, Kamath T, Guerin A, Ionescu-Iltu R, Nitulescu R, Gauthier-Loiselle M, Sicignano N, Butts E, Wu EQ, Barnett B.

**Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey.**

*Publication:* Cancer Med 2016 02; 5(2): 209-220. doi: 10.1002/cam4.580.

*Authors:* Lin PL, Hao Y, Xie J, Li N, Zhong Y, Zhou Z, Signorovitch JE, Wu EQ.

**Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: A retrospective claims study in the US.**

*Publication:* Current Medical Research and Opinion 2016 02; 32(2): 385-394.

*Authors:* Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Wu EQ, Guerin A.

**Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.**

*Publication:* Exp Hematol Oncol 2015 12; 4(31): 31. doi: 10.1186/s40164-015-0023-0.

*Authors:* Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Wu EQ.

**Economic Evaluations of Everolimus versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer from a US Payer Perspective.**

*Publication:* Clin Breast Cancer 2015 10; 15(5): e263-276. doi: 10.1016/j.clbc.2015.04.001.

*Authors:* Xie J, Hao Y, Zhou ZY, Qi CZ, De G, Gluck S.

**Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.**

*Publication:* Expert Opin Pharmacother 2015 10; 16(14): 2101-2111. doi: 10.1517/14656566.2015.1074182.

*Authors:* Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ.

**Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer.**

*Publication:* Breast Cancer (Auckl) 2015 09; 9: 67-72. doi: 10.4137/BCBCR.S30771.

*Authors:* Song Y, Hao Y, Macalalad AR, Lin PL, Signorovitch JE, Wu EQ.

**Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence after Resection.**

*Publication:* JAMA Oncol 2015 09; 1(6): 797-805. doi: 10.1001/jamaoncol.2015.2407.

*Authors:* Guerin A, Sasane M, Keir CH, Gauthier G, Macalalad AR, Wu EQ, Conley AP.

**Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting.**

*Publication:* Current Medical Research & Opinion 2015 08; 31(8): 1561-1572. doi: 10.1185/03007995.2015.1062356.  
*Authors:* Toy EL, Vekeman F, Lewis MC, Oglesby AK, Duh MS.

**Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer.**

*Publication:* Current Medical Research & Opinion 2015 08; 31(8): 1573-1582. e-pub ahead of print 2015/06/16; doi: 10.1185/03007995.2015.1062358.  
*Authors:* Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ.

**Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.**

*Publication:* J Comp Eff Res 2015 08; 4(4): 315-326. e-pub ahead of print 2015/08/15; doi: 10.2217/ce.15.25.  
*Authors:* Hao Y, Lin PL, Xie J, Li N, Koo V, Ohashi E, Wu EQ, Rogerio J.

**Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.**

*Publication:* Cancer Med 2015 08; 4(8): 1205-1213. doi: 10.1002/cam4.475.  
*Authors:* Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Abhyankar S, Reyes C, Guerin A, Yim YM.

**Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy.**

*Publication:* Current Medical Research & Opinion 2015 08; 31(8): 1587-1597. doi: 10.1185/03007995.2015.1057115.  
*Authors:* Guerin A, Sasane M, Wakelee H, Zhang J, Culver K, Dea K, Nitulescu R, Galebach P, Macalalad AR.

**ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.**

*Publication:* Cancer Epidemiol 2015 06; 39(3): 307-312. doi: 10.1016/j.canep.2015.04.005.  
*Authors:* Guerin A, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Culver K, Wu EQ, Wakelee H.

**Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.**

*Publication:* Curr Med Res Opin 2015 06; 31(6): 1095-1103. e-pub ahead of print 2015/05/15; doi: 10.1185/03007995.2015.1021906.  
*Authors:* Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ, Yardley DA.

**Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer.**

*Publication:* Am Health Drug Benefits 2015 06; 8(4): 185-195.  
*Authors:* Ellis LA, Lafeuille MH, Gozalo L, Pilon D, Lefebvre P, McKenzie S.

**Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.**

*Publication:* Current Medical Research & Opinion 2015 05; 31(7): 1377-1389. doi: 10.1185/03007995.2015.1048208.  
*Authors:* Bonthapally V, Yang H, Ayyagari R, Tan RD, Cai S, Wu E, Gautam A, Chi A, Huebner D.

**Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.**

*Publication:* Current Medical Research & Opinion 2015 05; 31(5): 993-1001. doi: 10.1185/03007995.2015.1030378.  
*Authors:* Bonthapally V, Wu E, Macalalad A, Yang H, Shonukan O, Liu Y, Chi A, Huebner D.

**Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.**

*Publication:* Int J Breast Cancer 2015 05; 2015: 240750. doi: 10.1155/2015/240750.  
*Authors:* Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ.

**Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.**

*Publication:* J Med Econ 2015 04; 18(4): 312-322. doi: 10.3111/13696998.2014.1003644.

*Authors:* Guerin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, Wu EQ.

**Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States.**

*Publication:* Expert Opin Pharmacother 2015 04; 16(6): 805-819. doi: 10.1517/14656566.2015.1020298.

*Authors:* Wong MK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Wang X, Liu Z, Culver K, Scott JA, George DJ, Vogelzang NJ.

**The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.**

*Publication:* Current Medical Research & Opinion 2015 03; 31(3): 537-545. doi: 10.1185/03007995.2015.1008131.

*Authors:* Macalalad AR, McAuliffe M, Yang H, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V.

**Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA.**

*Publication:* Drugs Context 2015 03; 4. doi: 10.7573/dic.212274.

*Authors:* Girvan AC, Carter GC, Li L, Kaltenboeck A, Ivanova J, Koh M, Stevens J, Hayes-Larson E, Lahn MM.

**A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments.**

*Publication:* BMC Cancer 2015 03; 15(175): 175. e-pub ahead of print 2015/04/18; doi: 10.1186/s12885-015-1182-4.

*Authors:* Wagner MJ, Amodu LI, Duh MS, Korves C, Solleza F, Manson SC, Diaz J, Neary MP, Demetri GD.

**The epidemiology of herpes zoster and its complications in Medicare cancer patients.**

*Publication:* BMC Infect Dis 2015 02; 15: 106. doi: 10.1186/s12879-015-0810-6.

*Authors:* Yenikomshian MA, Guignard AP, Haguinet F, LaCasce AS, Skarin AT, Trahey A, Karner P, Duh MS.

**Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).**

*Publication:* Current Medical Research & Opinion 2015 02; 31(02): 263-273. doi: 10.1185/03007995.2014.980885.

*Authors:* Macalalad AR, Hao Y, Lin PL, Signorovitch JE, Wu EQ, Ohashi E, Zhou Z, Kelley C.

**Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies.**

*Publication:* PLoS One 2014 12; 9(12): e114264. doi: 10.1371/journal.pone.0114264.

*Authors:* Heng DY, Signorovitch J, Swallow E, Li N, Zhong Y, Qin P, Zhuo DY, Wang X, Park J, Stergiopoulos S, Kollmannsberger C.

**Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.**

*Publication:* Lung Cancer 2014 12; 86(3): 350-357. doi: 10.1016/j.lungcan.2014.09.017.

*Authors:* Langer C, Ravelo A, Hazard SJ, Guerin A, Ionescu-Iltu R, Latremouille-Viau D, Wu EQ, Ramalingam S.

**Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.**

*Publication:* J Med Econ 2014 12; 17(12): 837-845. doi: 10.3111/13696998.2014.959589.

*Authors:* Campone M, Yang H, Faust E, Kageleiry A, Signorovitch JE, Zhang J, Gao H.

**Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population.**

*Publication:* Melanoma Res 2014 12; 24(6): 602-610. doi: 10.1097/CMR.0000000000000097.

*Authors:* Vekeman F, Cloutier M, Yermakov S, Amonkar MM, Arondekar B, Duh MS.

**The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy.**

*Publication:* J Med Econ 2014 12: 1-8. doi: 10.3111/13696998.2014.991787.

*Authors:* Guerin A, Sasane M, Gauthier G, Keir CH, Zhdavana M, Wu EQ.

**Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.**

*Publication:* Cancer Med 2014 12; 3(6): 1517-1526. doi: 10.1002/cam4.302.

*Authors:* Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P, McDermott R, Wagstaff J, Donnellan P, McCaffrey J, Vekeman F, Neary MP, Diaz J, Mehmud F, Duh MS.

**Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients—a chart extract-based approach.**

*Publication:* J Gastrointest Cancer 2014 12; 45(4): 431-440. doi: 10.1007/s12029-014-9600-4.

*Authors:* Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

**Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States.**

*Publication:* Current Medical Research & Opinion 2014 11; 30(11): 2343-2353. doi: 10.1185/03007995.2014.949645.

*Authors:* Signorovitch JE, Vogelzang NJ, Pal SK, Lin PL, George DJ, Wong MK, Liu Z, Wang X, Culver K, Scott JA, Jonasch E.

**Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.**

*Publication:* Current Medical Research & Opinion 2014 11; 30(11): 2317-2328. doi: 10.1185/03007995.2014.944973.

*Authors:* Guerin A, Chen L, Ionescu-Iltu R, Marynchenko M, Nitulescu R, Hiscock R, Keir C, Wu EQ.

**One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison.**

*Publication:* Current Medical Research & Opinion 2014 11: 1-8. doi: 10.1185/03007995.2014.977992.

*Authors:* Signorovitch JE, Betts KA, Reichmann WM, Thomason D, Galebach P, Wu EQ, Chen L, DeAngelo DJ.

**Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.**

*Publication:* Clin Lymphoma Myeloma Leuk 2014 10; 14(5): 380-388. doi: 10.1016/j.clml.2014.03.005.

*Authors:* Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL.

**Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.**

*Publication:* Current Medical Research & Opinion 2014 10; 30(10): 2041-2050. doi: 10.1185/03007995.2014.938730.

*Authors:* Jonasch E, Signorovitch JE, Lin PL, Liu Z, Culver K, Pal SK, Scott JA, Vogelzang NJ.

**Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.**

*Publication:* Oncologist 2014 09; 19(9): 930-936. doi: 10.1634/theoncologist.2014-0120.

*Authors:* Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH.

**Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.**

*Publication:* Oncologist 2014 09; 19(9): 901-908. doi: 10.1634/theoncologist.2014-0059.

*Authors:* Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Latremouille Viau D, Wu EQ, Lalla D.



**Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.**

*Publication:* Current Medical Research & Opinion 2014 08; 30(8): 1537-1545. doi: 10.1185/03007995.2014.908829.

*Authors:* Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J.

**Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.**

*Publication:* Current Medical Research & Opinion 2014 07; 30(7): 1345-1352. doi: 10.1185/03007995.2014.904281.

*Authors:* Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL.

**Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation.**

*Publication:* Aliment Pharmacol Ther 2014 07; 40(1): 83-92. doi: 10.1111/apt.12789.

*Authors:* Guerin A, Mody R, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ.

**Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis.**

*Publication:* Clin Lymphoma Myeloma Leuk 2014 06; 14(3): 245-251. doi: 10.1016/j.clml.2013.12.002.

*Authors:* DeAngelo DJ, Chen L, Guerin A, Styles A, Giguere-Duval P, Wu EQ.

**Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer.**

*Publication:* J Manag Care Spec Pharm 2014 05; 20(5): 477-484. doi: 10.18553/jmcp.2014.20.5.477.

*Authors:* Lafeuille MH, Grittner AM, Lefebvre P, Ellis L, McKenzie RS, Slaton T, Kozma C.

**Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis.**

*Publication:* Springerplus 2014 05; 3: 236. doi: 10.1186/2193-1801-3-236.

*Authors:* Guerin A, Lalla D, Gauthier G, Styles A, Wu EQ, Masaquel A, Brammer MG.

**Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.**

*Publication:* Current Medical Research & Opinion 2014 04; 30(4): 537-545. doi: 10.1185/03007995.2013.871243.

*Authors:* Wong MK, Yang H, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi CZ, George DJ.

**Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.**

*Publication:* Cancer Treat Rev 2014 03; 40(2): 285-292. doi: 10.1016/j.ctrv.2013.09.004.

*Authors:* Signorovitch J, Ayyagari R, Reichmann WM, Wu EQ, Chen L.

**Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia.**

*Publication:* J Med Econ 2014 02; 17(2): 89-98. doi: 10.3111/13696998.2013.862251.

*Authors:* Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL.

**Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population.**

*Publication:* Sarcoma 2013 12; 2013: 947413. doi: 10.1155/2013/947413.

*Authors:* Duh MS, Hackshaw MD, Ivanova JI, Kruse G, Miller LA, Lefebvre P, Karner P, Wong B.

**Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison.**

*Publication:* Exp Hematol Oncol 2013 12; 2(1): 32. doi: 10.1186/2162-3619-2-32.

*Authors:* Signorovitch J, Swallow E, Kantor E, Wang X, Klimovsky J, Haas T, Devine B, Metrakos P.

**Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.**

*Publication:* J Med Econ 2013 11; 16(2): 278-288. doi: 10.3111/13696998.2012.749788.

*Authors:* Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M.

**Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors.**

*Publication:* J Med Econ 2013 11; 16(2): 221-230. doi: 10.3111/13696998.2012.749789.

*Authors:* Ray S, Bonthapally V, Holen KD, Gauthier G, Wu EQ, Cloutier M, Guerin A.

**Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.**

*Publication:* Current Medical Research & Opinion 2013 09; 29(9): 1075-1082. doi: 10.1185/03007995.2013.812034.

*Authors:* Goldberg SL, Chen L, Guerin A, Macalalad AR, Liu N, Kaminsky M, Ericson SG, Wu EQ.

**Study of imatinib treatment patterns and outcomes among US veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia.**

*Publication:* J Oncol Pract 2013 09; 9(5): e212-219. doi: 10.1200/JOP.2012.000822.

*Authors:* Vander Velde N, Chen L, Guo A, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang H, Shi L.

**Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.**

*Publication:* Cancer 2013 08; 119(16): 2990-2998. e-pub ahead of print 2013/05/31; doi: 10.1002/cncr.28102.

*Authors:* Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW.

**Evaluating the utility of existing patient-reported outcome scales in novel patient populations with pancreatic cancer, lung cancer, and myeloproliferative neoplasms using Medicare current beneficiary survey data.**

*Publication:* Patient 2013 07; 6(3): 189-200. doi: 10.1007/s40271-013-0018-z.

*Authors:* Ivanova JI, Mytelka DS, Duh MS, Birnbaum HG, Cummings AK, San Roman AM, Price GL, Swindle RW.

**Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases.**

*Publication:* Am Health Drug Benefits 2013 07; 6(6): 307-316.

*Authors:* Lafeuille MH, Gravel J, Grittner A, Lefebvre P, Ellis L, McKenzie RS.

**Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.**

*Publication:* Current Medical Research & Opinion 2013 06; 29(6): 623-631. doi: 10.1185/03007995.2013.789012.

*Authors:* Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Ionescu-Iltu R, Wu EQ.

**Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach.**

*Publication:* J Gastrointest Cancer 2013 06; 44(2): 190-198. doi: 10.1007/s12029-012-9467-1.

*Authors:* Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

**The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.**

*Publication:* J Med Econ 2013 06; 16(1): 125-133. doi: 10.3111/13696998.2012.693896.

*Authors:* Guerin A, Wu EQ, Bollu VK, Williams D, Guo A, de Leon DP, Quintas-Cardama A.

**The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.**

*Publication:* Oncologist 2013 01; 18(1): 27-36. doi: 10.1634/theoncologist.2011-0380.

*Authors:* Garrison LP, Jr., Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, van de Velde H, Corzo D, Duh MS.

**Chemotherapy Treatment Patterns in Elderly Patients Initially Diagnosed with Advanced Ovarian Cancer.**

*Publication:* Clinical Ovarian and Other Gynecologic Cancer 2012 12; 5(2): 67-77. e61.

*Authors:* Johnson SJ, Sorg RA, Borker RD, Duh MS.

**Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.**

*Publication:* Urol Oncol 2012 11; 30(6): 848-855. doi: 10.1016/j.urolonc.2010.07.009.

*Authors:* Choueiri TK, McDermott D, Sheng Duh M, Sarda SP, Neary MP, Oh WK.

**Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis.**

*Publication:* Current Medical Research & Opinion 2012 11; 28(11): 1831-1839. doi: 10.1185/03007995.2012.741577.

*Authors:* Chen L, Guerin A, Xie J, Wu EQ, Yu AP, Ericson SG, Jabbour E.

**Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.**

*Publication:* Clin Breast Cancer 2012 08; 12(4): 247-258. doi: 10.1016/j.clbc.2012.04.001.

*Authors:* Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

**Beyond the Abstract - Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.**

*Publication:* UroToday.com 2012 07.

*Authors:* Xie J.

**The economic burden of metastatic breast cancer: a U.S. managed care perspective.**

*Publication:* Breast Cancer Res Treat 2012 07; 134(2): 815-822. doi: 10.1007/s10549-012-2097-2.

*Authors:* Montero AJ, Eapen S, Gorin B, Adler P.

**A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.**

*Publication:* Current Medical Research & Opinion 2012 07; 28(7): 1155-1162. doi: 10.1185/03007995.2012.705264.

*Authors:* Guerin A, Chen L, Wu EQ, Ponce de Leon D, Griffin JD.

**Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia.**

*Publication:* Leuk Lymphoma 2012 06; 53(6): 1146-1154. doi: 10.3109/10428194.2011.643405.

*Authors:* Lafeuille MH, Vekeman F, Wang ST, Kerrigan M, Menditto L, Duh MS.

**Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.**

*Publication:* Medical Oncology 2012 06; 29(2): 786-794. doi: 10.1007/s12032-011-9922-z.

*Authors:* Feinberg BA, Jolly P, Wang ST, Fortner B, Scott J, Gilmore J, Neary MP, Duh MS.

**Bioevaluation study of 32P-CP-PLLA particle brachytherapy in a rabbit VX2 lung tumor model.**

*Publication:* Appl Radiat Isot 2012 04; 70(4): 583-588. doi: 10.1016/j.apradiso.2011.12.047.

*Authors:* Xu Y, Yang M, Pan D, Wang L, Liu L, Huang P, Shao G.

**Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer.**

*Publication:* Chemother Res Pract 2012 04; 2012: 913848. doi: 10.1155/2012/913848.

*Authors:* Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB.

**Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients.**

*Publication:* J Med Econ 2012 04; 15(4): 786-795. doi: 10.3111/13696998.2012.682632.

*Authors:* Kim Le T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ.

**Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.**

*Publication:* Current Medical Research & Opinion 2012 02; 28(2): 213-219. doi: 10.1185/03007995.2011.649849.

*Authors:* Yood MU, Oliveria SA, Cziraky M, Hirji I, Hamdan M, Davis C.

**Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.**

*Publication:* Eur J Cancer 2012 02; 48(3): 311-323. doi: 10.1016/j.ejca.2011.05.017.

*Authors:* Cella D, Pickard AS, Duh MS, Guerin A, Mishagina N, Antras L, Neary MP, McCann L, Hodge R, Sternberg CN.

**The economics of the hematopoietic growth factors.**

*Publication:* Cancer Treat Res 2011 11; 157: 403-418. doi: 10.1007/978-1-4419-7073-2\_22.

*Authors:* Eldar-Lissai A, Lyman GH.

**Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.**

*Publication:* Urol Oncol 2011 11; 29(6): 756-763. doi: 10.1016/j.urolonc.2010.01.008.

*Authors:* Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antras L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK.

**Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.**

*Publication:* J Manag Care Pharm 2011 10; 17(8): 621-643.

*Authors:* Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.

**Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.**

*Publication:* Clin Lymphoma Myeloma Leuk 2011 08; 11(4): 326-335. doi: 10.1016/j.clml.2011.04.004.

*Authors:* Wu EQ, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje N.

**Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.**

*Publication:* J Med Econ 2011 07; 14(5): 542-552. doi: 10.3111/13696998.2011.596600.

*Authors:* Yang H, Yu AP, Wu EQ, Yim YM, Yu E.

**Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials.**

*Publication:* Current Medical Research & Opinion 2011 06; 27(6): 1263-1271. doi: 10.1185/03007995.2011.576238.

*Authors:* Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, Bollu VK, Williams D, Wei LJ, DeAngelo DJ.

**The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population.**

*Publication:* Prostate Cancer Prostatic Dis 2011 03; 14(1): 79-84. doi: 10.1038/pcan.2010.49.

*Authors:* Velde NV, Wu EQ, Guo A, Lu M, Yu AP, Sharma H, Liu J, Fan CP, Shi L.

**Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.**

*Publication:* BMC Cancer 2011 03; 11: 105. doi: 10.1186/1471-2407-11-105.

*Authors:* Porta C, Paglino C, Imarisio I, Canipari C, Chen K, Neary M, Duh MS.

**Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.**

*Publication:* Current Medical Research & Opinion 2010 12; 26(12): 2861-2869. doi: 10.1185/03007995.2010.533648.

*Authors:* Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD.

**Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.**

*Publication:* Oncologist 2010 10; 15(10): 1073-1082. doi: 10.1634/theoncologist.2009-0331.

*Authors:* Holloway RW, Grendys EC, Lefebvre P, Vekeman F, McMeekin S.

**Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.**

*Publication:* BJU Int 2010 05; 105(9): 1247-1254. doi: 10.1111/j.1464-410X.2009.08972.x.

*Authors:* Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy AG, Antras L, Jayawant SS, Chen K, Wang ST, Luka A, Neary MP, McDermott D, Oh WK.

**Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.**

*Publication:* Current Medical Research & Opinion 2010 01; 26(1): 61-69. doi: 10.1185/03007990903396469.

*Authors:* Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J.

**Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.**

*Publication:* J Cancer Res Ther 2010 01; 6(1): 31-35. doi: 10.4103/0973-1482.63570.

*Authors:* Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS.

**Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.**

*Publication:* Cancer 2009 10; 115(20): 4839-4848. doi: 10.1002/cncr.24535.

*Authors:* Heaney ML, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Duh MS.

**Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.**

*Publication:* Current Medical Research & Opinion 2009 08; 25(8): 2081-2090. doi: 10.1185/03007990903084800.

*Authors:* Duh MS, Dial E, Choueiri TK, Fournier AA, Antras L, Rodermund D, Neary MP, Oh WK.

**Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.**

*Publication:* Support Care Cancer 2009 06; 17(6): 719-725. doi: 10.1007/s00520-008-0553-7.

*Authors:* Diel IJ, Weide R, Koppler H, Antras L, Smith M, Green J, Wintfeld N, Neary M, Duh MS.

**Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.**

*Publication:* Transfusion 2009 05; 49(5): 895-902. doi: 10.1111/j.1537-2995.2008.02072.x.

*Authors:* Vekeman F, Bookhart BK, White J, McKenzie RS, Duh MS, Piech CT, Lefebvre P.

**Drug utilization and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.**

*Publication:* J Med Econ 2009 03; 12(1): 1-8. doi: 10.3111/13696990802648167.

*Authors:* Vekeman F, McKenzie RS, Bookhart BK, Laliberte F, Duh MS, Tak Piech C, Lefebvre P.

**An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.**

*Publication:* Cancer 2009 02; 115(4): 706-715. doi: 10.1002/cncr.24090.

*Authors:* Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V.

**Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.**

*Publication:* Current Medical Research & Opinion 2008 04; 24(4): 967-974. doi: 10.1185/030079908X280464.

*Authors:* Duh MS, Reynolds Weiner J, Lefebvre P, Neary M, Skarin AT.

**Psychometric validation of the Patient Symptom Assessment in Lung Cancer instrument for small cell lung cancer.**

*Publication:* Current Medical Research & Opinion 2007 11; 23(11): 2741-2752. doi: 10.1185/030079907X233331.

*Authors:* Chen L, Antras L, Duh MS, Levy N, Neary M, O'Brien ME, von Pawel J.

**Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.**

*Publication:* Am J Health Syst Pharm 2007 09; 64(18): 1943-1949. doi: 10.2146/ajhp060585.

*Authors:* Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS.

**Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients.**

*Publication:* Value Health 2007 09; 10(5): 408-414. doi: 10.1111/j.1524-4733.2007.00195.x.

*Authors:* Wu EQ, Mulani P, Farrell MH, Sleep D.

**The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.**

*Publication:* Cancer 2007 03; 109(6): 1090-1096. doi: 10.1002/cncr.22504.

*Authors:* Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antras L, Smith M, Neary MP, Duh MS.

**Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of four observational studies.**

*Publication:* Clin Ther 2006 10; 28(10): 1701-1708. doi: 10.1016/j.clinthera.2006.10.009.

*Authors:* Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS.

**Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application.**

*Publication:* J Oncol Pharm Pract 2006 09; 12(3): 165-178. doi: 10.1191/1078155206069925.

*Authors:* Cremieux P, Vekeman F, Lefebvre P.

**Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations.**

*Publication:* Current Medical Research & Opinion 2006 09; 22(9): 1623-1631. doi: 10.1185/030079906X120968.

*Authors:* Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS.

**Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.**

*Publication:* Clin Breast Cancer 2006 06; 7(2): 127-132. doi: 10.3816/CBC.2006.n.021.

*Authors:* Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynchenko M, Boyce SP, Mallett D, Perez EA.

**Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors.**

*Publication:* Dig Dis Sci 2006 05; 51(5): 877-884. doi: 10.1007/s10620-006-9345-4.

*Authors:* Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH.

**Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy.**

*Publication:* J Support Oncol 2006 05; 4(5): 243-250.

*Authors:* Chu E, Einhorn LH, Lefebvre P.

**Assessing the risk of clinical fracture in men with non-metastatic prostate cancer receiving gonadotropin-releasing hormone agonist therapy.**

*Publication:* J of Urology 2006 01; 175(1): 136-139.

*Authors:* Smith M, Boyce S, Moyneur E, Duh MS, Raut M, Brandman J.

**Dose-conversion ratio for epoetin alfa and darbepoetin alfa in chemotherapy patients with anemia and cancer.**

*Publication:* P AND T 2006 31(10): 594.

*Authors:* Gosselin A, McKenzie R, Lefebvre P, Mody S, Piech C, Duh M.

**Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.**

*Publication:* J Natl Compr Canc Netw 2005 11; 3(6): 807-816.

*Authors:* Campos SM, Duh MS, Lefebvre P, Rosberg J.

**The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.**

*Publication:* Current Medical Research & Opinion 2005 10; 21(10): 1677-1682. doi: 10.1185/030079905X65501.

*Authors:* Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.

**Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia.**

*Publication:* Current Medical Research & Opinion 2005 10; 21(10): 1527-1533. doi: 10.1185/030079905X65394.

*Authors:* Reed SD, Radeva JI, Daniel DB, Fastenau JM, Williams D, Schulman KA.

**Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia.**

*Publication:* Expert Rev Pharmacoecon Outcomes Res 2005 08; 5(4): 383-394. doi: 10.1586/14737167.5.4.383.

*Authors:* Duh MS, L Mark T.

**Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve.**

*Publication:* Oncologist 2005 06; 10(6): 438-448. doi: 10.1634/theoncologist.10-6-438.

*Authors:* Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ.

**Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.**

*Publication:* Womens Health Issues 2005 05; 15(3): 97-108. doi: 10.1016/j.whi.2004.11.006.

*Authors:* Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D.

**Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia : a meta-analysis.**

*Publication:* Clin Drug Investig 2005 25(1): 33-48.

*Authors:* Rosberg JH, Ben-Hamadi R, Cremieux PY, Fastenau JM, Piech CT.

**Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia.**

*Publication:* J Manag Care Pharm 2004 11; 10(6): 531-537.

*Authors:* Cremieux PY, Fastenau JM, Kosicki G, Piech CT, Fendrick AM.

**Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.**

*Publication:* Cancer 2002 08; 95(4): 888-895. doi: 10.1002/cncr.10763.

*Authors:* Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA.

**Anemia-related costs for cancer patients.**

*Publication:* Journal of Managed Care Medicine 2002 6(1): 20-28.

*Authors:* Barnett A, Cremieux P, Fendrick A, George M, Slavin M.

**Cost Effectiveness of rHuEPO in Oncology.**

*Publication:* Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology: Scientific and Clinical Aspects of Anemia in Cancer 2002.

*Authors:* Cremieux P, Dial E, Gustafson M, Saraokhan B, Slavin M.

**The costs of cancer: cancer-related conditions can add dramatically to overall costs of care.**

*Publication:* Journal of Managed Care Medicine 2002 6(1): 12-19.

*Authors:* Cremieux P, Slavin M, Fendrick A, Hiriak T, Kosicki G.

**The costs of cancer to a major employer in the United States: a case-control analysis.**

*Publication:* Am J Manag Care 2000 11; 6(11): 1243-1251.

*Authors:* Barnett A, Birnbaum H, Cremieux PY, Fendrick AM, Slavin M.

**Cost of outpatient blood transfusion in cancer patients.**

*Publication:* Journal of Clinical Oncology 2000 07; 18(14): 2755-2761.

*Authors:* Cremieux PY, Barrett B, Anderson K, Slavin MB.

**Costs Associated with Anemia and Cancer.**

*Publication:* ONE: Oncology Economics 2000 1(11): 1-7.

*Authors:* Cremieux PY GM, Holland M, Slavin MB.

**Understanding the Pharmacoeconomic profile of cancer.**

*Publication:* ONE: Oncology Economics 2000 1(10): 36-39.

*Authors:* Cremieux PY BH, Greenberg PE.

**Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia.**

*Publication:* PharmacoEconomics 1999 11; 16(5 Pt 1): 459-472.

*Authors:* Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB.

## Abstracts

**Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma**

San Diego, CA December 9-12, 2023.

*Authors:* Hansen DK, Gautam S, Lafeuille M-H, Rossi C, Moore B, Tardif-Samson A, Thompson-Leduc P, Fu AZ, Cortoos A, Kaila S, Fonseca R.

**Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) With Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated With Venetoclax (VEN) vs Other Therapies: Results from the AML Real World EvidenCe (ARC) Initiative.**

San Diego, CA December 9-12, 2023.



*Authors:* Desai P, J.S. G, Zeidner JF, Abedin S, Wolach O, Vachhani P, Y. M, A. PD, Lai C, LeBlanc TW, Xavier M, Nachmias B, Chen EC, Bathini S, Bhatti I, Bui CN, Guérin A, Burne R, Ma E, Montez M, Grunspan M, Frankel N, Goldberg AD.

**Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation.**

San Diego, CA December 9-12, 2023.

*Authors:* Ghosh N, Qureshi ZP, Ding Z, Lafeuille MH, Emond B, Gogna P, Moore B, Lefebvre P, Bokun A, Mavani H, Rogers KA.

**Incremental Healthcare Resource Utilization and Costs Associated with Non-optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine kinase inhibitors (TKI) in Early Lines of Therapy in the United States (US).**

San Diego, CA December 9-12, 2023.

*Authors:* Kota V, Wei D, Yang D, Romdhani H, Latremouille-Viau D, Guerin A, Jadhav K.

**Incremental Healthcare Resource Utilization and Costs Associated with Non-optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine kinase inhibitors (TKI) in Early Lines of Therapy in the United States (US).**

San Diego, CA December 9-12, 2023.

*Authors:* Kota V, Wei D, Yang D, Romdhani H, Latremouille-Viau D, Guerin A, Jadhav K.

**Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Asciminib in US Clinical Practice.**

San Diego, CA December 9-12, 2023.

*Authors:* Atallah EL, Wei D, Latremouille-Viau D, Rossi C, Damon A, Ferreira G, Guerin A, Jadhav K.

**Treatment effectiveness with venetoclax-based therapy after Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: an international real-world study.**

San Diego, CA December 9-12, 2023.

*Authors:* Ghosh N, Lamanna N, Eyre TA, Coombs CC, Manzoor BS, Brown JR, Tuncer HH, Ujjani C, Leslie LA, Roeker LE, Davids MS, Rhodes JM, Skarbnik A, Emechebe N, Fleury I, Hill BT, Fox CP, Barr PM, Jawaid D, Sinai W, Pearson L, Lansigan F, Choi Y, Jensen CE, Schuster S, Schuh A, Kennard K, Pivneva I, Watson T, ., Guerin A, Shadman M.

**Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US).**

San Diego, CA December 9-12, 2023.

*Authors:* Kota V, Wei D, Yang D, Romdhani H, Latremouille-Viau D, Guerin A, Jadhav K.

**Real-world comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib.**

Copenhagen, Denmark 12-15 November 2023.

*Authors:* Rogers KA, Qureshi Z, Ding Z, Emond B, Gogna P, Lafeuille MH, Bokun A, Fradley M.

**Economic burden and healthcare resource utilization (HRU) associated with cystectomy (CYS) in US patients with muscle invasive bladder cancer (MIBC).**

Boston, MA October 27 - October 28, 2023.

*Authors:* Shi Q, Emond B, Morrison L, Tardif-Samson A, Pilon D, Lefebvre P, Ellis L, Ireland A.

**Impact of next-generation sequencing versus polymerase chain reaction testing on costs and clinical outcomes throughout the treatment journey of patients with metastatic non-small cell lung cancer.**

Orlando, FL October 16 - 19, 2023.

*Authors:* Bestvina CM, Waters D, Morrison L, Emond B, Lafeuille MH, Hilts A, Mujwara D, Lefebvre P, He A, Vanderpoel J.

**Real-World Economic Burden Associated With Progression from Metastatic Castration-Sensitive to Metastatic Castration-Resistant Prostate Cancer.**

Orlando, FL October 16 - 19, 2023.

*Authors:* Kaye DR, Khilfeh I, Muser E, Morrison L, Urosevic A, Kinkead F, Lefebvre P, Pilon D, George D.

**Switching from covalent BTKi to BCL2iis associated with improved clinical outcomes compared to switching to a different covalent BTKi in patients with CLL/SLL treated in the real-world setting.**

Boston, MA October 6–9, 2023.

*Authors:* Eyre TA, Coombs CC, Lamanna N, Brown J, Manzoor BS, Ghosh N, Tuncer HH, Skarbnik A, Davids M, Emechebe N, Alhasani H, Leslie LA, Roeker LE, Ujjani C, Fleury I, Eichhorst B, Hill B, Rhodes JM, Lansigan F, Barr PM, Pearson L, Fox CP, Choi Y, Jensen CE, Jawaid D, Kennard K, Pivneva I, Watson T, Guerin A, Shadman M.

**Time-to-next treatment and overall survival among White and Black patients with homologous recombination repair positive metastatic castration-resistant prostate cancer who initiated first-line therapy.**

Orlando, FL October 16 - 19, 2023.

*Authors:* Bilen MA, Li KH, Khilfeh I, Rossi C, Muser E, Morrison L, Hilts A, Diaz L, Lefebvre P, Pilon D, George DJ.

**Treatment patterns and real-world clinical outcomes of first-line anti-PD(L)1-based combination therapy among patients with non-squamous metastatic non-small cell lung cancer in Japan.**

San Diego, CA November 1-5, 2023.

*Authors:* Leal TA, Dasgupta A, Latremouille-Viau D, Rossi C, Rai P, Barlesi F, Liu SV.

**Real-World Outcomes after Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients in Europe.**

Singapore September 9-12, 2023.

*Authors:* Leal TA, Dasgupta A, Latremouille-Viau D, Yang M, Hu X, Liu S, Barlesi F.

**Racial disparities in real-world treatment patterns and outcomes among patients with CLL.**

Frankfurt, Germany June 8-11, 2023.

*Authors:* Rhodes JM, Shadman M, Lamanna N, Manzoor BS, C.C. C, Ghosh N, Tuncer HH, Emechebe N, Brown JR, Alhasani H, Leslie LA, Roeker LE, Ujjani C, Eichhorst B, Fleury I, Skarbnik A, Hill BT, Lansigan F, Barr PM, Davids MS, Fox CP, Choi Y, Jensen CE, Schuh A, Kennard K, Jawaid D, Pivneva I, Watson T, Eyre TA.

**Real-world treatment and outcomes of patients with chronic lymphocytic leukemia (CLL) receiving first-line (1L) therapy in the novel agent era: An international study.**

Frankfurt, Germany June 8-11, 2023.

*Authors:* Lansigan F, Eyre TA, Ghosh N, Manzoor BS, Coombs CC, Lamanna N, Tuncer HH, Emechebe N, Brown JR, Roeker LE, Ujjani C, Alhasani H, Fleury I, Leslie LA, Skarbnik A, Rhodes JM, Hill BT, Barr PM, Davids MS, Fox CP, Choi Y, Schuh A, Kennard K, Jensen CE, Jawaid D, Sharma A, Pivneva I, Watson T, Shadman M.

**Real-world treatment and outcomes of patients with chronic lymphocytic leukemia (CLL) receiving first-line (1L) therapy in the novel agent era: an international study.**

Frankfurt, Germany June 8-11, 2023.

*Authors:* Lansigan F, Eyre TA, Ghosh N, Manzoor BS, Coombs CC, Lamanna N, Tuncer HH, Emechebe N, Brown JR, Roeker LE, Ujjani C, Alhasani H, Fleury I, Leslie LA, Skarbnik A, Rhodes JM, Hill BT, Barr PM, Davids MS, Fox CP, Choi Y, Schuh A, Kennard K, Jensen CE, Jawaid D, Sharma A, Pivneva I, Watson T, Shadman M.

**Real-World Targeted Literature Review of Intolerance with Tyrosine Kinase Inhibitor Treatment for Chronic Myeloid Leukemia.**

Boston, MA May 7 - 10, 2023.

*Authors:* Jadhav K, Damon A, Yang D, Latremouille-Viau D, Yang D, Guérin A, Sadek I.

**Association of intermittent vs continuous androgen deprivation therapy with cardiovascular disease and endocrine/metabolic disorders in patients with metastatic prostate cancer.**

San Francisco, CA February 16 -18, 2023.

*Authors:* Morgans AK, Ebrahimi R, Bobbili PJ, Nwokeji E, Gandhi R, Desai R, Horvath K, Ryan M, Hanson S, Duh MS, Preston MA.

**Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-sensitive prostate cancer.**

San Francisco, CA February 16-18, 2023.

*Authors:* DerSarkissian M, Gupta D, Ivanova J, Niyazov A, Zanardo E, Guo T, Wang J, Duh MS, Freedland SJ.

**Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study.**

New Orleans, LA December 10 - 13, 2022.

*Authors:* Hultcrantz M, Kleinman D, Vij R, Escalante F, Kotowsky N, Bitetti J, Mackay C, Boytsov N, Camadoo-O'Byrne L, Germain G, Duh MS, Laliberté F, Mahendran M, Urosevic A, Lee HC.

**Comparative Effectiveness of Lenalidomide/Dexamethasone-Based Triplet Regimens for Treatment of Relapsed and/or Refractory Multiple Myeloma in Subgroups Defined By Cytogenetic Risk.**

New Orleans, LA December 10 - 13, 2022.

*Authors:* Sanchez L, Cheng M, Cherepanov D, DerSarkissian M, Stull DM, Huang F, Hiltz A, Chun J, Duh MS, Ailawadhi S.

**Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia.**

New Orleans, LA December 10 - 13, 2022.

*Authors:* Roeker LE, DerSarkissian M, Ryan KJ, Chen Y, Wahlstrom SK, Hakre S, Yu L, Guo H, Mato AR.

**Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative.**

New Orleans, LA December 10 - 13, 2022.

*Authors:* Wolach O, Garcia JS, Desai P, Vachhani P, Zeidner JF, Abedin S, Sweet K, Lai C, Moshe Y, Pollyea DA, Xavier M, Nachmias B, Zuckerman T, Lee S, Chen EC, Bathini S, Edwards W, Bui CN, Cheng W-H, Miller C, Guerin A, Maitland J, Ma E, Montez M, Grunspan M, Goldberg AD.

**Economic Burden and Treatment Patterns Among Patients with Mantle Cell Lymphoma in the US: A Retrospective Claims Analysis.**

New Orleans, LA December 10 - 13, 2022.

*Authors:* Garg M, Satija A, Song Y, Sarpong E, Meade B, Lemus-Wirtz E, Gaburo K, Signorovitch J, Raut M, Ryland KE, Chakraborty S.

**Healthcare Resource Utilization and Costs of Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated with Ibrutinib.**

New Orleans, LA December 10 -13, 2022.

*Authors:* Zanardo E, Lejeune D, De Nigris E, Sarpong E, Farooqui M, Laliberté F.

**Prevalence of Ocular Comorbidities in Elderly Patients with Multiple Myeloma in the US: An Analysis of 100% Medicare Sample Data during 2007-2020.**

New Orleans, LA December 10 - 13, 2022.

*Authors:* Ailawadhi S, Ma Q, Jalbert JJ, Zhou M, Zhou Z-Y, Downes N, Zhang A, Chi L, Hampp C, Song X, Noguera-Troise I, Weyne J, Kroog GS, Rodriguez Lorenc K.

**Real-World Treatment Patterns and Clinical Outcomes with Brentuximab Vedotin or Other Standard Therapies in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Chart Review Study in the United States.**

New Orleans, LA December 10 - 13, 2022.

*Authors:* Barta SK, Liu N, DerSarkissian M, Chang R, Ye M, Duh MS, Surinach A, Fanale MA, Yu KS.

**Real-World Treatment Patterns, Healthcare Resource Use, and Costs Among Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of US Claims Data.**

New Orleans, LA December 10 - 13, 2022.

*Authors:* Garg M, Satija A, Song Y, Sarpong E, Meade B, Lemus-Wirtz E, Gaburo K, Signorovitch J, Raut M, Ryland KE, Chakraborty S.

**Treatment Patterns of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the Era of Targeted Therapy: A Real-World United States Study.**

New Orleans, LA December 10 - 13, 2022.

*Authors:* Yang X, Zanardo E, Lejeune D, De Nigris E, Sarpong E, Farooqui M, Donzella SM, Labiberte F.

**Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis.**

New Orleans, LA December 10 - 13, 2022.

*Authors:* Nicolini FE, Huguet F, Huynh L, Xu C, Bouvier C, Yocolly A, Etienne G.

**Disease management costs for patients with intermediate-high or high-risk renal cell carcinoma (RCC) following nephrectomy.**

Vienna, Austria November 6–9, 2022.

*Authors:* Y L, Song Y, Zhang S, Bhattacharya R, Carley C, Bensimon A.

**CLL-492 Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.**

*Abstract:* 2152-2669

Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S280-S281. doi: 10.1016/S2152-2650(22)01350-7., Houston, TX Sept 28, 2022 - October 1, 2022.

*Authors:* Lu X, Emond B, Qureshi Z, He J, Qian Y, Huang Q, Lefebvre P, Lafeuille MH, Jacobs R.

**CML-475 Real-World Treatment Patterns Among Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cycling Through Multiple Tyrosine Kinase Inhibitors (TKIs) in the United States (US).**

*Abstract:* 2152-2669

Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S300-S301. doi: 10.1016/S2152-2650(22)01389-1., Houston, TX September 28 - October 1, 2022.

*Authors:* Kota V, Maegawa R, Latremouille-Viau D, Jadhav K, Rossi C, Guérin A, Lorga Ş.

**Epidemiology, treatment patterns, and healthcare resource utilization in patients with acute myeloid leukemia in China: A retrospective observational study.**

Shanghai, China September 23-25, 2022.

*Authors:* Cheng LJ, Gong B, Young C, Krishnana P, Wang Y, Wei H, Zhou C, Wei S, Li Y, Fang Q, Zhong J, Wu E, Mi Y, Wang J.

**Real-world Treatment Characteristics and Clinical Outcomes in Medicare Beneficiaries With Newly Diagnosed Multiple Myeloma (NDMM) Treated With Bortezomib in Combination With Lenalidomide and Dexamethasone (VRd).**

Houston, Texas September 28, 2022 – October 1, 2022.

*Authors:* Richter J, Latremouille-Viau D, Saunders E, Lin P, Tekle C.

**Real-World Treatment Patterns Among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cycling Through Multiple Tyrosine Kinase Inhibitors (TKIs) in the United States (US).**

*Abstract:* Client: Novartis, Houston, TX Sept 28, 2022 - October 1, 2022.

*Authors:* Kota V, Maegawa R, Latremouille-Viau D, Jadhav K, Rossi C, Guérin A, Iorga Ş.

**Real-world disease-free survival as a predictor of overall survival in resected early-stage non-small cell lung cancer.**

Vienna, Austria August 6–9, 2022.

*Authors:* West H, Hu X, Chirovsky D, Song Y, Zhang S, Gao C, Carley C, Lerner A, Signorovitch J, Samkari A.

**Transfusion Independence Among Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax-Based Combinations Vs Other Therapies: Results from the AML Real world evidenCe (ARC) Initiative.**

*Abstract:* EHA 2022, Vienna, Austria June 9 - 12, 2022.

*Authors:* Garcia JS, Wolach O, Vachhani P, Zeidner J, Bathini S, Pollyea DA, Lai C, Moshe Y, Abedin S, Zuckerman T, Xavier M, Lee S, Edwards W, Chen E, Bui CN, Cheng W, Svensson A, Guérin A, Maitland J, Ma E, Montez M, Grunspan M, Goldberg AD.

**Treatment sequences and outcomes of patients with CLL treated with targeted agents in real-world settings.**

Vienna, Austria June 9-12, 2022.

*Authors:* Mato AR, Manzoor BS, Coombs CC, Lamanna N, Tuncer HH, Brown JR, Roeker LE, Shadman M, Allan JN, Ujjani C, Eichhorst B, Leslie L, Fleury I, Alhasani H, Rhodes J, Hill BT, Barr PM, Skarbnik A, Davids MS, Bannerji R, Fuldeore M, Lansigan F, Schuh A, Pearson L, Fox CP, Pivneva I, Popadic L, Guerin A, Eyre TA.

**Variation in recurrence rate and overall survival (OS) outcomes by disease stage and incremental impact of time to recurrence on OS in localized renal cell carcinoma (RCC).**

Chicago, IL June 4–6, 2022.

*Authors:* Haas NB, Bhattacharya R, Song Y, Willemann-Rogerio J, Zhang S, Carley C, Anderson A, Signorovitch J, Sundaram M.

**Economic Impact of Trilaciclib for Chemotherapy-Induced Myelosuppression (CIM) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Economic Evaluation from the Provider and Patient-Caregiver Perspectives in the United States.**

*Abstract:* ISPOR 2022, Washington D.C. May 15-18, 2022.

*Authors:* Abraham I, Xue W, Chen X, Zhou ZY, Huang H.

**Evaluating treatment patterns and outcomes for acute myeloid leukemia in adult patients in China – Methodology considerations of RWE.**

Guangzhou, China February 21, 2022.

*Authors:* Gong B, Wei H, Song Z, Zhong J, Bi S, Yuan M, Yang R.

**Healthcare resource utilization (HRU) and costs among patients with Von Hippel-Lindau disease (VHL)-associated renal cell carcinoma (RCC): A retrospective administrative claims analysis.**

San Francisco, CA February 17–19, 2022.

*Authors:* Jonasch E, Song Y, Freimark J, Berman R, Nguyen H, Signorovitch J, Sundaram M.

**Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative.**

*Abstract:* 63rd ASH Annual Meeting and Exposition, Atlanta, GA December 11-14, 2021.

*Authors:* Garcia JS, Wolach O, Vachhani P, Zeidner J, Talati C, Pollyea DA, Lai C, Moshe Y, Abedin S, Lavie D, Zuckerman T, Xavier M, Lee S, Edwards W, Chen E, Bui CN, Svensson A, Kye S, Burne R, Maitland J, Ma E, Montez M, Grunspan M, Goldberg AD.

**A Matching-Adjusted Indirect Comparison of Isatuximab Plus Carfilzomib and Dexamethasone Versus Daratumumab Plus Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma** *Abstract:* 63rd ASH Annual Meeting, Virtual December 8-17, 2021.

*Authors:* Richter J, Lin P, Garcia-Horton V, Guyot P, Singh E, Zhou Z, Sievert M.

**Patient and physician preferences for treatment of newly diagnosed acute myeloid leukemia (AML) in patients not candidates for intensive chemotherapy.**

Atlanta, GA December 11–14, 2021.

*Authors:* Zhou M, Yang H, Song Y, Marshall DA, Griffin JD, Saini L, Shah MV.

**Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative.**

*Abstract:* 63rd ASH Annual Meeting and Exposition, Atlanta, GA December 11-14, 2021.

*Authors:* Vachhani P, Wolach O, Garcia JS, Zeidner J, Talati C, Pollyea DA, Lai C, Moshe Y, Abedin S, Lavie D, Zuckerman T, Xavier M, Lee S, Chen E, Edwards W, Bui CN, Svensson A, Kye S, Burne R, Maitland J, Ma E, Montez M, Grunspan M, Goldberg AD.

**Impact of blood transfusions on treatment attributes, quality of life, and out-of-pocket costs in newly diagnosed acute myeloid leukemia ineligible for high-intensity chemotherapy: patient and physician perspectives.**

Denver, CO October 18–21, 2021.

*Authors:* Zhou M, Yang H, Song Y, Marshall DA, Griffin JD, Saini L, Shah MV.

**1390P Evaluation of event-free survival as a trial-level surrogate for overall survival for patients with gastric and gastroesophageal junction adenocarcinoma in neoadjuvant/adjuvant settings.**

*Abstract:* ESMO Congress 2021, Virtual Sept 16-21, 2021.

*Authors:* Xie J, Valderrama A, Yin L, Zhang S, Shih C, Gu C, Bhagia P, Wainberg Z.

**First-line treatments and clinical outcomes for hormone receptor-positive, human epidermal growth factor 2-positive advanced or metastatic breast cancer: A systematic literature review.**

*Abstract:* ESMO Congress 2021, Virtual Sept. 16-21, 2021.

*Authors:* Chang R, Law E, Xie J, Cha A, Chen X, Fang H, Kurosky S.

**Matching-adjusted indirect comparison for treatment of NTRK fusion cancer with larotrectinib versus entrectinib.**

*Abstract:* ESMO Congress 2021, Virtual Sept 16-21, 2021.

*Authors:* Garcia-Foncillas J, Bokemeyer C, Italiano A, Keating K, Paracha N, Fellous M, Marian M, Fillbrunn M, Gao W, Ayyagari R, Lassen U.

**A matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone versus daratumumab plus lenalidomide and dexamethasone for relapsed multiple myeloma.**

*Abstract:* 18th International Myeloma Workshop, Vienna, Austria September 8-11, 2021.

*Authors:* Richter J, Lin P, Garcia-Horton V, Guyot P, Singh E, Zhou Z, Sievert M.

**Real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis.**

*Abstract:* ESMO Congress 2021, Virtual Sept 2021.

*Authors:* George D, Agarwal N, Ramaswamy K, Sandin R, Russell D, Hong A, Yang H, Gao W, Hagan K, Freedland S.

**Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019.**

*Abstract:* ESMO Congress 2021, Virtual Sept 16-21, 2021.

*Authors:* Freedland S, Sandin R, Tagawa S, Klaassen Z, Bitting R, Ramaswamy K, Emir B, Bland C, Hong A, Yang H, Gao W, Song W, George D.

**Clinical pathways implementation in a community-based oncology practice: Real-world outcomes in patients with non-small cell lung cancer segmented by disease stage at diagnosis.**

*Abstract:* 2021 ASCO Annual Meeting, Virtual June 4-8, 2021.

*Authors:* Dickson NR, Beauchamp K, Perry TS, Roush A, Goldschmidt D, Edwards ML, Blakely LJ.

**Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).**

*Abstract:* 2021 ASCO Annual Meeting, Virtual June 4 - 8, 2021.

*Authors:* Schuster SJ, Zhang J, Yang H, Agarwal A, Tang W, Martinez-Prieto M, Bollu V, Ma Q, Kuzan D, Maziarz RT, Kersten MJ.

**Estimating costs of adverse events (AEs) and healthcare resource use (HRU) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) receiving tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel): A summary of real-world evidence.**

*Abstract:* 2021 ASCO Annual Meeting, Virtual June 4 - June 8, 2021.

*Authors:* Yang H, Qi CZ, Dalal A, Bollu V, Zhang J, Zhang S, Lim S.

**Real-world utilization of advanced therapies and racial disparity among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis.**

*Abstract:* 2021 ASCO Annual Meeting, Virtual June 4 - June 8, 2021.

*Authors:* Freedland SJ, Agarwal N, Ramaswamy K, Sandin R, Russell D, Hong A, Yang H, Gao W, Hagan K, George DJ.

**Treatment Patterns among Patients with Advanced/Recurrent Endometrial Cancer in the United States.**

*Abstract:* 2021 ASCO Annual Meeting, Virtual June 4-8, 2021.

*Authors:* Maiese EM, Émond B, Liu J, Lafeuille MH, Lefebvre P, Ghelerter I, Wu C, Hurteau J, Thaker PH.

**Cost of Chronic Myeloid Leukemia Care Among Patients in Advanced Phases or on Later Lines of Therapy in Chronic Phase in the United States from a Commercial and Medicare Perspective.**

*Abstract:* 2021 ISPOR Annual Meeting, Virtual May 17-20, 2021.

*Authors:* Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P.

**Effect of Earlier Use of Ibrutinib on Healthcare Resource Utilization (HRU) and Costs Among Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) in the United States.**

*Abstract:* Virtual IPSOR 2021, Virtual May 17-20, 2021.

*Authors:* Challagulla S, Lee P, Gafis N, Manceur AM, Fakhri I, Emond B, Iyengar R.

**Healthcare Resource Utilization Associated with Disease Recurrence Among Surgically-Treated Patients with Triple-Negative Breast Cancer.**

*Abstract:* Virtual ISPOR 2021, Virtual May 17-20, 2021.

*Authors:* Sieluk J, Haiderali A, Huang M, Hirsh.

**Productivity Costs Associated with Disease Recurrence Among Surgically-Treated Patients with Triple-Negative Breast Cancer.**

*Abstract:* Virtual ISPOR 2021, Virtual May 17-20, 2021.

*Authors:* Sieluk J, Haiderali A, Huang M, Hirshfield K, Signorovitch J, Song Y, Freimark J, Wang T.

**Real World Treatment Patterns of Patients with Ovarian Cancer: Analysis of Targeted Therapies in the French National Claims Data.**

Virtual May 17-20, 2021.

*Authors:* Wu E, Ben-Hamadi R, Jenkins M, Duberga J, Lopez J, Viola M, J. Z.

**Real-World Healthcare Costs in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States.**

*Abstract:* Virtual IPSOR 2021, Virtual May 17-20, 2021.

*Authors:* Laliberté F, Raut M, Germain G, Desai KD, Nahar A, Yang X, MacKnight SD, Duh MS.

**Treatment-Related Costs of Pharmacologic Regimens for Patients with Relapsed or Refractory Diffuse Large-Cell Lymphoma (R/R DLBCL) Who Have Received Two or More Prior Lines of Therapies.**

*Abstract:* Virtual ISPOR 2021, Virtual May 17-20, 2021.

*Authors:* Liao L, C. Y, Yang X, Chen L, Xie J.

**Adverse event costs of darolutamide vs apalutamide and enzalutamide in non-metastatic castration-resistant prostate cancer (nmCRPC).**

*Abstract:* Virtual AMCP 2021, Virtual April 12-16, 2021.

*Authors:* Jiang S, Garcia-Horton V, Terasawa E, Ayyagari R, Lott J, Waldeck R, Shore N.

**The Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) in the United States: A Cost of Care and Budget Impact Model of Venetoclax plus Obinutuzumab Sequences for CLL Patients.**

*Abstract:* AMCP 2021, Virtual April 12-16, 2021.

*Authors:* Davids MS, Manzoor BS, Hazra NC, Ravelo A, Fang H, Zhou Z, Sail K, Shapouri S, Shadman M.

**Healthcare resource utilization and costs among patients with EGFR mutated metastatic NSCLC who have discontinued EGFR-TKI and platinum-based chemotherapy regimens.**

*Abstract:* AMCP 2021 Virtual, Virtual April 13-16, 2021.

*Authors:* Marrett E, Kwong WJ, Xie J, Manceur A, Sendhil S, Wu E, Ionescu-Iltu R.

**Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy: A SEER-Medicare Analysis.**

*Abstract:* 2021 AMCP Annual Meeting, Virtual April 13-14, 2021.

*Authors:* Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P.

**Treatment Patterns Among Patients with EGFR-Mutated Metastatic NSCLC Who Have Discontinued EGFR TKI and Platinum-based Chemotherapy Regimens.**

*Abstract:* NCCN 2021 Virtual Annual Conference, Virtual March 18-20, 2021.

*Authors:* Marrett E, Kwong WJ, Xie J, Manceur A, Sendhil S, Wu E, Ionescu-Iltu R.

**Patient and physician perspectives on treatment attributes and the humanistic and economic burden of blood transfusions in patients with acute myeloid leukemia (AML) previously treated with hematopoietic stem cell transplantation (HSCT).**

Denver, CO October 18–21, 2021.

*Authors:* Zhou M, Yang H, Song Y, Marshall DA, Griffin JD, Saini L, Shah MV.

**Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations vs Other Therapies: Results from the AML Real world evidence (ARC) Initiative.**

*Abstract:* American Society of Hematology annual meeting (ASH) 2020, Virtual December 5th-7th, 2020.

*Authors:* Pollyea DA, Stahl M, Talati C, Asghari H, Lai C, Abedin S, Zeidner J, Muluneh B, Xavier M, Edwards W, Wolach O, Moshe Y, Lavie D, Zuckerman T, Choi M, Bui CN, Svensson A, Kye S, Burne R, Guérin A, Ma E, Montez M, Goldberg AD.

**Comparison of healthcare resource utilization and costs in women with HR+/HER2- metastatic breast cancer treated with ribociclib vs palbociclib or abemaciclib.**

*Abstract:* San Antonio Breast Cancer Symposium (SABCS) 2020, Virtual December 8th-12th, 2020.

*Authors:* Burne R, Balu S, Guerin A, Bungay R, Paul ML, Sin R.

**Cost per Outcome Analysis of Nivolumab Versus Dabrafenib+Trametinib As Adjuvant Therapy for Patients with STAGE Iiib/C BRAF Mutant Cutaneous Melanoma in Spain.**

*Abstract:* Virtual ISPOR Europe, Dec 2020.



*Authors:* Polanco Sánchez C, Moshyk A, Amadi A, Poretta T, Galan J, Vembusubramanian M, Betts KA, Du EX.

**Discontinuation of Tyrosine Kinase Inhibitor (TKI) Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in US Clinical Practice Following Updates to NCCN CML Practice Guidelines.**

*Abstract:* Proceedings of the Society of Hematologic Oncology Annual Meeting.

*Authors:* Ehab Atallah IS, Rodrigo Maegawa, Xiting Cao, Dominick Latremouille-Viau, Irina Pivneva, Carmine Rossi, Annie Guerin, Vamsi Kota, .

**Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) and Budget Impact Analysis of Venetoclax Plus Obinutuzumab Sequences for CLL Patients Not Eligible for Full Dose Fludarabine in France.**

*Abstract:* 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, Virtual Dec 5-8, 2020.

*Authors:* Fang H, Ravonimbola H, Hazra NC, Zhou Z, Manzoor BS, Levy V, Ysebaert L, Kabore N, Sail K.

**Effectiveness of second-line (2L) tyrosine kinase inhibitor (TKI) therapy after resistance or intolerance to a prior TKI in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.**

*Abstract:* 62nd American Society of Hematology (ASH) Annual Meeting, Virtual December 5-8, 2020.

*Authors:* Mukherjee S, Cao X, Sadek I, Maegawa R, Latremouille-Viau D, Pivneva I, Guerin A, Smith BD.

**Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy.**

*Abstract:* 62nd Annual (2020) ASH Annual Meeting, Virtual December 5, 2020.

*Authors:* Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Patwardhan P.

**A Study to Assess the Impact of Incorporating the Probability of Being in Response Function into an Economic Model for Nivolumab in Advanced Renal-Cell Carcinoma.**

*Abstract:* Virtual ISPOR Europe, Dec 2020.

*Authors:* Zhou J, Li J, Chai X, Wang Y, Ejzykowicz F, Malcolm B, Kurt M, May J, Borrill J.

**Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE).**

*Abstract:* American Society of Hematology (ASH) Annual Meeting and Exposition, Virtual December 2-11, 2020.

*Authors:* Zheng D, Sail K, Roeker LE, Manzoor BS, Tuncer HH, Allan JN, Ujjani CS, Barr PM, Brown JR, Eyre TA, Skarbnik A, Bannerji R, Eichhorst B, Brander DM, Sharmokh S, Jiang DD, Pena G, Kamalakar R, Emechebe N, Pivneva I, Burne R, Guerin A, Davids MS, Mato A.

**Early real-world experience on characteristics and treatment patterns among patients with metastatic HR+/HER2- breast cancer treated with ribociclib.**

*Abstract:* AMCP 2020, Virtual October 19-23, 2020.

*Authors:* Burne R, Balu S, Guerin A, Liang Y, Schloessmann R, Bungay R, Paul ML.

**Adherence to adjuvant therapy in patients (pts) with resected melanoma.**

*Abstract:* 7th Annual Meeting of the Society for Investigative Dermatology (SID) Annual Meeting, Scottsdale, AZ May 13-16, 2020.

*Authors:* Beisel C, Poretta T, Burke M, Sipsma H, Fuqua E, Stwalley B, Yang M.

**Discontinuation of Tyrosine Kinase Inhibitor (TKI) Therapy in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in US Clinical Practice After Guideline Updates.**

*Abstract:* 2020 ASCO Virtual Meeting, Virtual May 29-31, 2020.

*Authors:* Atallah EL, Sadek I, Maegawa R, Cao X, Latremouille-Viau D, Pivneva I, Rossi C, Guérin A, Kota V.

**Disease burden associated with progression in patients with high-grade non-muscle invasive bladder cancer receiving bladder preserving therapies after adequate BCG induction: A SEER-Medicare database study.**

*Abstract:* International Society of Pharmacoeconomics and Outcome Research 24th Annual Conference, Orlando, FL May 16-20, 2020.

*Authors:* Yang M, Georgieva M, Bocharova I, Vembusubramanian M, Qian K, Guo A, Kamat A.

**Estimation of health state utilities in FLT3-mutated relapsed/refractory acute myeloid leukemia.**

*Authors:* Cella D, Qi CZ, Yang H, Garnham A, Shah MV.

**Oncology sequence models in health technology assessment-A literature review.**

*Authors:* Xue W, Huang M, Ramsey SD, Gu C, Xie J, Wu E, Pellissier J, Briggs A.

**Real-world healthcare resource utilization and total cost of care among US Medicare patients with chronic lymphocytic leukemia receiving first-line ibrutinib vs chemoimmunotherapy.**

*Authors:* Huang Q, Emond B, Lafeuille MH, Gupta D, Lefebvre P, Sundaram M, Mato A.

**Treatment patterns and survival among patients with BCG unresponsive high-grade non-muscle invasive bladder cancer: An assessment of the SEER-Medicare data.**

*Abstract:* International Society of Pharmacoeconomics and Outcome Research 24th Annual Conference, Orlando, FL May 16-20, 2020.

*Authors:* Yang M, Georgieva M, Bocharova I, Qian K, Guo A, Kamat A.

**Early real-world experience on characteristics and treatment patterns among patients with metastatic HR+/HER2- breast cancer treated with ribociclib.**

*Abstract:* AMCP 2020, Houston, TX April 21-24, 2020.

*Authors:* Guerin A, Burne R, Liang Y, Schloessmann R, Bungay R.

**Healthcare costs in women with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors.**

*Authors:* Burne R, Balu S, Guerin A, Liang Y, Schloessmann R, Bungay R, Paul ML.

**Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study.**

*Abstract:* American Society of Hematology (ASH) Annual Meeting and Exposition, Orlando, FL, USA December 7-10, 2019.

*Authors:* Shadman M, Sail K, Manzoor BS, Yazdy MS, Hill BT, Tuncer HH, Allan JN, Ujjani CS, Emechebe N, Kamalakar R, Sharmokh S, Jiang DD, Pena G, Marshall T, Nielsen J, Barr PM, Brown JR, Schuh A, Eyre TA, Lamanna N, Wierda WG, Skarbnik A, Roeker LE, Bannerji R, Pauff JM, Schuster SJ, Follows GA, Cheson BD, Eichhorst BF, Brander DM, Pivneva I, Guerin A, Mato AR.

**Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies.**

*Abstract:* American Society of Hematology (ASH) Annual Meeting and Exposition, Orlando, FL, USA December 7-10, 2019.

*Authors:* Mato AR, Sail K, Yazdy MS, Hill BT, Shadman M, Manzoor BS, Tuncer HH, Allan JN, Ujjani CS, Sharmokh S, Jiang DD, Pena G, Marshall T, Nielsen J, Barr, PM, Brown, JR, Schuh, A, Eyre, TA, Wierda, WG, Skarbnik, A, Roeker, LE, Bannerji, R, Pauff, JM, Schuster, SJ, Follows, GA, Cheson, BD, Eichhorst, BF, Brander, DM, Pivneva, I, Lamanna, N. .

**Tyrosine-Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted After Guideline Updates.**

*Abstract:* 2019 ASH Annual Meeting, Orlando, FL December 7-10, 2019.

*Authors:* Atallah EL, Sadek I, Cao X, Latremouille-Viau D, Pivneva I, Rossi C, Guérin A, Kota V.

**Comparison of adverse event costs of nivolumab+ipilimumab versus sunitinib for previously untreated intermediate-/poor-risk advanced renal cell carcinoma in Portugal.**

*Authors:* Alves D, Polanco Sánchez C, Gooden KM, May J, Malcolm B, Du EX, Yin L, Betts KA.

**Comparison of adverse event costs of nivolumab+ipilimumab versus sunitinib for previously untreated intermediate-/poor-risk advanced renal cell carcinoma in Spain.**

*Authors:* Polanco Sánchez C, Gooden KM, May J, Malcolm B, Du EX, Yin L, Betts K.

**Economic burden of relapse after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML): a retrospective claims-based analysis.**

*Authors:* Griffin J, Shah MV, Song Y, Yang H, Tang W.

**Estimation of the healthcare resource utilization (HCRU) costs in patients with relapsed or refractory diffuse large b-cell lymphoma receiving tisagenlecleucel: a micro-costing study in the UK and France.**

*Authors:* Yang H, Ma Q, Chai X, Zhang J, Wu EQ, Jousseume E, Kuzan D, Hao Y, Duteil E, Jewitt K.

**Grade 3/4 adverse event (AE) costs of nivolumab versus dabrafenib + trametinib as adjuvant treatment in patients with stage III BRAF-mutated cutaneous melanoma in Portugal.**

*Authors:* Alves D, Amadi A, Moshyk A, Betts K, Du EX.

**The humanistic burden of multiple myeloma in newly diagnosed patient: a systematic literature review.**

*Authors:* Cizova D, Panjabi S, Abbas Z, Buchanan J, Rose D, Wilke T.

**Quantifying the relative clinical value of nivolumab plus ipilimumab vs. sunitinib in first-line advanced or metastatic renal cell carcinoma with the number needed to treat and number needed to harm in Spain and Portugal.**

*Authors:* Polanco Sánchez C, Alves D, Gooden KM, May J, Malcolm B, Du EX, Betts KA.

**A systematic literature review of the economic burden of newly diagnosed multiple myeloma.**

*Authors:* Cizova D, Panjabi S, Rose D, Abbas Z, Buchanan J, Wilke T.

**Grade 3/4 adverse event (AE) costs of nivolumab versus dabrafenib + trametinib as adjuvant treatment in patients with stage III BRAF-mutated cutaneous melanoma.**

*Abstract:* 15th International Congress of the Society for Melanoma Research, SMR 2018, Manchester, England Oct 24-27, 2018.

*Authors:* Freeman M, Jiang S, Betts KA, Du EX, Rao S, Shoushtari A.

**Real-world patient characteristics and outcomes of resected stage III melanoma patients in argentina and brazil**

*Abstract:* ISPOR Latin America Bogotá, Colombia September 12-14, 2019.

*Authors:* Villarroel R, Chacon M, Cuadros M, Maestre K, Amaral S, Burne R, R. I-I, Guerin A, Munhoz R.

**Consensus CRS and neurotoxicity regrading of " Juliet": Phase II prospective study of tisagenlecleucel therapy in patients with relapsed/refractory large B cell lymphoma.**

*Abstract:* 45th Annual Meeting of the European Society for Blood and Marrow Transplantation, Frankfurt, Germany March 24-27, 2019.

*Authors:* Maziarz R, Locke F, Ericson S, Rusch E, Romanov V, Signorovitch J, Maloney D, Schuster S.

**Factors Impacting Treatment Selection in Treatment-Naïve Patients with CLL: A Multicenter Study.**

Madrid, Spain November 7-9, 2019.

*Authors:* Rhodes J, Sail K, Yazdy M, Hill B, Shadman M, Tuncer H, Winter A, Kennard K, Allan J, Ujjani C, Brander D, Cho S, Sharmokh S, Jiang D, Nabhan C, Barr P, Brown J, Fox C, Schuh A, Mato A.

**Clinical events associated with cumulative corticosteroid use in patients with castration-resistant prostate cancer: An administrative claims analysis.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2019, Chicago, IL May 31 - Jun 4, 2019.

*Authors:* Lowentritt BH, Penson DF, Wilson SC, Song Y, Yang H, Ramaswamy K, Schultz NM.

**Clinical Heterogeneity among First-Line Sunitinib Patients with Metastatic Renal Cell Carcinoma (mRCC) Categorized as Intermediate Risk (IR) Group According to the International mRCC Database Consortium (IMDC) Risk Model.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Huynh L, Wells JC, Graham J, Steinharter J, McGregor B, Donskov F, Bjarnason GA, Vaishampayan U, Hansen A, Iafolla M, Zanotti G, Chang R, Cheng WY, Duh MS, Heng DYC.

**Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and lanreotide for the treatment of neuroendocrine tumors (NET).**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2019, Chicago, IL May 31 - Jun 4, 2019.

*Authors:* Huynh L, Cai B, Sharperson C, Lejeune D, Duh MS, Kim MK.

**Economic Burden Associated with Severe Adverse Events in Patients with Metastatic Non-Small Cell Lung Cancer Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Lejeune D, Pavilack M, Dersarkissian M, Fernandes A, Duh MS, Subramanian J.

**Economic burden of select adverse events (AEs) in patients (Pts) with advanced urothelial cancer (aUC) treated with first-line (1L) systemic therapy.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2019, Chicago, IL May 31 - Jun 4, 2019.

*Authors:* Grivas P, Laliberte F, Doleh Y, O'Connor C, Duh MS, Shenolikar R.

**Evaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant therapy.**

*Abstract:* ESMO Breast Cancer 2019, Berlin, Germany May 2-5, 2019.

*Authors:* Huang M, Qi CZ, Ramsey S, Briggs A, Zhao J, Haiderali A, Karantza V, Xie J, Gu C, Fasching PA.

**Matching-Adjusted Indirect Comparison of Efficacy and Safety of Acalabrutinib Versus Ibrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Telford C, Kabadi S, Abhyankar S, Song J, Signorovitch J, Zhao J, Yao Z.

**Real-World Adherence, Costs, and Treatment Dosage of Patients with Neuroendocrine Tumors (Net) Treated with Octreotide or Lanreotide.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Huynh L, Cai B, Lejeune D, Bhak R, Cheng M, Lax A, Duh MS, Kim M.

**Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2019, Chicago, IL May 31 - Jun 4, 2019.

*Authors:* Savard MF, Wells JC, Graham J, Steinharter JA, McGregor BA, Donskov F, Bjarnason GA, Vaishampayan UN, Hansen AR, Iafolla MAJ, Zanotti G, Huynh L, Duh MS, Heng DYC.

**Real-world clinical outcomes of pazopanib immediately following immunotherapy discontinuation for the treatment of advanced renal cell carcinoma.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2019, Chicago, IL May 31 - Jun 4, 2019.

*Authors:* Cao X, Tang D, Ratto BE, Poole A, Ravichandran S, Jin L, Gao W, Swallow E, Vogelzang NJ.

**Real-World Demographics and Clinical Characteristics of Patients Diagnosed with Primary Mediastinal B-Cell Lymphoma (PMBCL).**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Laliberte F, Yang X, Germain G, Raut M, Duh MS, Sen S, Lejeune D, Yee C, Desai K, Armand P.

**Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) in patients with metastatic colorectal cancer (mCRC): A single institution retrospective study.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2019, Chicago, IL May 31 - Jun 4, 2019.

*Authors:* Patel AK, Ng K, Duh MS, Barghout VE, Huynh L, Yenikomshian MA, Sharperson C, Brais LK, Fuchs CS.

**Us Care Pathways: Continued Focus on Oncology and Outstanding Challenges.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Chawla A, Westrich K, Dai A, Mantels S, Dubois RW.

**Patients' preferences for treatment attributes associated with ribociclib and abemaciclib in women with advanced or metastatic breast cancer (mBC): a discrete choice experiment.**

*Abstract:* AMCP's 31st Annual Meeting, San Diego, CA Mar 25-28, 2019.

*Authors:* Dalal AA, Gauthier G, Caria N, Gauthier-Loiselle M, Shohoudi A, Guerin A.

**Real-World Treatment Patterns and Clinical Outcomes in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations.**

*Abstract:* National Comprehensive Cancer Network Conference, Mar, 2019.

*Authors:* DerSarkissian M, Li S, Galaznik A, Bhak R, Bocharova I, Kulalert T, Lin HM, Huang H, Duh MS.

**Treatment duration and response among pre/perimenopausal women with HR+HER2- metastatic breast cancer: a chart review study in the US.**

*Abstract:* Miami Breast Cancer Conference 36th Annual Meeting, Miami, FL Mar 7-10 2019.

*Authors:* Dalal A, Goldschmidt D, Romdhani H, Guerin A, Costa O, O'Shaughnessy J.

**Consensus grading of cytokine release syndrome (CRS) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with tisagenlecleucel on the juliet study.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Schuster SJ, Maziarz RT, Ericson SG, Rusch ES, Signorovitch J, Romanov VV, Locke FL, Maloney DG.

**Cost-effectiveness analysis of lenalidomide for maintenance therapy after autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) patients: A united states payer perspective.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Zhou ZY, Parikh K, Chai X, Rokito A, Udeze C, Xie J, Agarwal A.

**Front-line ibrutinib treatment is associated with longer time to next treatment, net total cost reduction, and lower healthcare resource utilization compared to chemoimmunotherapy in patients with chronic lymphocytic leukemia.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Wang S, Emond B, Romdhani H, Lefebvre P, Sundaram M, Mato AR.

**Grading of neurotoxicity in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving tisagenlecleucel treatment in the juliet study.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Maziarz RT, Schuster SJ, Romanov VV, Rusch ES, Signorovitch J, Ericson SG, Maloney DG, Locke FL.

**Healthcare costs in patients with cancer increase with increasing risk of venous thromboembolism.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Streiff MB, McCrae KR, Kuderer NM, Milentijevic D, Germain G, Laliberte F, Le N, Lefebvre P, Lyman GH, Khorana AA.

**Healthcare resource utilization in adult patients with b-cell precursor acute lymphoblastic leukemia in first hematologic complete remission with and without minimal residual disease.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Rose D, Shah S, Despiegel N, Tibrewala S, Chawla A, Cong Z.

**The rate of venous thromboembolism in cancer patients varies by khorana risk category.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Khorana AA, Kuderer NM, McCrae KR, Milentijevic D, Germain G, Laliberte F, Le N, Lefebvre P, Lyman GH, Streiff MB.

**Treatment patterns and sequences among pre-menopausal women with HR+/HER2-metastatic breast cancer: A chart review study.**

*Abstract:* San Antonio Breast Cancer Symposium Annual Meeting, San Antonio, TX Dec 4-8, 2018.

*Authors:* Dalal AA, Goldschmidt D, Romdhani H, Kelkar S, Guerin A, Wang H, Caria N, Sawhney A, O'Shaughnessy J.

**Cost-Effectiveness of Tisagenlecleucel for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma : A Canadian Societal Perspective.**

*Abstract:* ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Yang H, Qi C, Zhang J, El Ouagari K.

**Cost-Effectiveness of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Canadian Societal Perspective.**

*Abstract:* ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Yang H, Zhang J, Hampe M.

**First-line nivolumab plus ipilimumab is associated with lower costs per responder versus sunitinib among patients with advanced renal cell carcinoma.**

*Abstract:* 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC, Washington, D.C. Nov 7-11, 2018.

*Authors:* Choueiri T, Betts K, Yang S, Du E, Rao S, George S.

**Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.**

*Abstract:* ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Chowdhury S, Oudard S, Hadaschik BA, Uemura H, Joniau S, Pilon D, Ladouceur M, Behl A, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J.

**A time and motion study of patients treated with Pembrolizumab and Nivolumab in Australia.**

*Abstract:* Society for Melanoma Research 2017 Congress. Australia, Brisbane, Australia October 18-21, 2017.

*Authors:* Pivneva I, Kothari S, Van Koeverden P, Pellissier J, Stone S, Herawati L, Guerin A.

**Symptoms Following Discontinuation of Tyrosine Kinase Inhibitor (TKI) Therapy After Achieving an Adequate Response in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).**

*Abstract:* 6th Annual Meeting of the Society of Hematologic Oncology (SOHO 2018), Houston, TX Sept 12-15, 2018.

*Authors:* Ritchie E, Sadek I, Pivneva I, Guerin A, Latremouille-Viau D, Ndife B, Joseph G, Atallah E.

**Chemoradiotherapy treatment patterns and 1-year survival rate among patients with unresectable, stage III non-small cell lung cancer: Time trends from 2009 to 2014.**

*Abstract:* 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Prague, Czech Republic Aug 22-26, 2018.

*Authors:* Bobbili PJ, Ryan K, Duh MS, Fernandez A, DerSarkissian M, Dua A, Pavilack M, Gomez JE.

**Deep molecular response in chronic phase-Chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: A multi-country retrospective chart review study.**

*Abstract:* 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Prague, Czech Republic Aug 22-26, 2018.

*Authors:* Cortes J, Huynh L, Mendelson E, Brandt P, Dalal D, Der Sarkissian M, Cortina D, Narkhede S, Duh MS.

**Real-world analysis of treatment patterns and long-term effectiveness among patients with advanced neuroendocrine tumors of lung origin: A multicenter study.**

*Abstract:* 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Prague, Czech Republic Aug 22-26, 2018.

*Authors:* Huynh L, Totev T, Dasari A, Bergsland EK, Benson AB, Cai B, Shea J, Duh MS, Neary MP, Kulke MH.

**Assessing the Value of Nivolumab (NIVO) versus Placebo (PBO) and Ipilimumab (IPI) as Adjuvant Therapy for Resected Melanoma.**

*Abstract:* American Society of Clinical Oncology, Chicago, IL June 1-5, 2018.

*Authors:* Freeman M, Shoushtari A, Betts KA, Gupte-Singh K, Du EX, Ritchings C, Rao S.

**Comparison of Adverse Event Costs of Nivolumab combined with Ipilimumab versus Sunitinib for Previously Untreated Metastatic Renal Cell Carcinoma.**

*Abstract:* American Society of Clinical Oncology, Chicago, IL(abstract accepted as online presentation) June 1-5, 2018.

*Authors:* Betts KA, Yang S, Du EX, Johansen J, Rao S.

**Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2018, Chicago, IL Jun 1-5, 2018.

*Authors:* Pennell NA, Mutebi A, Zhou ZY, Ricculli ML, Tang W, Wang H, Guerin A, Arnhart T, Culver KW, Otterson GA.

**Indirect treatment comparison of blinatumomab versus inotuzumab ozogamicin for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia receiving zero or one prior salvage therapy.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2018, Chicago, IL Jun 1-5, 2018.

*Authors:* Song J, Ma Q, Gao W, Cong Z, Xie J, Zimmerman ZF, Belton L, Franklin J, Palmer S.

**Indirect treatment comparison of blinatumomab vs inotuzumab ozogamicin for treating adult patients with relapsed or refractory acute lymphoblastic leukemia receiving zero or one prior salvage therapy.**

*Abstract:* 23rd Congress of the European Hematology Association, EHA 2018, Stockholm, Sweden Jun 14-17, 2018.

*Authors:* Song J, Ma Q, Gao W, Cong Z, Xie J, Zimmerman Z, Belton L, Franklin J, Palmer S.

**Indirect treatment comparison of nivolumab versus placebo as an adjuvant therapy for resected melanoma.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2018, Chicago, IL June 1-5, 2018.

*Authors:* Shoushtari AN, Freeman ML, Betts KA, Gupte-Singh K, Du EX, Ritchings C, Rao S.

**Novel treatment (TX) use and associated outcomes among African American patients (PTS) with multiple myeloma (MM): A SEERMedicare analysis.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2018, Chicago, IL June 1-5, 2018.

*Authors:* Parikh K, Clancy Z, Zhou ZY, Tang W, Cheung C, Zhou Z, Xie J, Ailawadhi S.

**Predictors of overall survival (OS) in veterans with non-metastatic castration resistant prostate cancer (nmCRPC).**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2018, Chicago, IL June 1-5, 2018.

*Authors:* Fuld AD, Young-Xu Y, Li S, Pilon D, Bhak R, Duchesneau E, Hellstern M, Kamstra R, Behl AS, Lefebvre P, Freedland SJ.

**Real-world adherence in patients with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI) or regorafenib (REG).**

*Abstract:* American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL Jun 1-5, 2018.

*Authors:* Patel AK, Barghout V, Yenikomshian MA, Germain G, Jacques P, Laliberte F, Duh MS.

**A seer-medicare analysis of novel treatment use and associated outcomes among african american patients with multiple myeloma.**

*Abstract:* 23rd Congress of the European Hematology Association, EHA 2018, Stockholm, Sweden June 14-17, 2018.

*Authors:* Ailawadhi S, Clancy Z, Zhou ZY, Tang W, Cheung C, Zhou Z, Xie J, Parikh K.

**Symptoms following TKI therapy discontinuation after achieving an adequate response in patients with chronic myeloid leukemia in chronic phase (CML-CP).**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2018, Chicago, IL June 1-5, 2018.

*Authors:* Ritchie EK, Sadek I, Pivneva I, Guerin A, Latremouille-Viau D, Ndife B, Joseph GJ, Atallah EL.

**Adherence to national comprehensive cancer network guidelines for BRCA testing among breast cancer patients.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, May, 2018.

*Authors:* Tung NM, Bobbili PJ, Olufade TO, DerSarkissian M, Bhak R, Reiff J, Briceno JM, Yu H, Shenolikar R, Duh MS.

**Assessment of change in quality of life (QoL), carcinoid syndrome (CS) symptoms, and health care resource utilization (HRU) in CS patients treated with somatostatin analogs (SSA)-results from longitudinal patient surveys.**

*Abstract:* ISPOR 23rd Annual International Meeting

. United States, May 18-23, 2018.

*Authors:* Huynh L, Bhak R, Narkhede S, Beaumont JL, Halperin DM, Cai B, Duh MS, Neary MP, Chang R, Cella D.

**Comparison of healthcare resource utilization (HRU) and costs related to pleural effusion (PE) between patients newly diagnosed with chronic myeloid leukemia (CML) treated with dasatinib or nilotinib as first-line therapy in the United States.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Seiter K, Latremouille-Viau D, Guerin A, Ndife B, Habucky K, Joseph GJ, Pivneva I, Gagnon-Sanschagrin P, Tang DH.

**Cost-effectiveness of ceritinib in previously untreated ALK-positive non-small cell lung cancer in the United Kingdom.**

*Abstract:* 23rd Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2018. United States.

*Authors:* Xie J, Knoll S, Slowley A, Bensimon A, Vieira J, Chilcott J, Paisley S, Zhou Z.

**Patterns of treatment and recurrence in patients with non-metastatic melanoma who underwent lymph node dissection surgery.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Ndife B, Tarhini A, Ionescu-Iltu R, Manceur AM, Jacques P, Laliberte F, Duh MS, Nakasato A, Gbate SR.

**Reimbursement landscape for molecular testing in non-small cell lung cancer (NSCLC) in the United States.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Nellesen D, Patton C, Mutebi A, Culver KW.

**Surrogate Outcomes in Oncology: How can they be used to predict overall survival in clinical practice and payer decision making?**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Ayyagari R, Xie J, Wu E, Song J.



**Systematic literature review of treatments for patients with untreated advanced or metastatic non-small cell lung cancer (NSCLC).**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Song J, Huang M, Kelkar SS, Zhou Z, Zhang Y.

**Characteristics of patients diagnosed de novo with AJCC7 stage III or regionally advanced cutaneous melanoma and trends in adjuvant therapy: An analysis of the SEER cancer registry in the United States.**

*Abstract:* Annual Meeting of the American Association for Cancer Research, AACR 2018, Chicago, IL April 14-18, 2018.

*Authors:* Tarhini A, Ghate S, Nakasato A, Ionescu-Iltu R, Shi S, Ndife B, Burne R, Laliberte F, Duh MS.

**Healthcare Resource Utilization (HRU) and Cost Comparison of Infection-Related Complications During Therapy With Dasatinib or Nilotinib in Patients (pts) With Chronic Myeloid Leukemia.**

*Abstract:* AMCP's 30th Annual Meeting, Boston, MA Apr 23-26, 2018.

*Authors:* Seiter K, Latremouille-Viau D, Guerin A, Ndife B, Habucky K, Joseph G, Pivneva R, Gagnon-Sanschagrín P, Tang D.

**Healthcare Resource Utilization and Costs among Premenopausal Women with HR+/HER2- Metastatic Breast Cancer.**

*Abstract:* AMCP's 30th Annual Meeting, Boston, MA Apr 23-26, 2018.

*Authors:* Dalal A, Gagnon-Sanschagrín P, Burne R, Guerin A, Gauthier G, Small T, Niravath P.

**Incidence of AJCC7 stage III or regionally advanced cutaneous melanoma in the United States.**

*Abstract:* Annual Meeting of the American Association for Cancer Research, AACR 2018, Chicago, IL April 14-18, 2018.

*Authors:* Tarhini AM, Ghate SR, Nakasato A, Ionescu-Iltu R, Shi S, Ndife B, Burne R, Laliberte F, Duh MS.

**Patterns of BRAF testing and treatment in patients with metastatic melanoma presumed BRAF positive.**

*Abstract:* Annual Meeting of the American Association for Cancer Research Chicago, IL Apr 14-18, 2018.

*Authors:* Ghate S, Nakasato A, Ionescu-Iltu R, Shi S, Ndife B, Burne R, Laliberte F, Duh MS.

**Patterns of treatment with immune check point inhibitors and targeted therapy in patients with metastatic melanoma presumed BRAF V600 positive.**

*Abstract:* Annual Meeting of the American Association for Cancer Research, AACR 2018, Chicago, IL April 14-18, 2018.

*Authors:* Ghate S, Nakasato A, Ionescu-Iltu R, Shi S, Ndife B, Burne R, Laliberte F, Duh MS.

**Real-world comparative effectiveness of treatment sequences in metastatic non-small cell lung cancer with squamous histology.**

*Abstract:* 8th European Lung Cancer Congress, Geneva, Switzerland Apr 11-14, 2018.

*Authors:* Yang H, Levy BP, Signorovitch JE, Patterson-Lomba O, Xiang CQ, Parisi M.

**Dosing patterns and economic burden of drug wastage among postmenopausal women with HR+/HER2- metastatic breast cancer receiving palbociclib.**

*Abstract:* 14th Annual Meeting for the Hematology/Oncology Pharmacy Association, Denver, CO Mar 21-24, 2018.

*Authors:* Dalal A, Gagnon-Sanschagrín P, Burne R, Guerin A, Gauthier G, Small T.

**Hematologic, cardiac, and hepatic function monitoring among post-menopausal women with HR+/HER2- metastatic breast cancer.**

*Abstract:* 2018 National Comprehensive Cancer Network 23rd Annual Conference, Orlando, FL Mar 22-24, 2018.

*Authors:* Dalal AA, Goldschmidt D, Romdhani H, Kelkar S, Guerin A, Gauthier G, Small T, Niravath P.

**A model estimating work productivity loss due to premature death associated with hepatic veno-occlusive disease/sinusoidal obstruction syndrome among hematopoietic stem cell transplant patients in the united states.**

*Abstract:* 14th Annual Meeting for the Hematology/Oncology Pharmacy Association, Denver, CO Mar 21-24, 2018.  
*Authors:* Zhou ZY, Tang W, Villa K.

**Treatment and monitoring patterns among premenopausal women with HR+/HER2- metastatic breast cancer.**

*Abstract:* 2018 National Comprehensive Cancer Network 23rd Annual Conference, Orlando, FL Mar 22-24, 2018.  
*Authors:* Guerin A, Dalal AA, Gagnon-Sanschagrinn P, Burne R, Gauthier G, Small T, Niravath P.

**Treatment patterns among post-menopausal women with HR+/HER2- metastatic breast cancer: a chart review study.**

*Abstract:* 2018 National Comprehensive Cancer Network 23rd Annual Conference, Orlando, FL Mar 22-24, 2018.  
*Authors:* Dalal AA, Goldschmidt D, Romdhani H, Kelkar S, Guerin A, Gauthier G, Small T, Niravath P.

**Comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in metastatic pancreatic cancer: A nationwide chart review in the United States.**

*Abstract:* Gastrointestinal Cancers Symposium, San Francisco, CA Jan 18-20, 2018.  
*Authors:* Kim SS, Signorovitch J, Yang H, Patterson-Lomba O, Xiang C, Ung B, Parisi M, Marshall J.

**Comparative effectiveness of non-cisplatin (cis)-based first-line (1L) regimens in patients with metastatic urothelial carcinoma (mUC): Veterans Affairs control cohorts vs. IMvigor210.**

*Abstract:* Genitourinary Cancers Symposium, San Francisco, CA Jan 18-20, 2018.  
*Authors:* Vander Velde NS, Guerin A, Ionescu-Iltu R, Shi S, Wu E, Lin SW, Hsu LI, Saum KU, Ducla SD, Wang J, Li S, Derleth CL, Liu S, Shi L, Leppert J.

**Comparison of enzalutamide and bicalutamide in patients with non-metastatic castration-resistant prostate cancer: Number needed to treat to achieve one additional patient free of clinical progression events.**

*Abstract:* Genitourinary Cancers Symposium, San Francisco, CA Jan 18-20, 2018.  
*Authors:* Karsh LI, Penson DF, Concepcion R, Flanders S, Brown BA, Yang H, Ramaswamy K, Schultz NM.

**Comparison of the real-world adherence and compliance patterns with trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).**

*Abstract:* Gastrointestinal Cancers Symposium, San Francisco, CA Jan 18-20, 2018.  
*Authors:* Patel AK, Duh MS, Barghout V, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS.

**Health care resource utilization and costs in metastatic castration-resistant prostate cancer patients treated with enzalutamide or abiraterone acetate.**

*Abstract:* Genitourinary Cancers Symposium, San Francisco, CA Jan 18-20, 2018.  
*Authors:* Kassabian V, Flanders S, Wilson S, Brown BA, Song Y, Yang H, Lechpammer S, Schultz NM.

**Improvement of carcinoid syndrome (CS) symptoms and quality of life (QoL) in CS patients treated with somatostatin analogs (SSAs): Results from longitudinal patient surveys.**

*Abstract:* Gastrointestinal Cancers Symposium, San Francisco, CA Jan 18-20, 2018.  
*Authors:* Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak R, Narkhede S, Duh MS, Neary M, Cella D.

**Real-world analysis of treatment patterns and persistence of octreotide LAR and other agents in patients with advanced gastrointestinal neuroendocrine tumors (GI NET): A multicenter study.**

*Abstract:* Gastrointestinal Cancers Symposium, San Francisco, CA Jan 18-20, 2018.  
*Authors:* Kulke MH, Benson AB, Huynh ADL, Cai B, Totev T, Roesner N, Duh MS, Neary M, Bergsland EK.

**Time to first-line (1L) therapy discontinuation in metastatic melanoma (MM).**

*Abstract:* ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA Jan 25-27, 2018.  
*Authors:* Luke JJ, Ghate S, Ionescu-Iltu R, Ndife B, Burne R, Laliberte F, Duh MS.

**Treatment duration and utilization patterns in metastatic castration-resistant prostate cancer patients receiving enzalutamide or abiraterone acetate.**

*Abstract:* Genitourinary Cancers Symposium, San Francisco, CA Jan 18-20, 2018.

*Authors:* Kassabian V, Flanders S, Wilson S, Brown BA, Song Y, Yang H, Lechpammer S, Schultz NM.

**Clinical benefits of achieving deep remission to second-line therapy in patients with relapse/refractory (R/R) chronic lymphocytic leukemia (CLL) - A real-world study.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* Wierda WG, Gauthier G, Meissner B, Guerin A, Samp JC.

**Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib as First-line and Second-line Therapy in the United States.**

*Abstract:* American Society of Hematology Annual Meeting, Atlanta, GA December 9-12, 2017.

*Authors:* Seiter K, Latremouille-Viau D, Guerin A, Ndife B, Habucky K, Joseph G, Pivneva R, Gagnon-Sanschagrín P, Tang D.

**Comparison of healthcare resource utilization and costs related to infections between patients newly diagnosed with chronic myeloid leukemia treated with dasatinib and nilotinib as first-line therapy in the United States.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington DC Dec 9-12, 2017.

*Authors:* Seiter K, Latremouille-Viau D, Guerin A, Ndife B, Habucky K, Joseph GJ, Pivneva I, Gagnon-Sanschagrín P, Tang DH.

**Cost offsets in the treatment journeys of patients with relapsed/refractory multiple myeloma (RRMM).**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 9-12, 2017.

*Authors:* Ailawadhi S, DerSarkissian M, Duh MS, Lafeuille MH, Posner G, Ralston S, Zagadailov E, Ba-Mancini A, Rifkin RM.

**Cost-effectiveness analysis of CTL019 for the treatment of pediatric and young adult patients with relapsed or refractory b-cell acute lymphoblastic leukemia in the united states.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington DC Dec 9-12, 2017.

*Authors:* Hao Y, Eldjerou LK, Yang H, Qi C, Globe D.

**Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in the United States.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* Stein EM, Xie J, Duchesneau E, Bhattacharyya S, Ndife B, Bonifacio G, Joseph GJ.

**Drivers of treatment patterns in patients with chronic lymphocytic leukemia (CLL) treated with B cell receptor inhibitors (BCRi) - A medical chart review study.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec. 9-12, 2017.

*Authors:* Mato AR, Samp JC, Gauthier G, Terasawa E, Brander DM.

**Managing acute myeloid leukemia in older patients: Are we making progress? an analysis of treatment patterns and healthcare resource utilization.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* Lafeuille MH, Sundaram M, Hoehn D, Emond B, Romdhani H, Lefebvre P.

**Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: A seer-medicare analysis.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington DC Dec 9-12, 2017.

*Authors:* Ailawadhi S, Parikh K, Zhou Z, Tang W, Clancy Z, Cheung C, Zhou ZY, Xie J, Abouzaid S.

**Real-world outcomes among patients who initiated pazopanib or sunitinib as first targeted therapy for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.**

*Abstract:* San Antonio Breast Cancer Symposium, San Antonio, TX Dec 6-10, 2016.

*Authors:* Li N, Du EX, Peeples M, Chu L, Xie J, Barghout V, Tang DH.

**Treatment characteristics and deep molecular response in chronic phase-chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: A multi-country retrospective chart review study.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington DC Dec 9-12, 2017.

*Authors:* Cortes JE, Huynh L, Mendelson E, Brandt P, Dalal D, Dersarkissian M, Cortina D, Narkhede S, Duh MS.

**Treatment patterns and healthcare resource utilization in patients with FLT3-mut and FLT3-wt acute myeloid leukemia: A multi-country medical chart study.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington DC Dec 9-12, 2017.

*Authors:* Griffin JD, Yang H, Song Y, Kinrich D, Bui CN.

**Treatment patterns in patients with chronic myeloid leukemia in chronic phase in US clinical practice, with a focus on tyrosine kinase inhibitor therapy discontinuation.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington DC Dec 9-12, 2017.

*Authors:* Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah E.

**Treatment patterns of hypomethylating agents in older ( $\geq 65$  Years) acute myeloid leukemia patients who did not receive intensive chemotherapy: A retrospective claims database analysis.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* Sundaram M, Lafeuille MH, Hoehn D, Emond B, Romdhani H, Lefebvre P.

**VTE recurrence and safety of anticoagulants among patients with cancer treated for venous thromboembolism.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff MB.

**Who is receiving novel therapies for relapsed/refractory follicular lymphoma? A retrospective chart review of recent real-world practice.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* Signorovitch J, Garcia-Horton V, Ricculli ML, McGuire M.

**Anticoagulant treatment patterns for cancer-associated thrombosis in a commercial insurance population.**

*Abstract:* Resuscitation Science Symposium, Anaheim, CA Nov 11-15, 2017.

*Authors:* Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff M.

**Dabrafenib and trametinib combination therapy versus docetaxel in previously treated metastatic NSCLC: An adjusted indirect comparison.**

*Abstract:* 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL Sep 14-16, 2017.

*Authors:* Sasane M, Li J, Zhang P, Zhao J, Ricculli ML, Signorovitch J.

**Healthcare resource utilization associated with venous thromboembolism in cancer patients treated with anticoagulants in a commercial insurance population.**

*Abstract:* Resuscitation Science Symposium, Anaheim, CA Nov 11-15, 2017.

*Authors:* Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff M.

**Patient preferences in advanced soft tissue sarcoma: A discrete choice experiment.**

*Abstract:* The Connective Tissue Oncology Society (CTOS) 2017 Annual Meeting, Maui, HI Nov 8–11, 2017.

*Authors:* Armstrong A, Wei W, Garcia-Horton V, Macaulay D, Schmerold L, Wu E, Shah D, Chao J.

**Assessment of the association between the burden of carcinoid syndrome symptoms and the quality of life among patients with carcinoid syndrome in the united states based on the FACT-G instrument.**

*Abstract:* 10th Annual Meeting of the North American Neuroendocrine Tumor Society, Philadelphia, PA Oct 19-21, 2017.

*Authors:* Huynh L, Totev T, Cai B, Beaumont JL, Halperin DM, Neary MP, Bhak R, Vekeman F, Duh MS, Cella D.

**Budget impact analysis of dabrafenib and trametinib combination therapy in the treatment of BRAF V600E-mutant advanced non-small cell lung cancer in the United States.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Zhou Z, Bensimon A, Cheng J, Dalal A.

**Budget impact analysis of first-line ceritinib in the treatment of ALK+ metastatic non-small cell lung cancer (NSCLC) in the United States.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Mutebi A, Zhou Z, Ricculli ML, Han S, Xie J, Dalal A, Culver K.

**Cost consequence analysis of different gene mutation testing modalities for BRAFV600E mutation in advanced non-small cell lung cancer using a decision analytic model.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Dalal A, Zhou Z, Tang W, Ricculli ML, Guerin A, Sasane M, Wu K, Culver K, Otterson G, Pennell N.

**Cost-effectiveness of ceritinib in previously untreated alk-positive non-small cell lung cancer in the united states**

*Abstract:* AMCP Nexus 2017, Dallas, TX Oct 16-19, 2017.

*Authors:* Zhou ZY, Mutebi A, Han S, Bensimon A, Ricculli ML, Xie J, Dalal AA, Culver KW.

**Costs associated with disease progression in advanced melanoma-a claims analysis using a novel staging algorithm.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Song J, Goldschmidt D, Driver M, Buchanan J, Murugappan S.

**Overall survival in patients with metastatic urothelial cancer by first-line therapy.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Vander Velde NS, Guerin A, Ionescu-Iltu R, Shi S, Wu E, Lin S, De Ducla S, Wang J, Li S, Derleth C, Leppert JT, Liu S, Shi L.

**Real world treatment patterns in metastatic and/or unresectable gastric cancer patients in Russia.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Tjulandin SA, Sholokhova E, Ivanova JI, Cheng WY, Schmerold LM, Thompson-Leduc P, Novick D.

**Systematic literature review for treatment outcomes (including immuno-oncology treatment) among patients with stage 3 unresectable non-small cell lung cancer (NSCLC).**

*Abstract:* ISPOR 20th Annual European Congress Glasgow, UK Nov 4-8, 2017.

*Authors:* Zhou Z, Song J, Ouwens MJ, Huhn M, Jiang H, Zhang Y, Dalevi D.

**Economic analysis of molecular mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.**

*Abstract:* 5th Annual NASP Annual Meeting and Educational Conference, Washington, DC Sept 18-20, 2017.

*Authors:* Dalal A, Dea K, Guerin A, Culver K.

**What are the treatment patterns and overall survival (OS) in patients with metastatic triple-negative breast cancer (mTNBC) in US clinical practice?**

*Abstract:* ESMO 2017 Congress, Madrid, Spain Sept 8-12, 2017.

*Authors:* Bajaj P, Latremouille-Viau D, Guerin A, Reyes C, Kurian A, Stein A, Cortazar P.

**Overall Survival In Patients with Glioblastoma Before and After Bevacizumab Approval.**

*Abstract:* 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management Montreal, QC, Canada Aug 26-30, 2017.

*Authors:* Johnson DR, Omuro AM, Ravelo A, Sommer N, Geuerin A, Ionescu-Ittu R, Shi S, Uhm JH.

**Severe Adverse Events Impact Overall Survival and Costs In Elderly Patients with Advanced NSCLC On Second-Line Therapy.**

*Abstract:* 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Montreal, QC, Canada Aug 26-30, 2017.

*Authors:* Borghaei H, YimYM, Guerin A, Gandhi M, Pivneva I, S S, Ionescu-Ittu R.

**Association between Duration of Somatostatin Analogs (SSAs) Use and Quality of Life in Patients with Carcinoid Syndrome in the United States Based on the FACT-G Instrument.**

*Abstract:* ASCO 2017, Chicago, IL June 2-6, 2017.

*Authors:* Halperin DM, Huynh L, Beaumont J, Cai B, Totev t, Bhak R, Duh MS, Vekeman F, Neary M, Cella D.

**Burden of illness in patients with acute myeloid leukemia aged 65 years ineligible for intensive chemotherapy.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Lafeuille MH, Sundaram M, Lefebvre P, Emond B, Romdhani H, Senbetta M.

**Comparative efficacy with endocrine-based combination versus monotherapy among postmenopausal women with HR+/ HER2- metastatic breast cancer: A network metaanalysis.**

*Abstract:* ASCO Annual Meeting, Chicago, IL June 2-6, 2017.

*Authors:* Tang D, Ayyagari R, Patterson-Lomba O, Zhou Z, Xie J, Niravath PA.

**Comprehensive genomic profiling (CGP) versus conventional molecular diagnostic testing of patients with advanced non-small cell lung cancer (NSCLC): Overall survival (OS) and cost in a U.S. Health plan population.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 2-6, 2017.

*Authors:* Signorovitch J, Zhou Z, Ryan J, Chawla A.

**Cost burden of first-line antineoplastic treatment failure in patients with chronic lymphocytic leukemia.**

*Abstract:* ASCO Annual Meeting, Chicago, IL June 2-6, 2017.

*Authors:* Senbetta M, Lafeuille MH, Lefebvre P, Romdhani H, Emond B, Wang S.

**Estimated cost of anticancer therapy directed by comprehensive genomic pro ling (CGP) in a single-center study.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 2-6, 2017.

*Authors:* Signorovitch J, Janku F, Wheler JJ, Miller VA, Ryan J, Zhou Z, Chawla A.

**Healthcare cost of Medicare patients with previously treated chronic lymphocytic leukemia.**

*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain June 22-25, 2017.

*Authors:* Reyes C, Gauthier G, Schmerold L, Guerin A.

**Impact of FDA approval of lenalidomide maintenance therapy in the firstline treatment of multiple myeloma after autologous stem cell transplant on total healthcare costs.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 2-6, 2017.

*Authors:* Xie J, Parikh K, Chen C, Yang C, Farrukh A, Cockrum P, Agarwal AB, Abouzaid S.

**Impact of U.S. FDA approval of lenalidomide maintenance therapy in the first-line treatment of multiple myeloma after autologous hematopoietic stem cell transplant on total healthcare costs.**

*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain June 22-25, 2017.

*Authors:* Parikh K, Xie J, Chen C, Yang C, Farrukh A, Cockrum P, Agarwal AB, Abouzaid S.

**Multi-country retrospective chart audit study to examine deep molecular response (MR4.5) associated with second-line tyrosine kinase inhibitors in chronic phase - Chronic myelogenous leukemia (CML-CP).**

*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain June 22-25, 2017.

*Authors:* Cortes J, Huynh L, Brandt P, DerSarkissian M, Zaccardelli G, Dalal D, Hussein J, Duh MS.

**Predictors of clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or placebo: An exploratory posthoc analysis of COU-AA-302 trial data.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 2-6, 2017.

*Authors:* Pilon D, Behl AS, Kamstra R, Xiao Y, Lafeuille MH, Lefebvre P, Freedland SJ.

**Progression-free survival and overall survival in patients with chronic lymphocytic leukemia - Clinical benefits of achieving a deep response to first-line therapy.**

*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain June 22-25, 2017.

*Authors:* Samp J, Guerin A, Foster R, Meissner B, Rokito A, Enschede SH, Gauthier G.

**Prostate-specific antigen (PSA) trajectories correlate with overall survival (OS) in men treated with abiraterone acetate plus prednisone (AA+P) or placebo plus prednisone: A post-hoc analysis of COU-AA-301 trial data  
Dominic Pilon.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 2-6, 2017.

*Authors:* Behl AS, Kamstra R, Xiao Y, Lafeuille MH, Lefebvre P, Freedland SJ.

**Realworld adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).**

*Abstract:* ASCO Annual Meeting, Chicago, IL June 2-6, 2017.

*Authors:* Patel AK, Duh MS, Barghout VE, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS.

**Reduced healthcare resource utilization in patients with chronic lymphocytic leukemia achieving complete remission to first-line therapy.**

*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain June 22-25, 2017.

*Authors:* Heitner Enschede S, Samp J, Guerin A, Foster R, Meissner B, Rokito A, Gauthier G.

**Relative progression-free survival over time of novel triplet regimens for the treatment of relapsed/refractory multiple myeloma.**

*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain June 22-25, 2017.

*Authors:* Betts K, Chen C, Zichlin M, Brun A, Signorovitch J, Makenbaeva D.

**Tyrosine kinase inhibitor (TKI) therapy discontinuation in patients with CML in chronic phase: A US clinical practice perspective.**

*Abstract:* ASCO Annual Meeting, Chicago, IL June 2-6, 2017.

*Authors:* Ritchie EK, Wolff JE, Latremouille-Viau D, Guerin A, Pivneva I, Briggs O, Joseph GJ, Atallah EL.

**Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Stein EM, Yang M, Gao W, Galebach P, Xiang CQ, Bhattacharyya S, Bonifacio G, Joseph GJ.

**Assessment of costs associated with adverse events in patients with cancer.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Cloutier M, Yim YM, Wong W, Gauthier-Loiselle M, Gagnon-Sanschagrinn P, Kim A, Guerin A.

**Assessment of the association between the burden of carcinoid syndrome symptoms and the quality of life among patients with carcinoid syndrome in the United States based on the FACT-G instrument.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Huynh L, Totev T, Cai B, Beaumont JL, Halperin DM, Neary MP, Bhak R, Vekeman F, Duh MS, Cella D.

**Association between time to progression and subsequent survival in previously treated BRAF V600E-mutant metastatic non-small cell lung cancer.**

*Abstract:* 7th European Lung Cancer Conference, Geneva, Switzerland May 5-8, 2017.

*Authors:* Sasane M, Li J, Zhang J, Zhao J, Ricculli ML, Redhu S, Signorovitch J.

**A meta-analysis and meta-regression of the efficacy of front-line treatment combinations with ponatinib versus 1st- and 2nd-generation tyrosine kinase inhibitors for ph+ acute lymphoblastic leukemia.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Jabbour E, DerSarkissian M, Duh MS, McCormick N, Cheng WY, McGarry L, Souroutzidis A, Huang H, O'Brien S, Ravandi-Kashani F, Kantarjian HM.

**Progression-free survival with endocrine-based therapies following progression on a non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A network meta-analysis.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Niravath PA.

**Real-world outcomes among patients who initiated pazopanib or sunitinib as first targeted therapy for advanced renal cell carcinoma (ARCC): A retrospective analysis of Medicare data.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Vogelzang NJ, Ghatge SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.

**Real-world treatment patterns and costs in Medicare beneficiaries newly diagnosed with acute myeloid leukemia.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Stein EM, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagrin P, Briggs O, Bonifacio G, Joseph G.

**Real-world treatment patterns and costs in patients with newly diagnosed acute myeloid leukemia.**

*Abstract:* AMCP's 29th Annual Meeting, Denver, CO Mar 27-30, 2017.

*Authors:* Stein EM, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagrin P, Briggs O, Bonifacio G, Joseph GJ.

**Association between duration of somatostatin analogs (SSAS) use and quality of life in patients with carcinoid syndrome in the United States based on the FACT-G instrument.**

*Abstract:* 10th Annual Meeting of the North American Neuroendocrine Tumor Society, Philadelphia, PA Oct 19-21, 2017.

*Authors:* Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak R, Duh MS, Vekeman F, Neary MP, Cella D.

**Evaluation of the impact of the burden of carcinoid syndrome symptoms on quality of life among treated patients with carcinoid syndrome in the United States based on the PROMIS-29 instrument.**

*Abstract:* 10th Annual Meeting of the North American Neuroendocrine Tumor Society, Philadelphia, PA Oct 19-21, 2017.

*Authors:* Neary MP, Huynh L, Totev T, Cai B, Beaumont JL, Halperin DM, Bhak R, Duh MS, Cella D.

**Oncologist preferences in advanced soft tissue sarcoma: A discrete choice experiment.**

*Abstract:* ASCO Quality Care Symposium, Orlando, FL Mar 3-4, 2017.

*Authors:* Hess LM, Ivanova JI, Horton VG, Graham S, Liu O, Zhu Y, Lorenzo M, Nicol SJ.

**Potential drug-drug interaction events in patients treated with abiraterone acetate plus prednisone or enzalutamide.**

*Abstract:* ASCO Quality Care Symposium, Orlando, FL Mar 3-4, 2017.

*Authors:* Pilon D, Behl AS, Emond B, Xiao Y, Lefebvre P, Kane CJ.



**Real-world economic outcomes during time on treatment among patients who initiated pazopanib or sunitinib as first targeted therapy for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.**

*Abstract:* AMCP's 29th Annual Meeting, Denver, CO Mar 27-30, 2017.

*Authors:* Nicholas J. Vogelzang, Sameer R. Ghatge, Nanxin Li, Elyse Swallow, Miranda Peebles, Miriam Zichlin, Mark Meiselbach, Jose Ricardo Perez, Neeraj Agarwal.

**Real-world palbociclib dosing patterns and potential wastage associated with dose modifications among post-menopausal women with HR-positive/HER2-negative metastatic breast cancer (mBC).**

*Abstract:* ASCO Quality Care Symposium Orlando, FL Mar 3-7, 2017.

*Authors:* Li N, Du EX, Chu L, Peebles M, Xie J, Barghout VE, Tang DH.

**Real-world economic outcomes among patients (pts) who initiated sunitinib or pazopanib as first targeted therapy (TT) for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.**

*Abstract:* Genitourinary Cancers Symposium, Orlando, FL Feb 16-18, 2017.

*Authors:* Vogelzang NJ, Pal SK, Ghatge S, Li N, Swallow E, Peebles M, Zichlin M, Meiselbach M, Perez JR, Agarwal N.

**Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices.**

*Abstract:* Genitourinary Cancers Symposium, Orlando, FL Feb 16-18, 2017.

*Authors:* Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Sztatrowski TP.

**Refill gaps and dose reductions in patients treated with abiraterone acetate plus prednisone (AA+P) or enzalutamide (ENZ).**

*Abstract:* 2017 Genitourinary Cancers Symposium, Orlando, FL Feb 16-18, 2017.

*Authors:* Pilon D, Behl AS, Emond B, Xiao Y, Lefebvre P, Kane CJ.

**Treatment Disruption of First-line Endocrine and Chemotherapy among Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer (mBC).**

*Abstract:* NCCN Annual Conference General Poster Session, Orlando, FL Mar 23-24, 2017.

*Authors:* Li N, Du EX, Peebles M, Chu L, Xie J, Barghout V, Tang DH.

**Access to Biomarker Testing in Patients with Advanced Non-Small Cell Lung Cancer.**

*Abstract:* 17th World Conference on Lung Cancer, Vienna, Austria Dec 4-7, 2016.

*Authors:* Ganti AK, Hirsch F, Wynes MW, Ravelo A, Ramalingam S, Ionescu-Iltu R, Pivneva I, Borghaei H.

**Ceritinib Dosing Patterns and Outcomes of Patients with ALK+ NSCLC in a Real-World Practice in the United States.**

*Abstract:* Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL Sep 22-24, 2016.

*Authors:* Bendaly E, Dalal A, Culver K, Galebach P, Bocharova I, Foster R, Struebbe G, Guerin A.

**Cost per month of overall survival and progression-free survival: Everolimus compared with cabozantinib, nivolumab, and axitinib for metastatic renal cell carcinoma.**

*Abstract:* 15th International Kidney Cancer Symposium, Miami, FL Nov 4-5, 2016.

*Authors:* Swallow E, Ghatge S, Messali A, McDonald E, Duchesneau E, Perez JR.

**Monitoring for and Characteristics of Crizotinib Progression: A Chart Review of ALK+ Non-Small Cell Lung Cancer Patients.**

*Abstract:* 17th World Conference on Lung Cancer, Vienna, Austria Dec 4-7, 2016.

*Authors:* Bendaly E, Dalal A, Culver K, Galebach P, Bocharova I, Foster R, Struebbe G, Guerin A.

**Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: A SEER-Medicare database analysis.**

*Abstract:* 15th International Kidney Cancer Symposium, Miami, FL Dec, 2016.

*Authors:* Vogelzang N, Pal S, Ghate S, Li N, Swallow E, Peeples M, Zichlin M, Perez JR, Agarwal N.

**Severe adverse events impact overall survival (OS) and costs in elderly patients with advanced NSCLC on second-line therapy.**

*Abstract:* 17th World Conference on Lung Cancer, Vienna, Austria Dec 4-7, 2016.

*Authors:* Borghaei H, Yim YM, Guerin A, Gandhi M, Pivneva I, Shi S, Ionescu-Ittu R.

**Time on treatment of everolimus versus endocrine monotherapy or chemotherapy for early-line treatment of HR+/HER2- metastatic breast cancer: A retrospective chart review study in the US.**

*Abstract:* SABCS 2016 Annual Meeting, San Antonio, TX Dec 6-10, 2016.

*Authors:* Li N, Ohashi E, Koo V, Xie J, Hao Y, Tang DH.

**Treatment Patterns and Early Outcomes of ALK+ Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.**

*Abstract:* IASLC 17th World Conference on Lung Cancer, Vienna, Austria Dec 4-7, 2016.

*Authors:* Bendaly E, Dalal A, Culver K, Galebach P, Bocharova I, Foster R, Struebbe G, Guerin A.

**Physician preference and experience with nivolumab and cabozantinib in the treatment of advanced renal cell carcinoma (aRCC) in the United States (US): A physician survey.**

*Abstract:* 15th International Kidney Cancer Symposium, Miami, FL Nov 4-5, 2016.

*Authors:* Ghate S, Li N, Swallow E, Zichlin M, Duchesneau E, Kang B, Perez JR.

**Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.**

*Abstract:* IKCS 2016 Annual Meeting, Miami, FL Nov 4-5, 2016.

*Authors:* Nicholas J, Vogelzang, Sumanta K, Pal, Sameer Ghate, Nanxin Li, Elyse Swallow, Miranda Peeples, Miriam Zichlin, Jose Ricardo Perez, Neeraj Agarwal.

**Clinical outcomes and dosing patterns of 2nd targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU.**

*Abstract:* 41st European Society for Medical Oncology Congress, Copenhagen, Denmark Oct 7-11, 2016.

*Authors:* Heng D, Park J, Signorovitch JE, Yang H, Song J, Weiss J, Dezzani L, Powles TB.

**Impact of severe adverse events during second-line therapy on healthcare costs in patients with advanced non-small cell lung cancer (aNSCLC).**

*Abstract:* 41st European Society for Medical Oncology Congress, Copenhagen, Denmark Oct 7-11, 2016.

*Authors:* Yim YM, Gandhi M, Guerin A, Ionescu-Ittu R, Pivneva I, Shi S, Wu E.

**Economic burden of relapsed/refractory chronic lymphocytic leukemia.**

*Abstract:* 16th International Workshop on Chronic Lymphocytic Leukaemia, Sydney, Australia Sept 6-9, 2015.

*Authors:* Guerin A, Ray S, Gauthier G, Hsu LI, Zhdanava M, Heroux J, Wu E.

**Economic evaluation of octreotide LAR versus lanreotide depot in the treatment of metastatic gastrointestinal neuroendocrine tumors.**

*Abstract:* 8th Annual Meeting of the North American NeuroEndocrine Tumor Society, Jackson, WY Sept 30 - Oct 1, 2016.

*Authors:* Ayyagari R, Neary M, Li S, Zhao C, Higuchi K, Xie J, Benson AB.

**Epidemiological assessment of real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: Perspectives from an academic tertiary center and community oncology practices.**

*Abstract:* 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland Aug 25-28, 2016.

*Authors:* Huynh L, Herring M, Duh MS, Vekeman F, Tiew A, Neary MP, Bergsland E.

**Patient characteristics and Overall Survival (OS) in the post-docetaxel Metastatic Castration-Resistant Prostate Cancer (mCRPC) community setting.**

*Abstract:* 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland Aug 25-28, 2016.

*Authors:* Cheng WY, Miao R, Duh MS, Vekeman F, Sung J, Gauthier-Loiselle M, Fortier J, Dhawan R, Oh WK.

**Access to biomarker testing in patients with advanced nonsmall cell lung cancer.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Borghaei H, Hirsch FR, Wynes M, Ravelo A, Ramalingam SS, Ionescu-Ittu R, Pivneva I, Ganti AK.

**Access to specialist care and treatment in patients with advanced non-small cell lung cancer.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Ganti AK, Borghaei H, Hirsch FR, Wynes M, Ravelo A, Ionescu-Ittu R, Pivneva I, Ramalingam SS.

**Disparities in treatment patterns and outcomes between caucasian and African American patients with multiple myeloma (MM).**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Safiya Abouzaid, Kejal Parikh, Zheng-Yi Zhou, Zhou Zhou, nxi Tang, Jipan Xie, Manali I. Patel.

**Economic burden of hematologic adverse events (AEs) associated with metastatic colorectal cancer (mCRC) treatment in the United States (US).**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C.

**Efficacy of front-line treatment combinations with ponatinib versus 1st-and 2nd-generation tyrosine kinase inhibitors for Ph+ acute lymphoblastic leukemia: A meta-analysis and meta-regression.**

*Abstract:* 21st Congress of the European Hematology Association. Denmark.

*Authors:* Jabbour E, DerSarkissian M, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, Duh MS.

**Overall Survival in Patients with Glioblastoma Before and After Bevacizumab Approval.**

*Abstract:* ASCO Annual Meeting, Chicago, Illinois Jun 3-7, 2016.

*Authors:* Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Macalalad AR, Shi S, Uhm JH.

**Quality of life by smoking status in patients with metastatic or advanced NSCLC from Phase 2 clinical trial of veliparib with carboplatin and paclitaxel.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Bonnet P, Cloutier M, McKee MD, Loiselle MG, Qian J, Mu F, Qin QQ, Guerin A, Wu EQ, Giranda VL.

**Reduction in hospital visits in patients with chronic myeloid leukemia (CML) with better adherence to tyrosine kinase inhibitors (TKI) and increased molecular monitoring frequency.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ.

**Temporal trends in overall survival and disease-specific survival among patients with advanced renal cell carcinoma during the targeted therapy era: A SEER-Medicare analysis.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Vogelzang NJ, Signorovitch JE, Swallow E, Peeples M, Koo V, Perez JR, Ghatge S, Pal SK.

**Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.**

*Abstract:* International Association for the Study of Lung Cancer, Chicago, IL May 29 - Jun 2, 2015.

*Authors:* Tan DS, Araujo A, Zhang J, Signorovitch J, Zhou ZY, Cai X, Liu G.

**Economic model to examine the cost benefit associated with resolution or improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotidellar in patients with neuroendocrine tumors based on data from a retrospective chart review study at three large tertiary oncology centers in the United States.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Huynh L, Totev T, Vekeman F, Neary M, Duh MS, Kulke M, Benson A.

**Real-world analysis of medical costs and healthcare resource utilization in elderly women with HR+/HER2-metastatic breast cancer receiving everolimus-based therapy or chemotherapy.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Hao Y, Li N, Fang A, Koo V, Peeples M, Kageleiry A.

**Real-world treatment patterns of everolimus + exemestane in patients with hormone-receptor-positive, human epidermal growth factor receptor-negative advanced breast cancer by line of therapy: A global chart review.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Costanzo V, Zarba J, Michelotti A, Livi L, Villanueva C, Bordonaro R, Sherstnev V, Kowalyszyn R, Marinsek N, Zhou Z, Macalalad AR, Koo V, Trieschman E, Xie J, Signorovitch J, Petracci F, Korbenfeld E, Ratto B, Higuchi K, Saghatchian M.

**Treatment sequences, patient characteristics, and overall survival of patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Oh WK, Miao R, Duh MS, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Fortier J, Dhawan R.

**Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC.**

*Abstract:* 6th European Lung Cancer Conference, Geneva, Switzerland Apr 13-16, 2016.

*Authors:* Daniel Shao-Weng Tan, Geoffrey Liu, Dong-Wan Kim, Michael Thomas, Enriqueta Felip, James Signorovitch, Jie Zhang, Tomek Szczudlo, Alice Shaw, et al.

**Economic Benefits Associated with Resolution or Improvement of Carcinoid Syndrome Symptoms Following Treatment with Above-Standard Dose of Octreotide LAR in Patients with Neuroendocrine Tumors: Data From a Multicenter Chart Review Study.**

*Abstract:* AMCP's 28th Annual Meeting, San Francisco, CA Apr 19-22, 2016.

*Authors:* Huynh L, Totev T, Vekeman F, Neary M, Duh MS, Kulke M, Benson A.

**The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer.**

*Abstract:* 6th European Lung Cancer Conference, Geneva, Switzerland Apr 13-16, 2016.

*Authors:* Jie Zhang, Yan Song, Zheng-Yi Zhou, Chenxue Zhang, James Signorovitch.

**Number needed to treat and associated incremental costs to achieve one additional patient free of event: indirect comparison of enzalutamide and abiraterone + prednisone in chemotherapy-naïve metastatic castration-resistant prostate cancer.**

*Abstract:* AMCP's 28th Annual Meeting, San Francisco, CA Apr 19-22, 2016.

*Authors:* Bui C, Massoudi M, Balk M, Guo J, Song Y, Brown B, Barlev A, Pandya BJ, H. Y.

**Real-World Treatment Patterns and Brain Metastases Development in ALK-Positive Non-Small Cell Lung Cancer.**

*Abstract:* AMCP's 28th Annual Meeting, San Francisco, CA Apr 19-22, 2016.

*Authors:* Betts K, Song J, Guo J, Wong W, Ravelo A, M. S.

**Treatment patterns and healthcare costs in newly diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States: A retrospective claims database analysis.**

*Abstract:* AMCP's 28th Annual Meeting, San Francisco, CA Apr 19-22, 2016.

*Authors:* Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon-Sanschagrin P, Chen L.

**Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: A US claims study. .**

*Abstract:* NCCN 21st Annual Conference, Hollywood, FL Mar 31 - Apr 2, 2016.

*Authors:* Li N, Hao Y, Tang D, Koo V, Fang A, Peebles M, Kageleiry A.

**Factors and treatment patterns associated with everolimus use among post-menopausal women with HR+/HER2- metastatic breast cancer.**

*Abstract:* NCCN 21st Annual Conference, Hollywood, FL Mar 31 - Apr 2, 2016.

*Authors:* Hao Y, Tang D, Li N, Peebles M, Fang A, Kageleiry A, V K.

**Treatment patterns and key factors associated with high treatment costs among commercially insured patients with advanced basal cell carcinoma.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Migden M, Wei J, Tang W, Herrera V, Xie J, Palmer J.

**Survival and Tumor Response Outcomes in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): A Systematic Literature Review.**

*Abstract:* Multidisciplinary Head and Neck Cancer Symposium, Scottsdale, AZ Feb 18-20, 2016.

*Authors:* Signorovitch J, Li N, Zhang C, Shaw J, Dastani H, Orsini L.

**Impact of symptomatic skeletal events on healthcare resource utilization, health-related quality of life and pain among patients with castration-resistant prostate cancer and bone metastases.**

*Abstract:* Genitourinary Cancers Symposium, San Francisco, CA Jan 7-9, 2016.

*Authors:* McKay RR, Haider B, Duh MS, Valdarrama A, Nakabayashi M, Fiorillo M, Ristovska L, Wen LK, Kantoff PW.

**Outcomes of second targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU.**

*Abstract:* Genitourinary Cancers Symposium, San Francisco, CA Jan 7-9, 2016.

*Authors:* Heng DYC, Park J, Signorovitch JE, Yang H, Song J, Patel D, Lin C, Powles T.

**Assessment of Multiple Myeloma Patient Preferences on Treatment Choices: An International Discrete Choice Study.**

*Abstract:* 57th American Society of Hematology Annual Meeting and Exposition, Orlando, FL Dec 5-8, 2015.

*Authors:* Leleu X, Mateos M-V, Delforge M, Lewis P, Schindler T, Gibson CJ, Yang M, Weisel K.

**A chart review of patient characteristics, treatment patterns and response in metastatic breast cancer patients treated with ado-trastuzumab emtansine in first-line therapy and beyond.**

*Abstract:* San Antonio Breast Cancer Symposium, San Antonio, TX December 8-12, 2015.

*Authors:* Gauthier G, Guerin A, Zhdanava M, Wu E.

**Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites.**

*Abstract:* 2015 San Antonio Breast Cancer Symposium, San Antonio, TX December 8-12, 2015.

*Authors:* Xie J, Hao Y, Li N, Lin P, Ohashi E, Koo V, Wu E.

**Five-year direct cost of pediatric patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic stem cell transplantation (HSCT): An analysis from US payers' perspective.**

*Abstract:* 57th Annual Meeting of the American Society of Hematology, Orlando, FL Dec 5-8, 2016.

*Authors:* Maziarz RT, Guerin A, Gauthier G, Heroux J, Zhdanava M, Wu EQ, Thomas SK, Chen L.

**The healthcare resource utilization, costs, and predictors of progression among relapsed and refractory CLL patients.**

*Abstract:* 57th Annual Meeting of the American Society of Hematology, Orlando, FL Dec 5-8, 2015.

*Authors:* Guerin A, Ray S, Gauthier G, Hsu L.-I, Zhdanova M, Wu E.

**The impact of ponatinib versus allogeneic stem cell transplant (SCT) on outcomes in patients with chronic myeloid leukemia (CML) or philadelphia chromosome-positive acute lymphoblastic leukemia (PH+ ALL) with the T315i mutation.**

*Abstract:* 57th Annual Meeting of the American Society of Hematology, Orlando, FL Dec 3-6, 2015.

*Authors:* Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes TP, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Kageleiry A, Yang M, Huang H, McGarry LJ, Kantarjian HM, Cortes JE.

**Nilotinib vs Dasatinib as Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) based on Real-World Data.**

*Abstract:* 57th Annual Meeting of the American Society of Hematology, Orlando, FL December 5-8, 2015.

*Authors:* Li N, Yang C, Fan L, Totev T, Guerin A, Chen L.

**Real-world effectiveness of everolimus subsequent to different first targeted therapies (TTs) for the treatment of advanced renal cell carcinoma (aRCC): Synthesis of three retrospective chart reviews.**

*Abstract:* 14th International Kidney Cancer Symposium Miami, FL Nov 6-7, 2015.

*Authors:* Pal SK, Signorovitch JE, Li N, Koo V, Liu Z, Perez JR, Vogelzang NJ.

**Real-world effectiveness of Everolimus versus endocrine monotherapy or chemotherapy in HR+/HER2- metastatic breast cancer patients with liver metastasis or multiple metastatic sites.**

*Abstract:* 2015 San Antonio Breast Cancer Symposium, San Antonio, TX December 8-12, 2015.

*Authors:* Li N, Hao Y, Lin P, Koo V, Ohashi E, Wu E, Xie J.

**Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2- metastatic breast cancer: A retrospective claims study in the US.**

*Abstract:* 2015 San Antonio Breast Cancer Symposium, San Antonio, TX December 8-12, 2015.

*Authors:* Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Guerin A.

**Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients.**

*Abstract:* 57th Annual Meeting of the American Society of Hematology, Orlando, FL Dec 5-8, 2015.

*Authors:* Guerin A, Ray S, Gauthier G, Hsu Ling-I, Zhdanova M, Wu EQ.

**What are the real-world treatment patterns and medical costs in patients with metastatic breast cancer treated with ado-trastuzumab emtansine?**

*Abstract:* 2015 San Antonio Breast Cancer Symposium, San Antonio, TX December 8-12, 2015.

*Authors:* Cloutier M, Guerin A, Heroux J, Emond B, Wu E.

**Comparative efficacy of treatments for previously treated advanced or metastatic non-small cell lung cancer (NSCLC): a network meta-analysis.**

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Zhang J, Zhou Z, Cai X, J. S.

**Cost-effectiveness of ceritinib in previously treated patients with crizotinib in anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer in Canada.**

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Zhou Z, Hury M, Jhang J, Fan L, Zhang C, J. X.

**Cost-effectiveness of ceritinib in the treatment of previously treated anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer in Canada.**

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Zhou Z, Jhang J, Fan L, Zhang C, J. X.

**Overall Survival (Os) and Quality-of-Life (QoL) Outcomes in Recurrent Or Metastatic Squamous Cell Carcinoma of the Head And Neck (Scchn): A Systematic Literature Review.**

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Signorovitch J, Li N, Zhong Y, Shaw J, Dastani H, L. O.

**Overall Survival (Os), Quality of Life (QoL), and Neurocognitive Function (Nf) in Recurrent Glioblastoma Multiforme (Gbm): A Systematic Literative Review.**

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Signorovitch J, Li N, Ohashi E, Dastani H, Shaw J, L. O.

**Patient relevant outcomes in recurrent glioblastoma: a systematic literature review.**

*Abstract:* Society for Neuro-Oncology Annual Scientific Meeting and Education Day, San Antonio, TX Nov 19-22, 2015.

*Authors:* Signorovitch J, Li N, Kim S, Dastani H, Shaw J, Orsini L.

**Real-world effectiveness, dosing, and drug costs of everolimus (EVE) and axitinib (AXI) as second targeted therapies (TTs) for advanced renal cell carcinoma (aRCC) in the US: A retrospective chart review.**

*Abstract:* 14th International Kidney Cancer Symposium, Miami, FL Nov 6-7, 2015.

*Authors:* Jonasch E, Pal SK, Signorovitch JE, Li N, Liu Z, Perez JR, Vogelzang NJ.

**Economic Benefits Associated with Resolution or Improvement of Carcinoid Syndrome Symptoms Following Treatment with Above-Standard Dose of Octreotide LAR in Patients with Neuroendocrine Tumors: Assessment Based on Data from a Multicenter Retrospective Chart Review Study.**

*Abstract:* 12th Annual Meeting of the International Society of Gastrointestinal Oncology, Arlington, VA Oct 22-23, 2015.

*Authors:* Huynh L, Totev T, Vekeman F, Neary M, Duh MS, Kulke MH, Benson AB.

**Real-world treatment patterns in advanced Pancreatic neuroendocrine tumors in the era of targeted therapy: Perspectives from an academic tertiary center and community oncology practices.**

*Abstract:* 8th Annual Meeting of the North American NeuroEndocrine Tumor Society, Austin, TX Oct 14-18, 2015.

*Authors:* Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary MP, Bergsland E.

**Real-World Treatment Patterns of Everolimus for Advanced Breast Cancer: A Multicountry Chart Review Study.**

*Abstract:* AMCP Nexus 2015, Orlando, FL Oct 26-29, 2015.

*Authors:* Hamm C, Zarba J, Xie J, Higuchi K, Macalalad AR, Zhou Z, Schraa S, Signorovitch J, Marinsek N, Villanueva C, Livi L, Lerzo G, Ratto B, Vega N, Sherstnev V, Los M.

**Access to cancer directed therapies and cancer specialists in patients with metastatic lung cancer.**

*Abstract:* 16th World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.

*Authors:* A.K. Ganti, F.R. Hirsch, M. Wynes, A. Ravelo, S.S. Ramalingam, R. Ionescu-Ittu, I. Pivneva, P. Lin, H. Borghaei.

**Characteristics and treatment patterns of ALK+ NSCLC patients who receive second-generation ALK inhibitors: A chart review study.**

*Abstract:* European Cancer Congress 2015, Vienna, Austria Sept 25-29, 2015.

*Authors:* Cadranel J, Park K, Pless M, Bendaly E, Patel D, Sasane M, Swallow E, Galebach P, Stein K, Marinsek N, Zhang J.

**Diverse characteristics of ALK+ NSCLC patients in the United States.**

*Abstract:* 16th World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.

*Authors:* Bendaly E, Sasane M, Zhang J, Swallow E, Macalalad AR, Patel D, Kageleiry A, Galebach P, Kercheval J, Stein K, Guérin A.

**Is there a difference in outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) who receive chemotherapy (CT) vs androgen receptor-targeted therapy (ART) after 1st-line ART in the community setting?**

*Abstract:* European Cancer Congress, Vienna, Austria Sep 25-29, 2015.

*Authors:* Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Fortier J, Dhawan R, Hennessy D, Duh MS.

**Physician decision-making on modifying or discontinuing crizotinib in ALK+ NSCLC: A survey of U.S. physicians.**

*Abstract:* 16th World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.

*Authors:* Guérin A, Sasane M, Zhang J, Swallow E, Macalalad AR, Stein K, Kageleiry A, Galebach P, Kercheval J, Patel D, Bendaly E.

**Real-world characteristics and outcomes for ALK+ NSCLC in Korea.**

*Abstract:* 16th World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.

*Authors:* Lim SH, Yoh KA, Lee JS, Ahn M, Kim YJ, Kim SH, Zhang J, Patel D, Swallow E, Kageleiry A, Yi H, Stein K, Degun R, Park K.

**Real-world patterns of access to cancer specialist care among patients with lung cancer in the United States: A claims database analysis.**

*Abstract:* 16th World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.

*Authors:* A.K. Ganti, H. Borghaei, F.R. Hirsch, M. Wynes, A. Ravelo, R. Ionescu-Iltu, I. Pivneva, P. Lin, S. Ramalingam.

**Symptoms of bone and liver metastases in patients with ALK+ Non-Small Cell Lung Cancer (NSCLC).**

*Abstract:* 16th World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.

*Authors:* Guerin A, Sasane M, Nitulescu R, Zhang J, Culver K, Wu EQ, Macalalad A.

**Testing and treatment practice of oncologists managing ALK+ NSCLC: International physician survey across four regions.**

*Abstract:* European Cancer Congress, Vienna, Austria Sep 25-29, 2015.

*Authors:* Arrieta O, Cadranel J, Park K, Pless M, Bendaly E, Patel D, Sasane M, Nosal A, Macalalad AR, Kercheval J, Stein K, Weiss J, Zhang J.

**Time to Progression and Post-Progression Survival in ALK+ Ceritinib-Treated NSCLC.**

*Abstract:* 16th World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.

*Authors:* Geoffrey Liu, J Zhang, Zheng-Yi Zhou, Junlong Li, Xiaopeng Cai, James Signorovitch.

**Treatment patterns and best response in a contemporary cohort of patients with relapsed / refractory chronic lymphocytic leukemia with 17p deletion.**

*Abstract:* Leukemia and Lymphoma Conference, Sydney, NSW Australia Sep 6-9, 2015.

*Authors:* Lamanna N, Hurst D, Latremouille-Viau D, Ionescu-Iltu, Guerin A, Yim YM, Reyes C.

**Treatment patterns and survival among ALK+ non-small cell lung cancer (NSCLC) patients: A chart review study.**

*Abstract:* European Cancer Congress Vienna, Austria Sep 25-29, 2015.

*Authors:* Park K, Cadranel J, Arrieta O, Pless M, Bendaly E, Patel D, Sasane M, Nosal A, Guerin A, Kageleiry A, Stein K, Marinsek N, Zhang J.

**What is the current evidence for adding docetaxel or bisphosphonates to androgen deprivation therapy (ADT) in men with hormone sensitive prostate cancer? A systematic review and meta-analyses.**



*Abstract:* European Cancer Congress, Vienna, Austria Sep 25-29, 2015.

*Authors:* Vale C, Rydzewska LH, Tierney JF, Albiges L, Clarke NW, Fisher DJ, Fizazi K, James ND, Mason MD, Parmar MK, Sweeney CJ, Sydes MR, Tombal B, Burdett S.

**Median overall survival meta-analysis comparing brentuximab vedotin with other therapies in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant.**

*Abstract:* 13th International Conference on Malignant Lymphoma, Lugano, Switzerland Jun 17-20, 2015.

*Authors:* Bonthapally V, Yang H, Ayyagari R, Tan R, Cai S, Wu E, Gautam A, Chi A, Huebner D.

**Real-world outcomes of patients with relapsed or refractory chronic lymphocytic leukemia with 17p deletion.**

*Abstract:* 20th Congress of the European Hematology Association, Vienna, Austria Jun 11-14, 2015.

*Authors:* Lamanna N, Hurst D, Latremouille-Viau D, Ionescu-Iltu R, Guerin A, Yim YM, Reyes C.

**Assessing the prognostic impact of intermediate outcomes on survival time in relapsed/refractory multiple myeloma (RRMM) patients (pts) via a robust and clinically interpretable quantitative procedure.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29 - June 2, 2015.

*Authors:* Ayyagari R, Cheng WY, Cai X, Jones C, Ma E, Bonthapally V, Zhu Y, Lefebvre P, Wei LJ, Duh MS.

**Association between duration of treatment (DOT) and healthcare costs in multiple myeloma (MM) patients receiving initial therapy with bortezomib.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29-June 2, 2015.

*Authors:* Xiao Y, Wong BJ, Lefebvre P, Fortier J, Ma E, Bonthapally V, Duh MS.

**Budgetary impact analysis of abiraterone acetate plus prednisone (AA+P) versus enzalutamide (ENZ) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).**

*Abstract:* AVBCC 5th Annual Conference, Washington, DC May 3-6, 2015.

*Authors:* Ellis L, Pilon D, Lefebvre P.

**Changes in treatment patterns among patients receiving at least two targeted therapies for metastatic renal cell carcinoma (mRCC) in the US: A comparison of retrospective chart reviews conducted in 2012 and 2014.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29 - Jun 2, 2015.

*Authors:* Perez JR, Pal SK, Signorovitch JE, Reichmann WM, Li N, Liu Z, Jonasch E, Vogelzang NJ.

**Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29 - Jun 2, 2015.

*Authors:* Oh WK, Miao R, Duh MS, Vekeman F, Sung J, Cheng WY, Hennessy D, Gauthier-Loiselle M, Fortier J, Dhawan R.

**Comparative effectiveness of everolimus and axitinib as second targeted therapy of metastatic renal cell carcinoma in the United States: a retrospective chart review.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29 - June 2, 2015.

*Authors:* Signorovitch JE, Pal SK, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ, Jonasch E.

**Comparative effectiveness of everolimus versus chemotherapies among post-menopausal women with HR+/HER2-metastatic breast cancer: A retrospective chart review of community oncology practices in the US.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29 - Jun 2, 2015.

*Authors:* Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ.

**Comparative effectiveness of everolimus versus endocrine monotherapies among post-menopausal women with HR+/HER2-metastatic breast cancer: A retrospective chart review of community oncology practices in the US.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29 - Jun 2, 2015.

*Authors:* Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ.

**Comparative effectiveness of everolimus vs. fulvestrant monotherapy among postmenopausal women with HR+/HER2-metastatic breast cancer.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ.

**Comparative efficacy of ceritinib and crizotinib in previously treated crizotinib-naive anaplastic lymphoma kinase-positive (ALK+) advanced or metastatic non-small cell lung cancer (NSCLC): An adjusted indirect comparison.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29 - Jun 2, 2015.

*Authors:* Tan DSW, Araujo A, Zhang J, Signorovitch JE, Zhou ZY, Cai X, Liu G.

**Cost-effectiveness of octreotide LAR versus lanreotide depot in the treatment of metastatic gastrointestinal neuroendocrine tumors (GI-NETs).**

*Abstract:* Association of Value-Based Cancer Care, Fifth Annual Conference, Washington, DC, May 3-6, 2015.

*Authors:* Ayyagari R, Neary M, Li S, Zhao C, Higuchi K, Xie J, Benson AB.

**Economic burden of relapsed/refractory chronic lymphocytic leukemia.**

*Abstract:* ASCO Annual Meeting, Chicago, IL May 29-Jun 2, 2015.

*Authors:* Guerin A, Ray S, Gauthier G, Hsu L, Zhdanova M, Heroux J, Wu EQ.

**The evolving treatment patterns in multiple myeloma (MM): Retrospective database analyses of U.S. community oncology electronic medical records and administrative claims.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29 - Jun 2, 2015.

*Authors:* MS D, Lefebvre P, Fortier J, Ma E, Bonthapally V, Wong BJ.

**Overall survival in post-menopausal women with HR+/HER2-metastatic breast cancer treated with 1st-line endocrine therapy vs. Chemotherapy.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Vekeman F, Hao Y, Cheng WY, Fortier J, Robitaille M, Duh MS.

**Realworld treatment patterns and effectiveness among patients with metastatic colorectal cancer (mCRC) treated with zivaflibercept (Z) in community oncology practices in the United States (US).**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29-Jun 2, 2015.

*Authors:* Ivanova JI, Saverno K, Sung J, Sheng Duh M, Zhao C, Cai X, Vekeman F, Peevyhouse A, Dhawan R, Fuchs CS.

**Systematic literature review (SLR) of clinical and realworld observational studies of octreotide LAR for treatment of neuroendocrine tumors (NETs).**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29-Jun 2, 2015.

*Authors:* Sorg R, Neary M, Tang C, Song C, Xie J.

**Treatment patterns and characteristics of post-menopausal women with HR+/HER2-metastatic breast cancer receiving everolimus.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29-Jun 2, 2015.

*Authors:* Vekeman F, Hao Y, Cheng W, Fortier J, Robitaille MN, Duh MS.

**Treatment patterns of endocrine therapy and chemotherapy among post-menopausal women with HR+/HER2-Metastatic Breast Cancer.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Lin PL, Hao Y, Signorovitch JE, Kelley C, Macalalad AR, Ohashi E, Zhou Z, Wu EQ.

**Overall survival with first line endocrine therapy or chemotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review study in the US.**

*Abstract:* AMCP's 27th Annual Meeting, San Diego, CA Apr 7-10, 2015.

*Authors:* Xie J, Hao Y, Li N, Lin PL, Koo V, Ohashi E, Wu EQ.

**Real-World Dosing and Drug Costs with Everolimus (EVE) and Axitinib (AXI) as 2nd Targeted Therapies (TTs) for Metastatic Renal Cell Carcinoma (mRCC): A Retrospective Chart Review.**

*Abstract:* AMCP's 27th Annual Meeting, San Diego, CA Apr 7-10, 2015.

*Authors:* Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ.

**Treatment sequences and pharmacy costs observed for abiraterone and enzalutamide: considerations for U.S. payors.**

*Abstract:* AMCP's 27th Annual Meeting, San Diego, CA Apr 7-10, 2015.

*Authors:* Ellis L, Lafeuille MH, Gozalo L, Pilon D, Lefebvre P, McKenzie S.

**Current treatment characteristics in postmenopausal women with HR+/HER2- metastatic breast cancer.**

*Abstract:* NCCN 20th Annual Conference, Hollywood, FL Mar 12-14, 2015.

*Authors:* Vekeman F, Hao Y, Cheng WY, Fortier J, Robitaille MN, Duh MS.

**Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for second-line treatment of metastatic renal cell carcinoma (mRCC) in the United States: A retrospective chart review.**

*Abstract:* 2015 Genitourinary Cancers Symposium, Orlando, FL Feb 26-28, 2015.

*Authors:* Vogelzang NJ, Pal SK, Signorovitch JE, Reichmann WM, Chopra P, Liu Z, Perez JR, Jonasch E.

**Treatment patterns of recently approved therapies for metastatic castration resistant prostate cancer (mCRPC): Real world evidence from three datasets.**

*Abstract:* ASCO Genitourinary Cancers Symposium, Orlando, FL Feb 26-28, 2015.

*Authors:* Ellis L, Lafeuille MH, Gozalo L, P L, Malangone-Monaco E, Wilson K, McKenzie S.

**Comparison of Survival, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib as a Second-Line Therapy.**

*Abstract:* American Society of Hematology, San Francisco, CA Dec 6-9, 2014.

*Authors:* Smith D, Liu J, Latremouille-Viau D, Zhou Z, Guerin A, Fernandex D, Yi D, Wang X, Wu EQ, Mhatre SK, Keir C, Chen L.

**Comparison of Treatment Patterns of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib as a Second-Line Therapy. .**

*Abstract:* American Society of Hematology, San Francisco, CA Dec 6-9, 2014.

*Authors:* Smith D, Liu J, Latremouille-Viau D, Zhou Z, Guerin A, Fernandex D, Yi D, Wang X, Wu EQ, Mhatre SK, Keir C, Chen L.

**Delay in Trastuzumab Initiation Leads to Decreased Overall Survival in Patients with HER2+ Early Stage Breast Cancer.**

*Abstract:* 2014 San Antonio Breast Cancer Symposium, San Antonio, TX Dec 9-13, 2014.

*Authors:* Gallagher CM, More KF, Sicignano N, Masaquel A, Barnett B, Kamath T, Guérin A, Ionescu-Iltu R, Gauthier-Louiselle M, Nitulescu R, Wu EQ.

**Impact of visceral metastases on treatment patterns for hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC).**

*Abstract:* 2014 SAN ANTONIO BREAST CANCER SYMPOSIUM, San Antonio, TX Dec 9-13, 2014.

*Authors:* Signorovitch J, Wang J, Tan R, Thomason D, Kageleiry A, Swallow E.

**Real-world treatment durations without chemotherapy (CT) for hormone-receptorpositive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC).**

*Abstract:* 2014 SAN ANTONIO BREAST CANCER SYMPOSIUM, San Antonio, TX Dec 9-13, 2014.

*Authors:* Swallow E, Wang J, Thomason D, Tan R, Kageleiry A, Signorovitch J.

**A retrospective analysis of treatment patterns in elderly patients with chronic myeloid leukemia receiving dasatinib or nilotinib as second-line therapy after imatinib.**

*Abstract:* 56th Annual Meeting of the American Society of Hematology, San Francisco, CA Dec 6-9, 2014.

*Authors:* Smith BD, Liu J, Latremouille-Viau D, Zhou Z, Guerin A, Fernandez D, Yi D, Wang X, Wu EQ, Mhatre SK, Keir CH, Chen L.

**Twelve-month cost per responder (CPR) analysis of nilotinib and dasatinib as front-line therapy in patients with philadelphia chromosome-positive (PH+) chronic myeloid leukemia in chronic phase (CML-CP).**

*Abstract:* 56th Annual Meeting of the American Society of Hematology, San Francisco, CA Dec 6-9, 2014.

*Authors:* Guerin A, Revol C, Ramanakumar AV, Foster R, Wu EQ, Mhatre SK, Chen L.

**Overall survival in patients with HER2+ early stage breast cancer patients treated with trastuzumab in the US department of defense practice setting.**

*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8-12, 2014.

*Authors:* Gallagher CM, More K, Masaquel AS, Kamath T, Guerin A, Ionescu-Ittu R, Gauthier-Loiselle M, Nitulescu R, Sicignano N, Barnett B, Wu EQ.

**Symptomatic and economic burden of brain metastases in patients with ALK+ NSCLC.**

*Abstract:* 19th Annual Scientific Meeting of the Society for Neuro-Oncology Conference, Miami, FL Nov 13-16, 2014.

*Authors:* Macalalad A, Sasane M, Zhang J, Culver K, Dea K, Nitulescu R, Wu E, Guerin A.

**Above standard dose of octreotide-lar in patients with neuroendocrine tumors (NET) for control of carcinoid syndrome symptoms: A multi-center retrospective chart review study.**

*Abstract:* 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Taipei, Taiwan (Republic of China) Oct 24-27, 2014.

*Authors:* Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH.

**Cost Effectiveness of Everolimus plus Exemestane for the Treatment of Advanced HR+, HER2- Breast Cancer in the United States. .**

*Abstract:* AMCP Nexus 2014, Boston, MA Oct 7-10, 2014.

*Authors:* Xie J, Hao Y, Zhou J, Qi C, De G, S G.

**Cost of treatment failure in patients with chronic lymphocytic leukemia: results of a large U.S. observational study.**

*Abstract:* AMCP Nexus 2014, Boston, MA Oct 7-10, 2014.

*Authors:* Senbetta M, Robitaille M, McKenzie RS, Lefebvre P.

**Description of ALK+ NSCLC patient characteristics and ALK testing patterns.**

*Abstract:* 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology Chicago, IL Oct 30 - Nov 1, 2014.

*Authors:* Wakelee HA, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Huang Q, Culver K, Wu EQ, Guerin A.

**Economic burden and treatments of progression to metastatic disease in ALK+ NSCLC patients.**

*Abstract:* 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL Oct 30 - Nov 01, 2014.

*Authors:* Guerin A, Sasane M, Zhang J, Culver K, Macalalad A, Nitulescu R, Wu E, Dea K.

**Economic burden of brain metastases among lung cancer patients.**

*Abstract:* AMCP Nexus 2014, Boston, MA Oct 7-10, 2014.

*Authors:* Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, Wu EQ, Guérin A.

**Treatment patterns in metastatic renal cell carcinoma in the US: A retrospective chart review.**

*Abstract:* 13th International Kidney Cancer Symposium, Chicago, IL Oct 24-25, 2014.

*Authors:* Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Liu Z, Perez JR, Vogelzang NJ.

**Association between Risk of Recurrence Assessment and Adjuvant Treatment (Tx) Duration in Patients (Pts) with Resected Gastrointestinal Stromal Tumors.**

*Abstract:* ESMO 2014 Congress, Madrid, Spain Sep 26-30, 2014.

*Authors:* Guérin A, Sasane M, Keir C, Gauthier G, Macalalad A, Wu EQ, Conley AP.

**Cost of treatment failure in patients with mantle cell lymphoma: results of a large U.S. observational study.**

*Abstract:* SOHO Annual Meeting, Houston, TX Sep 17-20, 2014.

*Authors:* Senbetta M, Robitaille M, McKenzie RS, Lefebvre P.

**Predictors of treatment (tx) response and progression in BRAF V600E metastatic melanoma (mM) patients (pts) with brain metastases (BM) receiving vemurafenib (vem) in a real-world setting.**

*Abstract:* 2014 European Society for Medical Oncology Congress, Sep 26-30, 2014 Sep 26-30, 2014.

*Authors:* Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Yeun MY, Sarang A, Reyes C, Guerin A.

**Treatment failure patterns in patients with mantle cell lymphoma: results of a large U.S. observational study.**

*Abstract:* ESMO Congress, Madrid, Spain Sep 26-30, 2014.

*Authors:* Senbetta M, Robitaille M, McKenzie RS, Lefebvre P.

**Incidence of hepatic resection among colorectal cancer patients with liver metastases.**

*Abstract:* 16th World Congress on Gastrointestinal Cancer, Barcelona, Spain Jun 25-28, 2014.

*Authors:* Betts K, Lu M, Zhuo D, Sharma H, Morlock R, Sommer N, Ogale S.

**Real-world treatment patterns among patients with advanced gastric cancer in Taiwan.**

*Abstract:* 16th World Congress on Gastrointestinal Cancer, Barcelona, Spain Jun 25-28, 2014.

*Authors:* Gebra CC, Anna K, Jasmina I, Astra L, Alexandra SR, Maria K, Helen LHJ, Howard B, Narayan R, Shaila B, Rebecca C, Jen-Shi C.

**Treatments and clinical burden among hodgkin lymphoma patients at high risk of relapse after autologous stem cell transplant: A literature review.**

*Abstract:* 19th Congress of the European Hematology Association, Milan, Italy Jun 12-15, 2014.

*Authors:* Bonthapally V, Ayyagari R, Yang H, Wu EQ, Shonukan O.

**Characteristics, treatment, and outcomes of patients with de novo HR+/HER2- advanced breast cancer: A retrospective chart review of community-based oncology practices.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30-Jun 3, 2014.

*Authors:* Lin PL, Macalalad AR, Hao Y, Signorovitch JE, Wu EQ, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA.

**Comparable outcomes and lower total healthcare cost with bortezomib-cyclophosphamidexdexamethasone (VCd) compared to bortezomiblenalidomide-dexamethasone (VRd) for initial treatment of newly diagnosed multiple myeloma (MM).**

*Abstract:* AVBCC 3rd Annual Conference, Hollywood, FL May 6-9, 2014.

*Authors:* Kumar SK, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille M, Lefebvre P, Cheng W, Dea K, Yap M, Saravanan S, Rembert D, Patt D, Niculescu L, Ma E, Quick M, Rajkumar SV.

**Impact of underestimation of risk on treatment duration and recurrence in GIST patients.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30 - Jun 2014.

*Authors:* Guerin A, Conley AP, Sasane M, Macalalad AR, Huang Q, Schwiep FA, Keir CH, Wu EQ.

**One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison.**

*Abstract:* ASCO 50th Annual Meeting, Chicago, IL May 30 - June 3, 2014.

*Authors:* Chen L, Signorovitch JE, Wu EQ, Betts KA, Reichmann WM, Thomason D, Galebach PJ.

**Patient characteristics, treatment, and outcomes in recurrent HR+/HER2- advanced breast cancer after adjuvant therapy: A retrospective chart review of community-based practice.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30-Jun 3, 2014.

*Authors:* Hao Y, Lin PL, Macalalad AR, Signorovitch JE, Wu EQ, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA.

**Physician treatment preferences for HR+/HER2- advanced breast cancer patients: A survey of community oncology practices in the United States.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30-Jun 3, 2014.

*Authors:* Wu EQ, Hao Y, Signorovitch JE, Lin PL, Macalalad AR, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA.

**Prescribing and monitoring patterns for HR+/HER2- advanced breast cancer: A survey of community-based oncologists.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30-Jun 3, 2014.

*Authors:* Lin PL, Hao Y, Signorovitch JE, Macalalad AR, Wu EQ, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA.

**Relapse impact on overall survival in trastuzumab-treated women with HER2+ early-stage breast cancer.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30-Jun 3, 2014.

*Authors:* Gallagher CM, More K, Masaquel A, Kamath T, Guerin A, Ionescu-Ittu R, Gauthier-Loiselle M, Nitulescu R, Wu EQ, Sicignano N, Butts E, Barnett B.

**Retrospective analysis of treatment patterns and outcomes with subcutaneous (SQ) bortezomib (BTZ) in patients (pts) with relapsed mantle cell lymphoma (MCL).**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30-Jun 3, 2014.

*Authors:* Bonthapally V, Lafeuille MH, Fortier J, Duh MS, Ng Y, Van De Velde H, Niculescu L, Ma E, Goy A.

**Symptomatic and economic burden of brain metastases in patients with ALK+ NSCLC.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30 - June 3, 2014.

*Authors:* Guerin A, Sasane M, Zhang J, Culver K, Dea K, Nitulescu R, Wu EQ, Macalalad AR.

**Treatment and survival patterns among ALK+NSCLC patients following crizotinib discontinuation.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Guerin A, Wakelee H, Sasane M, Zhang J, Galebach P, Jarvis J, Kageleiry A, Huang Q, Culver K, Wu EQ, Macalalad AR.

**Treatment patterns and outcomes in BRAF V600E mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30-Jun 3, 2014.

*Authors:* Gibney GT, Marynchenko M, Galebach PJ, Ayas C, Liu NS, Wu EQ, Yim YM, Abhyankar SS, Reyes CM, Guerin A.

**Treatment sequencing and duration among HR+/HER2- advanced breast cancer patients in community-based oncology practices.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30-Jun 3, 2014.

*Authors:* Hao Y, Signorovitch JE, Macalalad AR, Wu EQ, Lin PL, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA.

**Brain Metastases in Patients with ALK+ Non-Small Cell Lung Cancer: Treatment Patterns and Economic Burden.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Macalalad AR, Sasane M, Zhang J, Culver K, Dea K, Nitulescu R, Guérin A.

**Comparative overall survival with treatment sequences for metastatic renal cell carcinoma: A systematic review and meta-analysis of real-world observational studies.**

*Abstract:* 29th Annual Congress of the European Association of Urology, Stockholm, Sweden Apr 11-15, 2015.

*Authors:* Heng DY, Signorovitch J, Swallow E, Li N, Zhong Y, Wang X, Moonis M, Cattaneo A, Stergiopoulos S, Kollmannsberger C.

**Duration of treatment by line of therapy among post-menopausal women with HR+/HER2- metastatic breast cancer.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Macalalad AR, Hao Y, Signorovitch JE, Kelley C, Lin PL, Ohashi E, Zhou Z, Wu EQ.

**Economic burden of bone and liver metastases in patients with ALK+ non-small cell lung cancer.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Guerin A, Sasane M, Nitulescu R, Zhang J, Culver K, Wu EQ.

**Monitoring of multifunctional nanocomplex containing gold coated iron oxide particles in human prostate tumoral cells through MRI.**

*Abstract:* 2014 World Molecular Imaging Congress, Seoul, South Korea Sep 17-20, 2014.

*Authors:* Oghabian MA, Montazerabadi A, Delavari HH, Irajirad R, Muhammadnejad S.

**Overall survival following initiation of first-line treatment with a non-steroidal aromatase inhibitor or fulvestrant among post-menopausal women with recurrent HR+/HER2- metastatic breast cancer.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Song Y, Hao Y, Macalalad A, Lin PL, Signorovitch JE, Wu EQ.

**Robust feature selection and gene committee predictor for breast cancer patient survival prediction.**

*Abstract:* 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA Apr 5-9, 2014.

*Authors:* Yang HH, Lee MP.

**Symptoms of bone and liver metastases in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC).**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Guerin A, Sasane M, Nitulescu R, Zhang J, Culver KW, Macalalad AR, Wu EQ.

**Treatment and Costs Post Crizotinib Monotherapy in Patients with ALK+ Non-Small Cell Lung Cancer: A Retrospective Claims Database Analysis. .**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Guérin A, Sasane M, Zhang J, Culver K, Dea K, Nitulescu R, Macalalad AR.

**Treatment patterns and predictors of everolimus use among post-menopausal women with HR+/HER2- metastatic breast cancer in the US.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ.

**Underestimation of the Risk of Recurrence in Patients with Primary Resected Gastrointestinal Stromal Tumors.**

*Abstract:* NCCN 19th Annual Conference, Hollywood, FL Mar 13-15, 2014.

*Authors:* Conley AP, Sasane M, Guérin A, Macalalad AR, Huang Q, Schwiep F, Wu E.

**Assessment and management of the risk of recurrence of resected gastrointestinal stromal tumors.**

*Abstract:* 2014 Gastrointestinal Cancers Symposium, San Francisco, CA Jan 16-18, 2014.

*Authors:* Conley AP, Sasane M, Pelletier CL, Guerin A, Macalalad AR, Huang Q, Wu EQ.

**Prostate cancer patients demonstrate adherence to medication use while on abiraterone acetate (AA) therapy.**

*Abstract:* ASCO- Genitourinary Cancers Symposium, San Francisco, CA Jan 30-Feb 1, 2014.

*Authors:* Kozma C, Slaton TS, Ellis LA, McKenzie RS, Lafeuille M, Grittner AM, Lefebvre P.

**Real-world corticosteroid utilization in prostate cancer patients treated with two new oral agents.**

*Abstract:* ASCO- Genitourinary Cancers Symposium, San Francisco, CA Jan 30-Feb 1, 2014.

*Authors:* Lafeuille M, Ellis LA, McKenzie RS, Grittner AM, Lefebvre P.

**Real-world treatment patterns among patients with advanced gastric cancer in South Korea.**

*Abstract:* 2014 Gastrointestinal Cancers Symposium, San Francisco, CA Jan 16-18, 2014.

*Authors:* Carter GC, Kaltenboeck A, Ivanova J, Liepa AM, Roman AS, Koh M, Lee HJ, Rajan N, Ballal S, Birnbaum H, Bang YJ.

**Impact of low-grade adverse events (AES) on health-related quality of life (HRQOL) in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase (PH+ CML-CP) from the enestnd trial: 48-month follow-up.**

*Abstract:* 55th Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 7-10, 2013.

*Authors:* Chen L, Guerin A, Marynchenko M, Ionescu-Ittu R, Hiscock R, Nitulescu R, Pooja C, Hsu LI, Keir C, Wu EQ.

**Multi-center experience with CELLSEARCH circulating tumor cell kit on patients with metastatic breast cancer.**

*Abstract:* 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX Dec 10-14, 2013.

*Authors:* Montero AJ, Eapen S, Tran KN, Gorin B, Adler P.

**Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer.**

*Abstract:* ISPOR 16th Annual European Congress, Dublin, Ireland Nov 2-6, 2013.

*Authors:* Campone M, Yang H, Faust E, Kageleiry A, Signorovitch J, Zhang J, Gao H.

**Efficacy of brentuximab vedotin and other treatments in patients with relapsed or refractory (RR) systemic anaplastic large-cell lymphoma (SALCL): A systematic review.**

*Abstract:* ISPOR 16th Annual European Congress, Dublin, Ireland Nov 2-6, 2013.

*Authors:* Bonthapally V, Yang H, Macalalad AR, Wu EQ, Lutes R, Shonukan O, Chi A, Huebner D.

**Glioblastoma treatment patterns and outcomes and resource use in the united states.**

*Abstract:* 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in Conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology, San Francisco, CA Nov 21-24, 2013.

*Authors:* Girvan A, Carter G, Li L, Kaltenboeck A, Chawla A, Ivanova J, Koh M, Stevens J, Lahn M.

**Above Standard Dose of Octreotide-LAR in Patients with Neuroendocrine Tumors (NET).**

*Abstract:* 2013 Interntional Society of Gastrointestinal Oncology, Arlington, VA Oct 19, 2013.

*Authors:* Goldman J, Hulke MH, Strosberg JR, Huynh L, Duh MS, Sahai V, Rademaker A, Benso AB.

**Antitumor activity of brentuximab vedotin in patients with relapsed or refractory (RR) Hodgkin Lymphoma (HL) following autologous stem cell transplant (ASCT): Meta-analysis comparison.**

*Abstract:* 9th International Symposium on Hodgkin Lymphoma Conference, Cologne, Germany Oct 12-15, 2013.

*Authors:* Bonthapally V, Wu E, Macalalad A, Yang H, Shonukan O, Liu Y, Chi A, Huebner D.

**Association between guideline-adherent imaging and overall survival following 2nd-line targeted therapy for metastatic renal cell carcinoma.**

*Abstract:* 12th International Kidney Cancer Symposium, Chicago, IL Oct 25-26, 2013.

*Authors:* Lin PL, Pal SK, Jonasch E, Signorovitch JE, Liu Z, Culver K, Scott JA, Vogelzang NJ.

**Dose-Escalation of Octreotide-LAR in Patients with Neuroendocrine Tumors (NET).**

*Abstract:* NANETS 2013 Annual Conference, Charleston, SC Oct 4-5, 2013.

*Authors:* Kulke MH, Strosberg JR, Huynh L, Duh MS, Sahai V, Rademaker AW, Benson AB.

**Impact of regular molecular monitoring on tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.**

*Abstract:* 2013 Annual Meeting of the American College of Clinical Pharmacy, Albuquerque, NM Oct 13-16, 2013.



*Authors:* Guerin A, Chen L, Wu EQ, Dea K, Goldberg SL.

**Overall survival and hospitalization rates in Medicare patients diagnosed with advanced NSCLC treated with bevacizumab-paclitaxel-carboplatin vs paclitaxel-carboplatin: A retrospective cohort study.**

*Abstract:* 15th World Conference on Lung Cancer, Sydney, Australia Oct 27-30, 2013.

*Authors:* Langer CJ, Ravelo A, Hazard S, Guerin A L-VD, Ionescu-Iltu R, Wu EQ, Ramalingam SS.

**Survival advancements in advanced non-small cell lung cancer in the past 20 years: A story of hope.**

*Abstract:* 15th World Conference on Lung Cancer, Sydney, NSW Australia Oct 27-30, 2013.

*Authors:* Ravelo A, Guerin A, Latremouille-Viau D, Ionescu-Iltu R, Wu EQ.

**Survival following initiation of everolimus for 2nd-line treatment of metastatic renal cell carcinoma: Prognostic factors in clinical practice and comparison to clinical trials.**

*Abstract:* 12th International Kidney Cancer Symposium, Chicago, IL Oct 25-26, 2013.

*Authors:* Wong MK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Liu Z, Wang X, Culver K, Scott JA, George DJ, Vogelzang NJ.

**Análisis Costo-Efectividad De Everolimus Más Exemestano Para Pacientes Con Cáncer De Mama Avanzado Con Receptores Hormonales Positivos (RE+), HER2-, Que Fallaron a Los Inhibidores De Aromatasa No Esteroides (IANES) En México.**

*Abstract:* ISPOR 4th Latin America Conference, Buenos Aires, Argentina Sep 12-14, 2013.

*Authors:* Zhang J, Pramanik A, Fuentes-Albuero A, Anaya P, Tinajero-Ayala B, Zhou ZY, Xie J, Signorovitch J, Fan L.

**Predictors of complete response following disease recurrence in gastrointestinal stromal tumor (GIST) patient: A retrospective patient chart review analysis.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31-Jun 4, 2013.

*Authors:* Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep FA, Keir CH, Magestro M, Wu EQ.

**Association between guideline-adherent imaging and overall survival following second-line targeted therapy for metastatic renal cell carcinoma.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31-June 4, 2013.

*Authors:* Lin PL, Pal SK, Jonasch E, Signorovitch JE, Liu Z, Culver KW, Scott JA, Vogelzang NJ.

**Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: Analysis of two practice-based chart reviews.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31 - Jun 4, 2013.

*Authors:* Signorovitch JE, Vogelzang NJ, Pal SK, Lin PL, George DJ, Wong MKK, Liu Z, Wang X, Culver KW, Scott JA, Jonasch E.

**Comparison of discontinuation, health care resource utilization (HRU), and costs between metastatic breast cancer (mBC) patients (pts) who received trastuzumab (T) in an office clinic versus outpatient hospital setting.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31-Jun 4, 2013.

*Authors:* Brammer M, Lalla D, Gauthier G, Guerin A, Giguere-Duval P, Wu EQ, Santos E.

**Do oncology patients in an outpatient hospital receive the same care as patients in an office/clinic setting? A case study evaluating patients with non-metastatic HER2+ breast cancer (BC) receiving adjuvant trastuzumab.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL Jun 4, 2013.

*Authors:* Lalla D, Brammer M, Guerin A, Gauthier G, Giguere-Duval P, Wu EQ, Santos E.

**Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia (CML).**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31 - Jun 4, 2013.

*Authors:* Chen L, Guerin A, Wu EQ, Dea K, Goldberg SL.

**The economic burden of metastatic castration-resistant prostate cancer: U.S. Medicare perspective.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31 - Jun 4, 2013.

*Authors:* Eapen S, Andrews R, Gorin B, Higano CS.

**Health care resource utilization and cost of Medicare patients with non-small cell lung cancer (NSCLC).**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Yenikomshian M, Hackshaw M, Cai X, Trahey A, Arondekar B, Knoll S, Duh MS.

**Impact of Chronic Constipation Severity on the Risk of Developing Colorectal Cancer and Benign Neoplasm.**

*Abstract:* Digestive Disease Week 2013, Orlando, FL May 18-21, 2013.

*Authors:* Guérin A, Mody R, Fok B, Wu EQ, Lasch K, Talley NJ.

**Incremental cost of brain metastases among patients with metastatic melanoma.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Vekeman F, Cloutier M, Yermakov S, Amonkar M, Arondekar B, Duh MS.

**Meta-analysis of the efficacy and safety of bortezomib (BTZ) retreatment in patients (PTS) with multiple myeloma (MM).**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

**Observed abiraterone acetate utilization by prostate cancer (PC) patients in a large administrative claims database in the united states.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Lafeuille MH, Dean J, Lefebvre P, Ellis L, Senbetta M.

**Prescribing decision drivers in patients with recurrent gastrointestinal stromal tumor (GIST) previously treated with adjuvant imatinib: A retrospective chart extract-based approach.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31-Jun 4, 2013.

*Authors:* Guerin A, Sasane M, Gauthier G, Schwiep FA, Keir CH, Magestro M, Wu EQ, Conley AP.

**A single-center experience with CELLSEARCH system circulating tumor cell test on patients with metastatic breast cancer.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31-Jun 4, 2013.

*Authors:* Montero AJ, Eapen S, Andrews RM, Gorin B.

**Survival following initiation of everolimus for second-line treatment of metastatic renal cell carcinoma: Prognostic factors in clinical practice and comparison to clinical trials.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31-Jun 4, 2013.

*Authors:* Wong MK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Liu Z, Wang X, Culver K, Scott JA, George DJ, Vogelzang NJ.

**Tumor characteristics and treatment (trt) patterns following disease recurrence in gastrointestinal stromal tumor (GIST) patients (pts) who received adjuvant imatinib (IM) as primary trt: A retrospective chart extract-based approach.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31-Jun 4, 2013.

*Authors:* Gauthier G, Sasane M, Guerin A, Schwiep FA, Keir CH, Magestro M, Wu EQ, Conley AP.

**Comparison of healthcare resource utilization and costs between patients who received trastuzumab in an outpatient hospital vs. office clinic setting for the treatment of breast cancer.**

*Abstract:* AMCP's 25th Annual Meeting, San Diego, CA Apr 3-5, 2013.

*Authors:* Brammer M, Lalla D, Gauthier G, Guérin A, Giguere-Duval P, Wu EQ, Santos E.

**Meta-analysis of the efficacy and safety of bortezomib (BTZ) retreatment in patients (PTS) with multiple myeloma (MM).**

*Abstract:* 14th International Myeloma Workshop Conference, Kyoto, Japan Apr 3-7, 2013.

*Authors:* Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

**Outcomes of second-targeted therapy for mRCC: A retrospective chart review of community practices in the United States.**

*Abstract:* 2013 Genitourinary Cancers Symposium, Orlando, FL Feb 14-16, 2013.

*Authors:* Jonasch E, Signorovitch JE, Lin P, Liu Z, Culver KW, Pal SK, Scott JA, Vogelzang NJ.

**Sequential use of targeted therapies for metastatic renal cell carcinoma: A physician survey and chart review of community oncology practices in the United States.**

*Abstract:* 2013 Genitourinary Cancers Symposium, Orlando, FL Feb 14-16, 2013.

*Authors:* Vogelzang NJ, Signorovitch JE, Lin PL, Liu Z, Culver KW, Scott JA, Pal SK, Jonasch E.

**Benefits of early switching from imatinib to a second-generation tyrosine kinase inhibitor following 12 month complete cytogenetic response failure: A chart review analysis.**

*Abstract:* 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.

*Authors:* DeAngelo DJ, Chen L, Guerin A, Styles A, Aberki C, Giguere-Duval P, Wu EQ.

**Budget impact analysis of everolimus for estrogen receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients in the United States.**

*Abstract:* 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX Dec 4-8, 2012.

*Authors:* Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M.

**Characteristics of patients with chronic myelogenous leukemia in chronic phase switched to nilotinib or dasatinib as second-line therapy.**

*Abstract:* 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.

*Authors:* Macalalad AR, Chen L, Guerin A, Luo J, Wu EQ, Griffin JD.

**Comparison of disease outcomes for patients with chronic myelogenous leukemia in chronic phase switched to nilotinib or dasatinib as second-line therapy.**

*Abstract:* 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.

*Authors:* Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Wu EQ.

**Comparison of treatment changes for patients with chronic myelogenous leukemia in chronic phase switched from imatinib to nilotinib or dasatinib as second-line therapy.**

*Abstract:* 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.

*Authors:* Macalalad AR, Chen L, Guerin A, Luo J, Wu EQ, Griffin JD.

**Comparison of treatment patterns and outcomes in metastatic breast cancer patients initiated on trastuzumab vs. lapatinib; A retrospective analysis.**

*Abstract:* 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX Dec 4-8, 2012.

*Authors:* Gauthier G, Guerin A, Styles AL, Wu EQ, Masaquel A, Brammer MG, Lalla D.

**Frequency of molecular monitoring correlates with long term outcomes in chronic phase chronic myelogenous leukemia treated with first-line imatinib: Results of a community survey.**

*Abstract:* 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.

*Authors:* Goldberg SL, Chen L, Ericson SG, Macalalad AR, Guerin A, Liu N, Kaminsky M, Wu EQ.

**Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first and second-line chemotherapies.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Hurvitz SA, Guerin A, Brammer M, Guardino E, Zhou ZY, Kaminsky MS, Wu EQ, Lalla D.

**Investigation of gastrointestinal stromal tumor (GIST) care management in GIST patients (pts) receiving short-term versus long-term imatinib (IM) adjuvant therapy: A chart review analysis.**

*Abstract:* ASCO's Quality Care Symposium, San Diego, CA Nov 30-Dec 1, 2012.

*Authors:* Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

**Review of national institute for health and clinical excellence (NICE) recommendations for anti-cancer agents across multiple drug-indication combinations.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Chawla A, Oza A, Nellesen D, Brown J, Liepa AM, Price G, Nash-Smyth E, Cuyun Carter G, Boye ME.

**A systematic review of the heterogeneity of treatment effect in ovarian cancer (OC)-Are there implications for outcomes research?**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Chawla A, Nellesen D, Yee K, Brown J, Boye ME.

**Risk of developing colorectal cancer and benign neoplasm in patients with chronic constipation.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.

*Authors:* Mody R, Guerin A, Fok B, Zhou Z, Wu E, Brewer K, Zhou W, Lasch K, Talley N.

**Treatment patterns in metastatic renal cell carcinoma in the US: A retrospective chart review in community oncology practices.**

*Abstract:* 11th International Kidney Cancer Symposium Annual Meeting Proceedings, Chicago, IL Oct 5-6, 2012.

*Authors:* Vogelzang NJ, Signorovitch JE, Lin PL, Liu Z, Culver K, Pal SK, Scott JA, Jonasch E.

**Real-world study of imatinib treatment patterns and outcomes among veteran patients with chronic myeloid leukemia in chronic phase (CML-CP).**

*Abstract:* ESH-iCML International Conference, Baltimore, MD Sep 20-23, 2012.

*Authors:* Vander Velde NS, Chen L, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang HY, Guo A, Shi L.

**Budget impact analysis of everolimus for ER+, HER2-metastatic breast cancer patients in the United States.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Xie J, Diener M, De G, Wu EQ, Namjoshi M.

**Characteristics of gastrointestinal stromal tumor (GIST) patients receiving short-term versus long-term imatinib (IM) adjuvant therapy: A chart review analysis.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL June 1-5, 2012.

*Authors:* Guerin A, Conley AP, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

**Comparison of treatment patterns and outcomes in metastatic breast cancer (MBC) patients initiated on trastuzumab versus lapatinib: A retrospective analysis.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Gauthier G, Guerin A, Styles A, Wu EQ, Brammer MG, Lalla D.

**Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Hurvitz SA, Guerin A, Brammer MG, Guardino E, Zhou ZY, Kaminsky MS, Wu EQ, Lalla D.

**Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first-and second-line chemotherapies.**

*Abstract:* 2012 International MASCC/ISOO Symposium: Supportive Care in Cancer, New York, NY Jun 28-30- 2012.

*Authors:* Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Kaminsky M, Wu EQ, Lalla D.

**Drug treatment (tx) patterns and survival among patients (pts) with metastatic or recurrent soft tissue sarcoma (m/rSTS) refractory to at least one prior therapy.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Wagner M, Amodu L, Duh MS, Korves C, Solleza F, Mykletun A, Manson S, Diaz J, Neery MP, Demetri GD.

**Economic burden of hepatocellular carcinoma in China.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Wu EQ, Wu J, Yang HY, Zheng Y, Xie K, Yu R, Xie J.

**Health Care Utilization and Costs Among Lung Cancer Patients in China.**

*Abstract:* ISPOR 2012, Jun 2-6, 2012.

*Authors:* Zheng Y, Wu J, Xie J, Xie K, Yang H, Liu J, Wu E.

**Health care utilization and economic burden of dermatologic adverse drug reactions (ADRs) in patients with NSCLC treated with an epidermal growth factor receptor inhibitor (EGFRI).**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Bonthapally V, Guerin A, Wu EQ, Gauthier G, Cloutier M, Holen KD, Ray S.

**Monitoring and switching patterns in chronic myelogenous leukemia (CML) pts treated with imatinib (IM): A chart review analysis.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Chen L, Guerin A, Aberki C, Wu EQ, Ericson S, Jabbour E.

**Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective U.S. chart review.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Yang H, Wong MKK, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi Z, George DJ.

**Overall survival with everolimus, sunitinib, and placebo for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison of randomized trials.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Signorovitch JE, Swallow E, Kantor E, Wang X, Hass T, Klimovsky J, Metrakos P.

**Real-world study of imatinib treatment patterns and outcomes among veteran patients with chronic myeloid leukemia in chronic phase.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Vander Velde NS, Chen L, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang HY, Guo A, Shi L.

**Risk of disease recurrence and mortality in gastrointestinal stromal tumor (GIST) patients receiving short-term versus long-term imatinib adjuvant therapy: A chart review analysis.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

**Number needed to treat and risk benefit analysis of denosumab versus zoledronic acid in the treatment of castrate-resistant prostate cancer patients with bone metastases.**

*Abstract:* American Urological Association Annual Meeting, Atlanta, GA May 19-23, 2012.

*Authors:* Xie J, Diener M, Wu EQ, Sorg R, Yu AP, Namjoshi M.

**Comparison of adherence patterns with second-line nilotinib and dasatinib in patients with Chronic Myeloid Leukemia (CML).**

*Abstract:* 8th Annual Meeting of the Hematology/Oncology Pharmacy Association, Orlando, FL Mar 21-24, 2012.

*Authors:* Chen L, Guerin A, Guo A, Stepner M, Griffin JD, Wu EQ.

**Health care utilization and economic burden of dermatologic adverse drug reactions (ADRs) in patients with colorectal cancer treated with an epidermal growth factor receptor inhibitor (EGFRI).**

*Abstract:* 2012 Gastrointestinal Cancers Symposium, San Francisco, CA Jan 19-21, 2012.

*Authors:* Bonthapally V, Guerin A, Wu EQ, Gauthier G, Holen KD, Ray S.

**Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia.**

*Abstract:* 53rd Annual Meeting of the American Society of Hematology, San Diego, CA Dec 10-13, 2011.

*Authors:* Guerin A, Bollu VK, Guo A, Stepner M, Griffin JD, Wu EQ.

**Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases.**

*Abstract:* 2011 Breast Cancer Symposium Chicago, IL Nov 30 - Dec 3, 2011.

*Authors:* Wu EQ, Xie J, Signorovitch J, Diener M, Sorg R, Namjoshi M.

**Adherence patterns and dose adjustments with second-line nilotinib and dasatinib in patients with chronic myeloid leukemia: Evaluation in a real-world setting.**

*Abstract:* 2011 Annual Meeting of the American College of Clinical Pharmacy Conference, Pittsburgh, PA Oct 16-19, 2011.

*Authors:* Guerin A, Bollu V, Guo A, Griffin JD, Yu AP, Wu E.

**The association between treatment (TX) modifications due to adverse events (AES) and overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with sunitinib and sorafenib: Results from a multi-country study in europe.**

*Abstract:* 2011 European Multidisciplinary Cancer Congress, Stockholm, Sweden Sept 23-27, 2011.

*Authors:* Oudard S, Porta C, Castellano D, McDermott R, Nathan P, McCaffrey J, Neary MP, Korves C, Dial Suthoff E, Duh M.

**Comparing early intervention with zoledronic acid to no bisphosphonate (BP) therapy in patients with metastatic prostate cancer to bone: A study of the US Veterans Affairs (VA) population.**

*Abstract:* 10th International Conference on Cancer-Induced Bone Disease Conference, Sheffield, UK Sept 22-25, 2010.

*Authors:* Wu EQ, Guo A, Shi L, Lu M, Yu AP, Sharma H, Fan CPS, Vander Velde N.

**Complications associated with chemotherapy in patients with metastatic breast cancer.**

*Abstract:* 2011 European Multidisciplinary Cancer Congress, Stockholm, Sweden Sept 23-27, 2011.

*Authors:* Brammer M, Lalla D, Guerin A, Latremouille-Viau D, Yu AP, Wu EQ, Hurvitz S.

**Number needed to treat and risk benefit analysis of denosumab versus zoledronic acid in the treatment of castrate-resistant prostate cancer patients with bone metastases.**

*Abstract:* 2011 Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA Sept 16-20, 2011.

*Authors:* Yu AP, Diener M, Wu EQ, Namjoshi M.

**Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases.**

*Abstract:* 2011 Breast Cancer Symposium San Francisco, CA Sep 8-10, 2011.

*Authors:* Wu EQ, Xie J, Signorovitch J, Diener M, Sorg R, Namjoshi M.

**A pan-european study of treatment (TRX) patterns and toxicity of angiogenesis inhibitors in patients (pts) with advanced renal cell carcinoma (RCC).**

*Abstract:* 2011 European Multidisciplinary Cancer Congress Stockholm, Sweden Sep 23-27, 2011.

*Authors:* Levy A, Porta C, Hawkins R, Bellmunt J, Wagstaff J, Donnellan P, Neary MP, Sarda SP, Vekeman F, Duh MS.

**Sunitinib (SU) treatment (Trx) patterns and toxicity in patients (Pts) with advanced renal cell carcinoma (RCC) in United Kingdom (UK).**

*Abstract:* 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Chicago, IL Aug 14-17, 2011.

*Authors:* Hawkins R, Wagstaff J, Nathan P, Sarda SP, Vekeman F, Korves C, Dasgupta S, O'Mara S, Fitton S, Hayers J, Tham C, Luka A, Wei R, Mykletun A, Neary MP, Duh MS.

**Chemotherapy-related complication burden in patients with metastatic breast cancer in a real-world setting.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2011.

*Authors:* Hurvitz SA, Lalla D, Guerin A, Latremouille-Viau D, Yu AP, Wu EQ, Brammer M.

**Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a real-world setting.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2011.

*Authors:* Guerin A, Lalla D, Latremouille-Viau D, Yu AP, Wu EQ, Brammer M, Hurvitz SA.

**Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2011.

*Authors:* Yu AP, Namjoshi M, Xie J, Parikh K, Wu EQ, Guo A, Culver KW.

**Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomized phase III trial.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2011.

*Authors:* Pickard A, Cella D, Duh M, Guerin A, Mishagina N, Antras L, Neary M, McCann L, Hodge R, Sternberg C.

**Impact of pleural effusion (PE) on treatment adherence, discontinuation, switching, and dose modification in patients with chronic myelogenous leukemia (CML).**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2011.

*Authors:* Wu EQ, Guerin A, Bollu VK, Guo A, Cloutier M, Ponce de Leon Barido D, Ericson S, Quintas-Cardama A.

**Patterns of treatment (trx) and safety of angiogenesis inhibitors in patients (pts) with advanced renal cell carcinoma (RCC) in France.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2011.

*Authors:* Gross-Goupil M, Oudard S, Levy A, Elaidi R, Scotte F, Duh MS, Sarda SP, Korves C, Goglia R, Ramamurthy P, Neary M, Escudier B.

**Sunitinib (SU) treatment (trx) patterns and toxicity in patients (pts) with advanced renal cell carcinoma (RCC) in United Kingdom (UK).**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2011.

*Authors:* Wagstaff J, Hawkins RE, Nathan PD, Sarda SP, Vekeman F, Korves C, Dasgupta S, O'Mara S, Fitton S, Hayers J, Tham C, Luka A, Wei R, Mykletun A, Neary M, Duh MS.

**Treatment (trx) of metastatic renal cell carcinoma (mRCC) with angiogenesis inhibitors (AIs): Safety and treatment patterns observed in Taiwanese patients.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2011.

*Authors:* Chang Y, Ou Y, Huang C, Chiang P, Chuang C, Kina S, Vekeman F, Goglia R, Neary M, Duh MS.

**The cost-effectiveness of bortezomib plus melphalan and prednisone versus lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment for the initial treatment of multiple myeloma in the united states.**

*Abstract:* ISPOR 16th Annual International Meeting Baltimore, MD May 21-25, 2011.

*Authors:* Wang ST, Huang H, Ba-mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, Van De Velde H, Duh MS.

**Dosing pattern and cost comparison of epoetin alfa and darbepoetin alfa in chronic kidney disease and chemotherapy-induced anemia inpatients.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Lafeuille MH, Bailey RA, Senbetta M, McKenzie RS, Lefebvre P.

**Health care resource utilization and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Le TK, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ.

**New methods to adjust for selective crossover in survival analysis: In assessments of costeffectiveness of cancer therapies.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Delea TE, Duh MS, Wei LJ, Robins J.

**Patterns of angiogenesis inhibitor treatment in patients with metastatic renal cell carcinoma (MRCC) in Ireland.**

*Abstract:* ISPOR 16th Annual International Meeting Baltimore, MD May 21-25, 2011.

*Authors:* McDermott R, Donnellan P, McCaffery J, Keane F, Sarda SP, Korves C, Luka A, Wei R, Neary MP, Hanley R, Duh MS.

**Real world clinical resource utilization of metastatic prostate cancer patients in the United States: Results from two large claims databases.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Senbetta M LM, Dean J, McKenzie RS, Lefebvre P.

**Safety and treatment patterns of angiogenesis inhibitors in patientswith metastatic renal cell carcinoma (MRCC) in the United Kingdom: Preliminary results of an ongoing charts reviewstudy.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Hawkins R, Wagstaff J, Nathan P, Sarda SP, Vekeman F, Korves C, Dasgupta S, O'Mara S, Fitton S, Hayers J, Tham C, Wei R, Luka A, Neary MP, Duh MS.

**Treatment patterns and healthcare resource utilization of metastatic prostate cancer patients by physician specialty.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Senbetta M, Lafeuille MH, Dean J, McKenzie RS, Lefebvre P.

**Health care resource utilization and costs associated with bevacizumab versus cetuximab in second-line treatment of metastatic colorectal cancer patients.**

*Abstract:* AMCP's 23rd Annual Meeting, Minneapolis, MN Apr 27-29, 2011.

*Authors:* Yang H, Yu A, Yim Y, Yu E, Wu E.

**Treatment (trx) patterns and toxicity of angiogenesis inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) in United Kingdom (UK).**

*Abstract:* 26th Annual Congress of the European Association of Urology, Vienna, Austria Mar 18-22, 2011.

*Authors:* Hawkins R, Wagstaff J, Nathan P, Sarda SP, Vekeman F, Korves C, Dasgupta S, O'Mara S, Fitton S, Hayers J, Tham C, Wei R, Luka A, Duh MS, Neary MP.

**Treatment (trx) patterns of angiogenesis inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) in Ireland.**

*Abstract:* 2011 Genitourinary Symposium., Orlando, FL Feb 17-19, 2011.

*Authors:* McDermott RS, Donnellan PP, McCaffery J, Sarda SP, Korves C, Luka A, Wei R, Neary M, Hanley R, Duh MS.



**Treatment patterns and health care resource utilization of metastatic colorectal cancer (mCRC) patients who received bevacizumab or cetuximab in second-line regimen.**

*Abstract:* 2011 Gastrointestinal Cancers Symposium San Francisco, CA Jan 20-22, 2011.

*Authors:* Yang H, Yu AP, Yim Y, Yu E, Wu E.

**Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia.**

*Abstract:* 52nd Annual Meeting of the American Society of Hematology, Orlando, FL Dec 4-7, 2010.

*Authors:* Guerin A, Bollu V, Guo A, Griffin JD, Yu AP, Wu EQ.

**The economic burden of pleural effusions (PE) in patients with chronic myeloid leukemia (CML).**

*Abstract:* 52nd Annual Meeting of the American Society of Hematology, Orlando, FL Dec 4-7, 2010.

*Authors:* Wu EQ, Guerin A, Bollu V, Williams D, Guo A, De Leon Barido DP, Yu AP, Quintas-Cardama A.

**Comparison of skeletal complications and treatment patterns associated with early versus delayed zoledronic acid therapy in multiple myeloma.**

*Abstract:* 52nd Annual Meeting of the American Society of Hematology, Orlando, FL Dec 4-7, 2010.

*Authors:* Yu AP, Bensimon AG, Marynchenko M, Wu EQ, Namjoshi M, Guo A, Ericson SG, Raje N.

**Healthcare costs of second-line (2l) metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BV) versus cetuximab (CX).**

*Abstract:* 35th ESMO Congress, Milan, Italy Oct 8-12, 2010.

*Authors:* Yim Y, Wu EQ, Yu AP, Yang HY, Yu E.

**Active dose re-escalation of nilotinib following dose reduction is associated with improved efficacy in patients with chronic phase chronic myeloid Leukemia (CML-CP) who fail imatinib.**

*Abstract:* 15th Congress of the European Hematology Association, Barcelona, Spain Jun 10-13, 2010.

*Authors:* Nicolini F, Kim DW, Turkina A, Alimena G, Al-Ali HK, Shen Z, Jootar S, Smith G, De Souza C, Dorlhiac-Llacer P, Rizzieri D, Lyon-Caen S, Berton M, Szczudlo T, Le Coutre P.

**Comparison of health care resource utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia (CML).**

*Abstract:* ISPOR 2010, Atlanta, GA May 15-19, 2010.

*Authors:* Wu E, Bollu V, Guo A, Guerin A, Tsaneva M, Williams D, Griffin J.

**Costs of treatment with angiogenesis inhibitors (AIS) in patients with metastatic renal cell carcinoma (MRCC): Results from a medical chart review study.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Oh WK, McDermott DF, Duh MS, Antras L, Chen K, Sarda SP, Luka A, Whittemore S, Ramamurthy P, Neary MP, Choueiri TK.

**Costs to Medicare of treating chronic lymphocytic leukemia patients with alemtuzumab.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Lafeuille MH, Vekeman F, Kerrigan M, Wang ST, Duh MS.

**Health care costs associated with angiogenesis inhibitors (AIS) and mtor inhibitors (MTORS) in patients with metastatic renal cell carcinoma (MRCC) treated at US community oncology clinics.**

*Abstract:* ISPOR 15th Annual International Meeting Atlanta, GA May 15-19, 2010.

*Authors:* Chen K, SP S, Antras L, Whittemore S, Luka A, Ramamurthy P, Scott J, Fortner B, Neary MP, Duh MS, Jolly P.

**Health care costs associated with multikinase inhibitors (MKIS) for treatment of metastatic renal cell carcinoma (MRCC) in a clinical practice setting in Italy.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Paglino C, Porta C, Canipari C, Antras L, Chen K, Whittemore S, Luka A, Ramamurthy P, Neary MP, Duh MS.

**Incidence and cost of adverse events (AES) in patients with renal cell carcinoma (RCC) treated with angiogenesis inhibitors (AIs).**

*Abstract:* ISPOR 2010, Atlanta, GA May 15-19, 2010.

*Authors:* Dial E, Duh MS, Antras L, Rodermund D, Neary MP, Choueiri TK, Oh WK.

**Incidence and cost of adverse events (AEs) in patients with renal cell carcinoma (RCC) treated with angiogenesis inhibitors (AIs).**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Dial E, Duh MS, Antras L, Rodermund D, Neary MP, Choueiri TK, Oh WK.

**Lower health care resource utilization associated with managing nilotinib related adverse events in chronic myeloid leukemia (CML) patients: Evidence from a clinical practice setting study.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Guerin A, Bollu V, Williams D.

**Modeling the cost-effectiveness of bortezomib for the initial treatment of multiple myeloma in the United States.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Wang ST, Huang H, Shi H, Duh MS, Chen K, Chang E, Korves C, Dhawan R, Cakana A, Van De Velde H, Esseltine DL, Garrison L.

**Non-adherence to imatinib in chronic myeloid leukemia (cml) patients is associated with short-and long-term negative impacts on health care resource utilization and costs.**

*Abstract:* Cited from Google Scholar, May 15-19, 2010.

*Authors:* Guerin A, Bollu V, Guo A, Wu E, Yu A, Sirulnik L, Griffin J.

**Comparison of healthcare utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Wu EQ, Bollu VK, Guo A, Guerin A, Tsaneva M, Williams D, Griffin JD.

**Costs to Medicare of treating chronic lymphocytic leukemia patients with alemtuzumab.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Lafeuille MH, Vekeman F, Kerrigan M, Wang ST, Duh M.

**Efficacy and safety of nilotinib in elderly patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): A sub-analysis of the ENACT (expanding nilotinib access in clinical trials) study.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Le Coutre PD, Turkina A, Kim DW, Ceglarek B, Alimena G, Al-Ali HK, Shen Z, Jootar S, Smith G, De Souza CA, Dorlhiac-Llacer PE, Rizzieri DA, Szczudlo T, Berton M, Wang J, Wang ST, Nicolini FE.

**Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): Sub-analyses of the ENACT (expanding nilotinib access in clinical trials) study.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Nicolini FE, Kim DW, Ceglarek B, Turkina A, Alimena G, Al-Ali HK, Shen Z, Jootar S, Smith G, De Souza CA, Dorlhiac-Llacer PE, Rizzieri DA, Szczudlo T, Berton M, Wang J, Bieri C, Le Coutre PD.

**Molecular response, efficacy and safety analysis of 168 adult french patients with chronic myeloid leukemia (CML) in chronic phase (CP) from the ENACT (expanding nilotinib access in clinical trials) study.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Nicolini FI, Etienne G, Bordessoule D, Caillot D, Belanger C, Cayuela JM, Charbonnier A, Coiteux V, Guerci-Bresler A, Dubruille V, Lamy T, Huguet F, Rousselot P, Tulliez M, Cahn JY, Gardembas-Pain M, Legros L, Maloisel F, Rea D, Johnson-Ansah H, Lenain P, Delmer A, Berger M, Szczudlo T, Wang J, Duh MS, Guilhot F.

**Non-adherence to imatinib in chronic myeloid leukemia patients is associated with a short term and long term negative impact on healthcare utilization and costs.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Wu EQ, Bollu VK, Guo A, Guerin A, Yu AP, Sirulnik A, Griffin JD.

**Patterns and management of selected adverse events of adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) from the enact (expanding nilotinib access in clinical trials) study.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Le Coutre PD, Ceglarek B, Turkina A, Kim DW, Alimena G, Al-Ali HK, Shen Z, Jootar S, Smith G, De Souza CA, Rizzieri DA, Szczudlo T, Berton M, Wang J, Dial E, Nicolini FE.

**Safety and treatment (trx) patterns of angiogenesis inhibitors (AIs) in patients (pts) with metastatic renal cell carcinoma (mRCC): Evidence from US community oncology clinics.**

*Abstract:* Joint ECCO 15 - 34th ESMO Multidisciplinary Congress, Berlin, Germany Sep 20-24, 2009.

*Authors:* Wang S, Ivanova J, Antras L, Chang E, Ramamurthy P, Whittemore S, Fortner B, Scott J, Neary M, Duh M.

**Safety and treatment (trx) patterns of multikinase inhibitors (MKI) in patients (pts) with metastatic renal cell carcinoma (mRCC) in Italy.**

*Abstract:* Joint ECCO 15 - 34th ESMO Multidisciplinary Congress, Berlin, Germany Sep 20-24, 2009.

*Authors:* Di Cesare P, Porta C, Lasagna A, Ferraris E, Imarisio I, Paglino C, Antras L, Chen K, Neary MP, Duh MS.

**Comparison of infection-related hospitalization risk among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* Duh MS, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Heaney ML.

**Patients (Pts) with metastatic Renal Cell Carcinoma (mRCC) receiving Angiogenesis Inhibitor (AI) therapies: Treatment efficacy and safety in clinical practice.**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* McDermott D, Choueiri TK, Clement J, Brick AJ, Kwabi C, Shah K, Antras L, Jayawant SS, Wang ST, Luka A, Duh MS, Neary M, Oh WK.

**Pattern of utilization of pegfilgrastim (PEGFIL) in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* Skarin AT, Vekeman F, Laliberte F, Afonja O, Lafeuille MH, Barghout V, Duh MS.

**Treatment (Tx) and dosing patterns for Angiogenesis Inhibitor (AI) therapies in patients (Pts) with metastatic Renal Cell Carcinoma (mRCC).**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* Choueiri TK, Brick AJ, McDermott D, Clement J, Kwabi C, Shah K, Antras L, Chen K, Jayawant SS, Duh MS, Luka A, Neary M, Oh WK.

**Adverse events associated with imatinib dose escalation versus switching to dasatinib in patients with chronic myelogenous leukemia.**

*Abstract:* ASCO Annual Meeting, Orlando, FL May 29 - Jun 2, 2009.

*Authors:* Morgan JA, Guo A, Williams D, Guérin A, Latremouille-Viau D, Tsnaeva M, Yu P, Wu EQ, Signorovitch J, Demetri GD.

**A pilot study: Impact of Chemotherapy-associated peripheral neuropathy on chemotherapy related treatment patterns in metastatic breast and non-small cell lung cancer patients.**

*Abstract:* 2009 International MASCC/ISOO Symposium Rome, Italy Jun 25-27, 2009.

*Authors:* Pike C, Birnbaum H, Kaufman R, Muehlenbein C, Pohl G, Natale R.

**Budget impact analysis of sargramostim use in patients with chemotherapy-induced neutropenia.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Toy EL, Porter CL, Books P, Vekeman F, Barghout V, Duh M, Skarin AT.

**Comparison of infection-related hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Duh MS, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Heaney ML.

**Direct health care and workloss burden of chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and non-small cell lung cancer.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Pike C, Birnbaum HG, Kaufman R, Muehlenbein CE, Pohl G, Natale R.

**Health care resource utilization associated with escalating imatinib versus switching to dasatinib in patients with chronic myelogenous leukemia.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Yu AP, Guo A, Guerin A, Latremouille-Viau D, Tsaneva M, Xie J, Signorovitch J, Williams D, Wu E.

**Pattern of utilization of pegfilgrastim in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Vekeman F, Laliberte F, Afonja O, Lafeuille MH, Barghout V, Duh MS, Skarin AT.

**Real world treatment patterns of gastrointestinal stromal tumor patients.**

*Abstract:* ASCO Annual Meeting, Orlando, FL May 29 - Jun 2, 2009.

*Authors:* Wu EQ.

**Treatment patterns of chronic myelogenous leukemia patients who initiated their treatment on imatinib.**

*Abstract:* ASCO Annual Meeting, Orlando, FL May 29 - June 2, 2009.

*Authors:* Guérin A, Guo A, Williams D, Yu AP, Wu EQ, Latremouille-Viau D, Tsaneva M, Signorovitch J, Griffin JD.

**Symptom assessment in relapsed small cell lung cancer: cross-validation of the patient symptom assessment in lung cancer instrument.**

*Abstract:* International Association for the Study of Lung Cancer 2008.

*Authors:* Chen L, Antras L, Duh MS, Neary M, O'Brien ME.

**Patients (PTS) with metastatic renal cell carcinoma (MRCC) receiving angiogenesis inhibitor (AIS) therapies: Treatment efficacy and safety in clinical practice.**

*Abstract:* 34th Congress of the European Society for Medical Oncology Conference Stockholm, Sweden Sep 12-16, 2008.

*Authors:* McDermott D, Choueiri TK, Clement J, Brick AJ, Kwabi C, Shah K, Banerjee A, Duh MS, Neary MP, Oh WK.

**Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC).**

*Abstract:* 34th Congress of the European Society for Medical Oncology, Stockholm, Sweden Sep 12-16, 2008.

*Authors:* Choueiri TK, Brick AJ, McDermott D, Clement J, Kwabi C, Shah K, Chen K, Duh MS, Neary MP, Oh WK.

**Medical Costs Associated with Imatinib Non-compliance in Chronic Myeloid Leukemia Patients.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 1-5, 2007.

*Authors:* Wu EQ, Feng W, Johnson S, Beaulieu N, Cremieux P, Cortes J.

**Mapping FACT-P and EORTC QLQ-C30 to the EQ-5D health utility in metastatic hormone-refractory prostate cancer patients.**

*Abstract:* ISPOR 2006, 2006.

*Authors:* Wu E, Mulani P, Farrell M, Sleep D.

**Dose conversion of erythropoietic agents in chemotherapy-induced anemia: A meta-analysis.**

*Abstract:* ISPOR 2003, 2003.

*Authors:* Rosberg J, Oster E, Wu E, Fastenau J, Piech C.

## Renal

### Journal Articles

**Association of Calcium and Phosphate Levels with Incident Chronic Kidney Disease in Patients with Hypoparathyroidism: A Retrospective Case-Control Study.**

*Publication:* Int J Endocrinol 2022 11; 2022: 6078881. e-pub ahead of print 2022/11/18; doi: 10.1155/2022/6078881.

*Authors:* Gosmanova EO, Ayodele O, Chen K, Cook EE, Mu F, Young JA, Rejnmark L.

**CKD Progression and Economic Burden in Individuals With CKD Associated With Type 2 Diabetes.**

*Publication:* Kidney Med 2022 11; 4(11): 100532. e-pub ahead of print 2022/11/08; doi: 10.1016/j.xkme.2022.100532.

*Authors:* Mullins CD, Pantalone KM, Betts KA, Song J, Wu A, Chen Y, Kong SX, Singh R.

**Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States.**

*Publication:* Journal of International Medical Research 2022 05; 50(5): 03000605221098176. doi: 10.1177/03000605221098176.

*Authors:* Kraus SR, Li J, Kristy RM, Lockefer A, Yang H, Zhou M, Walker DR.

**Patient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based Survey.**

*Publication:* Kidney Med 2022 04; 4(4): 100439. doi: <https://doi.org/10.1016/j.xkme.2022.100439>.

*Authors:* Michalopoulos SN, Gauthier-Loiselle M, Aigbogun MS, Serra E, Bungay R, Clynes D, Cloutier M, Kahle E, Guérin A, Farag YMK, Wish JB.

**Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective.**

*Publication:* J Manag Care Spec Pharm 2021 12; 27(12): 1703-1713. e-pub ahead of print 2021/11/25; doi: 10.18553/jmcp.2021.27.12.1703.

*Authors:* Gauthier-Loiselle M, Michalopoulos SN, Cloutier M, Serra E, Bungay R, Szabo E, Guérin A.

**Primary Hyperoxaluria Type 1 Disease Manifestations and Healthcare Utilization: A Multi-Country, Online, Chart Review Study.**

*Publication:* Front Med (Lausanne) 2021 09; 8: 703305. e-pub ahead of print 2021/10/08; doi: 10.3389/fmed.2021.703305.

*Authors:* Wang X, Danese D, Brown T, Baldwin J, Sajeev G, Cook EE, Wang Y, Xu C, Yang H, Moritz ML.

**Regional Variations in Prevalence and Severity of Autosomal Dominant Polycystic Kidney Disease in the United States.**

*Publication:* Curr Med Res Opin 2021 05; 37(7): 1155-1162. e-pub ahead of print 2021/05/11; doi: 10.1080/03007995.2021.1927690.

*Authors:* Willey C, Gauthier-Loiselle M, Cloutier M, Shi S, Maitland J, Stellhorn R, Aigbogun MS.

**Risk of Chronic Kidney Disease and Estimated Glomerular Filtration Rate Decline in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study.**

*Publication:* Advances in Therapy. 2021 04; 38(4): 1876-1888. e-pub ahead of print 2021/03/10; doi: 10.1007/s12325-021-01658-1.

*Authors:* Gosmanova EO, Chen K, Rejnmark L, Mu F, Swallow E, Briggs A, Ayodele O, Sherry N, Ketteler M.

**Consequences of insurance denials among U.S. patients prescribed repository corticotropin injection (Acthar Gel) for nephrotic syndrome.**

*Publication:* Curr Med Res Opin 2021 03; 37(3): 431-441. e-pub ahead of print 2021/01/08; doi: 10.1080/03007995.2021.1872515.

*Authors:* Rice JB, Panaccio MP, White A, Simes M, Billmyer E, Downes N, Niewoehner J, Wan GJ.

**Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage.**

*Publication:* J Med Econ 2021 01; 24(1): 193-201. e-pub ahead of print 2021/01/20; doi: 10.1080/13696998.2021.1877146.

*Authors:* Gagnon-Sanschagrin P, Liang Y, Sanon M, Oberdhan D, Guérin A, Cloutier M.

**The societal economic burden of autosomal dominant polycystic kidney disease in the United States.**

*Publication:* BMC Health Serv Res 2020 02; 20(1): 126. e-pub ahead of print 2020/02/20; doi: 10.1186/s12913-020-4974-4.

*Authors:* Cloutier M, Manceur AM, Guerin A, Aigbogun MS, Oberdhan D, Gauthier-Loiselle M.

**The Economic Burden of Nocturia on the U.S. Health Care System and Society: A National Health and Nutrition Examination Survey Analysis.**

*Publication:* J Manag Care Spec Pharm 2019 09; 0(0): 1-13. doi: 10.18553/jmcp.2019.19191.

*Authors:* Jhaveri J, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Wu E.

**Economic and clinical benefits of early identification of acute kidney injury using a urinary biomarker.**

*Publication:* J Med Econ 2019 07; 1-9. e-pub ahead of print 2019/06/27; doi: 10.1080/13696998.2019.1636053.

*Authors:* Berdugo MA, Kirson NY, Zimmer L, Beyhaghi H, Toback S, Scarpati LM, Stone MN, Dember R, Tseng-Tham J, Wen J, Miller M.

**Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review.**

*Publication:* J Med Econ 2019 02; 1-12. e-pub ahead of print 2019/03/01; doi: 10.1080/13696998.2019.1588738.

*Authors:* Spinowitz B, Pecoits-Filho R, Winkelmayr WC, Pergola PE, Rochette S, Thompson-Leduc P, Lefebvre P, Shafai G, Bozas A, Sanon M, Krassa HB.

**Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.**

*Publication:* Curr Med Res Opin 2017 10; 33(10): 1891-1900. e-pub ahead of print 2017/06/08; doi: 10.1080/03007995.2017.1339674.

*Authors:* Weir MR, Berger JS, Ashton V, Laliberte F, Brown K, Lefebvre P, Schein J.

**The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States.**

*Publication:* Curr Med Res Opin 2017 08; 33(8): 1473-1480. e-pub ahead of print 2017/05/17; doi: 10.1080/03007995.2017.1331211.

*Authors:* Rice JB, White AG, Galebach P, Korenblat KM, Wagh A, Lovelace B, Wan GJ, Jamil K.

**Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.**

*Publication:* J Manag Care Spec Pharm 2016 10; 22(10): 1204-1214. doi: 10.18553/jmcp.2016.22.10.1204.

*Authors:* DerSarkissian M, Xiao Y, Duh MS, Lefebvre P, Swensen AR, Bell CF.

**Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.**

*Publication:* Diabetes Ther 2016 09; 7(3): 439-454. e-pub ahead of print 2016/08/10; doi: 10.1007/s13300-016-0189-4.

*Authors:* Thomas MC, Paldanius PM, Ayyagari R, Ong SH, Groop PH.

**Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database.**

*Publication:* Pharmacoepidemiol Drug Saf 2016 04; 25(4): 413-421. e-pub ahead of print 2016/02/19; doi: 10.1002/pds.3975.

*Authors:* Quinlan SC, Cheng WY, Ishihara L, Irizarry MC, Holick CN, Duh MS.

**Kidney involvement in tuberous sclerosis complex: The impact on healthcare resource use and costs.**

*Publication:* J Med Econ 2015 01; 18(12): 1060-1070. doi: <http://dx.doi.org/10.3111/13696998.2015.10759953>.

*Authors:* Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

**Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder.**

*Publication:* J Med Econ 2014 10; 17(10): 741-750. doi: 10.3111/13696998.2014.941066.

*Authors:* Ivanova JI, Hayes-Larson E, Sorg RA, Birnbaum HG, Berner T.

**Serum urate and incidence of kidney disease among veterans with gout.**

*Publication:* J Rheumatol 2013 07; 40(7): 1166-1172. doi: 10.3899/jrheum.121061.

*Authors:* Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu E, Tawk RH, Liu J, Shi L.

**Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy.**

*Publication:* Epilepsy Behav 2011 10; 22(2): 370-375. doi: 10.1016/j.yebeh.2011.07.020.

*Authors:* Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

**Measuring the health status burden in hemodialysis patients using the SF-36® health survey.**

*Publication:* Qual Life Res 2011 04; 20(3): 383-389. e-pub ahead of print 2010/10/26; doi: 10.1007/s11136-010-9764-8.

*Authors:* Yarlas AS, White MK, Yang M, Saris-Baglana RN, Bech PG, Christensen T.

**Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients.**

*Publication:* J Med Econ 2010 11; 13(4): 673-680. doi: 10.3111/13696998.2010.529032.

*Authors:* Vekeman F, Yameogo ND, Lefebvre P, Bailey RA, McKenzie RS, Piech CT.

**Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.**

*Publication:* Consult Pharm 2010 08; 25(8): 493-500. doi: 10.4140/TCP.n.2010.493.

*Authors:* Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbetta M, Piech CT, Lefebvre P.

**Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.**

*Publication:* Support Care Cancer 2009 06; 17(6): 719-725. doi: 10.1007/s00520-008-0553-7.

*Authors:* Diel IJ, Weide R, Koppler H, Antras L, Smith M, Green J, Wintfeld N, Neary M, Duh MS.

**Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.**

*Publication:* J Manag Care Pharm 2009 05; 15(4): 312-322.

*Authors:* Laliberte F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P.

**Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis.**

*Publication:* Clin J Am Soc Nephrol 2009 04; 4(4): 755-762. doi: 10.2215/CJN.02730608.

*Authors:* Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P.

**The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective.**

*Publication:* Dis Manag 2008 02; 11(1): 49-58. doi: 10.1089/dis.2008.111715.

*Authors:* Moyneur E, Bookhart BK, Mody SH, Fournier AA, Mallett D, Duh MS.

**Medical and work loss burden of pre-dialysis chronic kidney disease and related anemia: An employer's perspective.**

*Publication:* Journal of Health & Productivity 2007 10: 309.

*Authors:* Moyneur E BB, Mody SH, Founier A, Mallet D, Duh MS.

**The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease.**

*Publication:* Dis Manag 2007 02; 10(1): 37-45. doi: 10.1089/dis.2006.626.

*Authors:* Lefebvre P, Duh MS, Mody SH, Bookhart B, Piech CT.

**Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.**

*Publication:* Drugs Aging 2006 12; 23(12): 969-976.

*Authors:* Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT.

**Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease.**

*Publication:* J Am Soc Nephrol 2006 12; 17(12): 3497-3502. doi: 10.1681/ASN.2006030289.

*Authors:* Lefebvre P, Duh MS, Buteau S, Bookhart B, Mody SH.

**The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.**

*Publication:* Current Medical Research & Opinion 2006 12; 22(12): 2329-2336. doi: 10.1185/030079906X154024.

*Authors:* Cremieux PY, Van Audenrode M, Lefebvre P.

**Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.**

*Publication:* Current Medical Research & Opinion 2006 10; 22(10): 1929-1937. doi: 10.1185/030079906X132541.

*Authors:* Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY.

**Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.**

*Publication:* Clin Ther 2006 09; 28(9): 1443-1450. doi: 10.1016/j.clinthera.2006.09.020.

*Authors:* Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C.

**A retrospective claims database analysis to assess patterns of interstitial cystitis diagnosis.**

*Publication:* Current Medical Research & Opinion 2006 03; 22(3): 495-500. doi: 10.1185/030079906X80431.

*Authors:* Wu EQ, Birnbaum H, Kang YJ, Parece A, Mallett D, Taitel H, Evans RJ.

**Comorbidity contributes to high treatment cost of interstitial cystitis.**

*Publication:* PharmacoEconomics & Outcomes News 2006 02; (497): 6.

*Authors:* Wu E.



**Interstitial Cystitis: Cost, treatment and co-morbidities in an employed population.**

*Publication:* PharmacoEconomics 2006 02; 24(1): 55-65.

*Authors:* Wu EQ, Birnbaum H, Mareva M, Parece A, Huang Z, Mallett D, Taitel H.

**Employees with overactive bladder: work loss burden.**

*Publication:* Journal of Occupational Environmental Medicine 2005 05; 47(5): 439-446.

*Authors:* Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D.

**Interstitial Cystitis Costs, Treatment and Comorbidities in an Employed Population.**

*Publication:* Value in Health 2005 8(3): 415-416. doi: 10.1016/S1098-3015(10)63135-X.

*Authors:* Wu EQ, Birnbaum H, Parece A, Kang YJ, Mareva MN, Taitel H.

**Cost of stress urinary incontinence: a claims data analysis.**

*Publication:* PharmacoEconomics 2004 01; 22(2): 95-105.

*Authors:* Birnbaum HG, Leong SA, Oster EF, Kinchen K, Sun P.

**Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.**

*Publication:* Womens Health Issues 2003 11; 13(6): 204-213.

*Authors:* Birnbaum H, Leong S, Kabra A.

## Abstracts

**The multifaceted burden experienced by caregivers of individuals with Bardet-Biedl syndrome in Canada: findings from the CARE-BBS study.**

Whistler, BC, Canada May 14 - 17, 2023.

*Authors:* Forsythe E, Mallya UG, Yang M, Huber C, Cala M, Greatsinger A, Hagopian E, Pomeroy J, Haqq AM.

**A USRDS Retrospective Cohort Study: Epidemiology, Treatment Modalities, and Burden of End-Stage Kidney Disease Attributed to Focal Segmental Glomerulosclerosis (FSGS).**

*Abstract:* ISPOR 2022, Washington, D.C. May 15-18, 2022.

*Authors:* Bensink ME, Goldschmidt D, Taiji R, Zhou J, Wang K, Lieblich R, Bunke M.

**A USRDS Retrospective Cohort Study: Epidemiology, Treatment Modalities, and Burden of End-Stage Kidney Disease Attributed to Immunoglobulin A Nephropathy.**

*Abstract:* ISPOR 2022, Washington D.C. May 15-18, 2022.

*Authors:* Bensink M, E., Goldschmidt D, Taiji R, Zhou J, Wang K, Lieblich R, Bunke M.

**Disease manifestations, treatment, and healthcare resource use (HRU) in primary hyperoxaluria type 1 (PH1): An international online chart review study.**

*Abstract:* Kidney Week, Dec 22, 2020.

*Authors:* Wang X., Danese D.S., Brown T.A., Baldwin J., Sajeev G., Cook E., Wang Y., Xu C., Yang H., Moritz M.L.

**Reported caregiver burden in CKD with and without anemia: A US-based survey.**

*Abstract:* Kidney Week, United States Dec 2020.

*Authors:* Michalopoulos E.N., Gauthier-Loiselle M., Sanon M., Serra E., Bungay R., Clynes D., Cloutier M., Kahle E., Guerin A., Farag Y.M., Wish J.B.

**Reported Caregiver Burden in Chronic Kidney Disease With and Without Anemia: A US-Based Survey.**

*Abstract:* American Society of Nephrology Kidney Week 2020 Reimagined, October 22-25, 2020.

*Authors:* Michalopoulos EN, Gauthier-Loiselle M, Sanon M, Serra E, Bungay R, Clynes D, Cloutier M, Kahle E, Guérin A, Farag Y, Wish JB.

**Geographic Distribution in Autosomal Dominant Polycystic Kidney Disease (ADPKD): a US Population-Based Study.**

*Abstract:* National Kidney Foundation (NKF) Spring Clinical Meetings, New Orleans, LA March 25-29, 2020.

*Authors:* Willey C, Sanon M, Cloutier M, Shi S, Maitland J, Stellhorn R, Gauthier-Loiselle M.

**Regional Variation in Severity of Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States (US).**

*Abstract:* National Kidney Foundation (NKF) Spring Clinical Meetings, New Orleans, LA March 25-29, 2020.

*Authors:* Willey C, Gauthier-Loiselle M, Cloutier M, Shi S, Maitland J, Stellhorn R, Sanon M.

**Disease progression among patients who receive available bladder preservation therapies after failure of BCG therapy in the SEER-Medicare data.**

*Abstract:* 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), San Francisco, CA February 13-15, 2020.

*Authors:* Kamat AM, Georgieva MV, Song J, Bocharova I, Qian K, Guo A, Yang M.

**Healthcare resource utilization and associated costs of cytomegalovirus management among solid organ transplant recipients.**

*Abstract:* 2019 American Transplant Congress, ATC 2019, Boston, MA Jun 1-5, 2019.

*Authors:* Cheng WY, Thompson-Leduc P, Cheung H, Avery R, Bo T, Chavan S, Duh M, Hirji I.

**Clinical Heterogeneity among First-Line Sunitinib Patients with Metastatic Renal Cell Carcinoma (mRCC) Categorized as Intermediate Risk (IR) Group According to the International mRCC Database Consortium (IMDC) Risk Model.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Huynh L, Wells JC, Graham J, Steinharter J, McGregor B, Donskov F, Bjarnason GA, Vaishampayan U, Hansen A, Iafolla M, Zanotti G, Chang R, Cheng WY, Duh MS, Heng DYC.

**Prevalence and Factors Associated with Undiagnosed Chronic Kidney Disease in Diabetes Mellitus.**

*Abstract:* NKF 2019 Spring Clinical Meetings, Boston, MA May 8-12, 2019.

*Authors:* Bakris G, Coresh J, Vassalotti J, Weir M, Pilon D, Bailey R, Blais J, Durkin M.

**Societal Burden of Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States: Beyond Healthcare Costs.**

*Abstract:* ISPOR 24th Annual International Meeting, New Orleans, LA May 18-22, 2019.

*Authors:* Cloutier M, Manceur AM, Guerin A, Sanon MA, Oberdhan D, Gauthier-Loiselle M.

**Societal Burden of Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States: Beyond Healthcare Costs.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Cloutier M, Manceur AM, Guerin A, Sanon M, Oberdhan D, Gauthier-Loiselle M.

**Economic and humanistic burden of dialysisdependent patients with chronic kidney diseaserelated anemia: A systematic review.**

*Abstract:* 55th Annual Congress of the European Renal Association-European Dialysis and Transplant Association, Copenhagen, Denmark May 24-27, 2018.

*Authors:* Spinowitz B, Pecoits-Filho R, Winkelmayer W, Rochette S, Thompson-Leduc P, Lefebvre P, Bozas A, Krasa H.

**Development of a predictive model for hyperkalemia.**

*Abstract:* Kidney Week, Oct, 2017.

*Authors:* Betts K., Woolley J.M., Mu F., Bocharova I., Bensimon A.G., Wu E.

**Economic burden of hyperkalemia in the Medicare system.**

*Abstract:* Kidney Week, United States Oct. 2017.

*Authors:* Betts K., Woolley J.M., Mu F., Xiang C.Q., Dua A., Wu E.

**Indirect comparison of sodium zirconium cyclosilicate versus patiromer in the treatment of hyperkalemia through 48 hours.**

*Abstract:* Kidney Week, Oct. 2017.

*Authors:* Betts K., Woolley J.M., Song Y., Gao W., Wu E.

**Post-discharge economic burden of hyperkalemia-related hospitalizations.**

*Abstract:* Kidney Week, Oct. 2017.

*Authors:* Betts K., Woolley J.M., Mu F., Kelkar S.S., Xiang C.Q., Wang Y., Wu E.

**Prevalence of Hyperkalemia in Medicare Patients.**

*Abstract:* Kidney Week, United States Oct. 2017.

*Authors:* Betts K, Woolley J, Mu F, Tang W, Wang Y, Wu E.

**The economic burden of hyperkalemia among patients with chronic kidney disease and/or heart failure.**

*Abstract:* AMCP Nexus 2016, Baltimore, MD Oct 3-6, 2016.

*Authors:* Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Pham H, Hollenack K, Singhania A, Wu E.

**Resource utilization of adult patients with sporadic angiomyolipoma in the Netherlands.**

*Abstract:* 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland Aug 25-28, 2016.

*Authors:* Vekeman F, Magestro M, Karner P, Fortier J, Duh MS, Zonnenberg BA.

**Natural history for adult patients with sporadic angiomyolipoma in the Netherlands.**

*Abstract:* 53rd ERA-EDTA Congress, Vienna, Austria May 21-24, 2016.

*Authors:* Vekeman F, Magestro M, Karner P, Fortier J, Duh MS, Zonnenberg BA.

**Kidney involvement in tuberous sclerosis complex: The impact on health care resource use and costs in The Netherlands.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Zonnenberg BA.

**The healthcare cost impacts of switching antimuscarinic agents among patients with overactive bladder in a privately insured population.**

*Abstract:* AUGS/IUGA Scientific Meeting, Washington, DC Jul 22-26, 2014.

*Authors:* Ivanova J, Hayes-Larson E, Sorg R, Birnbaum H.

**Health care costs among patients who continue therapy or switch antimuscarinic agents for overactive bladder.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Ivanova J, Hayes-Larson E, Sorg RA, Birnbaum HG, Fitzmartin J, Berner T.

**Healthcare costs among patients who continue therapy or switch antimuscarinic agents for overactive bladder.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Ivanova JI, Hayes-Larson E, Sorg RA, Birnbaum HG, Berner G.

**Kidney dysfunction and healthcare resource utilization in tuberous sclerosis complex patients in the Netherlands.**

*Abstract:* 51st ERA-EDTA Congress, Amsterdam, Netherlands May 31-Jun 3, 2014.

*Authors:* Magestro M, Vekeman F, Nichols T, Karner P, Duh MS, Srivastava B, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

**Development and validation of a claims-based algorithm to identify urinary retention in patients receiving antiepileptic drugs.**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Duh MS, Ishihara L, Cheng W, Quinlan SC, Zhao Y, Irizarry M.

**Development and validation of a new chronic kidney disease risk equation: The role of pulse pressure.**

*Abstract:* European Society of Cardiology, Amsterdam, Netherlands Aug 31 - Sep 4, 2013.

*Authors:* Ayyagari R, Vekeman F, Faust E, Ong S, Trahey A, Lefebvre P, Machnicki G, Duh M.

**Vitala™ Continenace Control Device vs. Traditional Pouch System: A Comparison of Health-Related Quality-of-Life.**

*Abstract:* 12th European Council of Enterostomal Therapy Congress, Paris, France June 23-26, 2013.

*Authors:* Yan S, Warusavitarne J, Yang M, van den Broek N, Wu EQ, Thomason D, Hoch J.

**Impact of mirabegron treatment and symptom severity on work productivity and activity impairment in patients with overactive bladder.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* De G, Yang H, Runken M, Yan Y, Kelkar S, Bui C, Xie J, Wu E.

**Cost-effectiveness analysis of mirabegron versus tolterodine extended release in the treatment of patients with overactive bladder in the United States.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Xie J, Zhou ZY, Bui CN, Yan Y, De G, Runken MC, Wu EQ.

**Uncontrolled serum uric acid is associated with an increased risk of developing renal disease in veterans with gout.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL Nov 4-9, 2011.

*Authors:* Krishnan E, Sharma H, Pandya BJ, Marynchenko M, Yu A, Wu E, Liu J.

**Dosing pattern and cost comparison of epoetin alfa and darbepoetin alfa in chronic kidney disease and chemotherapy-induced anemia inpatients.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Lafeuille MH, Bailey RA, Senbetta M, McKenzie RS, Lefebvre P.

**Assessment of recent erythropoiesis-stimulating agent guidelines changes on dosing patterns in chronic kidney disease patients not on dialysis.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19 2010.

*Authors:* Lafeuille MH, Bailey RA, Laliberte F, Senbetta M, Vekeman F, McKenzie RS, Blacksmith A, Lefebvre P.

**Erythropoiesis-stimulating agent dosing and hemoglobin trends over time in chronic kidney disease patients not on dialysis.**

*Abstract:* ISPOR 15th Annual International Meeting Atlanta, GA May 15-19, 2010.

*Authors:* Lafeuille MH, Bailey RA, Laliberte F, Senbetta M, Vekeman F, McKenzie RS, Dea K, Lefebvre P.

**Seven year trends of pharmacy benefit erythropoiesisstimulating agent utilization and cost considerations of chronic kidney disease patients not on dialysis.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Vekeman F, Bailey RA, Laliberte F, Senbetta M, McKenzie RS, Lefebvre P.

# Respiratory

## Journal Articles

**Corticosteroid Use and Adherence in Patients Treated with Acthar Gel for Advanced Sarcoidosis.**

*Publication:* Adv Ther 2023 09. doi: 10.1007/s12325-023-02630-x.

*Authors:* Hayes K, Niewoehner J, Rice JB, Downes N, Hagopian E, Ma I, Wan GJ.

**Prioritising health: cost and tuberculosis elimination in high-burden, resource-limited settings.**

*Publication:* The Lancet Global Health 2023 08; 11(8): e1142-e1143. doi: 10.1016/S2214-109X(23)00301-7.

*Authors:* Safdar N, Malik AA.

**Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.**

*Publication:* J Med Econ 2023 07: 1-13. e-pub ahead of print 2023/07/13; doi: 10.1080/13696998.2023.2236867.

*Authors:* Chung Y, Maselli DJ, Mu F, Cook EE, Yang D, Young JA, Betts KA, Genofre E, Carstens D.

**Real-world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis (CRS) in the US: Impact of comorbidity and sinus surgery.**

*Publication:* Int Forum Allergy Rhinol 2023 06. e-pub ahead of print 2023/06/27; doi: 10.1002/alr.23220.

*Authors:* Silver J, Deb A, Laliberté F, Gao C, Bhattacharyya N.

**Respiratory Syncytial Virus-Related Complications and Healthcare Costs Among a Medicare-Insured Population in the United States.**

*Publication:* Open Forum Infect Dis 2023 05; 10(5): ofad203. e-pub ahead of print 2023/05/22; doi: 10.1093/ofid/ofad203.

*Authors:* DeMartino JK, Lafeuille MH, Emond B, Rossi C, Wang J, Liu S, Lefebvre P, Krishnarajah G.

**Incidence of non-invasive all-cause pneumonia in children in the United States before and after the introduction of pneumococcal conjugate vaccines: a retrospective claims database analysis.**

*Publication:* Pneumonia (Nathan) 2023 04; 15(1): 8. e-pub ahead of print 2023/04/05; doi: 10.1186/s41479-023-00109-5.

*Authors:* Hu T, Sarpong EM, Song Y, Done N, Liu Q, Lemus-Wirtz E, Signorovitch J, Mohanty S, Weiss T.

**Real-world experience of pediatric patients treated with Peanut (Arachis hypogaea) Allergen Powder-dnfp.**

*Publication:* Ann Allergy Asthma Immunol 2023 02. e-pub ahead of print 2023/02/05; doi: 10.1016/j.anai.2023.01.027.

*Authors:* Portnoy J, Shroba J, Tilles S, Romdhani H, Donelson SM, Latremouille-Viau D, Bungay R, Chen K, McCann W.

**Elucidating the Real-World Burden of Chronic Rhinosinusitis With Nasal Polyps in Patients in the USA.**

*Publication:* OTO Open 2022 10; 6(4): 2473974x221128930. e-pub ahead of print 2022/10/18; doi: 10.1177/2473974x221128930.

*Authors:* Benson VS, Germain G, Chan RH, Sousa AR, Yang S, Silver J, Duh MS, Laliberté F, Chang R, Han JK.

**Patient Preferences for Attributes of Biologic Treatments in Moderate to Severe Asthma: A Discrete Choice Experiment Study.**

*Publication:* Patient Preference and Adherence 2022 09; 16: 2649-2661.

*Authors:* Yang M, Chao J, Fillbrunn M, Mallya UG, Wang M-J, Franke L, Cohn L, Kamat S.

**Profiling Disease and Economic Burden in CRSwNP Using Machine Learning.**

*Publication:* J Asthma Allergy 2022 09; 15: 1401-1412. e-pub ahead of print 2022/10/11; doi: 10.2147/jaa.S378469.

*Authors:* Bhattacharyya N, Silver J, Bogart M, Kponee-Shovein K, Cheng WY, Cheng M, Cheung HC, Duh MS, Hahn B.

**Symptom control in patients with asthma using inhaled corticosteroids/long-acting  $\beta(2)$ -agonists (fluticasone furoate/vilanterol or budesonide/formoterol) in the US: a retrospective matched cohort study.**

*Publication:* J Asthma 2022 09; 59(9): 1805-1818. e-pub ahead of print 2021/08/11; doi: 10.1080/02770903.2021.1963767.

*Authors:* Averell CM, Laliberté F, Germain G, Duh MS, Lima R, Mahendran M, Slade DJ.

**Long-term burden of respiratory complications associated with extreme prematurity: An analysis of US Medicaid claims.**

*Publication:* Pediatrics & Neonatology 2022 07. doi: 10.1016/j.pedneo.2022.05.007.

*Authors:* Mowitz ME, Gao W, Sipsma H, Zuckerman P, Wong H, Ayyagari R, Sarda SP, Siffel C.

**Adherence and Persistence to Single-Inhaler Versus Multiple-Inhaler Triple Therapy for Asthma Management.**

*Publication:* The Journal of Allergy and Clinical Immunology: In Practice 2022 06. doi: 10.1016/j.jaip.2022.06.010.

*Authors:* Busse WW, Abbott CB, Germain G, Laliberté F, MacKnight SD, Jung Y, Duh MS, Averell CM.

**Impact of choice of inhalers for asthma care on global carbon footprint and societal costs: a long-term economic evaluation.**

*Publication:* J Med Econ 2022 06; 1-34. e-pub ahead of print 2022/06/11; doi: 10.1080/13696998.2022.2088196.

*Authors:* Kponee-Shovein K, Marvel J, Ishikawa R, Choubey A, Kaur H, Ngom K, Fakih I, Swartz N, Schatzki T, Signorovitch J.

**Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databases.**

*Publication:* J Manag Care Spec Pharm 2022 05; 1-13. e-pub ahead of print 2022/05/04; doi: 10.18553/jmcp.2022.21459.

*Authors:* Mesa-Frias M, Rossi C, Emond B, Bookhart B, Anderson D, Drummond S, Wang J, Lefebvre P, Lamerato LE, Lafeuille MH.

**Carbon footprint and associated costs of asthma exacerbation care among UK adults.**

*Publication:* J Med Econ 2022 04; 1-23. e-pub ahead of print 2022/04/14; doi: 10.1080/13696998.2022.2063603.

*Authors:* Kponee-Shovein K, Marvel J, Ishikawa R, Choubey A, Kaur H, Thokala P, Ngom K, Fakih I, Schatzki T, Signorovitch J.

**Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation.**

*Publication:* Int J Chron Obstruct Pulmon Dis 2022 03; 17: 491-504. e-pub ahead of print 2022/03/15; doi: 10.2147/copd.S337668.

*Authors:* Mannino D, Bogart M, Germain G, Huang SP, Ismaila AS, Laliberté F, Jung Y, MacKnight SD, Stiegler MA, Duh MS.

**Real-world effectiveness of benralizumab: results from the ZEPHYR 1 Study.**

*Publication:* Ann Allergy Asthma Immunol 2022 03. e-pub ahead of print 2022/03/06; doi: 10.1016/j.anai.2022.02.017.

*Authors:* Chung Y, Katial R, Mu F, Cook EE, Young J, Yang D, Betts KA, Carstens DD.

**Real-world Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Newly Treated Korean Patients With Asthma: A Retrospective Cohort Study.**

*Publication:* Allergy Asthma Immunol Res 2022 03; 14(2): 220-232. e-pub ahead of print 2022/03/08; doi: 10.4168/aair.2022.14.2.220.

*Authors:* Choi NK, Shantakumar S, Kim MS, Lee CH, Cheng WY, Bobbili P, Yang BR, Lee J, Hinds D, Duh MS, Korves C, Park HW.

**Patient Characteristics and Treatment Patterns of Elderly Asthma Patients Initiating FF/UMEC/VI.**

*Publication:* Journal of Allergy and Clinical Immunology 2022 02; 149(2): AB91. doi: 10.1016/j.jaci.2021.12.323.

*Authors:* Germain G, Settipane R, Abbott C, Averell C, Bogart M, Mahendran M, Laliberté F, Hiltz A, Duh M.

**Impact of adherence to treatment with inhaled corticosteroids/long-acting  $\beta$ -agonists on asthma outcomes in the United States.**

*Publication:* Ther Adv Respir Dis 2022 01; 16: 17534666221116997. e-pub ahead of print 2022/08/30; doi: 10.1177/17534666221116997.

*Authors:* Averell CM, Laliberté F, Germain G, Duh MS, Rousculp MD, MacKnight SD, Slade DJ.

**Development and validation of a claims-based model to identify patients at risk of chronic thromboembolic pulmonary hypertension following acute pulmonary embolism.**

*Publication:* Curr Med Res Opin 2021 09; 37(9): 1483-1491. e-pub ahead of print 2021/06/25; doi: 10.1080/03007995.2021.1947215.

*Authors:* Kanwar MK, Cole M, Gauthier-Loiselle M, Manceur AM, Tsang Y, Lefebvre P, Panjabi S, Benza RL.

**Disease burden and treatment adherence among children and adolescent patients with asthma.**

*Publication:* J Asthma 2021 08: 1-10. e-pub ahead of print 2021/08/05; doi: 10.1080/02770903.2021.1955377.

*Authors:* Averell CM, Laliberté F, Germain G, Slade DJ, Duh MS, Spahn J.

**Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.**

*Publication:* BMC Pulm Med 2021 08; 21(1): 253. e-pub ahead of print 2021/08/02; doi: 10.1186/s12890-021-01612-5.

*Authors:* Slade D, Ray R, Moretz C, Germain G, Laliberté F, Shen Q, Duh MS, Mahendran M, Hahn B.

**Health-care resource utilization associated with peanut allergy management under allergen avoidance among commercially insured individuals.**

*Publication:* Allergy Asthma Proc 2021 07; 42(4): 333-342. e-pub ahead of print 2021/07/01; doi: 10.2500/aap.2021.42.210047.

*Authors:* Meadows JA, Yu S, Hass SL, Guerin A, Latremouille-Viau D, Tilles SA.

**Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice.**

*Publication:* Chest 2021 05; 159(5): 1734-1746. e-pub ahead of print 2020/12/18; doi: 10.1016/j.chest.2020.11.060.

*Authors:* Wechsler ME, Peters SP, Hill TD, Ariely R, DePietro MR, Driessen MT, Terasawa EL, Thomason DR, Panettieri RA, Jr.

**Decreased antibiotic exposure using a procalcitonin protocol for respiratory infections and sepsis in US community hospitals (ProCommunity).**

*Publication:* Curr Med Res Opin 2021 05; 37(5): 727-733. e-pub ahead of print 2021/02/23; doi: 10.1080/03007995.2021.1893675.

*Authors:* DeSear KE, Thompson-Leduc P, Van Schooneveld TC, Kirson N, Chritton JJ, Ie S, Cheung HC, Ou S, Zimmer L, Schuetz P.

**Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States.**

*Publication:* J Manag Care Spec Pharm 2021 04; 27(4): 516-527. e-pub ahead of print 2021/01/21; doi: 10.18553/jmcp.2021.20389.

*Authors:* Blaiss MS, Meadows JA, Yu S, Robison DR, Hass SL, Norrett KE, Guerin A, Latremouille-Viau D, Tilles SA.

**Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities.**

*Publication:* Int J Chron Obstruct Pulmon Dis 2021 04; 16: 1149-1161. e-pub ahead of print 2021/04/30; doi: 10.2147/COPD.S298032.

*Authors:* Kalhan R, Slade D, Ray R, Moretz C, Germain G, Laliberte F, Shen Q, Duh MS, MacKnight SD, Hahn B.

**Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice.**

*Publication:* Chest 2020 12. e-pub ahead of print 2020/12/18; doi: 10.1016/j.chest.2020.11.060.

*Authors:* Wechsler ME, Peters SP, Hill TD, Ariely R, DePietro MR, Driessen MT, Terasawa EL, Thomason DR, Panettieri RA, Jr.

**Cost-effectiveness analysis of double low-dose budesonide and low-dose budesonide plus montelukast among pediatric patients with persistent asthma receiving Step 3 treatment in China.**

*Publication:* J Med Econ 2020 12; 23(12): 1630-1639. e-pub ahead of print 2020/09/30; doi: 10.1080/13696998.2020.1830410.

*Authors:* Wang X, Fang H, Shen K, Liu T, Xie J, Liu Y, Wu P, Chen Y, Zhong J, Wu E, Zhou W, Wu B.

**The cost-effectiveness of low-dose budesonide as a Step 2 treatment for pediatric asthma in China.**

*Publication:* J Comp Eff Res 2020 11. e-pub ahead of print 2020/11/07; doi: 10.2217/ce-2020-0102.

*Authors:* Wang X, Fang H, Shen K, Liu T, Xie J, Liu Y, Zhong J, Wu E, Zhou W, Wu B.

**Prevalence of chronic respiratory morbidity, length of stay, inpatient readmissions, and costs among extremely preterm infants with bronchopulmonary dysplasia.**

*Publication:* Expert Rev Pharmacoecon Outcomes Res 2020 11. e-pub ahead of print 2020/11/26; doi: 10.1080/14737167.2021.1848554.

*Authors:* Mowitz ME, Mangili A, Han L, Ayyagari R, Gao W, Wang J, Zhao J, Sarda SP.

**ProCommunity: procalcitonin use in real-world U.S. community hospital settings.**

*Publication:* Current Medical Research and Opinion 2020 06: 1-1. doi: 10.1080/03007995.2020.1793748.

*Authors:* DeSear KE, Thompson-Leduc P, Kirson N, Chritton JJ, Ie S, Van Schooneveld TC, Cheung HC, Ou S, Schuetz P.

**Health Care Burden of Bronchopulmonary Dysplasia Among Extremely Preterm Infants.**

*Publication:* Front Pediatr 2019 12; 7: 510. e-pub ahead of print 2020/01/11; doi: 10.3389/fped.2019.00510.

*Authors:* Mowitz ME, Ayyagari R, Gao W, Zhao J, Mangili A, Sarda SP.

**Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population.**

*Publication:* Int J Chron Obstruct Pulmon Dis 2019 12; 14: 343-352. e-pub ahead of print 2019/03/14; doi: 10.2147/COPD.S184653.

*Authors:* Bogart M, Stanford RH, Laliberte F, Germain G, Wu JW, Duh MS.

**Characterizing Real-World Use Of Tiotropium In Asthma In The USA.**

*Publication:* J Asthma Allergy 2019 10; 12: 309-321. e-pub ahead of print 2019/10/22; doi: 10.2147/jaa.S216932.

*Authors:* Averell CM, Laliberte F, Duh MS, Wu JW, Germain G, Faison S.

**Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs.**

*Publication:* J Asthma 2019 10: 1-10. e-pub ahead of print 2019/10/15; doi: 10.1080/02770903.2019.1663429.

*Authors:* Averell CM, Stanford RH, Laliberte F, Wu JW, Germain G, Duh MS.

**Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.**

*Publication:* Clin Ther 2019 10; 41(10): 1956-1971. e-pub ahead of print 2019/09/30; doi: 10.1016/j.clinthera.2019.07.021.

*Authors:* Kavati A, Zhdanova M, Ortiz B, Lecocq J, Schiffman B, Pilon D, Ho H, Lefebvre P, Stone B.



**A retrospective claims analysis of hospital length of stay, readmissions, and costs through 1 year corrected age among extremely preterm infants with and without chronic respiratory morbidity and bronchopulmonary dysplasia.**

*Publication:* Pediatrics 2019 07; 144(2 MeetingAbstract): 606-606. doi: 10.1542/peds.144.2\_MeetingAbstract.606.

*Authors:* Mowitz M, Sarda SP, Mangili A, Han L, Ayyagari R, Gao W, Wang J, Zhao J.

**Clinical burden of asynchrony in patients with asthma when using metered-dose inhalers for control.**

*Publication:* Allergy and Asthma Proceedings 2019 01; 40(1): 21-31. doi: <http://dx.doi.org/10.2500/aap.2019.40.4192>.

*Authors:* Ferro TJ, Sundaresan AS, Pitcavage JM, Ivanova JI, Schmerold L, Ariely R, Parikh R, Cheng WY.

**Health characteristics of patients with asthma, COPD and asthma-COPD overlap in the NHANES database.**

*Publication:* Int J Chron Obstruct Pulmon Dis 2018 09; 13: 2859-2868. e-pub ahead of print 2018/09/27; doi: 10.2147/COPD.S167379.

*Authors:* Llanos JP, Ortega H, Germain G, Duh MS, Lafeuille MH, Tiggelaar S, Bell CF, Hahn B.

**Burden of disease associated with a COPD eosinophilic phenotype.**

*Publication:* Int J Chron Obstruct Pulmon Dis 2018 08; 13: 2425-2433. e-pub ahead of print 2018/08/28; doi: 10.2147/COPD.S170995.

*Authors:* Ortega H, Llanos JP, Lafeuille MH, Germain G, Duh MS, Bell CF, Sama SR, Hahn B.

**Effects of Systemic Corticosteroids on Blood Eosinophil Counts in Asthma: Real-World Data.**

*Publication:* J Asthma 2018 08: 1-26. e-pub ahead of print 2018/08/22; doi: 10.1080/02770903.2018.1502301.

*Authors:* Ortega H, Llanos JP, Lafeuille MH, Duh MS, Germain G, Lejeune D, Sama S, Bell C, Hahn B.

**Procalcitonin guidance in patients with lower respiratory tract infections: a systematic review and meta-analysis.**

*Publication:* Clin Chem Lab Med 2018 07; 56(8): 1200-1209. e-pub ahead of print 2018/05/02; doi: 10.1515/cclm-2018-0126.

*Authors:* Hey J, Thompson-Leduc P, Kirson NY, Zimmer L, Wilkins D, Rice B, Iankova I, Krause A, Schonfeld SA, DeBrase CR, Bozzette S, Schuetz P.

**Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab.**

*Publication:* Allergy and Rhinology 2018 04; 9(no pagination). doi: <http://dx.doi.org/10.1177/2152656718763387>.

*Authors:* Kavati A, Pilon D, Ortiz B, Paknis B, Vegesna A, Schiffman B, Zhdanava M, Lefebvre P, Stone B.

**Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma.**

*Publication:* Allergy Asthma Proc 2018 03; 39(2): 127-135. e-pub ahead of print 2017/12/07; doi: 10.2500/aap.2018.39.4111.

*Authors:* Pilon D, Kavati A, Ortiz B, Paknis B, Vegesna A, Schiffman B, Zhdanava M, Lefebvre P, Stone B.

**Claims-based risk model for first severe COPD exacerbation.**

*Publication:* Am J Manag Care 2018 02; 24(2): e45-e53. e-pub ahead of print 2018/02/21.

*Authors:* Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M, Merrigan JFP, Duh MS.

**A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.**

*Publication:* Int J Chron Obstruct Pulmon Dis 2017 06; 12: 1825-1836. e-pub ahead of print 2017/07/08; doi: 10.2147/COPD.S129007.

*Authors:* Mapel D, Laliberte F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J.

**Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized beta2-Agonists.**

*Publication:* Drugs Real World Outcomes 2017 03; 4(1): 33-41. e-pub ahead of print 2016/11/20; doi: 10.1007/s40801-016-0097-y.

*Authors:* Bollu V, Guerin A, Gauthier G, Hiscock R, Wu EQ.

**Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.**

*Publication:* Hosp Pract 2017 02; 45(1): 1-8. e-pub ahead of print 2017/01/10; doi: 10.1080/21548331.2017.1279012.

*Authors:* Llop CJ, Tuttle E, Tillotson GS, LaPlante K, File TM, Jr.

**Comparative efficacy of long-acting beta2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.**

*Publication:* Int J Chron Obstruct Pulmon Dis 2017 02; 12: 367-381. e-pub ahead of print 2017/02/09; doi: 10.2147/copd.s119908.

*Authors:* Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, Gruenberger JB, Signorovitch JE.

**Burden of systemic glucocorticoid-related complications in severe asthma.**

*Publication:* Current Medical Research & Opinion 2017 01; 33(1): 57-65. e-pub ahead of print 2016/09/15; doi: 10.1080/03007995.2016.1233101.

*Authors:* Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA.

**Patient Characteristics, Clinical Outcomes and Healthcare Resource Utilization Among IPF Patients Stratified by Lung Function at Diagnosis.**

*Publication:* American Journal of Respiratory and Critical Care Medicine 2017: A1133-A1133. doi: 10.1164/ajrccm-conference.2017.195.1\_MeetingAbstracts.A1133.

*Authors:* Nathan S, Macaulay D, Garcia Horton V, Terasawa E, Yu Y.

**Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma.**

*Publication:* J Manag Care Spec Pharm 2016 07; 22(7): 833-847. doi: 10.18553/jmcp.2016.22.7.833.

*Authors:* Dalal AA, Duh MS, Gozalo L, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Lefebvre P.

**Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data.**

*Publication:* Ann Am Thorac Soc 2016 07; 13(7): 1067-1075. e-pub ahead of print 2016/04/14; doi: 10.1513/AnnalsATS.201508-493OC.

*Authors:* Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Vekeman F, Gauthier-Loiselle M, Duh MS, Merrigan JF, Schatz M.

**Acute and chronic systemic corticosteroid-related complications in patients with severe asthma.**

*Publication:* J Allergy Clin Immunol 2015 12; 136(6): 1488-1495. e-pub ahead of print 2015/09/29; doi: 10.1016/j.jaci.2015.07.046.

*Authors:* Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA.

**Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization.**

*Publication:* Respir Med 2015 12; 109(12): 1582-1588. doi: 10.1016/j.rmed.2015.11.001.

*Authors:* Yu YF, Macaulay DS, Reichmann WM, Wu EQ, Nathan SD.

**Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.**

*Publication:* BMC Pulm Med 2015 12; 15(167): 167. doi: 10.1186/s12890-015-0161-5.

*Authors:* Reichmann WM, Yu YF, Macaulay D, Wu EQ, Nathan SD.

**Clinical and Economic Burden of Pulmonary Exacerbations In Patients with Cystic Fibrosis Who are Homozygous for the F508del Mutation.**

*Publication:* International Society for Pharmacoeconomics and Outcomes Research 2015 11; 18(7): A658-659. e-pub ahead of print 2015/11/05; doi: 10.1016/j.jval.2015.09.2386.

*Authors:* O'Sullivan AK, Signorovitch JE, Fang A, Wagener J, Hodgkins P.

**Impact of a telehealth and care management program for patients with chronic obstructive pulmonary disease.**

*Publication:* Ann Am Thorac Soc 2015 03; 12(3): 323-331. doi: 10.1513/AnnalsATS.201501-042OC.

*Authors:* Au DH, Macaulay DS, Jarvis JL, Desai US, Birnbaum HG.

**Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.**

*Publication:* Antimicrob Agents Chemother 2015 02; 59(2): 1119-1126. doi: 10.1128/AAC.03643-14.

*Authors:* Lodise TP, Anzueto AR, Weber DJ, Shorr AF, Yang M, Smith A, Zhao Q, Huang X, File TM.

**Pulmonary medication adherence and health-care use in cystic fibrosis.**

*Publication:* Chest 2014 07; 146(1): 142-151. doi: 10.1378/chest.13-1926.

*Authors:* Quittner AL, Zhang J, Marynchenko M, Chopra PA, Signorovitch J, Yushkina Y, Riekert KA.

**Burden of illness of patients with allergic asthma versus non-allergic asthma.**

*Publication:* Journal of Asthma 2013 10; 50(8): 900-907. doi: 10.3109/02770903.2013.810244.

*Authors:* Lafeuille MH, Gravel J, Figliomeni M, Zhang J, Lefebvre P.

**Development and validation of a claims-based prediction model for COPD severity.**

*Publication:* Respir Med 2013 10; 107(10): 1568-1577. doi: 10.1016/j.rmed.2013.05.012.

*Authors:* Macaulay D, Sun SX, Sorg RA, Yan SY, De G, Wu EQ, Simonelli PF.

**A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.**

*Publication:* Pediatr Pulmonol 2013 10; 48(10): 954-961. doi: 10.1002/ppul.22741.

*Authors:* Sawicki GS, Ayyagari R, Zhang J, Signorovitch JE, Fan L, Swallow E, Latremouille-Viau D, Wu EQ, Shi L.

**Association between consistent omalizumab treatment and asthma control.**

*Publication:* The Journal of Allergy and Clinical Immunology: In Practice 2013 1(1): 51-57.

*Authors:* Lafeuille M-H, Gravel J, Zhang J, Gorsh B, Figliomeni M, Lefebvre P.

**Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.**

*Publication:* Ann Allergy Asthma Immunol 2012 07; 109(1): 59-64. doi: 10.1016/j.anai.2012.04.015.

*Authors:* Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

**Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma.**

*Publication:* J Allergy Clin Immunol 2012 05; 129(5): 1229-1235. doi: 10.1016/j.jaci.2012.01.039.

*Authors:* Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K.

**Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis.**

*Publication:* J Med Econ 2012 04; 15(2): 219-224. doi: http://dx.doi.org/10.3111/13696998.2011.638954.

*Authors:* Sangsiry SS, Joish VN, Boklage S, Goyal RK, Chopra P, Sethi S.

**Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.**

*Publication:* *Pediatr Pulmonol* 2012 01; 47(1): 44-52. doi: 10.1002/ppul.21521.

*Authors:* Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L.

**Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD.**

*Publication:* *Respir Med* 2011 12; 105(12): 1861-1871. doi: 10.1016/j.rmed.2011.07.001.

*Authors:* Yu AP, Guerin A, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum SI, Setyawan J.

**Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases.**

*Publication:* *Journal of Asthma* 2011 11; 48(9): 923-930. doi: 10.3109/02770903.2011.618568.

*Authors:* Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Swensen A, Lefebvre P.

**Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population.**

*Publication:* *Appl Health Econ Health Policy* 2011 11; 9(6): 377-387. doi: 10.2165/11592440-000000000-00000.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

**Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.**

*Publication:* *J Med Econ* 2011 10; 14(6): 805-815. doi: 10.3111/13696998.2011.623204.

*Authors:* Sun SX, Marynchenko M, Banerjee R, Cheng D, Mocarski M, Yin D, Yu AP, Wu EQ.

**Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.**

*Publication:* *Appl Health Econ Health Policy* 2011 09; 9(5): 293-303. doi: 10.2165/11592430-000000000-00000.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

**Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States.**

*Publication:* *Current Medical Research & Opinion* 2011 09; 27(9): 1763-1768. doi: 10.1185/03007995.2011.604310.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

**Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers.**

*Publication:* *J Med Econ* 2011 06; 14(4): 486-496. doi: 10.3111/13696998.2011.594123.

*Authors:* Yu AP, Guerin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J.

**Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.**

*Publication:* *J Med Econ* 2011 04; 14(3): 315-323. doi: 10.3111/13696998.2011.576295.

*Authors:* Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S.

**Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs.**

*Publication:* *Respir Med* 2011 03; 105(3): 435-441. doi: 10.1016/j.rmed.2010.09.006.

*Authors:* Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS.

**The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.**

*Publication:* *COPD* 2010 06; 7(3): 214-228. doi: 10.3109/15412555.2010.481697.

*Authors:* Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS.

**Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.**

*Publication:* *Current Medical Research & Opinion* 2010 02; 26(2): 355-363. doi: 10.1185/03007990903482418.

*Authors:* Signorovitch JE, Sheng Duh M, Sengupta A, Gu A, Grant R, Raut M, Mody SH, Schein J, Fisher AC, Ng D.

**Persistence and Adherence in Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Multiple vs Single Long-Acting Inhalers.**

*Publication:* CHEST Journal 2010 138(4\_MeetingAbstracts): 482A-482A.

*Authors:* Yu AP, Guérin A, de Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI.

**Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.**

*Publication:* Clin Ther 2009 12; 31(12): 2779-2803. doi: 10.1016/j.clinthera.2009.12.021.

*Authors:* Frois C, Wu EQ, Ray S, Colice GL.

**Comparability of the Asthma Control Test telephone interview administration format with self-administered mail-out mail-back format.**

*Publication:* Current Medical Research & Opinion 2009 03; 25(3): 717-727. doi: 10.1185/03007990802711602.

*Authors:* Kosinski M, Kite A, Yang M, Rosenzweig JC, Williams A.

**Asthma severity categorization using a claims-based algorithm or pulmonary function testing.**

*Publication:* Journal of Asthma 2009 02; 46(1): 67-72. doi: 10.1080/02770900802503099.

*Authors:* Birnbaum HG, Ivanova JI, Yu AP, Hsieh M, Seal B, Emani S, Rosiello R, Colice GL.

**Adherence to inhaled corticosteroid use and local adverse events in persistent asthma.**

*Publication:* Am J Manag Care 2008 12; 14(12): 801-809.

*Authors:* Ivanova JI, Birnbaum HG, Hsieh M, Yu AP, Seal B, van der Molen T, Emani S, Rosiello RA, Colice GL.

**Costs and resource use of mild persistent asthma patients initiated on controller therapy.**

*Publication:* Journal of Asthma 2008 05; 45(4): 293-299. doi: 10.1080/02770900801911178.

*Authors:* Colice GL, Yu AP, Ivanova JI, Hsieh M, Birnbaum HG, Lage MJ, Brewster C.

**Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature.**

*Publication:* Expert Opin Pharmacother 2008 04; 9(5): 751-766. doi: 10.1517/14656566.9.5.751.

*Authors:* Weiner JR, Toy EL, Sacco P, Duh MS.

**Use of inhaled corticosteroids and healthcare costs in mild persistent asthma.**

*Publication:* Journal of Asthma 2007 07; 44(6): 479-483. doi: 10.1080/02770900701424124.

*Authors:* Colice G, Wu EQ, Birnbaum H, Daher M, Maryna BM.

**Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study.**

*Publication:* Crit Care 2007 06; 11(3): R63. doi: 10.1186/cc5934.

*Authors:* Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF.

**Development of a COPD severity score.**

*Publication:* Current Medical Research & Opinion 2006 09; 22(9): 1679-1687. doi: 10.1185/030079906X115621.

*Authors:* Wu EQ, Birnbaum HG, Cifaldi M, Kang Y, Mallet D, Colice G.

**Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population.**

*Publication:* Journal of Occupational Environmental Medicine 2006 08; 48(8): 794-802. doi: 10.1097/01.jom.0000229819.26852.0e.

*Authors:* Colice G, Wu EQ, Birnbaum H, Daher M, Marynchenko MB, Varghese S.

**Treatment costs of community-acquired pneumonia in an employed population.**

*Publication:* Chest 2004 06; 125(6): 2140-2145.

*Authors:* Colice GL, Morley MA, Asche C, Birnbaum HG.

**Red blood cell transfusion and ventilator-associated pneumonia: A potential link?**

*Publication:* Crit Care Med 2004 03; 32(3): 666-674. e-pub ahead of print 2004/04/20.

*Authors:* Shorr AF, Duh MS, Kelly KM, Kollef MH.

**Lower respiratory tract infections: impact on the workplace.**

*Publication:* PharmacoEconomics 2003 06; 21(10): 749-759.

*Authors:* Birnbaum H, Morley M, Leong S, Greenberg P, Colice G.

**Economic burden of respiratory infections in an employed population.**

*Publication:* Chest 2002 08; 122(2): 603-611.

*Authors:* Birnbaum HG, Morley M, Greenberg PE, Colice GL.

**Direct and indirect costs of asthma to an employer.**

*Publication:* J Allergy Clin Immunol 2002 02; 109(2): 264-270.

*Authors:* Birnbaum HG, Berger WE, Greenberg PE, Holland M, Auerbach R, Atkins KM, Wanke LA.

**Economic burden of pneumonia in an employed population.**

*Publication:* Arch Intern Med 2001 12; 161(22): 2725-2731.

*Authors:* Birnbaum HG, Morley M, Greenberg PE, Cifaldi M, Colice GL.

**Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients.**

*Publication:* Ann Allergy Asthma Immunol 2000 11; 85(5): 356-361. e-pub ahead of print 2000/12/02; doi: 10.1016/S1081-1206(10)62545-8.

*Authors:* Duh MS, Walker AM, Lindmark B, Laties AM.

**Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis.**

*Publication:* Clin Ther 2000 01; 22(1): 140-151.

*Authors:* LeLorier J, Perreault S, Birnbaum H, Greenberg P, Sheehy O.

**Lack of Intraocular Pressure Effect of Budesonide Inhalation Therapy in a Mixed Asthmatic Population.**

*Publication:* Annals of Asthma Allergy & Immunology 2000: 356-361.

*Authors:* Duh M, Walker A, Lindmark B, Laties A.

## Abstracts

**Economic Burden of Gastroesophageal Reflux Disease, Barrett's Esophagus, and Esophageal Neoplasia in the United States.**

*Abstract:* ISPOR 2022, Washington, D.C. May 15-18, 2022.

*Authors:* Sharma P, Falk GW, Bhor M, Ozbay BA, Latremouille-Viau D, Guerin A, Shi S, Elvekrog MM, Limburg P.

**Screening and Surveillance Upper Endoscopy Utilization Patterns Among Patients with Gastroesophageal Reflux Disease, Barrett's Esophagus, and Esophageal Neoplasia in the United States.**

*Abstract:* ISPOR 2022, Washington, D.C. May 15-18, 2022.

*Authors:* Sharma P, Falk GW, Bhor M, Ozbay BA, Latremouille-Viau D, Guerin A, Shi S, Elvekrog MM, Limburg P.

**Chart Review Study of Pediatric Patients with Peanut Allergy Treated with Peanut (Arachis Hypogaea) Allergen Powder-dnfp.**

*Abstract:* Western Society of Allergy, Asthma and Immunology (WSAAI) 59th Annual Scientific Session, Wailea-Makena, HI February 6-10, 2022.

*Authors:* Portnoy J, Shroba J, Tilles S, Romdhani H, Donelson SM, Latremouille-Viau D, Bungay R, Chen K, Yassine M, McCann W.

**Physician Experience with Prescribing Peanut (*Arachis hypogaea*) Allergen Powder-dnfp in Pediatric Patients with Peanut Allergy.**

*Abstract:* ACAAI 2021 Annual Scientific Meeting, New Orleans, LA November 4 -- 8, 2021.

*Authors:* Portnoy J, Shroba J, Tilles S, Romdhani H, Donelson SM, Latremouille-Viau D, Bungay R, Chen K, Yassine M, McCann W.

**Real-World Adherence to Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy Among Asthma Patients in the US.**

*Abstract:* Virtual IPSOR 2021, Virtual May 17-20, 2021.

*Authors:* Averell C, Germain G, Laliberté F, MacKnight S, Jung Y, Duh M, Abbott CB.

**Characteristics of Real-world Users of Single-inhaler Fluticasone Furoate/Umeclidinium/Vilanterol or Multiple-inhaler Triple Therapy in Asthma in the US.**

*Abstract:* Virtual AMCP 2021, Virtual April 12-16, 2021.

*Authors:* Averell CM, Germain G, Laliberte F, Mahendran M, Duh MS, Abbott CB.

**Real-World Evidence of Improved Patient Outcomes with Reslizumab in Adults with Severe Eosinophilic Asthma (SEA): Subgroup Analyses of Patients Using Maintenance Oral Corticosteroids (OCS) Prior to Treatment Initiation.**

*Abstract:* AAAAI 2020, Phoenix, AZ November 12–16, 2020.

*Authors:* Panettieri Jr RA, Wechsler ME, Peters SP, Chipps BE, Hill T, Ariely R, DePietro M, Terasawa E, Thomason D.

**Real-World Evidence of Improved Patient Outcomes with Reslizumab in Non-Exacerbating Patients with Severe Eosinophilic Asthma (SEA): A Subgroup Analysis.**

*Abstract:* AAAAI 2020, Phoenix, AZ November 12–16, 2020.

*Authors:* Peters SP, Wechsler ME, Chipps BE, Hill T, Ariely R, DePietro M, Terasawa E, Thomason D, Panettieri J, R. A. .

**Real-World Evidence of Reductions in Health Resource Utilization (HRU) and Improved Efficacy Outcomes Associated with Reslizumab Treatment in Adults with Severe Eosinophilic Asthma (SEA) in the United States.**

*Abstract:* AAAAI 2020 Phoenix, AZ November 12–16, 2020.

*Authors:* Wechsler ME, Peters SP, Chipps BE, Hill T, Ariely R, DePietro M, Terasawa E, Thomason D, Panettieri J, R. A. .

**The estimated risk reduction of anaphylactic reactions associated with AR101 oral immunotherapy following accidental peanut exposure: an analysis based on clinical trial data.**

*Authors:* Tilles S, Yu S, Smith A, Wu E, Zhou J, Chai X, Wei LJ, Robison DR, Hass SL, Donelson S, Vickery B.

**Real-world evidence of improved patient outcomes with reslizumab in adults with severe eosinophilic asthma: A subgroup analysis of patients receiving reslizumab for more than 12 months.**

*Abstract:* ATS 2020, Philadelphia, PA May 15–20, 2020.

*Authors:* Wechsler ME, Peters SP, Chipps BE, Hill T, Ariely R, DePietro M, Driessen MT, Terasawa, E., Thomason D, Panettieri J, R. A. .

**Risk factors associated with reactions to peanut due to accidental exposure resulting in inpatient or emergency department visits.**

*Abstract:* ISPOR 2020, Orlando, FL May 16-20, 2020.

*Authors:* Stephen Tilles AM, Michael Blaiss, Steven L. Hass, Shengsheng Yu, Dan Robison, Dominick Latremouille-Viau, Annie Guérin.

**Evidence of Peanut Allergy Management in Healthcare Resource Utilization Among Commercially Insured Individuals with Peanut Allergy Despite Practicing Peanut Avoidance.**

*Abstract:* AMCP 2020, Houston, TX April 21-24, 2020.

*Authors:* Tilles S, Meadows A, Blaiss M, Hass SL, Yu S, Robison D, Latremouille-Viau D, Guérin A.

**Evidence of Peanut Allergy Management in Healthcare Resource Utilization Among Commercially Insured Individuals with Peanut Allergy Despite Practicing Peanut Avoidance.**

*Abstract:* AMCP 2020, Houston, TX April 21-24, 2020.

*Authors:* Guérin STAMMBSLHSYDRDL-VA.

**Real-World Evidence of Improved Patient Outcomes with Reslizumab in Adults with Severe Eosinophilic Asthma (SEA).**

*Abstract:* WSAAI 2020, Kauai, Hawaii February 2–6, 2020.

*Authors:* Wechsler ME, Peters SP, Chipps BE, Hill T, Ariely R, DePietro M, Driessen MT, Terasawa E, Thomason D, Panettieri J, R.A. .

**Prevalence of Peanut Allergy and Incidence of Related Healthcare Resource Utilization: A U.S. Claims Analysis.**

*Abstract:* American College of Allergy, Asthma and Immunology Annual Scientific Meeting, Houston, TX Nov 7-11, 2019.

*Authors:* Stephen Tilles MAM, MD; Shengsheng Yu, PhD; Dan R. Robison, MBA; Christine Birchwood, PhD; Steven L. Hass, PhD; Kevin E. Norrett, MS, MBA; Annie Guérin, MSc; Dominick Latremouille-Viau, MSc; J. Michael S. Blaiss, MD.

**Real-world evidence of improved patient outcomes with reslizumab in adults with severe eosinophilic asthma (SEA).**

*Abstract:* ACAAI 2019, Houston, TX November 7–11, 2019.

*Authors:* Wechsler ME, Peters SP, Chipps BE, Hill T, Ariely R, DePietro M, Terasawa E, Thomason D, Panettieri J, R.A. .

**Characteristics and Management of Patients Following Pulmonary Embolism: A Focus on Screening for Chronic Thromboembolic Pulmonary Hypertension.**

*Abstract:* ISHLT 39th Annual Meeting and Scientific Sessions, Orlando, FL Apr 3-6, 2019.

*Authors:* Kanwar M, Cole M, Gauthier-Loiselle M, Manceur AM, Lickert C, Greenberg M, Lefebvre P, Drake W, Benza R.

**Comorbidity and Economic Burden of Peanut Allergy in Privately-Insured Patients in the United States.**

*Abstract:* AMCP's 31st Annual Meeting, San Diego, CA Mar 25-28, 2019.

*Authors:* Tilles S, Birchwood C, Robison D, Damle V, Norrett K, Hass S, Guerin A, Latremouille-Viau D.

**Healthcare Resource Utilization and Direct Healthcare Cost Related to Peanut Allergy in Medicaid Patients.**

*Abstract:* AMCP's 31st Annual Meeting, San Diego, CA Mar 25-28, 2019.

*Authors:* Tilles S, Birchwood C, Robison D, Damle V, Norrett K, Hass S, Guerin A, Latremouille-Viau D.

**Biomarkers and Outcomes in Omalizumab-Treated Patients with Allergic Asthma: A Real-World Study in a Large Allergy Practice in the United States (US).**

*Abstract:* 2019 AAAAI Annual Meeting, San Francisco, CA Feb 22-25, 2019.

*Authors:* Ortiz B, Kavati A, Zhdanava M, Lecocq J, Schiffman B, Pilon D, Ho H, Stone BD.

**Long-Term Outcomes of Omalizumab in Chronic Idiopathic Urticaria (CIU): Evidence from a Large Allergy Practice in the United States (US).**

*Abstract:* 2019 AAAAI Annual Meeting, San Francisco, CA Feb 22-25, 2019.

*Authors:* Lecocq J, Kavati A, Zhdanava M, Ortiz B, Schiffman B, Cheung HC, Lefebvre P, Stone BD.

**Omalizumab Treatment Patterns in Chronic Idiopathic Urticaria (CIU): Evidence from a Large Allergy Practice in the United States (US).**

*Abstract:* 2019 AAAAI Annual Meeting, San Francisco, CA Feb 22-25, 2019.

*Authors:* Stone BD, Kavati A, Zhdanava M, Ortiz B, Lecocq J, Schiffman B, Cheung HC, Lefebvre P.

**Health care resource utilization of conjunctivitis in the general population and in patients with prior antibiotic-resistant infection: A retrospective US claims-based analysis.**



*Abstract:* 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Prague, Czech Republic Aug 22-26, 2018.

*Authors:* Cheng W, McCormick N, Duh MS, Cheung HC, Bobbili P, Joseph C, Sarda S.

**Characterizing real-world use of LAMAs in asthma in the US.**

*Abstract:* American Thoracic Society International Conference, ATS, San Diego, CA May 18-23, 2018.

*Authors:* Averell CM, Laliberte F, Duh M, Wu JW, Germain G, Katial R, Faison S.

**Do blood eosinophils play a role in burden of illness in patients with COPD?**

*Abstract:* American Thoracic Society International Conference, ATS, San Diego, CA May 18-23, 2018.

*Authors:* Hahn B, Ortega H, Bell C, Lafeuille M, Duh M, Germain G, Llanos J.

**Healthcare resource utilization of conjunctivitis in the general population and in patients with prior antibiotic-resistant infection: A retrospective us claims-based analysis.**

*Abstract:* ISPOR 23rd Annual International Meeting  
. United States, May 18-23, 2018.

*Authors:* Cheng WY, McCormick N, Duh MS, Cheung HC, Bobbili PJ, Joseph C, Sarda SP.

**Medication adherence and persistence in chronic obstructive pulmonary disease (COPD) patients on triple therapy in a us commercially-insured population.**

*Abstract:* American Thoracic Society International Conference, ATS, San Diego, CA May 18-23, 2018.

*Authors:* Bogart M, Laliberte F, Duh MS, Wu JW, Germain G, Stanford RH.

**A prospective assessment of healthcare utilization and costs associated with symptom burden measured by mmrc and cat.**

*Abstract:* American Thoracic Society International Conference, Washington, DC May 19-24, 2017.

*Authors:* Stanford RH, Mapel D, Roberts M, Pilon D, Laliberte F, Lefebvre P, Sama S, Emond B, Duh M.

**Characteristics and outcomes of patients with hospital-acquired pneumonia (HAP).**

*Abstract:* ISPOR 19th Annual European Congress, Vienna, Austria Oct 29 - Nov 2, 2016.

*Authors:* Han S, Xie J, Song H, Zhang C, Wu EQ.

**Feasibility of matching-adjusted indirect comparison (MAIC) of omalizumab (OMA) vs. mepolizumab (MEPO) in moderate-to-severe asthma.**

*Abstract:* ISPOR 19th Annual European Congress, Vienna, Austria Oct 29 - Nov 2, 2016.

*Authors:* Ayyagari R, Alvares L, Mu F, Hacking V, Martinez R, Signorovitch JE.

**Spectrum of idiopathic pulmonary fibrosis severity in clinical practice: implications for clinical trial feasibility and design.**

*Abstract:* American Thoracic Society International Conference, San Francisco, CA May 13-18, 2016.

*Authors:* Macaulay D, Nathan SD, Terasawa E, Yu Y.

**Inpatient Burden Among Patients with Cystic Fibrosis Who Are Homozygous for the F508del Mutation.**

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Hodgkins P, Ayyagari R, Guo J, Wagener J, O'Sullivan AK.

**Association of change in forced vital capacity with healthcare resource utilization in patients with newly diagnosed idiopathic pulmonary fibrosis.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Reichmann WM, Yu Y, Macaulay D, Nathan SD.

**Change in forced vital capacity and clinical outcomes in newly diagnosed idiopathic pulmonary fibrosis patients.**

*Abstract:* American Thoracic Society International Conference, Denver, CO May 15-20, 2015.

*Authors:* Nathan SD, Reichmann WM, Macaulay D, Yu YF.

**Cost and resource utilization in hospital-treated cap patients.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Tuttle EG, Llop CJ.

**Economic and clinical burden of acute and chronic systemic corticosteroid-related complications in asthma patients Respiratory Disease.**

*Abstract:* American Thoracic Society International Conference, Denver, CO May 15-20, 2015.

*Authors:* Lefebvre P, Mei Sheng D, Lafeuille MH, Gozalo L, Desai U, Albers F, Yancey S, Ortega HG, Forshag M, Lin X, Dalal AA.

**Impact of suspected idiopathic pulmonary fibrosis acute exacerbations on clinical and healthcare resource utilization outcomes.**

*Abstract:* American Thoracic Society International Conference, Denver, CO May 15-20, 2015.

*Authors:* Nathan SD, Reichmann WM, Macaulay D, Yu YF.

**Time to treatment augmentation among patients with chronic obstructive pulmonary disease (COPD) newly initiated on long acting muscarinic agents (LAMA) or inhaled corticosteroid (ICS) and long acting beta-2 agonist (LABA) combination therapy.**

*Abstract:* American Thoracic Society International Conference Denver, CO May 15-20, 2015.

*Authors:* Patel J, Mapel DW, Roberts MH, Sama S, Gilmore J, Sundaresan D, Laliberte F, Pilon D, Lefebvre P, Duh M.

**Budget impact model of ORALAIR® for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis in adults and children.**

*Abstract:* AMCP Nexus 2014, Boston, MA Oct 7-10, 2014.

*Authors:* Ivanova J, Diener M, Kelkar S, Bean S, King S, Birnbaum HG, Hocker S, Johnson M, Phipps R, Lankow R.

**Assessment of COPD exacerbation risk: Utilizing health claims data to develop and validate a risk equation.**

*Abstract:* American Thoracic Society International Conference, San Diego, CA May 16-21, 2014.

*Authors:* Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M, Merrigan J, Duh M.

**Risk assessment of first severe COPD exacerbation using predictive models based on health claims data.**

*Abstract:* American Thoracic Society International Conference, San Diego, CA May 16-21, 2014.

*Authors:* Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M, Merrigan P, Duh M.

**Risk of Hospital Readmissions in Patients with Chronic Obstructive Pulmonary Disease Receiving Arformoterol Tartrate versus Nebulized Short-Acting Beta2-Agonists Following Hospital Discharge.**

*Abstract:* COPD8USA Conference, Chicago, IL June 14-15, 2013.

*Authors:* Bollu VK, Guérin A, Gauthier G, Hiscock R, Wu EQ.

**Impact of integrated telehealth and care management program on resource utilization in Medicare beneficiaries with chronic obstructive pulmonary disease.**

*Abstract:* American Thoracic Society International Conference, Philadelphia, PA May 17-22, 2013.

*Authors:* Au DH, Jarvis J, Macaulay D, Birnbaum HG.

**Re-hospitalization risk in patients with chronic obstructive pulmonary disease (COPD) initiating nebulized long-acting vs. Short-acting beta2-agonists.**

*Abstract:* American Thoracic Society International Conference, Philadelphia, PA May 17-22, 2013.

*Authors:* Bollu V, Guerin A, Karafilidis J, Gauthier G, Hiscock R, Wu E.

**Annual healthcare costs for patients with cystic fibrosis from a Medicaid perspective.**

*Abstract:* 26th Annual North American Cystic Fibrosis Conference Orlando, FL Oct 11-13, 2012.

*Authors:* Zhang J, Marynchenko M, Chopra P, Ohashi E, Signorovitch J, Wu E.

**Lower adherence to chronic pulmonary medications is associated with increased health service utilization in patients with cystic fibrosis.**

*Abstract:* 26th Annual North American Cystic Fibrosis Conference, Orlando, FL Oct 11-13, 2012.

*Authors:* Quittner AL, Zhang J, Marynchenko M, Chopra P, Signorovitch J, Riekert KA.

**Pulmonary medication adherence among individuals with cystic fibrosis.**

*Abstract:* 26th Annual North American Cystic Fibrosis Conference Orlando, FL Oct 11-13, 2012.

*Authors:* Riekert KA, Zhang J, Marynchenko M, Chopra P, Signorovitch J, Quittner AL.

**A validated claims-based prediction model for COPD severity.**

*Abstract:* CHEST 2012 Atlanta, GA Oct 20-25, 2012.

*Authors:* Macaulay D, Sun S, Sorg R, Yan S, De G, Wu E, Simonelli P.

**Impact of omalizumab initiation on emergency-department visits, hospitalizations and corticosteroid use in patients with uncontrolled asthma using high-dose inhaled corticosteroids and long-acting beta2-agonists Respiratory Disease.**

*Abstract:* 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012.

*Authors:* Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

**Association of allergic rhinitis with asthma exacerbations and health care costs in asthma patients Respiratory Disease.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Ivanova JI, Desai U, Birnbaum HG, Cummings AK, Bornstein A, Karafilidis J, Spalding W.

**Comparisons of patient characteristics and health care costs by quartile among patients with allergic rhinitis.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Desai U, Ivanova JI, Birnbaum HG, Cummings AK, Bornstein A, Karafilidis J, Spalding W.

**Development of a pulmonary exacerbation risk score among cf patients not receiving recommended therapies for pulmonary care.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Sawicki G, Ayyagari R, Zhang J, Signorovitch J, Fan L, Latremouille-viau D, Shi L.

**Economic burden associated with acute exacerbations of chronic obstructive pulmonary disease in China.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Yang HY, Wu J, Zheng Y, Xie K, Jin L, Xie J, Wu EQ.

**Impact of omalizumab on emergency-department visits, hospitalizations and corticosteroid use in patients with uncontrolled asthma using high-dose inhaled corticosteroids Respiratory Disease.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

**Assessment of a pulmonary exacerbation risk score among cystic fibrosis patients free of recent exacerbations and not receiving recommended therapies for pulmonary care.**

*Abstract:* American Thoracic Society International Conference, San Francisco, CA May 18-23, 2015.

*Authors:* Sawicki G, Ayyagari R, Zhang J, Signorovitch J, Fan L, Swallow E, Shi L.

**Impact of omalizumab on emergency-department visits, hospitalizations and corticosteroid use in patients with uncontrolled asthma using high-dose inhaled corticosteroids Respiratory Disease.**

*Abstract:* 2012 Annual Meeting of the American Academy of Allergy, Asthma and Immunology, Orlando, FL Mar 2-6, 2012.

*Authors:* Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

**Development of a pulmonary exacerbation risk score among CF patients not receiving recommended therapies for pulmonary care.**

*Abstract:* 25th Annual North American Cystic Fibrosis Conference Anaheim, CA Nov 3-5, 2011.

*Authors:* Sawicki GS, Ayyagari R, Zhang J, Signorovitch J, Fan L, Latremouille-Viau D, Shi L.

**Effect of tobramycin inhalation solution on mortality in subgroups of patients with cystic fibrosis.**

*Abstract:* 25th Annual North American Cystic Fibrosis Conference Anaheim, CA Nov 3-5, 2011.

*Authors:* Latremouille-Viau D, Sawicki GS, Zhang J, Von Wartburg M, Signorovitch J, Wu EQ, Shi L.

**Prevalence of pseudomonas aeruginosa infection and antibiotic resistance by age group in the CFF patient registry in 2003 and 2008.**

*Abstract:* 25th Annual North American Cystic Fibrosis Conference, Anaheim, CA Nov 3-5, 2011.

*Authors:* Latremouille-Viau D, Zhang J, DeBonnett L, Signorovitch J, Von Wartbu M, Wu EQ, Shi L.

**Cost-effectiveness analysis of roflumilast/tiotropium combination therapy vs. tiotropium monotherapy in patients with severe to very severe COPD.**

*Abstract:* 2011 Annual Meeting of the American College of Clinical Pharmacy Pittsburgh, PA Oct 16-19, 2011.

*Authors:* Yu AP, Sun S, Marynchenko M, Banerjee R, Mocarski M, Yin D, Wu E.

**Concomitant asthma medication use in patients using omalizumab: Results from three large insurance claims databases Respiratory Disease.**

*Abstract:* 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Chicago, IL Aug 14-17, 2011.

*Authors:* Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Lefebvre P.

**Concomitant asthma medication use in patients usingomalizumab: Results from three large insurance claims databases Respiratory Disease.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Lefebvre P.

**Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis.**

*Abstract:* ISPOR 2011, May 21-25, 2011.

*Authors:* Signorovitch J, Sawicki G, Zhang J, Latremouille-Viau D, Wu E, von Wartburg M, Lizheng S.

**Concomitant asthma medication use in patients using omalizumab: Results from three large insurance claims databases Respiratory Disease.**

*Abstract:* 2011 American Academy of Allergy, Asthma and Immunology Annual Meeting San Francisco, CA Mar 18-22, 2011.

*Authors:* Lafeuille M, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Swensen A, Stanley EL, Lefebvre P.

**Association between private-to-Medicaid change in health insurance & healthcare utilization & outcomes among children with cystic fibrosis.**

*Abstract:* 24th Annual North American Cystic Fibrosis Conference Baltimore, MD Oct 21-23, 2010.

*Authors:* Zhivan N, Campbell CR, Signorovitch J, Zhang J, Shi L.

**Comparison of drug costs & clinical outcomes with tobramycin solution for inhalation & aztreonam lysine for inhalation in cystic fibrosis.**

*Abstract:* 24th Annual North American Cystic Fibrosis Conference, Baltimore, MD Oct 21-23, 2010.

*Authors:* Signorovitch J, Latremouille-Viau D, Dea K, Wu E, Zhang J.

**Persistence and adherence in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers.**

*Abstract:* CHEST 2010 Annual Meeting, Vancouver, BC, Canada Oct 30-Nov 4, 2010.

*Authors:* Yu AP, Guerin A, De Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI.

**Pulmonary arterial hypertension (PAH) cost of illness in the U.S. Privately-insured population.**

*Abstract:* Chest 2010 Meeting, Vancouver, BC, Canada Oct 30 - Nov 4, 2010.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

**Resource utilization and costs in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers.**

*Abstract:* CHEST 2010 Annual Meeting, Vancouver, BC, Canada Oct 30-Nov 4, 2010.

*Authors:* Yu AP, Guerin A, De Leon Barido DP, Ramakrishnan K, Xie J, Wu EQ, Setyawan J, Dembiski M, Blum SI.

**Risk of exacerbations among patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers.**

*Abstract:* CHEST 2010 Annual Meeting Vancouver, BC, Canada Oct 30-Nov 4, 2010.

*Authors:* Yu AP, Guerin A, De Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI.

**Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis.**

*Abstract:* 24th Annual North American Cystic Fibrosis Conference Baltimore, MD Oct 21-23, 2010.

*Authors:* Sawicki GS, Signorovitch J, Latremouille-Viau D, Von Wartburg M, Wu E, Zhang J, Shi L.

**Cost comparison among moderate or severe persistent asthma patients with and without asthma exacerbations Respiratory Disease.**

*Abstract:* American Thoracic Society International Conference, New Orleans, LA May 14-19, 2010.

*Authors:* Ivanova JI, Bergman RE, Birnbaum HG, Colice GL, Silverman R, McLaurin KK.

**Economic burden of exacerbations in chronic obstructive pulmonary disease.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Yu A, Yang H, Wu EQ, Dembiski M, Blum S, Setyawan J.

**Relationship between daily dosing frequency, compliance, health care resource use, and costs: Evidence from the treatment of chronic obstructive pulmonary disease (COPD).**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat C, Swensen A, Duh MS.

**Chronic thromboembolic pulmonary hypertension (CTEPH) cost of illness in the privately-insured population in the United States.**

*Abstract:* Chest 2010 Meeting, Vancouver, BC, Canada Oct 30 - Nov 4, 2010.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

**The direct economic impact of exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A review of the literature.**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* Toy EL, Gallagher KF, Stanley EL, Duh MS.

**The risk of hospitalization or emergency care following outpatient treatment of community-acquired pneumonia (CAP) with levofloxacin versus moxifloxacin.**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* Signorovitch JE, Gu A, Sengupta A, Raut M, Mody SH, Grant R, Schein J, Fisher AC, Ng D, Duh MS.

**The direct economic impact of exacerbations of chronic obstructive pulmonary disease (COPD): A review of the literature.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Toy EL, Gallagher KF, Stanley EL, Duh MS.

**Inpatient and Emergency Department Utilization of Persistent Asthma Patients.**

*Abstract:* American Thoracic Society.

*Authors:* Colice G, Crivera C, Wu EQ, Birnbaum HG, Daher M, Marynchenko MB, Faruqi R, Varghese ST.

**Acute exacerbation of chronic bronchitis (AECB) treatment effectiveness: Comparison of macrolides to fluoroquinolones.**

*Abstract:* ISPOR 2005, 2005.

*Authors:* Wu E, Birnbaum H, Cifaldi M, Kang Y, Colice G.

**Development of a COPD Severity Score in ClaimsDatabase.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR) European.

*Authors:* Wu EQ, Birnbaum H, Cifaldi M, Colice G, Kang Y.

**Healthcare Costs of Patients with Persistent Asthma.**

*Abstract:* AMCP's 2005 Educational Conference, Nashville, TN Oct 5-8, 2005.

*Authors:* Colice G, Crivera C, Varghese S, Faruqi R, Wu EQ, Birnbaum H, Daher M, Marynchenko MB.

**Assessing the cost implications of combined pharmacotherapy in the long term management of asthma.**

*Abstract:* ISPOR 2003, 2003.

*Authors:* Wu E, Johnson K, Nichol M.

## Substance Abuse

### Journal Articles

**Physician perceptions of drug utilization management: Results of a national survey.**

*Publication:* PLoS One 2022 09; 17(9): e0274772. e-pub ahead of print 2022/09/21; doi: 10.1371/journal.pone.0274772.

*Authors:* Edwards ML, Yin PT, Kuehn M, Bratti K, Kirson N, Jena AB, Howell S.

**Direct Costs of Opioid Abuse in an Insured Population in the United States.**

*Publication:* J Manag Care Spec Pharm 2020 10; 26(10): 1188-1198. e-pub ahead of print 2020/10/01; doi: 10.18553/jmcp.2020.26.10.1188.

*Authors:* White AG, Birnbaum HG, Mareva MN, Daher M, Vallow S, Schein J, Katz N.

**Assessment of Work Loss Associated With Prescription-Related Opioid Use Disorder: A Retrospective Analysis of Claims Data.**

*Publication:* Journal of Occupational and Environmental Medicine 2020 03; 62(3): 217-222. doi: 10.1097/jom.0000000000001802.

*Authors:* White AG, Spittle T, Fernan C, Billmyer E, Marrett E, Kwong WJ, Rossiter LF.

**Modeling the potential impact of abuse-deterrent opioids on medical resource utilization.**

*Publication:* J Med Econ 2019 10; 22(10): 1073-1079. e-pub ahead of print 2019/07/18; doi: 10.1080/13696998.2019.1645680.

*Authors:* Yenikomshian MA, White AG, Carson ME, Jia ZB, Mendoza MR, Roland CL.

**The Economic Burden of Abuse of Prescription Opioids: A Systematic Literature Review from 2012 to 2017.**

*Publication:* Appl Health Econ Health Policy 2018 10; 16(5): 609-632. e-pub ahead of print 2018/07/22; doi: 10.1007/s40258-018-0402-x.

*Authors:* Reinhart M, Scarpati LM, Kirson NY, Patton C, Shak N, Erensen JG.

**Opioid Abuse: A Detailed Examination of Cost Drivers over a 24-Month Follow-up Period.**

*Publication:* J Manag Care Spec Pharm 2017 11; 23(11): 1110-1115. e-pub ahead of print 2017/10/31; doi: 10.18553/jmcp.2017.17019.

*Authors:* Scarpati LM, Kirson NY, Jia ZB, Wen J, Howard J.

**Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.**

*Publication:* J Opioid Manag 2017 09; 13(5): 291-301. e-pub ahead of print 2017/12/05; doi: 10.5055/jom.2017.0398.

*Authors:* Yenikomshian MA, White AG, Carson ME, Garrison LP, Oderda GM, Biskupiak JE, Hlavacek PR, Roland CL.

**Drivers of excess costs of opioid abuse among a commercially insured population.**

*Publication:* Am J Manag Care 2017 05; 23(5): 276-282. e-pub ahead of print 2017/07/26.

*Authors:* Scarpati LM, Kirson NY, Zichlin ML, Jia ZB, Birnbaum HG, Howard JC.

**The Economic Burden of Opioid Abuse: Updated Findings.**

*Publication:* Journal of Managed Care and Specialty Pharmacy 2017 04; 23(4): 427-445. doi: 10.18553/jmcp.2017.16265.

*Authors:* Kirson NY, Scarpati LM, Enloe CJ, Dincer AP, Birnbaum HG, Mayne TJ.

**The Burden of Undiagnosed Opioid Abuse Among Commercially Insured Individuals.**

*Publication:* Pain Medicine 2015 07; 16(7): 1325-1332. doi: 10.1111/pme.12768.

*Authors:* Kirson NY, Shei A, Rice JB, Enloe CJ, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

**Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs.**

*Publication:* J Opioid Manag 2015 05; 11(3): 199-210. e-pub ahead of print 2015/05/20; doi: 10.5055/jom.2015.0269.

*Authors:* White AG, LeCates J, Birnbaum HG, Cheng W, Roland CL, Mardekian J.

**Sources of prescription opioids among diagnosed opioid abusers.**

*Publication:* Current Medical Research & Opinion 2015 04; 31(4): 779-784. doi: 10.1185/03007995.2015.1016607.

*Authors:* Shei A, Rice JB, Kirson NY, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

**Medical resource use and costs among pain patients with potential opioid-tolerability issues.**

*Publication:* J Opioid Manag 2014 09; 10(5): 305-310. doi: 10.5055/jom.2014.0220.

*Authors:* Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R, Michna E.

**Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.**

*Publication:* Pain Med 2014 09; 15(9): 1450-1454. e-pub ahead of print 2014/07/22; doi: 10.1111/pme.12489.

*Authors:* Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Rossiter LF, Michna E.

**Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data.**

*Publication:* Appl Health Econ Health Policy 2014 08; 12(4): 435-446. doi: 10.1007/s40258-014-0102-0.

*Authors:* Rice JB, Kirson NY, Shei A, Cummings AK, Bodnar K, Birnbaum HG, Ben-Joseph R.

**Use of prescription opioids with abuse-deterrent technology to address opioid abuse.**

*Publication:* Current Medical Research & Opinion 2014 08; 30(8): 1589-1598. doi: 10.1185/03007995.2014.915803.

*Authors:* Michna E, Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R.

**The economic burden of diagnosed opioid abuse among commercially insured individuals.**

*Publication:* Postgrad Med 2014 07; 126(4): 53-58. doi: 10.3810/pgm.2014.07.2783.

*Authors:* Rice JB, Kirson NY, Shei A, Enloe CJ, Cummings AK, Birnbaum HG, Holly P, Ben-Joseph R.

**Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.**

*Publication:* J Med Econ 2014 04; 17(4): 279-287. e-pub ahead of print 2014/02/25; doi: 10.3111/13696998.2014.897628.

*Authors:* Rossiter LF, Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Michna E.

**Systematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain management.**

*Publication:* Pain Medicine 2014 01; 15(1): 79-92. doi: 10.1111/pme.12233.

*Authors:* Michna E, Cheng WY, Korves C, Birnbaum H, Andrews R, Zhou Z, Joshi AV, Schaaf D, Mardekian J, Sheng M.

**The prevalence and economic impact of prescription opioid-related side effects among patients with chronic noncancer pain.**

*Publication:* J Opioid Manag 2013 07; 9(4): 239-254. doi: 10.5055/jom.2013.0165.

*Authors:* Ivanova JI, Birnbaum HG, Yushkina Y, Sorg RA, Reed J, Merchant S.

**Prescription opioid abuse: challenges and opportunities for payers.**

*Publication:* Am J Manag Care 2013 04; 19(4): 295-302. e-pub ahead of print 2013/06/04.

*Authors:* Katz NP, Birnbaum H, Brennan MJ, Freedman JD, Gilmore GP, Jay D, Kenna GA, Madras BK, McElhaney L, Weiss RD, White AG.

**A model to identify patients at risk for prescription opioid abuse, dependence, and misuse.**

*Publication:* Pain Med 2012 09; 13(9): 1162-1173. e-pub ahead of print 2012/08/01; doi: 10.1111/j.1526-4637.2012.01450.x.

*Authors:* Rice JB, White AG, Birnbaum HG, Schiller M, Brown DA, Roland CL.

**Economic impact of opioid abuse, dependence, and misuse.**

*Publication:* American Journal of Pharmacy Benefits 2011 05; 3(3): e59-e70.

*Authors:* White AG, Birnbaum HG, Schiller M, Waldman T, Cleveland JM, Roland CL.

**Societal costs of prescription opioid abuse, dependence, and misuse in the United States.**

*Publication:* Pain Med 2011 04; 12(4): 657-667. e-pub ahead of print 2011/03/12; doi: 10.1111/j.1526-4637.2011.01075.x.

*Authors:* Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL.

**Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications.**

*Publication:* Pain Medicine 2010 11; 11(11): 1718-1725. doi: 10.1111/j.1526-4637.2010.00979.x.

*Authors:* Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Latremouille-Viau D, Wei RS, Stangle BE, Lafeuille MH, Michna E, Greenberg PE.

**Analytic models to identify patients at risk for prescription opioid abuse.**

*Publication:* Am J Manag Care 2009 12; 15(12): 897-906. e-pub ahead of print 2009/12/17.

*Authors:* White AG, Birnbaum HG, Schiller M, Tang J, Katz NP.

**Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction.**

*Publication:* Appl Health Econ Health Policy 2009 06; 7(1): 61-70. e-pub ahead of print 2009/06/30; doi: 10.2165/00148365-200907010-00006.

*Authors:* White AG, Birnbaum HG, Rothman DB, Katz N.



**Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective.**

*Publication:* Clin J Pain 2006 10; 22(8): 667-676. e-pub ahead of print 2006/09/22; doi: 10.1097/01.ajp.0000210915.80417.cf.

*Authors:* Birnbaum HG, White AG, Reynolds JL, Greenberg PE, Zhang M, Vallow S, Schein JR, Katz NP.

**Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States.**

*Publication:* Health Serv Res 2006 06; 41(3 Pt 1): 837-855. doi: 10.1111/j.1475-6773.2006.00511.x.

*Authors:* Curtis LH, Stoddard J, Radeva JI, Hutchison S, Dans PE, Wright A, Woosley RL, Schulman KA.

**Direct costs of opioid abuse in an insured population in the United States.**

*Publication:* J Manag Care Pharm 2005 07; 11(6): 469-479. e-pub ahead of print 2005/07/07; doi: 10.18553/jmcp.2005.11.6.469.

*Authors:* White AG, Birnbaum HG, Mareva MN, Daher M, Vallow S, Schein J, Katz N.

## Abstracts

**Impact of Peripherally Acting Mu-opioid Receptor Antagonist (PAMORA) use in the Emergency Department on Healthcare Resource Utilization and Costs Among Patients with Opioid Induced Constipation.**

*Abstract:* EIM 2021, Virtual March 7-12, 2021.

*Authors:* Peacock F, Slatkin N, Gagnon-Sanschagrin P, Maitland J, Guérin A, Joseph G.

**Assessment of work loss and costs associated with opioid abuse: A retrospective claims analysis.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* White AG, Spittle T, Fernan C, Marrett E, Kwong J, Rossiter LF.

**A harm reduction model to quantify potential misuse/abuse reduction and misuse/abuse-related events avoided from extended-release abuse deterrent opioids.**

*Abstract:* 36th Annual Scientific Meeting of the American Pain Society, Pittsburgh, PA May 17-20, 2017.

*Authors:* White A, Spittle T, Niebler W, Brown C, Dayno J, Katz N.

**The costs and cost drivers of opioid misuse by diagnosis: Abuse, dependence, and overdose/poisoning.**

*Abstract:* 2016 Pain Week Conference, Las Vegas, NV Sept 6-10, 2016.

*Authors:* Howard J, Kirson N, Scarpati L, Dincer A, Hanway J, Zichlin M, Birnbaum H.

**The economic burden of opioid abuse and its drivers: Evidence from a payer perspective.**

*Abstract:* 2016 Pain Week Conference, Sept 6-10, 2016.

*Authors:* Howard J, Kirson N, Scarpati L, Dincer A, Hanway J, Zichlin M, Birnbaum H.

**A model to quantify potential medical events avoided and cost savings from abuse deterrent opioids.**

*Abstract:* Annual Scientific Meeting of the American Pain Society, Austin, TX May 11-14, 2016.

*Authors:* White AG, Yenikomshian M, Carson M, Masters ET, Roland CL.

**Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* White AG, Yenikomshian M, Carson ME, Garrison LP, Oderda G, Biskupiak JE, Hlavacek P, Roland CL.

**A model to estimate the health system burden of prescription opioid abuse in Europe.**

*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8-12, 2014.

*Authors:* Shei A, Hirst M, Kirson NY, Enloe CJ, Birnbaum HG, Dunlop W.

**Examining the use of ICD-9-CM diagnosis codes for opioid abuse and opioid dependence in commercial claims data.**

*Abstract:* AMCP Nexus 2014, Boston, MA Oct 7-10, 2014.

*Authors:* Shei A, Rice B, Kirson NY, Bodnar K, Cummings AKG, Birnbaum HG, Holly P, Ben-Joseph R.

**Comparing the prevalence and healthcare costs of opioid abuse using two commercial claims databases.**

*Abstract:* PAINWeek Conference, Las Vegas, NV Sep 2-6, 2014.

*Authors:* Rice B, Kirson NY, Shei A, Enloe CJ, Cummings AK, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

**Methods to estimate the prevalence and healthcare costs of undiagnosed opioid abuse among commercially-insured individuals.**

*Abstract:* PAINWeek Conference, Las Vegas, NV Sep 2-6, 2014.

*Authors:* Shei A, Rice B, Kirson NY, Enloe CJ, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

**Medical resource use and costs among pain patients with potential opioid tolerability issues.**

*Abstract:* ICOO 2014, Boston, MA Jun 8-10, 2014.

*Authors:* Birnbaum H, Kirson N, Shei A.

**The burden of opioid abuse among commercially-insured patients.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Rice JB, Kirson NY, Shei A, Enloe C, Cummings AK, Birnbaum HG, Ben-Joseph R.

**Differences between high-cost and low-cost patients diagnosed with opioid abuse.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Rice JB, Kirson NY, Bodnar K, Shei A, Birnbaum HG, Holly P, Ben-Joseph R.

**Characteristics of high-cost patients diagnosed with opioid abuse.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Birnbaum H, Kirson N, Shei A.

**Estimating the prevalence and healthcare costs of diagnosed opioid abuse in a large commercial claims database.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Birnbaum H, Kirson N, Shei A.

**Opioid utilization and abuse rates following the introduction of an abuse-deterrent formulation.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Birnbaum H, Kirson N, Shei A.

**The relationship between positive subjective measures in abuse liability studies and real-world non-medical use: potential impact of abuse deterrent opioids on rates of non-medical use and associated healthcare costs.**

*Abstract:* American Academy of Pain Medicine's 30th Annual Meeting, Phoenix, AZ Mar 6-9, 2014.

*Authors:* White AG, LeCates J, Cheng W, Roland CL, Schaaf D, Mardekian J.

**Estimating the payer-specific excess medical costs of opioid abuse in the United States.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Michna E, Kirson NH, Shei A, White A, Birnbaum HG, Ben-Joseph R, Rossiter LF.

**Characteristics and use patterns of chronic hydrocodone users.**

*Abstract:* 31st Annual Scientific Meeting of the American Pain Society, Honolulu, HI May 16-19, 2012.

*Authors:* Rice J, Samuelson T, Birnbaum H, Katz N.

**A systematic literature review of the efficacy and safety of abuse-deterrent formulation and non-abuse-deterrent formulation prescription opioids in non-cancer pain management.**

*Abstract:* 31st Annual Scientific Meeting of the American Pain Society, Honolulu, HI May 16-19, 2012.

*Authors:* Michna E, Cheng W, Korves C, Sarda S, Schaaf D, Andrews R, Zhou Z, Mardekian J, Joshi A, Birnbaum H, Duh M.

**Identifying predictors of chronic hydrocodone use.**

*Abstract:* 28th Annual Meeting of the American Academy of Pain Medicine, Palm Springs, CA Feb 23-26, 2012.

*Authors:* Rice JB, Samuelson TM, Birnbaum HG, Katz N.

**Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications.**

*Abstract:* 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Brighton, UK Aug 19-22, 2010.

*Authors:* Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Latremouille-Viau D, Wei RS, Stangle BE, Lafeuille MH, Michna E, Greenberg PE.

**Societal Costs of Prescription Opioid Abuse, Dependence, and Misuse in the United States.**

*Abstract:* ISPOR 15th Annual International Meeting Atlanta, GA May 15-19, 2010.

*Authors:* Birnbaum H, White A, Schiller M, Waldman T, Cleveland JM, Setnik BS, Pixton GC, Roland CL.

**Health care and work loss burden of prescription opioid abuse, dependence, and misuse.**

*Abstract:* AMCP's 2009 Educational Conference, San Antonio, TX Oct 7-9, 2009.

*Authors:* White AG, Birnbaum H, Schiller M, Waldman T, Cleveland JM, Setnik B, Roland CL.

## Other Diseases & Conditions

### Journal Articles

**Association of menopausal vasomotor symptom severity with sleep and work impairments: a US survey.**

*Publication:* Menopause 2023 09; 30(9): 887-897. e-pub ahead of print 2023/08/25; doi: 10.1097/gme.0000000000002237.

*Authors:* DePree B, Shiozawa A, King D, Schild A, Zhou M, Yang H, Mancuso S.

**Assessment of women's treatment preferences for vasomotor symptoms due to menopause.**

*Publication:* Expert Rev Pharmacoecon Outcomes Res 2023 08; 1-12. e-pub ahead of print 2023/08/31; doi: 10.1080/14737167.2023.2250916.

*Authors:* Shiozawa A, Thurston RC, Cook E, Yang H, King DD, Kristy RM, Mancuso S.

**Real-World Treatment Patterns among Patients with Alopecia Areata in the USA: A Retrospective Claims Analysis.**

*Publication:* Acta Derm Venereol 2023 08; 103: adv12445. e-pub ahead of print 2023/08/25; doi: 10.2340/actadv.v103.12445.

*Authors:* Done N, Bartolome L, Swallow E, Gao W, Carley C, Wang T, Mostaghimi A.

**Burden of hyperphagia and obesity in Bardet-Biedl syndrome: a multicountry survey.**

*Publication:* Orphanet J Rare Dis 2023 07; 18(1): 182. e-pub ahead of print 2023/07/07; doi: 10.1186/s13023-023-02723-4.

*Authors:* Forsythe E, Mallya UG, Yang M, Huber C, Cala ML, Greatsinger A, Hagopian E, Pomeroy J, Haqq AM.

**Caregiver burden in Bardet-Biedl syndrome: findings from the CARE-BBS study.**

*Publication:* Orphanet J Rare Dis 2023 07; 18(1): 181. e-pub ahead of print 2023/07/07; doi: 10.1186/s13023-023-02692-8.

*Authors:* Forsythe E, Mallya UG, Yang M, Huber C, Cala ML, Greatsinger A, Hagopian E, Pomeroy J, Haqq AM.

**Prescription opioid utilization patterns, and associated outcomes, among privately-insured patients prescribed opioids to manage pain associated with osteoarthritis.**

*Publication:* Curr Med Res Opin 2023 07: 1-18. e-pub ahead of print 2023/07/12; doi: 10.1080/03007995.2023.2234727.

*Authors:* Schepman P, Rice BJ, Beck CG, White A, Robinson RL, Thakkar S, Fernan C, Emir B, Silverman S.

**A multicenter chart review of patient characteristics, treatment, and outcomes in hereditary angioedema: unmet need for more effective long-term prophylaxis.**

*Publication:* Allergy Asthma Clin Immunol 2023 05; 19(1): 48. e-pub ahead of print 2023/05/30; doi: 10.1186/s13223-023-00795-2.

*Authors:* Mendivil J, DerSarkissian M, Banerji A, Diwakar L, Katelaris CH, Keith PK, Kim H, Lacuesta G, Magerl M, Slade C, Smith WB, Choudhry Z, Simon A, Sarda SP, Busse PJ.

**Patient characteristics associated with all-cause healthcare costs of alopecia areata in the United States.**

*Publication:* J Med Econ 2023 03: 1-13. e-pub ahead of print 2023/03/11; doi: 10.1080/13696998.2023.2188843.

*Authors:* Gao W, Mostaghimi A, Gandhi K, Done N, Ray M, Signorovitch J, Swallow E, Carley C, Wang T, Sikirica V.

**Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population.**

*Publication:* JAMA Dermatol 2023 03. e-pub ahead of print 2023/03/02; doi: 10.1001/jamadermatol.2023.0002.

*Authors:* Mostaghimi A, Gao W, Ray M, Bartolome L, Wang T, Carley C, Done N, Swallow E.

**Clinical and Cost Benefits of Anti-Obesity Medication for US Veterans Participating in the MOVE! Weight Management Program.**

*Publication:* Popul Health Manag 2023 02. e-pub ahead of print 2023/02/04; doi: 10.1089/pop.2022.0227.

*Authors:* Garvey WT, Cheng M, Ramasamy A, Smolarz BG, Park S, Kumar N, Kim N, DerSarkissian M, Bhak RH, Duh MS, Wu M, Hansen S, Young-Xu Y.

**Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study.**

*Publication:* Ann Dermatol 2022 10; 34(5): 349-359. e-pub ahead of print 2022/10/06; doi: 10.5021/ad.22.027.

*Authors:* Choi GS, Sim WY, Kang H, Huh CH, Lee YW, Shantakumar S, Ho YF, Oh EJ, Duh MS, Cheng WY, Bobbili P, Thompson-Leduc P, Ong G.

**Real-world treatment, dosing, and discontinuation patterns among patients treated with pegvaliase for phenylketonuria: Evidence from dispensing data.**

*Publication:* Mol Genet Metab Rep 2022 09; 33: 100918. e-pub ahead of print 2022/10/01; doi: 10.1016/j.ymgmr.2022.100918.

*Authors:* Lah M, Cook K, Gomes DA, Liu S, Tabatabaepour N, Kirson N, Chen E, Lindstrom K, Whitehall KB, Van Backle J, Burton BK.

**Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata.**

*Publication:* J Health Econ Outcomes Res 2022 08; 9(2): 11-18. e-pub ahead of print 2022/08/18; doi: 10.36469/001c.36229.

*Authors:* Ray M, Swallow E, Gandhi K, Carley C, Sikirica V, Wang T, Done N, Signorovitch J, Mostaghimi A.

**HSD35 Real-World Treatment Patterns Among US Adolescents with Alopecia Areata: A Retrospective Claims Analysis.**

*Publication:* Value in Health 2022 07; 25(7): S486. doi: 10.1016/j.jval.2022.04.1036.

*Authors:* Done N, Ray M, Gao W, Wang T, Carley C, Bartolome L, Swallow E, Mostaghimi A.

**Factors Associated with Increased Health-Related Quality of Life Benefits in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN) Treated with Inotersen.**

*Publication:* Muscle Nerve 2022 06. e-pub ahead of print 2022/06/30; doi: 10.1002/mus.27668.

*Authors:* Karam C, Brown D, Yang M, Done N, Dieye I, Bozas A, Vera Llonch M, Signorovitch J.

**Interdisciplinary Model-Informed Drug Development for Extending Duration of Elagolix Treatment in Patients with Uterine Fibroids.**

*Publication:* British Journal of Clinical Pharmacology 2022 06; n/a(n/a). doi: <https://doi.org/10.1111/bcp.15440>.

*Authors:* Beck D, Winzenborg I, Gao W, Mostafa NM, Chiuve SE, Owens C, Shebley M.

**Prevalence, severity, and associated factors in women in East Asia with moderate-to-severe vasomotor symptoms associated with menopause.**

*Publication:* Menopause 2022 05; 29(5): 553-563. e-pub ahead of print 2022/03/02; doi:

10.1097/gme.0000000000001949.

*Authors:* Yu Q, Chae HD, Hsiao SM, Xie J, Blogg M, Sumarsono B, Kim S.

**All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States.**

*Publication:* J Manag Care Spec Pharm 2022 04; 28(4): 426-434. e-pub ahead of print 2022/03/26; doi:

10.18553/jmcp.2022.28.4.426.

*Authors:* Mostaghimi A, Gandhi K, Done N, Ray M, Gao W, Carley C, Wang T, Swallow E, Sikirica V.

**Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018.**

*Publication:* Adv Ther 2022. e-pub ahead of print 2022/06/24; doi: 10.1007/s12325-022-02173-7.

*Authors:* Liu Y, Skup M, Yang M, Qi CZ, Wu EQ.

**Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer's perspective.**

*Publication:* BMJ Open Ophthalmology 2021 11; 6(1): e000896. doi: 10.1136/bmjophth-2021-000896.

*Authors:* Hariprasad SM, Joseph G, Gagnon-Sanschagrin P, Serra E, Bhattacharyya S, Bédard J, Guérin A, Albini TA.

**The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy.**

*Publication:* Adv Ther 2021 07; 38(8): 1-12. e-pub ahead of print 2021/07/09; doi: 10.1007/s12325-021-01843-2.

*Authors:* Yu S, Smith A, Hass S, Wu E, Chai X, Zhou J, Ayyagari R, Liu JS, Robison D, Donelson SM, Tilles S.

**Reducing the Prevalence of Alcohol-Exposed Pregnancies in the United States: A Simulation Modeling Study.**

*Publication:* Med Decis Making 2021 06; 272989x211023203. e-pub ahead of print 2021/06/25; doi:

10.1177/0272989x211023203.

*Authors:* Yaesoubi R, Mahin M, Martin G, Paltiel AD, Sharifi M.

**The Economic Burden of Tenosynovial Giant Cell Tumors Among Employed Workforce in the United States.**

*Publication:* Journal of Occupational and Environmental Medicine 2021 04; 63(4): e197-e202. doi:

10.1097/jom.0000000000002159.

*Authors:* Lin F, Ionescu-Ittu R, Pivneva I, Wynant W, Shi S, Wu EQ, Kwong WJ, Abraham JA.

**HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men.**

*Publication:* Liver Int 2021 03; 41(3): 482-493. e-pub ahead of print 2020/12/12; doi: 10.1111/liv.14762.

*Authors:* Adu PA, Rossi C, Binka M, Wong S, Wilton J, Wong J, Butt ZA, Bartlett S, Jeong D, Pearce M, Darvishian M, Yu A, Alvarez M, Velásquez García HA, Kraiden M, Janjua NZ.

**Integrating Real-World Data and Modeling to Project Changes in Femoral Neck Bone Mineral Density and Fracture Risk in Premenopausal Women.**

*Publication:* Clinical and translational science. 2021 03; 01.

*Authors:* Beck D, Winzenborg I, Gao W, Mostafa NM, Noertersheuser P, S EC, Owens C, Shebley M.

**Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.**

*Publication:* Expert Opin Pharmacother 2020 09; 1-9. e-pub ahead of print 2020/09/08; doi: 10.1080/14656566.2020.1811850.

*Authors:* Gorevic P, Franklin J, Chen J, Sajeev G, Wang JCH, Lin H.

**Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real-World Population.**

*Publication:* JBMR Plus 2020 08; 4(12): e10401. doi: <https://doi.org/10.1002/jbm4.10401>

*Authors:* Kilpatrick RD, Chiuve SE, Leslie WD, Wegrzyn LR, Gao W, Yang H, Soliman AM, Snabes MC, Koenigsberg S, Zhong J, Xiang C, Watts NB.

**A Longitudinal Assessment of the Impact of Endometriosis on Patients' Salary Growth and Risk of Leaving the Workforce.**

*Publication:* Adv Ther 2020 03; 37(5): 2144-2158. e-pub ahead of print 2020/03/22; doi: 10.1007/s12325-020-01280-7.

*Authors:* Estes SJ, Soliman AM, Yang H, Wang J, Freimark J.

**Burden of illness of spinal muscular atrophy type 1 (SMA1).**

*Publication:* Journal of the Neurological Sciences 2019 10; 405: 58. doi: 10.1016/j.jns.2019.10.325.

*Authors:* Droege M, Dabbous O, Arjunji R, Seda J, Gauthier-Loiselle M, Cloutier M, Sproule DM.

**Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.**

*Publication:* J Med Econ 2019 07; 1. e-pub ahead of print 2019/07/20; doi: 10.1080/13696998.2019.1646263.

*Authors:* Droege M, Sproule D, Arjunji R, Gauthier-Loiselle M, Cloutier M, Dabbous O.

**Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.**

*Publication:* Adv Ther 2019 03. doi: <http://dx.doi.org/10.1007/s12325-019-00923-8>.

*Authors:* Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guerin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM.

**Dry eye disease ranking among common reasons for seeking eye care in a large US claims database.**

*Publication:* Clin Ophthalmol 2019 02; 13: 225-232. e-pub ahead of print 2019/02/19; doi: 10.2147/OPHT.S188314.

*Authors:* Bradley JL, Ozer Stillman I, Pivneva I, Guerin A, Evans AM, Dana R.

**Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States.**

*Publication:* Ocul Immunol Inflamm 2019 02; 1-11. e-pub ahead of print 2019/02/23; doi: 10.1080/09273948.2018.1560476.

*Authors:* Albin TA, Rice JB, White AG, Johnson M, Reiff J, Lima AF, Bartels-Peculis L, Ciepiewska G, Nelson WW.

**Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System.**

*Publication:* Am J Ophthalmol 2019 02. e-pub ahead of print 2019/02/06; doi: 10.1016/j.ajo.2019.01.026.

*Authors:* Dana R, Bradley JL, Guerin A, Pivneva I, Stillman IO, Evans AM, Schaumberg DA.

**Indirect costs associated with premature mortality among those with veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan dysfunction post-hematopoietic stem-cell-transplant.**

*Publication:* Clinicoecon Outcomes Res 2018 12; 11: 13-22. e-pub ahead of print 2018/12/28; doi: 10.2147/ceor.S184883.

*Authors:* Zhou ZY, Tang W, Villa KF.

**Comorbidities and Prescribed Medications in Patients With or Without Dry Eye Disease: A Population-Based Study.**

*Publication:* Am J Ophthalmol 2018 10. e-pub ahead of print 2018/10/13; doi: 10.1016/j.ajo.2018.10.001.

*Authors:* Dana R, Bradley JL, Guerin A, Pivneva I, Evans AM, Stillman IO.

**The burden of non-infectious intraocular inflammatory eye diseases: a systematic literature review.**

*Publication:* Curr Med Res Opin 2018 09; 34(12): 2095-2103. e-pub ahead of print 2018/08/17; doi: 10.1080/03007995.2018.1512961.

*Authors:* Rice JB, White AG, Scarpati LM, Wan GJ, Nelson WW.

**Comparison of Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Treated with Finasteride and Alpha Blocker Combination Therapy Versus Alpha Blocker Monotherapy in China: An Analysis of Electronic Medical Record Data.**

*Publication:* Adv Ther 2018 08; 35(8): 1191-1198. doi: <http://dx.doi.org/10.1007/s12325-018-0748-3>.

*Authors:* Fu Y, Han S, Wang L, Gao W, Wu E, Cao X, Wang J.

**Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication.**

*Publication:* BMC Infect Dis 2018 08; 18(1): 438. e-pub ahead of print 2018/08/31; doi: 10.1186/s12879-018-3333-0.

*Authors:* Vekeman F, Weiss L, Aram J, Ionescu-Iltu R, Moosavi S, Xiao Y, Cheng WY, Bhak RH, Tawadrous M, Capparella MR, Montravers P, Duh MS.

**Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.**

*Publication:* Ophthalmology 2017 12; 124(12): 1799-1807. e-pub ahead of print 2017/07/12; doi: 10.1016/j.ophtha.2017.06.017.

*Authors:* Suhler EB, Thorne JE, Mittal M, Betts KA, Tari S, Camez A, Bao Y, Joshi A.

**Treatment Patterns, Complications, and Health Care Utilization Among Endometriosis Patients Undergoing a Laparoscopy or a Hysterectomy: A Retrospective Claims Analysis.**

*Publication:* Adv Ther 2017 11; 34(11): 2436-2451. e-pub ahead of print 2017/10/19; doi: 10.1007/s12325-017-0619-3.

*Authors:* Surrey ES, Soliman AM, Yang H, Du EX, Su B.

**Engagement in health and wellness: An online incentive-based program.**

*Publication:* Prev Med Rep 2017 09; 7: 86-90. e-pub ahead of print 2017/06/20; doi: 10.1016/j.pmedr.2017.05.013.

*Authors:* Gibson TB, Maclean JR, Carls GS, Moore BJ, Ehrlich ED, Fener V, Goldberg J, Mechanic E, Baigel C.

**Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests.**

*Publication:* J Med Econ 2017 08; 20(8): 777-785. e-pub ahead of print 2017/04/14; doi: 10.1080/13696998.2017.1314969.

*Authors:* Li J, Houle CR, Spalding JR, Yang H, Xiang CQ, Kitt TM, Kristy RM, Wu EQ.

**Effect of Adalimumab on Visual Functioning in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.**

*Publication:* JAMA Ophthalmol 2017 06; 135(6): 511-518. doi: 10.1001/jamaophthalmol.2017.0603.

*Authors:* Sheppard J, Joshi A, Betts KA, Hudgens S, Tari S, Chen N, Skup M, Dick AD.

**Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas.**

*Publication:* Urology 2017 06; 104: 110-114. e-pub ahead of print 2017/03/07; doi: 10.1016/j.urology.2017.02.036.

*Authors:* Swallow E, King S, Song J, Peeples M, Signorovitch JE, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Sparagana S.

**Retreatment Rates Among Endometriosis Patients Undergoing Hysterectomy or Laparoscopy.**

*Publication:* J Womens Health (Larchmt) 2017 06; 26(6): 644-654. doi: 10.1089/jwh.2016.6043.

*Authors:* Soliman AM, Du EX, Yang H, Wu EQ, Haley JC.

**Out-of-pocket medical costs and third-party healthcare costs for children with Down syndrome.**

*Publication:* Am J Med Genet A 2017 03; 173(3): 627-637. e-pub ahead of print 2016/12/15; doi: 10.1002/ajmg.a.38050.

*Authors:* Kageleiry A, Samuelson D, Duh MS, Lefebvre P, Campbell J, Skotko BG.

**Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis.**

*Publication:* JAMA Ophthalmol 2016 11; 134(11): 1237-1245. e-pub ahead of print 2016/09/09; doi: 10.1001/jamaophthalmol.2016.3229.

*Authors:* Thorne JE, Suhler E, Skup M, Tari S, Macaulay D, Chao J, Ganguli A.

**Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis.**

*Publication:* Acta Ophthalmol 2016 08; 94(5): e331-339. e-pub ahead of print 2016/03/05; doi: 10.1111/aos.12987.

*Authors:* Thorne JE, Skup M, Tundia N, Macaulay D, Revol C, Chao J, Joshi A, Dick AD.

**Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population.**

*Publication:* Reprod Health 2016 08; 13(1): 96. e-pub ahead of print 2016/08/24; doi: 10.1186/s12978-016-0211-3.

*Authors:* Law A, Pilon D, Lynen R, Laliberte F, Gozalo L, Lefebvre P, Duh MS.

**The direct and indirect costs associated with endometriosis: a systematic literature review.**

*Publication:* Hum Reprod 2016 04; 31(4): 712-722. e-pub ahead of print 2016/02/07; doi: 10.1093/humrep/dev335.

*Authors:* Soliman AM, Yang H, Du EX, Kelley C, Winkel C.

**Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.**

*Publication:* Ophthalmology 2016 03; 123(3): 655-662. e-pub ahead of print 2015/12/30; doi: 10.1016/j.ophtha.2015.10.028.

*Authors:* Dick AD, Tundia N, Sorg R, Zhao C, Chao J, Joshi A, Skup M.

**The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013.**

*Publication:* Am J Obstet Gynecol 2015 08; 213(2): 141-160. doi: 10.1016/j.ajog.2015.03.019.

*Authors:* Soliman AM, Yang H, Du EX, Kelkar SS, Winkel C.

**Using ClinicalTrials.gov to supplement information in ophthalmology conference abstracts about trial outcomes: A comparison study.**

*Publication:* PLoS One 2015 06; 10 (6) (no pagination)(e0130619). doi: <http://dx.doi.org/10.1371/journal.pone.0130619>.

*Authors:* Scherer RW, Huynh L, Ervin AM, Dickersin K.

**Incremental direct and indirect costs of untreated vasomotor symptoms.**

*Publication:* Menopause 2015 03; 22(3): 260-266. doi: 10.1097/GME.0000000000000320.

*Authors:* Sarrel P, Portman D, Lefebvre P, Lafeuille MH, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM.

**Healthcare utilization and costs among women diagnosed with uterine fibroids: A longitudinal evaluation for 5 years pre and post diagnosis.**

*Publication:* Current Medical Research and Opinion 2015 01; (0): 1-38.

*Authors:* Fuldeore M, Yang H, Soliman AM, Winkel C.



**Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases.**

*Publication:* Fertil Steril 2015 01; 103(1): 163-171. doi: 10.1016/j.fertnstert.2014.10.011.

*Authors:* Fuldeore M, Yang H, Du EX, Soliman AM, Wu EQ, Winkel C.

**Kidney involvement in tuberous sclerosis complex: The impact on healthcare resource use and costs.**

*Publication:* J Med Econ 2015 01; 18(12): 1060-1070. doi: http://dx.doi.org/10.3111/13696998.2015.10759953.

*Authors:* Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

**Duloxetine use in employees with low back pain: treatment patterns and direct and indirect costs.**

*Publication:* Pain Medicine 2014 06; 15(6): 1015-1026. doi: 10.1111/pme.12362.

*Authors:* Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW.

**Burden of venous leg ulcers in the United States.**

*Publication:* J Med Econ 2014 05; 17(5): 347-356. doi: 10.3111/13696998.2014.903258.

*Authors:* Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

**Medicaid spending on contraceptive coverage and pregnancy-related care.**

*Publication:* Reprod Health 2014 03; 11(1): 20. doi: 10.1186/1742-4755-11-20.

*Authors:* Laliberte F, Lefebvre P, Law A, Duh MS, Pocoski J, Lynen R, Darney P.

**Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copies.**

*Publication:* Expert Rev Clin Pharmacol 2013 11; 6(6): 691-701. doi: 10.1586/17512433.2013.843450.

*Authors:* Kaltenboeck A, Long G, Hayes-Larson E, Lopes Gde L.

**Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA.**

*Publication:* Journal of ophthalmic inflammation and infection 2013 11; 3(1): 64.

*Authors:* Chu DS, Johnson SJ, Mallya UG, Davis MR, Sorg RA, Duh MS.

**Systematic literature review of the costs of pregnancy in the US.**

*Publication:* PharmacoEconomics 2013 11; 31(11): 1005-1030. doi: 10.1007/s40273-013-0096-8.

*Authors:* Huynh L, McCoy M, Law A, Tran KN, Knuth S, Lefebvre P, Sullivan S, Duh MS.

**Medical resource use and costs associated with chylomicronemia.**

*Publication:* J Med Econ 2013 03; 16(5): 657-666. doi: 10.3111/13696998.2013.779277.

*Authors:* Gaudet D, Signorovitch J, Swallow E, Fan L, Tremblay K, Brisson D, Meyers C, Gruenberger JB.

**Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain.**

*Publication:* Pain Medicine 2012 09; 13(9): 1110-1120. doi: 10.1111/j.1526-4637.2012.01454.x.

*Authors:* Kavanagh S, Kwong W, Hammond G, Nelson W, Upmalis D, Yang M.

**Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.**

*Publication:* Pain Pract 2012 09; 12(7): 533-540. doi: 10.1111/j.1533-2500.2011.00526.x.

*Authors:* Reed C, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Mullen RE, Swindle R.

**Duloxetine use in chronic low back pain: treatment patterns and costs.**

*Publication:* PharmacoEconomics 2012 07; 30(7): 595-609. doi: 10.2165/11598130-000000000-00000.

*Authors:* Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW.

**Cost burden and treatment patterns associated with management of heavy menstrual bleeding.**

*Publication:* J Womens Health (Larchmt) 2012 05; 21(5): 539-547. doi: 10.1089/jwh.2011.3147.

*Authors:* Jensen JT, Lefebvre P, Laliberte F, Sarda SP, Law A, Pocoski J, Duh MS.

**Economic burden and quality of life of vulvodynia in the United States.**

*Publication:* Current Medical Research & Opinion 2012 04; 28(4): 601-608. doi: 10.1185/03007995.2012.666963.

*Authors:* Xie Y, Shi L, Xiong X, Wu E, Veasley C, Dade C.

**Effects of quinestrol and levonorgestrel on populations of plateau pikas, *Ochotona curzoniae*, in the Qinghai-Tibetan Plateau.**

*Publication:* Pest Manag Sci 2012 04; 68(4): 592-601. doi: 10.1002/ps.2302.

*Authors:* Liu M, Qu J, Yang M, Wang Z, Wang Y, Zhang Y, Zhang Z.

**Direct and indirect costs associated with Dupuytren's contracture.**

*Publication:* J Med Econ 2012 03; 15(4): 664-671. doi: 10.3111/13696998.2012.670678.

*Authors:* Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P.

**Prevalence and costs of osteoporotic patients with subsequent non-vertebral fractures in the US.**

*Publication:* Osteoporos Int 2011 10; 22(10): 2611-2621. doi: 10.1007/s00198-010-1494-9.

*Authors:* Pike CT, Birnbaum HG, Schiller M, Swallow E, Burge RT, Edgell ET.

**A qualitative study on feasibility of a web-based Women's Health Portal and Information System.**

*Publication:* Patient 2011 07; 4(1): 67-68. doi: 10.2165/11586790-000000000-00000.

*Authors:* Yang M, Kosinski M, Boulanger R.

**Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.**

*Publication:* J Med Econ 2011 04; 14(3): 324-334. doi: 10.3111/13696998.2011.578698.

*Authors:* Vekeman F, LaMori JC, Laliberte F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

**Analysis of genetic diversity of gemplasm of *Pinellia ternata* based on SRAP.**

*Publication:* China Journal of Chinese Materia Medica 2011 02; 36(3): 334-337.

*Authors:* Yang M, Chen K.

**Economic burden of privately insured non-vertebral fracture patients with osteoporosis over a 2-year period in the US.**

*Publication:* Osteoporos Int 2011 01; 22(1): 47-56. doi: 10.1007/s00198-010-1267-5.

*Authors:* Pike C, Birnbaum HG, Schiller M, Swallow E, Burge RT, Edgell ET.

**Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.**

*Publication:* PharmacoEconomics 2010 04; 28(5): 395-409. doi: 10.2165/11531040-000000000-00000.

*Authors:* Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET.

**Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder.**

*Publication:* Appl Health Econ Health Policy 2010 02; 8(2): 129-140. doi: 10.2165/11532210-000000000-00000.

*Authors:* Rendas-Baum R, Yang M, Gricar J, Wallenstein GV.

**Interpreting score differences in the Insomnia Severity Index: using health-related outcomes to define the minimally important difference.**

*Publication:* Current Medical Research & Opinion 2009 10; 25(10): 2487-2494. doi: 10.1185/03007990903167415.

*Authors:* Yang M, Morin CM, Schaefer K, Wallenstein GV.

**Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia.**

*Publication:* J Pain 2009 09; 10(9): 976-983. doi: 10.1016/j.jpain.2009.03.012.

*Authors:* White LA, Robinson RL, Yu AP, Kaltenboeck A, Samuels S, Mallett D, Birnbaum HG.

**Burden of premenstrual dysphoric disorder on health-related quality of life.**

*Publication:* J Womens Health (Larchmt) 2008 01; 17(1): 113-121. doi: 10.1089/jwh.2007.0417.

*Authors:* Yang M, Wallenstein G, Hagan M, Guo A, Chang J, Kornstein S.

**Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss.**

*Publication:* Journal of Occupational Environmental Medicine 2008 01; 50(1): 13-24. doi: 10.1097/JOM.0b013e31815c44b.

*Authors:* White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL.

**Actual versus predicted first-year utilization patterns of teriparatide in patients with employer-sponsored health insurance.**

*Publication:* Current Medical Research & Opinion 2007 12; 23(12): 3215-3222. doi: 10.1185/030079907X242908.

*Authors:* Meadows ES, Rousculp M, Sasser AC, Birnbaum HG, Moynour E, Mallet D, Johnston JA.

**Mapping MOS Sleep Scale scores to SF-6D utility index.**

*Publication:* Current Medical Research & Opinion 2007 09; 23(9): 2269-2282. doi: 10.1185/030079907X210796.

*Authors:* Yang M, Dubois D, Kosinski M, Sun X, Gajria K.

**The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids.**

*Publication:* Journal of Occupational Environmental Medicine 2007 05; 49(5): 493-506. doi: 10.1097/JOM.0b013e31805f6cf2.

*Authors:* Lee DW, Ozminkowski RJ, Carls GS, Wang S, Gibson TB, Stewart EA.

**Hemodynamic changes induced by positive pressure capnothorax during thoracoscopic thymectomy.**

*Publication:* Chirurgia (Bucur) 2007 05; 102(3): 263-270.

*Authors:* Tomescu D, Grigorescu B, Nitulescu R, Tomulescu V, Popescu I, Tulbure D.

**Annual costs associated with diagnosis of uterine leiomyomata.**

*Publication:* Obstetrics & Gynecology 2006 10; 108(4): 930-937. doi: 10.1097/01.AOG.0000234651.41000.58.

*Authors:* Hartmann KE, Birnbaum H, Ben-Hamadi R, Wu EQ, Farrell MH, Spalding J, Stang P.

**Lifetime Costs of Patients with Clinically Detected Uterine Fibroids: An Employer's Perspective.**

*Publication:* Drug Benefit Trends 2006 18(7): 405.

*Authors:* Wu E, Ben-Hamadi R, Birnbaum H, Farrell M, Spalding J, Stang P, Hartmann K.

**Assessing the economic impact of chronic conditions in postmenopausal women.**

*Publication:* Expert Opin Pharmacother 2005 09; 6(11): 1803-1814. doi: 10.1517/14656566.6.11.1803.

*Authors:* Sasser AC, Taylor M, Birnbaum HG, Schoenfeld MJ, Oster EF, Rousculp M.

**Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.**

*Publication:* Womens Health Issues 2005 05; 15(3): 97-108. doi: 10.1016/j.whi.2004.11.006.

*Authors:* Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D.

**Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently.**

*Publication:* J Rheumatol 2004 08; 31(8): 1621-1629.

*Authors:* Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Wolfe F.

**Economic Impact Analysis: Proposition 71 - California Stem Cell Research and Cures Initiative.**

*Publication:* Report Commissioned by Californians for Stem Cell Research and Cures 2004.

*Authors:* Baker L, Deal B.

**Economic cost and epidemiological characteristics of patients with fibromyalgia claims.**

*Publication:* J Rheumatol 2003 06; 30(6): 1318-1325.

*Authors:* Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ.

**The effects of chronic medical conditions on work loss and work cutback.**

*Publication:* Journal of Occupational Environmental Medicine 2001 03; 43(3): 218-225.

*Authors:* Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS.

**Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts.**

*Publication:* Pharmacoepidemiol Drug Saf 1999 07; 8(4): 275-283. doi: 10.1002/(SICI)1099-1557(199907)8:4<275::AID-PDS427>3.0.CO;2-D.

*Authors:* Duh MS, Walker AM, Kronlund KH, Jr.

**Calculating the workplace cost of chronic disease.**

*Publication:* Bus Health 1995 09; 13(9): 27-28, 30.

*Authors:* Greenberg PE, Finkelstein SN, Berndt ER.

**An alternative in terminal care: results of the National Hospice Study.**

*Publication:* J Chronic Dis 1986 01; 39(1): 9-26.

*Authors:* Greer DS, Mor V, Morris JN, Sherwood S, Kidder D, H. B.

**An Alternative in Terminal Care: Results of the National Advice on Hospice Care for Benefits Design.**

*Publication:* Business and Health 1985.

*Authors:* Birnbaum H.

## Abstracts

**Real-world utilization of assisted reproductive technology (ART) and controlled ovarian stimulation (COS) – a retrospective claims database study from 2016 to 2022.**

New Orleans, LA October 14 - 18, 2023.

*Authors:* Jungheim E, Yang M, Guo K, Song W, Jiang A, Meng Y, Zhao A, Guo A.

**Evaluation of NT-proBNP as surrogate endpoint in AL amyloidosis: development of a platform for federated, multi-institution meta-analysis of randomized trials.**

Heidelberg, Germany 04-08 September 2022.

*Authors:* Dispenzieri A, Signorovitch J, Maurer M, Huang X, Sanchowala V, Dunmon P, Klersy C, Gambini G, Brown D, Barbachano Y, Adigun R, Hsu K, Lousada I, Xiu L, Faller DV, Labotka R, Merlini G, Palladini G.

**Real-world Outcomes of Onasemnogene Asepavovec Alone or With Prior Nusinersen in Pediatric SMA: Interim Analysis of a US Chart Review.**

*Abstract:* World Muscle Society (WMS) 2021 Virtual Congress, Virtual September 20–24, 2021.

*Authors:* Dabbous O, Yang M, Georgieva M, Toro W, LaMarca N, Patel A, Minkoff N, Carley C, Zhu J, Anderson A, Wu E.

**The Economic Burden of Macular Edema (ME) Associated with Non-infectious Uveitis (NIU) – A US Commercial Payer's Perspective.**

*Abstract:* Virtual ISPOR 2021, Virtual May 17-20, 2021.

*Authors:* Hariprasad SM, Joseph G, Gagnon-Sanschagrin P, E. S, Bédard J, Guérin A, Albini TA.

**An Exploratory Analysis of the Survival Benefits in Commercially Insured Patients with Hepatic Encephalopathy (HE) Treated with Rifaximin versus Lactulose Alone using US Claims Data.**

*Abstract:* ISPOR 2021, Virtual May 17-20, 2021.

*Authors:* Volk ML, Guérin A, Shi S, Joseph G, Heimanson ZA, M.

**Outcomes of single-agent onasemnogene abeparvovec or nusinersen, and of nusinersen switching to onasemnogene abeparvovec, in patients with spinal muscular atrophy: Results of a provider survey in the United States.**

*Abstract:* American Academy of Neurology Virtual Annual Meeting, Virtual April 17 -22, 2021.

*Authors:* Yang M, Georgieva M, Wu E, Dabbous O, LaMarca N, Shenouda L, Patel A, Toro W, Bischof M, Minkoff N.

**A Chart Review Study of Dry Eye Disease Symptoms and Treatment Patterns Among Patients Receiving Lifitegrast in the United States and Canada.**

*Abstract:* Virtual ISPOR Europe, Dec 2020.

*Authors:* Syntosi A, Salzger MP, Castriota F, Nguyen C, Huynh L, Sloesen B.

**Indirect Burden of Illness in Patients with Palmoplantar Pustulosis in the United States.**

*Abstract:* Virtual ISPOR Europe.

*Authors:* Hanna M, Singer D, Tang W, Zhou J, Macaulay D, Valdecantos WC, Wu JJ.

**Identification of undiagnosed NASH: Development and application of a real-world prediction model.**

*Abstract:* 71st Annual Meeting of the American Association for the Study of Liver Diseases, Virtual Nov 2020.

*Authors:* Kponee-Shovein K, Bobbili P, Law A, Wong B, Titievsky L, Mozaffari E, Randhawa A, Davis P, Laliberte F, Mahin M, Fakhri I, Sheng Duh M.

**Outcomes of Pediatric Patients with Spinal Muscular Atrophy (SMA) Treated with Onasemnogene Abeparvovec: Results of a Provider Survey in the United States.**

*Abstract:* International Society of Pharmacoeconomics and Outcome Research Europe 2020 Conference, Milan, Italy November 14-18, 2020.

*Authors:* Dabbous O, Yang M, LaMarca N, Wu E, Patel A, N. M, Toro W, Bischof M, Droege M, Wolff D, Georgieva M, Reyna S.

**Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy in the United States.**

*Abstract:* AMCP-Nexus 2020 Congress November 19-21, 2020.

*Authors:* Arjunji R, Zhou J, Patel A, Edwards ML, Harvey M, Wu E, Dabbous O.

**Assessing the Relationship between Lifelong Value and Pricing for Orphan Drugs in Ultra-Rare Diseases.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Dabbous O, Zhou ZY, Tang C, Harvey M, Wu EQ, Arjunji R.

**Burden of Illness of Spinal Muscular Atrophy: An Update.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Droege M, Dabbous O, Arjunji R, Gauthier-Loiselle M, Cloutier M, Sproule DM.

**Comorbidity and Economic Burden of Peanut Allergy in Privately-Insured Pediatric Patients in the United States.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Tilles S, Birchwood C, Robison DR, Damle V, Norrett KE, Hass S, Guerin A, Latremouille-Viau D.

**Healthcare Resource Utilization and Direct Healthcare Cost Related to Peanut Allergy in Pediatric Medicaid Patients.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Tilles S, Birchwood C, Robison DR, Damle V, Norrett KE, Hass S, Guerin A, Latremouille-Viau D.

**Comparaison de la survie, de la fonction motrice et des étapes de développement moteur de l'AVXS-101 et du nusinersen dans le traitement des nourrissons atteints d'amyotrophie spinale de type 1 (ASI-1).**

*Abstract:* Journées de Neurologie de Langue Française - 2019 Congrès, Lille, France Apr 16-19, 2019.

*Authors:* Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner DE, Sproule DM.

**Outcomes comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1 (SMA1).**

*Abstract:* Muscular Dystrophy Association - 1st Clinical and Research Conference, Orlando, FL Apr 16-19, 2019.

*Authors:* Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner DE, Sproule DM.

**Number needed to treat in spinal muscular atrophy type 1 (SMA1) with AVXS-101 relative to nusinersen.**

*Abstract:* Association Francaise contre les Myopathies Telethon (AFMT), Bordeaux, France Mar 25-28, 2019.

*Authors:* Dabbous O CM, Guerin A, Pivneva I, Wu E Q, Droege M, Sproule D M.

**Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.**

*Abstract:* AMCP's 31st Annual Meeting, San Diego, CA Mar 25-28, 2019.

*Authors:* Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guerin A, Pivneva I, Wu EQ, Arjunji R, Feltner DE, Sproule DM.

**Real-World Experience of Generalized Lipodystrophy Patients Enrolled in the Metreleptin Early Access Program: Initial Results.**

*Abstract:* ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Cook K, Stears A, Araujo-Vilar D, Santini F, O'Rahilly S, Ceccarini G, Frois C, Bradt P, Savage D.

**Burden of illness associated with generalised lipodystrophy (GL) in leptin replacement therapy-naive patients: A longitudinal medical chart review study.**

*Abstract:* 54th Annual Meeting of the European Association for the Study Diabetes, EASD 2018, Berlin, Germany Oct 1-5, 2018.

*Authors:* Akinci B, Oral E, Neidert A, Rus D, Cheng W, Thompson-Leduc P, Salinardi T, Cochran E, Brown R.

**Number Needed to Treat in Patients with Spinal Muscular Atrophy Type 1.**

*Abstract:* 23rd International Annual Congress of the World Muscle Society, Mendoza, Argentina Oct 2-6, 2018

*Authors:* Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu EQ, Sproule DM.

**Number needed to treat in patients with spinal muscular atrophy type 1 with AVXS-101 relative to nusinersen**

*Abstract:* AMCP Nexus 2018, Orlando, FL Oct 22-25, 2018.

*Authors:* Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu EQ, Droege M, Sproule DM.

**Disability burden in patients with tenosynovial giant cell tumors in the United States from employer perspective.**

*Abstract:* ASCO Quality Care Symposium, Phoenix, AZ Sept 28-29, 2018.

*Authors:* Lin FI-I, R; Pivneva, I; Wynant, W; Shi, S; Shohudi Mojdehi, A; Wu, E.Q; Kwong, J; Abraham, J.A.

**Number needed to treat in patients with spinal muscular atrophy type 1 treated with AVXS-101 relative to nusinersen.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu EQ, Sproule DM.

**Tuberous Sclerosis Complex (TSC) and epilepsy manifestations: The impact of refractory epilepsy on health-related quality of life (HRQoL).**

*Abstract:* 70th Annual Meeting of the American Academy of Neurology, Apr 21-27, 2018.

*Authors:* Vergeer M, De Ranitz-Greven WL, Neary MP, Ionescu-Iltu R, Emond B, Duh MS, Zonnenberg B.

**Dry eye symptoms and treatment satisfaction with ophthalmic cyclosporine: results of a claims database survey.**

*Abstract:* American Academy of Ophthalmology, Chicago, IL Nov 11-14, 2017.

*Authors:* Bradley JL, Özer-Stillman I, Pivneva I, Guerin A, Evans AM, Dana R.

**Dry eye disease ranking among common reasons for seeking eye care in a United States claims database.**

*Abstract:* American Academy of Optometry, Chicago, IL Oct 11-14, 2017.

*Authors:* Bradley JL, Özer-Stillman I, Pivneva I, Guerin A, Evans AM, Dana R.

**Liver damage in lipodystrophy and impact of metreleptin: Experience from a large retrospective review.**

*Abstract:* 68th Annual Meeting of the American Association for the Study of Liver Diseases, Washington DC Oct 20-24, 2017.

*Authors:* Akinci B, Oral EA, Neidert A, Rus D, Cheng W, Yang M, Salinardi T, Cochran E, Brown RJ.

**Ranking of dry eye disease among common reasons for seeking eye care in a United States claims database.**

*Abstract:* Kongress der Deutschen Ophthalmologischen Gesellschaft (DOG) Berlin, Germany Sep 28 - Oct 1, 2017.

*Authors:* Özer-Stillman I, Bradley JL, Pivneva I, Guerin A, Evans AM, Dana R.

**A comparison of comorbidities among patients with and without dry eye disease in a large US healthcare system.**

*Abstract:* Congress of the European Society of Ophthalmology Symposium & Congress, Barcelona, Spain June 10-13, 2017.

*Authors:* Dana R, Bradley JL, Guerin A, Pivneva I, Dea K, Evans AM, Özer-Stillman I.

**HPR predicting the future development of spondyloarthritis among patients with idiopathic acute anterior uveitis using real-world data.**

*Abstract:* Annual European Congress of Rheumatology, Madrid, Spain June 14-17, 2017.

*Authors:* Haroon M, Betts KA, Mu F, Skup M, Anderson JK, Joshi AD.

**Incidence and prevalence of dry eye disease: Estimates from claims database analysis in a large United States health care system.**

*Abstract:* Congress of the European Society of Ophthalmology Symposium & Congress, Ottawa, ON, Canada June 28-30, 2017.

*Authors:* Özer-Stillman I, Bradley JL, Guerin A, Pivneva I, Evans AM, Dana R, Schaumberg DA.

**Treatment patterns and clinical characteristics among patients with tuberous sclerosis complex related angiomyolipomas.**

*Abstract:* 2017 International Research Conference on TSC & LAM, Washington, DC June 22-24, 2017.

*Authors:* Swallow E, Song J, Peebles M, Meiselbach M, Signorovitch J, Said Q, Prestifilippo J, Wong M, Northrup H, Frost M, Korf B, Sparagana S.

**Comorbidities among patients with dry eye disease in a large US healthcare system.**

*Abstract:* American Society of Cataract and Refractive Surgery•American Society of Ophthalmic Administrators Symposium & Congress, Los Angeles, CA May 5-9, 2017.

*Authors:* Dana R, Bradley JL, Guerin A, Pivneva I, Dea K, Evans AM, Özer-Stillman I.

**Estimates of incidence and prevalence of dry eye disease across age groups in the US using data from a large healthcare system.**

*Abstract:* American Academy of Optometry 95th Annual Meeting, Anaheim, CA Nov 9-12, 2016

*Authors:* Bradley JL, Guerin A, Pivneva I, Evans AM, Özer-Stillman I, Dana R, Schaumberg DA.

**Adherence and persistence with cyclosporine ophthalmic emulsion for treatment of dry eye disease in a large US healthcare System.**

*Abstract:* 2016 Annual Meeting of the American College of Clinical Pharmacy, Hollywood, FL Oct 23-26, 2016.

*Authors:* Schaumberg DA, Bradley J, Guerin A, Pivneva I, Evans A, Stillman IO, Dana R.

**Incidence and prevalence of dry eye disease in a large US healthcare system across a wide range of ages.**

*Abstract:* American Academy of Ophthalmology, Chicago, IL Oct 15-18, 2016

*Authors:* Dana R, Bradley JL, Guerin A, Pivneva I, Evans AM, Özer-Stillman I, Schaumberg DA.

**Impact of the introduction of newer Long Acting Reversible Contraceptive (LARC) methods on LARC use in a commercially insured population.**

*Abstract:* 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland Aug 25-28, 2016.

*Authors:* Law A, Pilon D, Lynen R, Laliberte F, Gozalo L, Lefebvre P, Duh MS.

**Development of a Risk Score for Fluconazole Failure among Patients with Invasive Candidiasis.**

*Abstract:* ASM 2016 | ICAAC 2016, Boston, MA Jun 16-20, 2016.

*Authors:* Ostrosky-Zeichner L, Harrington R, Azie N, Yang H, Li N HY, Xie J, Lin PL, Ohashi E, Koo V, Wu EQ, Zhao J, Koo V, Wu E.

**Comorbidities and symptoms among endometriosis patients: A systematic literature review.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Soliman AM, Yang H, Du EX, Wu EQ, Castelli-Haley J, Winkel C.

**Impact of the introduction of newer long acting reversible contraceptive (LARC) methods on LARC use in a commercially insured population.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Law A, Pilon D, Lynen R, Laliberte F, Gozalo L, Lefebvre P, Duh MS.

**Income growth trajectory for parents of children with down syndrome in the United States.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Samuelson D, Kageleiry A, Duh MS, Lefebvre P, Campbell JY, DerSarkissian M, Haider BA, Skotko BG.

**Measuring opportunities to improve health outcomes via individualized treatment assignment.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Patterson-Lomba O, Signorovitch J.

**Rates of subsequent endometriosis-related surgeries following an initial laparoscopy or hysterectomy: A longitudinal analysis of commercially insured endometriosis patient in the united states.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Soliman AM, Yang H, Du EX, Wu EQ, Castelli-Haley J, Winkel C.

**A systematic literature review of comorbidities and symptoms among uterine fibroids patients between 2000 and 2013.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Soliman AM, Yang H, Du EX, Kelkar S, Winkel C.

**Comparison of Annual Treatment Costs for Patients Treated with Infusion versus Injectable Biologics.**

*Abstract:* Academy of Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, CA Apr 19-22, 2016.

*Authors:* Skup M, Macaulay D, Wei J, Terasawa E, Chao J.

**Subependymal giant cell astrocytoma treatment patterns among patients with tuberous sclerosis complex.**

*Abstract:* 68th American Academy of Neurology Annual Meeting, Vancouver, BC, Canada Apr 15-21, 2016.

*Authors:* Krueger D, Song J, Swallow E, King S, Peebles M, Signorovitch J, Liu Z, Prestifilippo J, Korf B, Sparagana S, Wong M, Kohrman M.

**The Economic Burden Associated with Zygomycolosis-Related Hospitalizations in the U.S.**



*Abstract:* IDSA IDWeek annual meeting, San Diego, CA Oct 7-11, 2015.

*Authors:* Yang H, Song J, Yang C, Kelkar S, Lee E, Fan A, Azie N, Spalding J.

**Demographic and Clinical Characteristics of Patients with Tuberous Sclerosis Complex in a TSC Patient Database.**

*Abstract:* International TSC Research Conference, Windsor, UK Sep 10-12, 2015.

*Authors:* Swallow E, King S, Song J, Peeples M, Signorovitch J, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Northrup H, Sparagana S.

**Monitoring testing patterns among patients with tuberous sclerosis complex-related angiomyolipomas.**

*Abstract:* International TSC Research Conference, Windsor, UK Sept 10-12, 2015.

*Authors:* Swallow E, King S, Song J, Peeples M, Signorovitch J, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Northrup H, Sparagana S.

**Cellular rejuvenation and ageing-proteome by Ginsenoside 20(S)-Rg3.**

*Abstract:* 40th FEBS Congress: The Biochemical Basis of Life, Berlin, Germany July 4-9, 2015.

*Authors:* Kim YR, Baek SJ, Kang YM, Oh KS, Kwon J, Choi JS.

**Kidney involvement in tuberous sclerosis complex: The impact on health care resource use and costs in The Netherlands.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Zonnenberg BA.

**Out-of-pocket medical costs for parents with children with down syndrome in the united states.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Kageleiry A, Samuelson D, Duh MS, Lefebvre P, DerSarkissian M, Campbell JY, Skotko BG.

**Treatment patterns of women diagnosed with uterine fibroids 5 years pre and post diagnosis: A longitudinal retrospective claims analysis of a commercially insured population in the US.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C.

**Incremental direct and indirect cost of untreated vasomotor symptoms (VMS).**

*Abstract:* 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Taipei, Taiwan (Republic of China) Oct 24-27, 2014.

*Authors:* Sarrel P, Lefebvre P, Lafeuille MH, Gravel J, Sheng Duh M, Aupperle PM, Portman D.

**A longitudinal retrospective claims analysis of healthcare costs incurred by uterine fibroids patients.**

*Abstract:* 70th Annual Meeting of the American Society for Reproductive Medicine, Honolulu, HI Oct 18-22, 2014.

*Authors:* Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C.

**Treatment patterns among US women diagnosed with endometriosis: A retrospective claims analyses pre-and post-diagnosis.**

*Abstract:* 70th Annual Meeting of the American Society for Reproductive Medicine, Honolulu, HI Oct 18-22, 2014.

*Authors:* Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C.

**Diagnosis and treatment patterns among patients with tuberous sclerosis complex-related angiomyolipomas.**

*Abstract:* World TSC Conference, Washington, DC July 3-6, 2014.

*Authors:* Sparagana S, Krueger D, Swallow E, Nichols T, King S, Signorovitch J, Liu Z, Prestifilippo J, Nakagawa JA, Roberds S, Kohrman M, Frost M.

**Significant Economic Burden Among Endometriosis Patients before and after Diagnosis: A Retrospective Claims Database Analysis.**

*Abstract:* 96th Annual Meeting and Expo of the Endocrine Society, Chicago, IL June 21-24, 2014.

*Authors:* Soliman AM, Fuldeore MJ, Yang H, Du EX, Wu EQ, Winkel CA.

**Kidney dysfunction and healthcare resource utilization in tuberous sclerosis complex patients in the Netherlands.**

*Abstract:* 51st ERA-EDTA Congress, Amsterdam, Netherlands May 31-Jun 3, 2014.

*Authors:* Magestro M, Vekeman F, Nichols T, Karner P, Duh MS, Srivastava B, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

**Risk of leaving the workforce in non-infectious uveitis.**

*Abstract:* Association for Research in Vision and Ophthalmology, Orlando, FL May 4-8, 2014.

*Authors:* Tundia N, Skup M, Sorg R, Macaulay D, Chao J, Mulani P, Thorne JE.

**Risk of ocular complications in non-infectious uveitis.**

*Abstract:* Association for Research in Vision and Ophthalmology, Orlando, FL May 4-8, 2014.

*Authors:* Skup M, Tundia N, Sorg R, Chao J, Mulani P, Dick A.

**Clinical and economic burden of vasomotor symptoms among untreated menopausal women.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Sarrel P, Lefebvre P, Lafeuille M, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM, Portman D.

**Direct and indirect resource use and costs associated with non-infectious non-anterior uveitis.**

*Abstract:* 2014 Annual Meeting of the Association for Research in Vision and Ophthalmology, Orlando, FL May 4-8, 2014.

*Authors:* Thorne JE, Tundia N, Skup M, Macaulay D, Revol C, Chao J, Mulani P, Dick AD.

**Direct and indirect costs for women with vasomotor symptoms (VMS) receiving lower-versus higher-dose paroxetine.**

*Abstract:* 24th Annual Meeting of the North American Menopause Society, Dallas, TX Oct 9-12, 2013.

*Authors:* Portman D, Lafeuille MH, Lefebvre P, Gravel J, Duh MS, Aupperle PM, Sarrel P.

**Incremental direct and indirect cost of untreated vasomotor symptoms (VMS).**

*Abstract:* 24th Annual Meeting of the North American Menopause Society, Dallas, TX Oct 9-12, 2013.

*Authors:* Sarrel P, Lefebvre P, Lafeuille MH, Gravel J, Sheng Duh M, Aupperle PM, Portman D.

**Actuarial analysis of Medicaid spending for contraception and pregnancy care.**

*Abstract:* 1st Global Conference on Contraception, Reproductive and Sexual Health, Copenhagen, Denmark May 22-25, 2013.

*Authors:* Laliberte F, Lefebvre P, Law A, Sheng Duh M, Lynen R, Darney P.

**Medicaid spending for users of contraceptives and pregnancy-related care.**

*Abstract:* 1st Global Conference on Contraception, Reproductive and Sexual Health, Copenhagen, Denmark May 22-25, 2013.

*Authors:* Laliberte F, Lefebvre P, Law A, Sheng Duh M, Lynen R, Darney P.

**Medical, drug, and work-loss costs of venous leg ulcers.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

**Actuarial analysis of Medicaid spending for contraception and pregnancy care.**

*Abstract:* 21st Annual Women's Health Congress, Washington, DC April 22-24, 2013.

*Authors:* Laliberte F, Lefebvre P, Law A, Duh MS, Lynen R, Darney P.

**Health care costs and utilization for privately insured patients treated for non-infectious uveitis in the United States.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Johnson S, Duh MS, Mallya U, Diener M, Sorg R, Chu D.

**Direct and indirect costs associated with dupuytren's contracture.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P.

**Health care resource utilization and costs in females with newly diagnosed heavy menstrual bleeding: An employer's perspective.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-24, 2011.

*Authors:* Jensen JT, Lefebvre P, Laliberte F, Sarda SP, Law A, Pocoski J, MS. D.

**New methods to adjust for selective crossover in survival analysis: In assessments of costeffectiveness of cancer therapies.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Delea TE, Duh MS, Wei LJ, Robins J.

**Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.**

*Abstract:* 30th Annual Scientific Meeting of the American Pain Society, Austin, TX May 19-21, 2011.

*Authors:* Swindle R, Birnbaum H, Ivanova J, Schiller M, Waldman T, Mullen R, Reed C.

**Real-world use of duloxetine for chronic low back pain: Treatment pattern and costs.**

*Abstract:* ISPOR 13th Annual European Congress, Prague Czech Republic Nov 6-9, 2010.

*Authors:* Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle R.

**Evaluation of cardiovascular diseases (CVDs) risk for patients with fibromyalgia syndrome in the United States.**

*Abstract:* 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Brighton, UK Aug 19-22, 2010.

*Authors:* Mease PJ, Duh MS, Vekeman F, Lefebvre P, Laliberte F, Boerstoeel-Streefland M, Jiang W, Zimetbaum PJ.

**Real-world use of duloxetine for low back pain and chronic low back pain: Treatment pattern, direct and indirect costs.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Johnstone B, Faries D, Risser R, Swindle R.

**The costs of non-vertebral osteoporotic fractures in the United States.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Birnbaum HG, Pike C, Schiller M, Sharma H, Gu A, Burge RT, Edgell ET.

**Real-world use of duloxetine for low back pain.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Ivanova J, Birnbaum HG, Schiller M, Kantor E, Waldman T, Johnstone BM, Faries D, Risser R, Swindle R.

**Clinical and economic outcomes among women using levonorgestrel-releasing intrauterine system (LNG-IUS).**

*Abstract:* ISPOR 2008, May 3-7, 2008.

*Authors:* Yu A, Wu E, Perrson B, Chang J, Costales A, Gricar J.

**Annual Costs Associated with Diagnosis of Uterine Fibroids.**

*Abstract:* The American College of Obstetricians and Gynecologists.

*Authors:* Hartmann KE, Birnbaum H, Wu EQ, Ben-Hamadi R, Spalding J, Stang P.

**Lifetime Costs of Patients with Clinically-Detected Uterine Fibroids: An Employer Perspective.**

*Abstract:* The American College of Obstetricians and Gynecologists.

*Authors:* Wu EQ, Birnbaum H, Farrell MH, Spalding J, Stang P, Hartmann KE.

**Using a budget impact model to predict first-year use of a new osteoporosis therapy.**

*Abstract:* ISPOR 2005, 2005.

*Authors:* Sasser A, Rousculp M, Birnbaum H, Moyneur E, Wu E, Marcus R.

**Validation of a Budget Impact Model in Predicting First-Year Use of a New Osteoporosis Therapy.**

*Abstract:* AMCP 2005.

*Authors:* Rousculp MD, Sasser AC, Birnbaum HG, Moyneur E, Wu EQ, Mallet D, Marcus R.

## Other (Health Policy, Market Access, and other topics)

### Journal Articles

**Characteristics of health-state utilities used in cost-effectiveness analyses: a systematic review of published studies in Asia.**

*Publication:* Health and Quality of Life Outcomes 2023 06; 21(1): 59. doi: 10.1186/s12955-023-02131-z.

*Authors:* Yang Z, Zeng X, Huang W, Chai Q, Zhao A, Chuang L-H, Wu B, Luo N.

**Specialty pharmacy: Incorporating workflow management and medication access into pharmacy lecture and laboratory courses.**

*Publication:* Curr Pharm Teach Learn 2023 02; 15(2): 194-200. e-pub ahead of print 2023/03/11; doi:

10.1016/j.cptl.2023.02.026.

*Authors:* Lee S, Young J, Pearce S, Hansen BK, Custer B, Bradley CL.

**Burden of Comorbidities and Healthcare Resource Utilization Among Medicaid-Enrolled Extremely Premature Infants.**

*Publication:* J Health Econ Outcomes Res 2022 12; 9(2): 147-155. e-pub ahead of print 2023/01/10; doi: 10.36469/001c.38847.

*Authors:* Mowitz ME, Gao W, Sipsma H, Zuckerman P, Wong H, Ayyagari R, Sarda SP.

**Food Marketing Practices of Major Online Grocery Retailers in the United States, 2019-2020.**

*Publication:* Journal of the Academy of Nutrition and Dietetics 2022 12; 122(12): 2295-2310.e2292. doi:

10.1016/j.jand.2022.04.003.

*Authors:* Moran AJ, Headrick G, Perez C, Greatsinger A, Taillie LS, Zatz L, Bleich SN, Rimm EB, Khandpur N.

**Cost-effectiveness analysis of robotic-arm assisted total knee arthroplasty.**

*Publication:* PLoS One 2022 11; 17(11): e0277980. e-pub ahead of print 2022/11/29; doi:

10.1371/journal.pone.0277980.

*Authors:* Hua Y, Salcedo J.

**Improving access to health services through health reform in Lesotho: Progress made towards achieving Universal Health Coverage.**

*Publication:* PLOS Global Public Health 2022 11; 2(11): e0000985. doi: 10.1371/journal.pgph.0000985.

*Authors:* Ndayizigiye M, Allan-Blitz L, Dally E, Abebe S, Andom A, Tlali R, Gingras E, Mokoena M, Msuya M, Nkundanyirazo P, Mohlouoa T, Mosebo F, Motsamai S, Mabathoana J, Chetane P, Ntlamelle L, Curtain J, Whelley C, Birru E, McBain R, Andrea D, Schwarz D, Mukherjee JS.

**Advancing the development of real-world data for healthcare research in China: challenges and opportunities.**

*Publication:* BMJ Open 2022 07; 12(7): e063139. e-pub ahead of print 2022/07/30; doi: 10.1136/bmjopen-2022-063139.

*Authors:* Zhong J, Zhang J, Fang H, Liu L, Xie J, Wu E.

**The Physician and Administrator-Reported Cost of Drug Utilization Management to Physician Practices: A Cross-Sectional Survey.**

*Publication:* PharmacoEconomics - Open 2022 07. doi: 10.1007/s41669-022-00351-5.

*Authors:* Edwards ML, Yin PT, Kuehn M, Bratti K, Kirson N, Jena A, Howell S.

**Real-World Data for Healthcare Research in China: Call for Actions.**

*Publication:* Value Health Reg Issues 2021 11; 27: 72-81. e-pub ahead of print 2021/11/30; doi: 10.1016/j.vhri.2021.05.002.

*Authors:* Xie J, Wu EQ, Wang S, Cheng T, Zhou Z, Zhong J, Liu L.

**Estimating the drivers of urban economic complexity and their connection to economic performance.**

*Publication:* R Soc Open Sci 2021 09; 8(9): 210670. e-pub ahead of print 2021/09/28; doi: 10.1098/rsos.210670.

*Authors:* Gomez-Lievano A, Patterson-Lomba O.

**Impact of Medication Adherence on Healthcare Resource Utilization, Work Loss, and Associated Costs in a Privately Insured Employed Population Treated with Adalimumab in the United States.**

*Publication:* J Occup Environ Med 2021 08. e-pub ahead of print 2021/08/20; doi: 10.1097/jom.0000000000002354.

*Authors:* Mittal M, Yang M, Shah M, Gao W, Carley C, Sherman BW.

**Compliance With Cannabis Act Regulations Regarding Online Promotion Among Canadian Commercial Cannabis-Licensed Firms.**

*Publication:* JAMA Netw Open 2021 07; 4(7): e2116551. e-pub ahead of print 2021/07/13; doi: 10.1001/jamanetworkopen.2021.16551.

*Authors:* Sheikhan NY, Pinto AM, Nowak DA, Abolhassani F, Lefebvre P, Duh MS, Witek TJ, Jr.

**Continuing trends in U.S. brand-name and generic drug competition.**

*Publication:* J Med Econ 2021 01; 24(1): 908-917. e-pub ahead of print 2021/07/14; doi: 10.1080/13696998.2021.1952795.

*Authors:* Grabowski H, Long G, Mortimer R, Bilginsoy M.

**Measuring The Impact Of Air Pollution On Health Care Costs.**

*Publication:* Health Aff (Millwood) 2020 12; 39(12): 2113-2119. e-pub ahead of print 2020/12/08.

*Authors:* Birnbaum HG, Carley CD, Desai U, Ou S, Zuckerman PR.

**Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid and Medicare Insurance - The perspective of private and public payers.**

*Publication:* J Med Econ 2020 11; 23(11): 1345-1355. e-pub ahead of print 2020/08/21; doi: 10.1080/13696998.2020.1813144.

*Authors:* Shah NR, Bhor M, Latremouille-Viau D, Kumar Sharma V, Puckrein GA, Gagnon-Sanschagrין P, Khare A,

Kumar Singh M, Serra E, Davidson M, Xu L, Guerin A.

**ProCommunity: procalcitonin use in real-world US community hospital settings.**

*Publication:* Curr Med Res Opin 2020 09; 36(9): 1529-1532. e-pub ahead of print 2020/07/10; doi: 10.1080/03007995.2020.1793748.

*Authors:* DeSear KE, Thompson-Leduc P, Kirson N, Chritton JJ, Ie S, Van Schooneveld TC, Cheung HC, Ou S,

Schuetz P.

**Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis.**

*Publication:* J Comp Eff Res 2020 07; 9(10): 737-750. e-pub ahead of print 2020/06/04; doi: 10.2217/ce-2020-0042.

*Authors:* Swallow E, Patterson-Lomba O, Ayyagari R, Pelletier C, Mehta R, Signorovitch J.

**Open enrollment periods and plan choices.**

*Publication:* Health Econ 2020 07; 29(7): 733-747. e-pub ahead of print 2020/02/27; doi: 10.1002/he-4014.

*Authors:* Decarolis F, Guglielmo A, Luscombe C.

**Estimation of causal effects of multiple treatments in observational studies with a binary outcome.**

*Publication:* Stat Methods Med Res 2020 05; 29(11): 3218-3234. e-pub ahead of print 2020/05/27; doi: 10.1177/0962280220921909.

*Authors:* Hu L, Gu C, Lopez M, Ji J, Wisnivesky J.

**Financing Drug Innovation in the US: Current Framework and Emerging Challenges.**

*Publication:* PharmacoEconomics 2020 05: 1-7. e-pub ahead of print 2020/05/27; doi: 10.1007/s40273-020-00926-2.

*Authors:* Cutler D, Kirson N, Long G.

**Diagnostic Category Prevalence in 3 Classification Systems Across the Transition to the International Classification of Diseases, Tenth Revision, Clinical Modification.**

*Publication:* JAMA Network Open 2020 04; 3(4): e202280-e202280. e-pub ahead of print 2020/04/09; doi: 10.1001/jamanetworkopen.2020.2280.

*Authors:* Ellis RP, Hsu HE, Song C, Kuo T-C, Martins B, Siracuse JJ, Liu Y, Ash AS.

**The Relationship Between Follow-up Appointments and Access to Primary Care.**

*Publication:* Journal of General Internal Medicine 2020 03. doi: 10.1007/s11606-020-05785-3.

*Authors:* Price ME, Done N, Pizer SD.

**Federal government-interest patent disclosures for recent top-selling drugs.**

*Publication:* J Med Econ 2019 12; 22(12): 1261-1267. e-pub ahead of print 2019/06/14; doi: 10.1080/13696998.2019.1631832.

*Authors:* Long G.

**The Development of Health Technology Assessment in Asia: Current Status and Future Trends.**

*Publication:* Value Health Reg Issues 2019 10; 21: 39-44. e-pub ahead of print 2019/10/22; doi: 10.1016/j.vhri.2019.08.472.

*Authors:* Liu G, Wu EQ, Ahn J, Kamae I, Xie J, Yang H.

**Transparency in Health Economic Modeling: Options, Issues and Potential Solutions.**

*Publication:* PharmacoEconomics 2019 10. e-pub ahead of print 2019/10/09; doi: 10.1007/s40273-019-00842-0.

*Authors:* Wu EQ, Zhou ZY, Xie J, Metallo C, Thokala P.

**Real-world outcomes in stable originator biologic-treated adult patients who stayed on the therapy versus those who switched to biosimilar: a retrospective chart review study in Europe.**

*Publication:* Annals of the Rheumatic Diseases 2019 07.

*Authors:* Gibofsky A, Skup M, Yang M, Gao W, Doctor T.

**College affirmative action bans and smoking and alcohol use among underrepresented minority adolescents in the United States: A difference-in-differences study.**

*Publication:* PLoS Med 2019 06; 16(6): e1002821. doi: <http://dx.doi.org/10.1371/journal.pmed.1002821>.

*Authors:* Venkataramani AS, Cook E, O'Brien RL, Kawachi I, Jena AB, Tsai AC.

**Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review.**

*Publication:* Adv Ther 2019 06. e-pub ahead of print 2019/06/07; doi: 10.1007/s12325-019-00998-3.

*Authors:* Liu Y, Yang M, Garg V, Wu EQ, Wang J, Skup M.

**Beyond multidrug resistance: Leveraging rare variants with machine and statistical learning models in Mycobacterium tuberculosis resistance prediction.**

*Publication:* EBioMedicine 2019 05. e-pub ahead of print 2019/05/03; doi: 10.1016/j.ebiom.2019.04.016.

*Authors:* Chen ML, Doddi A, Royer J, Freschi L, Schito M, Ezewudo M, Kohane IS, Beam A, Farhat M.

**Validation of an ambient measurement system (AMS) for physical activities in a paediatric population.**

*Publication:* J Med Eng Technol 2019 04; 43(3): 182-189. e-pub ahead of print 2019/07/16; doi: 10.1080/03091902.2019.1640308.

*Authors:* Varsanik JS, Kimmel ZM, Laforet GA, Ricotti V, Sajeev G, Signorovitch J, Quiroz JA, Chevalier TW.

**Combining the Power of Artificial Intelligence with the Richness of Healthcare Claims Data: Opportunities and Challenges.**

*Publication:* PharmacoEconomics. 2019 03. doi: <http://dx.doi.org/10.1007/s40273-019-00777-6>.

*Authors:* Thesmar D, Sraer D, Pinheiro L, Dadson N, Veliche R, Greenberg P.

**Development of a classifier to identify patients with probable Lennox-Gastaut syndrome in health insurance claims databases via random forest methodology.**

*Publication:* Curr Med Res Opin 2019 03: 1-6. e-pub ahead of print 2019/03/15; doi: 10.1080/03007995.2019.1595552.

*Authors:* Vekeman F, Pina-Garza JE, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Sheng Duh M, Shen V, Saurer TB, Montouris GD, Isojarvi J.

**Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.**

*Publication:* The American journal of tropical medicine and hygiene 2019 02; 100(2): 392-398. doi: <http://dx.doi.org/10.4269/ajtmh.18-0493>.

*Authors:* Walsh KF, Souroutzidis A, Vilbrun SC, Peebles M, Joissaint G, Delva S, Widmann P, Royal G, Pry J, Bang H, Pape JW, Koenig SP.

**CMS hospital readmission reduction program and anticoagulants received following a total hip and knee arthroplasty discharge.**

*Publication:* Curr Med Res Opin 2018 11; 34(11): 1967-1974. e-pub ahead of print 2018/05/12; doi: 10.1080/03007995.2018.1475347.

*Authors:* Laliberte F, Coleman CI, Bookhart B, Schein J, Martin S, Wynant W, Xiao Y, Lefebvre P, Kaatz S.

**Examining a Statewide Educational Consulting Program for Pediatric Brain Injury.**

*Publication:* Clin Pediatr (Phila) 2018 06; 57(6): 645-655. e-pub ahead of print 2017/09/22; doi: 10.1177/0009922817732146.

*Authors:* Myers RK, Eagan-Brown BL, Conway AT, Nagele DA, Vaccaro MJ, Kendi S, Zonfrillo MR.

**Removal of ineligible outcome cases reduces confounding.**

*Publication:* Clin Epidemiol 2018 06; 10: 575-579. e-pub ahead of print 2018/06/07; doi: 10.2147/CLEP.S160482.

*Authors:* Walker AM, Schneeweiss S, DerSarkissian M, Duh MS.

**One-Year Effect of the Medicare Annual Wellness Visit on Detection of Cognitive Impairment: A Cohort Study.**

*Publication:* J Am Geriatr Soc 2018 04. e-pub ahead of print 2018/04/03; doi: 10.1111/jgs.15330.

*Authors:* Fowler NR, Campbell NL, Pohl GM, Munsie LM, Kirson NY, Desai U, Trieschman EJ, Meiselbach MK, Andrews JS, Boustani MA.

**Community health workers improve disease control and medication adherence among patients with diabetes and/or hypertension in Chiapas, Mexico: an observational stepped-wedge study.**

*Publication:* BMJ Glob Health 2018 03; 3(1): e000566. e-pub ahead of print 2018/03/13; doi: 10.1136/bmjgh-2017-000566.

*Authors:* Newman PM, Franke MF, Arrieta J, Carrasco H, Elliott P, Flores H, Friedman A, Graham S, Martinez L, Palazuelos L, Savage K, Tymeson H, Palazuelos D.

**Activity-based costing of health-care delivery, Haiti.**

*Publication:* Bull World Health Organ 2018 01; 96(1): 10-17. e-pub ahead of print 2018/02/07; doi: 10.2471/BLT.17.198663.

*Authors:* McBain RK, Jerome G, Leandre F, Browning M, Warsh J, Shah M, Mistry B, Faure PAI, Pierre C, Fang AP, Mugunga JC, Gottlieb G, Rhatigan J, Kaplan R.

**Retention in Care among Patients with Early HIV Disease in Haiti.**

*Publication:* J Int Assoc Provid AIDS Care 2017 11; 16(6): 523-526. e-pub ahead of print 2017/12/01; doi: 10.1177/2325957417742670.

*Authors:* Hennessey KA, Leger TD, Rivera VR, Marcelin A, McNairy ML, Guiteau C, Devieux JG, Marcelin Y, Charles B, Cremieux PY, Koenig SP, Pape JW.

**Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?**

*Publication:* CNS Drugs 2017 10; 31(10): 899-910. e-pub ahead of print 2017/09/01; doi: 10.1007/s40263-017-0462-8.

*Authors:* Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S.

**Outcomes-Based Contracting Experience: Research Findings from U.S. and European Stakeholders.**

*Publication:* J Manag Care Spec Pharm 2017 10; 23(10): 1018-1026. e-pub ahead of print 2017/09/26; doi: 10.18553/jmcp.2017.23.10.1018.

*Authors:* Nazareth T, Ko JJ, Sasane R, Frois C, Carpenter S, Demean S, Vegesna A, Wu E, Navarro RP.

**Consider Value Vs. Budget Impact In Mass. Drug Prices.**

*Publication:* Law360 2017 09.

*Authors:* Kirson N.

**Tracing the Path to Health Care Investigation Settlements.**

*Publication:* Law360 2017 04.

*Authors:* Weinstein KA, Pike CT, Greenberg PE.

**Can social media data lead to earlier detection of drug-related adverse events?**

*Publication:* Pharmacoepidemiol Drug Saf 2016 12; 25(12): 1425-1433. doi: 10.1002/pds.4090.

*Authors:* Duh MS, Cremieux P, Audenrode MV, Vekeman F, Karner P, Zhang H, Greenberg P.

**Reliable Analysis Is Key To Addressing Ascertainability.**

*Publication:* Law360 2016 12.

*Authors:* Cacciola S, Fink S.

**Rethinking the cost of healthcare in low-resource settings: the value of time-driven activity-based costing.**

*Publication:* BMJ Glob Health 2016 11; 1(3): e000134. e-pub ahead of print 2017/06/08; doi: 10.1136/bmjgh-2016-000134.

*Authors:* McBain RK, Jerome G, Warsh J, Browning M, Mistry B, Faure PAI, Pierre C, Fang AP, Mugunga JC, Rhatigan J, Leandre F, Kaplan R.

**Following Recent Trends in Affordable Care Act Insurance.**

*Publication:* Law360 2016 09.

*Authors:* Chawla A, Cook K.

**The Potential for Litigation in New Era of Biosimilars.**

*Publication:* Law360 2016 09.

*Authors:* Frois C, R M, White A.

**Practical Uses For Machine Learning In Health Care Cases.**

*Publication:* Law360 2016 09.

*Authors:* Yenikomshian M, Pinheiro LB, Royer J, Greenberg PE.

**Updated trends in US brand-name and generic drug competition.**



*Publication:* J Med Econ 2016 09; 19(9): 836-844. e-pub ahead of print 2016/04/12; doi: 10.1080/13696998.2016.1176578.

*Authors:* Grabowski H, Long G, Mortimer R, Boyo A.

**Machine-Learning Algorithms Can Help Health Care Litigation.**

*Publication:* Law360 2016 06.

*Authors:* Pinheiro L, Royer J, Dadson N, Greenberg P.

**The Myth of 'Price Disconnects' In US Pharma Markets.**

*Publication:* Law360 2016 05.

*Authors:* Fink S, Lewis M.

**Can The Life Sciences Industry Bank On Biosimilars?**

*Publication:* Law360 2016 04.

*Authors:* Greenberg P, Sisitsky T, Mortimer R.

**Viewing Recent Opioid Regulations In Context.**

*Publication:* Law360 2016 04.

*Authors:* Pike C, Weinstein K, Darling P, Greenberg P.

**Correlation Or Cause: Brand-Name Drug Prescription Rates.**

*Publication:* Law360 2016 03.

*Authors:* Greenbert P, Sisitsky T, R M.

**Care pathways in US healthcare settings: current successes and limitations, and future challenges.**

*Publication:* Am J Manag Care 2016 01; 22(1): 53-62. e-pub ahead of print 2016/01/23.

*Authors:* Chawla A, Westrich K, Matter S, Kaltenboeck A, Dubois R.

**An Analysis of the Economic Impact of the Mirebalais University Teaching Hospital on the Haitian Economy: An Input-Output Approach.**

*Publication:* Journal of Eastern Caribbean Studies 2015 12; 40: 234-250.

*Authors:* Pantal M, Faure P, Jerome J-G, Von M, Mugunga JC.

**Economists' Perspective on the Efficiency Defense in Provider Consolidations: What Works, What Doesn't Work, and What We Still Don't Know.**

*Publication:* AHLA Connections 2015 09.

*Authors:* Chipty T, Sendonaris A.

**The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation.**

*Publication:* PharmacoEconomics 2015 07; 33(7): 749-763. doi: 10.1007/s40273-015-0300-0.

*Authors:* Chawla A, Carls G, Deng E, Tuttle E.

**Gap Between Evidence and Patient Access: Policy Implications for Bariatric and Metabolic Surgery in the Treatment of Obesity and its Complications.**

*Publication:* PharmacoEconomics 2015 07; 33(7): 629-641. doi: 10.1007/s40273-015-0302-y.

*Authors:* Chawla AS, Hsiao CW, Romney MC, Cohen R, Rubino F, Schauer P, Cremieux P.

**The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals.**

*Publication:* Expert Opinion on Therapeutic Patents 2015 07; 25(7): 739-742. doi: 10.1517/13543776.2015.1040762.

*Authors:* Cockburn I, Long G.

**Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names.**

*Publication:* Adv Ther 2015 03; 32(3): 270-283. doi: 10.1007/s12325-015-0193-5.

*Authors:* Chao J, Skup M, Alexander E, Tundia N, Macaulay D, Wu E, Mulani P.

**The roles of patents and research and development incentives in biopharmaceutical innovation.**

*Publication:* Health Aff (Millwood) 2015 02; 34(2): 302-310. doi: 10.1377/hlthaff.2014.1047.

*Authors:* Grabowski HG, DiMasi JA, Long G.

**Evolving provider payment models and patient access to innovative medical technology.**

*Publication:* J Med Econ 2014 12; 17(12): 883-893. doi: 10.3111/13696998.2014.965255.

*Authors:* Long G, Mortimer R, Sanzenbacher G.

**Advanced Diagnostics: Innovation, Reimbursement, and Coverage Challenges.**

*Publication:* In Vivo 2014 10.

*Authors:* Gorin B, Tuttle E.

**Cost-effectiveness of health research study participant recruitment strategies: a systematic review.**

*Publication:* Clin Trials 2014 10; 11(5): 576-583. doi: 10.1177/1740774514540371.

*Authors:* Huynh L, Johns B, Liu SH, Vedula SS, Li T, Puhan MA.

**Random Selection Is Best For MDL Bellwether Trials.**

*Publication:* Law360 2014 10.

*Authors:* Brown L, Holian M, Rothman D.

**Big Data Can Yield Big Insights on Promotional Practices.**

*Publication:* Law360 2014 08.

*Authors:* Greenberg P, Sisitsky T.

**The impact of Brazil's Bolsa Familia conditional cash transfer program on children's health care utilization and health outcomes.**

*Publication:* BMC Int Health Hum Rights 2014 04; 14: 10. doi: 10.1186/1472-698X-14-10.

*Authors:* Shei A, Costa F, Reis MG, Ko AI.

**Recent trends in brand-name and generic drug competition.**

*Publication:* J Med Econ 2014 03; 17(3): 207-214. doi: 10.3111/13696998.2013.873723.

*Authors:* Grabowski H, Long G, Mortimer R.

**The role of health economics and outcomes research in health care reform in China.**

*Publication:* PharmacoEconomics 2014 03; 32(3): 231-234. doi: 10.1007/s40273-014-0141-2.

*Authors:* Liang W, Xie J, Fu H, Wu EQ.

**What Attorneys Should Know about FDA's MedWatch Data.**

*Publication:* Law360 2014 01.

*Authors:* Duh MS CP, Greenberg P, Ellman B.

**Biosimilars.**

*Publication:* Encyclopedia of Health Economics 2014.

*Authors:* Grabowski H, Long G, Mortimer R.

**Effects of care management and telehealth: a longitudinal analysis using Medicare data.**

*Publication:* J Am Geriatr Soc 2013 09; 61(9): 1560-1567. doi: 10.1111/jgs.12407.

*Authors:* Baker LC, Macaulay DS, Sorg RA, Diener MD, Johnson SJ, Birnbaum HG.

**Recent Average Price Trends for Implantable Medical Devices, 2007-2011.**

*Publication:* White Paper 2013 09.

*Authors:* Long G, Mortimer R, Sanzenbalcher G.

**Little Guidance for Lower Courts in FTC v. Actavis.**

*Publication:* Today's General Council 2013 08; 10(4).

*Authors:* John L, Leckerman J, Greenberg P.

**Brazil's conditional cash transfer program associated with declines in infant mortality rates.**

*Publication:* Health Aff (Millwood) 2013 07; 32(7): 1274-1281. doi: 10.1377/hlthaff.2012.0827.

*Authors:* Shei A.

**On-Market Pricing Strategies.**

*Publication:* Pharmaceutical Executive 2013 06.

*Authors:* Works J, Parece A.

**The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication.**

*Publication:* JHEOR 2013 01: 54-61.

*Authors:* C CF, TI OC, Pesa J, Fastenau J, Doshi D.

**Innovation in the Biopharmaceutical Pipeline: A Multidimensional View.**

*Publication:* White paper 2013 01.

*Authors:* Long G, Works J.

**Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research.**

*Publication:* Value in Health 2012 10; 15(6): 940-947. doi: 10.1016/j.jval.2012.05.004.

*Authors:* Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, Betts KA, Wu EQ.

**How to use Clinical-Trial Data in Court.**

*Publication:* Law360 2012 07.

*Authors:* Cremieux P GA, Pinheiro L.

**Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity.**

*Publication:* J Med Econ 2012 06; 15(6): 1078-1087. doi: 10.3111/13696998.2012.689270.

*Authors:* Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ.

**Prioritizing Safety versus Budget: FDA and CMS Adopt Different Stances.**

*Publication:* FDLI Update 2012 05.

*Authors:* Sisitsky T, Greenberg P.

**Recently Released FDA Guidance and Biosimilar Development: Implications for the Litigation Environment.**

*Publication:* Food and Drug Law Institute *Update* 2012 03: 19-21.

*Authors:* Long G, Mulhern C.

**Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.**

*Publication:* Health Aff (Millwood) 2011 11; 30(11): 2157-2166. doi: 10.1377/hlthaff.2010.0270.

*Authors:* Grabowski HG, Kyle M, Mortimer R, Long G, Kirson N.

**Interprofessional education about decision support for patients across cultures.**

*Publication:* J Interprof Care 2011 11; 25(6): 431-433. e-pub ahead of print 2011/10/21; doi: 10.3109/13561820.2011.618072.

*Authors:* Hagoel L, Volz S, Palileo LM, Eldar-Lissai A, Kamath CC, Cox ED.

**Integrated telehealth and care management program for Medicare beneficiaries with chronic disease linked to savings.**

*Publication:* Health Aff (Millwood) 2011 09; 30(9): 1689-1697. doi: 10.1377/hlthaff.2011.0216.

*Authors:* Baker LC, Johnson SJ, Macaulay D, Birnbaum H.

**Implementation of the biosimilar pathway: economic and policy issues.**

*Publication:* Seton Hall Law Rev 2011 07; 41(2): 511-557.

*Authors:* Grabowski H, Long G, Mortimer R.

**Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care.**

*Publication:* Spine J 2011 07; 11(7): 622-632. doi: 10.1016/j.spinee.2011.03.017.

*Authors:* Ivanova JI, Birnbaum HG, Schiller M, Kantor E, Johnstone BM, Swindle RW.

**Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change.**

*Publication:* J Clin Psychiatry 2011 06; 72(6): 787-794. doi: 10.4088/JCP.09m05868yel.

*Authors:* Signorovitch J, Birnbaum H, Ben-Hamadi R, Yu AP, Kidolezi Y, Kelley D, Phillips G, Lawson A, Ball DE.

**Competitor Collaborations in Health Care: Understanding the Proposed ACO Antitrust Review Process.**

*Publication:* CPI Antitrust Chronicle 2011 05.

*Authors:* Chipty T.

**Commercial importation of prescription drugs in the United States: short-run implications.**

*Publication:* J Health Polit Policy Law 2011 04; 36(2): 295-316. doi: 10.1215/03616878-1222730.

*Authors:* Danzon PM, Johnson SJ, Long G, Furukawa MF.

**President Reignites Biologics Exclusivity Battle with Proposal for Seven Years.**

*Publication:* Specialty Pharmacy News 2011 03.

*Authors:* Long G.

**Budget Proposals on Biosimilars, "Pay for Delay" Spark Controversy.**

*Publication:* AIS's Health Reform Week 2011 02; 2(6).

*Authors:* Long G.

**Reading of Biosimilar Law Could Mean One Day or Years Until Competitors on Market.**

*Publication:* Specialty Pharmacy News 2011 02; 8(2).

*Authors:* Long G.

**The role of public-sector research in the discovery of drugs and vaccines.**

*Publication:* N Engl J Med 2011 02; 364(6): 535-541. doi: 10.1056/NEJMsa1008268.

*Authors:* Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML.

**Data exclusivity for biologics.**

*Publication:* Nat Rev Drug Discov 2011 01; 10(1): 15-16. e-pub ahead of print 2011/01/05; doi: 10.1038/nrd3277.

*Authors:* Grabowski H, Long G, Mortimer R.

**An Effective Way to Quantify the Safety Profile of a Drug or Device When Background Toxicity Rates Are Low.**

*Publication:* FDLI Update 2011 01; Jan/Feb.

*Authors:* Wei E, Claggett B, Greenberg P, Wei LJ.

**CER The Fruits of Comparative Effectiveness Sometimes it's necessary to compare apples to oranges, as well as to other apples. New tools and a commitment to managing the impact of comparative effectiveness research grants payers the evidence they need to control drug costs.**

*Publication:* Pharmaceutical Executive 2010 11: 78.

*Authors:* Tuttle E, Chawla A, Nellesen D, Works J.

**Introducing perspectives on comparative effectiveness research.**

*Publication:* PharmacoEconomics 2010 09; 28(10): 787-788. doi: 10.2165/11535820-000000000-00000.

*Authors:* Birnbaum HG, Greenberg PE.

**Perspectives on comparative effectiveness research: views from diverse constituencies.**

*Publication:* PharmacoEconomics 2010 09; 28(10): 789-798. doi: 10.2165/11535790-000000000-00000.

*Authors:* Nellesen D, Birnbaum HG, Greenberg PE.

**ICONS: Managing Care and Costs: The Sustained Cost Impact of Reduced Hospitalizations in a Partnership-Measurement Model of Disease Management.**

*Publication:* Healthc Q 2010 01; 13(4): 30-39.

*Authors:* Paradis PE, Nemis-White J, Meilleur MC, Ginn M, Cox J, Montague T.

**The Growing Role of Economic Analysis in Off-Label Promotion Cases.**

*Publication:* Rx Compliance Report 2009 11; VIII(8): 7-8.

*Authors:* Greenberg P, Sisitsky T.

**Legal and economic perspectives concerning US government investigations of alleged off-label promotion by drug manufacturers.**

*Publication:* PharmacoEconomics 2009 10; 27(8): 623-625.

*Authors:* Kalb PE, Greenberg PE.

**The impact of drug vintage on patient survival: a patient-level analysis using Quebec's provincial health plan data.**

*Publication:* Value Health 2009 09; 12(6): 847-856. doi: 10.1111/j.1524-4733.2009.00532.x.

*Authors:* Lichtenberg FR, Grootendorst P, Van Audenrode M, Latremouille-Viau D, Lefebvre P.

**A comparative analysis of Medicaid long-term care policies and their effects on elderly dual enrollees.**

*Publication:* Health economics 2009 05; 18(3): 275-290.

*Authors:* Rice JB, Kasper JD, Pezzin LE.

**Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction.**

*Publication:* Biostatistics 2009 04; 10(2): 275-281. doi: 10.1093/biostatistics/kxn034.

*Authors:* Tian L, Cai T, Pfeffer MA, Piankov N, Cremieux PY, Wei LJ.

**Economic Analysis in Off-Label Promotion Cases.**

*Publication:* Law360 2009 02.

*Authors:* Greenberg P, Sisitsky T.

**Does generic substitution always make sense?**

*Publication:* J Med Econ 2008 11; 11(3): 547-553.

*Authors:* Greenberg PE.

**Drug Safety And Risk Management Practice: What Drug Companies Can Do.**

*Publication:* FDLI Update 2008 05; (3): 35-38.

*Authors:* Duh MS, Greenberg P, Antras L.

**The Role of Epidemiology in Drug Safety Litigations.**

*Publication:* Update (National Minority AIDS Council) 2007 11: 31-34.

*Authors:* Duh MS, Greenberg PE, Weiner JR.

**The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.**

*Publication:* Dis Manag 2007 08; 10(4): 216-225. doi: 10.1089/dis.2007.104649.

*Authors:* Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY.

**The Effect on Federal Spending of Legislation Creating a Regulatory Framework for Follow-on Biologics: Key Issues and Assumptions.**

*Publication:* White Paper 2007 08.

*Authors:* Grabowski H, Cockburn I, Long G, Mortimer R, Johnson S.

**Retrospective economic and outcomes analyses using non-US databases: a review.**

*Publication:* PharmacoEconomics 2007 07; 25(7): 563-576.

*Authors:* Shi L, Wu EQ, Hodges M, Yu A, Birnbaum H.

**Authorized generic drugs, price competition, and consumers' welfare.**

*Publication:* Health Aff (Millwood) 2007 05; 26(3): 790-799. doi: 10.1377/hlthaff.26.3.790.

*Authors:* Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E.

**Do drugs reduce utilization of other healthcare resources?**

*Publication:* PharmacoEconomics 2007 03; 25(3): 209-221.

*Authors:* Cremieux PY, Ouellette P, Petit P.

**The value of antihypertensive drugs: a perspective on medical innovation.**

*Publication:* Health Aff (Millwood) 2007 01; 26(1): 97-110. doi: 10.1377/hlthaff.26.1.97.

*Authors:* Cutler DM, Long G, Berndt ER, Royer J, Fournier AA, Sasser A, Cremieux P.

**Competition between Generic and Branded Drugs.**

*Publication:* Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective 2007.

*Authors:* Grabowski H.

**The Drug Delivery Delimma.**

*Publication:* SCRIP Supplement, Informa Health Care 2007.

*Authors:* Gorin B, Tuttle E.

**Pharmaceutical spending and health outcomes.**

*Publication:* Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective 2007: 226-241.

*Authors:* Cremieux P-Y, Jarvinen D, Long G, Merrigan P.

**Off-Label Marketing Investigations in the Pharmaceutical Industry.**

*Publication:* Analysis Group Forum 2006 11.

*Authors:* Greenberg P, Sisitsky T.

**A Roundtable Discussion: The Importance of Causation Analysis in Mass Tort Cases.**

*Publication:* Food and Drug Law Institute Update 2006 11.

*Authors:* Greenberg PE, Lykos G, Gourley S, Davies C.

**The market for follow-on biologics: how will it evolve?**

*Publication:* Health Aff (Millwood) 2006 09; 25(5): 1291-1301. doi: 10.1377/hlthaff.25.5.1291.

*Authors:* Grabowski H, Cockburn I, Long G.

**Retirement patterns from career employment.**

*Publication:* Gerontologist 2006 08; 46(4): 514-523.

*Authors:* Cahill KE, Giandrea MD, Quinn JF.

**A Regulatory Perspective on Productivity Claims: Implications for Future Productivity Research.**

*Publication:* Health and Work Productivity: Emerging Issues in Research and Policy. 2006 04; (Spring).

*Authors:* Greenberg PE, Birnbaum HG.

**Generic competition in the U.S. pharmaceutical industry.**

*Publication:* International Journal of the Economics of Business 2006 02: 15-38.

*Authors:* Saha A, Grabowski H, Birnbaum H, Greenberg P.

**Hospital cost flexibility in the presence of many outputs: a public-private comparison.**

*Publication:* Health Care Manag Sci 2005 05; 8(2): 111-120.

*Authors:* Cremieux PY, Ouellette P, Rimbaud F, Vigeant S.

**Public and private pharmaceutical spending as determinants of health outcomes in Canada.**

*Publication:* Health Economics 2005 02; 14(2): 107-116. e-pub ahead of print 2004/09/24; doi: 10.1002/hec.922.

*Authors:* Cremieux PY, Meilleur MC, Ouellette P, Petit P, Zelder M, Potvin K.

**Your patent is about to expire: what now.**

*Publication:* Pharm Exec 2004 11; 24(11): 88-98.

*Authors:* Parece A, Tuttle E, Hector A.

**Money can't buy happiness.**

*Publication:* Business & Health 2004 04; 2004.

*Authors:* Greenberg PE BH, Kessler RC.

**Product Liability in the Pharmaceutical Industry.**

*Publication:* Update (National Minority AIDS Council) 2004 03.

*Authors:* Cremieux P, Greenberg PE.

**Administrative Claims Data: A Valuable Tool in Pharmaceutical Litigation.**

*Publication:* FDLI Update 2004 01.

*Authors:* Birnbaum HG, Greenberg PE.

**Economic Impact Analysis: Proposition 71 - California Stem Cell Research and Cures Initiative.**

*Publication:* Report Commissioned by Californians for Stem Cell Research and Cures 2004.

*Authors:* Baker L, Deal B.

**Measuring hospital performance in the presence of quasi-fixed inputs: an analysis of Québec hospitals.**

*Publication:* Journal of Productivity Analysis 2004 21(2): 183-199.

*Authors:* Bilodeau D, Crémieux P-Y, Jaumard B, Ouellette P, Vovor T.

**Switching costs, price sensitivity and health plan choice.**

*Publication:* J Health Econ 2002 01; 21(1): 89-116.

*Authors:* Strombom BA, Buchmueller TC, Feldstein PJ.

**Hospital technology in a nonmarket health care system.**

*Publication:* Southern Economic Journal 2002: 511-529.

*Authors:* Bilodeau D, Cremieux P-Y, Ouellette P.

**Actual and perceived impacts of tobacco regulation on restaurants and firms.**

*Publication:* Tob Control 2001 03; 10(1): 33-37.

*Authors:* Cremieux PY, Ouellette P.

**Omitted variable bias and hospital costs.**

*Publication:* J Health Econ 2001 03; 20(2): 271-282.

*Authors:* Cremieux PY, Ouellette P.

**Impact of illness and its treatment on workplace costs: regulatory and measurement issues.**

*Publication:* Journal of Occupational Environmental Medicine 2001 01; 43(1): 56-63.

*Authors:* Greenberg PE, Birnbaum HG, Kessler RC, Morgan M, Stang P.

**Évaluation de l'efficacité budgétaire des CLSC au Québec à partir de la méthode DEA.**

*Publication:* L'Actualité économique 2001 77(3): 409-424.

*Authors:* Crémieux P-Y, Gadbois D, Jaumard B, Ouellette P, Vovor T.

**Modeling for health care and other policy decisions: uses, roles, and validity.**

*Publication:* Value Health 2001 4(5): 348-361. doi: 10.1046/j.1524-4733.2001.45061.x.

*Authors:* Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, Graham JD, Hammitt JK.

**Pharmaceutical spending and health outcomes in the United States.**

*Publication:* Research in Human Capital and Development 2001: 59-76.

*Authors:* Cremieux P-Y, Ouellette P, Meilleur M-C, Leong S, Greenberg P, Birnbaum H.

**Diagnosing the illness.**

*Publication:* POLICY OPTIONS-MONTREAL- 2000 21(4): 12-13.

*Authors:* Cremieux P-Y, Ouellette P.

**Hospital cost function in a non-market health care system.**

*Publication:* Review of Economics and Statistics 2000 82(3): 489-498.

*Authors:* Bilodeau D, Cremieux P-Y, Ouellette P.

**Health care spending as determinants of health outcomes.**

*Publication:* Health Economics 1999 11; 8(7): 627-639.

*Authors:* Cremieux PY, Ouellette P, Pilon C.

**Pharmacoeconomics and health policy. Current applications and prospects for the future.**

*Publication:* PharmacoEconomics 1999 11; 16(5 Pt 1): 425-432.

*Authors:* Greenberg PE, Arcelus A, Birnbaum HG, Cremieux PY, LeLorier J, Ouellette P, Slavin MB.

**Using healthcare claims data for outcomes research and pharmacoeconomic analyses.**

*Publication:* PharmacoEconomics 1999 07; 16(1): 1-8.

*Authors:* Birnbaum HG, Cremieux PY, Greenberg PE, LeLorier J, Ostrander JA, Venditti L.

**Tackling costs one disease at a time.**

*Publication:* Bus Health 1999 05; 17(5): 31-32, 37.

*Authors:* Greenberg P.

**Epidemiologic interpretation of artificial neural networks.**

*Publication:* Am J Epidemiol 1998 06; 147(12): 1112-1122.

*Authors:* Duh MS, Walker AM, Ayanian JZ.

**The Home Infusion Therapy/Relative Benefit Index: summary of an analysis using insurance claims data.**

*Publication:* Medical Care 1998 05; 36(5): 757-765.

*Authors:* Birnbaum HG, Tang M.

**Calculating Return on Investment from Reducing Workplace Costs of Illness.**

*Publication:* Drug Benefit Trends 1998 03.

*Authors:* Greenberg PE, Baker A, Berndt E, Finkelstein S, Russell J.



**Prediction and cross-validation of neural networks versus logistic regression: using hepatic disorders as an example.**

*Publication:* Am J Epidemiol 1998 02; 147(4): 407-413.

*Authors:* Duh MS, Walker AM, Pagano M, Kronlund K.

**Interpretation of the Weight Matrix in an Artificial Neural Network.**

*Publication:* American Journal of Epidemiology 1998: 1112-1122.

*Authors:* Duh MS, Walker Am, Ayanian JZ.

**La Performance des CLSC au Quebec, (Local health clinic performance in Quebec).**

*Publication:* L'Actualite Economique 1998 74(2): 157-181.

*Authors:* Cremieux PY, Ouellette P, Gadbois D.

**Prediction and cross-validation in modeling incident cases of hepatic disorders using automated medical data.**

*Publication:* American Journal of Epidemiology 1998: 407-413.

*Authors:* Duh M, Walker A, Pagano M, Kronlund K.

**Une analyse de la performance des CLSC au Québec.**

*Publication:* L'Actualité économique 1998 74(2): 157-181.

*Authors:* Crémieux P-Y, Gadbois D, Ouellette P.

**The Next Phase of Managed Care: Targeting Investments in Employee Health.**

*Publication:* On Managed Care 1997 09.

*Authors:* Greenberg PE, Berndt E, Finkelstein S.

**Une analyse du contexte budgétaire de l'activité médicale au Quebec (An analysis of the budgetary context of medical activity in Quebec).**

*Publication:* Le Medecin du Quebec 1997 08.

*Authors:* Cremieux PY, Ouellette P.

**Etude d'impact du projet de loi sur le tabac (Impact report on the proposed tobacco law).**

*Publication:* Ministry of Health and Social Services 1997.

*Authors:* Cremieux PY FP, Lavoie F, Ouellette P, St Pierre Y.

**Hospital Consolidation: Optimal Strategy for a Two-Hospital Town.**

*Publication:* Ambulatory Health Care 1996.

*Authors:* Deal B, Tiscornia JF.

**Price Growth of prescription pharmaceutical preparations: an update and extension.**

*Publication:* Competitive Strategies in the Pharmaceutical Industry 1996.

*Authors:* Berndt E, Greenberg P.

**Consolidation and restructuring: the next step in managed care.**

*Publication:* Health Care Manag 1995 10; 2(1): 221-235.

*Authors:* Danzon PM, Boothman LG, Greenberg PE.

**Consolidation is a Tonic for Health Care Providers: Trend Toward Managed Care and Ascent of Information Technology Fuel Restructuring of an Industry.**

*Publication:* The national Law Journal 1995 09.

*Authors:* Danzon P, Stamm L, Greenberg P.

**Economic consequences of illness in the workplace.**

*Publication:* MIT Sloan Management Review 1995 08; 36(4): 26.

*Authors:* Greenberg PE, Finkelstein SN, Berndt ER.

**The Health Care System in Canada.**

*Publication:* Financing Health Care 1994.

*Authors:* Mulhern C, Rozek R.

**Navigating the Changing Tides of Managed Care and Health Reform.**

*Publication:* American Medical Association Monograph 1994.

*Authors:* Sherwin R.

**When can a Medicare Insured Group (MIG) Succeed ?**

*Publication:* Inquiry 1994.

*Authors:* Birnbaum HG CN, Lang K.

**Savings estimate for a Medicare insured group.**

*Publication:* Health Care Financ Rev 1991 08; 12(4): 39-48.

*Authors:* Birnbaum H, Holland SK, Lenhart G, Reilly HL, Hoffman K, Pardo DP.

**Impacts of the New York long-term home health care program.**

*Publication:* Medical Care 1986 24(7).

*Authors:* Birnbaum HG, Gaumer G, Pratter F, Burke R, Franklin S, Ellington-Otto K.

**Implementing community-based long-term care: experience of New York's Long Term Home Health Care Program.**

*Publication:* Gerontologist 1984 08; 24(4): 380-386.

*Authors:* Birnbaum H, Burke R, Swearingen C, Dunlop B.

**What does hospice cost?**

*Publication:* American journal of public health 1984 07; 74(7): 689-697.

*Authors:* Birnbaum HG, Kidder D.

**The determinants of nursing home operating costs in New York State.**

*Publication:* Health Serv Res 1983 08; 18(2 Pt 2): 285-308.

*Authors:* Lee AJ, Birnbaum H.

**Medicare legislation for hospice care: implications of national hospice study data.**

*Publication:* Health Aff (Millwood) 1983 08; 2(2): 80-90.

*Authors:* Mor V, Birnbaum H.

**Home care in hospices.**

*Publication:* Caring 1983 06; 2(6): 40-44.

*Authors:* Birnbaum H, Mor V, Greer DS.

**Managing programs for the elderly: design of a social information systems.**

*Publication:* Health Care Financ Rev 1983 02; 5(2): 11-23.

*Authors:* Birnbaum H, Burke R, Pratter F.

**National hospice study analysis plan.**

*Publication:* J Chronic Dis 1983 01; 36(11): 737-780.

*Authors:* Greer DS, Mor V, Sherwood S, Morris JN, Birnbaum H.

**How nursing homes behave: a multi-equation model of nursing home behavior.**

*Publication:* Social Science and Medicine 1983 17(23): 1897-1906.

*Authors:* Birnbaum HG, Lee AJ, Bishop C.

**Why do nursing home costs vary? The determinants of nursing home costs.**

*Publication:* Medical Care 1981 11; 19(11): 1095-1107.

*Authors:* Birnbaum H, Bishop C, Lee AJ, Jensen G.

## Abstracts

**A Model of successful ART initiation in the context of massive civil unrest in Haiti.**

Seattle, Washington February 19-22, 2023.

*Authors:* Marc JB, Pierre S, Rivera VR, Zion A, Montreuil D, Homeus F, Andre D, Duchatellier CF, Fox E, Rouzier V, Liautaud B, Severe P, Guiteau C, Pape JW, Koenig SP.

**Potential cost-effectiveness of small-quantity lipid-based nutrient supplementation amongst young children in Niger.**

Virtual October 14 –October 15, 2021.

*Authors:* Viola M, Jenkins M, Yang D, Jabari R, Flignor M, Faye AC, Phelan K.

**Postdischarge Health Care Costs and Readmission in Patients with Hyperkalemia-Related Hospitalizations.**

*Abstract:* Kidney Week, Virtual 2020.

*Authors:* Betts KA, Woolley JM, Mu F, Wang Y, Wang Y, Dua A, Wu EQ.

**Matching Adjusted Indirect Comparisons: Recommendation for the Selection of Baseline Characteristics Used for Matching.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Gao W, Patterson-Lomba O, Signorovitch J, Wu EQ, Ayyagari R.

**Use of Machine Learning in Health Economics and Outcomes Research (HEOR): Optimizing Predictive Models.**

*Abstract:* ISPOR 2019, New Orleans, LA May 18-22, 2019.

*Authors:* Royer J, Wu E, Ayyagari R.

**Prevalence rates of biosimilar discontinuation and switchback to originator biologics following non-medical switching: a meta-analysis of real-world studies.**

*Abstract:* European Crohn's & Colitis Organisation 14th Annual Congress, Copenhagen, Denmark Mar 6-9, 2019.

*Authors:* Yifei L, Skup M, Yang M, Qi C, Doctor T.

**An Application of Artificial Intelligence-Based Methodology in Literature Reviews.**

*Abstract:* ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Wu EQ, Ayyagari R, Royer J, Li J, Wang J, Lefebvre P, Patterson-Lomba O.

**Artificial Intelligence Assisted Literature Reviews: Key Considerations for Implementation in Health Care Research.**

*Abstract:* ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Wu EQ, Royer J, Ayyagari R, Signorovitch J, Thokala P.

**Longitudinal Matching: A Method for Generating Comparable Samples of Treated and Treatment-Naive Patients with Progressive Conditions.**

*Abstract:* ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Cook K, Ali O, Gupta D, Holmqvist D, Ilin C, Lee D, Tuttle E, Bradt P.

**Economic impact of non-medical switching from originator biologics to biosimilars-a systematic literature review.**

*Abstract:* Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, Netherlands Jun 13-16, 2018.

*Authors:* Liu Y, Garg V, Yang M, Wu EQ, Skup M.

**Matching-adjusted indirect comparison (MAIC): Sensitivity analyses and graphical diagnostics.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Signorovitch J, Gao W, Rybkin V, Yao Z, Hellstern M.

**Retention of clinically stable art patients in a rapid model of care in Haiti.**

*Abstract:* 23rd Conference on Retroviruses and Opportunistic Infections, Boston, MA Feb 22-25, 2016.

*Authors:* Moise CG, Bellot C, Hennessey KA, Rivera VR, Severe P, Aubin D, Homeus F, Saint-Vil A, Koenig SP, Pape JW.

**Outcomes-based pricing and reimbursement arrangements for pharmaceutical products in The US and EU-5: Payer and manufacturer experience and outlook.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Nazareth T, Ko JJ, Frois C, Carpenter S, Demean S, Wu EQ, Sasane R, Navarro R.

**Statistical identification of potential selection bias in retrospective chart reviews.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Signorovitch JE, Reichmann WM, Li N, Liu Z, Hao Y, Perez JR.

**The randomized blind start trial: Evaluation of a new study design for assessing clinical outcomes in rare and heterogeneous patient populations.**

*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8-12, 2014.

*Authors:* Signorovitch J, Ayyagari R, Kakkis E.

**Evaluation of the value of webdata for detecting drug adverse events.**

*Abstract:* 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Taipei, Taiwan (Republic of China) Oct 24-27, 2014.

*Authors:* Duh MS, Cremieux P, Van Audenrode M, Vekeman F, Karner P, Giguere-Duval P, Xiao Y, Damron J, Greenberg P.

**Identifying high-value treatment populations in clinical trials and real-world data.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Signorovitch J, Shaw J, Betts K, Wu EQ.

**Outcomes-based contracting for pharmaceutical products in the United States: payer and manufacturer experience and outlook.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Frois C, Carpenter S, Demean S, Wu E, Navarro R.

**Estimating chronic disease prevalence from claims data: Reducing bias by accounting for diseased individuals who do not generate claims.**

*Abstract:* ISPOR 16th Annual European Congress, Dublin, Ireland Nov 2-6, 2011.

*Authors:* Signorovitch J, De G, Drabo E, Guerin A.

**The Randomized Blind Start Trial: A New Study Design to Assess Clinical Outcomes in Rare, Heterogeneous Patient Populations.**

*Abstract:* 12th International Congress of Inborn Errors of Metabolism (ICIEM), Spain September 3-6, 2013.

*Authors:* Kakkis ED, J. S.

**Beyond average adherence: Temporal patterns of medication adherence predict hospitalization risk more accurately than the medication possession ratio.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Signorovitch J, Chopra P, Cheng D, Ayyagari R, Wu EQ.

**Investigator-initiated approach to address an optimization problem in designing cost-efficient studies.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Huynh L, Clark M, Frick KD.

**Matching-adjusted indirect comparisons: A simulation study of statistical performance.**

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research 2013, May 18-22, 2013.

*Authors:* Signorovitch J, Ayyagari R, Cheng D, Wu E.

**Impact of Medicare part D coverage gap on beneficiaries' adherence to prescription medications.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Desai U, Carroll NV.

**Modeling the progression of chronic diseases in a dynamic market: Implications for budget impact analysis.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Eldar-Lissai A, Banerjee R, McBride S, Leaf-Herrmann W.

**Comparative effectiveness research using matching-adjusted indirect comparison – A method for improving the reliability and interpretability of indirect comparisons by incorporating individual patient data.**

*Abstract:* 3rd DEClDE Symposium on Comparative Effectiveness Research Methods, Baltimore, MD Jun 6-7, 2011.

*Authors:* Signorovitch JE, Wu EQ, Xie J, Lu M, Sikirica V, Hodgkins P, Erder MH.

**Utilizing rich data sources to identify patients' subgroups that can benefit most from a treatment.**

*Abstract:* 3rd DEClDE Symposium on Comparative Effectiveness Research Methods, Baltimore, MD Jun 6-7, 2011.

*Authors:* Wei LJ, Signorovitch JE, Wu EQ, Betts K, Yang H, Xie J, Setyawan J, Hodgkins P, Erder MH.

**Improved indirect treatment comparisons for comparative effectiveness research.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Signorovitch J, Navarro R, Betts K, Wu EQ.

**Selecting the optimal target population for formulary coverage.**

*Abstract:* ISPOR 4th Asia-Pacific Conference, Phuket, Thailand Sep 5-7, 2010.

*Authors:* Wu EQ, Yu D, Xie J, Gu.

**Comparative Effectiveness Research for Personalized Medicine.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Signorovitch J, Wu EQ, We LJ.

**Panel discussion: New imperatives for evidence to support successful licensing, reimbursement, and commercial strategy.**

*Abstract:* BIO International Convention, Chicago, IL May 6, 2010.

*Authors:* Chawla A (moderator), Szela M, Blansett L, Garrison L, Schroeder T.

**The role of compliance in telehealth adoption.**

*Abstract:* 15th Annual International Meeting of the American Telemedicine Association, San Antonio, TX May 16-18, 2010.

*Authors:* Newell D, Johnson S, Rutherford P, Welte I.

**Comparative Effectiveness without Head- To- Head Trials: Indirect Comparisons Using Primary and Published Clinical Trial Data.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Wu EQ, Signorovitch J, Yu A.

**Personalized medicine:trends in clinical studies based on national registry data.**

---

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Nellesen D, Person A, Yee K, Chawla A.

**Societal cost of rheumatoid arthritis (RA) in the United States: Methodology for incorporating intangible costs.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M.

**Assessing Step Therapy/Generic Switching: Clinical and Economic implications of Acquisition Costs vs. Total Health Care Costs Paradigm.**

*Abstract:* Congressional Budget Office, Washington DC 2007.

*Authors:* Wu EQ, Greenberg P, Erder MH.

**Systematic Differences in Subjective vs. Societal Preferences.**

*Abstract:* International Society for Quality of Life Research.

*Authors:* Sullivan PW, Ghushchyan V, Wu EQ.

**Instrument strength and performance of a parametric latent index model in estimating average treatment effect (ate).**

*Abstract:* ISPOR 2003, 2003.

*Authors:* Wu E, Johnson K, Nichol M.

**Performance of two conditional expectation methods under unobserved selection bias.**

*Abstract:* IPOR 2003, 2003.

*Authors:* Wu E, Nichol M, Johnson K.

**Comparative Econometric Models of Medical Costs.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR) 2000, 2000.

*Authors:* Wu EQ, Hay JW.



## **ABOUT ANALYSIS GROUP'S HEOR PRACTICE**

Founded in 1981, Analysis Group is one of the largest international economics consulting firms, with more than 1,000 professionals across 14 offices. Analysis Group's health care experts apply analytical expertise to health economics and outcomes research, clinical research, market access and commercial strategy, and health care policy engagements, as well as drug safety-related engagements in epidemiology. Analysis Group's internal experts, together with its network of affiliated experts from academia, industry, and government, provide our clients with exceptional breadth and depth of expertise and end-to-end consulting services globally.

[AnalysisGroup.com](https://www.analysisgroup.com)